<SEC-DOCUMENT>0001711279-21-000031.txt : 20211108
<SEC-HEADER>0001711279-21-000031.hdr.sgml : 20211108
<ACCEPTANCE-DATETIME>20211108071001
ACCESSION NUMBER:		0001711279-21-000031
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211108
DATE AS OF CHANGE:		20211108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Krystal Biotech, Inc.
		CENTRAL INDEX KEY:			0001711279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				821080209
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38210
		FILM NUMBER:		211386502

	BUSINESS ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		(412) 586-5830

	MAIL ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>krys-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:51c004c1-b4bb-4008-a736-d538f5596d86,g:ccbd04b3-aea9-417b-ad73-32d54787d8a0,d:527b7e782a7b4f2c9d55c09f08b7a4ae--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:krys="http://www.krystalbio.com/20210930" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>krys-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl8zLTEtMS0xLTA_1a1ccbb1-2c86-42a3-b93c-4a88252ce1bd">false</ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl81LTEtMS0xLTA_3734a0d7-2fa9-47ff-bc3d-18410516b028">2021</ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl82LTEtMS0xLTA_044f1f4d-dbde-45c0-ab46-49757c662f35">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl85LTEtMS0xLTA_b7d4a4ee-8bef-47fe-ae49-0d2f45dd305c">0001711279</ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl8xMC0xLTEtMS0w_5bbdd412-8a12-4a65-bef3-17847eaa05df">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="krys-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1dc32338fed74c97ac6221ff6cb01741_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i62b974e3062741518c63511eaaa01aa5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebef65754afc438aa569cd6c2fec349d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa15eaaa2f140849a241da763e04fb2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3709c8cd63614284a9610906266d0ebd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2061c660b06d4c9bbc11d16373c8f063_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i191055abec7b4144af0047f02b74e20e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae7f575f30640149beff34d2c2f617e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321a84171d8a42ae87ecd9326ac313d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e7561237f64188bc3c6ef3786ea8c5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d79a58b3e124f8a93f15786db349364_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7988751036404fc89eab96bb474330c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b21bf40faac4746a6d98991f9063b5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9c5a9d8dcc4e6ea4fd5c9f8e96d621_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aad2be9b4df4f7090d2f00cce76d403_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ec7da3b1424b85a57097d6c554f644_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4555af1344b5488aaea0d72479cf0596_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7bf6f5591b46edaa5e23d7d6b6d15b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bc922e8a45e4864948e7e52a210bbfe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8a7560e4e7401cb82d7df6b06ca5d8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27020da178fa4cab8a2ad787440d1369_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44581efe982d4dff9526f3d982194139_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f8d1355d9204ec8b58c5c853065bc30_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id45a96a79a604c8db109413461f12acf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39b992f7893b4bac997ab34d477d4884_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe11ab4cb70e4898bed01c9fa46af4c0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a155eabc104ac39191d0d03971f31d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic296d4384977465fb82b5010ed0ea42f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0ff4743b9f46b8b6897b102789984d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dfb9569024b4ddcba80967d823d97b7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa9f713e891499cbfa3fc8da6fec325_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic524439cfc7a482999097af4b55a5fd7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b5190d89144635b7cdcb97ae657284_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e0ff72fb3da4a59a200925afcdc7e65_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a04a026e0f40dfa4a678165d4d3da9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabae1d6edcd44228a05c3a846d30a2a3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3172719de6407c94ec038f29804c92_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06802d6ce84540babb361a9ca632edf7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dc0520a90d14ee7bc0c963570c38886_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85bc9503824447aacbf3a433d92baa0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i049d3f1f3d9c468bbc710632bed69c2e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9af2e9614184f199df0100b95b2f2ef_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74071e3de9484ae09acb8eb907fb8765_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide40bf231fce4273bf66acd14c1d53cc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i269d31cc46944354be67150726d053a7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0dbff202384819bd79871ce53f52a1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29e82c0f6cdf46378b20a960d57eccfc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21fb4954033b4b0b93ef3aa15fc789ce_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218df3debedb4042ab2ec6698e70d179_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633113795b2445609b4d35249439ee5d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a07000796ab4a10b2efb0c04206a552_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b693b748af4c179dafe11803d10f9d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56e37cfb5b8493ea7ea61e4a78142b6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7b3e8282d5e4574a43ae348d5c92c8d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdcb5badd1de447fb11c3b9a221fd47f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd8f55248c2407aafd07129677d082f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7b5967563e74e4aac849273cf4c06b3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeea9ac7058f4e22bd252caeea9844f2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b09cfbea34490790bb69bd5752f88a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee47238ea63d403bbafeb419adbbebcb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee384afa0dff40c49580804ce4258745_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc9e27c9f1f0448e9f321a4ae000e86b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32320f6c16064db8acd6e60f9ef524a7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe2b33ae24b422a847884207b6bff68_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5feb07b8aad34436985280cebd165fd9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc9353033fe471090a517b829a2055f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>krys:segment</xbrli:measure></xbrli:unit><xbrli:context id="i6d755a61291247e5ba23687314064f9e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7757281c81f42c3a6bb1ee3db3f83e8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i167897773af54ee49c97a24df909a026_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa3213055e3456e9e82b846221a93e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6515d6f7304602a6523f858a283c84_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c81b84b50ef47a0b86f109e196ba146_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b12af6efb72401a82a1e6a4b4c57dd0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480d95bb53374899b607426942f95dca_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ab6aacae2304361b0a72c97b35ee627_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc527d5b83e74effaf86ce8c575e458a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a05d3b447e84b38864ccb769d5da5fc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7336d71fe9424bb2a9bf72b1fab73a2a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9480bff926bb4e4d8942dbf68b065b31_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070c705902be4570bce920e02b91537c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7a535fd48142c7a5dcda9d399c631a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaa636ac23904975afc64924b8d01488_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i690f4828e5af45768504fbfe9abf5724_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i273373a6ceae4707bb9cc2cdb83bbbff_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ab38c37055a4a71b0214378f4574d16_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60050340c9ed4f90870cf907d27f9bfe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388aa2cdde1b460b8597bdff3339972b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb0b6fc4e57d4890b25ef6de39c2fdd4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia792c56b64d848e8878f44d2d236a376_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b82a410df0441049ce87afb941806cc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7cf6e72bd844925bb9e2348bf8f610b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c3d137419ce48cea5dcac2591a043e3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01d97ca6150480d87ec6af171de89fb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2eb16e1cce408fa52eed5e879feb37_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide270ebcff6b4424baa910b00caf1be1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92b64b50e3f47dd88ac7a91d623e520_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459ec248d46840ba8f88fd2b1cb42941_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i751bd4c59343464787b18cf531e5ba6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f22c8a22b747dc8c7ef55057b16a94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2214f04c270c4e8e98c8dcb8e54f8278_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i443bbe79aab14ee3afae2ad98fc04529_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fe2739a8ded43368c826619c379d66f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12454311b50448ccaea121ba9277c57f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad8ad72123e9462a98dbf3e4ec7a9939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a40d442dc8b42cf817bdc09ed7f53ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36fabffff72949f4b082a440b13e4c81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68505d0a06e4e8f8922085fadd5bf59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2eca019dc0c428095839c77f4815829_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6178f3db244647aae1348be50ad904_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2da3d7596b4625832ab659cb505863_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58cb6e2879a24124bd2b0493f3c58a56_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i491c64c69c5740d9a40094969e3b6070_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df18665bd86458f8795c8e7043272a1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf127646e3d4429283df0e2fb130d95b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77390b63e8b461882829e033c650015_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a9e853ed55449bae567c7f13b9c39f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7bb1d188c9c42d1af6298345aa0983e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73cfb9402d17457b94e8a0005fcfa94e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278e5912864d433589d7d35fd5a102f1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78abfaea77845eaa82d10a53ce7a880_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ifc4f34c83c884eb3be6bb60125c76063_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552d49a6c87f436ebf2aeb62b171e6bc_I20200121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91240de4fd2c49149368668c1fc1aa2c_D20201015-20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-15</xbrli:startDate><xbrli:endDate>2020-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51817723d8bc4777b149972dc507b6d6_I20201005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7ea7f3f0af418a9798c126d95ba2fb_I20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ibdb3c79bb37d40598236a397bfdf2732_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4d91bb10244ecf85e9ff55bf22c6a3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780d412ff27c4f4fb4ad7befad90ed62_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7481ea7a3508451e84e2ce446d95a16d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae859592e93741fba5e8767be4c58a3f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48eae196563f44c886012909931c2a7d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7867867a17654c0bba0b47e105576b16_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808f837ef3eb42e09cf35d83a641a5ce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6cf359423442cda103cac2e7b58836_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34e1df8bf9c941ec85693b9f008abbf2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icefbb0dcf23b4a9db9500e432e160acd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae80f11bf7c417fa7f665a031b58b73_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib295489090d1497185afd643ec967a56_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1760613e671947e5ba8f0fd15472bece_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0310113aa0194f0ba193480ce6faf7ef_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d81be4c0fa64dd0b8e80538f57a09e8_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e810f93dfa47a7ba2d68780daf21d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krys:StockSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cea238b09064f7bb11eb8a0267838ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krys:StockSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33152efbe744812957d7c93ebcf8473_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7666a417eef840ce9941f0b9297bde02_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic84fce3d22ab4e95a1361b9dc14e7326_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dacc94700004db9ad609717389032af_D20200521-20200521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64975891a997407ba786da1993f9bad1_I20200521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1fbc3d234f4c31903d00f50bd07271_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5feb93df6b024f7cbfaad880dd55f616_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f2bb01dacd44a89c7370650b2b2cca_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d40c5e7efd84df4a8f860d865bd0141_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e84783b0eec4936825763ed74abe018_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7444f7d4fc9f40e4b7424b6ec2b0fd54_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff24ad40df3743eca1aab0a8298c6f52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b83729187442bdba220a841af20bcc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb5f40093234fb2a5fbe54c4b287a17_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60121faa697c4cf4bdba3ea3cb5a3562_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c1f98d79c5f4e3aa04f39f090ddce51_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7affc8789534432280b25eb22852bb8c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26740af942247b2a3bb8eb3a07f6bef_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97da03d07b90493f982743fb141e7298_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d5be9cd51d4b70b5ec51f29beb8aee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8493f9588d450d89ac8a3c4f8dd0bb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2a828aba9334f18af2e6159a18dfa2c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e0e48d0c15d47f7a3586bad35785d87_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c821ed52594cc09bc5d3e97fd84ca7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1224c3cee3aa43cfa95fe86ed4bcfc62_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4451954ae1a4edab2286b6d5d667fdd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id703799af79f4f7a929cf79a1de29747_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8eaea3be6bb40f18cd2f3f4801f7642_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132e1504fcb94c2395a26312d77352a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib02e0c13ab2041b283dbcc71cc381e44_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24202ad4adbf4f7eab4c44f57bec5ea6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e866668c45429e8d1f0d8e8b8d3a48_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61932feef1d64f7bbbc45f3ed5b46e1d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c4bdc17ee04d84a5123fc95c1f8964_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id851b0ef34164eb1badf918d62103e06_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84499c680dce48a880d22dfb5d4f52a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769dbf11dfe64b2d8b252dbee0ed9486_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_1"></div><div style="min-height:27pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDYx_3e38c258-80e1-4950-9262-af4ee2bb639b">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6ODlkOWE0MTY5YThmNDdhNGFiYjk4NjBkY2IxMjFmNDAvdGFibGVyYW5nZTo4OWQ5YTQxNjlhOGY0N2E0YWJiOTg2MGRjYjEyMWY0MF8wLTAtMS0xLTA_0171c398-baf3-476f-ae7a-f5f281f987c6">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDI_3b6d5395-d5e2-4d94-bafd-68557a9f9bd6">September&#160;30, 2021</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6NDFhZDRiNDUxYmZjNDkwOGE2ZWFmMTY1NTBjYTI1MTAvdGFibGVyYW5nZTo0MWFkNGI0NTFiZmM0OTA4YTZlYWYxNjU1MGNhMjUxMF8wLTAtMS0xLTA_34429d68-b729-49de-a57d-8e47b8704c1d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDYy_fd955793-b4d9-4ca4-aebe-89de443ecf2a">001-38210</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY3_a8964d6f-a024-4550-9b27-3ce066e7a880">Krystal Biotech, Inc.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6NWI4N2U4MDhjYmI3NDk0NWFlOTViMDc3MmU3MWIyNzQvdGFibGVyYW5nZTo1Yjg3ZTgwOGNiYjc0OTQ1YWU5NWIwNzcyZTcxYjI3NF8wLTAtMS0xLTA_7531d682-b6e5-4384-863b-40fe3c9a8f2a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6NWI4N2U4MDhjYmI3NDk0NWFlOTViMDc3MmU3MWIyNzQvdGFibGVyYW5nZTo1Yjg3ZTgwOGNiYjc0OTQ1YWU5NWIwNzcyZTcxYjI3NF8wLTItMS0xLTA_f92ea663-793a-46d5-8c45-03a59fadc8b3">82-1080209</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY5_6d80a8eb-746e-4349-a865-c11fb1ce0342">2100 Wharton Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDcw_86f5d6ba-b329-4f92-860b-3c86634c87f7">Suite 701</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY0_84b1a627-7ef4-4d49-9b2d-7775bb159bb6">Pittsburgh</ix:nonNumeric>, <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDcy_8536fded-7954-4a0f-8505-30fc1c8bea44">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV81OTk_df835c9f-656c-400c-a823-9121af06e5a6">15203</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDU3_c4331ac7-4e4c-47f8-8baf-bb407f74c470">412</ix:nonNumeric>) <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDcz_a8dbb74b-d2f6-425c-b249-0ad4baeaa232">586-5830</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6MzFmODE4MTIzMmUyNGI2MTgxMDA3NWQ1OTk4NGQ3NzQvdGFibGVyYW5nZTozMWY4MTgxMjMyZTI0YjYxODEwMDc1ZDU5OTg0ZDc3NF8xLTAtMS0xLTA_eb6c0af1-5133-4f8b-8075-ea89e05eb0fe">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6MzFmODE4MTIzMmUyNGI2MTgxMDA3NWQ1OTk4NGQ3NzQvdGFibGVyYW5nZTozMWY4MTgxMjMyZTI0YjYxODEwMDc1ZDU5OTg0ZDc3NF8xLTEtMS0xLTA_e1fcbfba-d392-4301-8004-3ad5e6fce95e">KRYS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6MzFmODE4MTIzMmUyNGI2MTgxMDA3NWQ1OTk4NGQ3NzQvdGFibGVyYW5nZTozMWY4MTgxMjMyZTI0YjYxODEwMDc1ZDU5OTg0ZDc3NF8xLTItMS0xLTA_ac95fff2-6527-41a3-a241-1600e1b4d777">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY1_8dfc7c06-a0ff-4f8c-a800-d9d2d4024b65">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY2_762fff34-e639-40f8-8ea2-ce4bf1779bb6">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6ZTAzOTM1YWViN2E2NDMwMmIwZWUzY2Q1MGIzZTUzNTgvdGFibGVyYW5nZTplMDM5MzVhZWI3YTY0MzAyYjBlZTNjZDUwYjNlNTM1OF8wLTQtMS0xLTA_ac37778b-8172-43fd-9818-e5edfb73daa9">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6ZTAzOTM1YWViN2E2NDMwMmIwZWUzY2Q1MGIzZTUzNTgvdGFibGVyYW5nZTplMDM5MzVhZWI3YTY0MzAyYjBlZTNjZDUwYjNlNTM1OF8xLTYtMS0xLTA_c4ef5d64-dcc1-47cc-a2c5-410a5913bafe">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;&#160;            </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDU4_8b44f28d-08c1-4d81-86c3-0f21f3407ae6">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDU5_40bc4fa9-5d13-4ce6-aa67-b5950c6dd6fe">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDYw_ea70ceed-4bbc-4d8f-8a28-89de3f4d3aa1">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of October&#160;29, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i1dc32338fed74c97ac6221ff6cb01741_I20211029" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yMzkw_fa8ce1da-35c0-4978-8bcf-19415e7afa7a">22,237,984</ix:nonFraction> shares of the registrant&#8217;s common stock issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_16">September</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_16"> 30, 2021 and December 31, 20</a>20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_19">Nine</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_19"> Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_19">September</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_19"> 30, 2021 and 20</a>20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_22">Nine</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_22"> Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_22">September</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_22"> 30, 2021 and 20</a>20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_25">Nine</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_25"> Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_25">September</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_25"> 30, 2021  and 20</a>20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_61">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_61">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_85">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_85">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_88">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_88">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_88">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_91">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_94">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_94">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_97">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_97">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_97">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_100">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_100">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_100">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_103">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_103">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_103">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_106">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_106">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_106">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_109">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_109">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_109">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_112">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_112">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_112">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_115">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i527b7e782a7b4f2c9d55c09f08b7a4ae_115">62</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_16"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except shares and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNC0xLTEtMS0w_2c2a0c06-3f0b-494c-9fee-74cad59e2442">286,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNC0zLTEtMS0w_ae576392-b969-4dbc-ac47-6057d8595db4">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNS0xLTEtMS0w_aaf446a6-dabd-4e7e-8f3f-fd6ba48c5c5c">56,479</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNS0zLTEtMS0w_e8e8b613-73d8-435b-bf1c-c15a992e3af4">2,993</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNi0xLTEtMS0w_2a56711b-69db-49cc-bf30-adca5a19ccce">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNi0zLTEtMS0w_b39ffe54-1f7d-4d28-b0f4-00c5eea3a99d">3,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNy0xLTEtMS0w_48d1c9bf-8d7b-4a98-86be-0774d66754c0">345,812</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNy0zLTEtMS0w_dbe51281-11e1-487e-ae8b-e11bf6427bf6">275,058</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfOC0xLTEtMS0w_8e42aafc-2395-4ee2-9127-a48e2e7a3e33">78,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfOC0zLTEtMS0w_c8f5bc81-8e70-4f2a-9ed0-182c08165e20">30,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfOS0xLTEtMS0w_27d7369b-70f0-4809-845e-82772b2ad47b">19,237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfOS0zLTEtMS0w_6c71b3a9-1276-4688-899e-62351153671a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTAtMS0xLTEtMA_21c670d3-0df4-4487-b92b-4de82d8093ee">7,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTAtMy0xLTEtMA_1748dde9-24c2-4e53-9306-5c0e1b650c80">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTEtMS0xLTEtMA_06af6c0f-cbce-451a-8ca3-0da692b572ce">62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTEtMy0xLTEtMA_254a068d-f54e-4e49-845a-c181f79e22c9">1,612</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTItMS0xLTEtMA_6fd5350e-d54b-475d-8ea7-08b035846324">451,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTItMy0xLTEtMA_2992e6ec-7e7d-4e82-be48-6248ac66c3a8">310,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTUtMS0xLTEtMA_d8ba43d9-13dd-48e2-8c8c-8a8bd704bbd9">4,757</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTUtMy0xLTEtMA_61a24648-d364-4bcf-8557-0157ab5a18f3">2,105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTYtMS0xLTEtMA_79594e78-6a12-447c-b760-15cb4e015aad">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTYtMy0xLTEtMA_9defe35c-4ec2-4308-a8b8-5486638c1871">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTctMS0xLTEtMA_900cd813-6ec8-44cd-87d2-f90f7ba4c0f3">29,999</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTctMy0xLTEtMA_6d4f6ebd-7cea-4778-b8ba-0c235cb57c39">5,109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Build to suit lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:fixed-zero" name="krys:BuildToSuitLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTgtMS0xLTEtMA_f1814ee7-5a20-4543-9ec2-83cadf1570ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:BuildToSuitLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTgtMy0xLTEtMA_398b7156-d334-40ad-bc0e-92d85776c97d">7,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTktMS0xLTEtMA_5686bce7-38bc-4660-a645-c79a42e13e12">35,779</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTktMy0xLTEtMA_7edca33e-8e7f-4d10-ae5c-5262d557da90">15,452</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjAtMS0xLTEtMA_6a0036b8-48a6-42f0-9262-cc6e1660abbb">7,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjAtMy0xLTEtMA_52dd66a4-e5cd-4dec-b780-205e4721940d">3,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjEtMS0xLTEtMA_dcfdf11c-20ec-48f9-99ba-c37975d76adb">42,858</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjEtMy0xLTEtMA_6eaf0e30-c266-4a49-b9b0-f9485033a2f3">18,760</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjItMS0xLTEtMA_044db5df-d31a-4ee6-8de5-373eb23a6e30"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjItMy0xLTEtMA_8efc53c3-4b6c-41ff-adfb-ddbf46a25de1"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzIx_43c00e04-e262-4c28-84fc-19f5af5cf99e"><ix:nonFraction unitRef="usdPerShare" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzIx_9a10bf21-dbd1-4905-831e-910e234ff74d">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzM1_9f6c36ca-02b8-4b00-883a-69140f0e8168"><ix:nonFraction unitRef="shares" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzM1_afd08959-5701-468a-89b4-bd3114c6c5e8">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized at</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; September&#160;30, 2021 (unaudited) and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0Xzg1_9b687658-16d3-4aee-b6b4-d1b6bd84f0f8"><ix:nonFraction unitRef="shares" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0Xzg1_cd756276-b383-484f-b8b0-162f57079b82">2,061,773</ix:nonFraction></ix:nonFraction></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; shares issued, and <ix:nonFraction unitRef="shares" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzExMA_c9d7aad6-39b5-4bfa-92a9-cd1c7a3827cf"><ix:nonFraction unitRef="shares" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzExMA_e7105f57-9a56-4380-b27b-613f7cf775f8">no</ix:nonFraction></ix:nonFraction> shares outstanding at September&#160;30, 2021</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; (unaudited) and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMS0xLTEtMA_2dabe325-6654-40ab-9cb7-3cacdbe0a259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMy0xLTEtMA_14179fd5-5d33-41d2-a17f-4d8ea2862d67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzE4_372f866d-3679-411f-8be2-402f2a53d16d"><ix:nonFraction unitRef="usdPerShare" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzE4_6873c728-e3a2-430e-b5ff-c7bf4ee51667">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzMy_28780e3e-81fb-4b68-9b04-2bc4d5b93025"><ix:nonFraction unitRef="shares" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzMy_eecad1b6-241c-4d55-aa49-4975229ed93e">80,000,000</ix:nonFraction></ix:nonFraction> shares authorized at</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; September&#160;30, 2021 (unaudited) and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzgy_2a594522-cc57-4134-b35e-69c9a03425d9"><ix:nonFraction unitRef="shares" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzgy_f0f6e903-ead4-4930-b960-4516c72719e1">22,237,984</ix:nonFraction></ix:nonFraction></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; and <ix:nonFraction unitRef="shares" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzky_4d50beec-c074-4128-a10c-2bca41ca9b6e"><ix:nonFraction unitRef="shares" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzky_a2e8276e-b49b-4e24-a4c5-cdb2664618e1">19,714,220</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2021</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; (unaudited) and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMS0xLTEtMA_bbdd81d8-3d62-4849-84e5-36c47546fb4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMy0xLTEtMA_f7be4b6d-8094-4983-ba67-98e529357f92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjYtMS0xLTEtMA_fa17bd98-f6f3-4d44-8214-92ae7f16b795">527,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjYtMy0xLTEtMA_a15db3a1-ec79-4a4c-9be8-a4eb6180cc43">363,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (expense)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjctMS0xLTEtMA_1375ed48-bf45-4cf8-95f4-194b7908d7c6">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjctMy0xLTEtMA_0763d219-233b-4d44-b18e-e9f087e35ff7">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjgtMS0xLTEtMA_edc16784-25cd-4397-a2b0-49707ea441ae">118,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjgtMy0xLTEtMA_46cde1c1-dc2f-4cf0-96e0-824420663f8e">71,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjktMS0xLTEtMA_266f07ae-1ead-4b55-a0b1-8f89e740f247">408,237</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjktMy0xLTEtMA_cf8741b0-d1d9-4ba1-8208-3418878aba5c">292,084</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMzAtMS0xLTEtMA_fa9ea149-731a-4db6-aa09-b937e402fd6f">451,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMzAtMy0xLTEtMA_ff9a4a09-301d-486d-98d0-6f474d1bd850">310,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy0xLTEtMS0w_fe2a29ad-7464-457e-9e43-fca0af9b720c">6,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy0zLTEtMS0w_d8ba9ffe-a303-42ac-b915-ad8c22e75923">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy01LTEtMS0w_9f8f5113-880f-45a0-8f79-5ce3049a0df6"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy01LTEtMS0w_d4d4d113-fa8b-4e3a-bc21-aa803829aa3d">18,875</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy03LTEtMS0w_892c1a8e-cd57-47ad-97b7-7ac389f98aed">12,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC0xLTEtMS0w_dd55ed5d-d137-48f4-811f-d4c3894650c6">9,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC0zLTEtMS0w_b0071b0a-5e83-430d-8d7f-aca75f165a32">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC01LTEtMS0w_af9d19af-e2a0-499d-a610-7d057552e5af"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC01LTEtMS0w_e13bf50c-bcfc-441f-b2eb-fae190676ef9">27,524</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC03LTEtMS0w_e6e5f78d-28fe-4753-adbd-14fc94699a5e">10,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNS0xLTEtMS0w_02c85a43-3fbf-49ef-9d0b-82166d4795e3">15,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNS0zLTEtMS0w_2cd4cc33-d6d8-4ae2-b8b6-12aa7376bacb">9,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNS01LTEtMS0w_f0571c4c-0f53-4b73-862c-caebdc300cbc">46,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNS03LTEtMS0w_e3a8d914-beaf-423c-ad39-45dfa72cb57d">22,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNi0xLTEtMS0w_7f661bd5-729e-4e92-b7f9-afe26f2a3aa6">15,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNi0zLTEtMS0w_ad9216b9-f538-4a48-81d0-386a6a7af866">9,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNi01LTEtMS0w_4424ed0a-ce99-48f7-8d7f-dfc683b7665a">46,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNi03LTEtMS0w_535902e2-5a24-472c-a098-96f507c6dde8">22,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOC0xLTEtMS0w_d71d13db-ed0c-4479-85ab-b05100e4e7ba">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOC0zLTEtMS0w_76a46775-42c7-4c9b-af10-b62cf6ecbb12">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOC01LTEtMS0w_a240387c-0333-4411-a245-2ed9f6a71c19">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOC03LTEtMS0w_680c23ba-433d-44ce-89af-0ccc7f1affb9">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOS0xLTEtMS0w_de5ee3de-6a3e-4698-a492-060db19d06dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOS0zLTEtMS0w_2fb91f99-aff7-41a9-b22e-ea2446c0c8dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOS01LTEtMS0w_a1dcb3bb-da22-483d-a7cc-fe33fdab9c85">1,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOS03LTEtMS0w_cc18be20-c75a-4ab6-b159-49a806a35fa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9aa15eaaa2f140849a241da763e04fb2_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTAtMS0xLTEtMA_9e66a2fc-c802-4b87-9d91-006cab7477fb">15,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTAtMy0xLTEtMA_91e9d415-194e-4eae-a090-ce5955599e24">9,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTAtNS0xLTEtMA_cde5e2a9-ede8-4b6f-8975-e5c9af065d2a">47,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTAtNy0xLTEtMA_1dc1c119-58f3-40c5-9ab2-bbde52839a38">21,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3709c8cd63614284a9610906266d0ebd_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtMS0xLTEtMA_c8ac9d4f-8450-4a72-bd4c-4f0b835408a5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtMy0xLTEtMA_1f584842-4939-48e2-ad1f-a1d553318c26">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtNS0xLTEtMA_746d8e84-ee2f-4d8e-945a-6eb9de278cbc">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtNy0xLTEtMA_2e4c8c5f-f8ff-4fd8-a63e-c26cda204ef5"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtNy0xLTEtMA_b7e18a63-2d97-4226-a467-443d21db5127">10</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTItMS0xLTEtMA_73388789-d1be-45fd-a389-bbce19180b14">15,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTItMy0xLTEtMA_39e46218-69b7-4162-8365-654501a33ce4">9,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTItNS0xLTEtMA_91d4131a-89c8-4d26-930a-cd78954215d9">47,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTItNy0xLTEtMA_6296ca81-58d8-4e78-9911-462aea1f5e0c">21,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share:<br/>&#160;&#160; Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtMS0xLTEtMA_17b2fbbe-1f7a-44d8-ac3e-909aed7dd4f0"><ix:nonFraction unitRef="usdPerShare" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtMS0xLTEtMA_423563c4-81da-4a12-89ff-2ed76a196941">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtMy0xLTEtMA_79db09d9-1e2e-40e6-b10c-c9fc9963857b"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtMy0xLTEtMA_d33fbc29-30c4-4ffe-993e-8194a8c382b1">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtNS0xLTEtMA_38ff4121-f25c-416a-b68f-e2514a9f3863"><ix:nonFraction unitRef="usdPerShare" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtNS0xLTEtMA_c1998dc7-3a7c-4607-bbab-86957a5b8707">2.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtNy0xLTEtMA_65a95427-59b8-4aac-ad89-4df077ff140d"><ix:nonFraction unitRef="usdPerShare" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtNy0xLTEtMA_adc0e817-035d-46f9-8a21-973a8d758a44">1.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:<br/>&#160;&#160; Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtMS0xLTEtMA_879543fa-1c2e-4470-880f-eba17b0757d8"><ix:nonFraction unitRef="shares" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtMS0xLTEtMA_88afa434-aadf-41c3-91a5-df18717863e3">22,212,266</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtMy0xLTEtMA_5ddecceb-ad9b-43e5-acef-14776f2d213e"><ix:nonFraction unitRef="shares" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtMy0xLTEtMA_6f19be9c-5461-4ae9-8f31-d8b0eeaae9be">19,676,016</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtNS0xLTEtMA_921b9ab1-503c-4c26-a490-7eacc952cf2b"><ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtNS0xLTEtMA_f87a75ea-9796-44f8-bc1e-8d0d467bfb31">21,893,656</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtNy0xLTEtMA_50811767-fee5-4889-b9fc-f75624086dd0"><ix:nonFraction unitRef="shares" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtNy0xLTEtMA_c9a0d0a1-d67b-463e-bc58-0c5a8e36f35a">18,477,495</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.022%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2061c660b06d4c9bbc11d16373c8f063_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy0xLTEtMS0w_b207b2bd-0f45-43f5-b13d-d1b6f8324449">19,714,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2061c660b06d4c9bbc11d16373c8f063_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy0zLTEtMS0w_9ecebf68-50d9-4697-8699-cd7f393a4f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191055abec7b4144af0047f02b74e20e_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy01LTEtMS0w_2e0ba060-f45c-425e-ad83-4fc626e91486">363,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae7f575f30640149beff34d2c2f617e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy03LTEtMS0w_4745af09-9f68-4126-9ab1-19e358e37471">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i321a84171d8a42ae87ecd9326ac313d4_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy05LTEtMS0w_e25b37ff-a7bf-4274-8d63-3efb61f10e46">71,214</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy0xMS0xLTEtMA_dd4fde96-a9d0-4052-8267-fe9496814b5a">292,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40e7561237f64188bc3c6ef3786ea8c5_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNC0xLTEtMS0w_2f639208-265b-4a5b-a5f9-8d301e772f20">2,489,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d79a58b3e124f8a93f15786db349364_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNC01LTEtMS0w_c3a39ca3-7f87-4ac2-83c5-864f1b281bcd">152,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7988751036404fc89eab96bb474330c9_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNC0xMS0xLTEtMA_7359dbd2-0768-4b0e-bca5-39e43c1a8bbc">152,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d79a58b3e124f8a93f15786db349364_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNS01LTEtMS0w_22cffb2a-ef8a-4fdc-86f0-75cc5fbc5aa6">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7988751036404fc89eab96bb474330c9_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNS0xMS0xLTEtMA_b8ece724-122c-4b2e-8f49-b54fd3e000cb">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b21bf40faac4746a6d98991f9063b5f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNi03LTEtMS0w_0a70c12d-43fb-477c-824a-c4594080b085">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7988751036404fc89eab96bb474330c9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNi0xMS0xLTEtMA_2718da50-d5dc-41d0-808e-11dbb6deca06">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a9c5a9d8dcc4e6ea4fd5c9f8e96d621_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNy05LTEtMS0w_61df2195-d19e-4905-b2ec-ba7d52d3d86e">15,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7988751036404fc89eab96bb474330c9_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNy0xMS0xLTEtMA_f40a58c2-232f-4672-89f3-ee47c5fc0a31">15,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4aad2be9b4df4f7090d2f00cce76d403_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC0xLTEtMS0w_565ea254-dcad-459e-9f6c-accc4f5a3a74">22,204,057</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aad2be9b4df4f7090d2f00cce76d403_I20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC0zLTEtMS0w_c3b799ea-d149-4f71-a278-39fe4cab74bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ec7da3b1424b85a57097d6c554f644_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC01LTEtMS0w_9f2f28ee-84b6-4079-ab90-51d55f2ce340">517,675</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4555af1344b5488aaea0d72479cf0596_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC03LTEtMS0w_18647436-9ac3-4a50-ab5e-0d152ddf6102">3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b7bf6f5591b46edaa5e23d7d6b6d15b_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC05LTEtMS0w_b2c5f318-63fe-40f1-aaf0-c2bad724e0d3">87,026</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc922e8a45e4864948e7e52a210bbfe_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC0xMS0xLTEtMA_7450bc7e-04f3-46e7-8800-03d6f2a997ce">430,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c8a7560e4e7401cb82d7df6b06ca5d8_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOS0xLTEtMS0w_9b01587e-0834-4b0f-9445-8ac4437f0cce">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27020da178fa4cab8a2ad787440d1369_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOS01LTEtMS0w_96ebb8f4-9253-415a-9b14-8dde13bd0d36">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOS0xMS0xLTEtMA_86c61755-0481-442f-8e46-308770197a37">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27020da178fa4cab8a2ad787440d1369_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTAtNS0xLTEtMA_b9732ecf-b08d-450b-b568-5c9f156740a8">4,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTAtMTEtMS0xLTA_7878a4eb-e97f-4cc2-ba96-451b94a6c921">4,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44581efe982d4dff9526f3d982194139_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTEtNy0xLTEtMA_ce8be204-4ff4-4071-a0fd-a46872674bda">24</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTEtMTEtMS0xLTA_12cd6d21-9daa-4843-833c-c39ec9c140a1">24</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f8d1355d9204ec8b58c5c853065bc30_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTItOS0xLTEtMA_2b707a4a-0fcb-4e37-b934-d3d23fed861e">16,363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTItMTEtMS0xLTA_dcc46401-347f-44d7-81d8-bd1ec0aa2773">16,363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id45a96a79a604c8db109413461f12acf_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtMS0xLTEtMA_19d391ab-3060-499a-b39d-622d1db29cfd">22,205,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id45a96a79a604c8db109413461f12acf_I20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtMy0xLTEtMTAwNDk_4aeee7e9-bb87-446b-9cfb-d1be15aeacd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39b992f7893b4bac997ab34d477d4884_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtNS0xLTEtMA_752da646-7327-4266-b9b1-9ca3130a8c00">521,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe11ab4cb70e4898bed01c9fa46af4c0_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtNy0xLTEtMA_aeab23f1-060a-4427-a472-efbf1a80ccd3">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a155eabc104ac39191d0d03971f31d_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtOS0xLTEtMA_63da5448-333e-4c8d-8f3a-9f1129fad223">103,389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic296d4384977465fb82b5010ed0ea42f_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtMTEtMS0xLTA_1df0411a-dfaa-4289-9821-fc7a90d0164e">418,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e0ff4743b9f46b8b6897b102789984d_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTQtMS0xLTEtNzcwNw_9d016f56-919b-460a-8041-42c092442bf1">32,952</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfb9569024b4ddcba80967d823d97b7_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTQtNS0xLTEtOTQxNw_b9a419af-bc4f-475e-bf7f-d157c0c8beb6">1,534</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTQtMTEtMS0xLTEwMDIw_60c652f1-cfbb-463d-810a-23ffeb4d8c65">1,534</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfb9569024b4ddcba80967d823d97b7_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTUtNS0xLTEtNzcwNw_4cc72d6f-f9ea-48ef-8a74-2bc6ce33c955">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTUtMTEtMS0xLTEwMDIw_3d167049-3aef-43c0-9615-ca2e77503a01">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3709c8cd63614284a9610906266d0ebd_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTYtNy0xLTEtNzcwNw_c7dd6c78-9da5-4091-8997-89843e215d08">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTYtMTEtMS0xLTEwMDIw_6355b8d1-4769-457e-8d84-f75afa2258b6">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9aa15eaaa2f140849a241da763e04fb2_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTctOS0xLTEtNzcwNw_020bf5fa-6cce-4d64-8d3e-d377cd9b3d6e">15,589</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTctMTEtMS0xLTEwMDIw_b13afb01-736b-413e-841f-c910d0f5f168">15,589</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fa9f713e891499cbfa3fc8da6fec325_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtMS0xLTEtOTM4NA_33ee4668-d91b-437d-88a5-c40a40eb1ad1">22,237,984</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa9f713e891499cbfa3fc8da6fec325_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtMy0xLTEtMTAwNTU_d18ca903-6846-4892-8349-3da86fcc5b53">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic524439cfc7a482999097af4b55a5fd7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtNS0xLTEtOTM5Nw_8ccbba26-9122-4a01-86c4-29da29e0324c">527,229</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48b5190d89144635b7cdcb97ae657284_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtNy0xLTEtMTAwNTU_f75395ac-9c57-45f1-a8b3-69e4a622126f">14</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0ff72fb3da4a59a200925afcdc7e65_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtOS0xLTEtOTM4OA_0ed63630-6687-49ca-a917-a529f5b4da44">118,978</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtMTEtMS0xLTkzODY_2e8d56fd-ceec-4172-9efd-bafde48be1c0">408,237</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.022%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9a04a026e0f40dfa4a678165d4d3da9_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy0xLTEtMS0w_a373afc4-6638-42a3-8394-97629e02525d">17,354,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a04a026e0f40dfa4a678165d4d3da9_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy0zLTEtMS0w_7b30e982-debe-4127-aa26-64d83e363470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabae1d6edcd44228a05c3a846d30a2a3_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy01LTEtMS0w_82c723b8-3d75-4e28-8e5e-c8402b577a4d">241,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3172719de6407c94ec038f29804c92_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy03LTEtMS0w_efb11455-dfcd-4687-b428-3cdf6898b2d2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06802d6ce84540babb361a9ca632edf7_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy05LTEtMS0w_ca40ff9f-b677-4119-992c-1f7511dfe00b">39,047</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc0520a90d14ee7bc0c963570c38886_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy0xMS0xLTEtMA_013d2576-8927-4064-8a71-826cb5d64a9a">202,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia85bc9503824447aacbf3a433d92baa0_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNC0xLTEtMS0w_c4882511-7f9d-499a-bac9-f2151ba82920">16,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049d3f1f3d9c468bbc710632bed69c2e_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNC01LTEtMS0w_80425348-513c-4fbf-bd63-dbcc61e59d69">243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNC0xMS0xLTEtMA_e5623ac0-b272-44e5-9e35-bc8bcc12d0f5">243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049d3f1f3d9c468bbc710632bed69c2e_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNS01LTEtMS0w_72f31854-2749-4a0f-952f-52132b4ba14f">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNS0xMS0xLTEtMA_6517ba79-df4a-4737-8a94-0c584d87e002">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9af2e9614184f199df0100b95b2f2ef_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNi03LTEtMS0w_9ef0885e-88c4-4cc3-82a0-95be5082df26">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNi0xMS0xLTEtMA_fd0f0346-af87-41c3-9228-bb7eb2c80e6f">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74071e3de9484ae09acb8eb907fb8765_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNy05LTEtMS0w_f91a203b-482c-4854-8a6b-e00137192f58">5,341</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNy0xMS0xLTEtMA_b9bd453b-3159-4249-8852-05983963469d">5,341</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide40bf231fce4273bf66acd14c1d53cc_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC0xLTEtMS0w_5e212b6e-7e99-4d7b-9dbe-1956ce1037d6">17,370,564</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide40bf231fce4273bf66acd14c1d53cc_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC0zLTEtMS0w_b0d73435-dce5-4cbc-b836-8a2f10d4a1f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269d31cc46944354be67150726d053a7_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC01LTEtMS0w_bcb5bcbc-6385-45ad-9a08-73b3e2f8929f">242,733</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0dbff202384819bd79871ce53f52a1_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC03LTEtMS0w_f40747a7-eca3-485d-8345-f091622e109f">24</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e82c0f6cdf46378b20a960d57eccfc_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC05LTEtMS0w_d2709aca-7a76-476b-bb39-24fa967ae132">44,388</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21fb4954033b4b0b93ef3aa15fc789ce_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC0xMS0xLTEtMA_e02ffe16-603e-416d-8a08-eede15439fd7">198,369</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i218df3debedb4042ab2ec6698e70d179_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS0xLTEtMS0w_2c933597-ff75-495c-a819-3cc5a9350dec"><ix:nonFraction unitRef="shares" contextRef="i218df3debedb4042ab2ec6698e70d179_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS0xLTEtMS0w_e63e28a0-32d4-454e-8e0e-8b86e18452d4">2,293,495</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633113795b2445609b4d35249439ee5d_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS01LTEtMS0w_2acc8f55-c57f-4857-9e41-5dc73273b8f0"><ix:nonFraction unitRef="usd" contextRef="i633113795b2445609b4d35249439ee5d_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS01LTEtMS0w_984d7363-ea0b-46de-bb81-3a8b0e8015fc">117,337</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS0xMS0xLTEtMA_bc73a28a-9972-43be-8b5a-36e3dc36b5c3">117,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633113795b2445609b4d35249439ee5d_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTAtNS0xLTEtMA_11ff8f55-fc4b-4dd1-8037-1291f367d8c7"><ix:nonFraction unitRef="usd" contextRef="i633113795b2445609b4d35249439ee5d_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTAtNS0xLTEtMA_61f85f37-f5a8-45c0-b0e4-14e44ae548de">807</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTAtMTEtMS0xLTA_6e10dfc5-b567-4467-bb3f-64090ac8a3b8">807</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a07000796ab4a10b2efb0c04206a552_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTEtNy0xLTEtMA_11a2e715-2c2f-43f7-9265-b4ef13a50869"><ix:nonFraction unitRef="usd" contextRef="i7a07000796ab4a10b2efb0c04206a552_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTEtNy0xLTEtMA_579a3377-89a0-4443-8f09-0301b5721f35">16</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTEtMTEtMS0xLTA_62a32ed7-268b-44e6-b4ce-583f56d167b7">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12b693b748af4c179dafe11803d10f9d_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTItOS0xLTEtMA_1ed0bcd2-17e5-496c-85a9-55f3098cc4a3"><ix:nonFraction unitRef="usd" contextRef="i12b693b748af4c179dafe11803d10f9d_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTItOS0xLTEtMA_f98dbcd6-f586-44ef-ada3-df063cc3145d">6,833</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTItMTEtMS0xLTA_d0def37b-3249-40e5-a1b2-b3a28d84156c">6,833</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id56e37cfb5b8493ea7ea61e4a78142b6_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtMS0xLTEtMA_a7ef988d-4f7f-40c4-afa0-0f602afda0f2">19,664,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id56e37cfb5b8493ea7ea61e4a78142b6_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtMy0xLTEtMTAwNTk_7b9fe146-e8a9-4c19-8480-09093cae5b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b3e8282d5e4574a43ae348d5c92c8d_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtNS0xLTEtMA_41b07845-2428-44ef-b2ac-55409eb8b34f">360,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdcb5badd1de447fb11c3b9a221fd47f_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtNy0xLTEtMA_7f613b69-f6f0-4dee-a2ea-4c5c6a36c7e1">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fd8f55248c2407aafd07129677d082f_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtOS0xLTEtMA_46473a37-06f6-424c-bbec-878f69b9a04e">51,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b5967563e74e4aac849273cf4c06b3_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtMTEtMS0xLTA_5e283316-89d8-45eb-b4fc-e9e43e8ffddb">309,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeea9ac7058f4e22bd252caeea9844f2_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTQtMS0xLTEtNzI3NA_c2dbd8c7-8d92-4aa7-8a5d-722af0539140">42,811</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b09cfbea34490790bb69bd5752f88a_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTQtNS0xLTEtNzM5NQ_c8f55f09-7654-4a6b-8e1b-d2d500956553">298</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTQtMTEtMS0xLTEwMDYx_e7da2240-7f3e-4189-9d3d-d696d9152b24">298</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b09cfbea34490790bb69bd5752f88a_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTUtNS0xLTEtNzU0MA_f05e3085-a107-4392-96b8-858bb7852bf1">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTUtMTEtMS0xLTEwMDYx_6a537e27-9adc-4640-bf1b-f873e3f378a5">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee47238ea63d403bbafeb419adbbebcb_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTYtNy0xLTEtNzY3Ng_13ba7eb5-47d4-4083-8dfd-26f01d8099dd">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTYtMTEtMS0xLTEwMDYx_fc54f4c5-636b-4f66-a0ba-a0ad65557e2e">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee384afa0dff40c49580804ce4258745_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTctOS0xLTEtNzY4Mw_11fb5db4-1950-46bc-9004-0cdbf8789971">9,610</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTctMTEtMS0xLTEwMDYx_cf63b851-f474-4e9d-b076-28aab7a01413">9,610</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at September 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc9e27c9f1f0448e9f321a4ae000e86b_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtMS0xLTEtOTM2NQ_cdcb1f74-b87b-4d6d-a49d-518b87acb8ee">19,706,870</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9e27c9f1f0448e9f321a4ae000e86b_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtMy0xLTEtMTAwNTc_d7c8e7bf-53bf-465d-a0cb-8f71fecb5dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32320f6c16064db8acd6e60f9ef524a7_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtNS0xLTEtMTAwNTc_7d146231-a628-429b-8938-7965f152f494">362,531</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe2b33ae24b422a847884207b6bff68_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtNy0xLTEtMTAwNTc_7383f727-70fc-414c-a65f-1a52408339e2">20</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5feb07b8aad34436985280cebd165fd9_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtOS0xLTEtMTAwNTc_449a4406-9bf4-4d4b-9bad-7a5ab7cdf5d5">60,831</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc9353033fe471090a517b829a2055f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtMTEtMS0xLTEwMDU3_d0c264bf-32a1-49db-8339-759fa7fcc5b9">301,720</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMy0xLTEtMS0w_87214abf-384d-4d0d-8d93-1775ecca0150">47,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMy0zLTEtMS0w_005e4dc2-6e29-4741-a7c6-898ffb500ace">21,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNS0xLTEtMS0w_118856f7-7a46-4e7b-8c92-39e39ed8105f">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNS0zLTEtMS0w_c8738636-6460-45ee-adf2-b30a9839dac7">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNi0xLTEtMS0w_75692747-4308-4e5d-9df1-634f1ffbc9a7">10,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNi0zLTEtMS0w_f9513a94-45fc-44a7-b951-c6f2d38ea8c7">2,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposals of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainsLossesOnSalesOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNy0xLTEtMS0w_97d9e6cd-355f-4e66-a8bf-238a81d5fb24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnSalesOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNy0zLTEtMS0w_37bc3f4e-3895-460a-8836-f670c33387d6">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfOC0xLTEtMS0w_4ab11895-18a5-4942-88ba-31612886a0f3">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfOC0zLTEtMS0w_d98018c6-e11b-4443-ad07-a25fa2faf969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTEtMS0xLTEtMA_f1fb9840-4ef1-4b20-bcc7-9d60642279a9">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTEtMy0xLTEtMA_b5cbed93-063b-4c4d-9716-803994361a90">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInPrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTItMS0xLTEtMA_93a7bcc5-bd1c-43ea-8c78-260ad743b624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTItMy0xLTEtMA_a9483f1d-6a5e-4320-b6c8-0cbccec4b43f">2,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTMtMS0xLTEtMA_61f8c1f7-4ae6-4bb7-8a7a-670d77bb2c09">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTMtMy0xLTEtMA_23f0f13b-8fd4-46f4-823d-28003609d45e">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTQtMS0xLTEtMA_3bf7f335-2088-47bc-9189-a5865e087b49">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTQtMy0xLTEtMA_b9fb08e1-84a0-42fe-ba7a-b2fa905ba266">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTUtMS0xLTEtMA_9caf74a8-5f28-47c8-835e-efbb741f2503">6,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTUtMy0xLTEtMA_29cf507b-345f-459c-a68a-f74ddafbe051">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTYtMS0xLTEtMA_b961e20b-bfbb-4eac-9add-5439c0120dbe">27,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTYtMy0xLTEtMA_0cd25e66-9ace-4546-a4c3-145490095317"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTYtMy0xLTEtMA_9f14c9b8-b268-46cf-8de2-fc577fa82026">18,059</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTktMS0xLTEtMA_05a3c897-4d51-489d-95ea-b29a275c57cb">27,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTktMy0xLTEtMA_401d0ea0-c455-429b-b0ca-7f57380b9505">7,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjEtMS0xLTEtMA_e1de27af-770a-4ee0-b6f3-c5703c3c615f">83,810</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjEtMy0xLTEtMA_fd55b527-948c-4d5a-97f2-0fdba420662c">3,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjItMS0xLTEtMA_49ddcbff-402f-4197-aedd-fa21e7727bf9">11,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjItMy0xLTEtMA_d5a73094-6e73-4641-9480-43ec05556b37">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjQtMS0xLTEtMA_78eaba1d-7505-4620-9dde-cb4717568192">100,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjQtMy0xLTEtMA_bd45b505-685e-46d3-88a1-eb55c76dd299">4,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjctMS0xLTEtMA_65102006-047c-4f58-a9b2-8e81f54290ac">153,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjctMy0xLTEtMA_a74a3673-e259-46d3-b462-6a8aa8c2dd6d">117,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of ASTRA build to suit liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:PaymentsForSuitLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjgtMS0xLTEtMA_54cb1d97-c0d4-44c6-8f13-9924e910cd0a">7,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="krys:PaymentsForSuitLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjgtMy0xLTEtMA_7e67dc44-7f18-4d2c-b6d1-92d1e48437c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjktMS0xLTEtMA_801a409a-98b8-464e-9190-36700ff3f415">145,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjktMy0xLTEtMA_9fe1f158-f9ff-4530-a46e-000e809e62ac">117,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzEtMS0xLTEtMA_a4010d8a-c679-4aa2-9798-d4a3401adfcf">18,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzEtMy0xLTEtMA_81f3d8db-4603-4455-82a7-238ed3584ada">94,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzMtMS0xLTEtMA_9c023986-6b99-485c-bc71-f0957611c131">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc0520a90d14ee7bc0c963570c38886_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzMtMy0xLTEtMA_4284d1e2-2061-4722-9b11-0c58f179e64b">187,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzQtMS0xLTEtMA_b8edf62f-9a16-4ebd-aade-c2b878997a15">286,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc9353033fe471090a517b829a2055f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzQtMy0xLTEtMA_89ba8fef-5e89-4bb1-b9f8-db4701310727">282,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzctMS0xLTEtMA_3ab45185-57aa-405a-99bd-234914c2f7c5">23,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzctMy0xLTEtMA_36ea6f2a-408e-4c1d-9345-67f36073add6">3,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid offering costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" name="krys:OfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzgtMS0xLTEtMA_af26ef16-62bd-4c5c-a018-3945693c1f0f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="krys:OfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzgtMy0xLTEtMA_11916686-bb92-442c-b203-5c7017d60879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of right-of-use assets and modification</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzktMS0xLTEtMA_6c14f57b-a117-4c82-b977-1054d767ef64">4,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzktMy0xLTEtMA_4a570d48-1826-4435-b090-84d953b075fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zMS9mcmFnOjkxMWUzMjdjM2ZiODQxYjk4NzJlNzUzYzM4ZWJmMmE1L3RleHRyZWdpb246OTExZTMyN2MzZmI4NDFiOTg3MmU3NTNjMzhlYmYyYTVfMzMzNg_2861aba2-afd4-4c9d-be75-1a19f4c512f0" continuedAt="i30fdbd2330ae4715924ce81dbf48835d" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i30fdbd2330ae4715924ce81dbf48835d"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery for the treatment of serious rare diseases. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy to use, medicines to dramatically improve the lives of patients living with rare diseases.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zMS9mcmFnOjkxMWUzMjdjM2ZiODQxYjk4NzJlNzUzYzM4ZWJmMmE1L3RleHRyZWdpb246OTExZTMyN2MzZmI4NDFiOTg3MmU3NTNjMzhlYmYyYTVfMTcxNw_fe70a343-237b-4423-bfcf-dc4d613590f2">119.0</ix:nonFraction> million. With the net proceeds raised from its public and private securities offerings, including the public offering of its common stock completed on February 1, 2021, the Company believes that its cash, cash equivalents and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zMS9mcmFnOjkxMWUzMjdjM2ZiODQxYjk4NzJlNzUzYzM4ZWJmMmE1L3RleHRyZWdpb246OTExZTMyN2MzZmI4NDFiOTg3MmU3NTNjMzhlYmYyYTVfMTk3OA_aaa0e071-f907-4343-bee4-849722896d2a">343.1</ix:nonFraction> million as of September&#160;30, 2021 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div></ix:continuation><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjE_ca0fa73b-ea5e-4173-821e-fb0fadc98746" continuedAt="i479e65aa6e984a84b77b43728cd1af1e" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i479e65aa6e984a84b77b43728cd1af1e" continuedAt="i838df69d6c654e6eae37076342f0abb5"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjU_cf4dadb1-d734-4d68-adc3-06969c25de21" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended September&#160;30, 2021 and 2020, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, as filed with the SEC on March 1, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i838df69d6c654e6eae37076342f0abb5" continuedAt="i4bb150cf057e4ae5a465432ddf972001"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="krys:RisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjI_444d0a18-fd68-4a45-93ae-3222ee63e27b" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTg_c6149fd9-07a3-4a3b-bb7d-c561eeeaaa48" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTU_64ba7b38-e6d3-446b-870e-a3e01a0d2d71" continuedAt="i2b7d5147b21a4ea89309f0fbee664ecd" escape="true">Segment and Geographical Information</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2b7d5147b21a4ea89309f0fbee664ecd">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in <ix:nonFraction unitRef="segment" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMzczNA_6dcb7a91-7144-4c88-80e5-b3745f595234">one</ix:nonFraction> operating segment, which is the business of developing and commercializing pharmaceuticals.</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjM_04522fca-94dc-4245-960e-891b01b70ad5" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjY_96249dfd-4a77-45f6-998b-25a0b3166e3a" continuedAt="i62bb78080a0f43b7b0d60e9071a3f296" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i62bb78080a0f43b7b0d60e9071a3f296">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i4bb150cf057e4ae5a465432ddf972001" continuedAt="i49bd558322084646a0d0f4486ddcaff9"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTY_b67b042f-eaed-4c40-b796-2bafafdc14b3" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjQ_ede074b1-5a66-4a82-b6e8-737a121bf94e" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="krys:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTk_940ad529-cd93-4435-99fb-a3a7b58e7548" continuedAt="ic5ea02a82a5e44a19b9ce3ce282808e4" escape="true">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="ic5ea02a82a5e44a19b9ce3ce282808e4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d755a61291247e5ba23687314064f9e_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RhYmxlOmVhNjYyYjE1YjQ5ZTQ5MmQ5ZWM3NjRmMjI1MWFjNWNhL3RhYmxlcmFuZ2U6ZWE2NjJiMTViNDllNDkyZDllYzc2NGYyMjUxYWM1Y2FfMC0xLTEtMS0w_01bffc98-a17a-48ac-a793-1020a97d2ff9">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7757281c81f42c3a6bb1ee3db3f83e8_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RhYmxlOmVhNjYyYjE1YjQ5ZTQ5MmQ5ZWM3NjRmMjI1MWFjNWNhL3RhYmxlcmFuZ2U6ZWE2NjJiMTViNDllNDkyZDllYzc2NGYyMjUxYWM1Y2FfMS0xLTEtMS0wL3RleHRyZWdpb246ODg0OGRjZTJiODYwNGZlNzlmZDZkMDc4OTA3M2RhZjlfNA_438c5a44-bb8b-4d0e-a546-7b41bf41d3f9">3</ix:nonNumeric> -<ix:nonNumeric contextRef="i167897773af54ee49c97a24df909a026_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RhYmxlOmVhNjYyYjE1YjQ5ZTQ5MmQ5ZWM3NjRmMjI1MWFjNWNhL3RhYmxlcmFuZ2U6ZWE2NjJiMTViNDllNDkyZDllYzc2NGYyMjUxYWM1Y2FfMS0xLTEtMS0wL3RleHRyZWdpb246ODg0OGRjZTJiODYwNGZlNzlmZDZkMDc4OTA3M2RhZjlfOA_8a7f9b0e-e3b0-4274-bbc5-ecbe19840992">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8aa3213055e3456e9e82b846221a93e6_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RhYmxlOmVhNjYyYjE1YjQ5ZTQ5MmQ5ZWM3NjRmMjI1MWFjNWNhL3RhYmxlcmFuZ2U6ZWE2NjJiMTViNDllNDkyZDllYzc2NGYyMjUxYWM1Y2FfMi0xLTEtMS0w_0ed4d033-121d-4108-8417-d6345d8cb209">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5Mjc_796c33da-e769-4c1d-8253-ee643e9ec809" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has <ix:nonFraction unitRef="usd" contextRef="i2a6515d6f7304602a6523f858a283c84_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfOTg5MQ_66e7564e-7e18-44e3-9d20-0c5cd4316de6"><ix:nonFraction unitRef="usd" contextRef="i7c81b84b50ef47a0b86f109e196ba146_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfOTg5MQ_743c5570-cd1c-45fe-98ff-3e86b342b98a"><ix:nonFraction unitRef="usd" contextRef="i8b12af6efb72401a82a1e6a4b4c57dd0_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfOTg5MQ_a6e9b0fb-3615-4c99-8f0c-b7e51b7d031c"><ix:nonFraction unitRef="usd" contextRef="i480d95bb53374899b607426942f95dca_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfOTg5MQ_abe3023e-fecf-4fb2-8d31-61f3540a6043">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognized any impairment losses for the three and nine months ended September&#160;30, 2021 and 2020.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i49bd558322084646a0d0f4486ddcaff9" continuedAt="i254efd7ff163408797c92e755a3e5517"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTc_7fce9385-64d0-427b-b21f-099ef09b192c" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjA_4dfa7576-0587-49eb-b5cd-d05b95af8d88" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5Mjg_be95c7cf-c321-428d-8158-42dab3bfc660" continuedAt="i169433c88c4249ab9c1bb03ee38e5937" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation-Stock Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Due to the lack of sufficient history and trading volume of our Common Stock and a lack of Company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i254efd7ff163408797c92e755a3e5517"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i169433c88c4249ab9c1bb03ee38e5937">Due to the lack of Company-specific historical option activity, the Company has estimated the expected term of its employee and non-employee stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5Mjk_b2718b36-4a23-462e-a33e-aee81e6a3cf1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MzA_bf829481-2325-49ae-b086-bc58115928fc" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.</span></div></ix:nonNumeric></ix:continuation><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RleHRyZWdpb246ODMxMTYyMjVlZDMwNDI1ZmE5ZjkxY2QxMzk2Y2UzNDRfOTU5_5a8d632e-ae5c-453a-a4a0-9b12b2c31082" continuedAt="i576e98db80074940b1fc5b67908bdf02" escape="true">Net Loss Per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i576e98db80074940b1fc5b67908bdf02"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were <ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RleHRyZWdpb246ODMxMTYyMjVlZDMwNDI1ZmE5ZjkxY2QxMzk2Y2UzNDRfNjYz_865a2741-a363-405b-9690-9cdba735a683">1,900,638</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RleHRyZWdpb246ODMxMTYyMjVlZDMwNDI1ZmE5ZjkxY2QxMzk2Y2UzNDRfNjcw_d24cf128-e401-45ae-b3cf-813b61ad8662">853,336</ix:nonFraction> common share equivalents outstanding as of September&#160;30, 2021 and 2020, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RleHRyZWdpb246ODMxMTYyMjVlZDMwNDI1ZmE5ZjkxY2QxMzk2Y2UzNDRfOTU4_7453effc-e7b4-488e-a5ab-669b395b1c76" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:47.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except shares and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9aa15eaaa2f140849a241da763e04fb2_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNC0xLTEtMS0w_9e66a2fc-c802-4b87-9d91-006cab7477fb">15,589</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNC0zLTEtMS0w_8418bee9-b2b2-471c-99a4-8e315b0aad10">9,610</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNC01LTEtMS0w_cde5e2a9-ede8-4b6f-8975-e5c9af065d2a">47,764</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNC03LTEtMS0w_1dc1c119-58f3-40c5-9ab2-bbde52839a38">21,784</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi0xLTEtMS0w_bd0353df-4d85-4173-849c-e9d33b4a6cd5"><ix:nonFraction unitRef="shares" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi0xLTEtMS0w_d07db897-c32a-4c7c-a8e9-5416234e95e1">22,212,266</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi0zLTEtMS0w_152534a7-bc96-44ba-98b1-d863d546af19"><ix:nonFraction unitRef="shares" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi0zLTEtMS0w_29cbdb18-fd5a-4ed0-91db-7c8b443c6d87">19,676,016</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi01LTEtMS0w_921b9ab1-503c-4c26-a490-7eacc952cf2b"><ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi01LTEtMS0w_f87a75ea-9796-44f8-bc1e-8d0d467bfb31">21,893,656</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi03LTEtMS0w_50811767-fee5-4889-b9fc-f75624086dd0"><ix:nonFraction unitRef="shares" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi03LTEtMS0w_c9a0d0a1-d67b-463e-bc58-0c5a8e36f35a">18,477,495</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy0xLTEtMS0w_302908e3-9bfd-417e-95c6-89625efed515"><ix:nonFraction unitRef="usdPerShare" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy0xLTEtMS0w_3ce6b38f-aadc-4243-982d-dcff35690bc8">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy0zLTEtMS0w_53e62097-7cc4-4fba-9f8e-b180d9c048b6"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy0zLTEtMS0w_af45da3f-21b3-4571-b8ea-2c9033881de5">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy01LTEtMS0w_38ff4121-f25c-416a-b68f-e2514a9f3863"><ix:nonFraction unitRef="usdPerShare" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy01LTEtMS0w_c1998dc7-3a7c-4607-bbab-86957a5b8707">2.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy03LTEtMS0w_65a95427-59b8-4aac-ad89-4df077ff140d"><ix:nonFraction unitRef="usdPerShare" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy03LTEtMS0w_adc0e817-035d-46f9-8a21-973a8d758a44">1.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfNTEw_f61d28bb-3008-43ff-8da3-3e1dbc125120" continuedAt="i9374108843fb4abc85f194a2f8328cb1" escape="true">Fair Value Instruments</ix:nonNumeric></span></div><ix:continuation id="i9374108843fb4abc85f194a2f8328cb1"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfNTA5_c1ef7690-3e8d-4daf-8f20-b517c22a9b90" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2021 and December&#160;31, 2020, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab6aacae2304361b0a72c97b35ee627_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNC0xLTEtMS0w_fe8021cc-b4d1-43b1-8d28-cdac38a6dbe7">286,614</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab6aacae2304361b0a72c97b35ee627_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNC03LTEtMS0w_8c889cdb-506d-4b54-bd62-0196ba7a7038">286,614</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc527d5b83e74effaf86ce8c575e458a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNC05LTEtMS0w_0b5b40e8-926e-427b-baea-68daee1f9f7f">286,614</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a05d3b447e84b38864ccb769d5da5fc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNS0xLTEtMS0w_7044a784-2269-4fe5-91f5-82f5ad3d2b16">286,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a05d3b447e84b38864ccb769d5da5fc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNS03LTEtMS0w_e2c8bc77-cd0e-4a89-afcc-06bde235b03b">286,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7336d71fe9424bb2a9bf72b1fab73a2a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNS05LTEtMS0w_7cdba01e-0202-4f09-a8d2-1c62f16b5797">286,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9480bff926bb4e4d8942dbf68b065b31_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC0xLTEtMS0w_de85521e-14b0-4cf3-bee5-68ac0b04ad7a">22,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9480bff926bb4e4d8942dbf68b065b31_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC0zLTEtMS0w_4ac67a0b-78be-401c-a21d-7989e543ce39">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9480bff926bb4e4d8942dbf68b065b31_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC03LTEtMS0w_4a156203-eac5-4814-b6cd-26eb4ceee211">22,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070c705902be4570bce920e02b91537c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC0xMS0xLTEtMA_0309d9c2-cb2e-44df-981c-c3d574d80e16">22,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7a535fd48142c7a5dcda9d399c631a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC0xMy0xLTEtMA_5df74e2a-77d1-44a1-976c-ff4feb9070c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa636ac23904975afc64924b8d01488_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS0xLTEtMS0w_ef69d577-e35c-453d-be79-f44f779ba5c5">37,683</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa636ac23904975afc64924b8d01488_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS0zLTEtMS0w_188092db-a5cb-4fef-9ea1-6ac2639c6096">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifaa636ac23904975afc64924b8d01488_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS01LTEtMS0w_ae0a5d70-e0aa-4cd8-ae99-dda4e0382d21">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa636ac23904975afc64924b8d01488_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS03LTEtMS0w_37f531fe-48bf-4cbd-9306-be1328978eea">37,658</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690f4828e5af45768504fbfe9abf5724_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS0xMS0xLTEtMA_e659977e-fc0c-469d-80a7-ce25f7d85f47">29,465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273373a6ceae4707bb9cc2cdb83bbbff_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS0xMy0xLTEtMA_f75f3fda-525d-4792-b4b0-ef3a1fc0c194">8,193</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab38c37055a4a71b0214378f4574d16_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMS0xLTEtMA_bfd4fdd5-28b2-4e8a-ba4f-83038e2760f2"><ix:nonFraction unitRef="usd" contextRef="i60050340c9ed4f90870cf907d27f9bfe_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMS0xLTEtMA_d867ea85-f9eb-4967-a468-b08d75c20a24">15,567</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60050340c9ed4f90870cf907d27f9bfe_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMy0xLTEtOTE2MA_13f67633-827c-46dd-9212-0ed77276eb1e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60050340c9ed4f90870cf907d27f9bfe_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtNS0xLTEtMA_9bf759cf-703e-46dd-aad0-0f2f5ef9e82a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60050340c9ed4f90870cf907d27f9bfe_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtNy0xLTEtMA_a142b544-e256-4552-9821-dcf2b00ce421">15,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388aa2cdde1b460b8597bdff3339972b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMTEtMS0xLTA_289d9af5-4bc4-479d-aefe-8069ac170b0c"><ix:nonFraction unitRef="usd" contextRef="ibb0b6fc4e57d4890b25ef6de39c2fdd4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMTEtMS0xLTA_5c2495f0-1894-4380-8438-6461b0d395e6">4,522</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia792c56b64d848e8878f44d2d236a376_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMTMtMS0xLTA_e52005de-9fd9-49c0-9084-445c9899c311">11,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b82a410df0441049ce87afb941806cc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtMS0xLTEtMA_d8d6e673-9b97-4ac2-b6ac-cddddf1f982d">75,740</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b82a410df0441049ce87afb941806cc_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtMy0xLTEtMA_f1f4fd8f-6c49-4d52-9cba-436fadbbb45f">5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b82a410df0441049ce87afb941806cc_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtNS0xLTEtMA_b4212426-5b3a-4e2a-bcf4-a68795f08e3f">29</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b82a410df0441049ce87afb941806cc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtNy0xLTEtMA_7d91fa44-0c2d-4d7b-ab59-39c0d282253f">75,716</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cf6e72bd844925bb9e2348bf8f610b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtMTEtMS0xLTA_63d4f0e4-ecec-4087-bd91-ab80f2ed8034">56,479</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3d137419ce48cea5dcac2591a043e3_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtMTMtMS0xLTA_107f7ce5-ba37-4fd2-ab61-c7b646168dd9">19,237</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItMS0xLTEtMA_0b822786-fe8b-4316-8855-28978496dd12">362,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItMy0xLTEtMA_e9170931-f060-440d-b63d-fec25298a276">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItNS0xLTEtMA_fbd2593e-05b0-4ad5-a114-f6b104312ffa">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItNy0xLTEtMA_b53f66df-e890-4094-863d-5f099e15cb9b">362,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d97ca6150480d87ec6af171de89fb_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItOS0xLTEtMA_96b12b1e-32ca-459a-ae1a-83e3e537505b">286,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2eb16e1cce408fa52eed5e879feb37_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItMTEtMS0xLTA_f035b468-7c40-408d-bee5-afb42117caef">56,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide270ebcff6b4424baa910b00caf1be1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItMTMtMS0xLTA_f83f18fe-aecf-4f33-9050-1ae5e3faf6d8">19,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:22.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92b64b50e3f47dd88ac7a91d623e520_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMy0xLTEtMS0w_fe80a5ff-6135-4d24-9c64-a6a3c3c9b79f">268,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92b64b50e3f47dd88ac7a91d623e520_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMy03LTEtMS0w_0d2d204c-38d9-4bbc-aa9b-3c6a4997868f">268,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i459ec248d46840ba8f88fd2b1cb42941_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMy05LTEtMS0w_6a7b939d-1d5c-49e1-8c25-05430a8b2b10">268,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i751bd4c59343464787b18cf531e5ba6f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNS0xLTEtMS0w_753c30ce-31dc-40d3-8473-24a1db32d4ba">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i751bd4c59343464787b18cf531e5ba6f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNS03LTEtMS0w_8e286d9d-a348-4ea7-a023-b397e9ae0baf">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f22c8a22b747dc8c7ef55057b16a94_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNS05LTEtMS0w_e0707dbe-cbcd-478f-b0da-55c890a84c1d">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2214f04c270c4e8e98c8dcb8e54f8278_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy0xLTEtMS0w_6f4b3f4c-1e20-4e16-b13f-f8a53698b1ff">2,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2214f04c270c4e8e98c8dcb8e54f8278_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy0zLTEtMS0w_039dc931-0253-481d-8307-cd747d8678d6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2214f04c270c4e8e98c8dcb8e54f8278_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy03LTEtMS0w_e67d1677-e9c8-42df-87f8-ac29a4bf2200">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443bbe79aab14ee3afae2ad98fc04529_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy0xMS0xLTEtMA_6f806c7a-81d6-4493-9db6-cb3f4f9c1953">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe2739a8ded43368c826619c379d66f_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy0xMy0xLTEtMA_a9ebee2d-de07-40e9-a5d8-39f54156db37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12454311b50448ccaea121ba9277c57f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtMS0xLTEtMA_9e1eb2b0-1e55-4e29-97e3-35ffef278a7e">2,986</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12454311b50448ccaea121ba9277c57f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtMy0xLTEtMA_b2806112-cccf-4a0b-b018-298bb8736272">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12454311b50448ccaea121ba9277c57f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtNy0xLTEtMA_b3161fa1-a65c-43d9-a018-978015a38204">2,993</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8ad72123e9462a98dbf3e4ec7a9939_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtMTEtMS0xLTA_0416c5f5-7650-4972-aa7d-0847d109af5f">2,993</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a40d442dc8b42cf817bdc09ed7f53ce_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtMTMtMS0xLTA_20915829-a654-4fc5-a385-0d80af94004f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItMS0xLTEtMA_805c5aad-2b42-4eef-94bf-a67083bd1d1f">271,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItMy0xLTEtMA_79e60c3a-4d26-4b62-9ff1-66512b09c28d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItNy0xLTEtMA_e8ba7788-ee68-43e7-92d1-a930c5a558e5">271,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36fabffff72949f4b082a440b13e4c81_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItOS0xLTEtMA_ab3c9b16-a0e7-4159-b4b5-45622577281a">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68505d0a06e4e8f8922085fadd5bf59_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItMTEtMS0xLTA_4cf389b2-b929-40bc-b296-7f368e88d47c">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2eca019dc0c428095839c77f4815829_I20201231" decimals="-3" format="ixt:fixed-zero" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItMTMtMS0xLTA_67ce7189-b9b7-4a92-acce-d37854a913bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in <ix:nonNumeric contextRef="id7cf6e72bd844925bb9e2348bf8f610b_I20210930" format="ixt-sec:durwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfMjcy_c7c66446-21d8-41d9-aedf-108efba87494">one year</ix:nonNumeric> or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between <ix:nonNumeric contextRef="i4d6178f3db244647aae1348be50ad904_I20210930" format="ixt-sec:durwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfMTA5OTUxMTYyODI4OA_9d09c9bd-ca9f-497a-8768-e199234dd235">one year</ix:nonNumeric> and <ix:nonNumeric contextRef="i8a2da3d7596b4625832ab659cb505863_I20210930" format="ixt-sec:durwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfMzU4_b02cd64b-3674-4540-969c-1ca48fa67cd7">two years</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMzgw_ef21118e-5335-47a4-be92-e39d34fe7efb" continuedAt="icbe2b405d4a74dce808ca7f2325d720e" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="icbe2b405d4a74dce808ca7f2325d720e"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMzgx_5cb2bd64-8733-4c76-aee2-4249d4bfc307" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58cb6e2879a24124bd2b0493f3c58a56_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfMi0xLTEtMS0w_6b35ecb7-3828-46e6-89d2-3ffc31cd3199">70,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491c64c69c5740d9a40094969e3b6070_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfMi0zLTEtMS0w_d8127067-5a46-48ea-8429-592d36709e0e">23,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df18665bd86458f8795c8e7043272a1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfMy0xLTEtMS0w_382112d8-a645-461b-8b74-cefb91f3058f">5,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf127646e3d4429283df0e2fb130d95b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfMy0zLTEtMS0w_f87acc61-9662-4636-aeda-b33c9359fbf4">4,631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77390b63e8b461882829e033c650015_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNC0xLTEtMS0w_55ed84c7-5c5a-4ec1-b746-5f87ee3ce4e8">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a9e853ed55449bae567c7f13b9c39f_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNC0zLTEtMS0w_3a34c3c5-7e87-47c3-832a-857c182074fe">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7bb1d188c9c42d1af6298345aa0983e_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNS0xLTEtMS0w_471a9c5a-3e56-4715-87f6-64578a5f28e3">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73cfb9402d17457b94e8a0005fcfa94e_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNS0zLTEtMS0w_ddc2a24a-69ad-4bcf-af4c-2df13d567e75">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278e5912864d433589d7d35fd5a102f1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNi0xLTEtMS0w_e53e540e-6450-4bd6-b8e3-27a168dda3df">5,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78abfaea77845eaa82d10a53ce7a880_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNi0zLTEtMS0w_f9a10130-bc8c-4c07-9b13-8a797d472072">4,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNy0xLTEtMS0w_1a2fa103-4bcf-4ce6-941e-c52647eac30f">82,395</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNy0zLTEtMS0w_808b94e3-9437-4454-ab52-d97a228fcd57">33,244</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfOC0xLTEtMS0w_f5031622-1324-43fe-94ba-f304de9571b0">3,753</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfOC0zLTEtMS0w_4a7c882b-867e-4220-8fda-5ed59a1dde8d">2,368</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfOS0xLTEtMS0w_e4195725-2b4f-4048-801d-3852f8054a7b">78,642</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfOS0zLTEtMS0w_8ce935b8-c365-44ac-a7ec-14c16445a136">30,876</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMTU3_d2457f49-e4d8-43fe-948b-82cd3a888dcb">474</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMTY0_a1339a53-ade3-47fb-9d20-a544749a4570">1.4</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMTk4_49943db2-4a95-473f-b8be-87cb2d8a118e">399</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMjA1_10b600bc-a0f9-4ca8-bd56-f311fbee1b92">1.1</ix:nonFraction> million three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMzgy_116c22cd-6634-4604-a761-83fb13d42b1f" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:AccruedPreclinicalAndClinicalExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfMi0xLTEtMS0w_2f071066-2530-48d4-87ea-2648f54172cc">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:AccruedPreclinicalAndClinicalExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfMi0zLTEtMS0w_c5265bba-f0c8-4ea6-bd91-0a14c286553c">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfMy0xLTEtMS0w_403097fd-63d7-4bc8-bdbf-ed473829d531">1,903</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfMy0zLTEtMS0w_aa6ecc1a-ae55-4137-b98f-d04395815721">642</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:AccruedPayrollAndBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNC0xLTEtMS0w_e2bde78c-dec6-4ebc-8eac-6c37f1a37fe7">1,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:AccruedPayrollAndBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNC0zLTEtMS0w_c11ec3f2-e69f-4710-a964-27402fb16d7e">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNS0xLTEtMS0w_e627f735-c7b9-45f0-9f8f-2c75356abd3b">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNS0zLTEtMS0w_6311022d-4886-43ea-a902-b1c729a58445">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:AccruedConstructionInProgressCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNi0xLTEtMS0w_74f15b95-3492-496e-bf43-ac7bc973e29b">22,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:AccruedConstructionInProgressCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNi0zLTEtMS0w_1eb61152-c2bf-45b4-bb9f-e266a357080d">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNy0xLTEtMS0w_85440ac7-2d65-440c-ba84-ab629b30f3cc">447</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNy0zLTEtMS0w_4461e175-0d08-4665-9e63-3bfd1a740fb3">131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfOC0xLTEtMS0w_75aa164c-9961-4668-b9bc-da8945087fd3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfOC0zLTEtMS0w_5f7e832f-2efa-4719-9c3e-41b3b4314c64">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfOS0xLTEtMS0w_c4b7c945-516b-42b5-85cf-d03a7fa4d7c8">29,999</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="krys:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfOS0zLTEtMS0w_8418e689-9e8e-4cc8-bac8-6b7b90c2824d">5,109</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><span><br/></span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTAwNDI_7eac6911-9aab-4953-aea8-d5d9c7787b37" continuedAt="i06ca990bf61b4577b6cdc0b9897fbfc5" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i06ca990bf61b4577b6cdc0b9897fbfc5" continuedAt="ifbca6292b1284636abf6df28363efc40"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and expired on October 31, 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately <ix:nonFraction unitRef="sqft" contextRef="ifc4f34c83c884eb3be6bb60125c76063_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:AdditionalAreaOfRealEstatePropertyLeased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMzYy_7cc21594-3d9a-4e1e-bbfa-c417a04d7a97">44,000</ix:nonFraction> square feet.  As a result of the lease amendments, the lease expiration date was extended to October 31, 2031.  </span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, we entered into a lease agreement for our second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord" or "Northfield") with an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="ifbca6292b1284636abf6df28363efc40" continuedAt="ibd6ef7316fbe4d8abcd66159ab551ee8"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Ground Lease"). A cash contribution in the amount of $<ix:nonFraction unitRef="usd" contextRef="i552d49a6c87f436ebf2aeb62b171e6bc_I20200121" decimals="-5" format="ixt:num-dot-decimal" name="krys:PaymentToEscrowForReducingLeaseRentals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTgxNg_255bc3c9-89b0-4cae-9eb1-f5caf4a55fa2">2.4</ix:nonFraction>&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $<ix:nonFraction unitRef="usd" contextRef="i91240de4fd2c49149368668c1fc1aa2c_D20201015-20201015" decimals="-5" format="ixt:num-dot-decimal" name="krys:PurchasePriceOfPotentialBuildingPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTgzMA_91ca6a9b-31cc-450d-9f63-27ab04e2a7ea">9.4</ix:nonFraction>&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i51817723d8bc4777b149972dc507b6d6_I20201005" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg0NA_837142fb-3067-4260-833f-af05a74d36da"><ix:nonFraction unitRef="usd" contextRef="i51817723d8bc4777b149972dc507b6d6_I20201005" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg0NA_c912095a-0dc1-45f9-b492-b5550ff41dc6">10.0</ix:nonFraction></ix:nonFraction>&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $<ix:nonFraction unitRef="usd" contextRef="i51817723d8bc4777b149972dc507b6d6_I20201005" decimals="-5" format="ixt:num-dot-decimal" name="krys:PaymentToEscrowForReducingLeaseRentals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMjEwNA_1fea3d8c-b4c4-4e6d-ab67-2e8fefe41ed5">2.4</ix:nonFraction>&#160;million.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i91240de4fd2c49149368668c1fc1aa2c_D20201015-20201015" decimals="-5" format="ixt:num-dot-decimal" name="krys:PurchasePriceOfPotentialBuildingPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTc4OA_2c02b7c3-5e06-4eec-8e16-269e6b576568">9.4</ix:nonFraction>&#160;million. The Company held approximately $<ix:nonFraction unitRef="usd" contextRef="i1a7ea7f3f0af418a9798c126d95ba2fb_I20201015" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EscrowDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTgwMg_28321cbc-0a1e-46c6-bbfa-0cfbf0d56bcd">1.5</ix:nonFraction>&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of September&#160;30, 2021. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:LessorOperatingLeaseLiabilityAnnualLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg1OQ_2df5c464-e57c-4551-9229-6cecfc64cc35">82</ix:nonFraction>&#160;thousand, and are subject to a cumulative <ix:nonFraction unitRef="number" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="INF" name="krys:CumulativeEscalationClausePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg3Mw_a25c9c09-2ce5-4c8b-b511-216f814b736d">10</ix:nonFraction>% escalation clause every <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:duryear" name="krys:CumulativeEscalationClauseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg3Nw_43d54d8d-330e-466c-a23b-99af25802541">5</ix:nonNumeric> years through 2071. </span></div><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTAwNDM_3df4527e-ac9f-43ca-8177-2d0c1dc1231d" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:83.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfMS0xLTEtMS0w_1003fb4e-3337-4054-8ea1-d601e91c8b4e">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfMi0xLTEtMS0w_b248d1f0-5812-43bc-a4a4-cc2059760263">1,094</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfMy0xLTEtMS0w_836bb2f4-150a-4503-80ee-d6ce60b6df61">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfNC0xLTEtMS0w_808651e9-b302-411b-8fda-c3f7bad0750c">1,135</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfNS0xLTEtMS0w_3183300d-e6f9-43b4-99ed-052a689b9931">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfNi0xLTEtMS0w_90394464-7fee-4bae-ac38-2d3c8d9f2ec1">12,786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfNy0xLTEtMS0w_384cb42c-7bcb-4d0d-9fe7-fc1240c9eb50">17,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfOC0xLTEtMS0w_4261c4c5-c197-407f-ba12-ea2bdfeb352e">9,444</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfOS0xLTEtMS0w_0a587cbe-d31d-4062-b9a0-15bbedd590b0">8,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTAwNDQ_f8e7f86e-a298-424e-97b5-43d8361d2541" continuedAt="i822ae6bd7d974099becf386436a69d75" escape="true">Supplemental condensed consolidated balance sheet information related to leases is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="ibd6ef7316fbe4d8abcd66159ab551ee8" continuedAt="i4c508e4d736b47bb921e4c0b6a35c0d1"><div style="margin-top:2pt;text-indent:29.25pt"><ix:continuation id="i822ae6bd7d974099becf386436a69d75"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfMy0xLTEtMS0w_596b8690-865f-42a5-96a0-f9ca25229d42">7,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfMy0zLTEtMS0w_fcc41958-ea9f-45a5-b132-2eaf23fdaa0e">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNC0xLTEtMS0w_0a5863b9-538d-4a85-b7da-9ca10311a70e">1,023</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNC0zLTEtMS0w_3c288e23-705f-4f25-984a-68428c12a583">638</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNS0xLTEtMS0w_5f1ed284-a42d-4731-87cf-ad2c3184b540">7,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNS0zLTEtMS0w_0b3b824c-3224-45a1-bc0e-7e2e93b81409">3,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNi0xLTEtMS0w_17dffe06-421c-4f99-b8af-6c2a020c0749">8,102</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNi0zLTEtMS0w_803b9016-a9af-4c03-bccb-2ee7e7e737e6">3,946</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNy0xLTEtMS0w_c55111a7-e7dc-45f4-8b10-03dbe4153bf9">14.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNy0zLTEtMS0w_14370a36-505d-493b-ad76-24166971b201">16.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfOC0xLTEtMS0w_4716ef83-e973-4fea-9a77-d130bbb730b4">9.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfOC0zLTEtMS0w_48152e9d-24df-4065-98a4-3d3e31bf98b2">9.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded operating lease costs of $<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDU5Mg_c81ff07c-797c-4295-9dda-c419921d8da9">339</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDU5OQ_58313833-9309-44a0-ba95-d55d22a1df36">836</ix:nonFraction> thousand for the three and nine months ended September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDYzMw_6ce904c8-c6d0-4332-9256-2be4809491a5">148</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDY0MA_e731d197-9719-4fc1-81f2-d502656c5502">458</ix:nonFraction> thousand for the three and nine months ended September&#160;30, 2020, respectively, and variable lease costs of $<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDcxMw_fe0fe6f4-0273-4fff-be75-1fd28802e542">65</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDcyMA_ceadc5d4-42be-4509-baaa-b1f251a71c6f">183</ix:nonFraction> thousand for the three and nine months ended September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDc1NA_03ee01d1-b6ac-4b9e-9a0b-3b38a3a5cc14">60</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDc2MQ_7b352619-41bf-4a0c-89ef-6f070f23454a">88</ix:nonFraction> thousand for the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various agreements with Contract Manufacturing Organizations (&#8220;CMOs&#8221;) for the manufacture of sterile excipients that are formulated with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. The Company has also entered into agreements with third-party Contract Research Organizations ("CROs") to provide research and development services to further the Company&#8217;s analysis of its product candidates. The agreements entered into with the CMOs and CROs provide the terms and conditions for their respective services, which may include research and development activities, storage, packaging, labelling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of September&#160;30, 2021 under these agreements is approximately $<ix:nonFraction unitRef="usd" contextRef="ibdb3c79bb37d40598236a397bfdf2732_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="krys:RemainingCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNTgwOA_f799c0c9-eb13-4716-95da-34fc9ffa68e8">2.6</ix:nonFraction> million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $<ix:nonFraction unitRef="usd" contextRef="i3b4d91bb10244ecf85e9ff55bf22c6a3_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjAxNw_806b4c23-de2b-4884-8bf1-599a58f278d1">744</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i780d412ff27c4f4fb4ad7befad90ed62_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjAyNA_35c9e12a-be79-4526-9aba-5c2c3f36adfc">3.3</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i7481ea7a3508451e84e2ce446d95a16d_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjA1OA_ae499920-30c6-4c7f-8380-c467ceebb7f0">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae859592e93741fba5e8767be4c58a3f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjA2NQ_23486b3d-c2f7-4bf3-a7c3-df12619fad23">2.3</ix:nonFraction> million for the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate, B-VEC. These contracts typically call for the payment of fees for services upon the achievement of certain milestones.  The estimated remaining commitment as of September&#160;30, 2021 is $<ix:nonFraction unitRef="usd" contextRef="i48eae196563f44c886012909931c2a7d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="krys:RemainingCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjU5OQ_100848db-93f6-4066-ba5e-06e3473315e9">3.9</ix:nonFraction> million. The Company has incurred expenses under these activities of $<ix:nonFraction unitRef="usd" contextRef="i7867867a17654c0bba0b47e105576b16_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjY2Mw_3c352e54-53d9-42a8-b825-370115f4e0fc">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i808f837ef3eb42e09cf35d83a641a5ce_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjY3MA_91691859-50db-46a8-81ff-3a6d0c5c258b">4.1</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ica6cf359423442cda103cac2e7b58836_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjcwNA_fc727774-407d-4f8f-a4e7-116b1add0054">582</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i34e1df8bf9c941ec85693b9f008abbf2_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTY0OTI2NzQ1MzY2OQ_8c29f995-17ae-4ba6-aa38-2bcc82ab69f8">1.1</ix:nonFraction> million for the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2021 is $<ix:nonFraction unitRef="usd" contextRef="icefbb0dcf23b4a9db9500e432e160acd_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTY0OTI2NzQ1Mzc4Mg_a7138087-314c-4b1c-9002-8eb1e68da6b1">39.4</ix:nonFraction> million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to <ix:nonFraction unitRef="number" contextRef="icefbb0dcf23b4a9db9500e432e160acd_I20210930" decimals="INF" name="krys:CostOfWorkPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNzgzOA_f9e94f7a-c7a6-4c22-b996-e2131692d965">1.75</ix:nonFraction>% of the cost of work, subject to a guaranteed maximum price to be agreed upon in an amendment to the Agreement at a later date. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i4c508e4d736b47bb921e4c0b6a35c0d1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $<ix:nonFraction unitRef="usd" contextRef="icae80f11bf7c417fa7f665a031b58b73_I20210913" decimals="-5" format="ixt:num-dot-decimal" name="krys:LossContingencyGuaranteedMaximumPriceToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTY0NDU5Nw_9d6e2133-6fb6-4725-bb44-0908fcafdffb">78.9</ix:nonFraction> million, subject to certain additions and deductions by change orders as provided by the Agreement, and the date of Substantial Completion of Whiting-Turner's work under the Agreement is March 30, 2022. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against us in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and Chief Operating Officer, Krish Krishnan and Suma Krishnan, respectively. The complaint alleges breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserts were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, we filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. On July 29, 2020, PeriphaGen filed its response to our answer and counterclaim, denying the allegations in the counterclaim. On the same day, Messrs Wechuck and Krisky filed a motion to dismiss the third-party complaint on various grounds, and we opposed the motion. On December 1, 2020, the court ruled on Messrs. Wechuck and Krisky's motion to dismiss our third-party complaint. The court determined that our claims for contribution and indemnification based on PeriphaGen's state law claims for unfair competition and misappropriation of trade secrets can proceed. Our breach of contract claim will also go forward in full. Fact discovery is ongoing.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PeriphaGen is seeking monetary damages, injunctive relief, attorneys' fees and costs. While we are unable to provide any assurances as to the ultimate outcome of the case, we believe the allegations in the complaint are without merit, and we intend to vigorously defend against them. We are currently unable to estimate the costs and timing of any litigation, including any potential damages if PeriphaGen were to prevail on its claims.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received insurance proceeds during fiscal year 2021 relating to legal defense costs and expenses associated with the PeriphaGen litigation. During the three and nine months ended September&#160;30, 2021, the Company has received $<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="krys:LossContingencyReceivableReceivedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTY0OTI2NzQ1NDk0MA_1e88f5aa-e6ee-41e7-b173-f29db64c5823">954</ix:nonFraction> thousand of insurance proceeds and an additional $<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyRelatedReceivableCarryingValueAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTY0OTI2NzQ1NDk3Mg_4626f2d6-a856-4b80-9296-e9367825ee78">619</ix:nonFraction> thousand has been approved for reimbursement, which is expected to be received in November 2021 and has been recorded as a receivable within Prepaid Expenses and Other Current Assets on the Condensed Consolidated Balance Sheet as management determined that the amount was probable of collection. The reimbursements have been recorded as an offset to our legal fees included in General and Administrative expenses on the Condensed Consolidated Statements of Operations and within Operating Activities on the Condensed Consolidated Statements of Cash Flows.</span></div></ix:continuation><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTc1OA_616c6645-a03a-4a4f-b622-1d09fafefc12" continuedAt="icb42eace96ed445dae303570af5115a9" escape="true">Capitalization</ix:nonNumeric></span></div><ix:continuation id="icb42eace96ed445dae303570af5115a9" continuedAt="i6398c36d45f24876889f8fbb722ab655"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="ib295489090d1497185afd643ec967a56_D20210201-20210201" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTU2MA_a3e94126-518f-4f7b-88cb-7f04c4a37420">2,211,538</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i1760613e671947e5ba8f0fd15472bece_D20210201-20210201" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTU3MQ_8a106d86-ee24-499f-9238-a51e642a8687">288,461</ix:nonFraction> shares purchased by the underwriters, at $<ix:nonFraction unitRef="usdPerShare" contextRef="i0310113aa0194f0ba193480ce6faf7ef_I20210201" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTU4MA_083aca1e-4be3-409e-8638-cb248d8c5076">65.00</ix:nonFraction> per share.  Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="ib295489090d1497185afd643ec967a56_D20210201-20210201" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMjc1_f80cc1eb-36c9-45bb-9e23-45fb5a795684">134.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="ib295489090d1497185afd643ec967a56_D20210201-20210201" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTU4OA_d4c96043-b2dd-43d8-8b53-02a3510baa3b">8.6</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i2d81be4c0fa64dd0b8e80538f57a09e8_D20210201-20210201" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTY2Ng_6a9a2014-5f58-4443-b66a-cc6c51c88698">198</ix:nonFraction>&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program"), under which Cowen will act as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of our common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i35e810f93dfa47a7ba2d68780daf21d6_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfODIx_2375f7d0-136d-465b-9f3e-d4714fe8cfee">0.0001</ix:nonFraction> per share, having an aggregate offering price up to $<ix:nonFraction unitRef="usd" contextRef="i35e810f93dfa47a7ba2d68780daf21d6_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="krys:SaleOfStockAggregateOfferingPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfODc2_5901cff6-3e8b-499f-9704-bfcc530df5d4">150.0</ix:nonFraction>&#160;million ("Placement Shares").  Related offering expenses payable by the Company were $<ix:nonFraction unitRef="usd" contextRef="i6cea238b09064f7bb11eb8a0267838ee_D20200101-20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfOTU2_306d364d-fb50-4c12-96cd-f3eaae9167fb">172</ix:nonFraction> thousand.  The issuance and sale of the Placement Shares by the Company under the Sales Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form S-3. During the nine months ended September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="ib33152efbe744812957d7c93ebcf8473_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTE4NA_e64e46b3-fe25-4d89-ac8c-9aeeaf9951bf">262,500</ix:nonFraction> shares of common stock were issued pursuant to the ATM Program at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7666a417eef840ce9941f0b9297bde02_I20210930" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTI4MQ_2e2c3e2b-183e-4d63-883f-0c9768a06b72">66.50</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic84fce3d22ab4e95a1361b9dc14e7326_D20210201-20210201" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTY0OTI2NzQ0MzU3MQ_8daa17d2-cb69-4575-980d-c961755825a5">16.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="ic84fce3d22ab4e95a1361b9dc14e7326_D20210201-20210201" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTY0OTI2NzQ0MzY0OA_0eebc9ff-5e04-4048-a2d3-820f6f6cec27">524</ix:nonFraction>&#160;thousand, resulting in a remaining $<ix:nonFraction unitRef="usd" contextRef="ib33152efbe744812957d7c93ebcf8473_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="krys:SaleOfStockRemainingAvailableIssuanceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTM0Mw_2f87982e-386e-4972-bcaa-f519aebbbdd5">132.5</ix:nonFraction>&#160;million available for issuance under the ATM Program.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6398c36d45f24876889f8fbb722ab655">On May 21, 2020, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="i2dacc94700004db9ad609717389032af_D20200521-20200521" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTYwMg_ab98f263-928d-4031-a3e0-8e06867cd014">2,275,000</ix:nonFraction> shares of its common stock to the public at $<ix:nonFraction unitRef="usdPerShare" contextRef="i64975891a997407ba786da1993f9bad1_I20200521" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTYxMw_9c04491f-9907-46e0-a90d-e002e3f78da2">55.00</ix:nonFraction> per share. Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="i2dacc94700004db9ad609717389032af_D20200521-20200521" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTYyMQ_598384da-790d-4957-84a3-5e381de7fe6f">117.2</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i2dacc94700004db9ad609717389032af_D20200521-20200521" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTYzNw_6a492fa4-b3e1-419e-8c36-348645fe0daa">7.5</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i2dacc94700004db9ad609717389032af_D20200521-20200521" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTY1MQ_5a1428a5-387b-4397-b10b-e7e05adc7867">463</ix:nonFraction>&#160;thousand.</ix:continuation></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzI5OQ_1dc3d91e-0e1d-4649-9153-0604de5030cd" continuedAt="i7a2b71a5b56b4b0bad10227afacbad20" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i7a2b71a5b56b4b0bad10227afacbad20" continuedAt="i2dc76748217b44f2b6f3a1ed6b96fb83"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd non-employees ve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st ratably over <ix:nonNumeric contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwMA_c8eed7cf-781b-40bb-a6e2-36c590b3c2ee">four-year</ix:nonNumeric> periods and stock options granted to directors of the company vest ratably over <ix:nonNumeric contextRef="i9d1fbc3d234f4c31903d00f50bd07271_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQ0NQ_1382492f-38ff-4e59-ad4d-0297c4fa5a67">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i5feb93df6b024f7cbfaad880dd55f616_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwMw_b128b803-a0cc-42ff-b507-0b7becafc7b4">four-year</ix:nonNumeric> periods. Stock options have a life of <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjM0_46750a4d-79cd-45f2-af48-8c6278a2a91f">ten years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i01f2bb01dacd44a89c7370650b2b2cca_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjU5_b6234009-3cc4-44fc-b271-a8eb1a89adfd">322,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9d40c5e7efd84df4a8f860d865bd0141_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjY2_11669642-ed56-42a2-8978-a81eb4d7a601">1,122,450</ix:nonFraction> stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2021, respectively, and <ix:nonFraction unitRef="shares" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzc0_a983292b-53aa-459f-b4dd-7f36a9ee0b27">195,850</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzgx_1a276c17-c230-4c5a-a8d6-b90edfdc2ee2">740,250</ix:nonFraction> stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i7e84783b0eec4936825763ed74abe018_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNDc0Nw_b59b36dc-13a2-476f-8c0a-6976ab747683">50,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7444f7d4fc9f40e4b7424b6ec2b0fd54_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjc0ODc3OTA3NDA3MQ_70fe0b57-734a-4af3-bb04-146df43e74f4">zero</ix:nonFraction> stock options to non-employees during the three and nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwMQ_7419c657-2755-47eb-9950-e95e2446d3be" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:38.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMS0xLTEtMS0w_83b843bf-269b-4157-903c-3798c6fe265e">853,614</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMS0zLTEtMS0w_36864415-0903-4aac-bf03-bbe6363cdf51">40.31</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff24ad40df3743eca1aab0a8298c6f52_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMS01LTEtMS0w_2df20362-8ef2-4df2-b7ef-c93418a9e622">9.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMS03LTEtMS0w_2826dac3-f3df-42d7-ac9d-c6694f98c686">16,804</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMi0xLTEtMS0w_e4f7787f-12f5-43b4-ab76-21edd85d7764">1,172,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMi0zLTEtMS0w_dc6ad491-62bc-43e0-b315-76d7bedec0fa">67.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMy0xLTEtMS0w_c4531693-2150-4bf2-8777-35e856aa71c0">49,726</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMy0zLTEtMS0w_c4f23728-cea3-4f78-8d2e-e60ccbc482c9">38.11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNC0xLTEtMS0w_79f42be0-cfee-4dd9-b6d9-241faf78b8e7">172,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNC0zLTEtMS0w_7c8e4e4c-e1a9-4d6c-921f-6ecd155a8f5d">61.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS0xLTEtMS0xMDI1Ng_ee6270ce-3c4e-4003-80c3-5fecbc24b790">2,500</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS0zLTEtMS0xMDI1OA_28836dd3-6889-410c-81b0-4b46d9310a85">78.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS0xLTEtMS0w_4f442bc3-d170-48f6-aeb9-5e5cd1cd1ea4">1,801,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS0zLTEtMS0w_2831a30c-4c6a-4ab8-b7fe-8bb9a6b2aa28">55.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS01LTEtMS0w_c7df0bd1-d980-4de5-8652-ab8dbf2fb38e">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS03LTEtMS0w_7d659cfb-d0f3-42f8-a980-168344680b95">9,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNi0xLTEtMS0w_7579ffa4-f648-49ca-9c8c-8adea6ae8c31">265,843</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNi0zLTEtMS0w_8fddfa5d-4aaf-4bc0-bb47-364d43e9d467">30.02</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNi01LTEtMS0w_5b7a9ffc-dc8c-46b6-8412-52a8b77f7da5">7.4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNi03LTEtMS0w_898fefdd-f465-4e53-8358-55ee4dc684d2">6,087</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2021 and the exercise price of outstanding in-the-money options.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfOTA1_3d2219aa-ab06-4608-bd7d-fb542ae2222b">348</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfOTEy_db12f33c-f1ca-444c-8c27-1b479a3266fd">1.2</ix:nonFraction>&#160;million, respectively, and during the three and nine months ended September&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfOTY4_50b97ef5-dade-496c-807f-ec61f4f8d820">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfOTc1_b10ad57a-ac47-42a5-a1c8-437d6a3bcde3">2.9</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees and directors during the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTExMg_ce4242c4-c1a4-464b-b7ec-0336eecfb212">35.00</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTExOQ_1f8cb51e-cd99-4161-9e8f-ce4841468bb8">43.73</ix:nonFraction>, respectively, and during the three and nine months ended September&#160;30, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTE3NQ_c3e34e53-d007-479e-bc7f-601d2c48319f">27.44</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTE4Mg_c2854862-deba-4fc6-9e42-3836d4337f3b">30.58</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to non-employees during the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e84783b0eec4936825763ed74abe018_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQxNw_46e2d238-5924-47c0-8a80-e26dceb87a69">33.93</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7444f7d4fc9f40e4b7424b6ec2b0fd54_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQyMw_52207225-e9b1-49d7-b9ac-71463b54ba85">33.93</ix:nonFraction>, respectively, and during the three and nine months ended September&#160;30, 2020 was <ix:nonFraction unitRef="usdPerShare" contextRef="if0b83729187442bdba220a841af20bcc_D20200701-20200930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQyNg_a7d93b3d-988c-4aa9-bbff-01232653d672"><ix:nonFraction unitRef="usdPerShare" contextRef="i5eb5f40093234fb2a5fbe54c4b287a17_D20200101-20200930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQyNg_eb6dcc70-8b9c-48b2-9f3c-9683652e7059">zero</ix:nonFraction></ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i60121faa697c4cf4bdba3ea3cb5a3562_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTIxMA_3779fe43-1661-4701-b3cd-d8ec505780a9">51.9</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees and directors&#8217; option awards that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i1c1f98d79c5f4e3aa04f39f090ddce51_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTM2Ng_80158543-fbc5-4092-bafa-c6b9b64e6095">3.3</ix:nonNumeric> years as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i7affc8789534432280b25eb22852bb8c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNjQ4Nw_f2416aa8-bc2e-4e3b-b653-ff1b912e0f6c">1.7</ix:nonFraction> million of unrecognized stock-based compensation expense related to non-employees&#8217; option awards that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNjQ5OA_a24c8823-d170-4149-82b0-6bd34f2e9497">3.9</ix:nonNumeric> years as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwNA_99371ba2-086f-41a5-a8c6-7627294fb623" continuedAt="id02d18044d7b49aaa15b02e8416c55c2" escape="true">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020 as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i2dc76748217b44f2b6f3a1ed6b96fb83" continuedAt="i4883e53957f4496aa8d8791d348640f0"><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:continuation id="id02d18044d7b49aaa15b02e8416c55c2" continuedAt="ib3a40860372b409494301918c506d4f6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:36.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26740af942247b2a3bb8eb3a07f6bef_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfMy0xLTEtMS0w_7bc2f43d-c560-451c-beea-6fdf51810959">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97da03d07b90493f982743fb141e7298_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfMy0zLTEtMS0w_4763c5a9-fa72-474e-9111-ccd5a0e1fb11">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d5be9cd51d4b70b5ec51f29beb8aee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfMy01LTEtMS0w_cca657c2-2058-4a57-bdc8-91f320010980">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8493f9588d450d89ac8a3c4f8dd0bb_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfMy03LTEtMS0w_912ad4e5-cb7f-4fb3-9487-0fa4ce0b9a7b">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a828aba9334f18af2e6159a18dfa2c_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNC0xLTEtMS0w_ad2ef856-8347-4ed4-b052-0ecc8ca96429">2,502</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0e48d0c15d47f7a3586bad35785d87_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNC0zLTEtMS0w_6d762da1-e280-40f0-8f7c-68f33a8ba4da">1,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c821ed52594cc09bc5d3e97fd84ca7_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNC01LTEtMS0w_1cdd1ba5-24cd-4102-ac06-3f65ea1a5df0">6,742</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1224c3cee3aa43cfa95fe86ed4bcfc62_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNC03LTEtMS0w_41e071c3-dcdc-4d80-9499-ebfe759d140e">1,988</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNS0xLTEtMS0w_626dc61a-a413-4f47-9738-71891ab0cf8e">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNS0zLTEtMS0w_c20acc6d-a015-4c70-ab68-5098a138d66b">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNS01LTEtMS0w_d9451063-1339-45de-b512-2bb83a0472e2">9,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNS03LTEtMS0w_90c88b14-ba42-4389-a0cd-3ec8ee32234e">2,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $<ix:nonFraction unitRef="usd" contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTc0NQ_8d07c18e-d8cb-4d92-947c-8a543d33f675">79</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTc1Mg_5b37fbef-45f0-4024-b295-dcb3e4460f84">182</ix:nonFraction>&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2021, respectively, and <ix:nonFraction unitRef="usd" contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTg0OQ_85ef792d-8cdb-4941-8d54-da9400d3295f"><ix:nonFraction unitRef="usd" contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTg0OQ_ace512c4-1d58-4bff-80f9-bc2d9a43f323">zero</ix:nonFraction></ix:nonFraction> of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTk5OQ_e9c671dc-9ab0-4001-a429-3c0f71814fc3">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjAwNg_b3092904-3909-4e18-a87e-5b2f26e43e69">9.0</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjA1NQ_f648c18b-96c1-47ee-af5f-75238b5cf230">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjA2Mg_0ed7e2f8-f300-4f10-ac34-d1b00c221929">2.7</ix:nonFraction> million for the three and nine months ended September&#160;30, 2020, respectively. <ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwNQ_5c6fef0a-5378-4d76-a50d-71ea16c0f98f" continuedAt="i0abf1330a2644985a0332ef9f302515f" escape="true">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2021 and 2020:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:continuation id="i0abf1330a2644985a0332ef9f302515f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMi0xLTEtMS0w_bbb4d48f-339e-4800-96d3-8b43351ca28e">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMi0zLTEtMS0w_f2e25f68-cadd-4154-bd23-8db644592abe">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMi01LTEtMS0w_f94172c6-ddf4-43bb-b965-0a8f1940424f">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMi03LTEtMS0w_069a7568-5c08-45ca-b1bc-d3da85dac8d1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMy0xLTEtMS0w_0dabf538-ddf0-42f2-bfc5-a6a3c2ee79c0">6.23</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMy0zLTEtMS0w_eac853d2-9b45-4b16-bced-d30963b6abdf">6.20</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMy01LTEtMS0w_bb8c98aa-c1e8-4aa5-b3e7-7d1f3e00b328">6.19</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMy03LTEtMS0w_053dbd73-5c07-4108-9ad1-3de8aa653476">6.20</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNC0xLTEtMS0w_dbb33404-306f-4320-a51b-4f5cda0fe44c">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNC0zLTEtMS0w_421ed92a-cff1-4d62-8b1c-5b7dd300c6eb">0.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNC01LTEtMS0w_c045ada8-4359-43b2-a961-a23013d1d5bd">1.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNC03LTEtMS0w_79dba72b-a051-4604-8047-a91089cb67b9">0.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNS0xLTEtMS0w_b96033f2-320e-40a0-8c99-36ddaa878b2f">53.69</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNS0zLTEtMS0w_543078f4-3d4b-4e9d-aee6-d242c2c96e48">41.89</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNS01LTEtMS0w_d32b919a-daf5-41ae-ae5c-8f93cdcfbc18">67.15</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNS03LTEtMS0w_54042fb3-bf56-4fb2-ad55-96e214280410">46.46</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930" decimals="4" format="ixt:fixed-zero" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNi0xLTEtMS0w_7f102c9a-180c-4e8f-988c-6b3dc2a12157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNi0zLTEtMS0w_1fb1cad2-2af4-44f2-ad44-d47338a1f303">10.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930" decimals="4" format="ixt:fixed-zero" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNi01LTEtMS0w_4a4e76db-126b-4d09-81af-ffc3e7e01b91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNi03LTEtMS0w_e18c4aa1-887f-4cb2-bba1-d44ca33b6913">10.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a <ix:nonNumeric contextRef="id4451954ae1a4edab2286b6d5d667fdd_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwNg_579e070b-5d62-42f3-8c53-80fe12a5e06b">four-year</ix:nonNumeric> period. Restricted stock awards have a life of ten years.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjQ3MQ_d956c829-454c-4ac2-84e3-2d214503ddc8">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjQ3OA_76a31096-5883-4cfe-bcbe-6b81feb145ec">98,800</ix:nonFraction> RSAs to employees of the Company during the three and nine months ended September&#160;30, 2021, respectively, and <ix:nonFraction unitRef="shares" contextRef="id703799af79f4f7a929cf79a1de29747_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjU2Mw_1aa8779c-446e-45df-8f54-272db5883ffa"><ix:nonFraction unitRef="shares" contextRef="ia8eaea3be6bb40f18cd2f3f4801f7642_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjU2Mw_bff6776c-e10c-430b-96ff-b8135aaef7b3">zero</ix:nonFraction></ix:nonFraction> RSAs to employees of the Company during the three and nine months ended September&#160;30, 2020. </span></div><ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwNw_39bf9ba5-a17f-4f65-a823-7512cf154027" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSA activity:</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"></td><td style="width:50.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i132e1504fcb94c2395a26312d77352a0_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMS0xLTEtMS0w_a3794d76-3b52-4c64-861d-06fcd1e64310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i132e1504fcb94c2395a26312d77352a0_I20201231" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMS0zLTEtMS0w_2bcd228c-33c0-4ca1-b281-80404e099bb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMi0xLTEtMS0w_206be581-e369-4ba3-b8bc-b77faf9f2a73">98,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMi0zLTEtMS0w_7e56f25f-0e21-4e8c-bd57-9682720b352f">78.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMy0xLTEtMS0w_27e349da-bdf5-430d-8edc-5aa2027532bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMy0zLTEtMS0w_bacf110a-b087-4388-8e11-fae087341868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfNC0xLTEtMS0w_3696343a-2b40-4407-bff3-e8a877b45fdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfNC0zLTEtMS0w_a9b8a249-318f-4c24-907f-dc5676a92622">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib02e0c13ab2041b283dbcc71cc381e44_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfNS0xLTEtMS0w_d52bb82e-5975-4532-b37c-a95e9a75e859">98,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib02e0c13ab2041b283dbcc71cc381e44_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfNS0zLTEtMS0w_24994108-7d51-45c8-9dff-9bf7d6456a24">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><ix:continuation id="ib3a40860372b409494301918c506d4f6" continuedAt="ibed015a34a9a4eec8f21a6b8cbdf2d76"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="ib02e0c13ab2041b283dbcc71cc381e44_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjcxNg_eebb76bb-e029-4e02-a42c-cb749eb722f9">98,800</ix:nonFraction> RSAs were outstanding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock award was $<ix:nonFraction unitRef="usdPerShare" contextRef="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjc4Ng_12422e56-c69e-4e24-b8eb-5aa2aae2837b">78.89</ix:nonFraction> reflecting the closing price of our common stock on the grant date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs of $<ix:nonFraction unitRef="usd" contextRef="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjkzMA_3ef6bc74-e7c6-4506-8f69-24ef4694a509">491</ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjkzNw_9e6fa221-4d48-4385-a6cb-28783a5b6be9">1.2</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively, and <ix:nonFraction unitRef="usd" contextRef="ia8eaea3be6bb40f18cd2f3f4801f7642_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTA5OTUxMTYzMjUwMg_2cb96ea5-7846-4ffe-8e9c-83d226877a8b"><ix:nonFraction unitRef="usd" contextRef="id703799af79f4f7a929cf79a1de29747_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTA5OTUxMTYzMjUwMg_d9681128-3a3f-4f8e-9745-f43833627d1f">zero</ix:nonFraction></ix:nonFraction> for the three and nine months ended September&#160;30, 2020, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):</span></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i4883e53957f4496aa8d8791d348640f0"><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><ix:continuation id="ibed015a34a9a4eec8f21a6b8cbdf2d76"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:35.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24202ad4adbf4f7eab4c44f57bec5ea6_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfMy0xLTEtMS0w_9b5a96a8-0011-492e-9523-63ee04906855">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e866668c45429e8d1f0d8e8b8d3a48_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfMy0zLTEtMS0w_2ac61694-4695-434b-aa1b-3df0c0631d92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61932feef1d64f7bbbc45f3ed5b46e1d_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfMy01LTEtMS0w_a0e4e2f9-1ed9-4f18-9fca-fe46b18b4496">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c4bdc17ee04d84a5123fc95c1f8964_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfMy03LTEtMS0w_d22316e7-9408-4e5e-a7b0-63eb588d74d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfNC0xLTEtMS0w_ef2a1ade-5813-443c-ad4b-89990b2c573c">491</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id703799af79f4f7a929cf79a1de29747_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfNC0zLTEtMS0w_cf12c678-5b90-429b-ab41-133b4c72d442">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfNC01LTEtMS0w_69d1ad25-9fd2-4491-b56c-44f9419e3b5b">1,159</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eaea3be6bb40f18cd2f3f4801f7642_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfNC03LTEtMS0w_1e2fa292-b889-48cb-a584-0fc31490cf63">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares remaining available for grant under the Company&#8217;s stock incentive plan were <ix:nonFraction unitRef="shares" contextRef="id851b0ef34164eb1badf918d62103e06_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzIzOQ_8b83090a-41a5-4376-82db-da373f5d710b">1,381,481</ix:nonFraction>, with a sublimit for incentive stock options of <ix:nonFraction unitRef="shares" contextRef="i84499c680dce48a880d22dfb5d4f52a8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzI5MA_247cf3f1-990d-4f79-8726-980fb09bb909">379,921</ix:nonFraction>, at September&#160;30, 2021.</span></div></ix:continuation><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81NS9mcmFnOmEzZTEyNWM2Y2FmYTRhNzI4ZDQ4NGJjNzRmM2VjZjViL3RleHRyZWdpb246YTNlMTI1YzZjYWZhNGE3MjhkNDg0YmM3NGYzZWNmNWJfMjU5_348b8ae5-1705-43e7-be58-a5c3ad43cc2d" continuedAt="i32c6ce98987a43bcac6c915284d1a0ad" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i32c6ce98987a43bcac6c915284d1a0ad">In December 2019, the Company advanced $<ix:nonFraction unitRef="usd" contextRef="i769dbf11dfe64b2d8b252dbee0ed9486_D20191201-20191231" decimals="-3" format="ixt:num-dot-decimal" name="krys:AdvanceToRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81NS9mcmFnOmEzZTEyNWM2Y2FmYTRhNzI4ZDQ4NGJjNzRmM2VjZjViL3RleHRyZWdpb246YTNlMTI1YzZjYWZhNGE3MjhkNDg0YmM3NGYzZWNmNWJfNzQ_ff4b9941-49e8-4c2c-8fd6-4c866c92b511">420</ix:nonFraction> thousand to a member of our management team to cover the personal payroll and income taxes on their taxable income from NSO exercises. This employee repaid the Company in full in January 2020.</ix:continuation></span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81OC9mcmFnOmYxZjQyMTY0ZTBiMTQ3Zjk4MTEzNzgxZmRmNDA5NzBjL3RleHRyZWdpb246ZjFmNDIxNjRlMGIxNDdmOTgxMTM3ODFmZGY0MDk3MGNfMzcw_c17dafd0-5b80-498a-8c8c-e0a4d33a30b3" continuedAt="i4ee743e9e87d4b07a8b646a2c6d2d41e" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ee743e9e87d4b07a8b646a2c6d2d41e">The Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC, on March 1, 2021.</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Some of such factors include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in expectations with respect to the initiation, timing, progress and results of preclinical and clinical trials for B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and any other product candidates, including the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs and expenses;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing impact that the COVID-19 pandemic and measures implemented to prevent its spread may have on our business operations, access to capital, research and development activities, and preclinical and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope or results of regulatory filings and approvals, including timing of final US Food and Drug Administration (&#8220;FDA&#8221;), marketing and other regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain accelerated or orphan drug designations from the FDA;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our estimates regarding the potential market opportunity for B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and any other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise capital to fund our operations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs associated with our research and development programs for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our general and administrative expenses;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to successfully develop and commercialize our product candidates, including B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop new product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, recruit and retain key personnel;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability of our business model, strategic plans for our business, product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scalability and commercial viability of our proprietary manufacturing methods and processes;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates and gene therapy, in general;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position and our ability to protect and enforce our intellectual property;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations or obtain additional funding;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for or ability to obtain additional financing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ongoing litigation;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully resolve any intellectual property or other claims that have been brought against us to date and may be brought against us in the future;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global economic conditions; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in laws and regulations.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors&#8221; elsewhere in this Form 10-Q and in other filings we make with the SEC from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report. You should read this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Form 10-Q, unless the context requires otherwise, all references to &#8220;Krystal,&#8221; &#8220;the Company,&#8221; we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Krystal Biotech, Inc., together with its consolidated subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery for the treatment of serious rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases.  Our innovative technology platform is supported by in-house, commercial scale cGMP manufacturing capabilities.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our product candidates in various stages of clinical and preclinical development:</span><img src="krys-20210930_g1.jpg" alt="krys-20210930_g1.jpg" style="height:669px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">There can be no assurance that the upcoming milestones will be met on the expected timeline or at all.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Highlights and Recent Developments</span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;B-VEC is a topical gel containing our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL7A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of dystrophic epidermolysis bullosa ("DEB"), a serious rare skin disease caused by missing or mutated type VII collagen protein ("COL7"). The randomized, double-blind, placebo-controlled GEM-3 pivotal study was designed to evaluate topical B-VEC as compared to placebo in DEB patients. On October 25, 2021, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we announced completion of the GEM-3 study, and we expect to announce top line data in 4Q21. Details of the pivotal study can be found at www.clinicaltrails.gov under NCT identifier NCT04491604. During 2Q21, we began enrolling patients into an open label extension ("OLE") study, including patients who participated in the Phase 3 study, as well as new participants who meet all enrollment criteria.  Details of the OLE study can be found at www.clinicaltrails.gov under NCT identifier NCT04917874. Nothing included on this website shall be deemed incorporated by reference into this Quarterly Report on Form 10-Q. On September 9, 2021, we announced that the U.S. FDA approved a compassionate use request from a physician for the use of topical (eye drop) B-VEC in the system of a single DEB patient after undergoing surgical removal of the scarred layer of the cornea. </span></div><div style="padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;KB105 is a topical gel containing our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">TGM1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> transgene for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis ("TGM1-ARCI"), a serious rare skin disorder caused by missing or mutated TGM1 protein. A randomized, placebo-controlled Phase 1/2 study is ongoing. On July 1, 2021, we announced data from the fourth patient dosed in the trial, showing repeat topical KB105 dosing continued to be well tolerated with no adverse events or evidence of immune response. Details of the Phase 1/2 study can be found at www.clinicaltrials.gov under NCT identifier NCT04047732. Nothing included on this website shall be deemed incorporated by reference into this Quarterly Report on Form 10-Q.  </span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;KB407 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the full-length </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CFTR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of cystic fibrosis, a serious rare lung disease caused by missing or mutated cystic fibrosis transmembrane conductance regulator ("CFTR") protein. On September 29, 2021, we announced that the Bellberry Human Research Ethics Committee in Australia granted approval to conduct a Phase 1 clinical study of inhaled KB407 in patients with cystic fibrosis, and trial initiation is anticipated in 4Q21. More detailed data from the Good Laboratory Practice "GLP" toxicology and biodistribution study was presented at the virtual 2021 North American Cystic Fibrosis Conference that took place November 2-5, 2021. </span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;KB408 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SERPINA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene, that encodes for normal human alpha-1 antitrypsin protein, for the treatment of alpha-1 antitrypsin deficiency.  We presented preclinical pharmacology data for KB408 at the European Society of Gene &amp; Cell Therapy Virtual Congress that was held October 19-22, 2021.</span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;KB104 is a topical gel formulation of our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINK5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of Netherton Syndrome, a debilitating autosomal recessive skin disorder caused by missing or mutated SPINK5 protein. We expect to initiate a Phase 1 clinical study in 2022.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also leveraging the ability of our platform to deliver proteins of interest to cells in the skin in the context of aesthetic medicine via our wholly owned subsidiary Jeune Aesthetics, Inc. ("Jeune").  A summary description of Jeune&#8217;s key product candidate and its status is as follows: </span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;KB301 is a solution formulation of our novel vector for intradermal injection designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL3A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene to address signs of aging or damaged skin caused by declining levels of, or damaged proteins within the extracellular matrix, including type III collagen. A Phase 1 study is currently ongoing. On August 2, 2021, Jeune announced the dosing of the first patient in the second Cohort of the PEARL-1 study. This cohort is a randomized, double-blind, saline controlled evaluation of safety and efficacy of KB301 for the improvement of skin quality. Enrollment of this cohort completed in October 2021, and Jeune expects to announce initial data from Cohort 2 in early 2022. Details of the Phase 1 study can be found at www.clinicaltrials.gov under NCT identifier NCT04540900. Nothing included on this website shall be deemed incorporated by reference into this Quarterly Report on Form 10-Q</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeune has several other aesthetic medicine product candidates in various stages of preclinical development.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Highlights and Recent Developments</span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">On September 15, 2021, we announced the appointment of Laurent Goux as the General Manager of Europe.</span></div><div style="padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">On October 12, 2021, we announced a collaboration with GeneDx, Inc., a wholly-owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, to offer no-charge genetic testing for all types of Epidermolysis Bullosa (EB). The goal of the program, called Krystal Decode DEB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, is to help patients with the dystrophic form of this genetic condition, also known as DEB, get a definitive diagnosis sooner, with highly accurate results obtained with a blood or cheek swab sample.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has prompted governments and businesses to take unprecedented measures, such as restrictions on travel and business operations, temporary closures of businesses, and quarantines. In an effort to slow the spread of the virus, The Commonwealth of Pennsylvania where the Company&#8217;s primary offices, laboratory and manufacturing spaces are located, enacted stay-at-home orders, and sweeping restrictions to travel were initiated by corporations and governments. Although these restrictions have been lifted, it is not known at this time whether they will be reestablished or the extent to which the Company will be impacted. The degree of the pandemic&#8217;s effect on the Company&#8217;s clinical, operational and financial performance will depend on future developments, including additional protective measures that may be implemented by governmental authorities or the Company to protect its employees, or by investigators, caregivers or patients to minimize exposure, all of which are uncertain and difficult to predict. While to date the impact of the pandemic on our business and clinical trials has been minimal and the increased vaccination rates in the U.S. are encouraging, we will continue to assess the potential impact of the coronavirus disease ("COVID-19") pandemic on our business and operations, including our supply chain and preclinical and clinical trial activities. For additional information regarding the impact of the coronavirus pandemic, please see "Risk Factor - Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development efforts of our product candidates and adversely impact our business." </span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no approved products for commercial marketing or sale and have not generated any revenue from the sale of products or other sources to date. In the future, we may generate revenue from product sales, royalties on product sales, or license fees, milestones, or other upfront payments if we enter into any collaborations or license agreements. We expect that our future revenue will fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any such payments and sales.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred to advance our preclinical and clinical candidates, which include:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract manufacturing organizations, consultants and other vendors that conduct our preclinical activities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of acquiring, developing and manufacturing clinical trial materials and lab supplies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs, depreciation and other expenses, which include direct expenses for rent and maintenance of facilities and other supplies; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payroll related expenses, including stock-based compensation expense.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense internal research and development costs to operations as incurred. We expense third party costs for research and development activities, such as the manufacturing of preclinical and clinical materials, based on an evaluation of the progress to completion of specific tasks such as manufacturing of drug substance, fill/finish and stability testing, which is provided to us by our vendors.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses will increase as we continue the manufacturing of preclinical and clinical materials and manage the clinical trials of, and seek regulatory approval for, our product candidates and expand our product portfolio. In the near term, we expect that our research and development expenses will increase as we continue with our pivotal Phase 3 clinical trial for B-VEC, conduct our ongoing Phase&#160;1/2 clinical trial for KB105, conduct our phase 1 safety study for KB301 and incur preclinical expenses for our other product candidates. Due to the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration, costs and timing of our clinical trials, and, as a result, the actual costs to complete our clinical trials may exceed the expected costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of professional fees associated with corporate and intellectual property-related legal expenses, consulting and accounting services, facility-related costs and expenses associated with obtaining and maintaining patents. Other general and administrative costs include stock-based compensation and travel expenses.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support the continued research and development of our product candidates and to operate as a public company. These increases will likely include increased </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs for insurance, costs related to the hiring of additional personnel and payments to outside consultants, lawyers and accountants, among other expenses. Additionally, if and when we believe a regulatory approval of our first product candidate appears likely, we anticipate that we will increase our salary and personnel costs and other expenses as a result of our preparation for commercial operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASTRA Capital Expenditures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, we closed on the purchase of the building that was constructed to house our second cGMP facility, ASTRA. We are currently in the process of constructing the interior build-out of this facility and we have entered into a contract with Whiting-Turner who will manage the construction of ASTRA.  Further, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. We expect to continue to incur significant capital expenditures related to ASTRA as we construct and validate this facility, which is expected to be completed in 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of income earned from our cash, cash equivalents and investments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of non-cash interest expense recognized to accrete the build to suit financial obligation to a balance that equaled the cash consideration that was paid upon the close of the purchase of ASTRA.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes during the three and nine months ended September&#160;30, 2021 to our critical accounting policies, significant judgments and estimates as disclosed in our management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended September&#160;30, 2021 and 2020</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.695%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,680&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,652)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,680)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,972)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,589)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,610)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,979)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses&#160;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development expenses increased $980 thousand in the three months ended September&#160;30, 2021 compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended September&#160;30, 2020. Higher research and development expenses were due to an increase in preclinical, clinical and pre-commercial manufacturing activities of $538 thousand, payroll related expenses of $363 thousand, which were primarily driven by an increase in headcount to support overall growth, and includes a $327 thousand increase in stock-based compensation, software related costs of $167 thousand, and other research and development expenses of $191 thousand, primarily due to depreciation and rent. These increases were offset by decrease in outsourced research and development activities of approximately $279 thousand.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $5.0 million in the three months ended September&#160;30, 2021 as compared to the three months ended September&#160;30, 2020. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $3.1 million, which was primarily driven by an increase in headcount to support overall growth, and includes a $2.0 million increase in stock-based compensation, commercial preparedness expenses of approximately $1.2 million, medical affairs costs of $101 thousand, software related costs of $453 thousand, and other administrative expenses of $422 thousand, primarily due to rent and insurance costs. These increases were offset by a decrease in legal and professional fees of approximately $316 thousand, which includes $1.6 million of insurance proceeds.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the three months ended September&#160;30, 2021 and 2020 was $63 thousand and $70 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine Months Ended September&#160;30, 2021 and 2020</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.695%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,399&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,820)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,764)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,784)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,980)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses&#160;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development expenses increased $6.6 million in the nine months ended September&#160;30, 2021 compared to the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September&#160;30, 2020. Higher research and development expenses were due to an increase in outsourced research and development activities of approximately $2.0 million, preclinical, clinical and pre-commercial manufacturing activities of $1.8 million, payroll related expenses of $1.9 million, which was primarily driven by an increase in headcount to support overall growth, and includes a $1.6 million increase in stock-based compensation, travel related expenses associated with our clinical trial sites of $199 thousand, software related costs of $212 thousand, and other research and development expenses of $611 thousand, primarily due to depreciation and rent.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $17.2 million in the nine months ended September&#160;30, 2021 as compared to the nine months ended September&#160;30, 2020. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $9.0 million, which was primarily driven by an increase in headcount to support overall growth, and includes a $5.9 million increase in stock-based compensation, commercial preparedness expenses of approximately $2.2 million, medical affairs costs $437 thousand, software related costs of $715 thousand, legal and professional fees of approximately $3.6 million which includes $1.6 million of insurance proceeds, insurance costs of $408 thousand, and other administrative expenses of $768 thousand, primarily due to rent.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the nine months ended September&#160;30, 2021 and 2020 was $127 thousand and $795 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the nine months ended September&#160;30, 2021 and 2020 was $1.5 million and zero, respectively, and related to accretion of the financial obligation for the build to suit lease liability during the nine months ended September 30, 2021 to a balance that equaled the purchase consideration for ASTRA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, our cash, cash equivalents and short-term investments balance was approximately $343.1 million. Since operations began, we have incurred operating losses. Our net losses were $15.6 million and $9.6 million for the three months ended September&#160;30, 2021 and 2020 and $47.8 million and $21.8 million for the nine months ended September&#160;30, 2021 and 2020, respectively. At September&#160;30, 2021, we had an accumulated deficit of $119.0&#160;million. With the net proceeds raised from its public and private securities offerings, including the public offering completed on February 1, 2021 and the ATM Program, the Company believes that its cash, cash equivalents and short-term investments as of September&#160;30, 2021 will be sufficient to allow the Company to fund its operations for at least 12 months from the filing date of this Form 10-Q. </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. Furthermore, we expect to incur increasing costs associated with operating as a public company, meeting financial controls, satisfying regulatory and quality standards, maintaining product and clinical trials, and furthering our efforts around our current and future product candidates. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to clinical trials can be unpredictable and therefore there can be no guarantee that we will have sufficient capital to fund our continued clinical studies of B-VEC, KB105, KB301 or our planned preclinical studies for our other product candidates, or our operations.  Further, we do not expect to generate any product revenues until 2022, at the earliest, assuming we receive marketing approval for B-VEC on the schedule we currently contemplate. While we are in the process of building out our internal vector manufacturing capacity, some of our manufacturing activities will be contracted out to third parties. Additionally, we currently utilize third-party contract research organizations to carry out our clinical development activities. As we seek to obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses as we prepare for product sales, marketing, manufacturing, and distribution. Our funds may not be sufficient to enable us to conduct pivotal clinical trials for, seek marketing approval for or commercially launch B-VEC, KB105, KB301 or any other product candidate. Accordingly, to obtain marketing approval for and to commercialize these or any other product candidates, we may be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, if at all. Our failure to raise capital when needed could have a negative effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs for preclinical and clinical materials, third party clinical trial research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs.  In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, manufacturing, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timeline and cost of our pivotal Phase&#160;3 clinical trials for B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing, results and costs of our ongoing Phase 1/2 clinical trials for KB105;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, results and costs of our Phase 1 clinical trials for KB301;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of manufacturing of B-VEC for our pivotal Phase 3 clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued development and the filing on an IND application for future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of maintaining our own commercial-scale cGMP manufacturing facilities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the manufacturing process development and evaluation of third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, in the event we receive marketing approval for our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities for our current and future product candidates if we receive marketing approval for such product candidates we may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current license agreements remaining in effect and our achievement of milestones under those agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and licenses on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we&#160;acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will need to obtain substantial additional funding in order to receive regulatory approval and to commercialize our product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely affect our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves.&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,230)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,964)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,345&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,855&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September&#160;30, 2021 was $27.0&#160;million and consisted primarily of a net loss of $47.8&#160;million adjusted for non-cash items primarily of depreciation and amortization and stock-based </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation expense of $12.2&#160;million and build to suit interest expense of $1.5 million, as well as increases in net operating liabilities of approximately $7.1&#160;million.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September&#160;30, 2020 was $18.1&#160;million and consisted primarily of a net loss of $21.8&#160;million adjusted for non-cash items of depreciation and amortization and stock-based compensation expense of approximately $4.1&#160;million, and decreases in net operating liabilities of approximately $371 thousand. </span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September&#160;30, 2021 was $100.2&#160;million and consisted primarily of expenditures of $27.5&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $83.8 million on the purchase of short-term and long-term investments, partially offset by proceeds of $11.0&#160;million received from the maturities of short-term investments.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September&#160;30, 2020 was $5.0&#160;million and consisted primarily of purchases of $3.2&#160;million of short-term available-for-sale investment securities, and expenditures of $7.6&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, partially offset by proceeds of $5.9&#160;million received from the maturities of short-term investments.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September&#160;30, 2021 was $145.6&#160;million and consisted primarily of proceeds of $153.6&#160;million received from our public offering, ATM Program and exercises of stock options, partially offset by expenditures of $8.0&#160;million used for the purchase of the ASTRA building. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021 the Company completed a public offering of 2,211,538 shares of its common stock at $65.00 per share. Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million and other offering expenses of approximately $198&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, pursuant to the ATM Program the Company issued 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting underwriting discounts and commissions of approximately $524&#160;thousand. The Company also incurred $172 thousand of other offering expenses related to the ATM Program. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2021, the Company received proceeds of $1.9&#160;million&#160;from the exercise of stock options.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September&#160;30, 2020 was $117.9&#160;million and was primarily from proceeds from our public offering in May 2020 of 2,275,000 shares of our common stock to the public at $55.00 per share.  Net proceeds to the Company from the offering were $117.2&#160;million after deducting underwriting discounts and commissions of approximately $7.5&#160;million and other offering expenses of approximately $463&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements&#160;as defined in the rules and regulations of the SEC.</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020 other than as described in Note 6 &#8220;Commitments and Contingencies&#8221; of our condensed consolidated financial statements on this Form 10-Q.</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;the JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Beginning with our fiscal year ending December 31, 2022, we will cease to be an emerging growth company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qualitative and Quantitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and short-term investments of $343.1 million at September&#160;30, 2021, which consist primarily of money market, bank deposits, commercial paper, corporate bonds, and government agency securities. The investments in these financial instruments are made in accordance with an investment policy which specifies the categories, allocations and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments in which we invest could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include cash, cash equivalents and short and long-term investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Based on our current investment portfolio, we do not believe that our results of operations or our financial position would be materially affected by an immediate change of 10% in interest rates.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and short-term investments has significant risk of default or illiquidity. While we believe our cash, cash equivalents and short-term investments do not contain excessive risk, we cannot provide absolute assurance that any investments we make in the future will not be subject to adverse changes in market value. Our cash, cash equivalents and short and long-term investments are recorded at fair value.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span><br/></span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and our Chief Accounting Officer, with the participation of other members of the Company&#8217;s management, have evaluated the effectiveness of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Accounting Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of implementing new enterprise resource planning software, Microsoft Dynamics D365 (&#8220;Dynamics&#8221;), as part of a plan to integrate and upgrade our systems and processes. The implementation of this software is scheduled to continue in phases over a number of years. During the second quarter of 2021, we completed the implementation of the financial reporting and consolidation modules. During the third quarter of 2021, we completed the implementation of the procurement modules. As the phased implementation of this system occurs, we expect certain changes to our processes and procedures which, in turn, will result in changes to our internal control over financial reporting. We expect Dynamics to strengthen our internal financial controls by automating a number of accounting and reporting processes and activities, thereby decreasing the number of manual processes previously required. Management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as discussed above, no change in our internal control over financial reporting occurred during the quarter ended September&#160;30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_94"></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading &#8220;Legal Proceedings&#8221; in Note 6 of the Notes to Condensed Consolidated Financial Statements included in Item 1 of Part I of this Form 10-Q is incorporated by reference in response to this item.</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred recurring losses and negative cash flows from operations and, at September&#160;30, 2021, we had an accumulated deficit of $119.0&#160;million. Our ability to achieve profitability depends on our ability to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize our products candidates. We do not anticipate generating revenues from product sales for the next year, if ever. We have devoted substantially all our efforts to date to research and development of our gene therapy product candidates as well as to building out our infrastructure. We expect that it could be at least a year, if ever, before we have a commercialized product candidate. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our research and the clinical development of B-VEC, KB105, and KB301 including our current clinical trials and planned future trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate clinical trials for KB104, KB407, KB408 and preclinical studies for any additional product candidates that we may pursue in the future;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prepare our Biologics License Application ("BLA"), Marketing Authorisation Application and approvals in certain other countries for B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to operate our in-house commercial-scale cGMP manufacturing facility, ANCORIS, and complete the build out of our second cGMP manufacturing facility, ASTRA;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture material for clinical trials or potential commercial sales;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our gene therapy product candidate portfolio;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approval for B-VEC and additional product candidates in the European Union (&#8220;EU&#8221;) and in other key geographies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize one or more product candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing the clinical trials for our product candidates, developing and validating commercial scale manufacturing processes, obtaining marketing approval for our product candidates, manufacturing, marketing and selling any product candidates for which we may obtain marketing approval and satisfying any post-marketing requirements. If we were required to discontinue development of any of our product candidates, if any of our product candidates do not receive regulatory approval, if we do not obtain our targeted indications for our product candidates or if any of our product candidates fails to achieve sufficient market acceptance for any indication, we could be delayed by many years in our ability to achieve profitability, if ever, and this would materially adversely affect our business prospects and financial condition. Moreover, if we decide to leverage any success with our B-VEC, KB105, KB301, KB104 or KB407 product candidates to develop other product opportunities, we may not be successful in such efforts, and our business could be materially adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have three product candidates, B-VEC, KB105, and KB301 in clinical trials and we may never develop, acquire or in-license additional product candidates. We may never succeed in any or all these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause investors to lose all or part of their investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product and biological development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the European Medicines Agency ("EMA"), or other regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of B-VEC, KB105, and KB301 our expenses could increase and revenue could be further delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional funding in order to receive approval for our other product candidates. Such funding may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complete the process of obtaining regulatory approval for our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding. In addition, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. We anticipate that we may need additional funding to complete the development of B-VEC, KB105, KB301 and any future product candidates and to commercialize any such approved products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing, results and costs of our Phase 3 clinical trials for B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing, results and costs of our Phase 1/2 clinical trials for KB105;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing, results and costs of our Phase 1 clinical trials for KB301;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued development and the filing of investigational new drug ("IND") applications for KB104, KB407, KB408 and other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of building and maintaining our own commercial-scale cGMP manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the manufacturing process development and evaluation of third-party manufacturers, if necessary;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities for our current and future product candidates if we receive marketing approval for B-VEC, KB105, KB301 or any other product candidates we may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements, if any;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current license agreements, if any, remaining in effect and our achievement of milestones under those agreements; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. Our product candidates, if approved, may not achieve commercial success. Our product revenues, if any, will be derived from or based on sales of product candidates that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Furthermore, existing stockholders may not agree with our financing plans or the terms of such financings. Adequate additional financing may not be available to us on acceptable terms, or at all. The terms of additional financing may be impacted by, among other things, general market conditions, the market&#8217;s perception of our product candidates and growth potential and the market price per share of our common stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development-stage company that commenced operations in 2016. Our efforts to date, with respect to the development of our product candidates have been limited to organizing and staffing our company, business planning, raising capital, developing our vector platform and related technologies, identifying potential gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. While we have conducted clinical trials of B-VEC, KB105, and KB301, we have not yet demonstrated the ability to complete clinical trials of any of our product candidates, obtain marketing approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success, performance or viability may not be as accurate as they could be if we had more experience developing gene therapy products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We will need to transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business interruptions resulting from the coronavirus disease 2019 ("COVID-19") outbreak or similar public health crises could cause a disruption of the development efforts for our product candidates and adversely impact our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks could adversely impact our business. The COVID-19 pandemic is evolving, and to date has led to the implementation of various mitigation responses, including government-imposed quarantines, travel restrictions and other public health safety measures, as well as leading to reported adverse impacts on healthcare resources, facilities and providers across the United States and in other countries. The extent to which COVID-19 impacts our operations or those of our third-party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions to contain COVID-19 or address its impact in the short and long term, among others.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, timely initiation and completion of planned clinical trials is dependent upon the availability of, for example, clinical trial sites, researchers and investigators, regulatory agency personnel, and materials, which may be adversely affected by global health matters, such as pandemics. We plan to conduct clinical trials in geographies that are currently being affected by COVID-19.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we or governmental authorities were to modify or implement restrictions, our employees conducting research and development or manufacturing activities may not be able to access our laboratory or manufacturing spaces, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some factors from the COVID-19 pandemic that could delay or otherwise adversely affect the completion of our preclinical activities and the planned initiation of our clinical trials for our investigational drug product candidates, as well as our business operations generally, include:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential diversion of healthcare resources away from the conduct of preclinical activities and clinical trials to focus on pandemic concerns, including the availability of necessary materials and the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on travel that could interrupt key preclinical and clinical trial activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions, quarantines, or vaccine mandates that will impact the ability or willingness of patients, employees or contractors to travel to our research, manufacturing and clinical trial sites or secure visas or entry permissions, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact our ability to conduct preclinical and clinical activities as well as product approval timelines;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our business operations by local, state, or the federal government that could impact our ability to conduct our preclinical or clinical activities, including completing our IND-enabling studies or our ability to select future development candidates; and interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product candidates and conditioning drugs and other supplies used in our prospective clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in receiving, key materials from our suppliers and vendors due to staffing shortages, travel limitations, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in manufacturing our product candidates at our manufacturing facility in Pittsburgh or receiving supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, travel limitations, production slowdowns or stoppages and disruptions in delivery systems; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business disruptions caused by potential office, manufacturing and laboratory closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations, cyber security and data accessibility, or communication or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees, manufacturing sites, research sites and other important agencies and contractors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors arising from COVID-19 could adversely impact our ability to conduct clinical trials and our business generally and could have a material adverse impact on our operations and financial condition and results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. Further, conditions in the bank lending, capital and other financial markets may deteriorate as a result of the pandemic such that our access to capital and other sources of funding may be constrained.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The extent to which the outbreak may impact our business, preclinical studies and planned clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions and other actions to contain the outbreak or address its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and address the disease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a development-stage company. If we are unable to advance our product candidates through clinical trials, obtain regulatory approval and ultimately commercialize our product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development stage company, and B-VEC entered its first clinical trial in May 2018, KB105 entered its first clinical trial in September 2019, and KB301 entered its first trial in August 2020. The development and commercialization of our product candidates are subject to many uncertainties, including the following:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment and completion of clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive results from our current and planned future clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of regulatory approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful development of our internal manufacturing processes on an ongoing basis and maintenance of our existing arrangements with third-party manufacturers for clinical supply;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercial launch of our product candidates, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our lead candidate, B-VEC, is still in clinical development, and there is no guarantee that the results from preclinical studies will be indicative of our ability to complete or the results to be obtained in the current Phase 3 clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced positive interim results from the Phase 1 portion of our Phase 1/2 clinical trial of B-VEC in October 2018 and positive interim results from the Phase 2 portion in June 2019, and complete Phase 1/2 results in May 2020.&#160;&#160;We commenced Phase 3 clinical trials for B-VEC in July 2020. There is no guarantee that results of this or any potential future clinical trials will be positive or that we will be able to complete this or any potential future clinical trials on the anticipated timelines, or at all. The positive results we have observed for B-VEC may not be predictive of the ultimate outcome of any future clinical trials, and the current and future clinical trial process may fail to demonstrate that B-VEC is safe for humans and effective for indicated uses, which may cause us to abandon B-VEC. Furthermore, research and discoveries by us or others may identify serious adverse events, undesirable side effects or other unexpected properties of our current and future product candidates, including B-VEC, that could delay, prevent or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize B-VEC and the approval may be for a narrower indication than we seek.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if B-VEC meets its safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority or policy during the period of product development, clinical trials and the review process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a post-approval safety monitoring program. Regulatory authorities may require precautions or contra-indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of B-VEC. Any of the foregoing scenarios could materially harm the commercial prospects for B-VEC and materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B-VEC is based on a novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial requirements of the FDA, EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied product candidates. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either the United States or the EU or how long it will take to commercialize our product candidates. Approvals by the European Commission may not be indicative of what the FDA may require for approval, and approval by the FDA may not be indicative of what the European Commission would require for approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements and policy governing gene and cell therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. If we were to engage a National Institutes of Health funded institution to conduct a clinical trial, that institution&#8217;s Institutional Biosafety Committee as well as its Institutional Review Board (&#8220;IRB&#8221;), would need to review the proposed clinical trial to assess the safety of the trial. Similarly, the EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of B-VEC or future product candidates or lead to significant post-approval limitations or restrictions. As we advance B-VEC, we may be required to consult with these regulatory and advisory groups and will need to comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of B-VEC. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B-VEC may cause undesirable side effects or have other properties that could delay or prevent its regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several significant adverse side effects in gene therapy trials using other vectors in the past. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. The risk of cancer remains a concern for gene therapy, and we cannot assure that it will not occur in any of our planned or future clinical studies. There also is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. If any such adverse events occur with B-VEC, our clinical trials could be suspended or terminated. If we are unable to demonstrate that such adverse events were caused by the administration process or related procedures, the FDA, the European Commission, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, B-VEC for any or all targeted indications. Even if we can demonstrate that any serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of B-VEC, the commercial prospects may be harmed and our ability to generate product revenues may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if B-VEC receives marketing approval, the FDA could require us to adopt a post-approval safety monitoring program to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by B-VEC, several potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend or withdraw approvals of B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way B-VEC is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of B-VEC and could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in our clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the drug candidate for its intended indications. Clinical trials are expensive, time consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching a consensus with regulatory authorities on trial design;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in opening sites and recruiting suitable patients to participate in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or concerns with a class of drug candidates, or after an inspection of our clinical trial operations or trial sites;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrence of serious adverse events associated with the drug candidate that are viewed to outweigh its potential benefits; or</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we make manufacturing or formulation changes to a product candidate, we may need to conduct additional studies to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could limit our potential revenue or impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects. Any delays, setbacks or failures in our clinical trials could materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our drug candidates, we may:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval, if at all, or be required to conduct additional confirmatory safety and/or efficacy studies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be required to perform additional clinical trials to support approval;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be sued; or</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience damage to our reputation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we, the FDA or an IRB, may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#8217;s current Good Clinical Practice regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our IND applications or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our drug candidates could be negatively impacted, and our ability to generate revenues from our drug candidates may be delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited number of employees and limited corporate infrastructure and may experience difficulties in managing growth.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a small company with a limited number of employees and corporate infrastructure. We have experienced a period of significant expansion in headcount and expect to experience significant expansion of our facilities, infrastructure and overhead as we develop our own manufacturing facilities and increase our research and development efforts. Future growth will impose significant added capital requirements, as well as added responsibilities on members of management, including the need to identify, recruit, maintain and integrate new personnel. Our future financial performance and our ability to compete effectively will depend, in part, on our ability to manage any future growth effectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain any regulatory approval for B-VEC, our lead product candidate, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for B-VEC may also be subject to a post-approval safety monitoring program, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. Our current and each of our proposed clinical trials for B-VEC includes a five-year, long-term follow-up phase, limited to confirmed data collection from annual visits with standard care physicians. The holder of an approved BLA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or a regulatory authority disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of B-VEC or any future product candidate, a regulatory authority may:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue a warning letter asserting that we are in violation of the law;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrict the marketing or manufacturing of the product;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain the product or otherwise require the withdrawal of the product from the market;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to permit the import or export of product candidates; or</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize B-VEC or any future product candidates and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of B-VEC or any future product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may have obtained and we may not achieve or sustain profitability, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">While we have obtained orphan drug designation for B-VEC, KB105 and KB407, it may not effectively protect us from competition, and we may be unable to obtain orphan drug designation for our future product candidates. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates before us, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2017, the FDA granted orphan drug designation to our lead product candidate, B-VEC, for the treatment of DEB. On April 16, 2018, the European Commission granted the Orphan Medicinal Product Designation for B-VEC. On August 7, 2018, the FDA granted orphan drug designation to our second product candidate, KB105, currently in clinical development for treatment of patients with TGM1-deficient autosonmal recessive congenital ichthyosis ARCI, and on October 10, 2019, the European Commission granted the Orphan Medicinal Product Designation for KB105.  On August 17, 2020, the FDA granted orphan drug designation to our most recent product candidate, KB407, currently in preclinical development, for the treatment of cystic fibrosis. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the European Commission, upon a recommendation from the EMA&#8217;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than 5 in 10,000 persons in the EU. Additionally, orphan designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biologic product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and 10 years in the EU. The exclusivity period in the EU can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we have obtained orphan drug exclusivity for B-VEC, KB105 and KB407, that exclusivity may not effectively protect the product candidates from competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the EU, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the second applicant can establish in its application that its medicinal product, although like the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the holder of the marketing authorization for the original orphan medicinal product cannot supply enough quantities of orphan medicinal product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough therapy designation, Regenerative Medicine Advanced Therapy ("RMAT") designation, Fast Track designation or Rare Pediatric Disease designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that any of our product candidates will receive marketing approval in the United States.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted Fast Track designation in the United States for B-VEC on May 23, 2018 and for KB105 on October 24, 2019. In addition, B-VEC was granted RMAT by the FDA on June 21, 2019 and Priority Medicine (&#8220;PRIME&#8221;) by the EMA in March 2019. The receipt of any of these designations for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA and EMA procedures and does not assure ultimate approval by either the FDA or EMA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A RMAT/PRIME therapy product candidate is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease. Drugs designated as RMAT therapies by the FDA are eligible for accelerated approval and increased interaction and communication with the FDA designed to expedite the development and review process. If a drug, or biologic in our case, is intended for the treatment of a serious or life-threatening condition and the biologic demonstrates the potential to address unmet medical needs for this condition, the biologic sponsor may apply for FDA Fast Track designation. Even after having received Fast Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many biologics that have received Fast Track designation have failed to obtain approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. We received the designation of &#8220;rare pediatric disease&#8221; for B-VEC in December 2016, for KB105 in August 2018, for KB104 in April 2019, and for KB407 in September 2020, which could qualify us to receive a Rare Pediatric Priority Review Voucher.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance we will receive RMAT, PRIME or breakthrough therapy or Fast Track designations for any of our product candidates and the receipt of any of these designations for a product candidate may not result in a faster development process, review or approval and does not assure ultimate approval by the FDA. Further, even though we have received rare pediatric disease designation for B-VEC, KB105, KB104 and KB407, we may not experience a faster review or approval for a subsequent marketing application.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited financial and managerial resources. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts focuses on the potential approval of B-VEC, KB105, KB301, KB104, KB407 and KB408 a key component our strategy is to discover, develop and potentially commercialize a portfolio of product candidates to treat orphan diseases and ultimately, non-orphan diseases. Identifying new product candidates requires substantial technical, financial and human resources, whether any product candidates are ultimately identified. Even if we identify product candidates that initially show promise, we may fail to successfully develop and commercialize such product candidates for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the research methodology used may not be successful in identifying potential product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our product candidates obsolete;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in identifying and developing additional product candidates, our potential for growth will be impaired.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully market or commercialize our lead product candidate, B-VEC or any future product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several companies and institutions that are currently developing alternative autologous or palliative gene therapy approaches for DEB and cystic fibrosis. Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidate that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly or earlier than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render B-VEC or any future product candidate uneconomical or obsolete, and we may not be successful in marketing B-VEC or any future product candidate against competitors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, even if we commercialize a product candidate faster than our competitors, we could also face competition from lower cost biosimilars in the United States or in Europe.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of the expiration or successful challenge of our patent rights, we could face litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any product candidate that we may develop and commercialize.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in obtaining regulatory approvals of the process and facilities needed to manufacture our product candidates or disruptions in our manufacturing process may delay or disrupt our product development and commercialization efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can begin to commercially manufacture our product candidates, whether in a third-party facility or in our own facilities, we must pass a pre-approval inspection of our manufacturing facilities by the FDA before our product candidates can obtain marketing approval. A manufacturing authorization must also be obtained from the appropriate EU regulatory authorities. The timeframe required for us to obtain such approvals is uncertain. To obtain approval, we will need to ensure that all our processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that we may develop.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing process used to produce our product candidates is complex, novel and has not been validated for commercial use. In order to produce enough quantities of our product candidates for future clinical trials and initial U.S. commercial demand, we will need to increase the scale of our manufacturing process. The production of our product candidates requires processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we employ multiple steps to control our manufacturing process to assure that the process works and that our product candidates are made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we have established our own manufacturing facility for our product candidates, we may need to utilize third parties to conduct our product manufacturing for the near future. Therefore, we are subject to the risk that these third parties may not perform satisfactorily.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain the validation from the FDA of our cGMP manufacturing facility, we intend to maintain third-party manufacturing capabilities in order to provide multiple sources of supply. In the event that these third-party manufacturers do not successfully carry out their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements or if there are disagreements between us and these third-party manufacturers, we will not be able to complete, or may be delayed in completing, the preclinical studies required to support future IND submissions of product candidates or the clinical trials required for approval of our product candidates. In such instances, we may need to locate an appropriate replacement third-party manufacturer, which may not be readily available or on acceptable terms, which would cause additional delay or increased expense prior to the approval of our product candidates and would thereby have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our third-party manufacturer fails to comply with applicable cGMP regulations, the FDA and foreign regulatory authorities can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate or suspension or revocation of a pre-existing approval. Such an occurrence may cause our business, financial condition, results of operations and prospects to be materially harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of biologics manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our ability to produce our product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development timelines and our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to expand our market development capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any product revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a small market development organization. To successfully commercialize our product candidates, if approved, we plan to expand our capabilities to promote market access and build awareness. To successfully commercialize any products that may result from our development programs, we will need to further expand our market development organization, either on our own or with a third party. The development of our own market development team will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may enter into collaboration agreements regarding any of our product candidates with third parties to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any future collaborators do not commit sufficient resources to commercialize our products, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded medical affairs, marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our potential products. If any of our product candidates is approved but fails to achieve market acceptance among physicians, patients or third-party payors, we will not be able to generate significant revenues from such product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our gene therapy product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy remains a novel technology. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well- publicized adverse events, including cases of leukemia and death seen in trials using other vectors. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our product candidates are smaller than we believe they are, our product revenues may be adversely impacted, and our business may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have mainly focused our research and product development efforts to date on B-VEC for DEB. Our understanding of both the number of people who have this disease, as well as the subset of people with this disease who have the potential to benefit from treatment with B-VEC, are based on estimates in published literature. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of this disease. The number of patients in the United States, the EU and elsewhere may turn out to be lower than expected or these patients may not be otherwise amenable to treatment with B-VEC or may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there are several factors that could contribute to making the actual number of patients who receive B-VEC less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets. Further, the severity of the progression of a disease up to the time of treatment will likely diminish the therapeutic benefit conferred by a gene therapy due to irreversible cell damage. Lastly, certain patients&#8217; immune systems might prohibit the successful delivery of certain gene therapy products to the target tissue, thereby limiting the treatment outcomes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethical, social and legal concerns about gene therapy could result in additional regulations restricting or prohibiting our product candidates. Even with the requisite approvals from the FDA in the United States, the EMA in the EU and other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on the acceptance of physicians, patients and health care payors of gene therapy products in general, and our product candidates in particular, as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of gene therapy products and our product candidates, if approved for commercial sale, will depend on several factors, including:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety of our product candidates as demonstrated in clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential and perceived advantages of our product candidates over alternative treatments, if available;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of our product candidates relative to alternative treatments, if available;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which our product candidates are approved by the FDA or the EMA;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians to prescribe new therapies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of competitive products;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of products and their ability to meet market demand;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity concerning our product candidates or competing products and treatments;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">favorable third-party payor coverage and adequate reimbursement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates, if approved, which would adversely affect our revenue and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that coverage and reimbursement of pharmaceuticals may be increasingly restricted both in the U.S. and internationally. The escalating cost of health care has led to increased pressure on the health care industry to reduce costs. Drug pricing by pharmaceutical companies recently has come under increased scrutiny and continues to be subject to intense political and public debate in the U.S. and abroad. Government and private third-party payors have proposed health care reforms and cost reductions. A number of federal and state proposals to control the cost of health care, including the cost of drug treatments, have been made in the U.S. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. In some international markets, the government controls the pricing, which can affect the profitability of drugs. Current government regulations and possible future legislation regarding health care may affect coverage and reimbursement for medical treatment by third-party payors, which may render our product candidates, if approved, not commercially viable or may adversely affect our anticipated future revenues and gross margins.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, future price controls or other changes in pricing regulation or negative publicity related to the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our products, which would adversely affect our anticipated revenue and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our products, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford our product candidates. Accordingly, sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Coverage and reimbursement by a third-party payor may depend upon several factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If coverage and reimbursement are not available, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are available only at limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be adequate to realize a sufficient return on our investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. In the United States, third-party payors, including government payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare and Medicaid programs increasingly are used as models for how private payors and government payors develop their coverage and reimbursement policies. Currently, no gene therapy product has been approved for coverage and reimbursement by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the agency responsible for administering the Medicare program. It is difficult to predict what CMS will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these types of products. Moreover, reimbursement agencies in the European Union may be more conservative than CMS. For example, several cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European Union Member States. It is difficult to predict what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations generally are subject to extensive government price controls and other market regulations and increasing emphasis on cost-containment initiatives in the European Union, Canada and other countries may put pricing pressure on us. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. It also can take a significant amount of time after approval of a product to secure pricing and reimbursement for such product in many counties outside the United States. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable product revenues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by government and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Payors increasingly are considering new metrics as the basis for reimbursement rates, such as average sales price, average manufacturer price, and actual acquisition cost. The existing data for reimbursement based on some of these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates, and CMS has begun making pharmacy National Average Drug Acquisition Cost and National Average Retail Price data publicly available on at least a monthly basis. Therefore, it may be difficult to project the impact of these evolving reimbursement metrics on the willingness of payors to cover candidate products that we are able to commercialize. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional potential legislative and administrative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products such as ours.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal and social issues related to genetic testing may reduce demand for our product candidates, if approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that prior to receiving certain gene therapies, patients may be required to undergo genetic testing. Genetic testing has raised concerns regarding the appropriate utilization and the confidentiality of information provided by genetic testing. Genetic tests for assessing a person&#8217;s likelihood of developing a chronic disease have focused public attention on the need to protect the privacy of genetic information. For example, concerns have been expressed that insurance carriers and employers may use these tests to discriminate based on genetic information, resulting in barriers to the acceptance of genetic tests by consumers. Concerns have also been raised about the accuracy of genetic testing. This could lead to governmental authorities restricting genetic testing or calling for additional regulation of genetic testing, particularly for diseases for which there is no known cure. Any of these scenarios could decrease demand for our product candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for them outside of the United States, which would limit our market opportunities and adversely affect our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of B-VEC or other future product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA grants marketing approval for a product candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for our product candidates, if approved, is also subject to approval. We intend to submit a marketing authorization application to the EMA for approval of B-VEC in the EU but obtaining such approval from the European Commission following the opinion of the EMA is a lengthy and expensive process. Even if a product candidate is approved, the FDA or the European Commission, as the case may be, may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and the EU also have requirements for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for any of our product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects will be adversely affected.</span></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Increasing demand for compassionate use or expanded access of our unapproved therapies could negatively affect our reputation and harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are developing our product candidates for illnesses for which there are currently limited to no available therapeutic options. At least one other company has been the target of disruptive social media campaigns related to a request for access to unapproved drugs for patients with significant unmet medical need. If we experience a similar social media campaign regarding our decision to provide or not provide our product candidates under an expanded access corporate policy, our reputation may be negatively affected and our business may be harmed. Recent media attention to individual patients&#8217; expanded access requests has resulted in the introduction of legislation at the local and national level referred to as &#8220;Right to Try&#8221; laws, such as the Right to Try Act, which are intended to give patients access to unapproved therapies. New and emerging legislation regarding expanded access to unapproved drugs for life-threatening illnesses could negatively impact our business in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A possible consequence of both activism and legislation in this area is the need for us to initiate an unanticipated expanded access program or to make our product candidates more widely available sooner than anticipated. We are a small company with limited resources and unanticipated trials or access programs could result in diversion of resources from our primary goals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, some patients who receive access to unapproved drugs through compassionate use or expanded access programs have life-threatening illnesses and have exhausted all other available therapies. The risk for serious adverse events in this patient population is high which could have a negative impact on the safety profile of our product candidates if we were to provide them to these patients in accordance with our expanded access corporate policy, which could cause significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business. If we were to provide patients with our product candidates under our expanded access corporate policy, we may in the future need to restructure or pause ongoing compassionate use and/or expanded access programs in order to perform the controlled clinical trials required for regulatory approval and successful commercialization of our product candidates, which could prompt adverse publicity or other disruptions related to current or potential participants in such programs</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates and may fail to capitalize on programs or product candidates that may be a greater commercial opportunity or for which there is a greater likelihood of success.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends upon our ability to identify, develop and commercialize product candidates based on our gene therapy platform. Research programs to identify new product candidates require substantial technical, financial and human resources. Although certain of our product candidates are currently in clinical or preclinical development, we may fail to identify other potential product candidates for clinical development for several reasons. For example, our potential product candidates may be shown to have harmful side effects, may be commercially impracticable to manufacture or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our spending on current and future research and development programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage expected growth in the scale and complexity of our operations, our performance may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are successful in executing our business strategy, we will need to expand our managerial, operational, financial and other systems and resources to manage our operations, continue our research and development activities and, in the longer term, build a commercial infrastructure to support commercialization of any of our product candidates that are approved for sale. Future growth would impose significant added responsibilities on members of management. It is likely that our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and product candidates requires that we continue to develop more robust business processes and improve our systems and procedures in each of these areas and to attract and retain enough numbers of talented employees. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees, including scientific and technical personnel, and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on members of our management team, the loss of whose services may adversely impact the achievement of our objectives. Our employees are at-will employees, and the loss of one or more of them might impede the achievement of our research, development and commercialization objectives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, also will be critical to our success. There currently is a shortage of skilled individuals with substantial gene therapy experience, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and vector manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators and advisors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators and advisors. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions, provide accurate information to the FDA, the EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. Sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in criminal and civil penalties or sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition, results of operations and prospects, including the imposition of significant fines, criminal penalties, or other sanctions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future drug candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., there have been and continue to be a number of legislative efforts to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (&#8220;PPACA&#8221;), was passed, which substantially changes the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The PPACA, among other things: (i) addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (ii) increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (iii) establishes annual fees and taxes on manufacturers of certain branded prescription drugs; (iv) expands the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; and (v) establishes a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the PPACA, and we expect there will be additional challenges in the future. As a result, there have been delays in the implementation of, and action taken to attempt to repeal or replace, certain aspects of the PPACA. Litigation and legislation over the ACA may continue in the future, with unpredictable and uncertain results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the impact that such actions against the ACA or other health care reform efforts in the future will have on our business, and there is uncertainty as to what healthcare programs and regulations may be implemented or changed at the federal and/or state level in the United States, or the effect of any future legislation or regulation. However, it is possible that such initiatives could have an adverse effect on our ability to obtain approval and/or successfully commercialize products in the United States in the future. For example, any changes that reduce, or impede the ability to obtain, reimbursement for the type of products we intend to commercialize in the United States (or our products more specifically, if approved) could adversely affect our business plan to introduce our products in the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain providers, and increased the time for Medicare contractors to recoup Medicare overpayments to providers from three to five years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their marketed products and the cost of prescription drugs to consumers and government healthcare programs, which have resulted in several recent Congressional inquiries and proposed and enacted bills designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In addition, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs to limit the growth of government paid health care costs. For example, the United States government has passed legislation requiring pharmaceutical manufacturers to provide rebates and discounts to certain entities and governmental payors to participate in federal healthcare programs. Further, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs, and the current administration recently released a &#8220;Blueprint&#8221;, or plan, to reduce the cost of drugs. The current administration&#8217;s Blueprint contains certain measures that the US Department of Health and Human Services is already working to implement. Individual states in the United States have also been increasingly passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes may affect our business, including those governing enrollment in federal healthcare programs, reimbursement changes, fraud and abuse enforcement, and expansion of new programs, such as Medicare payment for performance initiatives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These initiatives, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms could result in reduced demand for our product candidates or additional pricing pressures and may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain FDA approval for our product candidates and begin commercializing in the United States, our operations will be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Anti-Kickback Statute, federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business as well as other jurisdictions. The laws that will affect our operations include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. The PPACA amended the intent requirement of the federal Anti-Kickback Statute to clarify that a person or entity does not have to have actual knowledge of this statute or specific intent to violate it;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent. The PPACA provides that a claim for items or services resulting from an Anti-Kickback Statute violation is a false claim under the federal False Claims Act. Cases against pharmaceutical manufacturers support the view that certain marketing practices, including off-label promotion, may implicate the False Claims Act;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, public or private);</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and its implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Notification Rules under HITECH and the Genetic Information Nondiscrimination Act; Other modifications to HIPAA, published in January 2013, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the CMS information related to: (i) payments or other &#8220;transfers of value&#8221; made to physicians and teaching hospitals and (ii) ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances, such as specific disease states; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Often, to avoid the threat of treble damages and penalties under the False Claims Act, health care providers will resolve allegations in a settlement without admitting liability. Any such settlement could materially affect our business, financial operations, and reputation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain a robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and regulations relating to occupational health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biologic materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance for certain costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may incur substantial costs to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including conditions that are outside of our control, such as the U.S. presidential election and the impact of health and safety concerns, such as the current coronavirus outbreak. The most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the most recent global financial crisis, could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption, or cause delays in payments by third-party payors or our collaborators. Any of the foregoing could harm our business and we cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyber-security incidents, including data security breaches or computer viruses, could harm our business by disrupting our delivery of services, damaging our reputation or exposing us to liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive, process, store, and transmit, often electronically, confidential data of others. Unauthorized access to our computer systems or stored data could result in the theft or improper disclosure of confidential information, the deletion or modification of records, or could cause interruptions in our operations. These cyber-security risks increase when we transmit information from one location to another, including transmissions over the Internet or other electronic networks. Despite implemented security measures, our facilities, systems, and procedures, and those of our third-party service providers, may be vulnerable to security breaches, acts of vandalism, software viruses, misplaced or lost data, programming and/or human errors, or other similar events which may disrupt our delivery of services or expose the confidential information of our customers and others. Any security breach involving the misappropriation, loss or other unauthorized disclosure or use of confidential information of others, whether by us or a third party, could: (i) subject us to civil and criminal penalties; (ii) have a negative impact on our reputation; or (iii) expose us to liability to our customers, third parties or government authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters could severely disrupt our operations or the operations of manufacturing facilities and have a material adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as manufacturing facilities, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans that we have in place currently are limited and may not prove adequate in the event of a serious disaster or similar event. Substantially all our current supply of our product candidates is located at our manufacturing facility in Pittsburgh, Pennsylvania.&#160;&#160;We are constructing an additional manufacturing facility and establishing a relationship with a third-party contract manufacturer as a back-up supplier </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the commercial supply of our products, if necessary. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate U.S. and foreign patent protection for our product candidates, including B-VEC, KB105, KB301, KB104, KB407, KB408 any future product candidates we may develop, and/or our vector platform, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technologies similar or identical to ours, and our ability to successfully commercialize our current product candidates, any future product candidates we may develop, and our platform technologies may be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to B-VEC, KB105, KB301, KB104, KB407, KB408 and additional product candidates in our pipeline, current and future innovations related to our vector platform, and our institutional knowledge. The patent prosecution process is expensive, time-consuming and complex; we may not be able to file, prosecute, maintain, and/or enforce all necessary or desirable patent applications and issued patents at a reasonable cost or in a timely manner. We currently have six issued patents in the United States: (1) U.S. patent No. 9,877,990, covering, in part, pharmaceutical formulations comprising our lead clinical product B-VEC, as well as methods of its use for treating wounds, disorders, and diseases of the skin, which we refer to as the &#8217;990 patent; (2) U.S. patent No. 10,155,016 covering pharmaceutical compositions containing B-VEC formulated for myriad routes of administration; (3) U.S. patent No. 10,441,614 covering aspects of our vector platform technology, and its uses in delivering any gene of interest to the skin; (4) U.S. patent No. 10,525,090, covering pharmaceutical compositions comprising our second clinical product candidate, KB105, and methods of its use for treating TGM1-deficient autosomal recessive congenital ichthyosis; (5) U.S. Patent No. 10,786,438 covering pharmaceutical compositions comprising vectors encoding cosmetic proteins, including our third product candidate, KB301, and methods for their use for improving skin condition, quality, and/or appearance; and (6) U.S. Patent No. 10,829,529 covering the methods of using KB407 for the treatment of cystic fibrosis and other diseases causing progressive lung destruction. Furthermore, we have international patent applications filed in accordance with the Paris Cooperation treaty directed to multiple discovery, preclinical, and clinical programs, including B-VEC, KB105, KB301, KB104, KB407, and KB-408, as well as multiple patent applications filed in foreign jurisdictions stemming from these international applications. B-VEC is also the subject of multiple patents granted in foreign jurisdictions, including European Patent No. 3 377 637 B1, covering pharmaceutical compositions containing B-VEC as well as uses thereof.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are granted the patents that we are currently pursuing, they may not issue in a form that will provide us with the full scope of protection we desire, they may not prevent competitors or other third parties from competing with us, and/or they may not otherwise provide us with a competitive advantage. Our competitors, or other third parties, may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. For example, there is no assurance that the &#8217;990 patent, or any other patent we are granted, will prevent third parties from developing competing technologies. Moreover, our patent estate, including the &#8217;990 patent, does not preclude third parties from having intellectual property rights that could interfere with our freedom to use our platform, including for dermatological indications. Even assuming patents issue from our pending and future patent applications, changes in either the patent laws or interpretation of the patent laws in the United States and foreign jurisdictions may diminish the value of our patents or narrow their scope of protection.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may not be aware of all third-party intellectual property rights potentially relating to technologies similar to our own. Publications of discoveries in the scientific literature often lag their actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, it is impossible to be certain that we were the first to develop the specific technologies as claimed in any owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on each and every one of our product candidates, current and future innovations related to our vector platform, and our institutional knowledge in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the United States may differ in scope from those eventually granted in the United States. Thus, in some cases, we may not have the opportunity to obtain patent protection for certain technologies in some jurisdictions outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do pursue patent protection. Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products. Such challenges in enforcing rights in these countries could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our current and future patent rights in foreign jurisdictions could result in substantial costs and may divert our efforts and attention from other aspects of our business; could put our patents at risk of being invalidated or interpreted narrowly; could put any future patent applications, including continuation and divisional applications, at risk of not issuing; and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce any intellectual property rights around the world stemming from intellectual property that we develop may be inadequate to obtain a significant commercial advantage in these foreign jurisdictions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability (and the ability of any potential future collaborators) to develop, manufacture, market and sell our product candidates, and to freely use our proprietary technologies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, without infringing the rights and intellectual property of others). Many companies and institutions have filed, and continue to file, patent applications related to various aspects of gene therapy. Because patent applications can take many years to issue, may be confidential for 18 months or more after filing, and can be revised before issuance, there may be applications now pending which may later result in issued patents that a third-party asserts are infringed by the manufacture, use, sale, or importation of our products. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. On May 1, 2020, a complaint was filed against us in the United States District Court for the Western District of Pennsylvania by PeriphaGen Inc., which also named our Chief Executive Officer and Chief Operating Officer, Krish Krishnan and Suma Krishnan, respectively. The complaint alleges breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserts were used to develop our product candidates, including the vector backbones, and our STAR-D platform. For more information, see "Legal Proceedings" in Note 6 of the Notes to Condensed Consolidated Financial Statements included in Item 1 of Part I of this Form 10-Q. We may in the future become party to, or be threatened with, other adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates or related technologies, including, for example, interference proceedings, post grant review challenges, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review before the United States Patent and Trademark Office ("USPTO"). For example, a third party may bring an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review challenging our patents and any future patent that may be granted to us. Our competitors or other third parties may assert infringement claims against us, alleging that our therapeutics, manufacturing methods, formulations or administration methods are covered by their patents. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue, and against whom our patent portfolio may therefore have no deterrent effect.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patents or other intellectual property rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize our products, including B-VEC. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. In such a hypothetical situation, there is no assurance that a court of competent jurisdiction would find that our product candidates or technologies do not infringe a third-party patent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcomes are uncertain. If we are found, or believe there is a risk that we may be found, to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required (or may choose) to obtain a license from such a third party to continue developing, manufacturing and marketing our technologies. However, we may not be able to obtain any required license on commercially reasonable terms, if at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and further, it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and commercializing the infringing technologies, including B-VEC. We also could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our technologies, including B-VEC, or force us to cease some or all our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming. Competitors may infringe our current or future patents, should such patents issue, or we may be required to defend against claims of infringement or other unauthorized use of intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our scientific and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating, or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are and may be subject to claims asserting that we, our employees or our advisors have wrongfully used or disclosed alleged trade secrets of other parties, including current or former employers, or claims asserting ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our employees or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including potential competitors, and we have and may in the future enter into agreements providing us with rights to intellectual property of third parties for limited purposes. Although we try to observe the terms of agreements under which we obtain access to third party intellectual property and to ensure that our employees and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property, including trade secrets or other proprietary information, of third parties or the current or former employers of employees or advisors. For instance, as described in Note 6 of the Notes to Condensed Consolidated Financial Statements included in Item 1 of Part I of the Form 10Q on May 1, 2020, a complaint was filed against us by PeriphaGen Inc., which also named our Chief Executive Officer and our Chief Operating Officer, Krish Krishnan and Suma Krishnan, respectively. The complaint alleges breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserts we used to develop our vector platform and product candidates. If we fail in defending any such claims, in addition to paying monetary damages, we may be subject to an injunction and may lose valuable intellectual property rights or personnel. Moreover, any such litigation, or the threat thereof, may adversely affect our ability to hire new employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our technologies, which would have an adverse effect on our business, results of operations, and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is our policy to require our employees and contractors who may be involved in the conception of intellectual property to execute agreements assigning such intellectual property rights to us, unforeseen complications may arise when fully and adequately executing such an agreement with each party who, in fact, conceives of intellectual property that we regard as our own. Examples of such complications may include, for example, when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached. Such complications may lead to us being forced to bring claims against third parties or current and former employees, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Moreover, individuals executing agreements with us may have preexisting or competing obligations to a third party, such as an academic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institution, and thus an agreement with us may be insufficient in fully perfecting ownership of inventions developed by that individual. Disputes about the ownership of intellectual property that we may own may have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act included several significant changes to U.S. patent law, including provisions that affected the way patent applications are prosecuted, and altered strategies regarding patent litigation. These provisions also switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allowed third-party submissions of prior art to the USPTO during patent prosecution, and set forth additional procedures to attack the validity of a patent through various post grant proceedings administered by the USPTO. As patent reform legislation can inject serious uncertainty into the patent prosecution and litigation processes, it is not clear what impact future patent reform legislation will have on the operation of our business. However, such future legislation, and its implementation, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain given the ever evolving and constantly shifting nature of precedential patent cases decided by both the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court. We cannot assure you that our efforts to seek patent protection for our technology and product candidates will not be negatively impacted by the future court decisions or changes in guidance or procedures issued by the USPTO. These decisions, and any guidance issued by the USPTO (or changes thereto), could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property rights in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of registering certain of our trademarks and trade names. Once trademarks or trade names have been registered, they may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which are important for building name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. There also could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trade names that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to patents, trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of current and future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make gene therapy products that are similar to our product candidates but that are not covered by the claims of our current patents, or of patents that we may own or license in the future;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or any future license partners or collaborators, might not have been the first to file patent applications covering certain aspects of the concerned technologies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies, or duplicate any of our technologies, potentially without falling within the scope of our current or future issued claims, thus not infringing our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our filed or future patent applications will not lead to issued patents;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents to which we currently hold rights or to which we may hold rights in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may have access to any future intellectual property rights licensed to us on a non-exclusive basis;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have or pursue patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents or other intellectual property rights of others may have an adverse effect on our business; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent application covering certain of our trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Chief Executive Officer and Chairman of the Board of Directors and our founder, Chief Operating Officer and director will have the ability to substantially influence all matters submitted to stockholders for approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, Krish S. Krishnan and Suma M. Krishnan, our Chief Executive Officer and Chairman of the Board and our founder, Chief Operating Officer and director, respectively, in the aggregate, beneficially owned shares representing approximately 17% of our capital stock. As a result, they will be able to substantially influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons would substantially influence the election of directors and approval of any merger, consolidation or sale of all or substantially all our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in management of our company that our public stockholders disagree with.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts publish negative evaluations of our stock, the price of our stock could decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If securities analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biopharmaceutical or pharmaceutical companies specifically has experienced extreme volatility that has often been unrelated to the operating performance of such companies. As a result of this volatility, you may not be able to sell your common stock at or above the price that you paid for it. The market price of our common stock may be influenced by many factors, including:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully proceed to and conduct clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement or termination of collaborations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire or in-license additional product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including intellectual property or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur costs as a result of becoming a public company, and such costs will increase when we cease to be an &#8220;emerging growth company.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we expect to continue to incur significant legal, accounting, insurance and other expenses, including costs associated with public company reporting requirements. The expenses incurred by public companies generally for reporting and corporate governance purposes have been increasing. We expect compliance with these public reporting requirements and associated rules and regulations to increase expenses, particularly after we are no longer an emerging growth company beginning in 2022, although we are currently unable to estimate these costs with any degree of certainty. We will be an emerging growth company until the end of 2021, after which, we will incur additional costs applicable to public companies that are not emerging growth companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain effective internal control over financial reporting, we may not be able to accurately report our financial results, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Beginning with our fiscal year ending December 31, 2022, we will cease to be an "emerging growth company" as defined by the JOBs Act. After we are no longer an emerging growth company under the JOBS Act, Section 404 of the Sarbanes-Oxley Act requires our auditors to deliver an attestation report on the effectiveness of our internal control over financial reporting in conjunction with their opinion on our audited financial statements. Substantial work on our part is required to implement appropriate processes, document the system of internal control over key processes, assess their design, remediate any deficiencies identified and test their operation. This process is expected to be both costly and challenging. We cannot give any assurances that material weaknesses will not be identified in the future in connection with our compliance with the provisions of Section 404 of the Sarbanes-Oxley Act. The existence of any material weakness would preclude a conclusion by management and our independent auditors that we maintained effective internal control over financial reporting. Our management may be required to devote significant time and expense to remediate any material weaknesses that may be discovered and may not be able to remediate any material weakness in a timely manner. The existence of any material weakness in our internal control over financial reporting could also result in errors in our financial statements that could require us to restate our financial statements, cause us to fail to meet our reporting obligations and cause investors to lose confidence in our reported financial information, all of which could lead to a decline in the per-share trading price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 80% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our bylaws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash, cash equivalents and marketable securities and may not use them effectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash, cash equivalents and marketable securities and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party expectations relating to environmental, social and governance factors may impose additional costs and expose us to new risks.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increasing focus from certain investors and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance factors. Some investors may use these factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased in number, resulting in varied and in some cases inconsistent standards. In addition, the criteria by which companies&#8217; corporate responsibility practices are assessed are evolving, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we elect not to or are unable to satisfy such new criteria or do not meet the criteria of a specific third-party provider, some investors may conclude that our policies with respect to corporate responsibility are inadequate. We may face reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. Furthermore, if our competitors&#8217; corporate responsibility performance is perceived to be greater than ours, potential or current investors may elect to invest with our competitors instead. In addition, in the event that we communicate certain initiatives and goals regarding environmental, social and governance matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors and other stakeholders or our initiatives are not executed as planned, our reputation and financial results could be adversely affected</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20210930ex3111.htm">Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20210930ex3121.htm">Certification of Periodic Report by Chief Accounting Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20210930ex3211.htm">Certification of Chief Executive Officer and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL (Extensible Business Reporting Language). The following materials from this Quarterly Report on Form 10-Q for the period ended September 30, 2021, formatted in Inline XBRL: (i) consolidated balance sheets of Krystal Biotech, Inc., (ii) consolidated statements of operations of Krystal Biotech, Inc., (iii) consolidated statements of comprehensive income/(loss) of Krystal Biotech, Inc., (iv) consolidated statements of changes in equity of Krystal Biotech, Inc., (v) consolidated statements of cash flows of Krystal Biotech, Inc. and (vi) notes to consolidated financial statements of Krystal Biotech, Inc. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL </span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i527b7e782a7b4f2c9d55c09f08b7a4ae_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.240%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRYSTAL BIOTECH, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;8, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>krys-20210930ex3111.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if5e605ec2b804344a033920b5ac83ac4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;8, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>krys-20210930ex3121.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3d8091d801794105a784d8f5f8d71464_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;8, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>krys-20210930ex3211.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibb16350c18b64a28b57568f706e2b9e0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended September&#160;30, 2021, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;8, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, Chief Accounting Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended September&#160;30, 2021, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;8, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>krys-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:51c004c1-b4bb-4008-a736-d538f5596d86,g:ccbd04b3-aea9-417b-ad73-32d54787d8a0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:krys="http://www.krystalbio.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.krystalbio.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.krystalbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.krystalbio.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholders" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders">
        <link:definition>2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersTables" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables">
        <link:definition>2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail">
        <link:definition>2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail">
        <link:definition>2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstruments" roleURI="http://www.krystalbio.com/role/FairValueInstruments">
        <link:definition>2112104 - Disclosure - Fair Value Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsTables" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables">
        <link:definition>2313303 - Disclosure - Fair Value Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1">
        <link:definition>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.krystalbio.com/role/BalanceSheetComponents">
        <link:definition>2115105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables">
        <link:definition>2316304 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>2321305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail">
        <link:definition>2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalization" roleURI="http://www.krystalbio.com/role/Capitalization">
        <link:definition>2125107 - Disclosure - Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail">
        <link:definition>2426413 - Disclosure - Capitalization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.krystalbio.com/role/StockBasedCompensation">
        <link:definition>2127108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables">
        <link:definition>2328306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail">
        <link:definition>2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
        <link:definition>2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
        <link:definition>2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
        <link:definition>2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.krystalbio.com/role/RelatedPartyTransactions">
        <link:definition>2134109 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>2435419 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.krystalbio.com/role/SubsequentEvents">
        <link:definition>2136110 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" abstract="false" name="LessorOperatingLeaseLiabilityAnnualLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_OtherContractualObligationsMember" abstract="true" name="OtherContractualObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedConstructionInProgressCurrent" abstract="false" name="AccruedConstructionInProgressCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_PlacementSharesMember" abstract="true" name="PlacementSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ASTRAFacilityMember" abstract="true" name="ASTRAFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="krys_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedPreclinicalAndClinicalExpenses" abstract="false" name="AccruedPreclinicalAndClinicalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_StockSaleAgreementMember" abstract="true" name="StockSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_OfferingCostsIncurredButNotYetPaid" abstract="false" name="OfferingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CumulativeEscalationClausePercent" abstract="false" name="CumulativeEscalationClausePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_AdvanceToRelatedParty" abstract="false" name="AdvanceToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PaymentsForSuitLiability" abstract="false" name="PaymentsForSuitLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_SaleOfStockRemainingAvailableIssuanceAmount" abstract="false" name="SaleOfStockRemainingAvailableIssuanceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_TwoThousandSixteenLeaseAgreementMember" abstract="true" name="TwoThousandSixteenLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_RemainingCommitmentAmount" abstract="false" name="RemainingCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AccruedFinancingFeesCurrent" abstract="false" name="AccruedFinancingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ClinicalSupplyAgreementMember" abstract="true" name="ClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LossContingencyGuaranteedMaximumPriceToBePaid" abstract="false" name="LossContingencyGuaranteedMaximumPriceToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_InterestIncomeExpenseAndOtherNonoperatingNet" abstract="false" name="InterestIncomeExpenseAndOtherNonoperatingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PaymentToEscrowForReducingLeaseRentals" abstract="false" name="PaymentToEscrowForReducingLeaseRentals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AccruedPayrollAndBenefits" abstract="false" name="AccruedPayrollAndBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CumulativeEscalationClauseTerm" abstract="false" name="CumulativeEscalationClauseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="krys_CostOfWorkPercentage" abstract="false" name="CostOfWorkPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="krys_BuildToSuitLeaseLiabilityCurrent" abstract="false" name="BuildToSuitLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PurchasePriceOfPotentialBuildingPurchase" abstract="false" name="PurchasePriceOfPotentialBuildingPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_NonEmployeeStockOptionMember" abstract="true" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AdditionalAreaOfRealEstatePropertyLeased" abstract="false" name="AdditionalAreaOfRealEstatePropertyLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="krys_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_LossContingencyReceivableReceivedAmount" abstract="false" name="LossContingencyReceivableReceivedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>krys-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:51c004c1-b4bb-4008-a736-d538f5596d86,g:ccbd04b3-aea9-417b-ad73-32d54787d8a0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f2a463a1-a5ff-42bb-b971-742044bf9efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_262ed447-38c3-4fcc-98bc-e3ccbfda7ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f2a463a1-a5ff-42bb-b971-742044bf9efd" xlink:to="loc_us-gaap_PreferredStockValue_262ed447-38c3-4fcc-98bc-e3ccbfda7ec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9e337fac-c846-4fbd-a561-70172e06951c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f2a463a1-a5ff-42bb-b971-742044bf9efd" xlink:to="loc_us-gaap_CommonStockValue_9e337fac-c846-4fbd-a561-70172e06951c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_98688780-b7bb-42f7-ba42-68ce31899427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f2a463a1-a5ff-42bb-b971-742044bf9efd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_98688780-b7bb-42f7-ba42-68ce31899427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c9a0a07c-e677-4599-9ce4-a5ca124ec62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f2a463a1-a5ff-42bb-b971-742044bf9efd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c9a0a07c-e677-4599-9ce4-a5ca124ec62c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c67ec08a-e0a7-4ac1-a776-dc6f3e474431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f2a463a1-a5ff-42bb-b971-742044bf9efd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c67ec08a-e0a7-4ac1-a776-dc6f3e474431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b5fad912-0b92-4033-ab17-dea0999bfc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1ca4cde3-d96c-4853-a8b8-27c78e10d8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b5fad912-0b92-4033-ab17-dea0999bfc06" xlink:to="loc_us-gaap_AccountsPayableCurrent_1ca4cde3-d96c-4853-a8b8-27c78e10d8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e3f15b48-3fcc-4493-98e0-300323d65b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b5fad912-0b92-4033-ab17-dea0999bfc06" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e3f15b48-3fcc-4493-98e0-300323d65b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0854bc36-9f32-404a-bd3f-bb0fb6a9b3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b5fad912-0b92-4033-ab17-dea0999bfc06" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0854bc36-9f32-404a-bd3f-bb0fb6a9b3f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BuildToSuitLeaseLiabilityCurrent_8d22c188-182d-4a4a-8136-091547e15ee8" xlink:href="krys-20210930.xsd#krys_BuildToSuitLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b5fad912-0b92-4033-ab17-dea0999bfc06" xlink:to="loc_krys_BuildToSuitLeaseLiabilityCurrent_8d22c188-182d-4a4a-8136-091547e15ee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4e03058-192e-41cd-8322-786ae4f47cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_63a4f4f4-5b8b-4e43-bd25-99b741487189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4e03058-192e-41cd-8322-786ae4f47cb4" xlink:to="loc_us-gaap_Liabilities_63a4f4f4-5b8b-4e43-bd25-99b741487189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_689141da-ad20-4019-929b-14addd09efad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4e03058-192e-41cd-8322-786ae4f47cb4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_689141da-ad20-4019-929b-14addd09efad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_29ba9117-fab9-4a70-a9cd-a05fe7d3c667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4e03058-192e-41cd-8322-786ae4f47cb4" xlink:to="loc_us-gaap_StockholdersEquity_29ba9117-fab9-4a70-a9cd-a05fe7d3c667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_18e5b700-b57f-4f90-b69e-dc7df4eb3b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_86a6c4e0-8149-434b-b853-9195b125786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_18e5b700-b57f-4f90-b69e-dc7df4eb3b58" xlink:to="loc_us-gaap_AssetsCurrent_86a6c4e0-8149-434b-b853-9195b125786d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5151591c-24cc-42f8-b0c3-4f475f9d4e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_18e5b700-b57f-4f90-b69e-dc7df4eb3b58" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5151591c-24cc-42f8-b0c3-4f475f9d4e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6deef3fa-80bb-4a4b-a96c-37bdb1529dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_18e5b700-b57f-4f90-b69e-dc7df4eb3b58" xlink:to="loc_us-gaap_LongTermInvestments_6deef3fa-80bb-4a4b-a96c-37bdb1529dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1c5f7274-5ca7-4e7d-a804-745ff55484ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_18e5b700-b57f-4f90-b69e-dc7df4eb3b58" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1c5f7274-5ca7-4e7d-a804-745ff55484ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c88b4ef5-bebe-4242-a684-fe0821cb59d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_18e5b700-b57f-4f90-b69e-dc7df4eb3b58" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c88b4ef5-bebe-4242-a684-fe0821cb59d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fa666291-a9e2-44e7-aa9b-d95d60f9c9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2d9943ea-5a9e-4bff-bf78-a06890e07d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa666291-a9e2-44e7-aa9b-d95d60f9c9c0" xlink:to="loc_us-gaap_LiabilitiesCurrent_2d9943ea-5a9e-4bff-bf78-a06890e07d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_36e8f6b1-ff06-4233-86de-90ce19fb66b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa666291-a9e2-44e7-aa9b-d95d60f9c9c0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_36e8f6b1-ff06-4233-86de-90ce19fb66b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c611a613-9dcc-4dba-a8b5-4a54b8925130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5be74814-0205-4d0d-8a59-5cd04455792b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c611a613-9dcc-4dba-a8b5-4a54b8925130" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5be74814-0205-4d0d-8a59-5cd04455792b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3b0dc2f2-4eec-48b6-b326-256a7f285f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c611a613-9dcc-4dba-a8b5-4a54b8925130" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3b0dc2f2-4eec-48b6-b326-256a7f285f25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_24036bf1-9473-4f53-b774-c98f4a837f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c611a613-9dcc-4dba-a8b5-4a54b8925130" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_24036bf1-9473-4f53-b774-c98f4a837f8c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0395d6d0-76ac-432b-a4cc-4ca448a0f7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10c41cbb-0e29-4d62-9c4a-4b0deaaef6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0395d6d0-76ac-432b-a4cc-4ca448a0f7c8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10c41cbb-0e29-4d62-9c4a-4b0deaaef6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_231a5c53-d314-4169-a41f-b6bb6c2f674f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0395d6d0-76ac-432b-a4cc-4ca448a0f7c8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_231a5c53-d314-4169-a41f-b6bb6c2f674f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_42e4f093-5d66-4fe1-b088-e1361aabec98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_28a42a71-0ec8-4d32-b401-5b7599509ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_42e4f093-5d66-4fe1-b088-e1361aabec98" xlink:to="loc_us-gaap_OperatingExpenses_28a42a71-0ec8-4d32-b401-5b7599509ec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_942754bb-1b54-4840-8465-d49429e711fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_31b36290-eb1c-47fc-a933-09488004e861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_942754bb-1b54-4840-8465-d49429e711fd" xlink:to="loc_us-gaap_OperatingIncomeLoss_31b36290-eb1c-47fc-a933-09488004e861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_f331d22b-bd29-4b75-8bff-02d4e041d0fc" xlink:href="krys-20210930.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_942754bb-1b54-4840-8465-d49429e711fd" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_f331d22b-bd29-4b75-8bff-02d4e041d0fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_919ad2f4-9193-4037-8b2e-8526e2dc1092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_942754bb-1b54-4840-8465-d49429e711fd" xlink:to="loc_us-gaap_InterestExpense_919ad2f4-9193-4037-8b2e-8526e2dc1092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3b96c18b-e90b-4f65-9c93-bb1542f51f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f9cacba1-8bf2-4122-ba5c-270b1fb9b73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3b96c18b-e90b-4f65-9c93-bb1542f51f9a" xlink:to="loc_us-gaap_NetIncomeLoss_f9cacba1-8bf2-4122-ba5c-270b1fb9b73f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c0187b67-39d6-48e8-afeb-df364653eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3b96c18b-e90b-4f65-9c93-bb1542f51f9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c0187b67-39d6-48e8-afeb-df364653eb9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8a5b04a0-58b4-47d3-9923-8f241dfeeab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_230deb7c-d6b2-4e74-91f3-2a7e1da6033e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8a5b04a0-58b4-47d3-9923-8f241dfeeab7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_230deb7c-d6b2-4e74-91f3-2a7e1da6033e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_abb12c80-97ec-4332-b6fd-df238e488049" xlink:href="krys-20210930.xsd#krys_PaymentsForSuitLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8a5b04a0-58b4-47d3-9923-8f241dfeeab7" xlink:to="loc_krys_PaymentsForSuitLiability_abb12c80-97ec-4332-b6fd-df238e488049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98f60453-3810-4fba-852b-fd4c7cd1007e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7e7d269-38e9-4733-a4df-66d2f6e56ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98f60453-3810-4fba-852b-fd4c7cd1007e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7e7d269-38e9-4733-a4df-66d2f6e56ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7d8dac09-e77f-40dc-8355-e797efab022b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98f60453-3810-4fba-852b-fd4c7cd1007e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7d8dac09-e77f-40dc-8355-e797efab022b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_ea11a884-0d3e-4004-9180-253ac7a27c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98f60453-3810-4fba-852b-fd4c7cd1007e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_ea11a884-0d3e-4004-9180-253ac7a27c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f808afe-48e2-48dc-b4b7-82461c49933c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e22e3a3b-44c5-496d-91b0-908da05beee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f808afe-48e2-48dc-b4b7-82461c49933c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e22e3a3b-44c5-496d-91b0-908da05beee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15aa11c0-e7ef-408a-876c-2a238daea79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f808afe-48e2-48dc-b4b7-82461c49933c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15aa11c0-e7ef-408a-876c-2a238daea79b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb0406f8-3043-43ba-849a-15aa57ebff36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f808afe-48e2-48dc-b4b7-82461c49933c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb0406f8-3043-43ba-849a-15aa57ebff36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0652253-dfe2-49fc-b093-712f3130f7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_NetIncomeLoss_a0652253-dfe2-49fc-b093-712f3130f7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_61aa01bf-e450-45da-a468-82b06499c885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_DepreciationAndAmortization_61aa01bf-e450-45da-a468-82b06499c885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a43084bc-483b-4612-8327-5edb1a4cf421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_ShareBasedCompensation_a43084bc-483b-4612-8327-5edb1a4cf421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_d9a50a05-eec8-4f7e-a566-042fd5944417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_OtherNoncashExpense_d9a50a05-eec8-4f7e-a566-042fd5944417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1109de03-e572-4e5e-8a62-168824e8d407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1109de03-e572-4e5e-8a62-168824e8d407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent_7827f68f-34d4-4cb0-b1af-927f6e7cc4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent_7827f68f-34d4-4cb0-b1af-927f6e7cc4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_d19fe766-238c-42b8-bc07-a62ee844534c" xlink:href="krys-20210930.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_d19fe766-238c-42b8-bc07-a62ee844534c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0b07f201-4727-4e72-b69c-969805b5f216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0b07f201-4727-4e72-b69c-969805b5f216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_589ea2a0-6d0b-436a-91a2-80e004b124f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_589ea2a0-6d0b-436a-91a2-80e004b124f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets_1b8d48c0-043d-4d36-8b0a-f364f2ba1e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1206242c-6fff-4e34-ae72-1eca1bd3e248" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets_1b8d48c0-043d-4d36-8b0a-f364f2ba1e9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_cd33c4a3-05c6-4567-a891-ce8c66850217" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_599b7b2a-ec45-4786-920d-2e5a6df3e660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_cd33c4a3-05c6-4567-a891-ce8c66850217" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_599b7b2a-ec45-4786-920d-2e5a6df3e660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2d4489e-371b-4916-8d0b-8c5fd89d0838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_cd33c4a3-05c6-4567-a891-ce8c66850217" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2d4489e-371b-4916-8d0b-8c5fd89d0838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_752c5182-1e16-4a78-b227-4f9ad8099f23" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6297187-6574-43f2-ae0a-6e65b6904f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_752c5182-1e16-4a78-b227-4f9ad8099f23" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6297187-6574-43f2-ae0a-6e65b6904f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_232ef0b7-8288-4554-9c45-45770c1b9611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_752c5182-1e16-4a78-b227-4f9ad8099f23" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_232ef0b7-8288-4554-9c45-45770c1b9611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_47a14e0e-5272-4c94-ada9-90fb0e309a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5be94409-7129-4419-93c3-d82f196796dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_47a14e0e-5272-4c94-ada9-90fb0e309a1d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5be94409-7129-4419-93c3-d82f196796dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_695b3ea5-e903-4158-8ef2-8cd072236ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_47a14e0e-5272-4c94-ada9-90fb0e309a1d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_695b3ea5-e903-4158-8ef2-8cd072236ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c935cdad-c0d5-4d9b-84aa-af10e304ba06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_47a14e0e-5272-4c94-ada9-90fb0e309a1d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c935cdad-c0d5-4d9b-84aa-af10e304ba06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20210930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_5ec58f3e-2bf9-48c9-9846-285d90813428" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_56f97783-0a77-4385-aaa3-3e72981c7fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_5ec58f3e-2bf9-48c9-9846-285d90813428" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_56f97783-0a77-4385-aaa3-3e72981c7fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a215afa1-6fff-4d89-a9dc-f5918632d5c2" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_5ec58f3e-2bf9-48c9-9846-285d90813428" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a215afa1-6fff-4d89-a9dc-f5918632d5c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d41caa6-78a0-4cd5-8b16-7f2d22b95d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_5ec58f3e-2bf9-48c9-9846-285d90813428" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d41caa6-78a0-4cd5-8b16-7f2d22b95d36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e947d875-3bed-436f-8e7c-57ea270479d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9c66827b-2601-4759-86ff-6de3a1b53e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e947d875-3bed-436f-8e7c-57ea270479d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9c66827b-2601-4759-86ff-6de3a1b53e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0ce67013-290c-4f10-851b-25ae6cd75edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e947d875-3bed-436f-8e7c-57ea270479d5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0ce67013-290c-4f10-851b-25ae6cd75edc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_58042ad1-f9f2-473b-8658-945bc6057ddc" xlink:href="krys-20210930.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_57d81420-a1d4-4846-a754-d55a91b3741d" xlink:href="krys-20210930.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_58042ad1-f9f2-473b-8658-945bc6057ddc" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_57d81420-a1d4-4846-a754-d55a91b3741d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_246d8c9e-cfc9-42ee-a218-7bf32de0e9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_58042ad1-f9f2-473b-8658-945bc6057ddc" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_246d8c9e-cfc9-42ee-a218-7bf32de0e9bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_56727c2b-1894-44c5-9e27-883c2a937b45" xlink:href="krys-20210930.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_58042ad1-f9f2-473b-8658-945bc6057ddc" xlink:to="loc_krys_AccruedPayrollAndBenefits_56727c2b-1894-44c5-9e27-883c2a937b45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_d09f84c2-e334-4c9f-803b-4209a053e931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_58042ad1-f9f2-473b-8658-945bc6057ddc" xlink:to="loc_us-gaap_AccruedIncomeTaxes_d09f84c2-e334-4c9f-803b-4209a053e931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_919a40be-665d-49d4-99f0-6c7ef3ee47e2" xlink:href="krys-20210930.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_58042ad1-f9f2-473b-8658-945bc6057ddc" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_919a40be-665d-49d4-99f0-6c7ef3ee47e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_fbed4cfa-d0c1-4b74-9112-cb71e1228918" xlink:href="krys-20210930.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_58042ad1-f9f2-473b-8658-945bc6057ddc" xlink:to="loc_krys_AccruedFinancingFeesCurrent_fbed4cfa-d0c1-4b74-9112-cb71e1228918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_46d331aa-926a-4a42-b244-149012752d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_58042ad1-f9f2-473b-8658-945bc6057ddc" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_46d331aa-926a-4a42-b244-149012752d9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f7877283-0613-44d2-8dda-9e636d2c0c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0e4b5390-673a-48aa-b80b-952edaeab6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f7877283-0613-44d2-8dda-9e636d2c0c90" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0e4b5390-673a-48aa-b80b-952edaeab6c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3ebc83ba-20c0-4532-81c2-61698cc019b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f7877283-0613-44d2-8dda-9e636d2c0c90" xlink:to="loc_us-gaap_OperatingLeaseLiability_3ebc83ba-20c0-4532-81c2-61698cc019b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6483a458-9a61-416d-98a0-a4b2db67701c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1b356f1f-64e2-4852-8dd1-3ad8473906a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6483a458-9a61-416d-98a0-a4b2db67701c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1b356f1f-64e2-4852-8dd1-3ad8473906a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_079f5f38-770a-48ba-9ee7-443d42c75899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6483a458-9a61-416d-98a0-a4b2db67701c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_079f5f38-770a-48ba-9ee7-443d42c75899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5af983db-91a6-466b-ac1e-85a67330ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6483a458-9a61-416d-98a0-a4b2db67701c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5af983db-91a6-466b-ac1e-85a67330ee88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a7be8e79-365c-46e8-aec5-69cfe0c59b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6483a458-9a61-416d-98a0-a4b2db67701c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a7be8e79-365c-46e8-aec5-69cfe0c59b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0d3e8a47-d9c9-4746-b264-d9bacd6a40d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6483a458-9a61-416d-98a0-a4b2db67701c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0d3e8a47-d9c9-4746-b264-d9bacd6a40d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1ba43e29-2c8c-408e-b6b2-440f56d65c32" xlink:href="krys-20210930.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6483a458-9a61-416d-98a0-a4b2db67701c" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1ba43e29-2c8c-408e-b6b2-440f56d65c32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7f64b834-075a-490a-960e-ee435a993dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_92ca9ff5-7bf3-4f76-98c2-ad19570b7384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7f64b834-075a-490a-960e-ee435a993dcb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_92ca9ff5-7bf3-4f76-98c2-ad19570b7384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_34217ac5-007e-433c-b001-49935dbc0c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7f64b834-075a-490a-960e-ee435a993dcb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_34217ac5-007e-433c-b001-49935dbc0c1f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>krys-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:51c004c1-b4bb-4008-a736-d538f5596d86,g:ccbd04b3-aea9-417b-ad73-32d54787d8a0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i586482ac1b0f42138d3bd7e85c4dfc59_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e10cd276-6c3f-4264-9e77-0feb5c8859b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e10cd276-6c3f-4264-9e77-0feb5c8859b0" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49ca02f3-8d72-40dc-91de-09bf1a27b89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_StockholdersEquity_49ca02f3-8d72-40dc-91de-09bf1a27b89b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_00b5765a-6942-420d-95aa-1c4b29f0934d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_SharesOutstanding_00b5765a-6942-420d-95aa-1c4b29f0934d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a60b03bb-c169-4689-b4eb-4b7eafbb6cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a60b03bb-c169-4689-b4eb-4b7eafbb6cc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f6855710-f1c3-4688-87d1-9e6586279696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f6855710-f1c3-4688-87d1-9e6586279696" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9b62593f-24b4-4a3c-924e-d5598a6d7d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9b62593f-24b4-4a3c-924e-d5598a6d7d0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bbd39bc2-079a-4f9c-9e20-eb0b8792bd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bbd39bc2-079a-4f9c-9e20-eb0b8792bd7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7f386ea-3081-471d-aae6-4977c3032761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_NetIncomeLoss_c7f386ea-3081-471d-aae6-4977c3032761" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c55b9da7-d005-4776-8447-98a408f9f117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_79b940d0-8d6c-4d30-b29c-83838dcbb1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3eed4de9-8018-469a-ac6a-3edec596d8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e10cd276-6c3f-4264-9e77-0feb5c8859b0" xlink:to="loc_us-gaap_StatementTable_3eed4de9-8018-469a-ac6a-3edec596d8d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d6d9e962-f47d-4c2d-8a6b-cb325b72a216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3eed4de9-8018-469a-ac6a-3edec596d8d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d6d9e962-f47d-4c2d-8a6b-cb325b72a216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6d9e962-f47d-4c2d-8a6b-cb325b72a216_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d6d9e962-f47d-4c2d-8a6b-cb325b72a216" xlink:to="loc_us-gaap_EquityComponentDomain_d6d9e962-f47d-4c2d-8a6b-cb325b72a216_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d6d9e962-f47d-4c2d-8a6b-cb325b72a216" xlink:to="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f61472f0-b84f-4b81-9055-1303ae129d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:to="loc_us-gaap_CommonStockMember_f61472f0-b84f-4b81-9055-1303ae129d95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ef3c7e34-6791-4b34-a10f-843d9a71c013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ef3c7e34-6791-4b34-a10f-843d9a71c013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8fc0a4d-4860-4f2c-a1a2-8053180172e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8fc0a4d-4860-4f2c-a1a2-8053180172e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9158b800-4553-42f7-bdc3-1b62e671f660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:to="loc_us-gaap_RetainedEarningsMember_9158b800-4553-42f7-bdc3-1b62e671f660" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i6cd02165f29d40b098eab645f36717f4_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_73956325-eab2-4470-8fb5-3f01c91824dc" xlink:href="krys-20210930.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_76818f40-dee6-47db-8dcc-631bcb1917d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_73956325-eab2-4470-8fb5-3f01c91824dc" xlink:to="loc_us-gaap_NumberOfOperatingSegments_76818f40-dee6-47db-8dcc-631bcb1917d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7c5621af-5635-4066-9949-a29daebd30a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_73956325-eab2-4470-8fb5-3f01c91824dc" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7c5621af-5635-4066-9949-a29daebd30a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_98a2ae0e-68ea-4c3a-a308-b5f211ff49ba" xlink:href="krys-20210930.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_73956325-eab2-4470-8fb5-3f01c91824dc" xlink:to="loc_krys_SignificantAccountingPoliciesTable_98a2ae0e-68ea-4c3a-a308-b5f211ff49ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc4be7a0-1c03-4531-8151-4315cf84c137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_krys_SignificantAccountingPoliciesTable_98a2ae0e-68ea-4c3a-a308-b5f211ff49ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc4be7a0-1c03-4531-8151-4315cf84c137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc4be7a0-1c03-4531-8151-4315cf84c137_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc4be7a0-1c03-4531-8151-4315cf84c137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc4be7a0-1c03-4531-8151-4315cf84c137_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f722810-2a48-4c58-98f2-1cab4d8b13b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc4be7a0-1c03-4531-8151-4315cf84c137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f722810-2a48-4c58-98f2-1cab4d8b13b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_67817d8d-323c-4cb0-8436-5e3ce3eeecbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f722810-2a48-4c58-98f2-1cab4d8b13b8" xlink:to="loc_us-gaap_EquipmentMember_67817d8d-323c-4cb0-8436-5e3ce3eeecbf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended" id="ib95fe8512bdd4ebc838f9bd051ef2e47_SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dc86c947-04e8-4cc1-9e87-5e63e95a8559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9337fd07-804e-46ec-aa38-adbc443995dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dc86c947-04e8-4cc1-9e87-5e63e95a8559" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9337fd07-804e-46ec-aa38-adbc443995dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dc86c947-04e8-4cc1-9e87-5e63e95a8559" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aeee91c1-3865-48cd-9920-a9c44c299d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aeee91c1-3865-48cd-9920-a9c44c299d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aeee91c1-3865-48cd-9920-a9c44c299d7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aeee91c1-3865-48cd-9920-a9c44c299d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aeee91c1-3865-48cd-9920-a9c44c299d7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aeee91c1-3865-48cd-9920-a9c44c299d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_9e0f6f3d-a80b-497a-96dd-e296e1d1a388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:to="loc_us-gaap_ComputerEquipmentMember_9e0f6f3d-a80b-497a-96dd-e296e1d1a388" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_06ee0ce9-9745-4988-9c64-f63233ec37a4" xlink:href="krys-20210930.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:to="loc_krys_LabEquipmentMember_06ee0ce9-9745-4988-9c64-f63233ec37a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_76aa9bcd-2fa2-43c4-8780-db961f7c9b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_76aa9bcd-2fa2-43c4-8780-db961f7c9b32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4f560fc4-1e73-46ab-bb09-ca15db2a7d98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:to="loc_srt_RangeAxis_4f560fc4-1e73-46ab-bb09-ca15db2a7d98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f560fc4-1e73-46ab-bb09-ca15db2a7d98_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4f560fc4-1e73-46ab-bb09-ca15db2a7d98" xlink:to="loc_srt_RangeMember_4f560fc4-1e73-46ab-bb09-ca15db2a7d98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6773c232-4147-4a2d-badc-025d5c5b842d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4f560fc4-1e73-46ab-bb09-ca15db2a7d98" xlink:to="loc_srt_RangeMember_6773c232-4147-4a2d-badc-025d5c5b842d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a5dc60f7-79ea-42c9-8085-6c9d7a723f9a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6773c232-4147-4a2d-badc-025d5c5b842d" xlink:to="loc_srt_MinimumMember_a5dc60f7-79ea-42c9-8085-6c9d7a723f9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b58ace8-9b1b-4af8-ac36-35aa0a37a046" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6773c232-4147-4a2d-badc-025d5c5b842d" xlink:to="loc_srt_MaximumMember_0b58ace8-9b1b-4af8-ac36-35aa0a37a046" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="ia82f91eefd474738b660a9416ca6f9c4_FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9677af83-db5f-4a92-893b-ad5f260e019a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9677af83-db5f-4a92-893b-ad5f260e019a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4931af18-1787-4d8f-8e9b-d5625aa8325d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4931af18-1787-4d8f-8e9b-d5625aa8325d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0c77fa2-e2bd-4719-badc-0abbde84b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0c77fa2-e2bd-4719-badc-0abbde84b5c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d3f4ab98-c964-4a3a-a815-998b99edebb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d3f4ab98-c964-4a3a-a815-998b99edebb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_980d7391-bd3d-4bca-9627-0f38991c0bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_980d7391-bd3d-4bca-9627-0f38991c0bec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5cabd86-957c-4060-a92d-c5dd40e75e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5cabd86-957c-4060-a92d-c5dd40e75e5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_90ef791d-c594-4a3c-b81e-bc20ce99d8bb" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_90ef791d-c594-4a3c-b81e-bc20ce99d8bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_56f7d1cf-bcf0-4614-a0e7-6c7612fc6e87" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_56f7d1cf-bcf0-4614-a0e7-6c7612fc6e87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_85057b0e-b2d0-4efd-8cd7-ec146186e8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_85057b0e-b2d0-4efd-8cd7-ec146186e8b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_54f05f3f-04bc-4d58-bb45-3710bed037b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_54f05f3f-04bc-4d58-bb45-3710bed037b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54f05f3f-04bc-4d58-bb45-3710bed037b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_54f05f3f-04bc-4d58-bb45-3710bed037b7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54f05f3f-04bc-4d58-bb45-3710bed037b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_54f05f3f-04bc-4d58-bb45-3710bed037b7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0b92c05a-c275-40e2-b590-118c4a815bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0b92c05a-c275-40e2-b590-118c4a815bba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_caa3a5a2-c3af-4028-af26-698485721b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_CommercialPaperMember_caa3a5a2-c3af-4028-af26-698485721b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_cdbaf0ff-e989-4f33-85b9-1885003bb42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_cdbaf0ff-e989-4f33-85b9-1885003bb42e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4bcab043-f484-4b34-984c-0f2196549613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4bcab043-f484-4b34-984c-0f2196549613" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_52bf183f-ca09-4665-8824-22b9de34882f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_CashMember_52bf183f-ca09-4665-8824-22b9de34882f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_04ef7de3-55a0-48ad-884d-2d960c1b4fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_04ef7de3-55a0-48ad-884d-2d960c1b4fad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1f6a76e-ed8a-4fa7-a722-78da3824ee03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1f6a76e-ed8a-4fa7-a722-78da3824ee03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1f6a76e-ed8a-4fa7-a722-78da3824ee03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1f6a76e-ed8a-4fa7-a722-78da3824ee03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1f6a76e-ed8a-4fa7-a722-78da3824ee03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cedc5a52-f229-4169-af64-c5435b1a70f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1f6a76e-ed8a-4fa7-a722-78da3824ee03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cedc5a52-f229-4169-af64-c5435b1a70f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d12d06bb-7603-4da4-b494-7564368948fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cedc5a52-f229-4169-af64-c5435b1a70f1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d12d06bb-7603-4da4-b494-7564368948fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88132ed8-b0d0-445e-acde-85b485fdfdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cedc5a52-f229-4169-af64-c5435b1a70f1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88132ed8-b0d0-445e-acde-85b485fdfdd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6e51ed90-f02c-4f9d-b95d-31f1a109e803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6e51ed90-f02c-4f9d-b95d-31f1a109e803" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6e51ed90-f02c-4f9d-b95d-31f1a109e803_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6e51ed90-f02c-4f9d-b95d-31f1a109e803" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6e51ed90-f02c-4f9d-b95d-31f1a109e803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6e51ed90-f02c-4f9d-b95d-31f1a109e803" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_1eb4a8bb-2445-422e-93b9-3917646bf2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_1eb4a8bb-2445-422e-93b9-3917646bf2ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_ce4a1a90-d081-4bcb-bb13-5d9b3c43a9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_ce4a1a90-d081-4bcb-bb13-5d9b3c43a9f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_c55a8219-1696-4345-b481-270be029f638" xlink:href="krys-20210930.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_c55a8219-1696-4345-b481-270be029f638" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a23f7a30-22d8-4d01-b769-85ad912ab963" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_srt_RangeAxis_a23f7a30-22d8-4d01-b769-85ad912ab963" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a23f7a30-22d8-4d01-b769-85ad912ab963_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a23f7a30-22d8-4d01-b769-85ad912ab963" xlink:to="loc_srt_RangeMember_a23f7a30-22d8-4d01-b769-85ad912ab963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d998609e-4c4b-4e32-85ea-2cc0c78f0635" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a23f7a30-22d8-4d01-b769-85ad912ab963" xlink:to="loc_srt_RangeMember_d998609e-4c4b-4e32-85ea-2cc0c78f0635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_68348c59-2d49-48bc-a19d-3478f87f258e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d998609e-4c4b-4e32-85ea-2cc0c78f0635" xlink:to="loc_srt_MinimumMember_68348c59-2d49-48bc-a19d-3478f87f258e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_611b14d7-afaf-4e79-9947-fbccfd5bb0f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d998609e-4c4b-4e32-85ea-2cc0c78f0635" xlink:to="loc_srt_MaximumMember_611b14d7-afaf-4e79-9947-fbccfd5bb0f5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="ib2a55342a2f642d2a86d0afd0f788b66_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2b77f645-0792-4c82-912e-ca88a3c6b560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2b77f645-0792-4c82-912e-ca88a3c6b560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a372dc22-5cb5-42aa-b3ce-cdee83db0e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a372dc22-5cb5-42aa-b3ce-cdee83db0e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63639bf2-1eab-46d4-9771-c8c6a26e712a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63639bf2-1eab-46d4-9771-c8c6a26e712a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a3c4b1e-7659-4f55-8f5b-804e8036c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a3c4b1e-7659-4f55-8f5b-804e8036c73f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d20504eb-1826-43db-9a69-007e55a4f732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a3c4b1e-7659-4f55-8f5b-804e8036c73f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d20504eb-1826-43db-9a69-007e55a4f732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d20504eb-1826-43db-9a69-007e55a4f732_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d20504eb-1826-43db-9a69-007e55a4f732" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d20504eb-1826-43db-9a69-007e55a4f732_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d20504eb-1826-43db-9a69-007e55a4f732" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2d77435b-b4dc-46a5-8af5-e314480a8a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_us-gaap_ConstructionInProgressMember_2d77435b-b4dc-46a5-8af5-e314480a8a80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9d6dfda4-a763-4803-b689-d3711c8f2924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9d6dfda4-a763-4803-b689-d3711c8f2924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_96259e26-4d76-4731-baca-6045cb23ed44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_96259e26-4d76-4731-baca-6045cb23ed44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_81681144-5781-4149-acdf-f489def7986a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_us-gaap_ComputerEquipmentMember_81681144-5781-4149-acdf-f489def7986a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_4c0c2d6a-b2be-4edb-874c-e0073fe3a7cd" xlink:href="krys-20210930.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_krys_LabEquipmentMember_4c0c2d6a-b2be-4edb-874c-e0073fe3a7cd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i34aafca69b8c4b6db0babae28298273e_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_3c812fcc-946e-44eb-8cc1-f3c34d9d3a6f" xlink:href="krys-20210930.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_3c812fcc-946e-44eb-8cc1-f3c34d9d3a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_95c26482-339c-4200-bd73-f919744b17cc" xlink:href="krys-20210930.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_95c26482-339c-4200-bd73-f919744b17cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_aa729d5d-101a-47e7-b61f-7e8c29298bee" xlink:href="krys-20210930.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_aa729d5d-101a-47e7-b61f-7e8c29298bee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_38dbc55f-c9bf-4b1a-9df9-11c9773cc206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_FinanceLeaseLiability_38dbc55f-c9bf-4b1a-9df9-11c9773cc206" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a035fa77-1b7d-486a-b7e2-56451e6f6b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_ConstructionInProgressGross_a035fa77-1b7d-486a-b7e2-56451e6f6b78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_4d0988e3-3d12-45ec-a5a8-58dfdac01406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_EscrowDeposit_4d0988e3-3d12-45ec-a5a8-58dfdac01406" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_533e74c1-52df-4573-a7b6-254966185b5e" xlink:href="krys-20210930.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_533e74c1-52df-4573-a7b6-254966185b5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_288cae3d-6b15-4ca4-a0ae-887d0fecb363" xlink:href="krys-20210930.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_CumulativeEscalationClausePercent_288cae3d-6b15-4ca4-a0ae-887d0fecb363" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_5b7043fb-896c-48f9-8e9c-3981e30d2abc" xlink:href="krys-20210930.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_CumulativeEscalationClauseTerm_5b7043fb-896c-48f9-8e9c-3981e30d2abc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d146470c-07e6-411c-aa03-e59c6157c345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_OperatingLeaseCost_d146470c-07e6-411c-aa03-e59c6157c345" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8421569a-960c-49ba-8980-d6f51fea82f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_VariableLeaseCost_8421569a-960c-49ba-8980-d6f51fea82f2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_e9aaea53-e324-4d26-8476-6c1a16c2b14f" xlink:href="krys-20210930.xsd#krys_RemainingCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_RemainingCommitmentAmount_e9aaea53-e324-4d26-8476-6c1a16c2b14f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_fd26302f-b433-42ff-9ba2-21ff1f7f04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_ProfessionalFees_fd26302f-b433-42ff-9ba2-21ff1f7f04cf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_4cce153d-b856-44f3-ae57-ca7d4bb8239b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_ContractualObligation_4cce153d-b856-44f3-ae57-ca7d4bb8239b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_ec69b690-d182-4a10-854f-acaa59308be0" xlink:href="krys-20210930.xsd#krys_CostOfWorkPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_CostOfWorkPercentage_ec69b690-d182-4a10-854f-acaa59308be0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_54791080-7fac-4df4-8dc5-cfd778e6a93a" xlink:href="krys-20210930.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_54791080-7fac-4df4-8dc5-cfd778e6a93a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyReceivableReceivedAmount_c7fa36f7-8c56-4b14-a1c3-409314e607d5" xlink:href="krys-20210930.xsd#krys_LossContingencyReceivableReceivedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_LossContingencyReceivableReceivedAmount_c7fa36f7-8c56-4b14-a1c3-409314e607d5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions_7d3f17fe-7dac-4345-a824-4d160ea90bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions_7d3f17fe-7dac-4345-a824-4d160ea90bee" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fdc31633-c766-40e6-b543-17bee03c09a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fdc31633-c766-40e6-b543-17bee03c09a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fdc31633-c766-40e6-b543-17bee03c09a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fdc31633-c766-40e6-b543-17bee03c09a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fdc31633-c766-40e6-b543-17bee03c09a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85b4c9d6-ad2e-4689-a87f-5426766fefd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fdc31633-c766-40e6-b543-17bee03c09a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85b4c9d6-ad2e-4689-a87f-5426766fefd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_b5806cab-d5ba-413e-ba36-255b5757d9ee" xlink:href="krys-20210930.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85b4c9d6-ad2e-4689-a87f-5426766fefd3" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_b5806cab-d5ba-413e-ba36-255b5757d9ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_3f3a04da-400d-4378-b318-4231666b6d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:to="loc_us-gaap_SupplyCommitmentAxis_3f3a04da-400d-4378-b318-4231666b6d26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_3f3a04da-400d-4378-b318-4231666b6d26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_3f3a04da-400d-4378-b318-4231666b6d26" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_3f3a04da-400d-4378-b318-4231666b6d26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_3f3a04da-400d-4378-b318-4231666b6d26" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_5bcf3d3c-085b-400c-81a8-10fa11dacc05" xlink:href="krys-20210930.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:to="loc_krys_ClinicalSupplyAgreementMember_5bcf3d3c-085b-400c-81a8-10fa11dacc05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_f80806b2-afc8-45a9-b232-c0106f1e71ea" xlink:href="krys-20210930.xsd#krys_OtherContractualObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:to="loc_krys_OtherContractualObligationsMember_f80806b2-afc8-45a9-b232-c0106f1e71ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_72871e1e-6fce-4dee-8272-57bfde15f4eb" xlink:href="krys-20210930.xsd#krys_ASTRAFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:to="loc_krys_ASTRAFacilityMember_72871e1e-6fce-4dee-8272-57bfde15f4eb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended" id="iacd41f8a0ccf4e878bdfe90fe5adf9c9_CapitalizationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc1ee572-355b-4333-9bad-feb91276dca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc1ee572-355b-4333-9bad-feb91276dca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_61acaf81-02e0-419c-a7fe-cc4ca35e6f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_61acaf81-02e0-419c-a7fe-cc4ca35e6f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_716daee7-8533-468e-a75e-dfbc7ed3ba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_716daee7-8533-468e-a75e-dfbc7ed3ba7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_a9331024-dd0d-4b23-966b-4e8e2dc0765e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_a9331024-dd0d-4b23-966b-4e8e2dc0765e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5cb0dc56-d3bb-4052-8b65-6276ee7e336c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5cb0dc56-d3bb-4052-8b65-6276ee7e336c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7b7900e-0d2f-4d18-8bbd-b3501193651d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7b7900e-0d2f-4d18-8bbd-b3501193651d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_176c840c-3b44-45b6-affe-41f9e048514f" xlink:href="krys-20210930.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_176c840c-3b44-45b6-affe-41f9e048514f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0df17f7e-6acd-489a-8559-cecd555aac16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0df17f7e-6acd-489a-8559-cecd555aac16" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_50b5da8f-d22e-48de-8b2e-aad98c8594a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_50b5da8f-d22e-48de-8b2e-aad98c8594a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_3af4d295-207c-47e3-98b8-b555af4af5c6" xlink:href="krys-20210930.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_3af4d295-207c-47e3-98b8-b555af4af5c6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10ef0106-02af-4446-82e2-ef0ea084067f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10ef0106-02af-4446-82e2-ef0ea084067f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10ef0106-02af-4446-82e2-ef0ea084067f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10ef0106-02af-4446-82e2-ef0ea084067f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10ef0106-02af-4446-82e2-ef0ea084067f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51fcebe7-ff10-4d4b-ad40-a604b9c7982b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10ef0106-02af-4446-82e2-ef0ea084067f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51fcebe7-ff10-4d4b-ad40-a604b9c7982b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockSaleAgreementMember_d44840d6-4a56-46c9-b0df-5e5896287036" xlink:href="krys-20210930.xsd#krys_StockSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51fcebe7-ff10-4d4b-ad40-a604b9c7982b" xlink:to="loc_krys_StockSaleAgreementMember_d44840d6-4a56-46c9-b0df-5e5896287036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_58aea9d7-825b-4321-8af3-8127696e9d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_58aea9d7-825b-4321-8af3-8127696e9d2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58aea9d7-825b-4321-8af3-8127696e9d2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_58aea9d7-825b-4321-8af3-8127696e9d2b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58aea9d7-825b-4321-8af3-8127696e9d2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_58aea9d7-825b-4321-8af3-8127696e9d2b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_db120754-e658-47d9-b5bb-6b46cd21eef8" xlink:href="krys-20210930.xsd#krys_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:to="loc_krys_PublicOfferingMember_db120754-e658-47d9-b5bb-6b46cd21eef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_7da74354-4c05-452c-bd67-6d52acbbef44" xlink:href="krys-20210930.xsd#krys_PlacementSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:to="loc_krys_PlacementSharesMember_7da74354-4c05-452c-bd67-6d52acbbef44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_5438e5f8-4a4e-40dd-a16d-63401bc4a78d" xlink:href="krys-20210930.xsd#krys_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:to="loc_krys_ATMProgramMember_5438e5f8-4a4e-40dd-a16d-63401bc4a78d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_c7eadc61-c04b-4bd3-828b-2a41153cd40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:to="loc_us-gaap_OverAllotmentOptionMember_c7eadc61-c04b-4bd3-828b-2a41153cd40b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="ib0aa0e6d10ca40c187bb4c5cc73d81dc_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2a0b712e-aee4-492e-b0d5-de5551bb25f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2a0b712e-aee4-492e-b0d5-de5551bb25f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_03537b97-fba0-4129-9280-37b69c54322d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_03537b97-fba0-4129-9280-37b69c54322d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_76e13206-7fc0-4c4b-9880-bd35dc812071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_76e13206-7fc0-4c4b-9880-bd35dc812071" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b13dafe5-ba56-4acd-8a76-9ddf10fb324f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b13dafe5-ba56-4acd-8a76-9ddf10fb324f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ed040e6f-c77b-4cde-b9f6-a68147430ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ed040e6f-c77b-4cde-b9f6-a68147430ce9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1419d4e5-8246-4bfb-b6d8-a35b4aced4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1419d4e5-8246-4bfb-b6d8-a35b4aced4d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65b094f1-7a7a-47a1-b9cb-b3cbdab519c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65b094f1-7a7a-47a1-b9cb-b3cbdab519c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3b2369e7-0dcc-40f7-9adf-cb8b653ea447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3b2369e7-0dcc-40f7-9adf-cb8b653ea447" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80a8c648-e843-4b5c-afa4-9c2b3746301a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80a8c648-e843-4b5c-afa4-9c2b3746301a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_faebfd68-ea07-4f7e-8842-656167d4ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_faebfd68-ea07-4f7e-8842-656167d4ba62" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b66eb6b-fb5f-40b1-b9c0-0500f77766db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b66eb6b-fb5f-40b1-b9c0-0500f77766db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3f7f80c-2736-4591-98d7-bc8f90d6a7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f7199f27-c791-450f-9c18-9bd85778ca07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f7199f27-c791-450f-9c18-9bd85778ca07" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_909eb8ef-5129-4a77-92f2-edf9037219eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_us-gaap_AwardTypeAxis_909eb8ef-5129-4a77-92f2-edf9037219eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_909eb8ef-5129-4a77-92f2-edf9037219eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_909eb8ef-5129-4a77-92f2-edf9037219eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_909eb8ef-5129-4a77-92f2-edf9037219eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_909eb8ef-5129-4a77-92f2-edf9037219eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_930692a7-9718-483a-b88b-b75fcd199f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_930692a7-9718-483a-b88b-b75fcd199f57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_cd319c52-ee7b-4411-a187-ee1cd8edeb20" xlink:href="krys-20210930.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:to="loc_krys_NonEmployeeStockOptionMember_cd319c52-ee7b-4411-a187-ee1cd8edeb20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_70876166-a2f3-4042-9d1f-5c534177fc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:to="loc_us-gaap_RestrictedStockMember_70876166-a2f3-4042-9d1f-5c534177fc7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_41dbbdc2-c519-44c4-b725-860dd4bd0a06" xlink:href="krys-20210930.xsd#krys_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:to="loc_krys_IncentiveStockOptionsMember_41dbbdc2-c519-44c4-b725-860dd4bd0a06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_srt_RangeAxis_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5" xlink:to="loc_srt_RangeMember_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51e4caa3-91eb-46dd-a677-c08e48ede637" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5" xlink:to="loc_srt_RangeMember_51e4caa3-91eb-46dd-a677-c08e48ede637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c5e5e6b1-2377-4ed3-a4ef-c58f17f7b21d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51e4caa3-91eb-46dd-a677-c08e48ede637" xlink:to="loc_srt_MinimumMember_c5e5e6b1-2377-4ed3-a4ef-c58f17f7b21d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e226d811-ed7f-42d5-874e-ab3d025bff30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51e4caa3-91eb-46dd-a677-c08e48ede637" xlink:to="loc_srt_MaximumMember_e226d811-ed7f-42d5-874e-ab3d025bff30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7f486375-bd1b-4fbd-a682-9cd703aa2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_us-gaap_PlanNameAxis_7f486375-bd1b-4fbd-a682-9cd703aa2d18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7f486375-bd1b-4fbd-a682-9cd703aa2d18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7f486375-bd1b-4fbd-a682-9cd703aa2d18" xlink:to="loc_us-gaap_PlanNameDomain_7f486375-bd1b-4fbd-a682-9cd703aa2d18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dd03ea92-3e9e-4091-a9ba-9460a36ed3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7f486375-bd1b-4fbd-a682-9cd703aa2d18" xlink:to="loc_us-gaap_PlanNameDomain_dd03ea92-3e9e-4091-a9ba-9460a36ed3c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_fe2b62a8-fb8b-46c3-9c71-378784be29f8" xlink:href="krys-20210930.xsd#krys_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dd03ea92-3e9e-4091-a9ba-9460a36ed3c7" xlink:to="loc_krys_StockIncentivePlanMember_fe2b62a8-fb8b-46c3-9c71-378784be29f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2c5b1ad7-dc22-41be-be11-9909948ec3bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_srt_TitleOfIndividualAxis_2c5b1ad7-dc22-41be-be11-9909948ec3bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c5b1ad7-dc22-41be-be11-9909948ec3bc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2c5b1ad7-dc22-41be-be11-9909948ec3bc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c5b1ad7-dc22-41be-be11-9909948ec3bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3238347-399c-422a-8d53-34b2b9003fe5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2c5b1ad7-dc22-41be-be11-9909948ec3bc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3238347-399c-422a-8d53-34b2b9003fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_575a01fb-9f69-4d7e-acde-3529baf69e5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3238347-399c-422a-8d53-34b2b9003fe5" xlink:to="loc_srt_DirectorMember_575a01fb-9f69-4d7e-acde-3529baf69e5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended" id="i3175bc4619834af7bf85ae532da13535_StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dd5b1d5-1f0e-43e8-8f8c-46a1292bfb93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa35c94d-314a-4e35-920d-1e1c38121ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dd5b1d5-1f0e-43e8-8f8c-46a1292bfb93" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa35c94d-314a-4e35-920d-1e1c38121ce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dd5b1d5-1f0e-43e8-8f8c-46a1292bfb93" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0551c179-7e10-4124-8e49-1314df259548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0551c179-7e10-4124-8e49-1314df259548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0551c179-7e10-4124-8e49-1314df259548_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0551c179-7e10-4124-8e49-1314df259548" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0551c179-7e10-4124-8e49-1314df259548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8900197e-f9cb-404d-9868-7f0022303c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0551c179-7e10-4124-8e49-1314df259548" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8900197e-f9cb-404d-9868-7f0022303c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6af9243b-3def-4553-8fc8-8cf891c3fd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8900197e-f9cb-404d-9868-7f0022303c4b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6af9243b-3def-4553-8fc8-8cf891c3fd6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6ea23212-4216-41ef-a7a8-a4abf65bbd82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8900197e-f9cb-404d-9868-7f0022303c4b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6ea23212-4216-41ef-a7a8-a4abf65bbd82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_871a1dd0-d235-4d54-978c-5ad492deec0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:to="loc_us-gaap_AwardTypeAxis_871a1dd0-d235-4d54-978c-5ad492deec0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871a1dd0-d235-4d54-978c-5ad492deec0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_871a1dd0-d235-4d54-978c-5ad492deec0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871a1dd0-d235-4d54-978c-5ad492deec0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0235c5fa-280c-46e0-91ec-4344a309c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_871a1dd0-d235-4d54-978c-5ad492deec0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0235c5fa-280c-46e0-91ec-4344a309c18e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e7f9b81f-f48f-4596-a6ea-1b2134e767a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0235c5fa-280c-46e0-91ec-4344a309c18e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e7f9b81f-f48f-4596-a6ea-1b2134e767a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ea5d1653-42f4-4f05-add0-683ed3a23dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0235c5fa-280c-46e0-91ec-4344a309c18e" xlink:to="loc_us-gaap_RestrictedStockMember_ea5d1653-42f4-4f05-add0-683ed3a23dd4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended" id="i9e6cf1d7e5ad4b0bbda916b8707fc877_StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3319710b-a19b-41b0-98bc-a3ce1e7bbc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3319710b-a19b-41b0-98bc-a3ce1e7bbc07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c515b3b5-031f-4347-85bb-442532789af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c515b3b5-031f-4347-85bb-442532789af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c9254065-a54b-4252-8be1-11a29aa847db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c9254065-a54b-4252-8be1-11a29aa847db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_426f2a20-5e3f-495b-9a12-3c68d37f8ed8" xlink:href="krys-20210930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_426f2a20-5e3f-495b-9a12-3c68d37f8ed8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_9ab54320-b7b4-4006-b4bd-430f02b84aae" xlink:href="krys-20210930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_9ab54320-b7b4-4006-b4bd-430f02b84aae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcf90c9f-57c0-4d1d-ae3e-f3997521c4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcf90c9f-57c0-4d1d-ae3e-f3997521c4c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d884af28-2c75-430e-9bf6-5f2e500a9180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcf90c9f-57c0-4d1d-ae3e-f3997521c4c9" xlink:to="loc_us-gaap_AwardTypeAxis_d884af28-2c75-430e-9bf6-5f2e500a9180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d884af28-2c75-430e-9bf6-5f2e500a9180_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d884af28-2c75-430e-9bf6-5f2e500a9180" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d884af28-2c75-430e-9bf6-5f2e500a9180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e43df3c-f485-42e2-8437-ff85762cd0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d884af28-2c75-430e-9bf6-5f2e500a9180" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e43df3c-f485-42e2-8437-ff85762cd0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4067af86-a958-4aab-be09-d8bce4ec0497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e43df3c-f485-42e2-8437-ff85762cd0f7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4067af86-a958-4aab-be09-d8bce4ec0497" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended" id="i56ccab67755a447e85115bc318f3f2f7_StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dba5af38-f4c6-41aa-a5ff-16e59c516e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dba5af38-f4c6-41aa-a5ff-16e59c516e2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e50b9cbc-a8f4-468c-8104-134e5822f594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e50b9cbc-a8f4-468c-8104-134e5822f594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fcd7d4d8-0eda-47d9-9651-c59d20c47188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fcd7d4d8-0eda-47d9-9651-c59d20c47188" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_442dbd74-ae9b-413a-91f9-0704e4eb85c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_442dbd74-ae9b-413a-91f9-0704e4eb85c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6453d2f9-5f45-4671-8cb4-0d6af5fdece8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6453d2f9-5f45-4671-8cb4-0d6af5fdece8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d1927b90-fb0e-4bf0-8c91-bb3babd394f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dba5af38-f4c6-41aa-a5ff-16e59c516e2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d7c79488-06b2-41d3-bda5-e6394a85ae35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d7c79488-06b2-41d3-bda5-e6394a85ae35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99ae6483-2ac4-4dca-ae8d-c4dfb54220b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99ae6483-2ac4-4dca-ae8d-c4dfb54220b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b092c5c-12ff-4d08-b772-3c0779740855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b092c5c-12ff-4d08-b772-3c0779740855" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_76283e0f-dcc9-4b8d-9e3b-879f3c877ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_76283e0f-dcc9-4b8d-9e3b-879f3c877ef0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82d7ad22-1747-4aea-a4aa-c8657ecb217b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0be993e-acc1-4a9b-befc-84be55a6454f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dba5af38-f4c6-41aa-a5ff-16e59c516e2a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0be993e-acc1-4a9b-befc-84be55a6454f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0be993e-acc1-4a9b-befc-84be55a6454f" xlink:to="loc_us-gaap_AwardTypeAxis_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06b43361-2703-4f5f-a361-a0bf4edef5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06b43361-2703-4f5f-a361-a0bf4edef5a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7eb5d81a-bc11-4f2b-a24a-a30a0fb4871a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06b43361-2703-4f5f-a361-a0bf4edef5a7" xlink:to="loc_us-gaap_RestrictedStockMember_7eb5d81a-bc11-4f2b-a24a-a30a0fb4871a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended" id="ibf06e15e68ab48f0822b3b1e8ac705bf_RelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5ccaeece-7c75-44b4-834d-0c2f344b1972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdvanceToRelatedParty_a68ab921-95ad-4d12-85f7-e8a899b179de" xlink:href="krys-20210930.xsd#krys_AdvanceToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5ccaeece-7c75-44b4-834d-0c2f344b1972" xlink:to="loc_krys_AdvanceToRelatedParty_a68ab921-95ad-4d12-85f7-e8a899b179de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47e2856d-7ffb-4003-a995-9928bd94fffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5ccaeece-7c75-44b4-834d-0c2f344b1972" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47e2856d-7ffb-4003-a995-9928bd94fffa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b5599949-949a-482b-adf2-1145b0bcd9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47e2856d-7ffb-4003-a995-9928bd94fffa" xlink:to="loc_srt_TitleOfIndividualAxis_b5599949-949a-482b-adf2-1145b0bcd9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b5599949-949a-482b-adf2-1145b0bcd9ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b5599949-949a-482b-adf2-1145b0bcd9ab" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b5599949-949a-482b-adf2-1145b0bcd9ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_db3e045f-5de7-4b95-a04e-f4781106b106" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b5599949-949a-482b-adf2-1145b0bcd9ab" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_db3e045f-5de7-4b95-a04e-f4781106b106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_c0c5ae9e-0485-4c70-9c18-9245e3174627" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_db3e045f-5de7-4b95-a04e-f4781106b106" xlink:to="loc_srt_ManagementMember_c0c5ae9e-0485-4c70-9c18-9245e3174627" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>krys-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:51c004c1-b4bb-4008-a736-d538f5596d86,g:ccbd04b3-aea9-417b-ad73-32d54787d8a0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_krys_StockSaleAgreementMember_6fe06a46-6f29-42ab-88b3-3f25ca949261_terseLabel_en-US" xlink:label="lab_krys_StockSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement</link:label>
    <link:label id="lab_krys_StockSaleAgreementMember_label_en-US" xlink:label="lab_krys_StockSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement [Member]</link:label>
    <link:label id="lab_krys_StockSaleAgreementMember_documentation_en-US" xlink:label="lab_krys_StockSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockSaleAgreementMember" xlink:href="krys-20210930.xsd#krys_StockSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_StockSaleAgreementMember" xlink:to="lab_krys_StockSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_e04cbbad-d6d8-424f-8080-33da38c14b78_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_487760a2-3cd6-4566-a9e9-346ccb28f726_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2d1a61da-6afc-4108-b3e0-56fb4c85d49b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OfferingCostsIncurredButNotYetPaid_400a0696-e5f9-4133-9bcf-e145c7546213_terseLabel_en-US" xlink:label="lab_krys_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid offering costs</link:label>
    <link:label id="lab_krys_OfferingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_krys_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_krys_OfferingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_krys_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OfferingCostsIncurredButNotYetPaid" xlink:href="krys-20210930.xsd#krys_OfferingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OfferingCostsIncurredButNotYetPaid" xlink:to="lab_krys_OfferingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ATMProgramMember_62fab466-24db-4013-b6f8-3e1026554543_terseLabel_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_krys_ATMProgramMember_label_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_krys_ATMProgramMember_documentation_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember" xlink:href="krys-20210930.xsd#krys_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ATMProgramMember" xlink:to="lab_krys_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9df4bce4-732c-4d8c-b456-781e4b3db2c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_016ced3f-7199-4e95-b24d-0d13211b32e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a6df611c-5324-4c6b-aaf9-e590d6d592c3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b06f94e7-d7cc-436d-810f-e3d952bb3805_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f10fa71d-bb93-4a2e-a1dc-d31b4a864dc1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_558a6841-9bce-4a20-9025-90a73bb1417e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a2576640-8dfd-4e12-a260-7c7e4f9a423d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_19a409a7-fb53-4f75-ad61-0c0cce3f800d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c548dd17-5505-4787-a65e-69d3ae92e3b2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_071fadba-63a6-40bb-95a7-ed27a6191591_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a0aaa9c2-f4e8-410b-aec7-558958c93561_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bfddd7b3-dbf4-4193-9705-a6ee3a57b527_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_34fefcba-6f48-4523-b9d2-7d90221284e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_65890384-d11e-44dc-9ce3-0976f37c315d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fbd7f04b-081d-4745-8103-67e5498952c6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_01a1bf7c-a685-435e-93ba-e8e6866727e0_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f7a7cab1-8ee5-44d4-a548-932fd77949e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_239d802b-7ed6-4b8d-828d-ba536d7a117e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_344b9a18-eb92-4513-9fcb-f58f435937d0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_895041f5-6e12-47fa-b72a-d6d80f642d68_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a6e3091b-e669-4756-b2e0-0cf316b962aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_0cb77dc3-a369-42f9-9239-356e8dba46c4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_74b3dde2-1fff-4248-a99c-bb6cfe25023d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cd643355-61bc-456e-b46c-fef1b0acee62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_05b30833-cba7-4b23-afde-6bc089101c4c_terseLabel_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, liability, annual lease payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_label_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_documentation_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:href="krys-20210930.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:to="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba599466-e739-48e5-8763-4141dc496048_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_121e369d-2f06-42d9-a55f-12e95c247483_terseLabel_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreements</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember" xlink:href="krys-20210930.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ClinicalSupplyAgreementMember" xlink:to="lab_krys_ClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_643a6a77-7d91-40be-a9ca-3657489c8ac7_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5ef96abf-d982-40c9-8fb3-6205fdf64f71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3fc91a6f-35f3-42c1-93d4-300d5898bb92_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_82142ab0-2759-4441-8878-1d41ceb493fa_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:href="krys-20210930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d8165455-8978-4ab2-b6fa-0a7d85c662fe_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_47f6314a-2255-4f18-8be6-d84f5d706e03_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems" xlink:href="krys-20210930.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems" xlink:to="lab_krys_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_06561b63-3269-4298-b54d-f1e4cd4c7422_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term, in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions_cd6b2cde-196a-40a4-8292-20a545a74899_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, receivable, additions</link:label>
    <link:label id="lab_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions_label_en-US" xlink:label="lab_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions" xlink:to="lab_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2b2a4c74-9dc0-46a7-acd9-ba63af490df3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_BuildToSuitLeaseLiabilityCurrent_620140ac-83d0-4489-bb0d-e4316a9b8fff_terseLabel_en-US" xlink:label="lab_krys_BuildToSuitLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build to suit lease liability</link:label>
    <link:label id="lab_krys_BuildToSuitLeaseLiabilityCurrent_label_en-US" xlink:label="lab_krys_BuildToSuitLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build To Suit Lease Liability, Current</link:label>
    <link:label id="lab_krys_BuildToSuitLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_krys_BuildToSuitLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build To Suit Lease Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BuildToSuitLeaseLiabilityCurrent" xlink:href="krys-20210930.xsd#krys_BuildToSuitLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_BuildToSuitLeaseLiabilityCurrent" xlink:to="lab_krys_BuildToSuitLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_968bd3ef-07f8-4931-b977-047bd5caa62a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_a18eb05d-134c-4325-b624-320a2ff9f165_terseLabel_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental condensed consolidated balance sheet information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="krys-20210930.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ecf80cc5-8175-4e86-879f-d8aabd77cdb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_17fc3083-d0f3-467e-9235-34e0f5ceb6e0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a426beed-ea50-4030-bf77-c3a8204e891d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e305a170-9720-4640-902a-4973b70c2f86_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_13604ea0-7286-4cf9-b91d-4e45ad55e3c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6ec8f8ff-feae-4691-8c88-ed5114a954d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1845e723-59b1-4d5a-baae-b78e3714f406_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_2a70a224-ea73-4759-bfd1-fe5b3b08f957_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_4cd90e38-b17b-43c6-864e-5c80fd05d61c_terseLabel_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_label_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll And Benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_documentation_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits" xlink:href="krys-20210930.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPayrollAndBenefits" xlink:to="lab_krys_AccruedPayrollAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_72b860b3-12b4-4ffc-b0f8-cd14a9ea55c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7b379c98-944f-4789-8adc-bd0217af4f6d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0510a5d0-c377-48bb-bff1-808f5364abf7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_bf17efb5-fbe3-473c-8fcd-e5e3e330a05a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2aa541dc-3167-4698-a3aa-4391420409a5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_88c06384-cc0f-4050-b324-9060865a1b1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b43fb774-5a0e-41aa-b03a-a1d057b8a5e3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_57f7d8f5-72a5-486d-96d7-bf14505c1f84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_56c92601-d803-4c4a-8e27-15d2460a349b_terseLabel_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:href="krys-20210930.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:to="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ec0153f-ff19-420e-9b7e-3d7bd94af0ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_646edcaf-c5e2-4c7b-96f4-91e6f6c8021c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dd8ad486-d2a4-4799-9c89-6cfcc6297799_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_08d29576-b6df-4a34-97e1-4e0d1d3a8c08_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2d0f24d1-7f96-400a-a767-5e04e454fc71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_20ae6a46-37b1-4361-9edc-5fc9f1084420_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_901ba1fe-fd38-44d3-b7d0-f92a5f66b406_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4f1b5072-e323-45e7-8da1-7fd31bcd3e65_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_1edfef69-da71-4232-a74c-d217e0dfc3d2_terseLabel_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_label_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_19aeb35c-d84d-4c6d-b3a3-a1ff8b6788e5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_890e1bcd-266e-4df4-86da-1213ed009bb4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8938532b-c8d6-4497-bd07-f7ec10f9fb3c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_36931c4e-3787-486b-bd7c-33765ec341e9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c496ed0f-1412-4fd5-898b-456db3fb7147_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_60740882-36ef-43a8-969b-6d6549b4edff_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5fe8bc5b-9648-483f-a8b2-c5105a9d7f4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_905b77b5-96f1-42e5-89e9-b2b26855ddb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per share of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e3b548f5-01ed-4bb2-9961-063e858a9566_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_f3bae935-2021-4ec0-90a5-07633260b3f0_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5ed37d1d-a6d8-49bd-a7a6-85c539ddb140_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2c787ac7-70b4-448a-bbf9-e3f0022b17ff_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d6febe45-f0ad-42c2-85da-c3c13445486e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fb89ab36-28fd-445c-a060-8c4df09c32ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f3dc969-fbfc-469f-81f0-f6ddfad26e80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_b24c87d9-5b37-43d7-89aa-2e26ca4b09cc_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_479ad7ef-5671-45fc-a451-0e9c4801575c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_f94f5d09-4709-46de-b861-61c00b38b7e5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_08fdf22e-3abd-4307-a76a-5d3173248ef5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_aa21f3ef-8de0-4c72-ad70-4171722cba93_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bd311b46-2e65-43bb-91f7-13512e5827b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8d02b31d-f624-478d-8571-ae799e103043_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2e9fdd3-d9b9-471e-b775-23093f3f54ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bb7ed8c2-800a-4551-839b-20ed77229151_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d4b2b55-b2ef-462d-afd8-587024c85e50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnSalesOfAssets_a6406839-0d20-4a79-879a-fd16ed4ded0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposals of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnSalesOfAssets_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets for Financial Service Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnSalesOfAssets" xlink:to="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_c27b74ea-d52d-49b3-b9fb-33d92efdfd4c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock; $0.00001 par value; 20,000,000 shares authorized at &#160;&#160; September&#160;30, 2021 (unaudited) and December&#160;31, 2020; 2,061,773 &#160;&#160; shares issued, and no shares outstanding at September&#160;30, 2021 &#160;&#160; (unaudited) and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9b9e70bc-bfeb-4028-8592-5f6023139a05_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38994df7-8611-477c-8b5f-f6587a4edb24_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de3f2514-a7f7-4afb-be0c-c1320efc0646_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0460e7c9-8bdc-440f-b735-2effca013efa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_d752bba8-4ac1-4c22-8a13-26d2be41faff_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1256c591-23f3-4bb3-a163-38d07e750013_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_da903812-f51e-4a9e-a72d-1b31fadc2c83_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_80dee462-3788-47be-a4ab-6b20067d2233_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75edc397-5aea-4afe-bbc9-83790597b341_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a57fe982-fe4f-4249-8493-b70b8b798c74_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_2b359c10-f838-42aa-99a3-02038e1d3723_terseLabel_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash contribution</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_label_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment To Escrow For Reducing Lease Rentals</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_documentation_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to escrow for reducing lease rentals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:href="krys-20210930.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:to="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LossContingencyReceivableReceivedAmount_629d6af0-55bc-41dd-b432-c47cdee514bd_terseLabel_en-US" xlink:label="lab_krys_LossContingencyReceivableReceivedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, receivable, received amount</link:label>
    <link:label id="lab_krys_LossContingencyReceivableReceivedAmount_label_en-US" xlink:label="lab_krys_LossContingencyReceivableReceivedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Received Amount</link:label>
    <link:label id="lab_krys_LossContingencyReceivableReceivedAmount_documentation_en-US" xlink:label="lab_krys_LossContingencyReceivableReceivedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Received Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyReceivableReceivedAmount" xlink:href="krys-20210930.xsd#krys_LossContingencyReceivableReceivedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LossContingencyReceivableReceivedAmount" xlink:to="lab_krys_LossContingencyReceivableReceivedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5a6f3775-499f-43fa-98f3-b48f150ee6f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ASTRAFacilityMember_e77f95f6-ae3f-49c7-8f40-32dc5d661b07_terseLabel_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA Facility</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_label_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A S T R A Facility [Member]</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_documentation_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember" xlink:href="krys-20210930.xsd#krys_ASTRAFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ASTRAFacilityMember" xlink:to="lab_krys_ASTRAFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ed670205-1922-4981-908b-765f9313cbe8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cd57cf96-5c91-46f1-a99d-f05b7b4e0050_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5b177625-20b2-44ab-b27b-44613922087c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_e56f5362-4285-4ce8-96f1-472e4e04062b_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, aggregate offering price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:href="krys-20210930.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:to="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6f42de90-59a8-4a05-bb09-936f50d42a3d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2f82f568-63f8-4ada-bc56-17fab9f04b82_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_StockIncentivePlanMember_e4eab9e6-d7d7-4a87-a6c3-3add9c714ef1_terseLabel_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_label_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember" xlink:href="krys-20210930.xsd#krys_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_StockIncentivePlanMember" xlink:to="lab_krys_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e919cacd-31a4-49f2-857a-f77be5bba10d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right-of-use assets and modification</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_ccaf2973-57ca-439a-b5f7-6decafd2ed1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f86a79d8-fdae-4720-8f9d-11639997528d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23d9919a-84ea-4a37-8284-4b785bd7d3c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4804ba39-9262-4d83-bd6e-f2cfcbe46e0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1300beeb-210f-45f1-95d4-9d44e97b12a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bbbba7c6-e18c-48cb-853b-03dcd06e62b8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8d3b6e5f-423e-439c-a457-3076d8644d38_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ea0b40e1-da9b-4da2-ac77-149599816e92_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7770956f-8af4-4933-acf2-689dcd7e4c93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_c42afe1a-e807-4ea7-993b-0754213efa8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_04899ea5-84b4-4325-b98f-799c911034c6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, amount capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54c35e88-b4be-423c-a3ca-d1676950ce60_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_f1229fcd-257e-4293-bd3d-92af42b94204_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining available issuance amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_label_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_documentation_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:href="krys-20210930.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:to="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c35aab96-e69d-4781-9523-012ca322dd37_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_f6a623b4-d11c-4251-8db5-07962d8b3f35_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_14ca1e7f-de42-4d86-9513-d7e47c462917_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5caa5090-aede-4739-a508-8d95bad23171_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_c526d83f-3858-4c4c-8f03-5d0c5127fd2e_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_79e9270e-0255-45a0-aadb-220304825e1a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_62b3eb93-4d8b-4393-a767-595d1a1d9e2f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_fdfe35b2-06ea-4f3b-bbee-392e03b37144_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ffb1e6f1-e316-433d-818d-f337dc5b9780_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cd092a47-e2cc-4227-b279-9271513e2d8d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_0b6049dc-892f-4b5a-9b11-ce82f6544a5d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4ce9c443-1693-4569-ad6f-ccd916e6d146_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_91468c71-1a04-4f9b-b8fe-ab8a8a0ae08b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1b044f2f-b5ff-4119-b2e2-699e9403e238_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8b218ab0-59a6-48e4-94cb-9b8dff238a7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d20021ec-b44e-4502-99bb-83c69cd74a07_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8066d46d-28f3-41bc-b7ae-c527efa0f9b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_02f35b03-b12c-4029-9428-4efa0094da8e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_b413880a-4fff-4f96-8eb9-5d8fa9df436f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_afc97606-92ba-4c79-8344-c131d4107a5a_terseLabel_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued financing costs</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_label_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_documentation_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent" xlink:href="krys-20210930.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedFinancingFeesCurrent" xlink:to="lab_krys_AccruedFinancingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03f301e9-0d52-4094-9105-549774d584e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c37e20a8-b2c4-4a1b-b48d-6a8af33ff24d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_dbb7a38c-d27f-4f16-8787-860ecc58c1a2_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_221413a5-1bcd-4eed-90bf-d584d9f21cb8_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_57f23099-8269-47cd-b82c-02af000df790_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a090e6ff-0966-4806-b31c-52ce5c9bc8df_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33f71553-5645-448e-9b79-5ceaa18ee697_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_0f22023f-f592-4e7b-82a1-43e8d982e1bc_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d5345d0a-6b3b-4a39-a7cd-b1969ef0fe40_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2809086f-f61c-4d49-8b1a-77fc8a7e9bb7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_a5f7eb82-3138-4ca8-8401-336dd2ded005_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_54caf80e-e70d-4e1d-9f6b-fa9bc8003662_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d41f3ada-f22a-4d83-871a-de20e4044549_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6da8e99d-a282-4590-a038-d499701a0d0a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4c24ba59-5321-4794-99f8-10c7229b22f6_terseLabel_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="krys-20210930.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_c6c47e5a-0552-4bcd-9283-1e38ea91db08_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PublicOfferingMember_633d21af-e94a-447a-8748-9e68e68c40b5_terseLabel_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_krys_PublicOfferingMember_label_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_krys_PublicOfferingMember_documentation_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember" xlink:href="krys-20210930.xsd#krys_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PublicOfferingMember" xlink:to="lab_krys_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_a1400579-968a-4918-98f5-0695433a7778_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_label_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent" xlink:href="krys-20210930.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClausePercent" xlink:to="lab_krys_CumulativeEscalationClausePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_9d736a9b-bdf2-4a5c-8eea-d6f1af37f548_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_dec3942a-21af-4564-b526-28133b98997d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a6ffe2e1-7091-41c6-9c59-0c9d589afb5d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f7f7a6be-8ce5-4994-ba7c-4372aaca257f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f310116b-1fb9-4d6d-b36f-6d278df710f0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec7d70b4-f4bf-4fc3-98e3-88c3428fa0f1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ef97dc64-3336-448e-8f29-0958034da1b6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ad66a953-4738-406c-a617-11043058e902_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e0a8ffee-7ee1-4cad-af68-c53d8db615ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_b6c7ad0a-2c9e-4bb2-872e-4be7e037c16d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_c06a1a8c-97ca-47a3-8f8e-6b620ffa569f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c6dc6bd1-b253-4254-a875-e3eec3ce7afe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_d5bba0de-5338-4b97-96d4-7719b572ed57_terseLabel_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of potential purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_label_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_documentation_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:href="krys-20210930.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:to="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_0ded837d-7bfb-40c9-9bee-b18e994f28ee_terseLabel_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, guaranteed maximum price to be paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_label_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_documentation_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:href="krys-20210930.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:to="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentsForSuitLiability_2bba254a-ec0f-448d-92fd-9b39e955684a_negatedTerseLabel_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of ASTRA build to suit liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_label_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_documentation_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability" xlink:href="krys-20210930.xsd#krys_PaymentsForSuitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentsForSuitLiability" xlink:to="lab_krys_PaymentsForSuitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_d867a433-10b2-46ed-b29b-b87c9bd7f42d_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value, total</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3aed9ef6-8f20-414d-ba39-e4dda1648f6e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_84138620-5cb3-4fbb-ac61-7a22af85e2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_872a714e-8a96-4d0a-8534-aa2e673fcd2f_terseLabel_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Lease Agreement</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_label_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Lease Agreement [Member]</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_documentation_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand sixteen lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:href="krys-20210930.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:to="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_3323cd3a-adbe-4594-9a46-4dc586f8c631_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause, term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_label_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm" xlink:href="krys-20210930.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClauseTerm" xlink:to="lab_krys_CumulativeEscalationClauseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ad495147-4050-4557-8d83-83e1978b3b8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ff43c01a-f5df-42db-9472-0486f09d3d7d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_920816d7-6721-4841-a1b9-f29aa886dda7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_2844a38f-22fb-49e4-adb2-d571ddd36689_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_37168aed-b2f8-482c-a130-582495f9e96b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized impairment losses for long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_498a4fa1-ede8-4ee4-bd4c-085c58976297_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_5195d3ab-7c49-45f7-a45f-bd0b1bfd1d2b_terseLabel_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Stock Option</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_label_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee stock option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember" xlink:href="krys-20210930.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NonEmployeeStockOptionMember" xlink:to="lab_krys_NonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93f537d4-0117-4ae1-8fdf-f42c2124473d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4ec877bc-019d-4bc1-9de5-055beec74d35_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial offering of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4113e561-2dbc-4ed7-a1af-61f18cb53ef3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ae8e85e8-00d0-4e68-b2f3-b69a92fdb4b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6334c80d-94bb-43be-bcb1-a153fb5caab3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c60d5fd1-9a32-4d1a-8148-9c4f0d8a5874_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_d8600c71-7e12-45ea-a3ec-3643aff79b14_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b1e79837-c97a-487f-8f94-826f5a965ea4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7ac95854-b829-4269-8bf7-c2a6988b54f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2284d68a-dc2a-476e-bd79-db10ec812a55_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_61e5d234-ea2b-4b08-897f-2297666b69db_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4aa52ad8-50fa-4b58-8462-c4748eac3bba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_767aae76-06d4-43e6-bef0-9a2238b41a99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_545f70e0-ccd2-4b3b-af67-36c84f842825_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6fbe101a-2cb7-4ff4-b3cc-1fa867625dbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9bc4ede3-bb28-4b75-9eea-6bb5cd3154db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_222e43b5-1bc7-4c43-8e2a-f748292dc98e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c0129a6c-10ae-49b4-a709-0a4b28151ac2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85bd3537-b6f6-46e4-86fb-e631a14677c5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RemainingCommitmentAmount_45535299-7675-46b2-ab18-8e1ced743350_terseLabel_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated remaining commitment</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_label_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Commitment Amount</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_documentation_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining commitment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount" xlink:href="krys-20210930.xsd#krys_RemainingCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RemainingCommitmentAmount" xlink:to="lab_krys_RemainingCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f47ed3f4-b2e6-4240-aeff-991e66785b50_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ac063970-0d4c-43c4-8906-96a9c045db4d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cecb9505-bd48-4511-8914-7395c73847a3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_13c5917a-1fe5-42ae-8170-4df3112322b9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_9f7ad27c-2dc8-42dd-82ba-cf4e9d10c52c_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable" xlink:href="krys-20210930.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesTable" xlink:to="lab_krys_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_40eee241-f668-40c0-adde-ee78f59cf869_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_13fa8a6d-4ebe-4af7-814a-9705a405140a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a3072412-4a55-4842-afd3-55128f6e4867_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_52ccdb0e-eec0-4dc3-bfba-8c154f9aba50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_046736e0-9777-44a7-b44f-a95058e072ad_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1bfc033d-8226-494c-bcf0-375a86a3255e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_10589375-d57f-41ec-a20b-5ebd5f5337cb_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_245c4510-ea79-4bc8-b08b-ba8a6f48aa41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c9a2e008-ede1-476f-b5c7-836d7f7294c7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d320f746-3737-4852-aaaf-8f9bff351b09_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_d3e989df-f9e7-41ca-a371-f51a17f3b354_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7f34d2ad-505e-4008-92bc-bfaac321c673_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_bfd4f067-c5d2-4e48-88db-35e6f5cefd26_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d23f373d-12a0-4f6f-9e23-2391dd803267_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_5c01c44b-33a5-4cb6-9d90-0b4000974033_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_7ef67d07-d702-4c62-b915-49826e61ec1b_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_abd1bdec-dd0b-4e91-8ba9-f909fa785230_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net, (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_4dd06d18-f943-47f5-ad8a-d0e4515a1ae5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_fb7eebae-faa4-44f7-9603-c418a284b5e0_totalLabel_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="krys-20210930.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7e609220-95ec-490d-bb8f-83847459b493_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c2f5c402-d7a6-4027-b80e-0c028d55a51f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b944efb0-c1c6-4f19-901d-e24778b717e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c9f8860e-fea6-4363-a750-651f8e68e6f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b2932eae-4e75-4207-b60d-624d1a765325_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.00001 par value; 80,000,000 shares authorized at &#160;&#160; September&#160;30, 2021 (unaudited) and December&#160;31, 2020; 22,237,984 &#160;&#160; and 19,714,220 shares issued and outstanding at September&#160;30, 2021 &#160;&#160; (unaudited) and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_48613dc3-fb11-48dd-9884-bf828e7b08f1_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_47f97771-ec56-4100-8f8a-cc9bc8589625_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e1180ac-ffd0-417f-8ac6-beaf5494cc8f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3a6fed6a-c84a-4167-9ae1-3544d2dff1de_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_3db2b0e6-dce0-4ce0-891f-40d8724caa77_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:href="krys-20210930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8fa56d1c-ef67-440d-8171-f4daa41285c5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d86bd57c-c3da-4b9e-99b3-42caa1ea1657_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c5cdd0df-4436-4b8f-91ab-8ab47ffa4f7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0a97f2fc-9416-4c5c-a1c2-4529128dd913_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d6ae418c-c15f-4703-8330-dccf2093578e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_076538d3-0598-49f7-8c25-cd09bfcc3678_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (expense)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f63ac5f1-dee8-4b08-a6e3-43db6ecd6060_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_62fec434-bfdc-401b-9f8d-a3d101d131e2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_83d209e0-2fe4-4339-88fa-adbbd625a24a_terseLabel_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Marketable Securities</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember" xlink:href="krys-20210930.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LongTermMarketableSecuritiesMember" xlink:to="lab_krys_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CostOfWorkPercentage_944d406f-e3e9-45ee-bad9-fc0f2e300d9a_terseLabel_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of work, percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_label_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_documentation_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage" xlink:href="krys-20210930.xsd#krys_CostOfWorkPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CostOfWorkPercentage" xlink:to="lab_krys_CostOfWorkPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11f9dfa4-1986-49d3-97e9-9dfc0e2fbdf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b412edd6-6aa7-4847-9b9b-459fbd3f6db4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7436f698-0af8-4d75-bce5-0fa1ffd663c5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_f3a9453b-923c-4aad-8453-35cce566c2ba_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_c8ac694f-0c41-4f29-8826-f2c06ef7e235_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:to="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2731801f-b1df-44e8-88a0-f9d0a1e72384_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ec8b2399-03b5-416c-b189-e5ee701d00bc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_dcab5195-02d4-4c74-87ec-68ae62238c82_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02f6c1af-d8c7-40c6-a3a2-b41065898b3e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_845dae8d-cc39-4aa4-a20f-ac09789b46c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_266a1ff5-4caa-4da3-9a6d-b175ceab4ff8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f8fc95cf-6669-4ef8-bd2c-49e0a4850473_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9ea9dc00-d33c-4dac-8b34-7c338462e3df_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_44f36e38-1ca1-495f-abb9-43f4c6c4149d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0ba2ec16-ef30-4845-897c-99a5291c091b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_95f83a93-0230-490c-aabf-e34e9385f1b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_f1a4a398-317b-4ade-88bd-c1d0526a43d1_terseLabel_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_label_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense And Other Nonoperating Net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_documentation_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense) and other nonoperating, net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:href="krys-20210930.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:to="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_0a6ac889-0bba-4c0b-9168-eeea7c8b3c53_terseLabel_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and uncertainties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:href="krys-20210930.xsd#krys_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_30198d60-0fea-4810-a9a5-ea16ea742878_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ef0443bb-bc8f-4070-99d8-c611399d71a0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6092c9ff-8d44-4664-8ae8-944f2a91a946_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8abbd86e-dda9-4897-9c2b-67cd751202fb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_8575c479-f2ae-4fb9-84c2-6c841e2636ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_310a1d1c-52cc-43a2-9088-d238035c42b5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_005e4404-c2e0-42da-b389-30ca10fa9f3f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f197bff-f0c9-48ee-98cd-fbc934d06d14_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_88c6c3e4-6b32-4e93-bc3e-d338ff89e541_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_9cf6f5aa-4b01-4d6c-85ad-e2ee158951e4_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_80d1d430-b0bd-4d14-9c02-c3ac79099438_terseLabel_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_label_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical And Clinical Expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_documentation_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:href="krys-20210930.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:to="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AdvanceToRelatedParty_47ac4dfa-d94b-4b0c-84c2-43a7c15c7b1a_terseLabel_en-US" xlink:label="lab_krys_AdvanceToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance to management team</link:label>
    <link:label id="lab_krys_AdvanceToRelatedParty_label_en-US" xlink:label="lab_krys_AdvanceToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance To Related Party</link:label>
    <link:label id="lab_krys_AdvanceToRelatedParty_documentation_en-US" xlink:label="lab_krys_AdvanceToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance to related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdvanceToRelatedParty" xlink:href="krys-20210930.xsd#krys_AdvanceToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AdvanceToRelatedParty" xlink:to="lab_krys_AdvanceToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_248b0a71-c531-4bb1-a35b-6a81c270b0cb_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_be9edfc3-3d11-4fca-8c64-c65e94c4e735_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8499bfc0-c553-457c-baf8-e5e6b32ffa81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_c0c12cad-1d91-4b02-bc1e-0493d0ca9204_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a8e4fa63-301b-47b2-a2b8-036b3be139aa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1dda29a0-2b3b-4a57-92f1-2b0fd599a1bb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_262468dc-4578-41fb-afb5-737fc39ee6e9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_2c0ad9cf-00cb-4f50-84f6-3434986c415a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f3265243-db92-4917-b8bc-74c51ae5af13_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_31467a63-7ea0-4db5-9203-c046c99f63f9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_02ae4584-8665-4ac1-b0de-3a92ceb2f889_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1f036db9-cfad-4373-adf1-0a8902f85ea6_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PlacementSharesMember_b333a5f5-12da-4e15-8433-aa8457eebb3f_terseLabel_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:label id="lab_krys_PlacementSharesMember_label_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares [Member]</link:label>
    <link:label id="lab_krys_PlacementSharesMember_documentation_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember" xlink:href="krys-20210930.xsd#krys_PlacementSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PlacementSharesMember" xlink:to="lab_krys_PlacementSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_a73b9af3-b09b-4d91-96a3-ac3db555a18f_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5e7c5fa6-34eb-4473-acdc-ec674f88e523_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_e2b98fb7-d02e-4ed5-824b-9ca56593a337_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7059d448-95ab-4a7e-8b18-6bae66061b05_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b44afde-8588-4a3a-844e-8330ed7cf058_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ff50fd96-a001-4207-bf13-3a4c0e2ab9de_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidRent_a1e9e290-ca69-4925-9d3d-024cdcab16fa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidRent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid rent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidRent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidRent" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_f87a70d5-bf26-4c87-9922-de635d5eeb7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project management service fee</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ec4336e1-b95a-481f-b020-448b2d6ee021_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0c39063f-8837-479c-b9c3-969f642d6098_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a048df9d-1476-4d91-88de-84d949420bb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_48dc377f-0451-44a5-8e5e-035e5f14117c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3ccd9747-4154-49dd-8e5f-9793af8834e3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_74612817-e609-47c6-b8ba-f4c9d9a0db00_terseLabel_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_label_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Area Of Real Estate Property Leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_documentation_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:href="krys-20210930.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:to="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0feb0794-9525-45a8-bcaa-f4093a7a59b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6efef397-121b-49bd-a48a-4ee76fd34237_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9d7869c1-31ca-4bbc-9420-741bcd015ae7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of the award (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_87f93f6d-0b29-4b44-b4b7-37204045225c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncentiveStockOptionsMember_62c8b8d5-2f6e-4140-9ea4-61ecfb7092b0_terseLabel_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember" xlink:href="krys-20210930.xsd#krys_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncentiveStockOptionsMember" xlink:to="lab_krys_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4d8d2ab1-05ab-47d2-a549-37fef96f11e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_d2116fcd-617a-4a31-b1c4-8237d38907fd_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3a30a73e-fc51-451b-b59b-3d3559c024be_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_daed6828-89b0-4863-81da-35c4e0d0e0e0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_6bcea0af-97fe-43df-a83f-af9a3312bdc3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4efbb420-a24e-4e04-a045-f6ee4355af48_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c1c8ee3d-612f-434c-8e81-932adbc254f3_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5e956b5f-f6f7-42f7-8cb5-afa64304f14b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_981ba341-aecd-4719-adf0-39564e9df937_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_439b8dee-5d67-49d6-aeef-dbce8d6dae57_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_6374378a-83ec-40d2-9366-3586b6b09a33_terseLabel_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_label_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction In Progress Current</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_documentation_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent" xlink:href="krys-20210930.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedConstructionInProgressCurrent" xlink:to="lab_krys_AccruedConstructionInProgressCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_585f5ffc-66d7-4e52-bfef-cd5124e8926f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_119cc748-8bee-4cc7-b1c8-bec481c0ba49_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="krys-20210930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4c93cca6-8b14-411a-81b7-3b2a8ddfdbf2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_9432dc64-7d83-439a-af27-47f0578dd57b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7fe2c93f-4584-42d2-8055-f1d05596bb45_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OtherContractualObligationsMember_99f8707a-2439-4214-b884-4023bc415b38_terseLabel_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_label_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations [Member]</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_documentation_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other contractual obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember" xlink:href="krys-20210930.xsd#krys_OtherContractualObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OtherContractualObligationsMember" xlink:to="lab_krys_OtherContractualObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bc2de3b3-9613-4bbb-b46c-ed6f68ab1e0d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dc996423-6a2f-4150-923f-a35fb9b2bfd6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4aff6612-1a25-4777-8edf-c88f6bd9bb51_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_58cd863c-29f1-46ba-81d5-93dcbe457fc8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f050aa6-bec7-4f69-90bd-dd0f2864bc32_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_69cae88b-b14c-4ffa-80f9-d5f669f8d9ee_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_cd0530eb-cffb-4217-8d22-66c2ef395640_terseLabel_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the estimated useful lives of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="krys-20210930.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_391d386f-b86e-41ed-9edf-c10ff3d8312c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9b5fb088-04a7-49cc-906d-dacb7f208ee3_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f31bae51-90e4-452d-a763-f35442b4f070_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c4a538a1-fd06-480a-aada-53bb3e6e3187_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9b88b1e-abf0-425b-afbf-d05d143c9704_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3690e965-5e00-4032-b6ae-776fff08fa67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a5f8b695-254d-464d-990b-d91faed52d52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9dff9d7e-eadc-4db3-ba67-aef27af091e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ac58dba7-bcf4-44e2-8dca-fedb50eaed9c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_57e4861a-835e-4115-b0dd-54687534f4c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e2306e3e-bf3f-427d-9c99-7f097e884037_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_84d6d26c-f466-470e-8761-32b30f7b694c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress, gross</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_73dd0ab7-17e6-4dac-9577-e52887d0127b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LabEquipmentMember_40a9c22d-4227-48c4-9067-e8381c6b0956_terseLabel_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_krys_LabEquipmentMember_label_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_krys_LabEquipmentMember_documentation_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember" xlink:href="krys-20210930.xsd#krys_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LabEquipmentMember" xlink:to="lab_krys_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_15cec1b8-675e-45c8-8484-cd0d547ee0c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_13c2d2ab-c0d0-425f-881c-7aad7c0c0e8d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c150bc60-6ade-4a22-a640-cdf45bc905b4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at September 30, 2021</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_30f960e6-a56f-468a-b9ca-1018fbb28d58_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f4d60475-20f9-4ec2-9051-1ad5f82b99d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_018fb96e-5778-4bff-adbf-c2464a90f259_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_6a6a30c0-d9f7-40c1-9092-e7e4333dba88_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6f997db0-5a40-40c1-8f1c-9c1112c54034_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d80b369f-07a3-4b90-99a7-d671503ed6f5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1cfb89b2-5da1-4082-8c69-cb24e386a45e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e7011077-6190-439b-be99-1f41d83d5f72_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5dc0585e-ba21-4f98-89bd-8b6b6fa6862f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50130bd0-192c-4a0b-b97c-c8ddb073c391_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>krys-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:51c004c1-b4bb-4008-a736-d538f5596d86,g:ccbd04b3-aea9-417b-ad73-32d54787d8a0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/Cover" xlink:type="simple" xlink:href="krys-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_04d1815a-dfe7-43ae-9d9b-471545207de6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_DocumentType_04d1815a-dfe7-43ae-9d9b-471545207de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_eb4e19de-68a5-4c4f-af73-1f336ab2daa0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_DocumentQuarterlyReport_eb4e19de-68a5-4c4f-af73-1f336ab2daa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bf4f78c9-4463-4143-88d3-450a18e8d468" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_DocumentPeriodEndDate_bf4f78c9-4463-4143-88d3-450a18e8d468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_446c8b80-a1f3-492e-b866-1292e1d5d04c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_DocumentTransitionReport_446c8b80-a1f3-492e-b866-1292e1d5d04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eec65d69-fbd9-4cd6-8665-bb5dc8d64953" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityFileNumber_eec65d69-fbd9-4cd6-8665-bb5dc8d64953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f4deef5a-2a4b-4529-807b-d270a69f0b98" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityRegistrantName_f4deef5a-2a4b-4529-807b-d270a69f0b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_89fc529f-6c5f-4675-9aaa-a2df1b35dfd5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityIncorporationStateCountryCode_89fc529f-6c5f-4675-9aaa-a2df1b35dfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_17fff979-dbbe-4314-b425-5004d37ee4ac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityTaxIdentificationNumber_17fff979-dbbe-4314-b425-5004d37ee4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f16affad-d127-4a46-94e6-eade2e7e3113" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityAddressAddressLine1_f16affad-d127-4a46-94e6-eade2e7e3113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_7a27414f-90ef-4a6f-b934-afa7d592841e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityAddressAddressLine2_7a27414f-90ef-4a6f-b934-afa7d592841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0897d96a-5e9b-493c-820e-05047129b695" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityAddressCityOrTown_0897d96a-5e9b-493c-820e-05047129b695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_596129f5-64f2-43b3-aa9f-607a3aee01c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityAddressStateOrProvince_596129f5-64f2-43b3-aa9f-607a3aee01c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8a43d50f-ebf0-4cce-a80c-af4df6c8db71" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityAddressPostalZipCode_8a43d50f-ebf0-4cce-a80c-af4df6c8db71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_40a11365-38c0-40db-994c-66d8b3faccb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_CityAreaCode_40a11365-38c0-40db-994c-66d8b3faccb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_860c5a3f-e19b-43f8-9451-609f5cdb1ccc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_LocalPhoneNumber_860c5a3f-e19b-43f8-9451-609f5cdb1ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2f90760f-bd98-4820-a785-514010b50cf0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_Security12bTitle_2f90760f-bd98-4820-a785-514010b50cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b35be473-2b4d-428f-8034-60881a4d1604" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_TradingSymbol_b35be473-2b4d-428f-8034-60881a4d1604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ab75ddd2-4d7a-445a-95ea-742d62beb70c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_SecurityExchangeName_ab75ddd2-4d7a-445a-95ea-742d62beb70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5962c575-bc9d-4a1f-988e-80b68de929a6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityCurrentReportingStatus_5962c575-bc9d-4a1f-988e-80b68de929a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_607f8e2d-5bee-4c2b-b8c0-b337d00ed7c3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityInteractiveDataCurrent_607f8e2d-5bee-4c2b-b8c0-b337d00ed7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_952b528a-5a5b-4aec-b002-217b35139ad5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityFilerCategory_952b528a-5a5b-4aec-b002-217b35139ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7cc93d1f-ff9e-4f20-87d8-229da724d73d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntitySmallBusiness_7cc93d1f-ff9e-4f20-87d8-229da724d73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ecd3c5d3-c1e2-44a0-ab72-80e28761af61" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityEmergingGrowthCompany_ecd3c5d3-c1e2-44a0-ab72-80e28761af61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_ab93c0e3-c335-4290-82da-0fc8c324e39c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityExTransitionPeriod_ab93c0e3-c335-4290-82da-0fc8c324e39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_54511182-573f-48f5-a9bb-948096d062d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityShellCompany_54511182-573f-48f5-a9bb-948096d062d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b6e4c359-f72a-4442-a8d0-38f2d5596897" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b6e4c359-f72a-4442-a8d0-38f2d5596897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a1790c8a-f702-478f-aa18-2d14d2e1ff31" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_AmendmentFlag_a1790c8a-f702-478f-aa18-2d14d2e1ff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_34486687-3012-4fbd-9032-2cabe1de7ed4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_DocumentFiscalYearFocus_34486687-3012-4fbd-9032-2cabe1de7ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_56e21e10-bf9c-4cb9-95ca-8b0ce0c7cff7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_DocumentFiscalPeriodFocus_56e21e10-bf9c-4cb9-95ca-8b0ce0c7cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1610743e-60f4-4e3c-bd25-7a4592fc1f79" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_EntityCentralIndexKey_1610743e-60f4-4e3c-bd25-7a4592fc1f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dd175330-3eed-4436-90b0-0cd65dd28725" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7aacd40a-023f-47a2-89b2-1bf6f940ac23" xlink:to="loc_dei_CurrentFiscalYearEndDate_dd175330-3eed-4436-90b0-0cd65dd28725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_78a589f3-d5b3-477d-b078-d310720fe64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_25843251-0c3d-43c5-aa7a-f12f781f82a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_78a589f3-d5b3-477d-b078-d310720fe64c" xlink:to="loc_us-gaap_AssetsAbstract_25843251-0c3d-43c5-aa7a-f12f781f82a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_fe09a6ee-dbd4-460e-a740-2ab96584b7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25843251-0c3d-43c5-aa7a-f12f781f82a7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_fe09a6ee-dbd4-460e-a740-2ab96584b7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bcc2bcea-feaa-4ef4-b010-610b16694b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fe09a6ee-dbd4-460e-a740-2ab96584b7a0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bcc2bcea-feaa-4ef4-b010-610b16694b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1f3e2b80-718f-431e-b854-1a3db26a6748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fe09a6ee-dbd4-460e-a740-2ab96584b7a0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1f3e2b80-718f-431e-b854-1a3db26a6748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3bd039f9-fb81-4531-bb93-28faa75d7462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fe09a6ee-dbd4-460e-a740-2ab96584b7a0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3bd039f9-fb81-4531-bb93-28faa75d7462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3bb6665a-2830-4e64-b9d6-e1d7f72f2636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fe09a6ee-dbd4-460e-a740-2ab96584b7a0" xlink:to="loc_us-gaap_AssetsCurrent_3bb6665a-2830-4e64-b9d6-e1d7f72f2636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6c7161c4-b93b-4bf3-89da-d158cbdf4b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25843251-0c3d-43c5-aa7a-f12f781f82a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6c7161c4-b93b-4bf3-89da-d158cbdf4b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_890f8707-85c7-43a9-88f7-761f4830a469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25843251-0c3d-43c5-aa7a-f12f781f82a7" xlink:to="loc_us-gaap_LongTermInvestments_890f8707-85c7-43a9-88f7-761f4830a469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6e7b584b-bd10-42c0-8793-e87a91f66963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25843251-0c3d-43c5-aa7a-f12f781f82a7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6e7b584b-bd10-42c0-8793-e87a91f66963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0f460b44-3397-4a2d-b352-e2a6f96f3461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25843251-0c3d-43c5-aa7a-f12f781f82a7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0f460b44-3397-4a2d-b352-e2a6f96f3461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_309db069-97f4-4e0a-bd38-98b34a338f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25843251-0c3d-43c5-aa7a-f12f781f82a7" xlink:to="loc_us-gaap_Assets_309db069-97f4-4e0a-bd38-98b34a338f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25c325d9-32cf-439e-a0fa-f718f05aae4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_78a589f3-d5b3-477d-b078-d310720fe64c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25c325d9-32cf-439e-a0fa-f718f05aae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f5332061-006e-44ed-a959-d03eb48c0401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25c325d9-32cf-439e-a0fa-f718f05aae4d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f5332061-006e-44ed-a959-d03eb48c0401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_cf27a118-0057-4cdb-8285-79b26d37fba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f5332061-006e-44ed-a959-d03eb48c0401" xlink:to="loc_us-gaap_AccountsPayableCurrent_cf27a118-0057-4cdb-8285-79b26d37fba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd61a571-8406-427c-887c-17cd8772b0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f5332061-006e-44ed-a959-d03eb48c0401" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd61a571-8406-427c-887c-17cd8772b0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1cc89c49-1299-46db-a5f3-6512474b14d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f5332061-006e-44ed-a959-d03eb48c0401" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1cc89c49-1299-46db-a5f3-6512474b14d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BuildToSuitLeaseLiabilityCurrent_b5dfba17-3488-49c2-b8be-005159241ec1" xlink:href="krys-20210930.xsd#krys_BuildToSuitLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f5332061-006e-44ed-a959-d03eb48c0401" xlink:to="loc_krys_BuildToSuitLeaseLiabilityCurrent_b5dfba17-3488-49c2-b8be-005159241ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a44c9b3-c18f-4ec8-b3cb-0632c1395fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f5332061-006e-44ed-a959-d03eb48c0401" xlink:to="loc_us-gaap_LiabilitiesCurrent_0a44c9b3-c18f-4ec8-b3cb-0632c1395fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02a77492-38bf-4e49-87ac-575a208a6826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25c325d9-32cf-439e-a0fa-f718f05aae4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02a77492-38bf-4e49-87ac-575a208a6826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d1338cb8-6a37-44e9-ae9d-470111e97983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25c325d9-32cf-439e-a0fa-f718f05aae4d" xlink:to="loc_us-gaap_Liabilities_d1338cb8-6a37-44e9-ae9d-470111e97983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_73e7d3d3-2fed-45ce-9754-8f9a397c694c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25c325d9-32cf-439e-a0fa-f718f05aae4d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_73e7d3d3-2fed-45ce-9754-8f9a397c694c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8cfb6ed5-0506-443c-9e2d-e43150112f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25c325d9-32cf-439e-a0fa-f718f05aae4d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8cfb6ed5-0506-443c-9e2d-e43150112f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0c4eaa19-69e1-492c-b91a-6f611e8c0472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8cfb6ed5-0506-443c-9e2d-e43150112f0d" xlink:to="loc_us-gaap_PreferredStockValue_0c4eaa19-69e1-492c-b91a-6f611e8c0472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_426cd0d3-ca23-41b1-aebd-7c5559e91da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8cfb6ed5-0506-443c-9e2d-e43150112f0d" xlink:to="loc_us-gaap_CommonStockValue_426cd0d3-ca23-41b1-aebd-7c5559e91da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fd0abba1-a3e1-4f1a-9caf-5e9139ba49d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8cfb6ed5-0506-443c-9e2d-e43150112f0d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fd0abba1-a3e1-4f1a-9caf-5e9139ba49d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_12e23078-8a6e-47d9-9858-a1711c0a8de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8cfb6ed5-0506-443c-9e2d-e43150112f0d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_12e23078-8a6e-47d9-9858-a1711c0a8de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea9a70e2-009b-4059-9354-315d4ee4bc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8cfb6ed5-0506-443c-9e2d-e43150112f0d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea9a70e2-009b-4059-9354-315d4ee4bc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ffc33a93-217e-406b-b04b-661d4736181a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8cfb6ed5-0506-443c-9e2d-e43150112f0d" xlink:to="loc_us-gaap_StockholdersEquity_ffc33a93-217e-406b-b04b-661d4736181a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_508533a7-c905-41d7-9ae0-598961bfb380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25c325d9-32cf-439e-a0fa-f718f05aae4d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_508533a7-c905-41d7-9ae0-598961bfb380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18fed1f1-ac04-48c4-abb1-ece73d242d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18fed1f1-ac04-48c4-abb1-ece73d242d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6bfd3184-a05a-4805-a8f9-525df9dc4ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6bfd3184-a05a-4805-a8f9-525df9dc4ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_76c48208-472b-4677-9f9f-f5071aaa0bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_76c48208-472b-4677-9f9f-f5071aaa0bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_76149a99-ff80-47ca-bc74-ed746a0a571d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_76149a99-ff80-47ca-bc74-ed746a0a571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1df52db1-7398-4d81-ae26-417222ad444e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1df52db1-7398-4d81-ae26-417222ad444e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f33e320e-ac90-4d54-8011-5bc2f84e6dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f33e320e-ac90-4d54-8011-5bc2f84e6dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_433ae50f-717a-4755-89b5-708bda1aa169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:to="loc_us-gaap_CommonStockSharesIssued_433ae50f-717a-4755-89b5-708bda1aa169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0d5ca673-c1e0-42c5-b92b-57005b3ad437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e355938b-0ac6-4fce-b0d3-e325667524a8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0d5ca673-c1e0-42c5-b92b-57005b3ad437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6879f1b8-a70a-4e37-97a4-d679d269fbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6879f1b8-a70a-4e37-97a4-d679d269fbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_329e8f94-1360-40e8-81f7-6d07aafca196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6879f1b8-a70a-4e37-97a4-d679d269fbc5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_329e8f94-1360-40e8-81f7-6d07aafca196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_11282377-ee30-480e-ae13-0a3eb0287a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6879f1b8-a70a-4e37-97a4-d679d269fbc5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_11282377-ee30-480e-ae13-0a3eb0287a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c61e9842-7c23-4dbf-870d-2d5c44db9750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6879f1b8-a70a-4e37-97a4-d679d269fbc5" xlink:to="loc_us-gaap_OperatingExpenses_c61e9842-7c23-4dbf-870d-2d5c44db9750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4b377ce3-01a5-479e-9c42-36ab727e43db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_OperatingIncomeLoss_4b377ce3-01a5-479e-9c42-36ab727e43db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac04e572-55b0-416c-8b27-743b68ae8994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac04e572-55b0-416c-8b27-743b68ae8994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_f0d16dbd-324a-4117-8158-4d1e2613cb1c" xlink:href="krys-20210930.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac04e572-55b0-416c-8b27-743b68ae8994" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_f0d16dbd-324a-4117-8158-4d1e2613cb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dd79c02b-b2c5-495e-9815-ab323fbb26ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac04e572-55b0-416c-8b27-743b68ae8994" xlink:to="loc_us-gaap_InterestExpense_dd79c02b-b2c5-495e-9815-ab323fbb26ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a15b831-2d3c-42e9-b278-5f6dd10efe8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_NetIncomeLoss_6a15b831-2d3c-42e9-b278-5f6dd10efe8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0ed6a290-1381-4be9-96ac-2bcf9179d376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0ed6a290-1381-4be9-96ac-2bcf9179d376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_39bac683-799e-4141-b230-1ba4191d68af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_39bac683-799e-4141-b230-1ba4191d68af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3ed7c247-f169-4a47-97ce-c016027fa7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_EarningsPerShareBasic_3ed7c247-f169-4a47-97ce-c016027fa7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f18ca4ba-0198-4930-b382-a828281c615a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f18ca4ba-0198-4930-b382-a828281c615a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2924c3e0-503d-4f4f-92e4-4f8ed9ea6c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2924c3e0-503d-4f4f-92e4-4f8ed9ea6c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44545b32-cb87-4dc6-bcb9-f904e029225d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ee6423-1ef4-4e34-be9d-ac35302282b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44545b32-cb87-4dc6-bcb9-f904e029225d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_735dea77-7e37-4a7b-a2c9-d646c3a4c40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3eed4de9-8018-469a-ac6a-3edec596d8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_735dea77-7e37-4a7b-a2c9-d646c3a4c40a" xlink:to="loc_us-gaap_StatementTable_3eed4de9-8018-469a-ac6a-3edec596d8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d6d9e962-f47d-4c2d-8a6b-cb325b72a216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3eed4de9-8018-469a-ac6a-3edec596d8d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d6d9e962-f47d-4c2d-8a6b-cb325b72a216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d6d9e962-f47d-4c2d-8a6b-cb325b72a216" xlink:to="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f61472f0-b84f-4b81-9055-1303ae129d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:to="loc_us-gaap_CommonStockMember_f61472f0-b84f-4b81-9055-1303ae129d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ef3c7e34-6791-4b34-a10f-843d9a71c013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ef3c7e34-6791-4b34-a10f-843d9a71c013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8fc0a4d-4860-4f2c-a1a2-8053180172e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8fc0a4d-4860-4f2c-a1a2-8053180172e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9158b800-4553-42f7-bdc3-1b62e671f660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4513e63d-6715-4425-ac7d-90cdb0da0db0" xlink:to="loc_us-gaap_RetainedEarningsMember_9158b800-4553-42f7-bdc3-1b62e671f660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e10cd276-6c3f-4264-9e77-0feb5c8859b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3eed4de9-8018-469a-ac6a-3edec596d8d4" xlink:to="loc_us-gaap_StatementLineItems_e10cd276-6c3f-4264-9e77-0feb5c8859b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e10cd276-6c3f-4264-9e77-0feb5c8859b0" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49ca02f3-8d72-40dc-91de-09bf1a27b89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_StockholdersEquity_49ca02f3-8d72-40dc-91de-09bf1a27b89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_00b5765a-6942-420d-95aa-1c4b29f0934d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_SharesOutstanding_00b5765a-6942-420d-95aa-1c4b29f0934d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a60b03bb-c169-4689-b4eb-4b7eafbb6cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a60b03bb-c169-4689-b4eb-4b7eafbb6cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f6855710-f1c3-4688-87d1-9e6586279696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f6855710-f1c3-4688-87d1-9e6586279696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9b62593f-24b4-4a3c-924e-d5598a6d7d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9b62593f-24b4-4a3c-924e-d5598a6d7d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bbd39bc2-079a-4f9c-9e20-eb0b8792bd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bbd39bc2-079a-4f9c-9e20-eb0b8792bd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7f386ea-3081-471d-aae6-4977c3032761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_NetIncomeLoss_c7f386ea-3081-471d-aae6-4977c3032761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c55b9da7-d005-4776-8447-98a408f9f117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_StockholdersEquity_c55b9da7-d005-4776-8447-98a408f9f117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_79b940d0-8d6c-4d30-b29c-83838dcbb1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_04f6fb39-2a72-4468-952d-6b011c3b73ff" xlink:to="loc_us-gaap_SharesOutstanding_79b940d0-8d6c-4d30-b29c-83838dcbb1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="krys-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_3b567d97-83c4-4421-b64e-a6c0d787ad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b1b14ecb-0452-4118-8030-ff515e04d320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_3b567d97-83c4-4421-b64e-a6c0d787ad6e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b1b14ecb-0452-4118-8030-ff515e04d320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a5843389-1252-4580-b044-d10b0124f462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b1b14ecb-0452-4118-8030-ff515e04d320" xlink:to="loc_us-gaap_NetIncomeLoss_a5843389-1252-4580-b044-d10b0124f462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2640da77-b329-46af-a37d-5d207461c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b1b14ecb-0452-4118-8030-ff515e04d320" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2640da77-b329-46af-a37d-5d207461c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_0fea7b9d-ed27-4c39-8a13-c42a7ca9d750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2640da77-b329-46af-a37d-5d207461c31d" xlink:to="loc_us-gaap_DepreciationAndAmortization_0fea7b9d-ed27-4c39-8a13-c42a7ca9d750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1c7cc9d2-cce8-41e8-b578-ad43add5b80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2640da77-b329-46af-a37d-5d207461c31d" xlink:to="loc_us-gaap_ShareBasedCompensation_1c7cc9d2-cce8-41e8-b578-ad43add5b80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets_81db0802-aa02-4f6e-9a4c-b71b3398510e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2640da77-b329-46af-a37d-5d207461c31d" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets_81db0802-aa02-4f6e-9a4c-b71b3398510e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_dd28c57e-d17a-4905-bc89-b00cff8199cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2640da77-b329-46af-a37d-5d207461c31d" xlink:to="loc_us-gaap_OtherNoncashExpense_dd28c57e-d17a-4905-bc89-b00cff8199cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0b19eff-0fd8-4d83-871d-114c82d6d266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b1b14ecb-0452-4118-8030-ff515e04d320" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0b19eff-0fd8-4d83-871d-114c82d6d266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b65109ac-4f4e-4369-9aca-e6f93a82375e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0b19eff-0fd8-4d83-871d-114c82d6d266" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b65109ac-4f4e-4369-9aca-e6f93a82375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent_5c1bf338-685e-483d-998f-b2ce7529ea2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0b19eff-0fd8-4d83-871d-114c82d6d266" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent_5c1bf338-685e-483d-998f-b2ce7529ea2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_945a0499-7be5-43b7-9484-cdf2b9d4f14e" xlink:href="krys-20210930.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0b19eff-0fd8-4d83-871d-114c82d6d266" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_945a0499-7be5-43b7-9484-cdf2b9d4f14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3ef65b9e-4d26-4a48-bc4b-f9c5deae42aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0b19eff-0fd8-4d83-871d-114c82d6d266" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3ef65b9e-4d26-4a48-bc4b-f9c5deae42aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_573992ee-5720-4391-bdfc-5e0cc0b2c82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0b19eff-0fd8-4d83-871d-114c82d6d266" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_573992ee-5720-4391-bdfc-5e0cc0b2c82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9cf2c1c-a6e8-44ce-98ea-5c1294a43b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b1b14ecb-0452-4118-8030-ff515e04d320" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9cf2c1c-a6e8-44ce-98ea-5c1294a43b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_050083a5-2583-4111-867d-8cd2660fec72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_3b567d97-83c4-4421-b64e-a6c0d787ad6e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_050083a5-2583-4111-867d-8cd2660fec72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7074d18-0d17-4df2-97a4-fe07f857cf24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_050083a5-2583-4111-867d-8cd2660fec72" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7074d18-0d17-4df2-97a4-fe07f857cf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ae55f14f-e7c0-4175-b5da-f45b5918d46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_050083a5-2583-4111-867d-8cd2660fec72" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ae55f14f-e7c0-4175-b5da-f45b5918d46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_359bbae8-4b88-4f8d-b2b8-b4d4e56ba0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_050083a5-2583-4111-867d-8cd2660fec72" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_359bbae8-4b88-4f8d-b2b8-b4d4e56ba0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14b43415-6717-488d-8392-734060bbddf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_050083a5-2583-4111-867d-8cd2660fec72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14b43415-6717-488d-8392-734060bbddf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_948295eb-674d-40cb-997a-b164e904f9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_3b567d97-83c4-4421-b64e-a6c0d787ad6e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_948295eb-674d-40cb-997a-b164e904f9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5cb57257-1018-4c6b-bd6e-cb76d443733c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_948295eb-674d-40cb-997a-b164e904f9f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5cb57257-1018-4c6b-bd6e-cb76d443733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_8221bef3-71fc-40a2-bf49-8addad60795c" xlink:href="krys-20210930.xsd#krys_PaymentsForSuitLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_948295eb-674d-40cb-997a-b164e904f9f3" xlink:to="loc_krys_PaymentsForSuitLiability_8221bef3-71fc-40a2-bf49-8addad60795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1445b897-1466-4a57-88c3-24277d741323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_948295eb-674d-40cb-997a-b164e904f9f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1445b897-1466-4a57-88c3-24277d741323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b0ff11f-da74-476f-8767-30574b09d078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_3b567d97-83c4-4421-b64e-a6c0d787ad6e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b0ff11f-da74-476f-8767-30574b09d078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3240330f-88ea-4fa7-9e33-52825bf0b83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_3b567d97-83c4-4421-b64e-a6c0d787ad6e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3240330f-88ea-4fa7-9e33-52825bf0b83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb95b9c7-52dc-48fb-8fc7-3e6e35519289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_3b567d97-83c4-4421-b64e-a6c0d787ad6e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb95b9c7-52dc-48fb-8fc7-3e6e35519289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_475d576d-aa13-4950-b4b5-209a66e1cc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_3b567d97-83c4-4421-b64e-a6c0d787ad6e" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_475d576d-aa13-4950-b4b5-209a66e1cc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c27c1c39-334e-4448-85eb-9b8552a6ad8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_475d576d-aa13-4950-b4b5-209a66e1cc0e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c27c1c39-334e-4448-85eb-9b8552a6ad8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OfferingCostsIncurredButNotYetPaid_6ae6aac5-5fe3-4428-af48-d7f8a5d28aac" xlink:href="krys-20210930.xsd#krys_OfferingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_475d576d-aa13-4950-b4b5-209a66e1cc0e" xlink:to="loc_krys_OfferingCostsIncurredButNotYetPaid_6ae6aac5-5fe3-4428-af48-d7f8a5d28aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a9a6b789-805e-457f-b326-45138bc97824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_475d576d-aa13-4950-b4b5-209a66e1cc0e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a9a6b789-805e-457f-b326-45138bc97824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Organization" xlink:type="simple" xlink:href="krys-20210930.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c38c81db-ba90-4b31-bcc1-18b0130c5b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b120357c-e6d0-4851-a4ac-f1ff0ba00927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c38c81db-ba90-4b31-bcc1-18b0130c5b52" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b120357c-e6d0-4851-a4ac-f1ff0ba00927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#OrganizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91497441-b4c0-44dc-868c-18d1b59ff4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2c59b98a-4992-42d2-82f6-6f4115104042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91497441-b4c0-44dc-868c-18d1b59ff4bf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2c59b98a-4992-42d2-82f6-6f4115104042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_2874f8bd-0144-425f-a91f-d677c9ad0dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91497441-b4c0-44dc-868c-18d1b59ff4bf" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_2874f8bd-0144-425f-a91f-d677c9ad0dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="krys-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_90f1878e-c587-4d8b-8028-6ff130564e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_46af4872-609a-42aa-b849-3246020f9fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_90f1878e-c587-4d8b-8028-6ff130564e61" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_46af4872-609a-42aa-b849-3246020f9fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="krys-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_22cbb44c-e8f6-46fd-a60f-cbe9e96d0178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_22cbb44c-e8f6-46fd-a60f-cbe9e96d0178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RisksAndUncertaintiesPolicyTextBlock_e55a2002-a0b8-47fc-b9e0-a27889dbeab3" xlink:href="krys-20210930.xsd#krys_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_krys_RisksAndUncertaintiesPolicyTextBlock_e55a2002-a0b8-47fc-b9e0-a27889dbeab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1f5d0484-f92a-45e9-a636-8e6678cf5e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_UseOfEstimates_1f5d0484-f92a-45e9-a636-8e6678cf5e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_450357cc-1f9f-4cc8-95b5-3678d0827b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_450357cc-1f9f-4cc8-95b5-3678d0827b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ef395871-6968-4589-a65c-f287caa0feb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ef395871-6968-4589-a65c-f287caa0feb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_00963c6f-544d-443b-8984-df7d3473835f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_00963c6f-544d-443b-8984-df7d3473835f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6e43fd91-bb83-490f-9783-0f4b2991727f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6e43fd91-bb83-490f-9783-0f4b2991727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ed3a3c0f-8ff0-4649-b392-87453041597b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ed3a3c0f-8ff0-4649-b392-87453041597b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e4926bab-f0a3-4976-9db8-37c3ab97eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e4926bab-f0a3-4976-9db8-37c3ab97eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_811a5fc9-5bda-4614-93e8-9c4cc0e9b64e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_811a5fc9-5bda-4614-93e8-9c4cc0e9b64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_424e2231-a06e-4fcd-8c1a-e30073422e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_424e2231-a06e-4fcd-8c1a-e30073422e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8ebc7238-975a-4da3-ba4f-7a0aad2e1ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8ebc7238-975a-4da3-ba4f-7a0aad2e1ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e5dcd3f1-7600-4437-b226-7b7524ef7eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e5dcd3f1-7600-4437-b226-7b7524ef7eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a4f073f8-beeb-4586-8641-9f681899a00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3f9d755-a1f1-4513-a7ec-83347c2c02b2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a4f073f8-beeb-4586-8641-9f681899a00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="krys-20210930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_df1952f1-e44d-4faf-b768-8f9a390601d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_45303faa-c9b0-4627-b2a5-321d2d8c46f8" xlink:href="krys-20210930.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df1952f1-e44d-4faf-b768-8f9a390601d4" xlink:to="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_45303faa-c9b0-4627-b2a5-321d2d8c46f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a81d9c1-d3d2-4fc0-8d1d-927bcf2cabaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_98a2ae0e-68ea-4c3a-a308-b5f211ff49ba" xlink:href="krys-20210930.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a81d9c1-d3d2-4fc0-8d1d-927bcf2cabaa" xlink:to="loc_krys_SignificantAccountingPoliciesTable_98a2ae0e-68ea-4c3a-a308-b5f211ff49ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc4be7a0-1c03-4531-8151-4315cf84c137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_98a2ae0e-68ea-4c3a-a308-b5f211ff49ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc4be7a0-1c03-4531-8151-4315cf84c137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f722810-2a48-4c58-98f2-1cab4d8b13b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc4be7a0-1c03-4531-8151-4315cf84c137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f722810-2a48-4c58-98f2-1cab4d8b13b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_67817d8d-323c-4cb0-8436-5e3ce3eeecbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f722810-2a48-4c58-98f2-1cab4d8b13b8" xlink:to="loc_us-gaap_EquipmentMember_67817d8d-323c-4cb0-8436-5e3ce3eeecbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_73956325-eab2-4470-8fb5-3f01c91824dc" xlink:href="krys-20210930.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_98a2ae0e-68ea-4c3a-a308-b5f211ff49ba" xlink:to="loc_krys_SignificantAccountingPoliciesLineItems_73956325-eab2-4470-8fb5-3f01c91824dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_76818f40-dee6-47db-8dcc-631bcb1917d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_73956325-eab2-4470-8fb5-3f01c91824dc" xlink:to="loc_us-gaap_NumberOfOperatingSegments_76818f40-dee6-47db-8dcc-631bcb1917d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7c5621af-5635-4066-9949-a29daebd30a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_73956325-eab2-4470-8fb5-3f01c91824dc" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7c5621af-5635-4066-9949-a29daebd30a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_09b17990-4512-4f5b-b222-694b753d2916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_09b17990-4512-4f5b-b222-694b753d2916" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aeee91c1-3865-48cd-9920-a9c44c299d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aeee91c1-3865-48cd-9920-a9c44c299d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aeee91c1-3865-48cd-9920-a9c44c299d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_9e0f6f3d-a80b-497a-96dd-e296e1d1a388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:to="loc_us-gaap_ComputerEquipmentMember_9e0f6f3d-a80b-497a-96dd-e296e1d1a388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_06ee0ce9-9745-4988-9c64-f63233ec37a4" xlink:href="krys-20210930.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:to="loc_krys_LabEquipmentMember_06ee0ce9-9745-4988-9c64-f63233ec37a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_76aa9bcd-2fa2-43c4-8780-db961f7c9b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3cd07152-4b58-4277-b5af-c030c634e993" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_76aa9bcd-2fa2-43c4-8780-db961f7c9b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4f560fc4-1e73-46ab-bb09-ca15db2a7d98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:to="loc_srt_RangeAxis_4f560fc4-1e73-46ab-bb09-ca15db2a7d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6773c232-4147-4a2d-badc-025d5c5b842d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4f560fc4-1e73-46ab-bb09-ca15db2a7d98" xlink:to="loc_srt_RangeMember_6773c232-4147-4a2d-badc-025d5c5b842d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a5dc60f7-79ea-42c9-8085-6c9d7a723f9a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6773c232-4147-4a2d-badc-025d5c5b842d" xlink:to="loc_srt_MinimumMember_a5dc60f7-79ea-42c9-8085-6c9d7a723f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b58ace8-9b1b-4af8-ac36-35aa0a37a046" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6773c232-4147-4a2d-badc-025d5c5b842d" xlink:to="loc_srt_MaximumMember_0b58ace8-9b1b-4af8-ac36-35aa0a37a046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dc86c947-04e8-4cc1-9e87-5e63e95a8559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fced3d4-2e8d-4d45-8cb4-ab995eb11063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dc86c947-04e8-4cc1-9e87-5e63e95a8559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9337fd07-804e-46ec-aa38-adbc443995dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dc86c947-04e8-4cc1-9e87-5e63e95a8559" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9337fd07-804e-46ec-aa38-adbc443995dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="krys-20210930.xsd#NetLossPerShareAttributabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b1a6182e-07b3-4226-8fd5-30b830ebd070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_681c7dd2-747e-4104-b896-d3a66717891b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b1a6182e-07b3-4226-8fd5-30b830ebd070" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_681c7dd2-747e-4104-b896-d3a66717891b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="krys-20210930.xsd#NetLossPerShareAttributabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a04b3990-2dac-4d6e-81a5-bdaf91b8f9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_890498e2-95a7-4562-97e0-d785934185a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a04b3990-2dac-4d6e-81a5-bdaf91b8f9fb" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_890498e2-95a7-4562-97e0-d785934185a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_eccdbbaa-a342-499e-b1f5-58d8f9497667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cb48b8dd-fc5c-4c28-8862-7e2a17412bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eccdbbaa-a342-499e-b1f5-58d8f9497667" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cb48b8dd-fc5c-4c28-8862-7e2a17412bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ae540961-52a6-4b03-bdd0-0b58024e61a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ae4cfbdf-a7aa-4968-992b-432c3319ed40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae540961-52a6-4b03-bdd0-0b58024e61a0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ae4cfbdf-a7aa-4968-992b-432c3319ed40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3926e706-1a74-4624-ae06-04740c014295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ae4cfbdf-a7aa-4968-992b-432c3319ed40" xlink:to="loc_us-gaap_NetIncomeLoss_3926e706-1a74-4624-ae06-04740c014295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ba08195a-b1d1-49d0-8816-1e413f2ce897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae540961-52a6-4b03-bdd0-0b58024e61a0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ba08195a-b1d1-49d0-8816-1e413f2ce897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5518fd67-4b35-4230-ae8a-170d74616a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae540961-52a6-4b03-bdd0-0b58024e61a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5518fd67-4b35-4230-ae8a-170d74616a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3c7e6e0d-eda2-46f4-adec-91ef883d811d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae540961-52a6-4b03-bdd0-0b58024e61a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3c7e6e0d-eda2-46f4-adec-91ef883d811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d221240b-e702-44fa-bdd0-bd8692dc643e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae540961-52a6-4b03-bdd0-0b58024e61a0" xlink:to="loc_us-gaap_EarningsPerShareBasic_d221240b-e702-44fa-bdd0-bd8692dc643e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3b5a7804-e5d5-4b4e-bcc8-af87035fc2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae540961-52a6-4b03-bdd0-0b58024e61a0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3b5a7804-e5d5-4b4e-bcc8-af87035fc2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="simple" xlink:href="krys-20210930.xsd#FairValueInstruments"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ac83786-e289-40e3-8ce1-6019d98c8a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d9a59140-7100-4bde-ab3a-492b99a378bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ac83786-e289-40e3-8ce1-6019d98c8a62" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d9a59140-7100-4bde-ab3a-492b99a378bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="simple" xlink:href="krys-20210930.xsd#FairValueInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6b51cf2d-712d-4765-89ff-0c442146208a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4f1dd595-1d9c-4521-a0f8-3793f4430ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6b51cf2d-712d-4765-89ff-0c442146208a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4f1dd595-1d9c-4521-a0f8-3793f4430ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2fa1a6be-9c38-4888-871e-236ce9920c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2fa1a6be-9c38-4888-871e-236ce9920c89" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_54f05f3f-04bc-4d58-bb45-3710bed037b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_54f05f3f-04bc-4d58-bb45-3710bed037b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_54f05f3f-04bc-4d58-bb45-3710bed037b7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0b92c05a-c275-40e2-b590-118c4a815bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0b92c05a-c275-40e2-b590-118c4a815bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_caa3a5a2-c3af-4028-af26-698485721b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_CommercialPaperMember_caa3a5a2-c3af-4028-af26-698485721b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_cdbaf0ff-e989-4f33-85b9-1885003bb42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_cdbaf0ff-e989-4f33-85b9-1885003bb42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4bcab043-f484-4b34-984c-0f2196549613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4bcab043-f484-4b34-984c-0f2196549613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_52bf183f-ca09-4665-8824-22b9de34882f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_CashMember_52bf183f-ca09-4665-8824-22b9de34882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_04ef7de3-55a0-48ad-884d-2d960c1b4fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fca4cdaf-be9e-458b-b915-578005e67d7f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_04ef7de3-55a0-48ad-884d-2d960c1b4fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1f6a76e-ed8a-4fa7-a722-78da3824ee03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1f6a76e-ed8a-4fa7-a722-78da3824ee03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cedc5a52-f229-4169-af64-c5435b1a70f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1f6a76e-ed8a-4fa7-a722-78da3824ee03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cedc5a52-f229-4169-af64-c5435b1a70f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d12d06bb-7603-4da4-b494-7564368948fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cedc5a52-f229-4169-af64-c5435b1a70f1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d12d06bb-7603-4da4-b494-7564368948fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88132ed8-b0d0-445e-acde-85b485fdfdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cedc5a52-f229-4169-af64-c5435b1a70f1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88132ed8-b0d0-445e-acde-85b485fdfdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6e51ed90-f02c-4f9d-b95d-31f1a109e803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6e51ed90-f02c-4f9d-b95d-31f1a109e803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6e51ed90-f02c-4f9d-b95d-31f1a109e803" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_1eb4a8bb-2445-422e-93b9-3917646bf2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_1eb4a8bb-2445-422e-93b9-3917646bf2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_ce4a1a90-d081-4bcb-bb13-5d9b3c43a9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_ce4a1a90-d081-4bcb-bb13-5d9b3c43a9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_c55a8219-1696-4345-b481-270be029f638" xlink:href="krys-20210930.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_42ce0507-5c1a-47f5-9869-fdbc5cb5f0d3" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_c55a8219-1696-4345-b481-270be029f638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a23f7a30-22d8-4d01-b769-85ad912ab963" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_srt_RangeAxis_a23f7a30-22d8-4d01-b769-85ad912ab963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d998609e-4c4b-4e32-85ea-2cc0c78f0635" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a23f7a30-22d8-4d01-b769-85ad912ab963" xlink:to="loc_srt_RangeMember_d998609e-4c4b-4e32-85ea-2cc0c78f0635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_68348c59-2d49-48bc-a19d-3478f87f258e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d998609e-4c4b-4e32-85ea-2cc0c78f0635" xlink:to="loc_srt_MinimumMember_68348c59-2d49-48bc-a19d-3478f87f258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_611b14d7-afaf-4e79-9947-fbccfd5bb0f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d998609e-4c4b-4e32-85ea-2cc0c78f0635" xlink:to="loc_srt_MaximumMember_611b14d7-afaf-4e79-9947-fbccfd5bb0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef1e5eec-4cbf-4659-a099-945f9cc2ae22" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9677af83-db5f-4a92-893b-ad5f260e019a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9677af83-db5f-4a92-893b-ad5f260e019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4931af18-1787-4d8f-8e9b-d5625aa8325d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4931af18-1787-4d8f-8e9b-d5625aa8325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0c77fa2-e2bd-4719-badc-0abbde84b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0c77fa2-e2bd-4719-badc-0abbde84b5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d3f4ab98-c964-4a3a-a815-998b99edebb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d3f4ab98-c964-4a3a-a815-998b99edebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_980d7391-bd3d-4bca-9627-0f38991c0bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_980d7391-bd3d-4bca-9627-0f38991c0bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5cabd86-957c-4060-a92d-c5dd40e75e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5cabd86-957c-4060-a92d-c5dd40e75e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_90ef791d-c594-4a3c-b81e-bc20ce99d8bb" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_90ef791d-c594-4a3c-b81e-bc20ce99d8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_56f7d1cf-bcf0-4614-a0e7-6c7612fc6e87" xlink:href="krys-20210930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_56f7d1cf-bcf0-4614-a0e7-6c7612fc6e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_85057b0e-b2d0-4efd-8cd7-ec146186e8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f166f572-ef69-4736-8928-bcbfb8dc93fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_85057b0e-b2d0-4efd-8cd7-ec146186e8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20210930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="krys-20210930.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_73a6fe0d-a17f-440c-b7e0-7a7988f4adc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_946b444a-62b8-4972-b6ae-4a45d9e84295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_73a6fe0d-a17f-440c-b7e0-7a7988f4adc0" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_946b444a-62b8-4972-b6ae-4a45d9e84295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="krys-20210930.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4086b3b7-26c7-4b91-9933-67a43f2927bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_cafa171c-30b6-4849-b3d3-ef63819dc6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4086b3b7-26c7-4b91-9933-67a43f2927bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_cafa171c-30b6-4849-b3d3-ef63819dc6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ee35e510-2ac4-4b50-9b6f-7619d43781ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4086b3b7-26c7-4b91-9933-67a43f2927bd" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ee35e510-2ac4-4b50-9b6f-7619d43781ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e374d8f6-b667-4ee3-8692-838705b49ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a3c4b1e-7659-4f55-8f5b-804e8036c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e374d8f6-b667-4ee3-8692-838705b49ddd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a3c4b1e-7659-4f55-8f5b-804e8036c73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d20504eb-1826-43db-9a69-007e55a4f732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a3c4b1e-7659-4f55-8f5b-804e8036c73f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d20504eb-1826-43db-9a69-007e55a4f732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d20504eb-1826-43db-9a69-007e55a4f732" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2d77435b-b4dc-46a5-8af5-e314480a8a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_us-gaap_ConstructionInProgressMember_2d77435b-b4dc-46a5-8af5-e314480a8a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9d6dfda4-a763-4803-b689-d3711c8f2924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9d6dfda4-a763-4803-b689-d3711c8f2924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_96259e26-4d76-4731-baca-6045cb23ed44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_96259e26-4d76-4731-baca-6045cb23ed44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_81681144-5781-4149-acdf-f489def7986a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_us-gaap_ComputerEquipmentMember_81681144-5781-4149-acdf-f489def7986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_4c0c2d6a-b2be-4edb-874c-e0073fe3a7cd" xlink:href="krys-20210930.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_21ddb4d5-b86f-4312-ac16-773b96f81fd4" xlink:to="loc_krys_LabEquipmentMember_4c0c2d6a-b2be-4edb-874c-e0073fe3a7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a3c4b1e-7659-4f55-8f5b-804e8036c73f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2b77f645-0792-4c82-912e-ca88a3c6b560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2b77f645-0792-4c82-912e-ca88a3c6b560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a372dc22-5cb5-42aa-b3ce-cdee83db0e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a372dc22-5cb5-42aa-b3ce-cdee83db0e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63639bf2-1eab-46d4-9771-c8c6a26e712a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b350591-2740-4c80-a14f-d5f43065c4fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63639bf2-1eab-46d4-9771-c8c6a26e712a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7df5b489-7241-49f3-8108-d6df2ed2cc22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_12daabd7-abae-4e44-b83c-74820b6d2255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7df5b489-7241-49f3-8108-d6df2ed2cc22" xlink:to="loc_us-gaap_Depreciation_12daabd7-abae-4e44-b83c-74820b6d2255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_7fd352b4-3901-46ff-b287-72ccc1f5412a" xlink:href="krys-20210930.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_7fd352b4-3901-46ff-b287-72ccc1f5412a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ba26db90-8a40-4dbc-9f2c-74da1bf2a0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ba26db90-8a40-4dbc-9f2c-74da1bf2a0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_67400c2e-6d6a-419d-863f-239d8fc82324" xlink:href="krys-20210930.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:to="loc_krys_AccruedPayrollAndBenefits_67400c2e-6d6a-419d-863f-239d8fc82324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_3167a679-fb6a-484b-820e-07eae0c4b477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:to="loc_us-gaap_AccruedIncomeTaxes_3167a679-fb6a-484b-820e-07eae0c4b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_b64cc0a4-3d51-4693-a82f-47a1b775b27b" xlink:href="krys-20210930.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_b64cc0a4-3d51-4693-a82f-47a1b775b27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_3e79ee83-a2eb-490f-a840-555d818e73a6" xlink:href="krys-20210930.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:to="loc_krys_AccruedFinancingFeesCurrent_3e79ee83-a2eb-490f-a840-555d818e73a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ac2754e6-284e-44ee-bf8e-c0edcf9531a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ac2754e6-284e-44ee-bf8e-c0edcf9531a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_ebec0fcc-a873-4dd1-a1c4-986d64481acd" xlink:href="krys-20210930.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65043da4-be51-4ad6-8a3f-dcf7b83a278e" xlink:to="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_ebec0fcc-a873-4dd1-a1c4-986d64481acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c93b32f-f805-4f60-bfc6-99cf6d84907f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ca8609c9-1eaa-4f30-b82f-b85a3ae07f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c93b32f-f805-4f60-bfc6-99cf6d84907f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ca8609c9-1eaa-4f30-b82f-b85a3ae07f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d998eb3-64a0-435b-bfbe-20eaa16e77de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_85093fbf-dc1e-4850-94b4-93561854ef48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d998eb3-64a0-435b-bfbe-20eaa16e77de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_85093fbf-dc1e-4850-94b4-93561854ef48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_502ce573-d3f8-4cef-91ec-a395bc013d1b" xlink:href="krys-20210930.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d998eb3-64a0-435b-bfbe-20eaa16e77de" xlink:to="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_502ce573-d3f8-4cef-91ec-a395bc013d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b767e5ea-87d9-43eb-98b4-ed9af237bb90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b767e5ea-87d9-43eb-98b4-ed9af237bb90" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fdc31633-c766-40e6-b543-17bee03c09a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fdc31633-c766-40e6-b543-17bee03c09a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85b4c9d6-ad2e-4689-a87f-5426766fefd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fdc31633-c766-40e6-b543-17bee03c09a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85b4c9d6-ad2e-4689-a87f-5426766fefd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_b5806cab-d5ba-413e-ba36-255b5757d9ee" xlink:href="krys-20210930.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85b4c9d6-ad2e-4689-a87f-5426766fefd3" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_b5806cab-d5ba-413e-ba36-255b5757d9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_3f3a04da-400d-4378-b318-4231666b6d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:to="loc_us-gaap_SupplyCommitmentAxis_3f3a04da-400d-4378-b318-4231666b6d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_3f3a04da-400d-4378-b318-4231666b6d26" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_5bcf3d3c-085b-400c-81a8-10fa11dacc05" xlink:href="krys-20210930.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:to="loc_krys_ClinicalSupplyAgreementMember_5bcf3d3c-085b-400c-81a8-10fa11dacc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_f80806b2-afc8-45a9-b232-c0106f1e71ea" xlink:href="krys-20210930.xsd#krys_OtherContractualObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:to="loc_krys_OtherContractualObligationsMember_f80806b2-afc8-45a9-b232-c0106f1e71ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_72871e1e-6fce-4dee-8272-57bfde15f4eb" xlink:href="krys-20210930.xsd#krys_ASTRAFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_f6ae3b35-be2a-4e21-aad6-f9940b2a67a1" xlink:to="loc_krys_ASTRAFacilityMember_72871e1e-6fce-4dee-8272-57bfde15f4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_58d9837d-fbd4-4019-97f9-3eacd823a054" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_3c812fcc-946e-44eb-8cc1-f3c34d9d3a6f" xlink:href="krys-20210930.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_3c812fcc-946e-44eb-8cc1-f3c34d9d3a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_95c26482-339c-4200-bd73-f919744b17cc" xlink:href="krys-20210930.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_95c26482-339c-4200-bd73-f919744b17cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_aa729d5d-101a-47e7-b61f-7e8c29298bee" xlink:href="krys-20210930.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_aa729d5d-101a-47e7-b61f-7e8c29298bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_38dbc55f-c9bf-4b1a-9df9-11c9773cc206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_FinanceLeaseLiability_38dbc55f-c9bf-4b1a-9df9-11c9773cc206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a035fa77-1b7d-486a-b7e2-56451e6f6b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_ConstructionInProgressGross_a035fa77-1b7d-486a-b7e2-56451e6f6b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_4d0988e3-3d12-45ec-a5a8-58dfdac01406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_EscrowDeposit_4d0988e3-3d12-45ec-a5a8-58dfdac01406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_533e74c1-52df-4573-a7b6-254966185b5e" xlink:href="krys-20210930.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_533e74c1-52df-4573-a7b6-254966185b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_288cae3d-6b15-4ca4-a0ae-887d0fecb363" xlink:href="krys-20210930.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_CumulativeEscalationClausePercent_288cae3d-6b15-4ca4-a0ae-887d0fecb363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_5b7043fb-896c-48f9-8e9c-3981e30d2abc" xlink:href="krys-20210930.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_CumulativeEscalationClauseTerm_5b7043fb-896c-48f9-8e9c-3981e30d2abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d146470c-07e6-411c-aa03-e59c6157c345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_OperatingLeaseCost_d146470c-07e6-411c-aa03-e59c6157c345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8421569a-960c-49ba-8980-d6f51fea82f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_VariableLeaseCost_8421569a-960c-49ba-8980-d6f51fea82f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_e9aaea53-e324-4d26-8476-6c1a16c2b14f" xlink:href="krys-20210930.xsd#krys_RemainingCommitmentAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_RemainingCommitmentAmount_e9aaea53-e324-4d26-8476-6c1a16c2b14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_fd26302f-b433-42ff-9ba2-21ff1f7f04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_ProfessionalFees_fd26302f-b433-42ff-9ba2-21ff1f7f04cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_4cce153d-b856-44f3-ae57-ca7d4bb8239b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_ContractualObligation_4cce153d-b856-44f3-ae57-ca7d4bb8239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_ec69b690-d182-4a10-854f-acaa59308be0" xlink:href="krys-20210930.xsd#krys_CostOfWorkPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_CostOfWorkPercentage_ec69b690-d182-4a10-854f-acaa59308be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_54791080-7fac-4df4-8dc5-cfd778e6a93a" xlink:href="krys-20210930.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_54791080-7fac-4df4-8dc5-cfd778e6a93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyReceivableReceivedAmount_c7fa36f7-8c56-4b14-a1c3-409314e607d5" xlink:href="krys-20210930.xsd#krys_LossContingencyReceivableReceivedAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_krys_LossContingencyReceivableReceivedAmount_c7fa36f7-8c56-4b14-a1c3-409314e607d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions_7d3f17fe-7dac-4345-a824-4d160ea90bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_059b9bbe-a564-47d6-b225-1b3992addf0f" xlink:to="loc_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions_7d3f17fe-7dac-4345-a824-4d160ea90bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cab563fe-35bc-4c09-9652-0283fa4a41b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cab563fe-35bc-4c09-9652-0283fa4a41b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0e58a9b0-8033-41bb-a6e2-817b4119e660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0e58a9b0-8033-41bb-a6e2-817b4119e660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8a3cc322-0b8b-42a6-a89b-aeef1f393758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8a3cc322-0b8b-42a6-a89b-aeef1f393758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77c99ee4-4034-4adf-9cf1-5e7a9d631216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77c99ee4-4034-4adf-9cf1-5e7a9d631216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_15984799-261d-465c-ace5-f9e6dfd0f643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_15984799-261d-465c-ace5-f9e6dfd0f643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_5aa57e09-28fd-4e0d-aae5-70b63a7da040" xlink:href="krys-20210930.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_5aa57e09-28fd-4e0d-aae5-70b63a7da040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d46f591-014e-41ee-8156-272c06e1800c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d46f591-014e-41ee-8156-272c06e1800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c39ceca2-c4a5-44ab-95a5-7e4fab2907e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c39ceca2-c4a5-44ab-95a5-7e4fab2907e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7b0b773e-1561-4b3c-b23c-fab596e121b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48c7c3c5-c9cd-4242-8fc2-ed8f7cbadac1" xlink:to="loc_us-gaap_OperatingLeaseLiability_7b0b773e-1561-4b3c-b23c-fab596e121b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44b8da69-3a9e-469f-8f4e-00d56a5d7e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fa56bf1f-6b49-46ff-92aa-d47b59985e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44b8da69-3a9e-469f-8f4e-00d56a5d7e62" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fa56bf1f-6b49-46ff-92aa-d47b59985e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_45bb9df6-0e27-4f6c-9fcb-379f1e48b293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fa56bf1f-6b49-46ff-92aa-d47b59985e88" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_45bb9df6-0e27-4f6c-9fcb-379f1e48b293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_89877bdb-fcdc-472a-8a99-91eca2d3f545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fa56bf1f-6b49-46ff-92aa-d47b59985e88" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_89877bdb-fcdc-472a-8a99-91eca2d3f545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c7bf17c3-a657-4587-a99c-b73e3ed996d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fa56bf1f-6b49-46ff-92aa-d47b59985e88" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c7bf17c3-a657-4587-a99c-b73e3ed996d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_db52bea7-202e-4c48-87e8-83ff6ed68ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fa56bf1f-6b49-46ff-92aa-d47b59985e88" xlink:to="loc_us-gaap_OperatingLeaseLiability_db52bea7-202e-4c48-87e8-83ff6ed68ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9cd86659-47a8-4bdc-8e0e-523917bfada6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fa56bf1f-6b49-46ff-92aa-d47b59985e88" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9cd86659-47a8-4bdc-8e0e-523917bfada6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_56a6f507-d4a6-4341-a91b-6ef402ace24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fa56bf1f-6b49-46ff-92aa-d47b59985e88" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_56a6f507-d4a6-4341-a91b-6ef402ace24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Capitalization" xlink:type="simple" xlink:href="krys-20210930.xsd#Capitalization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Capitalization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b3f435c5-1f3c-431c-87f7-3d4a732d6854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8a6b3173-7b7e-4071-9eb4-cfca257bf9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b3f435c5-1f3c-431c-87f7-3d4a732d6854" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8a6b3173-7b7e-4071-9eb4-cfca257bf9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_814d56f1-69ec-489b-aa6d-20271d31e8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_814d56f1-69ec-489b-aa6d-20271d31e8df" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10ef0106-02af-4446-82e2-ef0ea084067f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10ef0106-02af-4446-82e2-ef0ea084067f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51fcebe7-ff10-4d4b-ad40-a604b9c7982b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10ef0106-02af-4446-82e2-ef0ea084067f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51fcebe7-ff10-4d4b-ad40-a604b9c7982b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockSaleAgreementMember_d44840d6-4a56-46c9-b0df-5e5896287036" xlink:href="krys-20210930.xsd#krys_StockSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51fcebe7-ff10-4d4b-ad40-a604b9c7982b" xlink:to="loc_krys_StockSaleAgreementMember_d44840d6-4a56-46c9-b0df-5e5896287036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_58aea9d7-825b-4321-8af3-8127696e9d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_58aea9d7-825b-4321-8af3-8127696e9d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_58aea9d7-825b-4321-8af3-8127696e9d2b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_db120754-e658-47d9-b5bb-6b46cd21eef8" xlink:href="krys-20210930.xsd#krys_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:to="loc_krys_PublicOfferingMember_db120754-e658-47d9-b5bb-6b46cd21eef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_7da74354-4c05-452c-bd67-6d52acbbef44" xlink:href="krys-20210930.xsd#krys_PlacementSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:to="loc_krys_PlacementSharesMember_7da74354-4c05-452c-bd67-6d52acbbef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_5438e5f8-4a4e-40dd-a16d-63401bc4a78d" xlink:href="krys-20210930.xsd#krys_ATMProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:to="loc_krys_ATMProgramMember_5438e5f8-4a4e-40dd-a16d-63401bc4a78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_c7eadc61-c04b-4bd3-828b-2a41153cd40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88e6eaec-9552-4724-9b75-466cb90caa13" xlink:to="loc_us-gaap_OverAllotmentOptionMember_c7eadc61-c04b-4bd3-828b-2a41153cd40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1e4c78c2-48bd-4e09-8a9e-92d036315b60" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc1ee572-355b-4333-9bad-feb91276dca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc1ee572-355b-4333-9bad-feb91276dca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_61acaf81-02e0-419c-a7fe-cc4ca35e6f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_61acaf81-02e0-419c-a7fe-cc4ca35e6f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_716daee7-8533-468e-a75e-dfbc7ed3ba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_716daee7-8533-468e-a75e-dfbc7ed3ba7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_a9331024-dd0d-4b23-966b-4e8e2dc0765e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_a9331024-dd0d-4b23-966b-4e8e2dc0765e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5cb0dc56-d3bb-4052-8b65-6276ee7e336c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5cb0dc56-d3bb-4052-8b65-6276ee7e336c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7b7900e-0d2f-4d18-8bbd-b3501193651d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7b7900e-0d2f-4d18-8bbd-b3501193651d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_176c840c-3b44-45b6-affe-41f9e048514f" xlink:href="krys-20210930.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_176c840c-3b44-45b6-affe-41f9e048514f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0df17f7e-6acd-489a-8559-cecd555aac16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0df17f7e-6acd-489a-8559-cecd555aac16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_50b5da8f-d22e-48de-8b2e-aad98c8594a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_50b5da8f-d22e-48de-8b2e-aad98c8594a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_3af4d295-207c-47e3-98b8-b555af4af5c6" xlink:href="krys-20210930.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_aea1eb52-c8db-43b6-8604-8830cb72f44e" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_3af4d295-207c-47e3-98b8-b555af4af5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0f03486-5f1d-4b27-af17-0d0c9edd35be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aca5e625-4c0e-41f6-ad70-e97fb2fc699c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0f03486-5f1d-4b27-af17-0d0c9edd35be" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aca5e625-4c0e-41f6-ad70-e97fb2fc699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d876ca87-ffae-426f-944f-6f750787834e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_10b41fcc-8830-4280-8491-1fc9f7d9ba24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d876ca87-ffae-426f-944f-6f750787834e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_10b41fcc-8830-4280-8491-1fc9f7d9ba24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1dadeb7c-284a-4f89-8aad-4ae7359f457e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d876ca87-ffae-426f-944f-6f750787834e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1dadeb7c-284a-4f89-8aad-4ae7359f457e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c5d6be9d-5cb8-431e-bfcc-66ccbb388a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d876ca87-ffae-426f-944f-6f750787834e" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c5d6be9d-5cb8-431e-bfcc-66ccbb388a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9a8490c0-83b8-427d-a896-707ef20edca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d876ca87-ffae-426f-944f-6f750787834e" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9a8490c0-83b8-427d-a896-707ef20edca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd88c640-fe87-43cf-baf9-0aa9bb084945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd88c640-fe87-43cf-baf9-0aa9bb084945" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_909eb8ef-5129-4a77-92f2-edf9037219eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_us-gaap_AwardTypeAxis_909eb8ef-5129-4a77-92f2-edf9037219eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_909eb8ef-5129-4a77-92f2-edf9037219eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_930692a7-9718-483a-b88b-b75fcd199f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_930692a7-9718-483a-b88b-b75fcd199f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_cd319c52-ee7b-4411-a187-ee1cd8edeb20" xlink:href="krys-20210930.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:to="loc_krys_NonEmployeeStockOptionMember_cd319c52-ee7b-4411-a187-ee1cd8edeb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_70876166-a2f3-4042-9d1f-5c534177fc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:to="loc_us-gaap_RestrictedStockMember_70876166-a2f3-4042-9d1f-5c534177fc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_41dbbdc2-c519-44c4-b725-860dd4bd0a06" xlink:href="krys-20210930.xsd#krys_IncentiveStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1da92e7-ffdc-4fd8-8af9-ab1322dc50e6" xlink:to="loc_krys_IncentiveStockOptionsMember_41dbbdc2-c519-44c4-b725-860dd4bd0a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_srt_RangeAxis_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51e4caa3-91eb-46dd-a677-c08e48ede637" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ce510c3b-bfe2-48cc-85d8-67e671bfa7b5" xlink:to="loc_srt_RangeMember_51e4caa3-91eb-46dd-a677-c08e48ede637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c5e5e6b1-2377-4ed3-a4ef-c58f17f7b21d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51e4caa3-91eb-46dd-a677-c08e48ede637" xlink:to="loc_srt_MinimumMember_c5e5e6b1-2377-4ed3-a4ef-c58f17f7b21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e226d811-ed7f-42d5-874e-ab3d025bff30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51e4caa3-91eb-46dd-a677-c08e48ede637" xlink:to="loc_srt_MaximumMember_e226d811-ed7f-42d5-874e-ab3d025bff30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7f486375-bd1b-4fbd-a682-9cd703aa2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_us-gaap_PlanNameAxis_7f486375-bd1b-4fbd-a682-9cd703aa2d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dd03ea92-3e9e-4091-a9ba-9460a36ed3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7f486375-bd1b-4fbd-a682-9cd703aa2d18" xlink:to="loc_us-gaap_PlanNameDomain_dd03ea92-3e9e-4091-a9ba-9460a36ed3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_fe2b62a8-fb8b-46c3-9c71-378784be29f8" xlink:href="krys-20210930.xsd#krys_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dd03ea92-3e9e-4091-a9ba-9460a36ed3c7" xlink:to="loc_krys_StockIncentivePlanMember_fe2b62a8-fb8b-46c3-9c71-378784be29f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2c5b1ad7-dc22-41be-be11-9909948ec3bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_srt_TitleOfIndividualAxis_2c5b1ad7-dc22-41be-be11-9909948ec3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3238347-399c-422a-8d53-34b2b9003fe5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2c5b1ad7-dc22-41be-be11-9909948ec3bc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3238347-399c-422a-8d53-34b2b9003fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_575a01fb-9f69-4d7e-acde-3529baf69e5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3238347-399c-422a-8d53-34b2b9003fe5" xlink:to="loc_srt_DirectorMember_575a01fb-9f69-4d7e-acde-3529baf69e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cc8bb0b-0840-4d3a-b2cb-4b7db5650bd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2a0b712e-aee4-492e-b0d5-de5551bb25f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2a0b712e-aee4-492e-b0d5-de5551bb25f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_03537b97-fba0-4129-9280-37b69c54322d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_03537b97-fba0-4129-9280-37b69c54322d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_76e13206-7fc0-4c4b-9880-bd35dc812071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_76e13206-7fc0-4c4b-9880-bd35dc812071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b13dafe5-ba56-4acd-8a76-9ddf10fb324f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b13dafe5-ba56-4acd-8a76-9ddf10fb324f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ed040e6f-c77b-4cde-b9f6-a68147430ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ed040e6f-c77b-4cde-b9f6-a68147430ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1419d4e5-8246-4bfb-b6d8-a35b4aced4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1419d4e5-8246-4bfb-b6d8-a35b4aced4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65b094f1-7a7a-47a1-b9cb-b3cbdab519c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65b094f1-7a7a-47a1-b9cb-b3cbdab519c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3b2369e7-0dcc-40f7-9adf-cb8b653ea447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3b2369e7-0dcc-40f7-9adf-cb8b653ea447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80a8c648-e843-4b5c-afa4-9c2b3746301a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80a8c648-e843-4b5c-afa4-9c2b3746301a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_faebfd68-ea07-4f7e-8842-656167d4ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_faebfd68-ea07-4f7e-8842-656167d4ba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b66eb6b-fb5f-40b1-b9c0-0500f77766db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b66eb6b-fb5f-40b1-b9c0-0500f77766db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3f7f80c-2736-4591-98d7-bc8f90d6a7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f7199f27-c791-450f-9c18-9bd85778ca07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff84c60b-4091-4dfd-8971-74ac20dd315f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f7199f27-c791-450f-9c18-9bd85778ca07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e2a2093-80b0-4f26-bb1e-19c83be83f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e2a2093-80b0-4f26-bb1e-19c83be83f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bee63b2d-f937-473f-bbd1-d50bdd3c7f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e2a2093-80b0-4f26-bb1e-19c83be83f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bee63b2d-f937-473f-bbd1-d50bdd3c7f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_826451e1-b199-40c2-b4d3-969f4fb42b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e2a2093-80b0-4f26-bb1e-19c83be83f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_826451e1-b199-40c2-b4d3-969f4fb42b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d121a09f-c2ff-47c7-b591-b4ac98468bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e2a2093-80b0-4f26-bb1e-19c83be83f0f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d121a09f-c2ff-47c7-b591-b4ac98468bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f99b5085-c786-4d3b-b1fc-ebd8e54b03ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e2a2093-80b0-4f26-bb1e-19c83be83f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f99b5085-c786-4d3b-b1fc-ebd8e54b03ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f8bdecda-5571-4a5d-9b1d-0b33dabe0532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e2a2093-80b0-4f26-bb1e-19c83be83f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f8bdecda-5571-4a5d-9b1d-0b33dabe0532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6c8ae08-a3b0-410e-8916-8f1858a75da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e2a2093-80b0-4f26-bb1e-19c83be83f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6c8ae08-a3b0-410e-8916-8f1858a75da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5e2dec01-1ca9-497e-82ac-cfe893763078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5e2dec01-1ca9-497e-82ac-cfe893763078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d219305a-399b-4a0a-99c9-adee57bffbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d219305a-399b-4a0a-99c9-adee57bffbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e26f2e0b-1eef-4d26-b903-d501240be0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d219305a-399b-4a0a-99c9-adee57bffbc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e26f2e0b-1eef-4d26-b903-d501240be0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a8b33fb4-42df-4a2a-942b-2a11a1f0fe44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d219305a-399b-4a0a-99c9-adee57bffbc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a8b33fb4-42df-4a2a-942b-2a11a1f0fe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eae37147-92d4-4e5f-bb83-de38617a124e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d219305a-399b-4a0a-99c9-adee57bffbc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eae37147-92d4-4e5f-bb83-de38617a124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_36429a9e-f653-48aa-8279-0b18fab08c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d219305a-399b-4a0a-99c9-adee57bffbc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_36429a9e-f653-48aa-8279-0b18fab08c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d4c36bb0-d4f8-4d0b-8feb-c13c923fd123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d219305a-399b-4a0a-99c9-adee57bffbc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d4c36bb0-d4f8-4d0b-8feb-c13c923fd123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_479c75a4-ba20-4407-8ceb-7e13bf7999fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d219305a-399b-4a0a-99c9-adee57bffbc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_479c75a4-ba20-4407-8ceb-7e13bf7999fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1d414c51-2ea9-4b60-bd9c-f7594b1f94ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1d414c51-2ea9-4b60-bd9c-f7594b1f94ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cfd5cd5e-c45b-4edf-add7-23ba723405eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cfd5cd5e-c45b-4edf-add7-23ba723405eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fd91bf1c-b94a-43d1-bc5a-674394a0a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cfd5cd5e-c45b-4edf-add7-23ba723405eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fd91bf1c-b94a-43d1-bc5a-674394a0a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_85b74338-0538-45d0-9b28-df7d53644f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_85b74338-0538-45d0-9b28-df7d53644f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_d065ef75-68c0-4171-9fd9-ca93c7b2d890" xlink:href="krys-20210930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_d065ef75-68c0-4171-9fd9-ca93c7b2d890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_abd3abe4-13b6-4934-a7c4-df38bcb668c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_d065ef75-68c0-4171-9fd9-ca93c7b2d890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_abd3abe4-13b6-4934-a7c4-df38bcb668c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0675ec44-f41a-4adb-8ebb-be7cafbfe353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0523bff8-cfa2-47d4-8cbf-588c70e55d09" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0675ec44-f41a-4adb-8ebb-be7cafbfe353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c5fba68-fb2e-46c4-a74f-282c6c325560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c5fba68-fb2e-46c4-a74f-282c6c325560" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0551c179-7e10-4124-8e49-1314df259548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0551c179-7e10-4124-8e49-1314df259548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8900197e-f9cb-404d-9868-7f0022303c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0551c179-7e10-4124-8e49-1314df259548" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8900197e-f9cb-404d-9868-7f0022303c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6af9243b-3def-4553-8fc8-8cf891c3fd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8900197e-f9cb-404d-9868-7f0022303c4b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6af9243b-3def-4553-8fc8-8cf891c3fd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6ea23212-4216-41ef-a7a8-a4abf65bbd82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8900197e-f9cb-404d-9868-7f0022303c4b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6ea23212-4216-41ef-a7a8-a4abf65bbd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_871a1dd0-d235-4d54-978c-5ad492deec0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:to="loc_us-gaap_AwardTypeAxis_871a1dd0-d235-4d54-978c-5ad492deec0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0235c5fa-280c-46e0-91ec-4344a309c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_871a1dd0-d235-4d54-978c-5ad492deec0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0235c5fa-280c-46e0-91ec-4344a309c18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e7f9b81f-f48f-4596-a6ea-1b2134e767a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0235c5fa-280c-46e0-91ec-4344a309c18e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e7f9b81f-f48f-4596-a6ea-1b2134e767a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ea5d1653-42f4-4f05-add0-683ed3a23dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0235c5fa-280c-46e0-91ec-4344a309c18e" xlink:to="loc_us-gaap_RestrictedStockMember_ea5d1653-42f4-4f05-add0-683ed3a23dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dd5b1d5-1f0e-43e8-8f8c-46a1292bfb93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0d998db-d71e-4b0f-9929-c3886f49f17c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dd5b1d5-1f0e-43e8-8f8c-46a1292bfb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa35c94d-314a-4e35-920d-1e1c38121ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dd5b1d5-1f0e-43e8-8f8c-46a1292bfb93" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa35c94d-314a-4e35-920d-1e1c38121ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3525e88d-e2ba-48d2-938f-615fd5a38f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcf90c9f-57c0-4d1d-ae3e-f3997521c4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3525e88d-e2ba-48d2-938f-615fd5a38f2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcf90c9f-57c0-4d1d-ae3e-f3997521c4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d884af28-2c75-430e-9bf6-5f2e500a9180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcf90c9f-57c0-4d1d-ae3e-f3997521c4c9" xlink:to="loc_us-gaap_AwardTypeAxis_d884af28-2c75-430e-9bf6-5f2e500a9180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e43df3c-f485-42e2-8437-ff85762cd0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d884af28-2c75-430e-9bf6-5f2e500a9180" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e43df3c-f485-42e2-8437-ff85762cd0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4067af86-a958-4aab-be09-d8bce4ec0497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e43df3c-f485-42e2-8437-ff85762cd0f7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4067af86-a958-4aab-be09-d8bce4ec0497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcf90c9f-57c0-4d1d-ae3e-f3997521c4c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3319710b-a19b-41b0-98bc-a3ce1e7bbc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3319710b-a19b-41b0-98bc-a3ce1e7bbc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c515b3b5-031f-4347-85bb-442532789af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c515b3b5-031f-4347-85bb-442532789af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c9254065-a54b-4252-8be1-11a29aa847db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c9254065-a54b-4252-8be1-11a29aa847db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_426f2a20-5e3f-495b-9a12-3c68d37f8ed8" xlink:href="krys-20210930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_426f2a20-5e3f-495b-9a12-3c68d37f8ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_9ab54320-b7b4-4006-b4bd-430f02b84aae" xlink:href="krys-20210930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51c8bedc-059e-493d-a330-c7c01c345219" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_9ab54320-b7b4-4006-b4bd-430f02b84aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20210930.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14a9cc38-892f-4f6c-893b-6ad69b836889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0be993e-acc1-4a9b-befc-84be55a6454f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14a9cc38-892f-4f6c-893b-6ad69b836889" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0be993e-acc1-4a9b-befc-84be55a6454f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0be993e-acc1-4a9b-befc-84be55a6454f" xlink:to="loc_us-gaap_AwardTypeAxis_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06b43361-2703-4f5f-a361-a0bf4edef5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a01b4f38-e81a-4167-a96f-b3b8a9a3a4af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06b43361-2703-4f5f-a361-a0bf4edef5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7eb5d81a-bc11-4f2b-a24a-a30a0fb4871a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06b43361-2703-4f5f-a361-a0bf4edef5a7" xlink:to="loc_us-gaap_RestrictedStockMember_7eb5d81a-bc11-4f2b-a24a-a30a0fb4871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dba5af38-f4c6-41aa-a5ff-16e59c516e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0be993e-acc1-4a9b-befc-84be55a6454f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dba5af38-f4c6-41aa-a5ff-16e59c516e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dba5af38-f4c6-41aa-a5ff-16e59c516e2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e50b9cbc-a8f4-468c-8104-134e5822f594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e50b9cbc-a8f4-468c-8104-134e5822f594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fcd7d4d8-0eda-47d9-9651-c59d20c47188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fcd7d4d8-0eda-47d9-9651-c59d20c47188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_442dbd74-ae9b-413a-91f9-0704e4eb85c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_442dbd74-ae9b-413a-91f9-0704e4eb85c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6453d2f9-5f45-4671-8cb4-0d6af5fdece8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6453d2f9-5f45-4671-8cb4-0d6af5fdece8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d1927b90-fb0e-4bf0-8c91-bb3babd394f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77d38de9-93c0-401a-8290-93a510c65ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d1927b90-fb0e-4bf0-8c91-bb3babd394f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dba5af38-f4c6-41aa-a5ff-16e59c516e2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d7c79488-06b2-41d3-bda5-e6394a85ae35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d7c79488-06b2-41d3-bda5-e6394a85ae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99ae6483-2ac4-4dca-ae8d-c4dfb54220b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99ae6483-2ac4-4dca-ae8d-c4dfb54220b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b092c5c-12ff-4d08-b772-3c0779740855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b092c5c-12ff-4d08-b772-3c0779740855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_76283e0f-dcc9-4b8d-9e3b-879f3c877ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_76283e0f-dcc9-4b8d-9e3b-879f3c877ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82d7ad22-1747-4aea-a4aa-c8657ecb217b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3126d95-db1e-47ea-9a44-9440324c23b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82d7ad22-1747-4aea-a4aa-c8657ecb217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="krys-20210930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3677dbd9-c8db-455b-bde7-e08922619f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_923415c0-ae10-47a4-af50-556b4df9face" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3677dbd9-c8db-455b-bde7-e08922619f3c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_923415c0-ae10-47a4-af50-556b4df9face" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20210930.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_cf13532a-7499-4bc4-a45e-8a3430a18e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47e2856d-7ffb-4003-a995-9928bd94fffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_cf13532a-7499-4bc4-a45e-8a3430a18e41" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47e2856d-7ffb-4003-a995-9928bd94fffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b5599949-949a-482b-adf2-1145b0bcd9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47e2856d-7ffb-4003-a995-9928bd94fffa" xlink:to="loc_srt_TitleOfIndividualAxis_b5599949-949a-482b-adf2-1145b0bcd9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_db3e045f-5de7-4b95-a04e-f4781106b106" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b5599949-949a-482b-adf2-1145b0bcd9ab" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_db3e045f-5de7-4b95-a04e-f4781106b106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_c0c5ae9e-0485-4c70-9c18-9245e3174627" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_db3e045f-5de7-4b95-a04e-f4781106b106" xlink:to="loc_srt_ManagementMember_c0c5ae9e-0485-4c70-9c18-9245e3174627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5ccaeece-7c75-44b4-834d-0c2f344b1972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47e2856d-7ffb-4003-a995-9928bd94fffa" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_5ccaeece-7c75-44b4-834d-0c2f344b1972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdvanceToRelatedParty_a68ab921-95ad-4d12-85f7-e8a899b179de" xlink:href="krys-20210930.xsd#krys_AdvanceToRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5ccaeece-7c75-44b4-834d-0c2f344b1972" xlink:to="loc_krys_AdvanceToRelatedParty_a68ab921-95ad-4d12-85f7-e8a899b179de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="krys-20210930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_09e22033-94b6-4735-a015-03ec1da891e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2a7263da-ff47-44fe-9fa4-77709b426999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_09e22033-94b6-4735-a015-03ec1da891e6" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_2a7263da-ff47-44fe-9fa4-77709b426999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>krys-20210930_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 krys-20210930_g1.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X3=X17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(Q.C$P.C,P(# V.C0W.C4Y   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,T-P  DI(  @    ,T-P  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,3HQ,#HS," P-CHT-SHP,@ R,#(Q.C$P.C,P(# V.C0W.C R      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  )<P         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ ^@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M<MB/[$OF;EU:=5W$[/,7'4G'KCFI4@C6[^T&^+88D)OXP<\=??\ 0>E#J7Z
MH^9$UM%<%9Q?RPOL"@1R@ 8)[<C)S^E.2T1?O:I,_P ZOS(.QSCCL>]'/I:P
M<I<FGB\B3$L9^4_Q#TK%9KI;J21=/T]@LA9"'4,W+$$G/4\?B31"W5V"5^@'
M.6(T:Q)((YE3I_\ 7J_#;V$UN#<6EG'(P.Y1M..?7\!3E))>[)@EW1<22WCC
M5$DC"J, ;AP*BNQ%=0&(79BS_%&X!K-.SN4UI8I_8N<_VS<=_P"-?4'^GZT?
M8 ) ZZM-G<"<N#P#T_+BM/:+L3R>9J++&QPLB$^@84^LBPK-GGB2?:S@,V2
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MF33"-!P69L 4!N)]KCVY\\8(S]ZC[7'@'SN#T.>M"UU GMI/,D4ARRGWJ[0
M5CWEE%=OF0L,+MX/;@_T%3."G'E9<)N$N9$3:9 [[G+GVW>^?ZU;50BA5&%
MP!2A34+V'.HYVN5[QS&@(;!SQE-U107,9DVL^XG QY6T9R:LS+H50<A0/PI:
M *WV&'.?G'T<TOV.( CY\'_:- !]BBR#E\@8^^:ECC6)=JEB,YY.: (9K:*X
MG_> G:HQR1W--_LVU_N'_OHUG.C&3NS6%:<59!_9MK_</_?1IL>G6S1(2AY
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M\*1+>1,?Z3(P!S@@<T 07NGI?3C=<3Q;%_Y9/MSD]ZK?\(_'_P _]]_W^_\
MK5:E9$\MP_X1^/\ Y_[[_O\ ?_6IL>@1&)#]NON5'_+6GS^0<H[_ (1^/_G_
M +[_ +_?_6IIT"+S5'VZ^Y4G_6_2A3\@Y2&;PNLMQ"XOKG:F2=SY;\#VK>CC
M$42H&9@HQECDGZFE*5P4;#8/]0N/2I*EE#)O]1)_NFJK6[F5S]FAVDG!W')^
MM'0!9+=V8$P1MZDFIXH(XAE4"L1SBD!+10!0;32\TDS3L7<8SC@<=AGVI)-+
M\WDW$JL?O8/!ZGI^-:4ZG([V)E&YI6B>6T:==HQ5^H;N[E$<D0D9"2?D.1]:
M:($8 G.2/6D(7[/'[_G1]GC]_P Z!A]FC]_SH^SQ^_YT 'V>/W_.D^S1^_YT
M +]GC]_SH^SQ^_YT 'V>/W_.C[/'[_G0!&+=//;K]T=_<U)]GC]_SI@'V>/W
M_.HX;=/)CZ_='>D!)]GC]_SJ,VZ>>O7[I[_2F@)/L\?O^='V>/W_ #I 16]N
MGD+G/YU+]GC]_P Z&!'-;IY$G7[I[^U/^SQ^_P"=/H OV>/W_.C[/'[_ )T@
M#[/'[_G1]FC]_P Z #[/'[_G2?9X_?\ .@!RPHC;AG(]ZDH *R]2T^\O43[+
M?O:XC*X7/7(.>".P(_&FA,A_LG4?M/F'4V*%P=@W<#?NP.?3CFMJAM B.9)&
M7]W)L8=R,U&8K@J1]IP2.H0>_P#];\J0PCBN0^7N RYZ!,58H K&&YSQ=<9S
M]P4>3<^65^U?-NSNV#IZ4 .,5P1Q<8XQ]P4V.&Y7&ZYW ')R@Y'I0!7O[6\N
M;A?LM^UKM3YL1AMW)]:J_P!E:O\ ]!Z3_OPE6FK;$V9571-9&KK<'6&\L( 7
MV#+<GC;T_$^M=##_ *B/_='\J)-/8(IK<DJ,_P"O7_=/]*@HDHH BM_]0M2T
M,".?_42?[I_E4E !10 44 9SV-R\\DINL%APH'"G Z?E^M-FTZZE&5OGC)SD
M <=3T_.M*<U%ZJY,DWL:$2E(E0G) P3ZT^H>Y055-PR_* .!2 3[2_HM'VE_
M1: #[4_HM'VE_1: #[2_HM'VI_1: #[2_HM'VE_1: #[2_HM'VE_1: &"Y?S
MVX7[HXQ[FG_:7]%IL ^TOZ+3(;E_)CX4_*.:0#_M+^BTPW+^>O"_=/&/I30#
M_M+^BT?:7]%I 1V]R_D+]T^^*D^TOZ+0P&37+^1)PH^4\X]J?]I?T6GT /M+
M^BT?:7]%I 'VE_1:/M3^BT 'VE_1:/M3^BT /CG9Y I P:L4 %<]JUOJ4[#[
M!=)#\A!W#^+(P>A[9X]Z:$RO]DUG[06-[%Y98$+D\#=GT].*V*';H"(Y1*0/
M*=5(_O#.:(A,"?-9&_W5(_K2&244 5]MUGB6+&?[A_QI=MULQYD6[=UV'&/S
MH 4BYQP\73NIZ_G2(MT,;Y(FYY^0]/SH @O(;V6<?9+I(,+\VZ,-GDU7^R:U
M_P!!.+_OP*M.-M439W#[)K7_ $$XO^_ IL=IK/E)C4X@-HP# *=X]A6EW&:5
M9ZQ#=2/=W:M"7/R$9)YZC^[6P?\ 7K_NG^E*33>@U>VH^BH*(X/]0O&*DIL!
MDW^HD[_*:?1T **0!10!0:VO6FDD\]0&'RH&.%./U_\ KTV2UOG&4N]F>JXZ
M=>A_*M:<HQ?O*Y,DWL:=H&5HU8Y8#DYS5^LWN4%5_LX8!MW4>E( ^RC^^?RH
M^RC^^?RH /LH_OG\J/LH_OG\J #[*/[Y_*C[*/[Y_*@ ^RC^^?RH^RC^^?RH
M /LH_OG\J/LH_OG\J &"U'GM\_\ ".WN:?\ 91_?/Y4V ?91_?/Y4R&U'DQ_
M/_".U(!_V4?WS^5,-J//7Y_X3V^E- /^RC^^?RH^RC^^?RI 1V]J/(7Y\_A4
MGV4?WS^5# 9-:CR)/G_A/;VI_P!E']\_E3Z 'V4?WS^5'V4?WS^5( ^RC^^?
MRH^RC^^?RH /LH_OG\J/LH_OG\J ') $<-NSCVJ:@ K*U-=69(_[->)1Y?._
M&=V1CJ#QC/XXIJW43(0OB#[3G?;B'<.&(R%WG/0==N!_]>MNAVZ KE:\+",%
M/-!]8QD]1VJ.%6F/^LND('5P!GG/YTACQ:2!L_;)BO7!Q_A4\<9C# NSY8M\
MQZ9[?2@"(_;,\"#&?>C_ $SRSQ!OW<<G&/\ &@!2;K'"Q=.Y/6D0W?'F"'KS
MM)Z4 5;^+4I+A?L%Q#" GS^8F[/)QBJWV;Q'_P!!"S_[\FK3C;4G4/LWB/\
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MW^HD_P!TU1:XE\YE6Y4 ,1@Q'CG_  H L&.[X(G3..04XIQ2YV#$J;NYV\4
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M<;7X]%- ">:/[K_]\FCS1_=?_ODT 'FC^Z__ 'R:/-']U_\ ODT 'FC^Z_\
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M6)_K6K7/+<U6P44AA10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^ABTK_P-C_\ BJ -ZBL'_A/?#/\ T,6E?^!L?_Q5'_">^&?^ABTK_P #8_\
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MK!_X3WPS_P!#%I7_ (&Q_P#Q5'_">^&?^ABTK_P-C_\ BJ -ZBL'_A/?#/\
MT,6E?^!L?_Q5'_">^&?^ABTK_P #8_\ XJ@#>HK!_P"$]\,_]#%I7_@;'_\
M%4?\)[X9_P"ABTK_ ,#8_P#XJ@#>HK!_X3WPS_T,6E?^!L?_ ,51_P )[X9_
MZ&+2O_ V/_XJ@#>HK!_X3WPS_P!#%I7_ (&Q_P#Q5'_">^&?^ABTK_P-C_\
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M>HK!_P"$]\,_]#%I7_@;'_\ %4?\)[X9_P"ABTK_ ,#8_P#XJ@#=S2;JP/\
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M^ABTK_P-C_\ BJ/^$]\,_P#0Q:5_X&Q__%4 ;U%8/_">^&?^ABTK_P #8_\
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M/?#/_0Q:5_X&Q_\ Q5 &]16#_P )[X9_Z&+2O_ V/_XJC_A/?#/_ $,6E?\
M@;'_ /%4 ;U%8/\ PGOAG_H8M*_\#8__ (JC_A/?#/\ T,6E?^!L?_Q5 &]1
M6#_PGOAG_H8M*_\  V/_ .*H_P"$]\,_]#%I7_@;'_\ %4 ;U%8/_">^&?\
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M /BJ/^$]\,_]#%I7_@;'_P#%4 ;U%8/_  GOAG_H8M*_\#8__BJ/^$]\,_\
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M@@BK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVJ_]_8__ (W7K-% 'DW_  S7X9_Y_M5_[^Q__&Z/^&:_#/\ S_:K_P!_8_\
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M#/\ S_:K_P!_8_\ XW7K-% 'DW_#-?AG_G^U7_O['_\ &Z/^&:_#/_/]JO\
MW]C_ /C=>LT4 >3?\,U^&?\ G^U7_O['_P#&Z/\ AFOPS_S_ &J_]_8__C=>
MLT4 >3?\,U^&?^?[5?\ O['_ /&Z/^&:_#/_ #_:K_W]C_\ C=>LT4 >3?\
M#-?AG_G^U7_O['_\;H_X9K\,_P#/]JO_ ']C_P#C=>LT4 >3?\,U^&?^?[5?
M^_L?_P ;H_X9K\,_\_VJ_P#?V/\ ^-UZS10!Y-_PS7X9_P"?[5?^_L?_ ,;H
M_P"&:_#/_/\ :K_W]C_^-UZS10!Y-_PS7X9_Y_M5_P"_L?\ \;H_X9K\,_\
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M_M5_[^Q__&Z/^&:_#/\ S_:K_P!_8_\ XW7K-% 'DW_#-?AG_G^U7_O['_\
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M&?\ G^U7_O['_P#&Z/\ AFOPS_S_ &J_]_8__C=>LT4 >3?\,U^&?^?[5?\
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MQ6^*G"=:4Z.W0SH*4(+G>IY5_P ,U^&?^?[5?^_L?_QNC_AFOPS_ ,_VJ_\
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M?LPZ3'\:SXB77A-8-I@MC$+$[,>;]HW9WAO[@_2O>!^S?X8*Y^VZK_W]C_\
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M]JO_ ']C_P#C=>LT4 >3?\,U^&?^?[5?^_L?_P ;H_X9K\,_\_VJ_P#?V/\
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M&?\ G^U7_O['_P#&Z/\ AFOPS_S_ &J_]_8__C=>LT4 >3?\,U^&?^?[5?\
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MM5_[^Q__ !NC_AFOPS_S_:K_ -_8_P#XW7K-% 'DW_#-?AG_ )_M5_[^Q_\
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MHP]C[+^2-_5[G#A93_><_P#-H24M%%>6=P4444 %%%% !1110 4444 %%%%
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M95-Q:6BBN(Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &%N_:O./CMXVO?AC\+]9\2Z5%:S7=CY'EQ741:,[IXT(.UE/1S
MWKT8\Y%>2?M1Z3>^(/@;XDT[3+.XU&_F^S>5;6D+2R/BZB8X"@YX!_*NC"\K
MKT^?:ZOZ&5;F5*3CN:OP)\;7OQ.^%^C>)=5BM8;N^\_S(K6(K&-L\B #<S'H
M@[UZ.&[]J\C_ &7-)O?#_P #?#>G:G9W&G7\/VGS;:[A:*1,W4K#(8#'!'YU
MZV.,"C%<JKU.3:[MZ!1YG2BY;DE%%%<YJ%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M110 445$+A/F!."N-WMGM0!)2U&)AM)*D 9ST/3Z5)2U0";J0MBH6NDR1\Q
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M00I(.,=!U^M+5[ /I:C$PVDE2 ,YZ'I]*DHU6X!1113 **** "BBB@ HHHH
M*0]#2TC?=/TH$<+\/?BYX2^*'VX>%]5_M0Z>4^TM]GDBV;]^,[T7^ZU=Q]*^
M.O\ @G[#M?QT1(TF[[ 6)R,G_2,YR37V*V=M>AF&&C@\5.C!W2_R.7"576HQ
MFU83M@U^;O[6W_)PGBSZV_\ Z1P5^D35^;O[6W_)PGBWZV__ *1P5[G#'^^3
M?]U_H>;F_P# BN[)O%WC"X_:F^-FGVHU:/2-#O+DV&E"^*D018!8X!'[QVCX
M7G<SHHD/RX^_/#/A?3O".@V&D:/8PZ=IMDOEPVT:?*J\GGDDMDDEB226).2:
M^,OVSOA/<>%_$Z>,["WCCT;5OW%PJL!Y5W\Q9]J@'#A0V?FRX<MCY:^COV<_
MB]'\6_ "74I5=:T\K9ZC"2F[SBJL)0BX*B3.<,!AE8#A<U6:Q]O@J%?#Z4UI
M;L_/^OS)P?[NO.%7XY'S]^TY\8O$?C+XAM\._"EX\-G#,MA,;*X7=?S2HJO%
M(_1$!?RRA. 5<L"=NS,\8?L?^(OASX-7Q-IWB>.\U/2534&L[-3;21*@WN8)
M_,RPB/S@;$W+[\5YO\1O#<M]\>=>T?4[@:%;WOB*=&FN%6)+>&:<G[2=S)GB
M4R9)PP&>F*]T3]@9EWK_ ,)VK.V'$?\ 8XQ\IR,YF/RYZCN.*]67U;!4:*C5
MY4U=^[?F^9Q1<Z\Y-Q;:\[&=H?B2]^/7[+'B6TUG4(KS7_"C_;H[J9I3,MO$
MN5DDVY\V1XENE!ZD@'AOGJ;]@OQ)LU?Q-X8F%R4F@BU"W^7$,>QRDBX.,%BZ
M$;5Y",3C S[)\ OV?_\ A1L.O.^OMK":IY!=!:BV6#RA+_TU;((D Q_LCU-?
M*+PP? #]J+?B./3]-U,AT'FR);6%Q&221]Y_+MW(X##*]2:XZ4J&,CBL+06C
MUB:R]IAW0K3>VYTW[55Y>?$K]H2R\)P%85LUMM)MS-,S0![CRI/-*@'9EI8E
MR,G$2^HQ]SV-@NG6L5M&\KQPQ^6/M$SS.P]3(Y+$^Y)KXE_9+TF\^)7QOU_Q
MQ?Q[?LHN+S,+!4CN+AFPA4DMM(,N"!_RR&2<G/W0%SS^%>1G/+0=+!QWA'7U
M/1P"=3GK2^T<9\9FS\(?&X_Z@5Z?_)=Z^0?V#_\ DK^J?]@"3_TH@K['^*%A
M<:[\./%6EV$+7%_>Z1=6\$/W2[O$RJ,G ZD5\2_L6>)-,\-?&"8:C>PVIOM.
M;3K;>V!+<-)&ZH#T!98VQN(R2 ,D@5U9;%RRW%*+[:'-C9*.,H77J?H#)G]#
M7YP_LC_\G">$\_\ 3S_Z1W%?H7XF\4:9X2T.[UG6+R/3].M4+2SS' '. /<L
M2  .22 !D@5^?W['NE7>H?'C1+NW@,MMIT%Q<W<H==L49@DB#$YP<O(@PN2,
MY( YHRB,E@,9.6D4K7[[E8Y<^)P]M;,]4_X*!PJW_"$;P"#]LSQG./(QGGW/
MYUS/@'X1>-_VDOA[#?W7BA=(TC2XH=-TO2V21K>;[+&$$A"L A9MP,FUV^=P
M  H!ZC_@H)_S(_\ V^_^V]>H?L>ZM8WGP/TZTMI"\VG7-Q:7*%&4HYF>4#Y@
M,_),IXSUQ]X$#J]H\/DU&I3BN92M>U]-?\CG4?:XV<9/0^</V7_BAKW@#XG:
M5X2U/4+N'0KR22QFTR]AD=;>?<X01KG$;^>Q5MJ@-N.[<0I'MW[8'QFU;X>Z
M)I^B^'[A;'5M81_.NHSFXMX5QG8.S/D@/G*[6P-VUE^9_#>SQ/\ M16FIZ7!
M-=6=]XL6[@:.*4EH#=^9YGJGR@N0P!4*Q. ":[K]NNUF;XHZ+=+#(+:31UB:
MY ^7Y)I2=OJ0LJY]-\>?O#/I5,+0K9G14H6O&\EYF,:U2.$ERO8/AM^R#JWQ
M5\)VOBG6?$HTV75GDN/+N+1KB:X))"SRGS%PQ"Y_C."/FKV/1?%?C+X#_ OQ
M'?>/I_M>O65_/%I$MQ="X%Z'5/)).]79=YD8J<2;%)"YP*])^ ^L6FL?!OP;
M-:R?:!#I=O;.S*0-\2"&0#(Y(='&>AQG.""?(_VU=1MM>^$,$VD7$6JII?B.
M.*^:RD65;>7RY(F278&,9#3(IR 060'J*^?^L5,=C%AJR2AS6V2M\SO]G&AA
M_:TW=VN>/?#OX>>,_P!K;4M0U'Q%XLGBL=+1$AO9(_,C:X;"D1PKLC0%4!;;
MCG;G=N.,[QAHOC+]D;QY80:7KOVJRNDCNX[G9(MM?;"RO%<1!^2 S ?,V R$
M;3P/;OV$=<L?^%?^(-)21?MEOJOGF#!X62%-I!Q@\PR<#D;3D#(SRG[?6I6T
M^L>"M/C+/>6D-S=/"(VV>7)L"DMC:?FA(P#D=P,KGVJ=:=3-G@/9+V7\MM-C
MCE#_ &/V\9/F]3T/XW>-+?XE?LCZEXFLQO6]L[.Y$0((BE%S&)$5B,Y5@RGZ
M5\_? 'PSXW^*^CZAX1T77/\ A&/#,4C:A?WT"R,\BRVZPK"<.&D4^3C;E!Q(
M26(05ZEJVE7&D_L"BUO;;R;KR8;QHE(.$EU))D) R0&5@Q'4#.1GBJ__  3_
M (S-)X[D9V9O] VGIC'VGC'IR?S-84XT\+E^)JTU=QG:-]=-#2IS5L33A-[Q
MN>):I=>*?V:/BWJ&FZ=K6^?3)HVE6$N+:_C\I9$$T6X X$IX)8H6;:V0&/<_
M&;X!^-K/P'-\1_%OBQM1UN,1&\TV>-F-M!),56-&!QD&49C4*GSR8SM7/*_M
M<?\ )PGBW_MW_P#2."OKS]K-?)_9[\4'<W_+JQV\%B+J$#)KKKUO9SP<XQ5Z
MG+S:+7;_ #.:G14E73;]S;7U_P CCOV+?B3K7CSPWK^E:S=SZG+I4\;Q:A>2
MF2:2*;>?*8XR0I1R"68_.!T09^<OVM<G]H#Q0K1JI4VN65@0!]D@)P"O^T:]
MC_X)\_\ ,\_]N7_M>O'OVM_^3A/%G_;M_P"D=O5X6A2AGE>$8)14=NGV?\RZ
MU6;P-*2=FW;\SZ,_;L4K\(]*)8_-KD.5Z\^1.<9],@?E7CGP9^&_C/X^^!;?
M1QXD;P]X(T$/;>5$CRB\F>7[1^]4/'O*ADY)^4A"%)9F'LO[>'_)(='_ .P[
M%_Z3W%)^PBN[X5:Y*&)>37YF9CZFWM^,>@Q^@KR*-3V&3^UBES<UKM7.FI'V
MN.]G)Z6N?/GP"\<>(_A3\9=+\-W-Q>0VUQJ;:9?:*LP:#S)9A"7*JI165PK
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M^?OCM^T]_P *4\86^AMX:76#-IZWRW0O1 P8NZ $>6W=#^8KZ!]*^"_V\/\
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MB*)L_,[9.7/Z5["TR=/XO[N.:^ /@/\ '#7O ?@/5?#OA'PK=>*=?NM0.HR
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M#NW&$89YR?SKN/VG/CQK?P5M/#MOHMA87ESJLLH>:]1GCB6/9NPB,I)S(O\
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M*[^RF 7$(5&5PHP#RS*=N1N4CJ#7L@ND?A6W>NW!P.>>/I7D7[-GQ8UGXQ>
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M?W2Q_*SDDE5. 2H);&<?,[M@;MM>)_MI?"G5O$NM:'XET#1M2UJ9X&L+M+6
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MUI:* (O+QT IVT\T^BE\PU"BBBF 4444 %%%% !1110 4444 %%%% !1110
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M[4VL-\4OCQH.@:1>O+ D-G80/(0;0SW+%Q,KKG*%)(=Q S^[! (P3ZE^UO\
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M-@'"NK/&QP2%<D D 5VXFO2IPR^I)_#O_P"2F-"E*7UA05K['QA\"?B-\0O
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M7TI^W=_R2/2,C_F/1?\ I/<5\Y?\W:9[_P#";YVX.<?;\Y^F._2OHS]NYO\
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MX], C%"V?RJ">%X _P \U:HHLK6!V:M8IK9M\I8(67HV,'MSD?CGUI_V4KM
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M&3]GWQ2 #_RZ_P#I5":]DW'BLW5M&T[Q%92V&JV5KJEE)CS+6\A66,X((RC
MYY K?#S]C6A5>O*[_<958.K3E36AY;^R.#'^S[X6!!_Y>O\ TJF->S+67I.C
M:=X=LHK#2K*UTNRCSY=K9PK%&,DDX10,<DUI;CS1B*GMJTZJTYG<*4'2A&F]
M23%0FWPK8 )8[B"?;_ZPJ:EK U&;3U[U"UKEE[J,=6)Z9/\ /%6:*0K%=867
MG:N[/+9ZC/T] *3[,<''R<;1M/0?3IV%6:* LK6*S6Y;O[AL\CG_  I/L[G.
M54#.0 ?;Z>M6J*;U5@]"O]G/!SDC\,_I[TTV[[0 %QG)7/'3Z>M6J*EQYM&5
MJ5T@91VR!@,#]/7\:22W=\<\]0<\CZ?A5FBJ>HM+W(!;E?0_A1Y!*N#AM_4-
MT_*IZ*5NH=;L:5W=:@:W;C"J><D$\=/IZU9HI<JO>P:=2J;0MD%OE;@CG^?7
MMZU/M-/HJNMP"BBB@ HHHH **** "BBB@ IK?=/TIU(: /CC_@G[(J-X[#$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ.P85>%QTKZ&YKQSX,?"O5?A[XZ^(FLZA<V5Q:^)-3^VV:VDCLZQ^;,_S@J
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M@4$XTHJ6Y)124M<YL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!F&I0I[TZBE;6
MX!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ"XO(K6"6:9O*AB4N\C_*
M H&2>>P%9/\ PGGAK_H8=+_\#8__ (J@#=HK"_X3SPU_T,.E_P#@;'_\51_P
MGGAK_H8=+_\  V/_ .*H W:*PO\ A//#7_0PZ7_X&Q__ !5'_">>&O\ H8=+
M_P# V/\ ^*H W:*PO^$\\-?]##I?_@;'_P#%4?\ ">>&O^AATO\ \#8__BJ
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M.E_^!L?_ ,51_P )YX:_Z&'2_P#P-C_^*H W:*PO^$\\-?\ 0PZ7_P"!L?\
M\51_PGGAK_H8=+_\#8__ (J@#=HK"_X3SPU_T,.E_P#@;'_\51_PGGAK_H8=
M+_\  V/_ .*H W:*PO\ A//#7_0PZ7_X&Q__ !5'_">>&O\ H8=+_P# V/\
M^*H W:*PO^$\\-?]##I?_@;'_P#%4?\ ">>&O^AATO\ \#8__BJ -VBL+_A/
M/#7_ $,.E_\ @;'_ /%4?\)YX:_Z&'2__ V/_P"*H W:*PO^$\\-?]##I?\
MX&Q__%4W_A/O#/\ T,&E_P#@;%_\50!OT5A?\)YX:_Z&'2__  -C_P#BJ/\
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M&O\ H8=+_P# V/\ ^*H W:*PO^$\\-?]##I?_@;'_P#%4?\ ">>&O^AATO\
M\#8__BJ -VBL+_A//#7_ $,.E_\ @;'_ /%4?\)YX:_Z&'2__ V/_P"*H W:
M*PO^$\\-?]##I?\ X&Q__%4?\)YX:_Z&'2__  -C_P#BJ -VBL+_ (3SPU_T
M,.E_^!L?_P 51_PGGAK_ *&'2_\ P-C_ /BJ -VBL+_A//#7_0PZ7_X&Q_\
MQ5'_  GGAK_H8=+_ / V/_XJ@#=HK"_X3SPU_P!##I?_ (&Q_P#Q5'_">>&O
M^AATO_P-C_\ BJ -VBL+_A//#7_0PZ7_ .!L?_Q5'_">>&O^AATO_P #8_\
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M_ V/_P"*H_X3SPU_T,.E_P#@;'_\50!NT5A?\)YX:_Z&'2__  -C_P#BJ/\
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M@_\ "J?A[J?B<:?_ &H+ 1[;4S&(MOD6,?/M;NX[= :VV\=>&CD?\)!I>/\
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M=^&MI_XJ'2__  -C_P#BJ!'F?[/OQ_/QU;6\:#_8@TLPX_TTSF3S-^,_(O\
MSS/KU%>S].:^-OV&[RW\(?\ ":_V[/'HOF?8]G]H.(-V/.SC?CID5]6?\)WX
M;S_R,&EX_P"OV/\ ^*KTLRHTJ.*G"A\'_ .3"SE*E%U-S>VT8-8G_">>&O\
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M#I?_ (&Q_P#Q5-_X3[PS_P!#!I?_ (&Q?_%4 ;]%87_">>&O^AATO_P-C_\
MBJ/^$\\-?]##I?\ X&Q__%4 ;M%87_">>&O^AATO_P #8_\ XJC_ (3SPU_T
M,.E_^!L?_P 50!NT5A?\)YX:_P"AATO_ ,#8_P#XJC_A//#7_0PZ7_X&Q_\
MQ5 &[16%_P )YX:_Z&'2_P#P-C_^*H_X3SPU_P!##I?_ (&Q_P#Q5 &[16%_
MPGGAK_H8=+_\#8__ (JC_A//#7_0PZ7_ .!L?_Q5 &[16%_PGGAK_H8=+_\
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MH **** ,K7]/35=#U*RG)6"XM9(&:/A@KH02,]Z\=_X4)H'_ #_:I_W]C_\
MC=>VWW_'G<?]<OZ&N;VB@#S;_A0F@?\ /]JG_?V/_P"-T?\ "A- _P"?[5/^
M_L?_ ,;KTG:*-HH \V_X4)H'_/\ :I_W]C_^-T?\*$T#_G^U3_O['_\ &Z])
MVBC:* /-O^%":!_S_:I_W]C_ /C='_"A- _Y_M4_[^Q__&Z])VBC:* /-O\
MA0F@?\_VJ?\ ?V/_ .-T?\*$T#_G^U3_ +^Q_P#QNO2=HHVB@#S;_A0F@?\
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MV/\ ^-UZ3M%&T4 >;?\ "A- _P"?[5/^_L?_ ,;H_P"%":!_S_:I_P!_8_\
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M &J?]_8__C=>D[11M% 'FW_"A- _Y_M4_P"_L?\ \;H_X4)H'_/]JG_?V/\
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M_:I_W]C_ /C=>D[11M% 'FW_  H30/\ G^U3_O['_P#&Z/\ A0F@?\_VJ?\
M?V/_ .-UZ3M%&T4 >;?\*$T#_G^U3_O['_\ &Z/^%":!_P _VJ?]_8__ (W7
MI.T4;10!YM_PH30/^?[5/^_L?_QNC_A0F@?\_P!JG_?V/_XW7I.T4;10!YM_
MPH30/^?[5/\ O['_ /&Z/^%":!_S_:I_W]C_ /C=>D[11M% 'FW_  H30/\
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MW]C_ /C=>D[11M%><=IYM_PH30/^?[5/^_L?_P ;H_X4)H'_ #_:I_W]C_\
MC=>D[11M% 'FW_"A- _Y_M4_[^Q__&Z/^%":!_S_ &J?]_8__C=>D[11M% '
MFW_"A- _Y_M4_P"_L?\ \;H_X4)H'_/]JG_?V/\ ^-UZ3M%&T4 >;?\ "A-
M_P"?[5/^_L?_ ,;H_P"%":!_S_:I_P!_8_\ XW7I.T4;10!YM_PH30/^?[5/
M^_L?_P ;H_X4)H'_ #_:I_W]C_\ C=>D[11M% 'FW_"A- _Y_M4_[^Q__&Z/
M^%":!_S_ &J?]_8__C=>D[11M% 'FW_"A- _Y_M4_P"_L?\ \;H_X4)H'_/]
MJG_?V/\ ^-UZ3M%&T4 >;?\ "A- _P"?[5/^_L?_ ,;H_P"%":!_S_:I_P!_
M8_\ XW7I.T4;10!YM_PH30/^?[5/^_L?_P ;H_X4)H'_ #_:I_W]C_\ C=>D
M[11M% 'FW_"A- _Y_M4_[^Q__&Z/^%":!_S_ &J?]_8__C=>D[11M% 'FW_"
MA- _Y_M4_P"_L?\ \;H_X4)H'_/]JG_?V/\ ^-UZ3M%&T4 >;?\ "A- _P"?
M[5/^_L?_ ,;H_P"%":!_S_:I_P!_8_\ XW7I.T4;11OH!Y%I/PM\'ZS?:E:V
M&OW%^;/]U=0V^H0S?9SM/$GRGYMQ?ICH:U/^%":!_P _VJ?]_8__ (W7$?LW
MK*OQ6^,Y"28_MK=(JJ<,?.O.#M/ P3U]J^@-HKMQ5!X6MRMW^'_TDYL/5]M#
MFV9YM_PH30/^?[5/^_L?_P ;H_X4)H'_ #_:I_W]C_\ C=>D[11M%<1TGFW_
M  H30/\ G^U3_O['_P#&Z/\ A0F@?\_VJ?\ ?V/_ .-UZ3M%&T4 >;?\*$T#
M_G^U3_O['_\ &Z/^%":!_P _VJ?]_8__ (W7I.T4;10!YM_PH30/^?[5/^_L
M?_QNC_A0F@?\_P!JG_?V/_XW7I.T4;10!YM_PH30/^?[5/\ O['_ /&Z/^%"
M:!_S_:I_W]C_ /C=>D[11M% 'FW_  H30/\ G^U3_O['_P#&Z/\ A0F@?\_V
MJ?\ ?V/_ .-UZ3M%&T4 >;?\*$T#_G^U3_O['_\ &Z/^%":!_P _VJ?]_8__
M (W7I.T4;10!YM_PH30/^?[5/^_L?_QNC_A0F@?\_P!JG_?V/_XW7I.T4;10
M!YM_PH30/^?[5/\ O['_ /&Z/^%":!_S_:I_W]C_ /C=>D[11M% 'FW_  H3
M0/\ G^U3_O['_P#&Z/\ A0F@?\_VJ?\ ?V/_ .-UZ3M%&T4 >;?\*$T#_G^U
M3_O['_\ &Z/^%":!_P _VJ?]_8__ (W7I.T4;10!YM_PH30/^?[5/^_L?_QN
MC_A0F@?\_P!JG_?V/_XW7I.T4;10!YM_PH30/^?[5/\ O['_ /&ZBNO@AX:T
M^S^UW5_J5C'"#,\KS1< ,>6_=_="J<UZ=M%<E\7%9OA3XQ!#N?[#O S'JH:&
M3/3OFMJ<%*I"!%1\L)6Z'(>'_A7X/\3V$EWI/B"?4 Q:%IM/U&&;D,W'R+][
M;MK3_P"%":!_S_:I_P!_8_\ XW7$?L6^=_PJO5%99"4UJ1U:12#GR8./F/3)
M-?0&T5OBJ'U7$3H-WY3'#U?;TXO8\V_X4)H'_/\ :I_W]C_^-T?\*$T#_G^U
M3_O['_\ &Z])VBC:*XCI/-O^%":!_P _VJ?]_8__ (W1_P *$T#_ )_M4_[^
MQ_\ QNO2=HHVB@#S;_A0F@?\_P!JG_?V/_XW1_PH30/^?[5/^_L?_P ;KTG:
M*-HH \V_X4)H'_/]JG_?V/\ ^-T?\*$T#_G^U3_O['_\;KTG:*-HH \V_P"%
M":!_S_:I_P!_8_\ XW1_PH30/^?[5/\ O['_ /&Z])VBC:* /-O^%":!_P _
MVJ?]_8__ (W1_P *$T#_ )_M4_[^Q_\ QNO2=HHVB@#S;_A0F@?\_P!JG_?V
M/_XW1_PH30/^?[5/^_L?_P ;KTG:*-HH \V_X4)H'_/]JG_?V/\ ^-T?\*$T
M#_G^U3_O['_\;KTG:*-HH \V_P"%":!_S_:I_P!_8_\ XW1_PH30/^?[5/\
MO['_ /&Z])VBC:* /-O^%":!_P _VJ?]_8__ (W1_P *$T#_ )_M4_[^Q_\
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MFW_"A- _Y_M4_P"_L?\ \;H_X4)H'_/]JG_?V/\ ^-UZ3M%&T4 >;?\ "A-
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M_A0F@?\ /]JG_?V/_P"-UZ3M%&T4 >;?\*$T#_G^U3_O['_\;H_X4)H'_/\
M:I_W]C_^-UZ3M%&T4 >;?\*$T#_G^U3_ +^Q_P#QNC_A0F@?\_VJ?]_8_P#X
MW7I.T4;10!YM_P *$T#_ )_M4_[^Q_\ QNC_ (4)H'_/]JG_ ']C_P#C=>D[
M11M% 'FW_"A- _Y_M4_[^Q__ !NC_A0F@?\ /]JG_?V/_P"-UZ3M%&T4 >;?
M\*$T#_G^U3_O['_\;H_X4)H'_/\ :I_W]C_^-UZ3M%&T4 >;?\*$T#_G^U3_
M +^Q_P#QNC_A0F@?\_VJ?]_8_P#XW7I.T4;10!YM_P *$T#_ )_M4_[^Q_\
MQNC_ (4)H'_/]JG_ ']C_P#C=>D[11M% 'FW_"A- _Y_M4_[^Q__ !NC_A0F
M@?\ /]JG_?V/_P"-UZ3M%&T4 >;?\*$T#_G^U3_O['_\;J*X^ N@"+S!?:IC
M_KK'_P#&Z].VBHKC_CQH \[_ .%":!_S_:I_W]C_ /C='_"A- _Y_M4_[^Q_
M_&Z])VBC:* /-O\ A0F@?\_VJ?\ ?V/_ .-T?\*$T#_G^U3_ +^Q_P#QNO2=
MHHVB@#S;_A0F@?\ /]JG_?V/_P"-T?\ "A- _P"?[5/^_L?_ ,;KTG:*-HH
M\V_X4)H'_/\ :I_W]C_^-T?\*$T#_G^U3_O['_\ &Z])VBC:* /-O^%":!_S
M_:I_W]C_ /C='_"A- _Y_M4_[^Q__&Z])VBC:* /-O\ A0F@?\_VJ?\ ?V/_
M .-T?\*$T#_G^U3_ +^Q_P#QNO2=HHVB@#S;_A0F@?\ /]JG_?V/_P"-T?\
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M?\*$T#_G^U3_ +^Q_P#QNO2=HHVB@#S;_A0F@?\ /]JG_?V/_P"-T?\ "A-
M_P"?[5/^_L?_ ,;KTG:*-HH \V_X4)H'_/\ :I_W]C_^-T?\*$T#_G^U3_O[
M'_\ &Z])VBC:* /-O^%":!_S_:I_W]C_ /C='_"A- _Y_M4_[^Q__&Z])VBC
M:* /-O\ A0F@?\_VJ?\ ?V/_ .-T?\*$T#_G^U3_ +^Q_P#QNO2=HHVB@"WX
M)\.P>&?#MKI]I)+)%!YFR2=@7^=V<Y( '5O2NCJEI/\ QYK5V@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K??\
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M #:*-HHVBC:* #:*-HHVBC:* #:*Q?%OAT>(O#.LZ2)I+$ZI;S6[7*\O\P9
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M% !1110 4444 %%%% !1110!5OO^/.X_ZY?T-<WM%=)??\>=Q_UR_H:YO:*
M#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:*
M#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:*
M#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:*
M#:*-HHVBC:* #:*BM_\ CQJ7:*BM_P#CQH EVBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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M9'8YPJUTVT5TXVNL17G75_0SPM-T:<:,W<-HHVBC:*-HKA.D-HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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M)Z7_ ,E#U_\ [!&G_P#HV\JTM&R)-J21TM]_QYW'_7+^AKF]HKI+[_CSN/\
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M\)VNDJ_A'4-.:_N=0%O*6#KY@(\T/Y0Y%OP5S^\7^\N3E;V"4DCU3S(_W@W
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M[O\ [X7_ .*H_M'#?SA_9N+_ .?;.MVBC:*Y+_A96E_\^]W_ -\+_P#%4?\
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MK2_^?>[_ .^%_P#BJ/[1PW\X?V;B_P#GVSK=HHVBN2_X65I?_/O=_P#?"_\
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MV,_W><97/GE]I.MS?M.>(HM-UK_A%+F?3XT@NI+*.87$2)#NB17 7&0V"I)
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M8=(W7(W $\@=0"?QKY[^.7[?W@WX/_%;3_!$5A/XDU!Y(X=2NM-?'V.1WV;
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M27VOW)Z@^U>,_!W2X_A_\2/&/@*"VE&D2!=6TK-N#"L95(Y"&SN8?ZN(<_\
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MFUAYQ,]TVVTW8/FD#+;?H.3_ (\5\K:;9ZK\2/&"PJ_G:A=']Y.Y.V%/[[$
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M+B*+Q%-:2E4-Q.[+*87!Z.L95 #QNC SCFO"?A+^VUXO_9F\$V'PH^)OPO\
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M7Q@N,_(/F[]<':#748%>/> _V?X]%OK?4M<U%KN[@D$D=K:L1"I&[DL0&/\
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M)VFZS:WVB7VA^&]2L_L]LUVJ)=LSHPE)B5B5 W#;NQ[XKN%4(TCC.[;M0;L
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MK.*\U/\ T5YX'07"[[@[DR.1BD\4:'J,W[3?A74X["Z?38],</>K WD(Q2[
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M#5.245T_%7.>CF%>I'FYV<__ ,(+HO\ SXQ_]]R?_%T?\(+HO_/C'_WW)_\
M%UT&T4;17-]4H?R(Z/K=?^=G/_\ ""Z+_P ^,?\ WW)_\71_P@NB_P#/C'_W
MW)_\770;11M%'U2A_(@^MU_YV<__ ,(+HO\ SXQ_]]R?_%T?\(+HO_/C'_WW
M)_\ %UT&T4;11]4H?R(/K=?^=G/_ /""Z+_SXQ_]]R?_ !='_""Z+_SXQ_\
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MC_A!=%_Y\8_^^Y/_ (NN@VBC:*/JE#^1!];K_P [.?\ ^$%T7_GQC_[[D_\
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MJUAI6HW7]LZ5)N(077/G0''13DJ5Z;'QV%?KK;VL5K%'"D#".,"-"J%=L8&
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MX_#I36\*:/)XD3Q ^CVYUM(FC6^^S_Z1C'RCS,9QV^E'*^S#0U]HHVBD_P"
M/_WP:-T>X 2*2>G-'*WLF'O?RB[11M%&T4;14B#:*-HHVBC:* .ATG_CS6KM
M4M)_X\UJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% #*Y/2_^2AZ__P!@C3__ $;>5UE<GI?_ "4/7_\ L$:?_P"C;RM%
M\+,Y?%$Z6^_X\[C_ *Y?T-<WM%=)??\ 'G<?]<OZ&N;VBLS0-HHVBC:*-HH
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MRI=HJ+_E\H EVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBN3^*\<DGPO\
M%P6-B?[)O(U &2Y-NV, <_Q"NLVBF2-#_I!9HTVA@SGD*F,-N!XZ>]:4:BC4
MC)(QJ+FAJ> ?L4E6^&.KA'CD)UB0@(X8X\BW'0'UKZ"VBJT/\9DB9=T\A9V1
MD&[=Z'C[JCO5G:*Z,77^L5ZE>2M<SH4_8TXT5J&T4;11M%&T5QG4&T4;11M%
M&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%
M&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%
M&T4 &T5Y/^U*C#X$^)5*LK+]FX*D$_Z1'T&,UZQM%5KF.-M,N/WBS++CS'95
M(X+$<*0.NWO73AZCHUJ=5:I.YE5@ZM.44['F'[+:/_PHGP^@C=V7[3D1J6(_
MTF7L/]W]17K&T5%(ZQDKYT4$0R8I&55'/)X;CJ3WJ7:*6(J.M6J56K)NX4H.
ME3C%NX;11M%&T4;17.:AM%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T
M4;11M%.XK!M%&T4;11M%(8;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;1
M1M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;12;12[11M%-;B
MW/E+]A<'/C7;\^_['LV?-NQ]HSC%?5NT57CV?O\ *;-NW=ND*;>NW=Q_M-5C
M:*]#'XAXS$2K6LSFP])4:2I+5H-HHVBC:*-HKSCJ#:*-HHVBC:* #:*C^SQ[
M8U**R_Q[UW$_CFI-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBHKC_ (\:EVBHKC_CQH EVBC:*-HHVB@ VBC:
M*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:
M*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:
M*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:
M*-HHVB@ VBC:*-HHVB@#H=)_X\UJ[5+2?^/-:NT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 RN3TO_DH>O_\ 8(T__P!&
MWE=97)Z7_P E#U__ +!&G_\ HV\K1?"S.7Q1.EOO^/.X_P"N7]#7-[1727W_
M !YW'_7+^AKF]HK,T#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHV
MBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHV
MBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHV
MBC:* #:*-HHVBC:* #:*-HHVBC:* #:*BM_^/&I=HJ*W_P"/&@"7:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*B_Y?*EVBHO^7R@"7:*-HHVBC:* #:*
M-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*
M-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*
M-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*
M-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*
M-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* /E3#_\ #=?F_-YO
M][R?E_Y!F.O3K[]:^J]HKR+_ (4;%_PO;_A9']M)C_H'>1\O_'O]E_UV[T^;
M[O6O7=HKU<PK4JWL?8._NI/YG#A82H\_.[^\&T4;11M%&T5Y1W!M%&T4;11M
M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M
M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M
M% !M%&T4;11M%-;@?/G[.,<LGQ2^-&Y9 RZQM#8\P,OG7?&.B<*M?0>T5YU\
M-_A3_P *_P#$WCC5O[5%X-;U#[7]F, A2U3+/U#YDXD'7')KT7:*[<;5IU:Z
M=)W1S8>$J4??=PVBC:*-HHVBN$Z0VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBN3^+'F1_"OQEPSC^R;
MN9E'R[6\EMO(YSE376;16+XM\.CQ%X9UG21-)8G5+>:W:Y7E_F#(!CIU8'Z5
MO0DE.',95/@/%_V*8Y8_A;JFU)$5-9D55=>=ODP<9.#U)KZ"VBO.?@;\*3\(
M?#-]I3:J-7,]_)=BY\@0N$PB<@.PZQ,?H1[X]&VBNC'5:=;$3J47>/8SPL)4
M:$>9W8;11M%&T4;17 =(;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M
M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M
M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;17D_P"U%/(OP)\2N%$?D_9]BK*5
M/,\0/+9/3=^=>L;17)?%;P3+\1OAWJ>A)?"S-SY>+W[.)6/ENLAX]PN![UU8
M6I&CB(2GJKF&(3E3E;<Y/]ELI_PH_P -3/@M+]HWJ\I7I/*!\WTV_E7K.T5R
M7PM\!_\ "L_A_IGATWINFMO-_P!-CMQ"!OE9Q^[)(Z-CKUKK=HHQ52-;$3E#
M17##IQIQON&T4;11M%&T5RFX;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
M;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
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M0 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;145O_ ,>-2[145O\ \>-
M$NT4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
M &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
M &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
M &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T5%_R^5+M%1?\ +Y0!+M%&
MT4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&
MT4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&
MT4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&
MT4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&
MT4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% 'B'_
M  NC6_\ AIC_ (0/[)I_]B_\]MDGVG_CR^T??WX^_P"U>W[17S/_ ,(EKO\
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MZ0W4,!_>%>G[12QG(JU14]N;0*3<J4)2^(-HHVBC:*-HKE- VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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M% '0Z3_QYK5VJ6D_\>:U=H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ:C^R[C_ )XM71;6_OFC:W]\T <[_9=Q_P \6H_LNX_YXM71;6_OFC:W]\T
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MYXM1_9=Q_P \6KHMK?WS1M;^^: .=_LNX_YXM1_9=Q_SQ:NBVM_?-&UO[YH
MYW^R[C_GBU']EW'_ #Q:NBVM_?-&UO[YH YW^R[C_GBU']EW'_/%JZ+:W]\T
M;6_OF@#G?[+N/^>+4?V7<?\ /%JZ+:W]\T;6_OF@#G?[+N/^>+4?V7<?\\6K
MHMK?WS1M;^^: .=_LNX_YXM1_9=Q_P \6KHMK?WS1M;^^: .=_LNX_YXM1_9
M=Q_SQ:NBVM_?-&UO[YH YW^R[C_GBU']EW'_ #Q:NBVM_?-&UO[YH YW^R[C
M_GBU']EW'_/%JZ+:W]\T;6_OF@#G?[+N/^>+4?V7<?\ /%JZ+:W]\T;6_OF@
M#G?[+N/^>+4?V7<?\\6KHMK?WS1M;^^: .=_LNX_YXM1_9=Q_P \6KHMK?WS
M1M;^^: .=_LNX_YXM1_9=Q_SQ:NBVM_?-&UO[YH YW^R[C_GBU']EW'_ #Q:
MNBVM_?-&UO[YH YW^R[C_GBU']EW'_/%JZ+:W]\T;6_OF@#G?[+N/^>+4?V7
M<?\ /%JZ+:W]\T;6_OF@#G?[+N/^>+4?V7<?\\6KHMK?WS1M;^^: .=_LNX_
MYXM1_9=Q_P \6KHMK?WS1M;^^: .=_LNX_YXM1_9=Q_SQ:NBVM_?-&UO[YH
MYW^R[C_GBU']EW'_ #Q:NBVM_?-&UO[YH YW^R[C_GBU,ETFZDM_+$1S72[6
M_OFC:W]\T <[_9=Q_P \6H_LNX_YXM71;6_OFC:W]\T <[_9=Q_SQ:C^R[C_
M )XM71;6_OFC:W]\T <[_9=Q_P \6H_LNX_YXM71;6_OFC:W]\T <[_9=Q_S
MQ:C^R[C_ )XM71;6_OFC:W]\T <[_9=Q_P \6H_LNX_YXM71;6_OFC:W]\T
M<[_9=Q_SQ:C^R[C_ )XM71;6_OFC:W]\T <[_9=Q_P \6H_LNX_YXM71;6_O
MFC:W]\T <[_9=Q_SQ:C^R[C_ )XM71;6_OFC:W]\T <[_9=Q_P \6H_LNX_Y
MXM71;6_OFC:W]\T <[_9=Q_SQ:C^R[C_ )XM71;6_OFC:W]\T <[_9=Q_P \
M6H_LNX_YXM71;6_OFC:W]\T <[_9=Q_SQ:C^R[C_ )XM71;6_OFC:W]\T <[
M_9=Q_P \6H_LNX_YXM71;6_OFC:W]\T <[_9=Q_SQ:C^R[C_ )XM71;6_OFC
M:W]\T <[_9=Q_P \6H_LNX_YXM71;6_OFC:W]\T <[_9=Q_SQ:C^R[C_ )XM
M71;6_OFC:W]\T <[_9=Q_P \6H_LNX_YXM71;6_OFC:W]\T <[_9=Q_SQ:C^
MR[C_ )XM71;6_OFC:W]\T 5].C,-N$;J/2K=(%"]!2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 RN3TO_DH>O_\ 8(T_
M_P!&WE=97)Z7_P E#U__ +!&G_\ HV\K1?"S.7Q1.OHHHK,T"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR,*,H^SO'8?2T45SFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ,KD]+_Y*'K__ &"-/_\ 1MY7
M65R>E_\ )0]?_P"P1I__ *-O*T7PLSE\43KZ***S- HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHHH **** "BBF&3E@%9L#/&.?84 /HHHH **** "BBB@ HHHH ****
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MSDTZ@ HHHH **** "BBB@ HJ,3*<\XP<<\9^E+YGS;=ISMW8R/RZT /HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &5R>E_\E#U__L$:
M?_Z-O*ZRN3TO_DH>O_\ 8(T__P!&WE:+X69R^*)U]%%%9F@444E !NI-_7C%
M0^8&R!SCN*//3#$\*/XCT-):["VM<E\P?6CS!ZU"9@.BLQYX&/2CSDW$ ' .
M,\>W^/Z4M7>P]G9]2QFDW>U1B3U&*;YVX\(_OD8 _P ?PS1=2T3U)OU)MW'2
M@-GMBF9X]Z86 !/S-CT%$6MKCNMV3[J-U1"4*"3T SFB1@N,T)J6B8:O9$@;
M/:ES5?[8FX@\ 9RW&!C'!].OZ&D^V(W!.UNV2.?IS2YH\W*V4HLLALTFZH9+
ME54-M9@3U7''J?\ /-.>8+M'3/<U6I-];=42;Z3S!VYJ/.[D$K2AUZ]/?BE=
MAJKW)J*C$PW;0"6]./;_ !!IOVI<@*K,,9R!].GKU[4]1DU%,\WYE&#@]\CC
MVZTBS!F"XP3R.1T]<9]Q^=,"2BBB@ I,U$MTK+G:>OJ.F>O7IC!^AJ6D[@+1
M113 **** "BBB@ HHHH *S]7AO\ ^R+Q-,:%M0\B3[*UV2(Q-M_=[B 3MW8S
M@$^QK0HH ^=_BA\3OBW\)=!M]7U>'P;<VT]TMHJV2W3.'*.X)#%1C$9[]Q7?
M^&/^%HKK5NOB.3P>ND?.;@Z2+I;C[F$VJ_'WNO/3I7$?MK?\DMTG_L-1_P#I
M/<5V'[1FJWV@_!SQ!J&GWEQ97<7V?RI[69X9%S/$I^92"."P_&@#TO[0HX.X
M-@-MQDX_"D^TIYBH-S%B0"H)'!YR>@Q[UY#\%_!.O7NA^&/%/B'Q?J^HWQL4
MDBL8;GR[-H9(0$69-N9I I#&1R6W8Y(4$Q>+O#=HWB*\/B7XOZAHMW<F66ST
M^QU*'3!;VF3L'EG<9"I#?O#C.#QQ0![']I7Y H+%@",8Z'\?J?PH:Z1<YW#_
M 'AC\.?H:\,_9M\=:SXDF\6Z%J^LP>)H=!GC@M=74+NNHB9$W$J2K B%"-Q9
MOF;<S5S/P_LO%GQ*^)7Q)TA_%VI:7H-CJKK-):W4GVQ5%Q<B*&W9LK AVJ7*
M $B)5Q@D@ ^FFN$1E!SEO\_Y'7FFK>1,VU3O/<+U'S;<D=<9!YZ<&O!/#]_K
MOPU^/6G^ IO$6I>)M"UJP:ZB.K2AY[:0*Y+&0J3)_P >Y^7Y5_>MQP*Q?B!X
MFU#5/C[<>&]?\7WW@;PM:6 N()M/D-I]I8QEB6F)(R"K#=]W]V4QN;) /I=;
MA6+?*P"G&<>Y_P#K'Z$4PWD>]57+;EW@CH1SR/7MT_O#UKF_!OAFY\(:6^G7
M6OZGKL"S[[6YU)E::.,A1Y3R #S/GWL"0#APO\(SX;\-K'7?VA=,UOQ1=^-=
M?\.QRW4]IIVFZ1<"*.W0 N-Y55\T@R8_A?Y/O\C !],?:%WE0K$@XZ?3^AS7
MC_[,/CC7/'W@6_U/Q!?2:C?#46MP[1Q(5"P1'I&J@?,6_,5SG[*#7/B;0+GQ
M/J'B?7M6NHFEL);.^U,W5H<^7*)$0Y(8*=G#'H_K7/?L^S3V?[,_Q!N+:=[>
M>&74)89H?D966RCP?J#S0!]3><AX!R?;K^5(TP1@"K8_O<8'!.?I_B*\T_9S
MU6^U[X.>']0U"\N+V[E^T>;/=3/-(V)Y5'S,23P%'X5QGP:U#4?%WC?XTZ3J
M&O:G+!'J#6=L!=R'["CO=#,)S^[( 7[N/N+0!ZCIOQ3TK5?B1JW@J&UOAJVF
MVRW4LK1J(65EC("G=NS^]7JH[UU:W:,Q3#;QCY>__P!?OT]#7R9X9^%\EY^T
MIXI\/?\ "5>([<VFF17!U:'4,7\K>7;_ "R2[,.O[UOX?X%KW#QQX;G3PKI]
MK<^/+WPSH-A"8=1O?,C2[N /+\I_M3 >6XVG=A3OWD?4 ]#6\C:,R#=L"AB3
MQC(!P1U!P1UIYN%7;U^;IQ7RY<>,)OA[\2/!5GX7^(DWCG2=<OHK2]M=2OHM
M0-MF18P5=<%05F?&T#F(%MXXKJ?VDM>\1:-XT^&-KX=U!K">\OY$\IKB1+>>
M3?;I&LRI]Z/,ASWQV- 'O/VE!&KL2JMP-RD?GZ?C]*/M,>TMN^4=6SP/0?7F
MOGGXL>"_$?PO\&7OC>P^(?B*^UVT\OSHKZ97LI/,=4D\NVQLBR6&.&V#.,GF
MEU[PSXL\6?"NZ^(%[XSU#2-;71_[2LM/T.9X+&*%8O,$;@DN[NN=SEN"PQG8
M"0#U_P"(5QX@L_#-[<^&=/M=2UR,Q"VL[O:$DQ("_)=0,(6/4'Y3UXK1\/W%
M_/X=TU]7B6TU-[6-[V.$@B.<IF09'& >E>)>(OB!JVN?LFR^*8;B;3M;EA@2
M2^M91'*TJ7B0/+E5 !;:6P!CYB.E:/C[7-7T[]E2UUFVU2[AU5M(TMWO8YW6
M=G9X [F4'?E@S9.<\F@#W#[4K;-BLX9=P('!&/?ZC\_KARS!PI4$JPR&'3_/
MZ5X/X1^%GB7Q]X"T75]4^(.O:7J<^FQ&UCT:[:.W2-H@8VG!&^>4EM\C;UW,
MQ P%!-_X$^/=8^*_PBN;FXU'9KT4\]BVJ>7%*BRX#)-Y815PA=<+T/EC)&3@
M ]H-PH&2K@<?P'N*7SAZ'KC^G\^*^:?&MI9>%]'U?48/C=J,OBO3H9KQ;2?6
M+?R9+U 7:+[)G.TE2%@)PF1PU=#:_$_Q7>_LMGQC RR^)_LS*)8[<.I9;HPM
M,(P3DA 7Q]W/\.WY* /=/.&[&TXS@-Q@^_7\*43*=O8MT!X)]Z^?/@?H*^)M
M%T?Q#9?$_7-3UB%(I-0L)+[S[:WRY,D$ML^2K;49!(6R67> 1\M;W[17Q-U;
MP-I^@Z7H=Y!I.LZ[>K;KJU^B_9K2%6C$CR,3A>)-PSV5^X (![%]LCXY('&=
MPVXST!SW]NM/,RC'.<G''./K7REXRU)/AMH5IXD\,?%^;Q-KVGSPM<:=J&OI
M<VMS&_[N0"W!.<OS@L, $[M_S5](>$=>;Q)X3T36?+C@74+*.X-O$=ZH70/C
M..PXH K^/?B)IOP]T:'4+ZWO;YKB=+6WL]/@\V>>5CPJC('XD@>]>;?#'XS>
M)?&WQ2U'PYK.@P>'(+?3A=I9,[2W*.5MV =^%Q^\/1*]K:#=M^56VC@GU'3Z
M?6O!/!^3^V-X[ .UFT:+GKC]W9T ?05%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 ?)W_"
M7:__ ,-S?V#_ &]J?]BY_P"0;]KD^S?\@W=_J\[?O?/TZU]79PO2O 6^!NNC
M]J;_ (62;S31H.,F#S9/M(_T+R/N[-OWN?O=!Z\5[WYHW?\ ZJ]+,*M&HZ2I
M65H)/U.+"TZD.=SZNZ]";/M1GVJ'[0/?]*/M ]_TKR?:0_F.ZS[$V?:C/M4/
MV@>_Z4?:![_I1[2'\P6?8FS[49]JA^T#W_2C[0/?]*/:0_F"S[$V?:C/M4/V
M@>_Z4?:![_I1[2'\P6?8FS[49]JA^T#W_2C[0/?]*/:0_F"S[$V?:C/M4/V@
M>_Z4?:![_I1[2'\P6?8FS[49]JA^T#W_ $H^T#W_ $H]I#^8+/L39]J,^U0_
M:![_ *4?:![_ *4>TA_,%GV)L^U&?:H?M ]_TH^T#W_2CVD/Y@L^Q-GVHS[5
M#]H'O^E'V@>_Z4>TA_,%GV)L^U&?:H?M ]_TH^T#W_2CVD/Y@L^Q-GVHS[5#
M]H'O^E'V@>_Z4>TA_,%GV)L^U!/!J'[0/?\ 2@S@@CG]*/:0_F%9]CY]_9S\
M1:OK_P 4OC!;:CJMY?6UCK7E6D-S.\JVZ>==+MC#$[!A5X7'2OH;FO'O@S\)
M=7^'?CCXBZSJ5Q936OB+4_MEHMK(S.B>;.^) R@ XE7H3T//KZ[YZ^_YBNS&
M5:4JUX/33\CEPL:D86FM2;/M1GVJ'[0/?]*/M ]_TKC]I#^8Z[/L39]J,^U0
M_:![_I1]H'O^E'M(?S!9]B;/M1GVJ'[0/?\ 2C[0/?\ 2CVD/Y@L^Q-GVHS[
M5#]H'O\ I1]H'O\ I1[2'\P6?8FS[49]JA^T#W_2C[0/?]*/:0_F"S[$V?:C
M/M4/V@>_Z4?:![_I1[2'\P6?8FS[49]JA^T#W_2C[0/?]*/:0_F"S[$V?:C/
MM4/V@>_Z4?:![_I1[2'\P6?8FS[49]JA^T#W_2C[0/?]*/:0_F"S[$V?:C/M
M4/V@>_Z4?:![_I1[2'\P6?8FS[49]JA^T#W_ $H^T#W_ $H]I#^8+/L39]J,
MU#]H'O\ I1]H'O\ I1[2'\P6?8DKCOBW<7-C\*?&=Q:W+VEU%HUY+%<0?*\;
MB!B&7W!&:ZW[0J]<_I7/>/M%F\6>!?$>BV;QQW6I:;<V<+S-A%>2)D4L1D@9
M89P#]*NE4@IQN]"*D9<NB/(/V+?$NL>*OACJMSK6JWFKW*:S+"LU].\KA/)A
M(3+$\98_G7T+Q7CO[-/PGU?X,^![_1M;N+*YNKC4GO%:PD9T"-%$@!+*ISF,
M]NXYKUWS@O)S^E=>.K4IXF<J;7+T.?"QJ1I1C-:DV?:C/M4/V@>_Z4?:![_I
M7#[2'\QUV?8FS[49]JA^T#W_ $H^T#W_ $H]I#^8+/L39]J,^U0_:![_ *4?
M:![_ *4>TA_,%GV)L^U(Q^4\=JB^T#W_ $H-P/?]*7M(?S!9]CYO\5@R>(-4
M!X?[7)R/^NE5M/U"[TNX,UI.T,Q&/,4GIZ,/XOIP/:K/B=@WB#4W7YP;V8?+
M[-NJAM%?F=2HXUI2@]C]6H4XSH0C-:,]+\,?%X[O+U:U8N!@31 9/X&O2],U
MJRUBW$MK<)*A.,@]#Z$=C['FOFB0-)'SP_J*L:?J%WI5P9K2=H9B,>8I/3T8
M?Q#V.![5Z^&SF='W*NJ/&QF1TZOOX?1GTVTH7KQ3B^.<5Y+X:^+S,PCU6V.\
M#_71 9/X'%>EZ;K-GJ]N)K2XCE0G'!Z'T(['V/-?74,91Q'PL^-Q&#KX27[Q
M:%_=[4NZH_,V]2*>6P*Z]M6<=[Z#J***8!1110 4444 %%%)0 UN*\D_:BUK
M4/#WP/\ $>H:;>W&G7L/V?R[FSF>*5=UQ$IPRD$<,1^->M=<>]>>_'?P)?\
MQ,^%>L^&],FMK>^OO)\J2\9EC^2>.0YVJQZ(>W7%=&%E&.(IRGLFK^AC73E2
MDH[F/^R[K6H>(?@?X<U#4KVXU&]F^T>9<WDSRRMMN)5&68DGA0/PKUM>:\\^
M!'@2_P#AG\*]&\-ZG-;7%]8^=YLEFS-'\\\D@QN53T<=NN:]"Z9]J,5*,L14
ME#9O3T"@G&E%2W)**2EKG-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_CU\2=1M?&6@> M&U^U\'R:G ]Q=Z[=;42&W^=1L9C\K8288&QMPCVNF20
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M'S#GKBNM_9T\,ZI;W'C#Q5JMC/HT_B'47G33;I6\VW4&5CG."Q+2G&5' /\
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MJ[5494+] /\ /%(+1_,!WC:$VE2"03ZXZ#_/3N ?'WCKQ!X8\0?%WX8S^$]
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M>U<'XF_Y3#6O_89MO_3='19#NS]7]HHVBEHHLA!1113 **** "BBB@ HHHH
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MJ7.F1Q['%A91VETVW_5G[0&9^._][OB@#G?VT&:?X7Z4J1L6&M1 J!DY,$P
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M1L/HOY__ %J/[%PW=_>']O8KLON/!?\ A6OB/_H&'_O_ !__ !5'_"M?$?\
MT##_ -_X_P#XJO>MA]%_/_ZU&P^B_G_]:C^Q<-W?WA_;V*[+[CP7_A6OB/\
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MOB/_ *!A_P"_\?\ \51_PK7Q'_T##_W_ (__ (JO>MA]%_/_ .M1L/HOY_\
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MU>5#G=T9T>(L36IJ2BE?R/!_^%:^(_\ H&'_ +_Q_P#Q5'_"M?$?_0,/_?\
MC_\ BJ]ZV'T7\_\ ZU&P^B_G_P#6KG_L7#=V:?V]BNR^X\%_X5KXC_Z!A_[_
M ,?_ ,51_P *U\1_] P_]_X__BJ]ZV'T7\__ *U&P^B_G_\ 6H_L7#=W]X?V
M]BNR^X\%_P"%:^(_^@8?^_\ '_\ %4?\*U\1_P#0,/\ W_C_ /BJ]ZV'T7\_
M_K4;#Z+^?_UJ/[%PW=_>']O8KLON/!?^%:^(_P#H&'_O_'_\51_PK7Q'_P!
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M)&0<$CF@#=J"2W,C;LG<J\8=@,^X!J>B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O/:BXA>*159'!5A['K7C&L
M?LG>%=<U-KN[N]4F#9\R&2ZW+)Z<D9'X5[?16%6A3K?Q%<[<)C<3@9.6&FXM
M]C \*^"M+\%Z;%8:1;+:VR]0H&6]R:F\0^&;/Q5H-UI&J6\=U8741AEB?D;2
M.W'4=C6S16U.*I)*&EMCDJRE7DYU7=O>_4_+/X[?!2]^"?C/[+--,VERGS=/
MU(DJ!$G2-2/^6@[_ *9KZ'^ _P <H/B-X/U;1]5NE_X2W[+;*K=[V*-LI(I[
MMCJ#BOI7XD?#;1OBGX9GT36[9+BWD^>-R/G@E'W9$/J#V[U\(>/OV4?B#\+=
M>&HZ&+K5K**5F@OM)'[Z/^ZWEK\V1Z8Q[U];'$T<RHQI8C2:V9X,J,\'5]M3
M^'L?9^I,/^$FU0?>SK.FY(/ ^1/\/U%<9\3?$FE^&=/N]0OSYFMC4[@:;$X&
M9(^V1V1>Q_2N"^%/Q.\>>)F%CK_P_P!2EU8F*XCU;R&BC,\28C,J'&![@FNI
MO?V:_$OB[Q%=:CXCUZTD$[DF6W9R^T]5"E %'T->+'+</[91Q\ERIW[G37QN
M)4&\%'WF>)^'M!U'XC^([G,TDGGOYU]?,<);1G_EJQ[;>RBOM+X<V>B:=X/L
M[/0V4V$0VEN ^[N6_P!JN;OO@O8Z3X._LK06-I(6WS29P;AO]LCM[5YQX+\8
MWW@/5W5H_P#1GXGM3QL_VOK7RG$7%4\/CZ.%E2Y</W[>I[60\.PGA95H5.;$
M/='TU2<^M4=)UJTUNSCN;242Q2#*L*O!OFP17J4Y0JQYJ;NC&47!VDK,?7YP
M_P#!97)\%?#+Y2#]OO!CCO'$/Z_H:_1ZOD+_ (*'?LN^*?VF/ OAFS\)-:RZ
MOI%Y).T%S<B'='(@#;21C/ ZXK41P7[+_P"PUX+\0?L>2)J,<5SXA\>:0EW)
MK$B!7LV8;[=(^#@(2,GJ:^;OV'_C1JW[(G[0VK?"_P :.++0M5U$Z7J'GDA+
M>\'RPS@_W3E8B>ZLC8PM?J=\#? ,_P +_@[X.\'W<L5U<Z+I=O8S21L6C=T0
M!BI(!(STR!7R+^WY^P7KGQ[\5:7XS^'\-FNNB#[/J=C-<B#S]@(AF5B,>8%(
M4Y(^5%'/6@#5_P""NEQ&W[,.D_-C=XFML=_^7:Z.>/8$UZ?_ ,$^+5+/]CSX
M<HI$8DMKF4,,94M>3%NH]2*YO]J3]FCQQ\8OV2?"O@2RO;;4O&6B/83SS7$N
MQ+F2*W>&4[B.<B1B"<9[XKV#]F/X6WOP9^ O@SP7J$D-S?:3:M#/)$S%"S2.
M[;25!(RW<"@#Q/\ X*<?"D_$+]FO4-9MD,FK>%)EUB$1C!:('RYP< \!&5F]
MHZ^'_C9^T)=_&;]D;X#?#C3BU]K_ -N-G?6RXW.]LYM+)6YR2ZR;O]Y?3FOV
M&\2:7I_B#P_JVF:HL;:7>VTUI=[V&T1.A$BD]AM9LDX[5^-O_!.OX06?Q!_:
M\M)8V_MC0/!9N=5%PP*K/L?99R 8ZEV209QT)[8H _1OXH^"?AA\)_V1;'P)
M\2KN&T\$VNFVFDS7B@1N]PJA@\8'/F%U>3CU;\?CK6O^"=_Q'^']O'XK^"/Q
M%35K"1$O[15N'M9YD8J\9 !,<@8;NI')'OC] /VE_@!IW[2'PIU+PAJ-Q]CG
M=UN;"^"[OLMRARC[>_=3[.U?%7A7]GS]M#X3^'6\$>%/%^BW7AA8G@MKY9XV
M^RQEONQ>8H9!CIQQVH ] _X)P?M=>,?CK=>)/!7CF?\ M'6-#M8[V#5%@$9G
MC\QHV5P.ZML [GYL@=_"?@J57_@KGXA9SL8:WK2^6P^;!MKC##U!KZX_8A_8
MOD_9=TC7-2UG6X]=\6ZZ\?VR> $P1QQDE40LJDEC\S,0.:\(_:-_83^,+_M(
M7_Q2^$>I6<-S>S_;89'NUBGLYFB*2##@!E))[]^E 'J__!1+]K*]_9O\+Z#I
M'AZSLYO$NO22R)->1>;':1Q!%$NP]R7XQV1N<X!\L^%_P)_: _:J^'^C>*/&
M7Q>F\->&=6MQ=6FFZ-"(;CR7Z B/8 L@Z?-Q5_XD?L#_ !3^,WP#T2#QGXMM
MM:^*>D7MQ)#<328ADLYA$&MG?;T5XC(#CJY'2LKX7?LO_M<:?X6@^'5YXUT_
MPGX&5FB-]9W"SW5O;G[T<# >:?;+C% 'DW_!-72[+1?VWO%MA97K:A:6>FZG
M##J$YW/=HES$HDSW++R?I6YXDD5O^"PUIAN?[8MCC!Z?V='S7L/[/_\ P3_\
M5?L\?M=6?BC0M7CNOAY!92$R7$G^DNSP,C1%,?\ /7:W7H,]>*W]4_8T\7W_
M /P4(A^+ZW=JO@])8M1+-,//\U+583#LQ_>7/7&._:@#[BHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%X/_ ![_  J(?$KPP%VKK$,?^[D_S6M'_A#= _Z >G_^ R?X4?\ "&Z!_P!
M/3__  &3_"O5Y,S_ )H?<SCYL!VG]Z_R*0^)WA<=-7@_\>_PIC?$KPRRX&MQ
MJ/;/]16A_P (;H'_ $ ]/_\  9/\*/\ A#= _P"@'I__ (#)_A1R9G_-#[F'
M-@.T_O7^1GO\2_#,B@'5[8_W@P8C\L4H^)WAK<Q.KV_^S][_  J__P (;H'_
M $ ]/_\  9/\*/\ A#= _P"@'I__ (#)_A1R9G_-#[F/FP':?WK_ "/A;]KO
MX._%CXN?$;4]2\#?&2STCP=J5E':3^'[G4;JVBPJX8%(XW1]QZDX->E?L5_
M_P )?LI^#]0AN_%-GKOBC6)$FU&_17"+L#!(HB5!V#?(>0/O=.*^GE\%Z$O3
M1M._\!$_PI?^$-T#_H!Z?_X#)_A2Y,S_ )H?<PYL!VG]Z_R*?_"S_#'_ $%X
M/_'O\*C_ .%F>&E "ZS;X_V@Q/YUH?\ "&Z!_P! /3__  &3_"C_ (0W0/\
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MT5ZCK59U&MW<*45&G&,=A]%)2UB:!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2-]T_2EI* /E']ASP?KWA ^,/[=
MT34-&-P+,Q"_M7@+X\_=C<!TR,_45]6=O2N?\.^,O#WBSSO[!UW3M:-OM,IL
M+J.;;NSC.PGK@XKH!79C<1/%XB5>I'E;.?#TE1IJFM;#ZA\I]O49Z;>V/3_(
MZ?G4U%<9T$'DN\9#!5;.X!2<9]#ZBHVLV;*[AL(QW))[Y[$$ =O7GFK=% $
MA90@&URHV[V R!] .>0/2D^R\-E\GD#(&,<X!'<#)JQ10!5>S$GF!DC9'X96
M&X-]<CM_GV<UJ&7IS]X<\!LYR/?)/-6** *E]J'V.UGE2VFNY8H_,^S0!?,?
MV7<0,_C7E?P&^&NI^#]%U74_$MO_ ,53KEVU[?+N5@C@DJ%V,8P=SRR%E5>9
M2,8 )]:\IF4JSG';:<''N:#&?+9%"*O\/''Y4 2U$T"EMVT9V[=WM_DFI:*
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %(WW3]*6D/0T"9\<?L
MAC+XYWH8R5T_*G=\N#=8/)]A7V(JG:1WKS#X.? 70/@J=6.AWFH77]I"$2_;
MWC8_NM^W&Q%_OFO3U)YKT<QQ%/&8N=:B]'_DCCPE.5&C&G-W9)124M><=H44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>#YU0BJFXZBBBO-.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T
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M1)"P1'R-C,,8<=^H-=[W)]:^6/V)M2FM_A;JT:E=W]M2 +G/_+O;\^E?0O\
M:MWZK^9KJQU".'Q$Z</ACL<^'JN=*+GN=)2US?\ :UW_ 'E_,T?VM=_WE_,U
MP'6=)17-_P!K7?\ >7\S1_:UW_>7\S0!TE%<W_:UW_>7\S1_:UW_ 'E_,T =
M)17-_P!K7?\ >7\S1_:UW_>7\S0!TE%<W_:UW_>7\S1_:UW_ 'E_,T =)17-
M_P!K7?\ >7\S1_:UW_>7\S0!TE%<W_:UW_>7\S1_:UW_ 'E_,T =)17-_P!K
M7?\ >7\S1_:UW_>7\S0!TE%<W_:UW_>7\S1_:UW_ 'E_,T =)17-_P!K7?\
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M7?\ >7\S0!TE%<W_ &M=_P!Y?S-']K7?]Y?S- '245S?]K7?]Y?S-']K7?\
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M7?\ >7\S0!TE%<W_ &M=_P!Y?S-']K7?]Y?S- '245S?]K7?]Y?S-']K7?\
M>7\S0!TE%<W_ &M=_P!Y?S-']K7?]Y?S- '245S?]K7?]Y?S-']K7?\ >7\S
M0!TE%<W_ &M=_P!Y?S-']K7?]Y?S- '245S?]K7?]Y?S-']K7?\ >7\S0!TE
M%<W_ &M=_P!Y?S-']K7?]Y?S- '245S?]K7?]Y?S-']K7?\ >7\S0!TE%<W_
M &M=_P!Y?S-']K7?]Y?S- '245S?]K7?]Y?S-']K7?\ >7\S0!TE%<W_ &M=
M_P!Y?S-']K7?]Y?S- '245S?]K7?]Y?S-']K7?\ >7\S0!TE%<W_ &M=_P!Y
M?S-']K7?]Y?S- '245S?]K7?]Y?S-']K7?\ >7\S0!TE%<W_ &M=_P!Y?S-'
M]K7?]Y?S- '245S?]K7?]Y?S-']K7?\ >7\S0!TE%<W_ &M=_P!Y?S--N-8N
MEB\P%<4 =-17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T
M=)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM
M=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?
MVM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,
MT =)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T =)17-_
MVM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,
MT?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE
M_,T =)17-_VM=_WE_,T?VM=_WE_,T =)17-_VM=_WE_,T?VM=_WE_,T ='GG
M%+573Y3-;AVZFK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ,KD]+_P"2AZ__ -@C3_\ T;>5UE<GI?\ R4/7_P#L$:?_
M .C;RM%\+,Y?%$Z6^_X\[C_KE_0US>T5TE]_QYW'_7+^AKF]HK,T#:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*BM_\ CQJ7:*BM_P#CQH EVBC:*-HHVB@ VBC:*3D[MJ[BK%<;@,G&
M0.3W!!&>Q!Z$4B,DD;.K J$,F>Q Z\^H]Z ';11M%&T4;10 ;11M%&T4C?(0
M&4JV,E3U YY^G!_(T +M%&T4;11M% !M%&T4;11M% !M%&T4;11M.X?NY"I*
M@.J%E.?H#0 ;11M%-R-^SK)C[B\MG.,$#H<\<X&>.M*WRLX88*^O?Z4 +M%&
MT4;11M% !M%&T4;11M% !M%&T4WHQ#HT9QGYA^E*WR$!E*MC)4]0.>?IP?R-
M "[11M%&T50U'7--T>>TAOK^ULY;QMEJL\Z(9VR!M3)Y.6% %_:*-HHVBC:*
M #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:*
M #:*B_Y?*EVBHO\ E\H EVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC
M:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC
M:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC
M:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC
M:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC
M:*-HHVB@ VBC:*-HHVB@#D/^%9^&_P#A8G_"9_8/^*E_Z"'VF3=_J_(^YOV?
M<X^YU_.NOVU\S_\ "6:U_P -F?V-_:][_8O_ $#?M#_9O^0=O_U>[;][YNG6
MOIC:*]'&4:F'4>=WYHQMZ'+AZD)<]E]H-HHVBC:*-HKSCJ#:*-HHVBC:* #:
M*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:
M*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:
M*-HHVBC:*!',>%/ FC>$]8U_5=(L(X;S6+GSK^X\R1A.V7/ W]<N>F>]=/M%
M>%_ /7M4UOXC?%NWOM4O;RWM-5\JU@N9WE2!?/N!^[W$[.$'2O=-HKLQ=.=&
MK:H[_#_Z2<^'J1E3T6@;11M%&T4;17&=(;11M%&T4;10 ;11M%&T4;10 ;11
MM%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11
MM%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;15+6-(M]>T>]TJ
M\C>XL]1AD2>W7&0KC!Y!]*N[17+?$ZXFL/AQXJN+:XDM9X=*NI89[?Y'4K 2
M/U4UI"\IPMN9U/@?F.\ ^!=&^'>CR:5X?L(],LWN9)FMXY))#NP!U=VYPJUT
M^T5X7^R#KVJ^(OASJD^KZK>ZM.FJ21+/>SO,^WR(#_$Q[D_G7NFT5OC*<\/B
M9TIN\F8X>I&4(R2T#:*-HHVBC:*Y#J#:*-HHVBC:* #:*-HHVBC:* #:*-HH
MVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HH
MVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*P_%WAG3?%/A6XT;
M5[4W-C+CS(7+1G@@C[H!ZJO:MS:*\N_:2U2]T/X)>(KS3;N>QO%^S^7<6TIB
ME&9X@?G0#MN_.NK"TY5JM*--V?,C&JU&E*^QVGACPEI'A'1;?1M&@^R:?%GR
MX(7WGDDG[^X]6:MW:*\R_9PUB]U[X-^'M0U*\N;VZ<W'F7%S.\LIQ/*!\SD]
MMOY5Z;M%3B:<J-6K&H[OF84I*5.%M@VBC:*-HHVBN<V#:*-HHVBC:* #:*-H
MHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-H
MHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-H
MHVBC:* #:*-HHVBC IK<3V.1^'_PS\-_#C^U?^$<L/[+^U>5]I\NYDDZ9QC>
M[?WFKKMHKYG_ &-/%FM>)CXQ_MC5KW5O)^Q[/MMP\N,^?G[S'T7\J^F-HKT,
MPI3P^)E2JN\N_P CGPM2%:E&5-60;11M%&T4;17G'2&T4;11M%&T4 &T4;11
MM%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11
MM%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11
MM%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11
MM%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11
MM%&T4 &T5%<?\>-2[145Q_QXT 2[11M%&T4;10 ;11M%&T4;10 ;11M%&T4;
M10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;
M10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;
M10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;
M10!T.D_\>:U=JEI/_'FM7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 97)Z7_ ,E#U_\ [!&G_P#HV\KK*Y/2_P#DH>O_
M /8(T_\ ]&WE:+X69R^*)TM]_P >=Q_UR_H:YO:*Z2^_X\[C_KE_0US>T5F:
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
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M2G","&494=&_@6@#VNXNH+.UGN;B58+>W&Z:64[5C7:&W'/;##]17"?\+\\
MC5&T]O$,2W22F&3,$OEH=^S)EV[-I/\ $&*X^;.WFN9_:NU2?3_A;':0S;/M
M^H6]JQSYC31'S)2IZ<;D#_3VYK/US3_%>I?#^X\*VWPE&GZ.;?9!&NO0[8E5
MLB3D#<5;]XRDY=N68T >ZY4;"WRQO]R3.5;Z8KQ']KD+)\/-,+%D=]3B5F3D
M[?)GXY_V@*[OX/Z!K/AOX?Z9I^N>?#J=B9O,69EDVYFDV98$@Y5DZ$]#[5P?
M[7'_ "3O2?\ L)Q?^B[B@"7QY\"_#?AKPKJ6K>&1<>'=4TJ*6\CN[6ZD!"QJ
M?,CP\A 1]I!*[2.@!'RUVOPM\8-XG^&.D^(]5DC@!MI?/E>10%DC=UDF//5P
MNXCLK BN8\0>#?BAXXL9=&U;6?#NC:/=<74FCQSM.5",H0!\##9&[GIQR/EK
M"_:*T^'P#\$M'\/:.XAL_MEM8@+''NFC\N1\G"?Q/$DC?4GE>* .Z_X7YX!&
MJ-I[>(8ENDE,,F8)?+0[]F3+MV;2?X@Q7'S9V\UUOB3Q'I_@_19]5U>1K.QA
MV;I3&SCYW")C:#]XL,5XYKFG^*]2^']QX5MOA*-/T<V^R"-=>AVQ*K9$G(&X
MJW[QE)R[<LQJOXL\/ZQX:_93U'3=;AFM]2M3&+@/*6*_Z='Y/S!B#A>F"??%
M 'H6L?'3P+H368O->CC^U6D=Y'L@EDQ'(F]-VU#M8K@[3@X920,BMSQ-X^\/
M>#]%M-7U74D@TRZD2*"Y2-Y5=F1G7&Q2>0O7U(%<U\.?!&A3?!K1]-;2[>*Q
MU'3X;B]@$9(GFE52YWG)+%G4@[A]V/'R@5SO[)^I7%]\,9[6292MCJ4]I&NT
M)Y, 2)RH P.6<OGL.G% &;\$?CW::UI'V/Q;XCDFU^_OTBLXFLR5<,D2+\\,
M*J,ONZGODUV.K:5X5?XV>'[Z74KU/%L5F?+LO*.RXB"S$[CLZX,G\7I7+?LD
MR%OAK?[%P&U-RJQKN!'V>/)7"EE!^Z3T&00233O%WS_M6^#%9B%ATR3:JYVG
M]W<]1G_9- 'IOB[X@>'O EM#/KNHQV*32F*-<&5W(QDA4W,0-PSQQD \LH/C
M'Q0\6:-XR\:?"'4M$O$O+(ZTQB8((BDBRVP,95QN4_>^\ .5.<,I.G:VT7BS
M]J?6$U5%U2+1=*6XL898^+5CY)!!&-V!-*W(X\Q67!50(/CEI%E8_%;X9ZC'
M!'#>:AJ@BO6,>W<L;VY3<.,E00<@9*E5[+@ ]@\6>.O#W@6SCN==U:VTY)<>
M2DK?O)LD#Y$'S-C<"<#@<GBLWPG\7/!WC>^DLM&UVWNKQ"%^SNKQ.Q.[[JNH
M+8V-G&<8YK-^(GCBP\+Z[X=LK?0/^$G\7W9<:7"JQ++$"%1F\QR3&I1&^8 J
M0K E0I(\E^)6JZWK7Q0^&D_B'PM_PC,\.IQ+')]MBO)+I1.@(W1@;-HW?3<^
MW&* />_&/Q \.^ +>";7]3CT\3S&&-61W=F'4A54G ^G?'7BF^#_ (A>'O'D
M-Y)H=_\ ;?LDJQ3HT4D3H6QM.UU!P<]?8^AK@/BO\/\ 7[CXA>%_&>@Z78^)
M%TQ!;S:7=D0*5 D(E\QV"YS*P7)^5D1OF[='\-?BCH?Q$DO8+6/^RO$5LJKJ
M%C=PA)K;!(*AB!O16=U#'D'@@;^ #:\7?$CPMX%C1M:UNUM#(5"QJQED.2P^
MX@+8RC#=C&1C.<"G^$?B!X>\=P74NAZBE]]ED$<T9C>*1,J6#%'"G:0K\XQE
M''52*\(\(ZEK<_Q@^(FLVG@U?%%]97TEJEU+=I;BVA4O$%&X=?* 3=C=B/KA
MN>D\/>%_%^H_'*Q\73^$G\.6,EH8+SR]2BN!*JQR>6Q56W;=RQ*5V_>C5J /
M==HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HJ+_E\J7:*B_Y?* )=HHVB
MC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVB
MC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVB
MC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVB
MC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVB
MC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH \/_X4
MSK/_  TI_P )[]MTW^Q_^??SG^T_\>?D?<V8^]\W7[OOQ7N&T5Y+_P +R?\
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M:* #:*-HHVBC:* #:*BN/^/&I=HJ*X_X\: )=HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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M?^/-:NU2TG_CS6KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ,KD]+_Y*'K__ &"-/_\ 1MY765R>E_\ )0]?_P"P1I__
M *-O*T7PLSE\43I;[_CSN/\ KE_0US>T5TE]_P >=Q_UR_H:YO:*S- VBC:*
M-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*
M-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*
M-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*
M-HHVB@ VBHK?_CQJ7:*BM_\ CQH EVBC:*-HHVB@ "EE;9')(ZG!C1"6!]^.
M/QHVBO#_ (#A9/B'\60"P1=3VE6^8,OG3\<_=^51TKLY/CGX'ATD:E)K?EVK
M7#6J%[697=U57;"%-VT*ZG=C'S+S\RY .]VBJ$>N:;-JKZ8E_:OJ<:J[V2SI
MYZ*>C&/.['*]OXA5/PKXTT'QM8M=Z)J<%_$K*C!,AE8LR@,"!C[C=?2O&M.U
MBP\,_M0^-]3U69;&SAT1 \DRC(4"U.5P"Q)"#"YR22H&[B@#Z VBD;Y" RE6
MQDJ>H'//TX/Y&N1\*_%KPCXVO'L]%UJ&\O%7<MMM:.21<.<JK@$C]VWZ>HK%
MU;2O"K_&SP_?2ZE>IXMBLSY=EY1V7$068G<=G7!D_B]* .ZDUS38=533'O[5
M-3D5G2R:=//=1U81YW8X;M_":O[17A/CB:"Q_:J\*WEP\<%M#HT@DF=D51'M
MNCYA8X.,.>^>.E>A^%?B_P"$/&FK_P!EZ/JZ7-\8FE6)XGBW[<$A2Z@,<,#P
M3@!LXVM@ [+!PI"DACM7_:;:3@>^%-)U8!$:0XS\H_2O./CEI/A74/"-BOBW
M4KS1=.BO5\N\MHC(_FF.3KA&XKE_C]\:/^$0L8]+\/:W)9^);.Y5[NW6V!6.
M$P.=Q>2)E(R\?0YZ\<4 >X[11M%<QX,^)'ASX@O>#0-0^WBSV>>WDR1A=Q;;
MC>HW<*3\N>"*R=;^.G@;PYK%QI>HZXL%[;LR21K;S2J&'4;T0KP?E//!X.#0
M!WNT4;169X?\1Z9XJTQ=0T>\AU&T(!,D+@[<X^]S\I&X95L$>G%<U>?&SP/I
M\FK1W/B"W@DTRY^QW$<J2(YFW!0D:E09#D_P C&">""0#N-HH*E57?')&['
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M/S"HO#_B;1_%EBMYHVHV^I6S $20,3\Q7=L.?NL%Y(.".]>1?LAJL?PWU-5
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M&76?E/OGR\?K1["?E]X?6:?9_<=AN3^^OYT;D_OK^=<A_;GC'_H4K;_P<_\
MVNC^W/&/_0I6W_@Y_P#M='L)^7WA]9I]G]QU^Y/[Z_G1N3^^OYUR']N>,?\
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M4$ ]1ZL*Z?:*^:OV;Q'_ ,)Y=RE S?8)7P^6&/,C]Z^DV:..-G=U1%&XNQX
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M% !M%&T4;11M% !M%&T4;11M% !M%16__'C4NT5%;_\ 'C0!+M%&T4;11M%
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MBNS\-7-R\.MWD33VUH8)"94&_)#!2H_U4G4C[ON,[8*G?R!LW;LG@;?O<^U
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M]N:G_P!!2]_[_O\ _%4?VYJ?_04O?^_[_P#Q5']OT_\ GVP_U?J_SH]I_P"
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M>_\ ?]__ (JC^WZ?_/MA_J_5_G1[3_P$_F*/^ G\Q7BW]N:G_P!!2]_[_O\
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MZ?\ S[8?ZOU?YT>T_P# 3^8H_P" G\Q7BW]N:G_T%+W_ +_O_P#%4?VYJ?\
MT%+W_O\ O_\ %4?V_3_Y]L/]7ZO\Z/:?^ G\Q1_P$_F*\6_MS4_^@I>_]_W_
M /BJ/[<U/_H*7O\ W_?_ .*H_M^G_P ^V'^K]7^='M/_  $_F*/^ G\Q7BW]
MN:G_ -!2]_[_ +__ !5']N:G_P!!2]_[_O\ _%4?V_3_ .?;#_5^K_.CVG_@
M)_,4?\!/YBO%O[<U/_H*7O\ W_?_ .*H_MS4_P#H*7O_ '_?_P"*H_M^G_S[
M8?ZOU?YT>T_\!/YBC_@)_,5XM_;FI_\ 04O?^_[_ /Q5']N:G_T%+W_O^_\
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M:VKIP-T0;KMKQ'X'_&-O'7A/5-)U>7;XDL-,:UB9L9NH0^=_7EE'4?SKV[Q
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MY.[;CIU-?GW\2OVXOB;\._B;\(!XGT:U\*Z#K>F6EUK=E+%EF\R4I,=_\.P
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MC^I_] R]_P# :3_"C_A']3_Z!E[_ . TG^%'L9]G]P>WI?SQ^\H[11M%7O\
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M&7O_ (#2?X4>QGV?W![>E_/'[RCM%&T5>_X1_4_^@9>_^ TG^%'_  C^I_\
M0,O?_ :3_"CV,^S^X/;TOYX_>4=HHVBKW_"/ZG_T#+W_ ,!I/\*/^$?U/_H&
M7O\ X#2?X4>QGV?W![>E_/'[RCM%&T5>_P"$?U/_ *!E[_X#2?X4?\(_J?\
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MM%&T4 &T4;11M%&T4 &T4;11M%)@4UJQ/8P_#OBC0?%GVO\ LC7;'4_)^_\
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MN[ST"Y X /7OAA\0-<NO%_B'P/XE+:CK&G@7":PHCA%U:$IM+QAB%)$@/&>
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M/_=7%<1X$_:,\/>.%D:Y+:9X@DN+>=+3R2R3&-,-M/?VSBH?$GA+QO\ $;Q
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M;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%16__'C4NT5%;_\
M'C0!+M%4]3TR#5["[L+J$26=U!);31ARIDC?[RY'W?J.:N;11M% 'S!^T3\)
M?"?@/P3IE]H>GRV-X]^L3,EQ(PP89\??+_Q 5ZFWP[^'7PC!\5'3CI:Z:RH;
MGSKF8AI L."-S#G< ..H-<U^UQ_R3O2?^PG%_P"B[BO6/%GAJ+Q9X6U?19C'
M&NH6[1&9XS(1(58*^-PY5MK#W% &I:7$%_:1W=M-%<VLD:S)-#(KJZ,,JPP>
MA!4@^C"N7_X6IX6.@W^N#5%?1[&Y^R7-\D3M&DA*[<8&7!#J0R!AAAS7D_@W
MXG/X,^ ^O6^I7?\ 9^O>'IYM$A3[1%+*9BV(#AR1M4EEVYVE8#ACBI?%G@]_
MA[^R[=Z3<F*WOIUMYKD"#8QF:ZC)#@,=X .T,W9%^7T /0]8^.G@70FLQ>:]
M'']JM([R/9!+)B.1-Z;MJ':Q7!VG!PRD@9%=O!=0W5JES#(DT$FWRY(W#"3(
MS\A!^; ]*\_^'/@C0IO@UH^FMI=O%8ZCI\-Q>P",D3S2JI<[SDEBSJ0=P^['
MCY0*X3X#Z]JMM^SKXAN8'3S=+^W?8&:/<;?RX?-7&?\ 6?O/G&=W'M0!Z3X@
M^-?@CPOJ/V#4M?ABNL'*01R7 5E8JR$Q*P#*PP03D9'J*ZC0]<T_Q+I-EJ>E
MW*7MC>1K)#-'T.>BG.-K=<@X(P<XP:^??@3?^(O#/@6VGT/X<1:O#>AI9M4_
MMB*!KMDDD5048951G8H'RMG("[CN[#]G[P7X@\'7GBB/4M#FT/3;F[2?3;'[
M8+E$8>;O4X/+#Y-S-C=CV7 ![%M%?,7[.WPB\*^._ E_J>NZ=+>7']H-"DLE
MRZH (8,_-&R]V:OIH2*Q8 $[>O!'\^M>8S?LU_#RXM98(]$$#S!XT=+R4.5*
M >9\SE=V0.U '9^$_!NB>![)=-T.T^Q6YF^U>0LLDSB7Y?FRQ/\ >''3@UO;
M17C_ , ?$6MWEYXN\+ZUJ;:TWAR^\JWO+E1YCC=*N'9MP)_=G[I/W:]@VB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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M9>'=+L[I"66>"U1)$)^\ R@'#=^>:VYXUN(Y4EC2=)@8YHY1E9(R,$'\.O\
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M(RDF?9(W\22KB/\ W16)_P *_P!#_P"?:3_P(E_^+H_X5_H?_/M)_P"!$O\
M\71[7&?RQ^]ARX7^=_<;?GQ!,!H^O_/0;OKN_IC%*\T<R3*]RQ$WWD$BA1]
M*P_^%?Z'_P ^TG_@1+_\71_PK_0_^?:3_P ")?\ XNCVN,_EC][#EPO\[^XV
MC<H[?,( -V<K(,?]\^F?FQG&:<;B)Q)NE0OG*-E<C\<],_-CIFL/_A7^A_\
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M_KE_0US>T5F:!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
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M*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HKR_\
M:1U2]T/X)>(KS3;N>QO$^S^7<6TIAE&9X@?G0#MN_.O4-HKAOC5X*OOB!\+]
M6T#3I8(KRZ\G8]P6$8V2JYR55CT4]J[,&XQQ%.4]N;4PQ"<J,HQW,O\ 9PUB
M^U[X-^'M0U*\N;Z[?[1YEQ<SO+*<3R@?,Y/;;^5>F[17#?!CP1J'P[^&>F^'
MM1>&XO+'SO,DLRSQMOE9QMRH;HPZ@5W.T4L6X2Q%24-N;0,.G&C"+W#:*-HH
MVBC:*Y#<-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHV
MBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHV
MBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVT;11M%..Z$]CYG_8S\6:UXF_
MX3'^V-7O=6\G['L^VW#RXSY^?O,?[HKZ8VBO#OV;?@SK/PA_X24ZQ>Z;=_VA
M]G\G^SYGD_U?F[LY1?[XQCWKW':*]3-)TJF,E*BTX^1P8*,HX>*GN&T4;11M
M%&T5Y1Z ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M
M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M
M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M
M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M
M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;145Q_QXU+M%17'_ !XT 2[11M%&
MT4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&
MT4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&
MT4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&
MT4;10 ;11M%&T4;10 ;11M%&T4;10!T.D_\ 'FM7:I:3_P >:U=H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!E<GI?_)0
M]?\ ^P1I_P#Z-O*ZRN3TO_DH>O\ _8(T_P#]&WE:+X69R^*)TM]_QYW'_7+^
MAKF]HKI;Q2UK*!U9-H_6N:V/_P \G_*LS0-HHVBC8_\ SR?\J-C_ //)_P J
M #:*-HHV/_SR?\J-C_\ /)_RH -HHVBC8_\ SR?\J-C_ //)_P J #:*-HHV
M/_SR?\J-C_\ /)_RH -HHVBC8_\ SR?\J-C_ //)_P J #:*-HHV/_SR?\J-
MC_\ /)_RH -HHVBC8_\ SR?\J-C_ //)_P J #:*-HHV/_SR?\J-C_\ /)_R
MH -HHVBC8_\ SR?\J-C_ //)_P J #:*-HHV/_SR?\J-C_\ /)_RH -HHVBC
M8_\ SR?\J-C_ //)_P J #:*-HHV/_SR?\J-C_\ /)_RH -HHVBC8_\ SR?\
MJ-C_ //)_P J #:*-HHV/_SR?\J-C_\ /)_RH -HHVBC8_\ SR?\J-C_ //)
M_P J #:*-HHV/_SR?\J-C_\ /)_RH -HJ*W_ ./&I=C_ //)_P J9;QR?9_+
M\ML_2@!^T4;11L?_ )Y/^5&Q_P#GD_Y4 <])X)M6\;1^*([FZM[X6@L&@1T,
M1B$AD'5-P.]MWRE?N@="V>AVBC8__/)_RHV/_P \G_*@ VBC:*-C_P#/)_RH
MV/\ \\G_ "H -HHVBC8__/)_RHV/_P \G_*@ VBC:*-C_P#/)_RHV/\ \\G_
M "H -HHVBC8__/)_RHV/_P \G_*@ VBC:*-C_P#/)_RHV/\ \\G_ "H -HKG
MM4\%6FK>*]&UV6YNXYM'BN(K6WB=!'NF0K)(6*&3<0Q7[_ 4$<E@>AV/_P \
MG_*C8_\ SR?\J #:*-HHV/\ \\G_ "HV/_SR?\J #:*-HHV/_P \G_*C8_\
MSR?\J #:*-HHV/\ \\G_ "HV/_SR?\J #:*-HHV/_P \G_*C8_\ SR?\J #:
M*-HHV/\ \\G_ "HV/_SR?\J #:*-HHV/_P \G_*C8_\ SR?\J #:*-HHV/\
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M?_GD_P"5 !M%&T4;'_YY/^5&Q_\ GD_Y4 &T4;11L?\ YY/^5&Q_^>3_ )4
M&T4;11L?_GD_Y4;'_P">3_E0 ;11M%&Q_P#GD_Y4;'_YY/\ E0 ;11M%&Q_^
M>3_E1L?_ )Y/^5 !M%&T4;'_ .>3_E1L?_GD_P"5 !M%&T4;'_YY/^5&Q_\
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M/.1@?Z1+U.<?P_J*]9V/_P \G_*EC*2H8B<8?#&6@4)2E2A*>X;11M%&Q_\
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MOEK_ '1^5'EK_='Y4ZB@!OEK_='Y4>6O]T?E3J* &^6O]T?E1Y:_W1^5.HH
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M #?+7^Z/RH\M?[H_*G44 -\M?[H_*CRU_NC\J=10 WRU_NC\J/+7^Z/RIU%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(WW32T4
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M'%= *[,;B)XO$2KU(\K9SX>DJ--4UK8?1117&= 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% #*Y/2_^2AZ__P!@C3__ $;>5UE<GI?_ "4/7_\
ML$:?_P"C;RM%\+,Y?%$Z^BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_B:/^%J>&/\ H(_^0I/_ (FCZYA_YT'U;$?\^W]S.NW'THW'TKD?^%J>&/\
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M  \RN8UD_9RY=QG[./BS5O'GP=T+7=;N1=:K>?:/.F,:*/EN)47 15'117J
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M6_VB-"\"?!;3K#7](&HQZ=+=30&0ZE+NQ(L>#^[0=F[CYON\T>UC_*@^KO\
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ML?Y4'U=_S,^IO[?\=?\ 0I67_@X_^UU-8ZWXUEO$%SX6LK:V;_6M'J_F,/\
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MEB,1A<3*DGRN4K2MZGSK^RV,_$74!_TX2?\ H<%?6G7W%?)G[+'_ "4;4/\
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M !'G2_,!AB6&X[> #N]:\4Z1X;MXKC5]3M-)@E?8DE].D*LV"< L1SA6..N
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M<PRNMF-/'3O:UVK?:_R./_9B\$F'2KOQ). TEZ/)MV4':T*-\S#YCRQ 7_@
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M?I.HEAV\YRV-HR!T].,5+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_OZO^-$>MZ?-)LCO8)'_NK(I/\ .CZQ1_G7WH7LY_RO[F:-%)2UT&84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ,KD]+_Y*'K__ &"-/_\ 1MY765R>E_\ )0]?_P"P1I__ *-O*T7PLSE\
M43KZ***S- HHHH 3GZTTJ3P>E/HI6 C>,LI&:;Y;>O;%344UHK!N-P::T9;K
M_.I**0K)Z,85/'/%!!/T^M/HHL,3FDP>].HHLF Q0P/;%(5+=0,5)11Z"MW(
M]I]!1L]LU)118+#-II2I[4ZBFM L)BDVGFG44#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8T]A]%)2USFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $I.:=10(;BC;3J*0QFT^@IB
MH^T9"J>^WFIJ*+ 4KS38-1A"75O#,.ZR*&'ZUF-X%T)^6T73V/\ M6R'_P!E
MKH**RE1IR?-**;]$:*I4BK1DTC"_X0G0/^@'IO\ X")_A1_PA.@?] /3?_ 1
M/\*W:*CZM0_D7W(KVU3^9_>87_"$Z!_T ]-_\!$_PH_X0G0/^@'IO_@(G^%;
MM%'U:A_(ON0>VJ?S/[S"_P"$)T#_ * >F_\ @(G^%'_"$Z!_T ]-_P# 1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%% !1110 4444 %%%% !1110 4444 %%%)0 VO&?VN@TG[/OB@ '/\ HO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 RN3TO_ )*'K_\ V"-/
M_P#1MY765R>E_P#)0]?_ .P1I_\ Z-O*T7PLSE\43KZ***S- HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ I*6DH ^-]L7_#P#S.-W3.TY_P"07_>_SS7V(WWOPKQ?_AGR/_AH
M0?$O^WTSG?\ V5]B&?\ CT^S?ZW?TQ\WW>M>SX^8?2O2S"M2K^Q]B]H13T_K
M[SAPU.5/GYW?WB6EI*6O-.X**** "BBB@ HHHH **** "BBB@ HHHH ****
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M I&^Z?I2TAZ&@3V/CC_@GZL4;>-PF",6)4A2OWO/SC/T%?8OO7BO[/O[/:_
MMM?:/7DUH:N82=MD+?R_+\S@ .V1^\_2O:N:]',:M.OBIU*+]W_@''A*<J5"
M,9N['T4E+7G':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2;O:DSM'/-<EX6
M^)WACQP\R:+JJ7<T)_>0%6BE4<?-L<!MO(&<8R<=:?+-J\5<RE4A'XW8Z[=[
M4ZJ_VE5.">-VT'(P?\X/Y5(LRR*&3]XO]Y2"*GY&OS%KD]+_ .2AZ_\ ]@C3
M_P#T;>5UE<GI?_)0]?\ ^P1I_P#Z-O*U7PLSE\43KZ**9YB?WA69H/HIGF)_
M>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z
M*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?
MWA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]
MX4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /H
MIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_
M>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?W
MA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^B
MF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]
MX4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>
M%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*
M9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?W
MA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X
M4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HI
MGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>
M% #Z*9YB?WA1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA
M1YB?WA0 ^BF>8G]X4>8G]X4 /HIGF)_>%'F)_>% #Z*9YB?WA1YB?WA0 ^BF
M>8G]X4>8G]X4 /I*;YB?WA1YB?WA0!X OQTUYOVIA\-_LNG_ -B8_P"/CRW^
MT_\ 'EY^=V_;][C[O2O??NKDU\>_+_P\(QN&[KMSSC^R\9^F>/K7V"9%+#GB
MO4S"G2I>Q]DMX1OZGGX24GS\_P#,2TM,\Q?[PH\Q/[PKRST!]%,\Q/[PH\Q/
M[PH ?13/,3^\*/,3^\* 'T4SS$_O"CS$_O"@!]%,\Q/[PH\Q/[PH ?13/,3^
M\*/,3^\* 'T4SS$_O"CS$_O"@!]%,\Q/[PH\Q/[PH ?13/,3^\*/,3^\* 'T
M4SS$_O"CS$_O"@!]%,\Q/[PH\Q/[PH ?13/,3^\*/,3^\* 'TAZ&F^8G]X4&
M1<'YA0!XY\&_BMK/Q#\<_$C1K^WL8;3P[J7V.TDMHW21U\R=,RY<ACB%.FWJ
M:]BW;AD5\T?LNS!?BU\;@ 7SKFX%.01]HNN1Z]1TKZ5WKV(KMQU.%*ORP6GN
M_C%/\SFH2<J=Y;DU%,\Q?[PH\Q/[PKB.D?13/,3^\*/,3^\* 'T4SS$_O"CS
M$_O"@!]%,\Q/[PH\Q/[PH ?13/,3^\*/,3^\* 'T4SS$_O"CS$_O"@!]%,\Q
M/[PH\Q/[PH ?13/,3^\*/,3^\* 'T4SS$_O"CS$_O"@!]%,\Q/[PH\Q/[PH
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MO"CS$_O"N4W'T4SS$_O"CS$_O"@!]%,\Q/[PH\Q/[PH ?13/,3^\*/,3^\*
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M3^\*/,3^\* 'T4SS$_O"CS$_O"@!]%,\Q/[PH\Q/[PH ?13/,3^\*/,3^\*
M'T4SS$_O"CS$_O"@!]%,\Q/[PH\Q/[PH ?13/,3^\*/,3^\* 'T4SS$_O"CS
M$_O"@!]%,\Q/[PH\Q/[PH ?13/,3^\*/,3^\* 'T4SS$_O"CS$_O"@!]%,\Q
M/[PH\Q/[PH ?13/,3^\*/,3^\* 'T4SS$_O"CS$_O"@!]%,\Q/[PH\Q/[PH
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MK_;K?\\5_.C^W6_YXK^=96T4;10!J_VZW_/%?SH_MUO^>*_G65M%&T4 :O\
M;K?\\5_.FIX@,D7F"$8^M9FT5%;_ /'C0!M?VZW_ #Q7\Z/[=;_GBOYUE;11
MM% &K_;K?\\5_.C^W6_YXK^=96T4;10!J_VZW_/%?SH_MUO^>*_G65M%&T4
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M^>*_G65M%&T4 :O]NM_SQ7\Z/[=;_GBOYUE;11M% &K_ &ZW_/%?SH_MUO\
MGBOYUE;11M% &K_;K?\ /%?SH_MUO^>*_G65M%&T4 :O]NM_SQ7\Z/[=;_GB
MOYUE;11M% &K_;K?\\5_.C^W6_YXK^=96T4;10!J_P!NM_SQ7\Z/[=;_ )XK
M^=96T4;10!J_VZW_ #Q7\Z/[=;_GBOYUE;11M% &K_;K?\\5_.C^W6_YY+^=
M96T4;10!7_X6-H']O?V/_:.F_P!JXQ]@^VIY_P!S=_JOO?=YZ=*VAK+  >6/
MSKY"W2?\-V_ZK]YG[G.?^01_WU[]:^J]HKT\=A?JOLE>_/&,O3R.7#5?;<UE
M]HU?[=;_ )Y+^=']NM_SQ7\ZRMHHVBO,.HU?[=;_ )XK^=']NM_SQ7\ZRMHH
MVB@#5_MUO^>*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_ #Q7\ZRMHHVB
M@#5_MUO^>*_G1_;K?\\5_.LK:*-HH U?[=;_ )XK^=']NM_SQ7\ZRMHHVB@#
M5_MUO^>*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_ #Q7\ZRMHHVB@#5_
MMUO^>*_G1_;K?\\5_.LK:*-HH U?[=;_ )XK^=']NM_SQ7\ZRMHHVB@#5_MU
MO^>*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_ #Q7\ZRMHHVB@#5_MUO^
M>*_G1_;K?\\5_.LK:*-HIB(M'\=:7K%YJ,&GWEG>3Z?($N([6[23R>#Q+@D[
ML[N/]DUL_P!N-_SR'YU\U?LVLW_"V/C$$+'S-:W,J@C<WVB[&.,=BW_?-?0.
MT5U8NBL/7]GO\/\ Z2<^'J^VIW2-7^W6_P">2_G1_;K?\\5_.LK:*-HKD.DU
M?[=;_GBOYT?VZW_/%?SK*VBC:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[
M=;_GBOYT?VZW_/%?SK*VBC:* -7^W6_YXK^=']NM_P \5_.LK:*-HH U?[=;
M_GBOYT?VZW_/%?SK*VBC:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_G
MBOYT?VZW_/%?SK*VBC:* -7^W6_YXK^=']NM_P \5_.LK:*-HH U?[=;_GBO
MYT?VZW_/%?SK*VBC:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT
M?VZW_/)?SK*VBC:* -,:VP_Y9#\Z@N_$D=G92W%]$EI;+$7D>5\A1R&+#'W0
M%/?\*I[17)_%S#?";QB=YFSHMZI8]54V\A+?@:NG'FE&+,Y>[ ZG0/'6E^*+
M%[C2KRRU&W:1XVDL;M+CIQC"$C=@#BM?^W&_YY#\Z^:OV+68_"G5,LS[-:D=
M68,/F\B [>3ZLU?0.T5T8RE]5Q,J*U,L/5]M3BTK&K_;K?\ /)?SH_MUO^>*
M_G65M%&T5R'2:O\ ;K?\\5_.C^W6_P">*_G65M%&T4 :O]NM_P \5_.C^W6_
MYXK^=96T4;10!J_VZW_/%?SH_MUO^>*_G65M%&T4 :O]NM_SQ7\Z/[=;_GBO
MYUE;11M% &K_ &ZW_/%?SH_MUO\ GBOYUE;11M% &K_;K?\ /%?SH_MUO^>*
M_G65M%&T4 :O]NM_SQ7\Z/[=;_GBOYUE;11M% &K_;K?\\5_.C^W6_YXK^=9
M6T4;10!J_P!NM_SQ7\Z/[=;_ )XK^=96T4;10!J_VZW_ #Q7\Z/[=;_GBOYU
ME;11M% &K_;K?\\5_.C^W6_YXK^=96T4;10!I_VTW'[H<>]9NN>,K+0M+N+[
M4)+:TL82NZYO+E8D!) &<@8Y(I-HKR/]J=MOP(\4(0F)/L7F1L%(7-W&#]X'
MM71A:/ML1"E?XI'/6FHTY21Z]HOC"RUW2X[W39+6[T^?=LNK2Z65&P6!Q@'/
M(-:/]M-S^Z'/O7BG[++;O@3X750I\O[9Y<:A0&Q=R ?= [5ZQM%&*H^QQ$Z5
M[\L@HU%*G&3-7^W6_P">*_G1_;K?\\5_.LK:*-HKG.@U?[=;_GBOYT?VZW_/
M%?SK*VBC:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_/%?
MSK*VBC:* -7^W6_YXK^=']NM_P \5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK
M*VBC:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*V
MBC:* -7^W6_YXK^=']NM_P \5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*VBC
M:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*VBC:*
M -7^W6_YXK^=']NM_P \5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*VBDP*:U
M=A/8@\/_ !&\/^*S<'1]0TW5?) $OV&\2XQ_=SLSUR<5N?VXW_/)?SKY!_89
M,D;>.]D)FS]CSNW?+CS\=3WVK7U5M%>CF.%^I8B6'3YO-Z'/A:OUBA&LE8U?
M[=;_ )XK^=']NM_SQ7\ZRMHHVBO-.DU?[=;_ )XK^=']NM_SQ7\ZRMHHVB@#
M5_MUO^>*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_ #Q7\ZRMHHVB@#5_
MMUO^>*_G1_;K?\\5_.LK:*-HH U?[=;_ )XK^=']NM_SQ7\ZRMHHVB@#5_MU
MO^>*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_ #Q7\ZRMHHVB@#5_MUO^
M>*_G1_;K?\\5_.LK:*-HH U?[=;_ )XK^=']NM_SQ7\ZRMHHVB@#5_MUO^>*
M_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_ #Q7\ZRMHHVB@#5_MUO^>*_G
M1_;K?\\5_.LK:*-HH U?[=;_ )XK^=']NM_SQ7\ZRMHHVB@#5_MUO^>*_G1_
M;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_ #Q7\ZRMHHVB@#5_MUO^>*_G1_;K
M?\\5_.LK:*-HH U?[=;_ )XK^=']NM_SQ7\ZRMHHVB@#5_MUO^>*_G1_;K?\
M\5_.LK:*-HH U?[=;_GBOYT?VZW_ #Q7\ZRMHHVB@#5_MUO^>*_G1_;K?\\5
M_.LK:*-HH U?[=;_ )XK^=']NM_SQ7\ZRMHHVB@#5_MUO^>*_G1_;K?\\5_.
MLK:*-HH U?[=;_GBOYTU_$!CB\PPC'UK,VBHKC_CQH VO[=;_GBOYT?VZW_/
M%?SK*VBC:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_/%?
MSK*VBC:* -7^W6_YXK^=']NM_P \5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK
M*VBC:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*V
MBC:* -7^W6_YXK^=']NM_P \5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*VBC
M:* -7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*VBC:*
M -7^W6_YXK^=']NM_P \5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*VBC:* -
M7^W6_P">*_G1_;K?\\5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*VBC:* -7^
MW6_YXK^=']NM_P \5_.LK:*-HH U?[=;_GBOYT?VZW_/%?SK*VBC:* -7^W6
M_P">*_G1_;K?\\5_.LK:*-HH Z:SF^T1!QT/K5BJ6D_\>:U=H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH BD3=&17RS\)OV?]%^('@6Q
MU?5=5U*0W44T<$=D\<<4<(E==@#H=ISEL#;RS?+G<6^IV[@]Z\4UKX 7?]K7
M<WA?Q?J?A'3[MS*]C8AS$)3R77$B[1P..G0= H'?A*SC&45/E/,Q=+FG&3AS
M'&ZAK6I:[X/T?0=>OC>I:^.8O#\L^3";RU0_\M,$C)';.<JASO&:[2^T&Q\$
M_'#PA-H<,.EPZS;7EG=P6T4<<<GEJ)5)0*#G<1EL_P!T# )SEM^S7/:M!!8^
M.-6M]$B<2V=CR#;R9+!U8,%)\SYL!%..^[YJW_ WPS\8_P#"61:_XXURTU:6
MQMS%806K,$1V&&=@$1<D9_A/WA_<&>VI4HVO"=T[Z?D<<*=522E&\EU/7ZY/
M2_\ DH>O_P#8(T__ -&WE=97)Z7_ ,E#U_\ [!&G_P#HV\KQU\+/:E\43I;[
M_CSN/^N7]#7-[1727W_'G<?]<OZ&N;VBLS4-HHVBC:*-HH -HHVBC:*-HH -
MHHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -
MHHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -
MHHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HJ*W_P"/&I=H
MJ*W_ ./&@"7:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:
M*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:
M*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:
M*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*B_Y?*EVBHO^
M7R@"7:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* ///^%*:/_P +;_X3O[3J']M?\\?,B^R_\>_D?=VY^YQ][K7H>T5\]?\
M"SO$G_#5W_"'?V@/^$8_Z!_V>+;_ ,>'G??V>9_K/]OI7T+M%>AC*=6ER>V=
M[J+7H<M"<)<_(OM!M%&T4;11M%>>=0;11M%&T4;10 ;11M%&T4;10 ;11M%&
MT4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&
MT4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;13 XKP)\,
M=,\$^(?%NJ:?)>7=UK]U]JO5NV1_(EQ(_P OR 8S-)W]*[7:*\;^"GCC6_&'
MCKXH:9JFH23V.DZKY5A$(XAY*^;<)UV<\(.M>R;179C(3I5;5'=^[_Z2<]&4
M'3]U:!M%&T4;11M%<1T!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T
M4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T
M4;11M% !M%&T4;11M% !M%&T4;11M% !M%9WB318O$WAW4]*O@;:VO+:2RF:
M/D-'(&#X[]&%:.T5SOQ U:ZT'P-XDU2R(@OK33KJ>WF^]@K 2,CZJ:NG?F@H
M[F<O@]XS?A3\,],^%GAV32M(DO);9KN2Z9[QHR/-R$_A1#C"KVKM-HKQO]E[
MQQK7Q"\#ZGJ?B"_DU.^CU62)99(XH_E\J!\8C1>Y->R;173BX3I5I>V=V9T9
M1E3CR+0-HHVBC:*-HKC.@-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HH
MVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HH
MVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HKF?B!X/L/B%X&U/0;N]N8]/OM
MGFW&GR8<;7#C^%L<QG\Q^'3;17G?[0/B?4O"?PC\1:QI5S]CU!/L_ES! ^,S
MH#PV>Q-=.'IU)5HQ@]>;0QK->RES;'0> _"%C\.?!]AX;M+J[FL=.W^7<WDG
MF,=SLYZ*,\M^AKI-HKS[X!^+M6\9?"?1=;U:Z%YJ4YN"\\B!<XGE X3:.FW\
MC7H.T45Z=2-:49O7FU"BU[*%M@VBC:*-HHVBN8V#:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC IK<3V///A'\$]'^#O\ ;7]B7.H3_P!H>7YOVR2)L^7G9C:J
M?WFKT/:*^>OV4?B;XD^)'_"4?\)%J U3[!]E\CS((H_O>?G/EHOH*^A=HKOS
M"%2EB)4L0^:?<YL+4A6IQ]DK(-HHVBC:*-HKSSJ#:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*BN/^/&I=HJ*X_X\: )=HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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M;11M% !M%&T4;11M% '0Z3_QYK5VJ6D_\>:U=H **** "BBB@ HHHH ****
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M1M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T5%_R^5+M%1?\OE
M$NT4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
M &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
M &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
M &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
M &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
M ?,__"6:U_PV9_8_]KWO]B_] W[0_P!G_P"0=O\ ]7NV_>^;IUKZ8VBO$/\
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MN:8&=.?-*-1S?FK#JY/2_P#DH>O_ /8(T_\ ]&WE=97)Z7_R4/7_ /L$:?\
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M"LS<3_9H=#25;<R%HC(\\X=ROKA1BOO>ST^VT^U@MK6WCMK:W000P0C;&D0
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MV>BV%W>WLZPVMI;R75Q+@L(XDZL0H)/L!DU<VBF%6+<[&&20H0*O/7([CVH
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MR 2'< $ZY.,_3-<Q\0OB%:_#_28[FX634]1DN%MM/TR, R3N64?*H.?XP?Q
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M=A=/IL>F.'O5@;R$8I=@*9,;<\KW_B%>R;11EEC=0<[CNY9L ^@&<8X7MW-
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MD8/ZT >#^/M-\56_CSP%XTOO#I\26=C:QI<Z7I:+*MGJ'S>9,D8+ =5PQ;^
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M[G/\-<[=_LX:!JFF1V>HZOKNI+"B):O>7WF&P11@I NWRP&4!3N0C 'R\+M
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M!L#=N)W  < *J@',^-+BUN/VEOAW=W5RD^BW5@SZ?-<N&M)'_?,AC9@5WG=
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M (NOK/RS_?\ Y_XT>6?[_P#/_&CZ[(/J\3Y,_P"%&>-?^@,O_@9!_P#%T?\
M"C/&O_0&7_P,@_\ BZ^L_+/]_P#G_C1Y9_O_ ,_\:/KL@^KQ/DS_ (49XU_Z
M R_^!D'_ ,71_P *,\:_] 9?_ R#_P"+KZS\L_W_ .?^-'EG^_\ S_QH^NR#
MZO$^3/\ A1GC7_H#+_X&0?\ Q='_  HSQK_T!E_\#(/_ (NOK/RS_?\ Y_XT
M>6?[_P#/_&CZ[(/J\3Y,_P"%&>-?^@,O_@9!_P#%T?\ "C/&O_0&7_P,@_\
MBZ^L_+/]_P#G_C1Y9_O_ ,_\:/KL@^KQ/DS_ (49XU_Z R_^!D'_ ,71_P *
M,\:_] 9?_ R#_P"+KZS\L_W_ .?^-'EG^_\ S_QH^NR#ZO$^3/\ A1GC7_H#
M+_X&0?\ Q='_  HSQK_T!E_\#(/_ (NOK/RS_?\ Y_XT>6?[_P#/_&CZ[(7U
M>)\DQ_!/QC,S"/25E*R>60EW 2#SU&_C[IZT_P#X49XU_P"@,O\ X&0?_%UV
MO[.!ED^*?QIWQ2976=H;F3<OG7?&,83@+7OWEG^__/\ QKJQ56IAJO(WII^*
MN8T*4:\.:)\F?\*,\:_] 9?_  ,@_P#BZ/\ A1GC7_H#+_X&0?\ Q=?6?EG^
M_P#S_P :/+/]_P#G_C7+]=D;?5XGR9_PHSQK_P! 9?\ P,@_^+H_X49XU_Z
MR_\ @9!_\77UGY9_O_S_ ,:/+/\ ?_G_ (T?79#^KQ/DS_A1GC7_ * R_P#@
M9!_\71_PHSQK_P! 9?\ P,@_^+KZS\L_W_Y_XT>6?[_\_P#&CZ[(/J\3Y,_X
M49XU_P"@,O\ X&0?_%T?\*,\:_\ 0&7_ ,#(/_BZ^L_+/]_^?^-'EG^__/\
MQH^NR#ZO$^3/^%&>-?\ H#+_ .!D'_Q='_"C/&O_ $!E_P# R#_XNOK/RS_?
M_G_C1Y9_O_S_ ,:/KL@^KQ/DS_A1GC7_ * R_P#@9!_\71_PHSQK_P! 9?\
MP,@_^+KZS\L_W_Y_XT>6?[_\_P#&CZ[(/J\3Y,_X49XU_P"@,O\ X&0?_%T?
M\*,\:_\ 0&7_ ,#(/_BZ^L_+/]_^?^-'EG^__/\ QH^NR#ZO$^3/^%&>-?\
MH#+_ .!D'_Q='_"C/&O_ $!E_P# R#_XNOK/RS_?_G_C1Y9_O_S_ ,:/KL@^
MKQ/DS_A1GC7_ * R_P#@9!_\71_PHSQK_P! 9?\ P,@_^+KZS\L_W_Y_XT>6
M?[_\_P#&CZ[(/J\3Y,_X49XU_P"@,O\ X&0?_%T?\*,\:_\ 0&7_ ,#(/_BZ
M^L_+/]_^?^-'EG^__/\ QH^NR#ZO$^3/^%&>-?\ H#+_ .!D'_Q='_"C/&O_
M $!E_P# R#_XNOK/RS_?_G_C1Y9_O_S_ ,:/KL@^KQ/DS_A1GC7_ * R_P#@
M9!_\71_PHSQK_P! 9?\ P,@_^+KZS\L_W_Y_XT>6?[_\_P#&E]=D+ZO$^3/^
M%&>-?^@,O_@9!_\ %TC_  .\:QJY;1<",$N3<P@*!UR2]?6GEG^__/\ QKE_
MBQ)-'\+/&1P7']D7<S*%5=A\EMO(YSE36M/%3E*,>XI4(*-SYQ7X)^,2N6TE
M8QO:/,EY HR.O)>G_P#"C/&O_0&7_P #(/\ XNNU_8I\V/X6ZIMBD4)K,BJL
MF?N^3!QD@'J37OWEG^__ #_QK;%U9X6O*@WJC*C2C7IQE'J?)G_"C/&O_0&7
M_P #(/\ XNC_ (49XU_Z R_^!D'_ ,77UGY9_O\ \_\ &CRS_?\ Y_XUR_79
M&_U:)\F?\*,\:_\ 0&7_ ,#(/_BZ/^%&>-?^@,O_ (&0?_%U]9^6?[_\_P#&
MCRS_ '_Y_P"-'UV0?5XGR9_PHSQK_P! 9?\ P,@_^+H_X49XU_Z R_\ @9!_
M\77UGY9_O_S_ ,:/+/\ ?_G_ (T?79!]7B?)G_"C/&O_ $!E_P# R#_XNC_A
M1GC7_H#+_P"!D'_Q=?6?EG^__/\ QH\L_P!_^?\ C1]=D+ZO$^%[ZRDTR^N;
M2Z7R9[>5XG#>J-@X]LU#M%=!X\E?_A//$TK!96^WW*('Z ^8?_B37/J%DDD5
M&5]G5EZ'Z5Z\7>-V>9+0-HH4+))(J,K[.K+T/TI?+^8C&0!DXYX]0.I'N 17
M<>#/@SKGC-H[AK;^R])QE[B;*Y'K@ MCWQCWHE.,=V-)RV1P_E_,1C( R<<\
M>H'4CW (KN/!GP9USQFT=PUM_9>DXR]Q-E<CUP 6Q[XQ[U[UX)^"OASP6HF6
M)M2U,'/V^Z W9]57HI]QEO>N\*[H=F?*YS^['.?7/K[XQ[5YM7&)?"=\,*_M
M'!^"?@KX=\%J)5B;4M3!S]ON@-V?55Z*?<9;WKO"NZ'9GRN<_NQSGUSZ^^,>
MU+M%&T5YDIRGNSLC%1V#:*-HHVBC:*@H-HHVBC:*-HH -HHVBC:*-HH -HHV
MBC:*-HH ,"LS7M+L?$&A7%KJ%M;7]C+CS(+A%FAX((^5B1U5>]:>T5Y/^U%.
MZ_ CQ*X41^5]GV*LI4\SQ \MD]-WYUTX:G+$5Z5*+L^8YZ\U&G-H]'TO2=-\
M.V<%II]O9Z;919\N&**.WAYY.%  ZEN]:.!7DW[+;1_\*.\-2OR\OVC>KRE>
MD\H'S?3;^5>L[11B*<L/7JTI.[Y@HS4J4&PVBC:*-HHVBN8Z VBC:*-HHVB@
M VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
M VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
M VBC:*-HHVB@ VBC:*-HI,"FMQ/8Q/#?A31/"W]H_P!DZ39:/YWE>;]DMT@V
MXSC.U5_O-6YM%?*G["N\'QCDLO\ QY[O,AQLSY^>I'H*^J]HKTLQP\L-B)49
M.\NYAAZJQ%",HJP;11M%&T42*8V52C9+;>AP#]>G7(^O'4@'S#H&AD^<%U#J
M,[">2/84[:*\:\1^(M0@_:4\(Z/%J%PNF76DM+):_:',#L%G/" [#G:,<<XS
MT()]DQ\NX*V,9Z=NN?ICGZ4 +M%,+ 2-'C,B]54@G]#2AD+%0RD@9(STX!_J
M!GIDXS7#^//B4_@;Q%X0TDZ>]XNNSFW2;[4(VMV#1J2NU3N ,J]?0^E '=;1
M1M%"J68@HR\9!8$9''3\QQUY%)M8#'EOYF2!$!E^!GD#IQZXH 7:*;U8!$:0
MXS\H_2A?G8JBER#@XXQ[\URWQ$TOQ=J&BV<7@_4TTO44N0SSS1AHF0QR+@'R
M93G<R'IT!^A .KVBC:*0;2X3D2$_ZLJ0V-V-P&.1GTY]J%*R*6C(D(ZA3GN,
MX/1L<DX)X!H 7:*:OS1+($;RV^ZQXS]* W[PHRLC#KN['T^M97B[7[KPSX;O
M-4ATZ\UV[L]OD:=:P^8SY?9P%..O/7I0!J>9&-H9@C,,A6/+>X_O#W&1[T_:
M*\/TGXB?$)_C9X<\/^(8;+2++4H9KD:- B2/C_2-N^7.=WR#[N![5[/JFH6V
MBZ==7U[)Y%O:P-<2MM+8159F/&>BJ3^(H L':JN6*J4^\K, 1Z]^W?T[XHRK
M?=(8YVX!YSC./KCG'7'.,<UX[H&N>//BQ#_:^B:O:^"_#;RW$5FKVB7MW+L;
M9ND4G;@,&'#'E3]ZC5/&'BWX0ZCITOC6YM_$/A*]E^SC6(H?)N8CY0^_&.BY
MWMP2?D;GHI /8%967.#]%^8_^.YIPP9"F#D=2 6 _$9_'T[XK$\7W?B7^QX8
M_#-M:7%\\FR2:^<^5",,=[%!G;\O50>HKRKQS=?$GX3V<'B2X\1V_BO0X71=
M2MFTZ&T\L,5"M\FXD;G4 =1R2& ) ![<'1H7D!RB]#TW?2G8'[L8),F[:%!.
M<?3\JYZ;Q'J6O^#K;5O#UFEYJ-\D4EC;WW[E KA#E\9QM$@)QGH<9KSCQEI_
MQ2\*:!-XAM?$]IJBVH%[>:7'I\44$=L!O>.)\>85Q\N2P?9SNW?+0![.WRQ-
M(4;RU^\PYQ]:=M%8'@#QC%X^\'V/B"V5[%;_ '^9;X!&59T(Z]<QG\Q6_M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
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ME>1HB^&"YR <$9!!PW7H33-K[67S6*Y4IO\ F,9_B8'UI=HHVBAZ@M!'WS*
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MH -HHVBC:*-HH -HHVBC:*-HH -HJ*W_ ./&I=HJ*W_X\: )=HHVBC:*-HH
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M1M%&T4!S!M%&T4;11M% <P;11M%&T4;10',&T4;11M%&T4!S!M%&T4;11M%
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M:* #:*-HHVBC:* #:*BN/^/&I=HJ*X_X\: )=HHVBC:*-HH -HHVBC:*-HH
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MO^/.X_ZY?T-<WM%=)??\>=Q_UR_H:YO:*S- VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBHK?_CQJ7:*
MBM_^/&@"7:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-
MHHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-
MHHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-
MHHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*B_P"7RI=HJ+_E
M\H EVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@#Y2_YOJ\O_EI_<_B_Y!>.G7KQ]:^K=HK#_P"$LT#^WO[%_M;3_P"T?^@=
M]N7[3]S=]S[WW>>G2MO KT<=B:F(]E>%N2,8^OF<6'IJC[2SO>0NT4;11M%&
MT5YQVAM%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;
M11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;
M11M% !M%&T4;11M% !M%&T4;11M%-;@?/G[.)6'XG_&8RO'$%UC.7< ']_='
M@YYX(KZ#VBLC1?$&E:I=:G;:?J%C?S6LVZ\CM;A&-J^T_*Y4DD[M_7^Z:U]H
MKIQE;VU55&K(YZ%-4:=D[AM%&T4;11M%<IT!M%&T4;11M% !M%&T4;11M% !
MM%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !
MM%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%<G\5XY)/A?
MXN"QL3_9-Y&H R7)MVQ@#G^(5UFT5!>7$%G:W%U>;;.%5):27G;'@ABPZ8 4
MUI1J*-2,DC&HN:&IX)^Q25;X8ZN$>.0G6)" CACCR+<= ?6OH+:*R/#NO:5X
MFM'NM,U"QU2!II"TMC<I-\^X<81B,[56M?:*Z,;7]MB*E9JS9.'IJC1C23NP
MVBC:*-HHVBN,Z VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB
MG< VBC:*-HHVBD ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;
M10 ;11M%&T4;10 ;11M%&T4;10 ;17E'[4D;?\*)\2J0RLOV;@J<G_2(^@ZU
MZOM%9FN:AIVC:'>W.I7]O:V/R^==WS1QH/F^7(RO\3)^1_'IP]1T:M.HE>TC
M*I!U*<H['G7[+:/_ ,*)\/($=V'VG(C4L1_I,O8?[OZBO6-HJCI.K66O:?%>
MZ9?6MUILF[R+JU9)4/S-NX4D==U7MHI8BHZU6I4:M>0Z<'2IQC>X;11M%&T4
M;17.:!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;
M11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;
M11M% !M%&T4;11M% !M%&T4;11M% !M%)M%+M%&T4UN)['RE^PP#GQKM^<2?
M8]FSYMV/M&<8KZMVBL/P]XLT'Q5]L_L?5]/U;R<;_L%\LN.NW=LSUW-6YM%=
M^.Q$\7B)5IPY#DPM-4:4:2U8;13#"/,0[V:-/NQ,!C]0:?M%&T5YYV#!"/,5
MBS#8=X; 8N?0\=.%_,T&$>8AWLT:?=B8#'Z@T_:*-HH C\O (54"'C:=Q X4
M;NOS'&[KD\]:D$DK1[68?[K?,/TQ1M%&T4 ,:$;D?>S2+_$0.?O=<@_[/Y4N
MT#*JO!QAY&WE,=,<9_(BG;11M% #6W22.SA55B'VIV(Z >U.C+1R2,I^7&Q%
MW,H ]>".:-HHVB@ ;=+'M8X9AM=BS,6''/!'/ INPC)#*'7=L<*5/7*YPP[T
M[:*-HH :VZ21V<*JL0^U.Q'0#VHV$9(90Z[MCA2IZY7.&'>G;11M% #?WG][
M]31L)P2REVV[W*ECURV,L>].VBC:* &-&)&=G1&9_O\ WL2_[P).:41@R9+2
M*,9W(V&]-O3&/TQVS\U.VBC:* ,+P[X%T'PC?:A=:-IEOISWPC6=+53'$P3.
MTB,':A^8_<Q6W^\_O?J:=M%&T4 &>VQ=OX9].N,]/?K3?WG][]33MHHVB@ D
M+221LQ^7&QUW,P(]>2>:-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHV
MBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHV
MBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*BN/^/&I=HJ*X_P"/
M&@"7:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC
M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*R/%<]K;^&-<?5+8S:6
MMI.+F-0#NC\OYPOJWIG'U%:^T5'-:Q7$4\<Z_:(9LJ\,GW"I3!%:T[*HK[('
MJ4M%-M/I=B;59+6V6TA%NN '$9[-S][Z9K1VBHX[=( B1C$:851_LCH*DVBI
MJ-7N@#:*-HHVBC:*@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-
MHHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@#H=)_X\UJ[5+2?^/-:N
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E $;#UYKRZ/]
MGGX>F8YT$(44(-]U/N/)&22^>O?.>*]/EW+'QUKY:N/!MS\5O GB#QYXBUB^
M96@O;C2M-BF"I:+&'!4$KG<1%C"@<)EN20.["J=I2]IRH\W%RC=)T^9GJX_9
MZ^'(D"G07R>G^FW'/7_II[=3Q7IZJ%X KP_Q/JMWH?P \-:QIEY<6U]IT.EW
MBK:N52?F)-DBJ1OC<.<KNY/?BO<6[5EB)59*]23EON:X?V2_AQ2V_$=7)Z7_
M ,E#U_\ [!&G_P#HV\KK*Y/2_P#DH>O_ /8(T_\ ]&WE9+X6=,OBB=+??\>=
MQ_UR_H:YO:*Z2^_X\[C_ *Y?T-<WM%9F@;11M%&T4;10 ;11M%&T4;10 ;11
MM%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11
MM%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11
MM%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;145O\ \>-2[145
MO_QXT 2[11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%
M&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%
M&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%
M&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;147_ "^5+M%1?\OE
M $NT4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T
M4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T
M4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T
M4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T
M4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T
M4 ?*FZ3_ (;M_P!5^\S]SG/_ ""/^^O?K7U7M%>>?\*3T?\ X6W_ ,)W]IU#
M^VO^>/F1?9?^/?R/N[<_<X^]UKT+;7JYAB:=;V7([<L8Q?F^YP86G*CS\[O[
MPNT4;11M%&T5Y1WAM%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11
MM% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11
MM% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%-;B/GW]FUF_P"%K_&+:6/F
M:SN95!&YOM%V,<8[%O\ OFOH+:*XKP)\,=,\$^(/%NJZ?)>7=UK]U]JO5NV1
M_(EQ(_R_(!C,TG?TKM=HKKQM:-6HIQ5D<V%IRHQ]]W#:*-HHVBC:*XSJ#:*-
MHHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-
MHHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-
MHHVBC:* #:*Y+XN8;X3>,2',V=%O5+'JJFWD);\#76[16=XDT6'Q-X=U/2KX
M&VMKRVDLIFBY!CD#!\=^C"M:-1<\-#*I\!X?^Q:S'X4ZGEF?9K4CJS!@=WD0
M';R?5FKZ!VBN+^%/PSTOX6>'9-*TB2\EMGNY+MGO'C8>;D)_ B'&%6NTVBNC
M'5HUL5.M%678QPM.5&E&G)W?<-HHVBC:*-HKB.L-HHVBC:*-HH -HHVBC:*-
MHH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-
MHH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HKR/]J=M
MOP(\4(53$GV+S(V"D+F[C!^\#VKUS:*YGQ_X/L/B%X'U30;R]N8]/OMGFW&G
MR8<;7#C^%N\9_,?AU86I&CB(5IJZYMC/$0=:$N1V.-_99;=\"?"Z *1']L\N
M-0H#8NY /N@=J]8VBN<\!^$+'X<^#[#PW9W5W/8Z=O\ +N;R3S&.YV<]%&>6
M_0UT>T4L34C6Q$ZT%9<VP8>#HPCSNX;11M%&T4;17,:!M%&T4;11M% !M%&T
M4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T
M4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T
M4;11M% !M%&*-HHVBFMQ/8^5?V&3)&WCO9#YV?L6=P;Y<>?CJ>^U:^JMHKSS
MX1_!/1_@[_;7]BW.H3_VAY?F_;)(FSY>=F-JI_>:O0]HKTLRQ%/&8N5:C*Z[
M'#@Z<J-*-.;N^X;11M%&T4;17F'>&T4;11M%&T4 &T4;11M%&T4 &T4;11M%
M&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%
M&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%
M&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%
M&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T5%<?\
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M_G0!SFY:-RUT?]CVW]T_G1_8]M_=/YT <YN6C<M='_8]M_=/YT?V/;?W3^=
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M_G0!SFY:-RUT?]CVW]T_G1_8]M_=/YT <YN6C<M='_8]M_=/YT?V/;?W3^=
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MT <YN6C<M='_ &/;?W3^=']CVW]T_G0!SFY:-RUT?]CVW]T_G1_8]M_=/YT
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ME6^+J945"-.,:>P^BDI:YS<**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBDH 9N_6O/_CM\/]1^)WPMUKPWI4UK!?7GD^7)>,RQ
M#9/'(<E58]$/8\XKT';TKF/B1\0-/^&/@W4/$NJ0W,]C9^7YD=FJM*=\BQC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $S3/.']UNN/UQ3N]8_B1KYO#^IMI.Q]3%M(MIN;"F0IE,GZXH5V
MT@9KK)N_A(YQS3ZR]$:\.EV;7J@7GV>(3*#TDVY<5IMTIO1V 6BBBD 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I*6B@#XWVQ?\/ /,^7=TSM.?^07_ 'O\\U]A_P 0
MKQC_ (9[3_AH3_A9O]N#&=W]E_81G/V/[-CS=^>GS8V]:]G!RN:]/'UJ=?V/
MLU;E@D_5'#A:<H\_,_M$M%)2UYAW!1110 4444 %%%% !1110 4444 %%%%
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M=+"(B0TC./DR<?>]>U=UZT8J2G7J2ALW=!03C2C&6X^BBBN<W"BBB@ HHHH
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MB "IX[Y#!7#<*<'RRW#GG*-T>I?#?XM>&_BMX3MO$/AZ[:YLI/DEC9,2VLH
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M,A'+]>U=AX)U'Q??>(/$J^)=.M;#2[>Z\K2)[-N;F$/*NZ11(Q! \L]%Z_D
M=U47VA=S#!^4X[>F?P_'%<EIOQ3TK5?B1JW@J&UOAJVFVRW4LK1J(65EC("G
M=NS^]7JH[U7\;:CXOL?$'AI?#6G6M_I=Q=>5J\]XW-M"7B7=&ID4DD>8>C=/
MS .ZHJ)IU7@@DXR,?Q?3_/<4C72HNXAC[*-Q_ #K0!-142W"R(77E,9# C!]
M@<TGVI6V;%9PR[@0.",>_P!1^?UP 345#]I7YLAA@^F<^A'L:7SANQM.,X#<
M8/OU_"@"6BBB@ HHHH *2EI* /$O^&@&7]H(?#%M"(;/_(4^VDG_ (]/M/\
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MBXZ?WMQ_&JW[8$@;X3VVWD#486)'0 I)57]C/_DG>L?]A>7_ -%QUP+#TO\
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MV> 635;@2>*]&"Q:N@@\I6W$F&:/!((=%;<."'1L *5)^5_^"CT@D^-6C'D
M^'K<\CIBXN\Y'6N/#Q<:VITU7S4KHR_"?Q6_:;TOPUHEIH%GXHET"UM8X;)H
M_"BR*ULJ1^2=PMLYVUYIX;\?067QJ;Q'\6O#][XLN8[O-_I]U(MLZ2HQ0>9"
M8]K>6FX"VRH( 0D(A5OU!^!(V_!7P&LT<D(3P[IP*2D97%LF0W3# @YKXQ_X
M*)^+/#/B+Q1X7M]%O=-U'7M+6\BU.:S DDM466-1#)(/E!#I*I1B64N?E7S
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M#$)&H&%D5.!T4GK7K]?/O[%4B?\ "L-54.CEM6>0;'#<&WM\=#7T%0 4444
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M6:Z4)CL  ,?0U].5Y>/I1HU^6.WN_P#I-SMPTN:EJ24445Q'6%%%% !1110
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M[,LAW; G!5%XP!7HG]N:=_S_ %M_W^7_ !H_MS3O^?ZV_P"_R_XT 7J^<O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 444E $;<J17DG[4FDWOB#X'>(].TNSN-1OYOLWEVUI"\LCXNHF. H.>
M3^%>N#M7.>,O%VC^ _#\^N:Y=?9-(M_+\VY*O(%W.%7(7)/S,O:M:%1T:L)Q
M5VGH9U%%TY1GL<-^RWI-[X?^!WAS3M4L[C3K^'[3YEM=PO%(F;J5AD,!C@@_
MC7K:\*!7.^#?%VC^//#\&N:'=?:](N/,\JY"O&&VN5; ;!'S*W:NC/>BO4=:
MK.4E9MA248PC&.Q)124M9&@4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!E<GI?_)0]?_[!&G_^C;RNLKD]+_Y*'K__ &"-/_\ 1MY6B^%F
M<OBB=?11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4E+10 SM7"_&)0OPG\;[$#R?V'?*RK\H/\ H\F,UW59.N:3;^(-)O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ;MIGEG><!57J"#SD]>*EHI 1JA&. ,<#'I3R*6BF 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #*Y/2_^2AZ_P#]@C3_
M /T;>5UE<GI?_)0]?_[!&G_^C;RM%\+,Y?%$Z^BBBLS0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\
M/=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT
M 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\
M/=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT
M 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\
M/=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT 7**I_VO:?\ /=:/[7M/^>ZT
M 7**I_VO:?\ /=::FM6<D7F"9=M %ZBJ?]KVG_/=:/[7M/\ GNM %RBJ?]KV
MG_/=:/[7M/\ GNM %RBJ?]KVG_/=:/[7M/\ GNM %RBJ?]KVG_/=:/[7M/\
MGNM %RBJ?]KVG_/=:/[7M/\ GNM %RBJ?]KVG_/=:/[7M/\ GNM %RBJ?]KV
MG_/=:/[7M/\ GNM %RBJ?]KVG_/=:/[7M/\ GNM %RBJ?]KVG_/=:/[7M/\
MGNM %RBJ?]KVG_/=:/[7M/\ GNM %RBJ?]KVG_/=:/[7M/\ GNM %RBJ?]KV
MG_/=:/[7M/\ GNM %RBJ?]KVG_/=:/[7M/\ GNM %RBJ?]KVG_/=:/[7M/\
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MNM']KVG_ #W6@"Y15/\ M>T_Y[K1_:]I_P ]UH N453_ +7M/^>ZT?VO:?\
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MZF=%0]G'V>P;11M%&T4;17,;AM%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
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MD/P)^!\?P8.N_P#$XCUL:C]GW;81#GR_-SC#-_ST'Y&O7MHKR7X$_')_C/\
MV]_Q*?[&_LSRMG^D>?GS-^W^%?[AS]17K6T5V8SVTJTG7?O'-A^3V453V#:*
M-HHVBC:*XCJ#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #
M:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #
M:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #
M:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #
M:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*BN/^/&I=HJ*X_X\: )=HHV
MBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHV
MBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHV
MBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHV
MBC:*-HH -HHVBC:*-HH -HHVBC:*-HH Z'2?^/-:NU2TG_CS6KM !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,KD]+_P"2
MAZ__ -@C3_\ T;>5UE<GI?\ R4/7_P#L$:?_ .C;RM%\+,Y?%$Z6^_X\[C_K
ME_0US>T5TE]_QYW'_7+^AKF]HK,T#:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*BM_\ CQJ7:*BM_P#C
MQH EVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBHO^7RI=HJ+_E\H EVB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@#Y2
M_P";ZO+_ .6G]S^+_D%XZ=>O'UKZMVBL/_A+- _M[^Q?[6T_^T?^@=]N7[3]
MS=]S[WW>>G2MO KT<=B:F(]E>%N2,8^OF<6'IJC[2SO>0NT4;11M%&T5YQVA
MM%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !
MM%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !
MM%&T4;11M% !M%&T4;11M%-;@?/G[.)6'XG_ !F,KQQ!=8SEW !_?W1X.>>"
M*^@]HK(T7Q!I6J76IVVGZA8W\UK-NO([6X1C:OM/RN5)).[?U_NFM?:*Z<96
M]M551JR.>A35&G9.X;11M%&T4;17*= ;11M%&T4;10 ;11M%&T4;10 ;11M%
M&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%
M&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;17)_%>.23X7^+@L;
M$_V3>1J ,ER;=L8 Y_B%=9M%07EQ!9VMQ=7FVSA526DEYVQX(8L.F %-:4:B
MC4C)(QJ+FAJ>"?L4E6^&.KA'CD)UB0@(X8X\BW'0'UKZ"VBLCP[KVE>)K1[K
M3-0L=4@::0M+8W*3?/N'&$8C.U5K7VBNC&U_;8BI6:LV3AZ:HT8TD[L-HHVB
MC:*-HKC.@-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HH
MVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HH
MVBC:*-HH -HHVBC:*-HH -HKRC]J2-O^%$^)5(967[-P5.3_ *1'T'6O5]HK
M,US4-.T;0[VYU*_M[6Q^7SKN^:.-!\WRY&5_B9/R/X].'J.C5IU$KVD95(.I
M3E'8\Z_9;1_^%$^'D".[#[3D1J6(_P!)E[#_ '?U%>L;15'2=6LM>T^*]TR^
MM;K39-WD75JR2H?F;=PI(Z[JO;12Q%1UJM2HU:\ATX.E3C&]PVBC:*-HHVBN
M<T#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:
M* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:
M* #:*-HHVBC:* #:*-HHVBC:* #:*3:*7:*-HIK<3V/E+]A@'/C7;\XD^Q[-
MGS;L?:,XQ7U;M%8?A[Q9H/BK[9_8^KZ?JWDXW_8+Y9<==N[9GKN:MS:*[\=B
M)XO$2K3AR')A::HTHTEJPVBC:*-HHVBO/.P-HHVBC:*-HH -HHVBC:*-HH -
MHHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -
MHHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -
MHHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -
MHHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -
MHJ*X_P"/&I=HJ*X_X\: )=HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HH
MVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HH
MVBC:*CFFAM89I9Y5AAA!9Y'. %"Y)^@%5RMRL@)-HHVBHXYHYE5XV$B, RLO
M1E/0CV-2;14RT -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-H
MH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH Z'2?\ CS6K
MM4M)_P"/-:NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 RN3TO_DH>O\ _8(T_P#]&WE=97)Z7_R4/7_^P1I__HV\K1?"
MS.7Q1.EOO^/.X_ZY?T-<WM%=)??\>=Q_UR_H:YO:*S- VBC:*-HHVB@ VBC:
M*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:
M*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:
M*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBHK
M?_CQJ7:*BM_^/&@"7:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*B_P"7
MRI=HJ+_E\H EVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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M&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T5%;_\
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MT5%_R^4 2[11M%&T4;10 ;11M%-7YHED"-Y;?=8\9^E-\Z)<;G5>,MSDI_O
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M=FW 8^O(_,4 +M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
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M[.78.>/<Z#:*-HKG_P#A8'A?_H8M)_\  Z+_ .*H_P"%@>%_^ABTG_P.B_\
MBJ/9R[!SQ[G0;11M%<__ ,+ \+_]#%I/_@=%_P#%4?\ "P/"_P#T,6D_^!T7
M_P 51[.78.>/<Z#:*-HKG_\ A8'A?_H8M)_\#HO_ (JC_A8'A?\ Z&+2?_ Z
M+_XJCV<NP<\>YT&T4;17/_\ "P/"_P#T,6D_^!T7_P 51_PL#PO_ -#%I/\
MX'1?_%4>SEV#GCW.@VBC:*Y__A8'A?\ Z&+2?_ Z+_XJC_A8'A?_ *&+2?\
MP.B_^*H5.5]A<\>YQ7P@^)>J>.?&WC_3-0BM((/#]_\ 8[4V:/&98_-E3Y\N
M><0)T]Z]5VBOG#X :YIVC?$KXL3:A?VMC%?:OOLWNITB%ROGW1W1[B-PPPZ5
M[?\ \+ \+_\ 0Q:3_P"!T7_Q5=N.I*E67(M/=_%7.3"U5[/W]SH-HHVBN?\
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M -HHVBC:*-HH Z'2?^/-:NU2TG_CS6KM !1110 4444 %%%% !1110 4444
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MMX_O'J<=\_AFN;V_3_OH?XU]3"C&$8P6S47^%SP:E1U')OO<7/\ M2?]]?\
MUJ,_[4G_ 'U_]:DV_3_OH?XT;?I_WT/\:JQ-F+G_ &I/^^O_ *U&?]J3_OK_
M .M2;?I_WT/\:-OT_P"^A_C18+,7/^U)_P!]?_6HS_M2?]]?_6I-OT_[Z'^-
M&WZ?]]#_ !HL%F+G_:D_[Z_^M1G_ &I/^^O_ *U)M^G_ 'T/\:-OT_[Z'^-%
M@LQ<_P"U)_WU_P#6HS_M2?\ ?7_UJ3;]/^^A_C1M^G_?0_QHL%F+G_:D_P"^
MO_K49_VI/^^O_K4FWZ?]]#_&C;]/^^A_C18+,7/^U)_WU_\ 6HS_ +4G_?7_
M -:DV_3_ +Z'^-&WZ?\ ?0_QHL%F+G_:D_[Z_P#K49_VI/\ OK_ZU)M^G_?0
M_P :-OT_[Z'^-%@LQ<_[4G_?7_UJ,_[4G_?7_P!:DV_3_OH?XT;?I_WT/\:+
M!9BY_P!J3_OK_P"M1G_:D_[Z_P#K4FWZ?]]#_&C;]/\ OH?XT6"S%S_M2?\
M?7_UJ,_[4G_?7_UJ3;]/^^A_C1M^G_?0_P :+!9BY_VI/^^O_K49_P!J3_OK
M_P"M2;?I_P!]#_&C;]/^^A_C18+,7/\ M2?]]?\ UJ,_[4G_ 'U_]:DV_3_O
MH?XT;?I_WT/\:+!9B;5,B,0#@;,LJL0-IY.0<G<3TVT[/^U)_P!]?_6I-OT_
M[Z'^-&WZ?]]#_&A+6_I^&@];W%S_ +4G_?7_ -:C/^U)_P!]?_6I-OT_[Z'^
M-&WZ?]]#_&BPK,7/^U)_WU_]:C/^U)_WU_\ 6I-OT_[Z'^-&WZ?]]#_&BP68
MN?\ :D_[Z_\ K49_VI/^^O\ ZU)M^G_?0_QHV_3_ +Z'^-%@LQ<_[4G_ 'U_
M]:C/^U)_WU_]:DV_3_OH?XT;?I_WT/\ &BP68N?]J3_OK_ZU&?\ :D_[Z_\
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M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HJ*X_X\:EVBHKC_ (\: )=HHVBC:*-HH -H
MHVBC:*-HH -HHVBC:*-HH -HHVBN5M?BAX4O_B#=>"+76K:X\46D!N;C3HR=
M\* @$OQ\IY7@]CGIDCJ-RK(J,RH6^[N< M]!G)_*@!VT5\1?!/\ Y2.?$_\
M[!ES_P"C+.OMK<#NPNX*V"5(8 ?WC@\#ZXKXA_9KG3Q1^WO\6]>L?WVE6UK<
MVC7'56D\^W0!2.H)AEP>X0F@#[AVBOS@G^(/BOX>_MT?$C4_!WA*;QOJ;0RV
MK:7;NZ#R<V[^9E5/.(R/J17Z/[17Q'\#VV_\%&?BNZ.TTBZ9)&I\HEOOV@[,
M!G#&@#;_ .&J/CI_T;UJ'_?=Q_\ &Z]Q^ OQ \9?$;0M3O/&/@NZ\#WUM?\
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M;11M%&T4;10 ;11M%&T4;10!T.D_\>:U=JEI/_'FM7: "BBB@ HHHH ****
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M[*7L_,^?_AY^W!X&\)?#SPWH-YI'B*2\TW2[>RF>"WMS&SQQ*C%29P2,J<9
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M&,].U=+M%&T4 >6?"GX1WGA'X<ZOX9URZAD?4)IB9=.D)Q%)"L1Y=!\V%/\
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MK%3N'L('@T?[,;REPGB5F>,[9%^PD%#MW<_O<?EFG?\ #+[_ /0S_P#DB?\
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M0.$VCIM_(UZ#M%%:E.-64)O7FU"@U[*'+L&T4;11M%&T5SFP;11M%&T4;10
M;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
M;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
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M4*,8QIQC#8-HHVBC:*-HKG-@VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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M 4444 %%%% !1110 4444 ,KD]+_ .2AZ_\ ]@C3_P#T;>5UE<GI?_)0]?\
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M1M%&T4;17E'H!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%17'_'C4NT5%<?\>- $NT4
M;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4
M;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4
M;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4
M;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 =#I/_'FM7:I:3_QYK5V@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &5R>E_\
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MK?W&H -HHVBC:W]QJ-K?W&H -HHVBC:W]QJ-K?W&H -HHVBC:W]QJ-K?W&H
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M6_N-0 ;11M%&UO[C4;6_N-0 ;11M%&UO[C4;6_N-0 ;11M%&UO[C4;6_N-0
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M_A&U_P"?AZVJ* ,7_A&U_P"?AZ/^$;7_ )^'K:HH Q?^$;7_ )^'H_X1M?\
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M  C:_P#/P];5% &+_P (VO\ S\/1_P (VO\ S\/6U10!B_\ "-K_ ,_#T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV?G9N<N:]DKHQ$*D*K5;XNI-/E=./)L.HHHKF-0HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 97)
MZ7_R4/7_ /L$:?\ ^C;RNLKD]+_Y*'K_ /V"-/\ _1MY6B^%F<OBB=?11169
MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%)0!\H'PAKI_;F_M_^Q=0_L+&?[4^RO\ 9O\
MD&[/];C;][Y>O7BOJM,\YKB/^%M>$O\ A8X\$_VQ_P 51C'V#[/+_P \O._U
MFS9_J_F^]TKM\_,*[L77JU_9>UCRVA%+T./#TU2<[=9$M%)2UPG8%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C=#2TAH
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M.IX9^Q7X>U;PK\+]5M=:TN]T>Z;6))A;W]N\+[#!  V& XR#^1KZ'W8YKC_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 97)Z7_P E#U__
M +!&G_\ HV\KK*Y/2_\ DH>O_P#8(T__ -&WE:+X69R^*)U]%%%9F@4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !114;3!4WE6Q[+D_D.OX4 245%]HZXCD/S8Z
M>X&?IS^AIWFKM8]0O4_AF@!]%%% !1110 4444 %%%-5MW;!Z$<4 .HIBR!L
MX!('\0Z4+(&S@$@?Q#I0 ^BBB@ HHHH **BDN(XMY=PH12S,3@ #J2:3[2@7
M)##Y=^W:=V/]WK^E $U%1O<1QKEW5%]6. :DH **** "BBB@ HHHH **** "
MBH_.&]EVMD8[>O\ ^JCSANP05.<#W_SU_&@"2BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"DI:0]#0!\<>3_QG[CS&SNSM^;_H%8SG.,X]NE?8;#O7"K\'_"A^(0\<?V4W
M_"3X_P"/[[5+C_5>5_JMWE_<X^[_ (UW298#->ACL0L5[.R^"*7S1QX6E*CS
M\SOJ24M%%>>=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !2-]TTM% 'S!^R[M;XK?&X!0\<6N;U);)#&XO,CDY'&WKBOIS
M..O-<CX7^'>@>#]4UK4])TXVFHZW=?:M0E61V\V3YCNP[L%&7;_5XZUU[$X%
M=6*JJO5]HOZT.>C3=..K'4445RG0%%%)0 WS05W*"XQD;<<TNZO X?VD8]'\
M9:CHGB+2TM;.#4)H(=0MSE55)"B!T)X.5)W@^GRU[+H/BK2_%&G)?:7>Q7EJ
MQ"^9&<[6(!VL.JM\PRK $=Q6DZ<H;HSC4BS8S2U%YR@D8;Y1DG'&.?\ #^52
MUDK]30****8!1110 4444 %%%% !1110 4444 %%%% !24M)0 VN&^,*!?A/
MXWV(KR?V'?*RK\H/^CR8S7<K65KFD6_B#2K_ $V_C,FG7UL]M<1GC,;JRL/7
M.#54Y*,HLSG\)\^?L*A'^%>KD@%SKDS[5R!N%O!Q@DU],9P*Y+P-\.= ^&>D
MR:9X<TXZ?ITES]I:(2239D8 %LN['H!75@E@<UTXRLL17G674RPU-T:<:4G<
MDI:2EKD.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "DI:* &5XO^ULI_P"&>_$L<A8^9]E5MSA"NZZA'48Q@G^=>T5SOBSPGI7C
M[PY<Z+KD#7^DW6SSH2TB%]K!QRA4]5'Y5OAZBHUH5'LFF958.I3E%'G/[)*G
M_AGOPU'&6'E_:E7:X<MMNIAU.<Y(_E7M%<[X3\)Z5X!\.6VBZ' UAI-KO\F$
M-(Y3<Q<\N6/5C^==%1B*BK5IU%LVV%*#ITXQ8ZEHHK U"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;[I^E+24 ?
M''_!/Z'$GCHB1I-WV LS9!)_TC.<DU]BJ<UP_P ._@]X4^%8O/\ A%]);2_M
MVS[1NNI9]VW./]8S?WC7<BN_,,1'%XJ5>&B?0Y,+2E0I*G)WL.HHHK@.L***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HH7I4%U>0V=K)<SN(
M8(D,DCN<!% R2?H*-;@3TM0V]Q'<1)+&P>-P&5E.00>A%34, HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** &5R>E_P#)0]?_ .P1I_\ Z-O*
MZRN3TO\ Y*'K_P#V"-/_ /1MY6B^%F<OBB=?11169H%%%% "9HKDM%^+/@KQ
M)J::;I'B_0M5U%\E;.QU*&:9L#)PBL6X')XZ5TJW2MSM?'/.W^G7\!T[XI:I
MV8DT]BS17#:?\</A[JEU:VUGXY\.75S=3I;6\$6K6[/-(YPB(H?+,QX &23Q
MZUJ^)OB)X9\%M"OB'Q!IF@-.6$(U2]BMC*%QN*;V&X#(SCUJK.]A<RM<Z/=1
MNKA%^/?PT8(?^%A>%E\P$KNUFV!('4X+]JW_  SXZ\.^--/>^\/:YIVO62-L
M:XTNZCNHPV =I:,L-V"#CKR*+,=S<S14?G+M!PPR1C=QU^O\NM>?^/?VA/AW
M\,KI[3Q%XLT^SU".18Y-/B<W%VC,F]=T$8:15*\[BH7!'/(RK-[ VEN>A[O:
MEW5Y9X+_ &H/A9\0+];+1O&>GO=22QP0PWN^S>>20X2.(3JAE8GC:FX@D XR
M,^F)=1R-MCP[;BK;6!VXZYY^GOR*<DX[H%)/8L4FZN>\8>/] ^'^AW&L>(]4
MM]'TZ#(::Z;;N(4MM0=78A6PJY8X( )XKS+3OVT?@YJE_;6D7C%4DN'6.-Y[
M"ZBCW$X^9VB"H!QEF(7'.< X:A)]!<R/;MU&ZJ-EJ]IJFG6]_8S)?6=S$L]O
M-;.KI-&P!5D(."""#GIR*N5.Q6^P[=1NKFO$/Q*\)^$-1CL-=\3:/HM[*BR1
MV^H7\4$CJS%00K,"06! /0D8'2K/AWQIH7C*SDO/#^L6.N6<;F)KC3KE+B,.
M "5W(3S@BG9K7H&[LC=HI*6D 4444 %%%% !1110 4444 %%%% !1110 444
M4 %9NL:2=6TN\LC<7%M]IAD@-Q;2F.:,.,%D;'RLO;Z"M*B@#Y6_:$\'ZO\
M"CP/9:GI7Q \8S7,U^MGF[U=W&PQ2M_ $YR@KU/3_AQ9> ;^V\1:E\0O%,UG
M8@[X]>UA3:,&&T&0,B]\?B17*_MK?\DMTG_L-1_^D]Q7JOQ)\&'QUX"US024
M,M]:M'%NE>)%D W1DE<D .JYP,XSUZ$ Z-[R./)/3.U3D ,V<;02>N>*S)/&
MN@PV=Y>/K-@EG97'V6ZN&NHQ';RY V.Q;"MD@8/.2*\8^&OQ0N?#_P"SGJ.J
M7V4UCPW;S:>8[RW*#S47_18O+7D@;X8ST;(;)&,USFL>!G\#_L>:A9W4:6-U
M?K!?7>V1S\\MS%@%6SM98Q&C!<+D-@'N ?0.H_$?PMI,<$E[XBTFUCN+;[7
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M/OCK[U]*^M>EF3I2Q4_8:0Z6]#CPG/["*J;CJ***\T[0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH 3-<[XV2PF\'ZW'JLAATZ2PG%W*A^Y$8
MR'(]\9Q70US_ (RO++3_  GK=SJ%L;RQAM9)+FV0!C*@C.4P?454/C2)D[*Y
M;\.K9QZ#IJV,OG6(MXEMY<YW1JHVG\JUMU8WAJ6&ZT'3Y;:V:VM9[:.2. @
M0@H/DQVQTK7I2^)HI:CZ***0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHOM489E).Y1G&,G\NO\ C6=XH\36?A'P[J.M7^\6=C ]Q)LQN(49VKD@;B>
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M[(RF/]GWPL"#G_2O_2J8U[,.U&+IQHUYPCM&3L%"4I4HRGN.I:**P-PHHHH
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M R&Z=Q5^TA[*UB>27.?4-%%%><=H4444 %%%% !1110 4444 %%%% !1110
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MK[GFWO)(1Q\H=B6V=]F<9[4 >2^%=1M;7]LSQ?'-<11/=:2D<"NX!D80VCX
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MQN'6.-Y4@4@Y4" /Y87.25VX)))Y)R >:>-]:L;;]HWX:>,Y[E+?PQJ&C/\
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MSK\0/^@!_P"3EO\ _'*^T_+]C_WT:/+]C_WT:/KM0/J\#XL_X9U^('_0 _\
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M/,N;R9Y96Q<2H,LQ)/"@?A7K7I[T5J4L/6J0F[M,*;4H1DMAU+1169J%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M)2TC?=/TH YSP[X-T'P@+@Z#H.FZ.9P/-_L^TCM_-VYV[MH&<9/6NAR:^4/V
M&_%VO^+6\:G6M=U+6/*%EY/]HWDEQY.?/WA=Y.,[5_*OJ_G%=N-H3PN(E0J.
M\D88>K&O2C.&B'T4E+7$;A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%<=9_&#P=J'Q O? ]KK
MUK/XKLK4WESIB$F6&,%1EN, _.IP3G!STYKK&N$CSNR/0'JWT'>@"6O@[X#\
M?\%,OBU_V"[G_P!&6=?=:W4;MM!RV> I!R/7CM]:^#_V9[A?$W_!0SXQ>(+#
M]_I4-K=6AG7# R"XMT !&1@F&3'/(0F@#[VK\PW^('C3X;_MY_%+6/!W@RZ\
M=:L\$ML^EP.4Q S6["7*@_W5!K]/*^"?@*Q;_@I5\8=P57&EW"J[A@>)K+"C
MD#&-WYB@#I?^&MOV@?\ HW'5/^^I_P#XBO=_V>_B5XX^)GA_5;SQOX$E\!W]
MK>>1;V<K.WFP_P!\;E7]*]7^?_(_^O445ND+?)"B<8W* #B@"Q7SE_P4&_Y-
M#\=?6Q/_ )/VYKZ):95+;N N.3C'-> _MY:;<ZO^R?X]MK:,L\=O;W+MV6.*
MYBDD8XYP%0GI0!K?L9-G]E_X>?\ 8-_]J/7IGBZQ&I^$=7MFO6TG[192HUY&
M<&W)C(\P'_9Z_A7CW[#?B*SUS]ESP*UBYN%MK:2SE*X^25)G5E(SD'H?H0:]
M?\:)I\W@_6X]5E,.FR6,ZWDT>3Y<7ED2-QZ#-.G\461+X2YH-J;/1;" 71O!
M'"B&Z8Y:8;0-Y]S7S'^VPV[4O":=_)N?_:=?2_A\6?\ 8&F+82>;9"VB\B0G
M&Z,*-A.>>17RS^V9KEG>>,/#^F0RB2]M+:5Y8AU ?;M_/:>M?6\+QG+-X.*O
M;FO]QYF8-?56UU/=OV>_F^#/A7VMB?\ Q]J\X_;6.?!_A_\ Z^W_ /19KT[X
M$6<VF_!_PM#<1F.7[$C%3U&XD@'WP17F'[:W_(HZ!_U]O_Z+-:9;:?$*<=G.
M7ZAB+QP-GVL<9X)^"UK\4/@+:75L%MM<L9[C[/.<CS(]^3$Y )QCOR>*Y/X(
M_%K4?A#XIDTC5(9&T624Q7=L^%-M(/O2*/4=QT]#7T-^RBS?\*>L3QN%S.&]
M,AL?SKG/VF/@6/$5K/XJT.T,NJ0*/M%I$,?:8QT90.KKZ' /<U[U/,Z-3&XG
M+,?K2G)J+[:G"\-.-*%>C\1>_:RU"VU7X-Z?=VDRSV\]]!)%(AR'#1R;<?7(
MIG[&7_)/=8_["\O_ *+CKYB;Q_?W7PX3PA<R-<64<T-[;-_'%A6!3GLY;@=1
MSP*^G?V,_P#DGNK_ /87E_\ 1<=/,LNGE>13P\W?]YH_(>'K_6,9[2/:QR/[
M;'_'_P"%/^N-S_[3K@?!O[2GBWP7X5T_1=*T[3KJRLX,0%[>0Y_>>H?%=]^V
MR/\ 3O"?_7&Y_P#:=>Q?L_QK)\'O#3/'AW@RZ'YOXSU-3#%8?"\/X:=>BJBY
MFK/3^84J52IC)\LK'C/PZ_:<\;>*/'FCZ-?6&GPVUW=F*X86T@\M<=B7Q7U@
M%#+DBHEMT4L0@&[G&,<_6IBP[&O@\PQ5#&55*A15-+HM3VL/3J45:I.Y)2TF
M<8I:\PZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** &5R>E_\E#U_P#[!&G_ /HV\KK*Y/2_^2AZ_P#]
M@C3_ /T;>5HOA9G+XHG7T445F:!1110! L+*W&%3_9)]NW3U_2IB*6BC<"O]
MG*@A>AXVYP!DY)'7FF&RW3>:0N_L>I7KCG'/4XSTW&K=% QFT^@JN;5VSS@J
M<HP8YR>?P'MS5NBDU=6%L0^6S9SM('W5['COQZTC1.RD$(<C!#<CZ?2IZ*8%
M(V1VLH5-NW 7L<'(!]L]O0G\+E+10)*Q76W*R*1M"C)XQDD]^GN?\FD6U^5<
MA21T7@A?IP*LT4:VL#2>Y (G7&-H!ZCL..W'K4H7%.HHZW'MH0&U!"\X9>C<
M$]",\CW- M0 W.6;JW /0#/ ]A4]%'2P=;A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'R9\+/#OB?7/BA\6O^$;\5KX1:'6G-S_Q+8+S[
M1NN+G:6WXVXP>GKWKZ*\&Z/KNCZ/+;Z]K_\ PD5WYS2)=1VD=K^[XQ'L4D8Z
M\YSS7BW@O0_B#\-?'OQ$U"Q\!?V_9Z]J37,<XUB"W!3S9W'!).<2J.G4&O7_
M  /XB\4:XU[_ ,)'X1_X1;R-GD?\3&.\\S/7[@&* /+OV+;A(OA=J^X_\QJ4
M9R,<6T!//3L:QM/UWX5WFG:AI_A[X7ZWXHTR.-HCJFFZ*;EF+H&=1<RMYNX;
ML;20PQTP4)Z'X(_"/7=&^#?B+POXBBDT6^U:6Z12TT=PT*30+&' C;;N!!.,
M]._-9GP]TCXM^#?! \#67AJQL&@-S'9>))M31HXP7+[WB*L[L2SX.W'W25P"
M& (/V8[74]>^ ?BBQM+Z:UOY;J\M+&;SFB%LS6\8CV%<F,;WW_(.":YGX86O
M@CP5HL/A/XD>"3HVM73S1?VYJED6AN"7";8K@9,>T!<LA$0"A]^7Q7I?[._P
M_P#%7PY^%>M:7>VD5CKMQ=SW-E'>3I(@<P1)'O,9< ;D).,\>O2L+QYH_P 2
M_C)X5@\/:AX%T_0RTD4SZQ<ZK%<Q!E.YBB*&>/<<KD$D*2"3G@ Z']J30=-N
MOA'KNJR:7:RZK#!;K#>- IN(H_M,8*I( 2H&]NA/WCC-=)\&?"NCZ7\/_"^H
MZ?I.G6NIW.C6OGWEO9HDC[HHV?>0 S;F^;GO3/&7PFNO$?P/_P"$$M[RV2Z2
MPMK9;N>-C$\D)C8%ESG:QC/<D9'6J'P8N/&NGZ-I'AWQ/X071K+2M+C@CU*.
M_BE21HU5%!C1B1\HR>3S^8 /+/@*F?V7_B1M 1&_M':J_+C_ $&,'@<5U7[-
MOPP\-ZY\*='UK6-)M]<O;A9%7^U%6Y2U1)95$4*LN%3)9B<;F9R6)P,'PC^&
M?B7PK\!?&GAW5-,-KK.H?;OLUMYT;F3S+943#*Q')4]Z[_X#^&-4\$_"G1M$
MUFS:TU*V\[S(0Z2#YI7<?,I(Z,._6@#SW]F*U_LGQ1\3O#UC^YTG2];_ -&M
MW)?RU\R6+ <_.?DMXOO,1\O3DU]#UX[\%_ ^N>#O'WQ+U#5K'[-8ZUJ?VBPF
M$T;B9/-G?HK$KQ*OW@.0?Q]BH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH ^?\ _A1.OC]J;_A9
M7VO3O["Q_P >_F2?:O\ CR\C[FS;][G[W3WXKWDR?/CMBO'/^%_/_P -"_\
M"L/[#Y_Z"GVT_P#/K]H_U6SU^7[W3GVKV39E@?;%=V+G7E[/VW2*2_P]#CHJ
MG[WL^^I)@T;32TM<1VC=IHVFG44 -VFC::=10 W::-IIU% #=IHVFG44 -VF
MC::=10 W::-IIU% #=IHVFG44 -VFC::=10 W::-IIU% #=IHVFG44 -VFC:
M:=10 W::-IIU)0(\;^"_PIU;X=^./B+K.HW-C<VOB34OMMFMG(SNL?FS/\X*
MC!Q,OW2PX//3/L6,"O+_ (6_%Y_B1XO\:Z*-,^P'PSJ'V%KEKCS3=+OE3(4*
MNSF+/4]17J7M6^)E4G5YJN^GX*R_ YZ*A&%H;"8-&TTZBN<Z1NTT8-.HI@?
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 ,W
M_C7GOQV\!W_Q.^%NL^&]+GMK>^OO)\I[QF2/Y)XY#G:K'HA[=<5Z%MQCVKB?
MB[\0/^%4_#S5/$XL/[4_L\1[;4S&(MOD6,?/AN[CMT!K3#N<:L94_B3T,JT8
MRIRC/8I_ GP'?_#'X6Z-X;U2>VN+ZQ\[S7LV9X_GGDD&-RJ>CCMUS7H6X#\*
MXGX1?$#_ (6M\/-+\3FP_LO^T!)NM1,92NR1HS\^%[H>W0BNVVYS[T8ASE5E
M*I\5]0HQC&G&,-B2BDI:S-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#MYSEL;1D#IZ<8J6B@"O]G.T  *HV[54X"X/&!CTIYC/ELBA%7^'CC\JEHH
M@^SG=N#%6(^;;CYCZGBIZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ3S7;CL1+%XB=:4.5OH<N&IJC2C33N244E+7$=84444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;[^STO\ R@UV8!+M"R*Y^3(!^YZ]ZWPM2-'$0G/;F1AB(N5.26YR/[)KF/\
M9_\ "[2LJJOVK&2 &'VF7;S],?E7L[993BN&^#OP\;X4_#W3/"@OO[02P\T+
M=B 1;@TC./DR0/O^O:NZ]:,54C6Q$YPVYF&'3C3BGN.I:2EK W"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM]T_
M2G4AZ&@3V/C?]@%@TGCDY&&&G=-P''VC&-W_  &OL9:\5_9]_9[7X%MK[1Z\
MFM#5S"3MLA;^7Y?F< !VR/WGZ5[5S7I9G6AB<7.M3E=/_(XL'3E1H1C-W8^B
MDI:\T[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;MK-U[0H
MO$6@ZAI=R2L-];26TI0\A70J<?G6I10M'=!OH4M+TN/2=-M;*+)BMHDA0DY.
MU  ,_E5PBEHI[NX;!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** &5R>E_P#)0]?_ .P1I_\ Z-O*ZRN3TO\ Y*'K_P#V"-/_ /1MY6B^%F<O
MBB=?11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'S]_PO37O^&IO^%;&UT_^Q,8^
MT>6_VG_CR\_.[?M^]Q]WI7OBG=^%?*G_  A^O']N;_A(/[%U#^P<9_M3[*_V
M;_D&[/\ 6XV_>^7KUKZKW8<#\:]3'TZ-/V7L>L(W]3@PKE^\Y_YM"6BBBO+.
M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML\U/[Z_G1YJ?WU_.N3^?^^:/G_OF@#K/-3^^OYT>:G]]?SKD_G_OFCY_[YH
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M3BOJOY_[YKTL;A%A53Y7?F47]YR8:JZ_-=6M(ZP2IC[Z_G1YJ?WU_.N3^?\
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MCY_[YH ZSS4_OK^='FI_?7\ZY/Y_[YH^?^^: .L\U/[Z_G1YJ?WU_.N3^?\
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M -\UR'4=9YJ?WU_.CS4_OK^=<G\_]\T?/_?- '6>:G]]?SH\U/[Z_G7)_/\
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MCY_[YH ZSS4_OK^='FI_?7\ZY/Y_[YH^?^^: .L\U/[Z_G1YJ?WU_.N3^?\
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MJ?WU_.CS4_OK^=<G\_\ ?-'S_P!\T =9YJ?WU_.CS4_OK^=<G\_]\T?/_?-
M'6>:G]]?SH\U/[Z_G7)_/_?-'S_WS0!UGFI_?7\Z/-3^^OYUR?S_ -\T?/\
MWS0!UGFI_?7\Z/-3^^OYUR?S_P!\T?/_ 'S0!UGFI_?7\Z/-3^^OYUR?S_WS
M1\_]\T =9YJ?WU_.CS4_OK^=<G\_]\T?/_?- '6>:G]]?SH\U/[Z_G7)_/\
MWS1\_P#?- '6>:G]]?SH\U/[Z_G7)_/_ 'S1\_\ ?- '6>:G]]?SH\U/[Z_G
M7)_/_?-'S_WS0!UGFI_?7\Z/-3^^OYUR?S_WS1\_]\T =9YJ?WU_.CS4_OK^
M=<G\_P#?-'S_ -\T =9YJ?WU_.CS4_OK^=<G\_\ ?-'S_P!\T =9YJ?WU_.C
MS4_OK^=<G\_]\T?/_?- '6>:G]]?SI#/&.KK^=<I\_\ ?-173/Y7F*YQ^M '
M8^:G]]?SH\U/[Z_G7)_/_?-'S_WS0!UGFI_?7\Z/-3^^OYUR?S_WS1\_]\T
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MM%&T4;10 ;11M%&T4;10!T.D_P#'FM7:I:3_ ,>:U=H **** "BBB@ HHHH
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MBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBN0^+3)_PJWQ@2X"KH]X-S9
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M-HHVBC:*\\Z@VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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M5XGN_#.N6+^'_$]OLQI_VM;F.8,N[*.@"G"X)!(/7CAL 'H$C"&+S)!Y<?\
M>9@/ZTGF)MW;EQZ[ACKZ]/?Z5YSXD^,$FE^+7\+^%]!O_%/B..#SY;:.9;:W
MBX#;6=P0#M9#GI\X&<Y TM/\>>(]0T35@/"%S#XIT[RF?29KI 98Y),)+'<#
M*%3&)!S@YB?CH2 =N5^9E4>80,_+]0/YD_\ ?)I!@F,<DOTP"<?7%?,7PC\0
M>)['QU\0YM(\$+JU[/JOF7]DFJQ0K9'S+CY'W9WKRW3;T'%>S>/OB-;>"[FP
MTBUT^35_$6H/MM]%AG,>U/F_>.1]U/D;GKPW'RM@ [>/$TGEQCS)/[JG--+
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MU/*?\" K5XVJP!8-]W;SN^F*X))QW1U7YMF.VBC:*-HHVBD4&T4;11M%&T4
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ML*O8/;TNYUVT4;17'?\ "U_#?_/:\_\  "?_ .(H_P"%K^&_^>UY_P" $_\
M\11["KV#V]+N=CM%&T5QW_"U_#?_ #VO/_ "?_XBC_A:_AO_ )[7G_@!/_\
M$4>PJ]@]O2[G8[11M%<=_P +7\-_\]KS_P  )_\ XBC_ (6OX;_Y[7G_ ( 3
M_P#Q%'L*O8/;TNYV.T4;17'?\+7\-_\ /:\_\ )__B*/^%L>&_\ GO>?^"^?
M_P"(H]A5[![>EW.QVBC:*X[_ (6OX;_Y[7G_ ( 3_P#Q%'_"U_#?_/:\_P#
M"?\ ^(H]A5[![>EW.QVBC:*X_P#X6MX;_P">]W_X 7'_ ,13O^%HZ!MSF_QC
M.?[.N,8]<[,4>PJ]@]O2[G7;11M%<?\ \+6\-_\ />[_ / "X_\ B*EL_B=X
M>O[JWMH;BY,TS;%5K*88/N=E'L*G8/;TNYU>T4;11M%&T5@;AM%&T4;11M%
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M^Z/E 7L20"+X0&U7X7^$Q82P& :='$\T. GFA3YJG:<%@X*G&?F!/4$5Y_\
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M<<9SSU_#)H =M%&T4SS(S#)(KJXC&XA3D],_RYH\Q,S#(/DY\PY&$P><GH.
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MF4!TPRLJ"+<KD#]^C9'%>+^(M,U;]DW]H426BR&/1+E[JQED.T76GRN5P79
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ME'W,,#<!G[C=/[IH W-HHVBFR,(8O,D'EQ_WF8#^M$;":+S(QYD?]Y6!_K0
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M:L<^;:D^@RRX_NMM["@#ZT_X*NQJ_P"S/I[.'7_BH+;<HZG]Q<'C\:7]@?\
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MD9'84 >:_P#!-F\E'[8'B](M._LBVN=,U!&TU>#;8NH75#Z[#N7GUK7\0?\
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M&$O'3?U!XW\8KWO3_P"S_P"S[9;..!K&"-9(Q$3Y*1X_=A"/E52.GH.1@<T
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MMHHVBC:* $5/+D+++(-OW&PN?QQBFK&L;.%CW1N=[*SD'(Z#(QQZT_:*-HH
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M:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*Q?%GAT>(O#.LZ2)I+
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -/6N2TO_DH>O_\
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M &T4;11M%&T4 =#I/_'FM7:I:3_QYK5V@ HHHH **** "BBB@ HHHH ****
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MR[C_ )XM0!6VBC:*L_V7<?\ /%J/[+N/^>+4 5MHHVBK/]EW'_/%J/[+N/\
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M/_"Z=%_X6[_P@7V?4?[8_P"?CRHOLW^I^T]=V_[O/3[W'3FO1=HKY7^RR?\
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MC:*L_P!EW'_/%J/[+N/^>+4 5MHHVBK/]EW'_/%J/[+N/^>+4 5MHHVBK/\
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MC:*L_P!EW'_/%J/[+N/^>+4 5MHHVBK/]EW'_/%J/[+N/^>+4 5MHHVBK/\
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MVM_?-&UO[YI]% #-K?WS1M;^^:?10 S:W]\T;6_OFGT4 ,VM_?-&UO[YI]%
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MVM_?-&UO[YI]% #-K?WS1M;^^:?10 S:W]\T;6_OFGT4 ,VM_?-&UO[YI]%
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M_?-&UO[YI]% "!0O04M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!XWXI^-%_J?C&X\&> [#3_$/B."(2W4U[=!+6P'F(C[E!W3%-Q9@A
M!&<#+ K5W3?$7Q(T?4+-?%6@Z-JNG7,\=N;SPY<3+]BWN$#3138,B_.I)7&
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M^)O&^L>"TT^8VFE:7IURUE]L3SL(X+CEF#+C&3)YBE<*FV@#ZB6X5MN 3N)
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M1R<Y]*NGH*Z,35]M4]I:QS8>G[&'*W<=1117.=(4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6DI:P-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIK1EO5NE<N$1R0%+#&)!W[&NP^%?Q6OO'5UK6@:YI'_".>)=%55NK??N#9!
MEC&=V.%;: 0!)'\YW8 !ZMN]B!C.33J\6_9A\?:Q\0/ >HZKKNI/J=VFH&$2
MM'%'A!! <X1$&,LQS7LDEPD62[;54%BS'  '4GVH EHJ+[1'N*@DL.J@$D?7
MTH^T)Q][.<8(P>H']: ):*B^T1GHPZA3R.">G\Q^8H6X5MN 3N) _#U].>.>
M] $M%1-<*I PQXR>.@QU]^W3/44@N5VY(8?-M_S_ )]?2@":HA.#(R8.X=N.
M>G(]N?TJ6OF;XA?M4:IINB#4_"OAN230?M*VXUS5HG2*Y<^;\D4(*NP^09D!
MRO\ $@H ^F:**C,P49*LO..?KC]: )**A6ZC:3RPWSYQM_#/\N:PO'GCJQ^'
MOA6^U_48+JXL[/9YB6J*TAWNJ  ,RCJXZD<4 ='165X?\1VWB3P[INLVT<Z6
MM_:PW<:2)^\"2('4$ GG##.">]::MN[8/0CB@!U%,\T8R 3QD8QR/;\Z8UU$
MI +X8C.T\'' Z?4@4 .\[K\C9QD=\_Y]ZDKQ;XT>.M9\+^./AUIFEW\D-CK&
MH_9KV/R$?S!Y]N I)1MIQ(W3&0#Z5[(+A6S@,2O7C_.: ):*@:Z1& 8,!TW$
M8 /3'USCCOD8J>@"+[0NY1@_,<=O3/X_AFI:X;P7J'B^\U[Q*OB33[.QTJWN
M NC3V;C-U!ND&7'F-@X\OLO)KLVND7.=P_WAC\.?H: )J*B:X1&4'.6_S_D=
M>:EH **** "BBB@ HHHH ***2@!-WM1NKE?&?Q,\-?#_ $U[S7M5M]/4(9%B
MFE5)''HJL0<UYOH7[87P[US43:"ZNK';]Z:\$21@>N1(<CZ UM'#U:BYH1=O
M0QE6IQ^*1[BLF[M2J^>Q%9^EZM8ZK9QW-C<QW4$OW)(G# _E5?5O%6DZ&/\
M3M1M[0[MH\Z15R?Q-83:IZRT-Z<9U7RP5WV6IL&0 9ZTGF<9P:Y+7?B5HFA6
M<<[-)>POT:S D ^IR *;X?\ BAH'B.01PW!MI&^XEQA2WTP37!+,,+"LL/*H
ME)]+ZG5]2Q/)[3V;LM]#L-WM1N]JB5E;[KU)SMXKNNWTL<H^BDI%D5LX.2*H
M0NZDW>U127$<,;/*PC11DLYP!^-57UJP5@INX5;TWBJC&3V5R)2479NQ?W>U
M&_VJA_;VG?\ /[!_WV*/[>T[_G]@_P"^Q1R3[,/:0[K[R_O]J-_M5#^WM._Y
M_8/^^Q1_;VG?\_L'_?8HY)]F'M(=U]Y?W^U&_P!JH?V]IW_/[!_WV*/[>T[_
M )_8/^^Q1R3[,/:0[K[R_O\ :C?[50_M[3O^?V#_ +[%']O:=_S^P?\ ?8HY
M)]F'M(=U]Y?W^U&_VJA_;VG?\_L'_?8H_M[3O^?V#_OL4<D^S#VD.Z^\O[_:
MC?[50_M[3O\ G]@_[[%']O:=_P _L'_?8HY)]F'M(=U]Y?W^U&_VJA_;VG?\
M_L'_ 'V*/[>T[_G]@_[[%')/LP]I#NOO+^_VHW>U4/[>T[_G]@_[[%']O:=_
MS^P?]]BCDGV8O:0[K[R_N]J-WL:SO[<TW_G]@_[^"G0:U8W+!(;N"60\B-)5
M9C^ -'++L"J1?5&C124M2:!1110 4444 %%%% !1110 4444 %%%% !1110
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M@MU91T[U8TO6K;6-/M+VT)EM;I%DCDZ JPR#@\\BO(_CC-XJ@\.>(Q,OA_\
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M?\*PU50Z.6U9Y!L<-P;>WQT--\'2JO[9'C?<R(7T>,(K.NYL+:@X7.?X3VH
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MJQ?^$PT+_H,6'_@0G^-'_"8:%_T&+#_P(3_&CVL>Z^\/8U/Y']QM;J-U8O\
MPF&A?]!BP_\  A/\:/\ A,-"_P"@Q8?^!"?XT>UCW7WA[&I_(_N-K=1NK%_X
M3#0O^@Q8?^!"?XT?\)AH7_08L/\ P(3_ !H]K'NOO#V-3^1_<;6ZC=6+_P )
MAH7_ $&+#_P(3_&C_A,-"_Z#%A_X$)_C1[6/=?>'L:G\C^XVMU&ZL7_A,-"_
MZ#%A_P"!"?XT?\)AH7_08L/_  (3_&CVL>Z^\/8U/Y']QM;J-U8O_"8:%_T&
M+#_P(3_&C_A,-"_Z#%A_X$)_C1[6/=?>'L:G\C^XVMU&ZL7_ (3#0O\ H,6'
M_@0G^-'_  F&A?\ 08L/_ A/\:/:Q[K[P]C4_D?W&UNHW5B_\)AH7_08L/\
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M45/;F=ATG*5.,I;CZ6BBL#0**** "BBB@ HHHH **** "BBB@ HHHH ****
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MYO\ P.\*^(M<^!&J^'_%$EYIUU=1W5A9M=HS2VL#PB-?D;#':2V ?X<*,#@
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MG'5ER?E5.Y'X9IWAW0?$/QB\6;]0U&3#XGN[JX7=';(2 ".PSE>#_>]CBO\
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M(I&0QA7!X)QQ]*X/QYXF^"?PR\3:)X>\3R:'H^KZP_EV=K<( S'HI/\ =!/
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M=4DC;8]NUM*(,\;MI;;CZ4>UJ_SO[P]A2_E1^LW_  J7PC_T+VG_ /?D4?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!E<GI?\
MR4/7_P#L$:?_ .C;RNLKD]+_ .2AZ_\ ]@C3_P#T;>5HOA9G+XHG7T445F:!
M3)?]6_T-/IDO^K?Z&IELQK<^'O@QKEEX;^(NCZEJ4Z6MI;"X:1V/0?9W[#FM
M..PUKX_>/+MD(MH)O]86;?';Q*0$.#SD?.1MQN?+?(.5P/ACX:MO&7CC2]%O
M(EDM+Q)DE*Y23Y87888>^:TO#>H:Q\$/B4MK<(S):R+'>0A5<7$!&<JQ8<XP
MZ]#N],,I_$L/)^PIQKJU#GO)^>G^9^ZXR,?K-26&=\1[-**\O>_'_@'V)I.@
MVOA[2H-/TZ"*SMH1M1(UQM&<_B>223R<DGDYKYE_:I7;\1M-XZZ?&?\ Q^>O
MIW0_$%CXBTNUU&QG6XM+H;HY5Z'G&/KGC'7-?,?[57_)1M-_[!T?_H<]?><1
MN"RMNE\/0_.^%XR>;Q53?WKW/1?!?QR\%:+X1T2SO=7:&:TL8(WC6VFP&$:\
M$A2.,&O)O'5]<?&[XI1IX7@$WV>-+0SRIM 56;S)6R,HN6Q@ YVCG^&N]\*?
MLU^&?$'AG2M1DU#5;>YN[:.YDCBDB";FC&[Y?*Z<UYG\5?AG+\)]<T^>VU%K
MF&Z,D]DT>^.2%HW4C+@_*0''[SY03DD=,_/9E/,OJ</K<%['W=MSZ#+(Y;#'
M5/J51JL^:W,M/P/K7PSI(\.>&]-T\SF?[!;10-,0 9!&H4G . <]<5\T:L]Y
M\?OBU#96LF=&LUP,,P1;8,/,<JW&]MP 7;U"9R%)K7NOBQJ5]^SW(QB+7ANO
M[%:Z\S<_E[ =YSGYBH"GW.[VK&^#?Q2\.?#'1+B*;3[^34+B0N_V58A$%&=J
M@&4>I8G:.6/H*]#&9CAL=/#X=SY:3CS/T['#@,NQ6!AB<3&'-5YN16Z/JSG?
MCG;1Z?\ $[6K6WC6*WACMX@JC''V=%"_0#./>OK?Q=JD^B^$=6U"$*9;.QFG
M0-_>"$C^5?&GQ1\41>-/'.JZO;6T]O%=>45AG"AQMC5#G:Q'49Z]*^BV^+.E
M_$CP#XVBT^SOK:6STR176[B52Y>&0KMPQS]VL,GQ5/ZQC(PE;F^'S^(WSO!X
MA87!2G#X5[U^GPGD?[,VFVU]\2'>>'>]G9R30,7.$?,:9"@ 8VN>.G/2OJW5
M-+M]4T^[LKN+[1;7,3Q2*Q/S*P(8'VQ7RY^RW(D?Q(U!2P9O[/D!4=5.^$@>
M_ /3/0U]7F1=I)^Z!RV1CKS7L\-*,LMTZW/$XHE)9FWV2_I'QO\ L]7UW#\4
MM(MX;C$5U'/!-&T8^>,1M(!GMAD3I[U]C^2&D3+8"]%7(_.OC?\ 9[M9V^+&
MB2I"SQP+-)*ZXQ&K0.,GZ$@?4BOL2\U"WTVWFN+F>.WBC0R.\C!0JCJ23VK/
MA5M8&?-LI2^Y'1Q=%/'PY=W&-_5GS]^U)XJBM]/TW0(F=Y)IA=76TMDJI(56
M&/NDAV'H81P:T?V8_!_]FZ#<Z_<VZI=WTGD0L61@(48_,,$_>?*G']Q.P!KQ
M/Q!?7_Q6^)4]Q:66+G5)Q;P1W4;C9",*"<$XQ&!(<?[7O7VCX;T*/P_HECIT
M,LCPVL*0KYA&2%& 3@#G%<V5_P#"EFE7&M>['2)T9I+^R\II9?%VG+61RWQG
MT/\ M_X;>(K,IPMN;A5,>]G:(B; &><E%'YUK?#FWEL_ WAZWF1HY8M/MPZM
MV.Q>/KQ71M )(PI50%XP>01TQ3A&4(P  >6_IBOL_J_^T>WZVM^I\3]8?U=4
M.E[_ #V/"=4\=6'PO^,_B*36\&PU^"WN([B/+" 1QF/#(%RP9@1\H8Y*<8W;
M+/@GQ98^._C9J6IV%Y$;&TT9;6/S'*2SCS YE,912 &)C.>5VCCYP:]"TGP#
M::+XIUG78Y7N]0U3:)))UC!B5 0JIM0'&-@YS]P'KG,UYX'LKKQAIWB,2W%O
MJ%G;O;XCG81S*W(61/X@#R.>O7.!CR883$7NW[OM.;EZ_?\ B>K/&85II)\S
MAR\U]+VMM^'XGGWQMU'Q!=>']=TA?"S7.@_9UG.K?VC#%@IME),9&0 ZX;UJ
M]\(]>\1W6C^&M.G\*K;Z.MC&G]J1ZA&R_+$"A$8Y(/3-=WXP\&VWC;P_=:3J
M$TT-O= "1[1PC[0VX+D@\=CQS5S0/#UOX=TFQT^V!DBLX$MXVE(+;47:N2!U
MQ73]3K?7/K/-I:WRO>WH<_UJE]2^K<BO>_7>UK[[FO1117LGD!1110 4444
M%%%% !1110 4444 5OLI;!8X;'+JQR,]0/;_ #UJ1H%+;MHSMV[O;_)-2T4
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M;CE&;GMG.>]:?P6TNUT7X5^&;>U0P0_V?!,PW-DO*HE9FSGYF9R3G'7. "
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MNK^9HVBC:* U[AN;^ZOYFC<W]U?S-&T4;10&O<-S?W5_,T;F_NK^9HVBC:*
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M1_X*JZ]9>*OV0?#.MZ7(;O3=0URQO+69!_K8Y+6X9"!UY4@_C7LG_!/N1O\
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M^R;^U-\-(O',\NB?#_6[BU,]\EEJ:6L]C<%?G$ENS;&.>A\O)[&@#TK]B_\
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M6*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &5R>E_\E#U__L$:?_Z-O*ZRN3TO_DH>O_\ 8(T_
M_P!&WE:+X69R^*)U]%%%9F@4V3_5M]#3J0]#FD]589\4? &40_%[P\IX<-<
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MCY8Y=F$7]TO\/\;5[MJOA&^TWP#:Z5:>.M0TVULRTE]KE_+'/>36A$AD!N&
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M8T4?+<2HN BJ.BCM7J&.I]:*\9QJR4WK?4*+3IQML244E+61J%%%% !1110
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M\-7,=Q:Z-"UQ%]R6<F0_CFO00H7H*6JGC*\VWS6OT6B,?J="ZDXW:[G+^-/
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M5S'[.<BQ_$[XPLS*HDU;>IW#&/M%WW_$5[YY+!65=L8SE2HZ9Z\?4FFI 8U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4AZ4M)0!\S+\)_%?_#8@\<?V2?\ A%_^?[SXO^@?Y7^KW[_O_+]W].:^
ME=VY1CJ:\P_X7EH/_"YQ\-OL>H?VY_S\>5']ESY'G]=^[[O^S][VYKT_'(^E
M=V,J5ZGLG7C:T8I>G3_ASDP\81Y_9_S$E+24M<)UA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %(>AI:2@#PKX"?#_7O!?Q
M"^*.J:O8?9K#7M8\_3IEE2031^;</NPK$J,2+]X#FO<E4@<\UP/@'XKZ5\0_
M$GBK1]-@O8KOPY=_8;N2[1%25][IE-K$D9B?J%ZCCGCOV^M=&*G.=3FJZ/3\
M%9?@845%0M'8?124M<YN%%%% !1110 4444 %%%% !1110 4444 %%%% ";J
M\F^-DBL^D@G;GSL9[XV5ZQVK.O-%M=0NK6XNK=)I[8$12-VSC)Q^%<>+H/$T
M73B]SKPF(6%KQJM;'B/AWX?:QXB/F20+;V^.'F.T'],UZAX=^&FE:&PF=/M5
MT#GS9.Q]5'\)]^OO74B$*05)4]/;\JE;.*Y,/EM'#1NU=G9BLUKXQV;LB/R"
MK!E^4]..GY5(5..*?17KK38\?K<;@TO.*6DI6&-W;N:Y3XG:?<Z_\.?%6EV$
M+7%_>Z1=000CY2[O$RJ,G ZD?G75A<5C>)]:B\+^&]7UJ\\V2TT^UDOI(X0&
MDVQH78+D@$D*<9(JX74HM;F<]8ZGDG[)OP]\0?#'X=W^F>)-.;3[^?5Y+A(1
M+'+\ABB0$E&(ZHW?IBO<^>F:X+X/_%K2OC%X;N-8T>&^M[6WNVLF34$1)"RH
MCEAL9AC$@[]CQ7>UMBISE7E*MI(B@HQI15/8DHHHKG-PHHHH **** "BBB@
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MQC#8DHI*6LC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMK %1\VY3@G!/)[^I/X<4 3T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 W::-IIU%*P$!ME;JB_@,4?9U_N+^0
MJ>BGKW B\O\ V%H\K_86I:*- (O*_P!A:/*_V%J6BBR B\K_ &%H\K_86I:*
M+("+RO\ 86CRO]A:EHHL@(O*_P!A:/*_V%J6BBR B\K_ &%H\K_86I:*+("+
MRO\ 86CRO]A:EHHL@(O*_P!A:/*_V%J6BBR B\O_ &%I!$^<;CM^O/\ *IJ*
M5E>X/56"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ,KD]+_ .2AZ_\ ]@C3_P#T;>5UE<GI?_)0]?\
M^P1I_P#Z-O*T7PLSE\43KZ***S- HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\9IQ^_D$*V[N&\A1Y3$[,<$* 1R/I+1]).DZ79V0N+BY^S0QP"XN93)-($&
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MA;J*>:LS+J[S*596/S6\#>_<FO?UA95P H'0J.F,GVZXQ0!X+XR_Y/(\#?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0]*6DH ^3AXNU\_MRC0O[=U/^Q>O]F_:
MG^S?\@W=_J\[?O?-TZU]6^]>!?\ "B]>_P"&J/\ A9'VO3_["_Y]_,D^U?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!E<GI?_)0]?_[!&G_^C;RNLKD]
M+_Y*'K__ &"-/_\ 1MY6B^%F<OBB=?12;OFQ2UF:!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI#!U^T77S#'4<BOI7IP*[,=3C1K<D-M/Q5W^)ST).5/FEN2T4E+7&= 4444
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M1I?#_P  X\'4E6HQE/1DE%)2UYQVA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%)GG%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4Q9 W3^8H9MJYKQ;1_VDM.21;?Q=HNI^#;XP>?Y-S#)-&5SC /EJY/\
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M^\OYFC^UKO\ O+^9JKM%&T4 6O[6N_[R_F:/[6N_[R_F:J[11M% %K^UKO\
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M% %K^UKO^\OYFC^UKO\ O+^9JKM%&T4 6O[6N_[R_F:/[6N_[R_F:J[11M%
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M* +7]K7?]Y?S-']K7?\ >7\S57:*-HH M?VM=_WE_,T?VM=_WE_,U5VBC:*
M+7]K7?\ >7\S1_:UW_>7\S57:*-HH M?VM=_WE_,T?VM=_WE_,U5VBC:* +7
M]K7?]Y?S-']K7?\ >7\S57:*-HH M?VM=_WE_,T?VM=_WE_,U5VBC:* +7]K
M7?\ >7\S1_:UW_>7\S57:*-HH M?VM=_WE_,T?VM=_WE_,U5VBC:* +7]K7?
M]Y?S-']K7?\ >7\S57:*-HH M?VM=_WE_,T?VM=_WE_,U5VBC:* +7]K7?\
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MF(0'<,9)Y ]/IP./K734QSJ1Y'%6]-?O.6CE].D_:*;O^'W%FN3TO_DH>O\
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MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@#H=)_X\UJ[5+2?^/-:NT
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M;11M% !M%&T4;11M% !M%&T4W.0A"L58XW8X'N:7!PI"DACM7_:;:3@>^%-
M"[11M%-ZL B-(<9^4?I3MHH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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MNG^)NH> OB!\-]&U/5M<O++P[/>M]BU.SMY&>60+*I^7RV8#Y3U%9/BB0?\
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M].^.O%>4?M2VEOI6E>'O$MI'LURTU6&W@U"1-TD:,)),-N!1\2Q@_-NP00,
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M1M%&T5PG4&T4;11M%&T4 )F/S"I=1_M'.*7:*XR/X@K;:M?VM[;;H3*T2>6
M2"&P>I'%=58ZA;:E;^=:RK.G^P>?RKEIXJE5?*G9G95P=:DN9K0L[11M%,\Q
M,9S@^G?\J?M%=33BKMW1R+WG9*S#:*-HHVBC:*!!M%&T4;11M% !M%&T4;11
MM% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11
MM% !M%<[\0=6N=!\"^)-4LB(;ZTTZZGMYOO8*P$C(^JFNBVBN;^(6F76O> ?
M$VFV$#7-_-IEQ!';KPS-)$R+UXZL,\UO1:]I'FV,:E^3W3S_ /9=\<:U\0O
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MBP?.L/&,]PVBC:*-HHVBO+.X-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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M/C,+G%6C67.[P?3H:/@;X@1ZI(MA>R8G;[LO&P_0]?TKO 06QM/U[5\^^(M
M;PYJTD<+'R(<BVF0_*Y'5<^M>H?#[QA_;EJUK=2!;H="W1OI7F9#G513>78W
M2?1_U^'<[<TRV+IK'87X>J.TVBL;Q)XLTSPII\UYJ$XBBB.-HQN9O[H![U;U
MC6K'0=+N;^]N$AM[>/S)"QY7_9^M?(GCSQUJ7Q,\1O.Z*T7W(+*,GEO4C^]^
MGO7ZUE^!>*;<MH[ON?FV9X]8&"2UE+;R.[N/C%XI\>>)ETSPVJV2GYBAR65?
M[QQGBO5K7X<7S6<<=]XLUB>3^,K(H!_2J_P?^&\'@/PZL\BQOK%QS)-R2/\
M9&1TKT#:*K%XFG"?LJ*]T6"PL^3VN*=Y>1QW_"NY/^ADUS_P+'_Q-5[KP7#8
M31177BW5K5YI/*B$U^J^8_\ =7(Y-=SM%?F+_P %8/$FK:1\4_ 5K8ZK>64$
M&E_:HEMY2F9_/(WMCV4UP?6*G<[?J>'_ )?S/T)_X5W(6VCQ'KA/_7V.OI]W
MK4$G@N"&]ALY?%VJPWLV?*MI+]1(^.N%QFL#XK?'71?@;\'%\8>)KLR&6W5K
M>-MOF7-TT/$<8SR=W7) ]Z^ _P!E'2_B9^U=^U-'\5]3N;VTT33;\7%VZS,M
MO$5^Y91CHP;^(]N]'UBIW#ZEA_Y?S/TB_P"%=R?]#)KG_@6/_B:/^%=R?]#)
MKG_@6/\ XFNCU;6M.T&W\[4;ZVL8S((4:YF6/S)#T1=Q&2:CN/$6EVM\EC-J
M%K#?N"5M9)T64^@VDYY[4?6*G</J6'_E_,P/^%=R?]#)KG_@6/\ XFC_ (5W
M)_T,FN?^!8_^)KI(M8L)M2FTY+N%M2AB\Z6R\Q?.1?4IG-275_;6-O<7%S(L
M%M;J7FGD.U$4'!))] &/T4T?6*G</J6'_E_,Y?\ X5W)_P!#)KG_ (%C_P")
MH_X5W)_T,FN?^!8_^)KJ+2^M[^QCO;:1)[.3[MQ%(KH><?>!(Z\5E1>.O#L]
MU]FBUO3Y)L9$:W<>_'KMW;OTH^L5.X?4L/\ R_F9G_"NY/\ H9-<_P# L?\
MQ--'@']XJ'Q1K09FV ?:\_-\W!PO'W3UQU%==-<06R;Y98XTXP[. N#T)/0#
MOSBOSD_X)Y?&C7O%'[2?Q3C\2^)9+S3[RUN+QH[Z\ A$WVI$54)^Z<,3QVH^
ML5.X?4L/_+^9]W_\*[D_Z&37/_ L?_$T?\*[D_Z&37/_  +'_P 3772RQ6\3
M2S2)!"JEGED8!4&>,GWZCVK#B\?>&9[@01Z_IKS[<F,7294_W3SUH^L5.X?4
ML/\ R_F9R_#N0K&?^$EUL!^G^ECCZ_+56T\'0:AYWV7Q=JUR87\N80WZL8GY
M^5L#@_*:Z^_FVZ7*T9R0N]64Y&-K'/\ X[^HK\Y?^"3WBK6-8\8?$R&]OIKR
M*XM;>[87$K/MD,TF6&>^VCZQ4[E_5J7;\6?>G_"NY/\ H9-<_P# L?\ Q-6]
M'\%/I>H?:WUK4;D_\\9)?DKIMHHVBE[:0UAZ:V0;11M%&T4;17.=(;11M%&T
M4;10!T.D_P#'FM7:I:3_ ,>:U=H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHI* &.,J<=:\M\ ^!K_2_!>O>"]421=,WSP6&H1N&DFM9][
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MY_O>9$>/QW?@17TDQ?#$A25"J@/3;_%FM<ERVACL%4KXB"E*3U?7Y"SS,:^
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M*\T=J5 E "MM9B<..JCO7K&T4;10!PWQ@^&:?$_P3+I$5R;"[CG2[MGR2BR
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M]NXI=#^'&IZ9\;M<\8RSVK:9?6:6\<2.QF#!( 2PV[<9B;HQZC\/1MHHVB@
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MHH -HHVBC:*-HH -HHVBC:*-HH X_P#X6AX;_P"%@?\ "(?VHW_"3?\ 0/\
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M^Q7X&^*'P3L?$/PV^(D^K_$,6<5R\;7^U#<!=S0[2=WMUKZ[_;&^(7PG\"^
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M"&T4;11M%&T4 =#I/_'FM7:I:3_QYK5V@ HHHH **** "BBB@ HHHH ****
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M^'.A^';34()[O39(':ZOW9/.*1,CNQ56.XEACBNM^('@&Q^(/A6YT:YS:"1
MT4T?S-#*&)!7/;:2O^Z=M 'F&N:?XKU+X?W'A6V^$HT_1S;[((UUZ';$JMD2
M<@;BK?O&4G+MRS&N5^*^@:SX=_9M\,Z;KT4EOJ5GK!CF!?<1&3<LB9#$'*[>
M02:],T_P]\6;&'^SV\0>'[F#<(O[:N(9GOO+ VB79_J_,"]%S@G[Q>I/B_\
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M^3_XJC_A"-8_Y]%_[_)_\57KF!_='Z?X48']T?I_A1_8F&_F#^W\1_*>1_\
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M558(VYN 2W)YKV9L[1]*JO[*45.DK)W_  'AG6C.4*KNU;\1U<GI?_)0]?\
M^P1I_P#Z-O*ZRN3TO_DH>O\ _8(T_P#]&WE8+X6=DOBB=+??\>=Q_P!<OZ&N
M;VBNDOO^/.X_ZY?T-<WM%9F@;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
M;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
M;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
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MVBC:*WNSG>O0-HHVBC:*-HI &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
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MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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MHH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HJ*X_P"/&I=HJ*X_X\:
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M*CRU_NC\J .3V/\ \\G_ "HV/_SR?\JZSRU_NC\J/+7^Z/RH Y/8_P#SR?\
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M+7^Z/RH Y/8__/)_RHV/_P \G_*NL\M?[H_*CRU_NC\J .3V/_SR?\J-C_\
M/)_RKK/+7^Z/RH\M?[H_*@#D]C_\\G_*C8__ #R?\JZSRU_NC\J/+7^Z/RH
MY/8__/)_RHV/_P \G_*NL\M?[H_*CRU_NC\J .3V/_SR?\J-C_\ /)_RKK/+
M7^Z/RH\M?[H_*@#D]C_\\G_*C8__ #R?\JZSRU_NC\J/+7^Z/RH Y/8__/)_
MRHV/_P \G_*NL\M?[H_*CRU_NC\J .3V/_SR?\J-C_\ /)_RKK/+7^Z/RH\M
M?[H_*@#D]C_\\G_*C8__ #R?\JZSRU_NC\J/+7^Z/RH Y/8__/)_RHV/_P \
MG_*NL\M?[H_*CRU_NC\J .3V/_SR?\J-C_\ /)_RKK/+7^Z/RH\M?[H_*@#D
M]C_\\G_*C8__ #R?\JZSRU_NC\J/+7^Z/RH Y/8__/)_RHV/_P \G_*NL\M?
M[H_*CRU_NC\J .3V/_SR?\J-C_\ /)_RKK/+7^Z/RH\M?[H_*@#D]C_\\G_*
MC8__ #R?\JZSRU_NC\J/+7^Z/RH Y/8__/)_RHV/_P \G_*NL\M?[H_*CRU_
MNC\J .3V/_SR?\J-C_\ /)_RKK/+7^Z/RH\M?[H_*@#S;_A*-!_X23^P?[;L
M?[7_ .?#[3']H_O_ .JSG[O^STK=V/\ \\G_ "KYC6,_\/!-VUMF?]9CC_D$
M]-WZ]:^Q610O 'Y5Z6-POU7V>M^>,9>GD<N'J^VYM-I'+;'_ .>3_E1L?_GD
M_P"5=9Y:_P!T?E1Y:_W1^5>:=1R>Q_\ GD_Y4;'_ .>3_E76>6O]T?E1Y:_W
M1^5 ')['_P">3_E1L?\ YY/^5=9Y:_W1^5'EK_='Y4 <GL?_ )Y/^5&Q_P#G
MD_Y5UGEK_='Y4>6O]T?E0!R>Q_\ GD_Y4;'_ .>3_E76>6O]T?E1Y:_W1^5
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M[H_*@#D]C_\ /)_RHV/_ ,\G_*NL\M?[H_*CRU_NC\J .3V/_P \G_*C8_\
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ME1Y:_P!T?E0!R>Q_^>3_ )4;'_YY/^5=9Y:_W1^5'EK_ '1^5 ')['_YY/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!E<GI?\
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MA4I5>6J[O3\C&C*+I^ZM!]+117.;!1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &5R>E_\E#U__L$:
M?_Z-O*ZRN3TO_DH>O_\ 8(T__P!&WE:+X69R^*)U]%%%9F@4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH48QC3C&&P^BDI:Q-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I&Y4BEI#0!\T?L=_";Q9\+&\5CQ/I!TS[;]E%O
M_I$4H?9YN[[CM_?'7WKZ59MO;-<-\/?B[X3^*?V]?#.IKJ9T_;Y[?9Y8Q"6W
M;1\Z+_<;\J[A<^M=>-JU*U>4ZRM,PP\(0IJ-/8?2T45R&X4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #*Y/2_\ DH>O_P#8(T__ -&WE=97)Z7_
M ,E#U_\ [!&G_P#HV\K1?"S.7Q1.OHHHK,T"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2
M@#XX\G_C/['F/G=NV_-U_LK&<YQG'MTK[$_BYKA/^%0^%/\ A88\;_V2_P#P
ME&/^/[[5+_SQ\K/E;O+^YQ]W_&NY4DA2?0UZ&-Q4,5[+DC;EBHOS?<X\/1E3
MY[N_O$U%)2UYYV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %(WW32T4 ?,/[+9!^*WQN 421Q:YO4ELG<;B\R.3E?X>N*^
MFZY+PO\ #KP]X.U;7-2TBR6UO]:N/MFH3I*[><^7.[#NVSEF^YCK76MG KIQ
M555:GM$K?\,<]"#IPLQ]%%%<QT!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ,]ZX7XQ(%^%'C?8@>3^P[Y65?E!_P!'DQFN
MZK)US2;?Q!I-_IMZGG6%]!):3PYQN1E96 /N#54Y*$XMF=17B?/W["NQOA3J
MY.-YUV:3:N0-PM[?C!)KZ8%<EX%^'/A[X:Z3)I?ARQ&G:?).;MH/-DF)D( +
M9=F/11^5=9D\UT8NM'$5YU(*R9G0@Z5*,):L?124M<IT!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444E #:\7_ &MES^SWXE20
ML=_V56W.$*[KJ(=1C&":]F]*P/%_A'2O'?A^ZT/6X/M^EW.SS[<R/&6VL'&2
MA4CD#\JVP]14:T*C6S1E5@ZL)4T[,\X_9)7'[/?AI(RPV?:E7:X<MMNI1U.<
MY(KVBN>\(>$=*\">'[70]$@^P:7;;_(MQ(\A7<Q<X+EB>2?SK?\ 6EB*BK5I
MU$K784H.E"--N[):*2EK(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &5R>E_\ )0]?_P"P1I__ *-O*ZRN3TO_ )*'K_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "DI:2@#Y._X2[7_ /AN;^PO[>U+^Q<Y_LW[7)]F_P"0;N_U>=OW
MOGZ=:^K-P;![5X/_ ,*&U_\ X:G_ .%D?:]-_L+_ )]_-D^T_P#'EY'W=FW[
MW/WNGOQ7O*IA<5ZF85:57V/LEM!)^J//PL)Q]IS_ ,VGH24M)2UY9Z 4444
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M **** "BBB@ HHHH *1ONGZ4M(>AH$SY._8;\6Z_XL;QI_;6NZEJXB%EY/\
M:-V]QY.?/W[=Y.,[5_*OJ_Z5X+^RS\!M?^"?_"2?VY=Z;=?VC]G\G^SY9'V^
M7YN[=O1<??&,9Z&O>NU>GF52E5Q<YT/A_P" <>$A*%!1ENA]%%%>8=H4444
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MT?\ GY^ _:5O^??XH[[>/?\ *C>/?\JX'_A4=G_T'O$/_@TE_P :/^%1V?\
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MK\Y-0XPZ2'&I5>\/Q1UM%(.E+6)TA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 RN3TO_ )*'K_\ V"-/_P#1
MMY765R>E_P#)0]?_ .P1I_\ Z-O*T7PLSE\43KZ***S- ILC;48^@IU-D_U;
M?0TI;,:W/G7X8_'[Q#XV\<:9HE[::>EI=^;ODMT='!6,L,9<]P:]G\8>-=,\
M&Z'+JFI.RVZK\@0#=*Q&5102,L>WYG !-?)7P#G2W^*WAZ24^6 )WPQQQY#Y
M/X#!^E:'Q/\ '6H_%_QM:Z;H\DUWIJ3;+&VAB&97*D%VYX!'(9L!0,-MPV?S
MC!9Q5HY=.=67-4<K1_#_ #/TO'Y#2JYE"G17)24.:7IK_D=Q\//CEXQ\;>*;
M'2H[+2C#/(#,YMY?EMUX=@?,..2,$\$D#J0*W?C-\;-:^'6OV.DZ;:V,ADA6
M9Y;J-W^4E@,;77GY#^E=U\-_A=IOPUT-;2T7S[EP#<74@^>=OUVKR<(.!]22
M?!?VJ/\ DHVG?]@^/_T.>NS&5,?E^5>TJ57[2YYV!CE^99NJ<**5.ST%_P"&
MI?%Y4O\ V?HYCQN5UMI2''MB2NE\'_M3/)*MMXETJ.W4S+%]LL251 2H+M&Y
MR%4L,\D\'@UZM\.7@'@3P\IVQRK8P&0/@L&,0)W9]\U\U?'BSTB;XD30Z#")
MFN%6.X2"-F N=Y+;0 =S'*+M'<$=017'B*F8Y?2CBH8KVC?V6D=V%CE>95ZF
M#GA/9I7]Y-GV1'<QO&'#93&0P.0?I7,^/_'%MX"\,7.L70-P8V58H.%+LQP
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M/L5W'-LW$A<[6.,D$<^E &U167?^)]*TF[L;6_U"UL;J^8I:P7,Z1O.P(!5
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M^!1_^(H_M3"?SA_9.,_D/5O,_P!D_I_C1YG^R?T_QKRG_A=3_P#0''_@4?\
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M>2VQ;K@[L_GP?^! U]%A<ZE3_CZGS6*R.G-\V'E8^EUD#+D<BE#Y[5YIX?\
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M?]4_T-/IDO\ JW^AJ9;,:W/@GP)X?O?%GBBSTG3[O['>3K<"WN=Q4KB!SM)
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M!*><=L[:]&^(?P4\)Z/\)?$JKI%O>7L&FW5T=4O%\R\FN C2M/)-PS.T@#$
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MWSBL+X=^'O&'P^^ -AI5G8VL'BJPCFD6SO63R"/M+2%2T9V@F-CCG&3R0.:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDCKYDZ9ERY#'$2<C;WKV->:Z,4JL:O[]W>GY?Y&-%0Y?W>P^BBBN<V"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH ;NXKG?
M&GAO_A+/"NM:*L[60U2SFL7NB-YC61&3*@GKELUT6.*YSX@:Y<>%? OB36[9
M5FNM.TVXO8HY3\A>.)G4'VRM.%^:-MR)6Y=3C_@/\'#\%_"=YHQU(:U]HOVO
M1=>0(6W-'''RNYO^>9/T->I\#->.?LT?%?6OC)X'O];UJ&SM;N'4FLUCL4=8
MPHBA;/SLW.7->R5TXJ-2-:7MOBZF=%0]G'V>PZBBBN4W"BBB@ HHHH ****
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M^9HV?3\S2^JXG_G]_P"2H7MJ/_/M?>SDO^%B2?\ 0OZU_P" $G^%'_"Q)/\
MH7]:_P# "3_"NMV?3\S1L^GYFCZKB?\ G]_Y*@]M1_Y]K[V<C_PL.3_H7]9_
M\ )/\*/^%AR?]"_K/_@!)_A77;/I^9HV?3\S3^JXG_G]_P"2H?MZ/_/M?>SD
MO^%B2?\ 0OZU_P" $G^%'_"Q)/\ H7]:_P# "3_"NMV?3\S1Y?T_,T?5<3_S
M^_\ )4+VU'_GVOO9R/\ PL9O^@!K/_@!)_A6CH/BXZS<-%_96J6@ SYEW:F-
M3^)K<VAOX/U-#194+U'N<UK"CB(S]^K=?X4*=2G:T:>OJ6*6DI:] Y HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ;MK$L]"N+?Q5JFIL\9@NK&UM44$[@T3W#,3QC&)EQSV/3ONT4[O832;3
M"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***2@#XY9@?^"@V[//7;WQ_9>,_3/'UK["
M7(SGFN?_ .$T\/GQ(- _MS3/[>VY.E_:X_M.-N[_ %6=WW>>G2MU<EE/;'-=
MV,Q4\1[*\+<D8Q];=3CP]-4N>W61/2T45PG8%%%% !1110 4444 %%%% !11
M10!&5SFO%/#OPFU+5L3ZDWV&U/2'<1)^(QC]:]NIBQ\Y+%O;M7%B,)3Q/+[3
MH=N'Q=7"J2I.U_T,70_!NF>'8@+&U1)0-OG,,R$>FX]O;I[5LK$>K,6]NU2T
M5U0IPIZ05CEJ3E5ES3=V)MHQ2T59 4444 %%%% !1110 4C?=-+10!\R?LM2
M#_A;?QO PW_$\W?*P8$>?=<\'WKZ8QMK!TOQ-I.L7%_!IVHZ?>W=B_EWMM:W
M2226K88[9-I.ULAOO;>A]*WCG'%=.*K.M4]HUV_!6.>A35*'*G<?124M<QT!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "5
MQ'QBWR_"/QNJ1.S'1+U551DL3;O@ #OSBNV6J&H74-G:W,]X4@M(HC)+/(1L
M P=Q/L *JG*TXLRJ+FC8^=OV#VQ\)=7(^;=K<K#:1ROV>WYZ]*^F%/>L+P_X
MFT?Q5:RW&@ZC8:Q9[]LES8W*7$>X 94E"><8XK<SUK?%5G7KSK25F^A&'IJC
M2C3O<DHHHKF.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"-N01ZUXO^UT2W[/OB=5!9V^R[4Z,W^E0G@'%>T-WK)U76+'0
M]-:\U:^MK"SCV[[J\D6&)>>,EF '.*UH5'1JPJ)7LT9U(>TIRB>6_LBDK^S[
MX85@5=?M6Y.K+_I4QY S7M"\ #TK)TK6+'7--6\TF^MK^SDW;+JSD6:)N><%
M6(/.:UE[45ZCK59U&K7;%3A[.G&-[DE%%%9&H4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C?=/TI:0T"/CG_ ()]
ML%_X3@X)!^QA3C[V/M&<5]B=JY_PUXR\/>*_/_L+7--UCR0OFG3[I)PH.=N=
MA/7!_*M]2>:[<=B)XO$SKSARMG-AJ:HTHTT[DE%)2UQ'4%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!'Y9_R:/+_P YJ2BE9"LANVC;3J*+(8W;1MIU%%D
MW;1MIU%%D W;1MIU%%D W;1MIU%%D W;1MIU%%D W;1MIU%%D W;1MIU%%D
MS:3UI-K#IC\:DHIK0-+W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I#T-+24 ?&ZE_^'@'W#Y>[_6?-_P! GIUQ[U]B]NE>7_\ "AM!_P"%
MR#XD&\U'^W"/^/??%]F_X]_(SMV;_N?[76O358Y53U->EC\33KNER:<L8Q?F
M^YPX6G*ES\SO>1-2TE+7FG<%%%% !1110 4444 %%%% !1110 W::-IIU% K
M!1110,**** "BBB@ HHHH **** "D;[II:2@#YB_9C5?^%O?&TJ^[_B=[F9>
M/F\^[&#CKU/7/2OIDL0HQ7G_ ('^$>D^ ?$'BG6]/DOI[_Q'=B[NH[R2-XX)
M/WC?NL(-HS*_][K]:]"/%=6+JQJUO:15E_P#EPU.5&%I.XZEI*6N4Z@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!M<3\9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %)2T4 ?,S?%KQ8/VQ/^$(.KG_
M (1K&/[/^S18_P"/#SL^9MWY\SWZ5]*[0>>XXKYJ_P"%3^*O^&QO^$Y_LEO^
M$7_Y_O/B_P"@?Y7^KW;_ +_R_=_3FOI3=@@?C7IYA[!^Q]BEI"*?^+K\S@PO
M/>IS_P VA+124M>8=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2'H:6D/0T >#_ /XA>(?&7Q&^*FF:QJ#7MAHNJ_9+"%
MHXU\J/SKA<91%)X0?>STZU[O7A7P%^'^O>"_B)\4-4U>P-M8:[K'GZ=,LJ2"
M:/S;A]V%8E>)%^\!S7NU=>,<'5_=[:?D<N&YN3W]Q:***Y#J"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;7)_$S5KWP_\
M#GQ7JEDZQ7]CI=U=6\G4"1(&8$CZBNLSTKD_B=I]QKWPY\5:780M<7][I%U!
M;PCY2[O$RJ,G ZD?G5TK<\;[&52_)H>:_LE?$+Q%\2OAWJ>I>(M0.IWT>JO:
MK*8XX?W8@A8<1HHSEF_.O=1FO"_V2_A_K_PQ^'5_IOB33FT^_N-7DN%A$L<I
M\LQ1("2C$=4;OTQ7NM=6.<'B9^R^'H987G5"*GN.HHHKB.H**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 81Z_C7E_[1WBS5
MO ?P=UW7=$N1:ZK9_9_)F$:,/FN(D;(=6'1C7J'7'O7F7[1WA'5O'?P<\0:'
MH5F;[5+D0^5!O6/=LGCD/S.0.B'OUQ6^&Y/;T^?X>97,:R?LY<NXS]G'Q9JW
MCSX.Z%KNMW(NM5O/M'G3&-%'RW$J+@(JCHHKU #T_"O,OV<?".K>!/@YX?T/
M7;,V.J6PF\V#>LFW?/)(/F0D=''?KFO3>F?:C$\GMZGL_AYM HI^SCS;DE%)
M2U@;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2-]T_2EI&^Z:!/8^9_V._BSXM^*7_"5CQ-JW]J&Q^S?9C]FBAP'
M\[.?+4?W5_*OI;FOFO\ 8Y^$_BOX6MXK_P"$GTDZ;]L-L+?_ $B*7?L\W=]Q
MSC[XZ^]?2OK7I9DZ,L5-X=)1\O0X\'SJA%5-QU%%%>:=H4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 SS.6&UC@C\<TZLKQ%>7.GZ+J-S9
MQ^9=0VLDD*==S $BO'/^%K?$O_H4!_X)[O\ ^+H ]XHKP?\ X6M\2_\ H4!_
MX)[O_P"+H_X6M\2_^A0'_@GN_P#XN@#WBBO!_P#A:WQ+_P"A0'_@GN__ (NC
M_A:WQ+_Z% ?^">[_ /BZ />**\'_ .%K?$O_ *% ?^">[_\ BZ/^%K?$O_H4
M!_X)[O\ ^+H ]XHKP?\ X6M\2_\ H4!_X)[O_P"+H_X6M\2_^A0'_@GN_P#X
MN@#WBBO!_P#A:WQ+_P"A0'_@GN__ (NC_A:WQ+_Z% ?^">[_ /BZ />**\'_
M .%K?$O_ *% ?^">[_\ BZ/^%K?$O_H4!_X)[O\ ^+H ]XHKP?\ X6M\2_\
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M />**\'_ .%K?$O_ *% ?^">[_\ BZ/^%K?$O_H4!_X)[O\ ^+H ]XHKP?\
MX6M\2_\ H4!_X)[O_P"+H_X6M\2_^A0'_@GN_P#XN@#WBBO!_P#A:WQ+_P"A
M0'_@GN__ (NC_A:WQ+_Z% ?^">[_ /BZ />**\'_ .%K?$O_ *% ?^">[_\
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M">[_ /BZ />**\'_ .%K?$O_ *% ?^">[_\ BZ/^%K?$O_H4!_X)[O\ ^+H
M]XHKP?\ X6M\2_\ H4!_X)[O_P"+H_X6M\2_^A0'_@GN_P#XN@#WBBO!_P#A
M:WQ+_P"A0'_@GN__ (NC_A:WQ+_Z% ?^">[_ /BZ />**\'_ .%K?$O_ *%
M?^">[_\ BZ/^%K?$O_H4!_X)[O\ ^+H ]XHKP?\ X6M\2_\ H4!_X)[O_P"+
MH_X6M\2_^A0'_@GN_P#XN@#WBBO!_P#A:WQ+_P"A0'_@GN__ (NC_A:WQ+_Z
M% ?^">[_ /BZ />**\'_ .%K?$O_ *% ?^">[_\ BZ/^%K?$O_H4!_X)[O\
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M .%K?$O_ *% ?^">[_\ BZ/^%K?$O_H4!_X)[O\ ^+H ]XHKP?\ X6M\2_\
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M7_T* _\ !/=__%T >\45X/\ \+6^)?\ T* _\$]W_P#%T?\ "UOB7_T* _\
M!/=__%T >\45X/\ \+6^)?\ T* _\$]W_P#%T?\ "UOB7_T* _\ !/=__%T
M>\45X/\ \+6^)?\ T* _\$]W_P#%T?\ "UOB7_T* _\ !/=__%T >\45X/\
M\+6^)?\ T* _\$]W_P#%T?\ "UOB7_T* _\ !/=__%T >\45X/\ \+6^)?\
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M* _\$]W_ /%T?\+6^)?_ $* _P#!/=__ != 'O%%>#_\+6^)?_0H#_P3W?\
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MUOB7_P!"@/\ P3W?_P 70![Q17@__"UOB7_T* _\$]W_ /%T?\+6^)?_ $*
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MA0'_ ()[O_XNC_A:WQ+_ .A0'_@GN_\ XNH-#WBBO!_^%K?$O_H4!_X)[O\
M^+H_X6M\2_\ H4!_X)[O_P"+H ]XHKP?_A:WQ+_Z% ?^">[_ /BZ/^%K?$O_
M *% ?^">[_\ BZ />**\'_X6M\2_^A0'_@GN_P#XNC_A:WQ+_P"A0'_@GN__
M (N@#WBBO!_^%K?$O_H4!_X)[O\ ^+H_X6M\2_\ H4!_X)[O_P"+H ]XHKP?
M_A:WQ+_Z% ?^">[_ /BZ/^%K?$O_ *% ?^">[_\ BZ />**\'_X6M\2_^A0'
M_@GN_P#XNC_A:WQ+_P"A0'_@GN__ (N@#WBBO!_^%K?$O_H4!_X)[O\ ^+H_
MX6M\2_\ H4!_X)[O_P"+H ]XHKP?_A:WQ+_Z% ?^">[_ /BZ/^%K?$O_ *%
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M/_"UOB7_ -"C_P"4>[_^+K?$QIPJRC2=T8T>;D7/N>\T5X/_ ,+6^)?_ $*
M_P#!/=__ !='_"UOB7_T* _\$]W_ /%U@;'O%%>#_P#"UOB7_P!"@/\ P3W?
M_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM
M;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/
M_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q
M= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#
M_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7
M_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\
MP3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 7
M1_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_
M]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=
M_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O
M%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"
MUOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"
M@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?
M_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM
M;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/
M_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q
M= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#
M_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7
M_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\
MP3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 7
M1_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_
M]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=
M_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O
M%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"
MUOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"
M@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?
M_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM
M;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/
M_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q
M= 'O%%>#_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#
M_P#"UOB7_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7
M_P!"@/\ P3W?_P 71_PM;XE_]"@/_!/=_P#Q= 'O%%>#_P#"UOB7_P!"@/\
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MW_.:-O\ G-.HH ;M_P YHV_YS3J* &[?\YHV_P"<TZB@!NW_ #FC;_G-.HH
M;M_SFC;_ )S3J* &[?\ .:-O^<TZB@!NW_.:-O\ G-.HH ;M_P YHV_YS3J*
M &[?\YHV_P"<TZB@!NW_ #FC;_G-.HH ;M_SFC;_ )S3J* &[?\ .:-O^<TZ
MB@!NW_.:-O\ G-.HH ;M_P YHV_YS3J* &[?\YHV_P"<TZB@!NW_ #FC;_G-
M.HH ;M_SFC;_ )S3J* &[?\ .:-O^<TZB@!NW_.:-O\ G-.HH ;M_P YHV_Y
MS3J* &[?\YHV_P"<TZB@!NW_ #FC;_G-.HH ;M_SFC;_ )S3J* &[?\ .:-O
M^<TZB@!NW_.:-O\ G-.HH ;M_P YHV_YS3J* &[?\YHV_P"<TZB@!NW_ #FC
M;_G-.HH ;M_SFC;_ )S3J* &[?\ .:-O^<TZB@!NW_.:-O\ G-.HH ;M_P Y
MHV_YS3J* &[?\YHV_P"<TZB@!NW_ #FC;_G-.HH ;M_SFC;_ )S3J* &[?\
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M3J* &[?\YHV_YS3J* &[?\YHV_YS3J* &[?\YHV_YS3J* &[?\YHV_YS3J*
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MHV_YS3J* &[?\YHV_P"<TZB@!NW_ #FC;_G-.HH ;M_SFC;_ )S3J* &[?\
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MS]!0!UGF#< .3C(Q^M/KPKX@:YJEE^RK8ZS;ZI>6VJ_V5ILKZC%._P!H+.T
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M9S@<]J%NHV<(&!++N7D?,,XR/7M^8H FHJ+[0FYE!W%>N,?E[=1U]12?:DW
M$-DJ&Z9Z_3\,^F10!-14#W:Q[B5;8I^9^-H'/.?3(Q[?3FA;M&Z!B",J<?>'
M<@=<?SR,9H GIBR!E) ) [^OTKG_ !;X\T[P8^BI?1W$K:MJ<.DVXMU5L2R9
MP6RPPHVG)Z^QJKX_O->M_#5]=>&;&UU'6HQ&;>VO"OE-B12P+%U ^4G'(Y%
M'4B8,,A6;G''UQ^E25A^';R^N=!TW^UHTM-6>TBDO(874^7.5&]<@XQN)QZX
MK8\Y=P4<MC..,X^G6@"2BH_.!5F )4=^,'C/%(MU&R@[N#GW''7GVH EJ/SA
MP3P#T.1^7^?2L#PCXZT_QHVN+81W$9T?4YM*N//51F:+;N*X8Y4[A@G'?@5C
MZ;JWB^X^)&I6]WI5K#X*AM?-LK_(-Q++B/@XE.!\TWWE7H* .[HJ)KA8V4.&
M0L=H!'7KZ?3/L.32"Z1L%0S KN#*I8$9[$<4 345 MY$QC!;:TGW%;@G@D<?
M0$_@?2E^U)QSDG@#CD^E $U1?:$&_G[@W-CG YY_0TGVI-V.1]>.V>G7^O->
M:_&[4;[2_P#A OL5[<6AN/%MA;3^1*R>;"_F;T;!Y4\<>U 'J%%%% $7VA H
M)^7.#R1_.I:\K\$ZQ?7'QB^)MA=7=Y);6JZ8UK:RRMY40:W)?RDS\NYASC/(
MKU#S1MSM8CC''6@"2BHFN%C90X9"QV@$=>OI],^PY-"W*-D(=YZC:1\WT]:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'9"&=BC",+G:H#X&6./6O"O@B^T/XE>./$,\MN]EKGV'[-'&S&1/)B9'W@J
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M=[H$6GMJ-]9>&HMTMZLC/"(I5RK)$ KAB&.[S NT'#5SOAYK7PSXT\.2> ?
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M@"D<;3G)&!C&:L?$WP3?>-/^$5^Q2V\7]E>(+359_M#,-T46[<JX4Y8[A@'
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MT#4=*E>2>WFC?=ME!8L5DC ..1G/7)</TOP]P/C;\5D:)XU4Z40[.Q#9MV/
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MP(P.N20 _9GU:XOO VK6=U-=R66E:O=:;81ZD L]O:QJI2*3!.70'!R>.BX
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M/.0 JAN<<'VCQQH<_B;P;KND6KQQW-]87%K&TQ(0-)$R*6(!.,L,X!K-\/\
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M>(?!OASQI8:[;S0WD7C"^BF%O=_-@S2/(_SI*#S\B!]P#?*VQO=OCY_S3O\
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MYR.B,_92].U'X8^+O!_BK4=6^'E_I*VNL.\]_I?B!IW@2X;;^^CV98EMO()
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MP?U#6?A_X<T/POJ$5A?>')[2?3[C4/G5V@C:)/,PA' 8-]T@L.@ZT <Q\:O
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M/2;?^%> C<#XPTY!ARI4'S,\C[P]C7 ?$WQ0OB7XK:MX?UK2?%GB#PUHMK!
MVC>'83-'=S31K+YMP5*, ,J%0EANC#94;E/L?Q-\$WWC3_A%?L4MO%_97B"T
MU6?[0S#=%%NW*N%.6.X8!P/<5@>+?AIXDL?%TGBKP'?V%GJE]&MOJ=CK#RM9
M7:(A6)]J?,KJ,#@_E\V\ \^^&LBZ9\5-'MO"OA'QGX9\,W$=U#J5MKMM<)8K
M+M5XKB/<[?O2T9B)+ ;2%"G[U4?%NC:';^//$MS\6O#VJZGIK3O/IWB*&2ZD
ML8;$C]W"ZPD>64<E5P"6:4GIM=O:?!>C>/?[6FO_ !=K>DM!Y#6\6DZ+;/Y
M;<I6X,LA\S?C<I7[N,'.:P-:T/XQ0WVNPZ/K?AJ[T^[DE>QNM2CECN+-6'R(
M$1#&?+/1FW%CDL#PJ@'?>&X[>'0=.BM+^35+>.VA6*\:X$\EQ&H^65I!]\L.
M2>AR:W*\CN/A?XM\'?#/0_#GP_UZTL=3L)6>:_U*-2LZN)'D4+Y;[ TKJW<@
M#&3W]<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+_ (0S2_\
MA+/^$D^S?\3C[!_9OVK<=WD;]^S'U[]:W:** "L'P]X-TWPHNI_V7;^0=2U"
M34[C+D[IY-OF-^..G2MZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*PM3\&Z7K&N:/K-W;>;J6DF8V<V\CRO-&U^._'K6[10 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS#_SH/JV(_Y]O[F==N/I1N/I7(_\+4\,?]!'_P A2?\ Q-'_  M3PQ_T$?\
MR%)_\31]<P_\Z#ZMB/\ GV_N9UVX^E&X^E<C_P +4\,?]!'_ ,A2?_$T?\+4
M\,?]!'_R%)_\31]<P_\ .@^K8C_GV_N9UVX^E&X^E<C_ ,+4\,?]!'_R%)_\
M31_PM3PQ_P!!'_R%)_\ $T?7,/\ SH/JV(_Y]O[F==N/I1N/I7(_\+4\,?\
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M1N/I7(_\+4\,?]!'_P A2?\ Q-'_  M3PQ_T$?\ R%)_\31]<P_\Z#ZMB/\
MGV_N9UVX^E&X^E<C_P +4\,?]!'_ ,A2?_$T?\+4\,?]!'_R%)_\31]<P_\
M.@^K8C_GV_N9UVX^E&X^E<C_ ,+4\,?]!'_R%)_\31_PM3PQ_P!!'_R%)_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M )Z_^.?_ %Z-HHVB@ _>?\]?_'/_ *]'[S_GK_XY_P#7HVBC:* #]Y_SU_\
M'/\ Z]'[S_GK_P".?_7HVBC:* #]Y_SU_P#'/_KT?O/^>O\ XY_]>C:*-HH
M/WG_ #U_\<_^O1^\_P">O_CG_P!>C:*-HH /WG_/7_QS_P"O1^\_YZ_^.?\
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M_P"O1M%#+LV;E9?,.%RI!)],=:/BV*O&.X?O/^>O_CG_ ->C]Y_SU_\ '/\
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MHH /WG_/7_QS_P"O1^\_YZ_^.?\ UZ-HHVB@ _>?\]?_ !S_ .O1^\_YZ_\
MCG_UZ-HHVB@!/WG_ #T'_?)_QKZA7.P<\XKY?VBOJ!?NBOJ\A;_>>1\7Q!_R
MYT[DM+24M?7GR 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?AWXAT;XO_#"ST_3?$>EWFEZ?JFAS*T5O/):3*H=/.E4AC(C*-T;*J2$!]I
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MH%^Z*^KR'_EZ?%\0?\NO^WB6EI*6OKSY **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HJ-9E<(5!96_B X'UIOV@>7O*D #)Y7Y3Z'GK0!-113%DW;2%;#>HQ
MC\* 'T45&9MJJ2I&<9R0,9]>: )**8LRL"0<C_9Y_E3Z "BHOM4>Y5W#+?=&
M1ST_QJ6@ HHI@D!P,,"?4&@!]%%% !1110 45%]H3/4_=WYP<8]:EH ****
M"BBB@ HIBR;MI"MAO48Q^% DX!VL/EW=.GM0 ^BBB@ HHHH **** "BF+)NV
MD*V&]1C'X4"3@':P^7=TZ>U #Z*** "BBB@ HJ+[5'N9=PROWAD<=?\ "I:
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M#CGC/TH DHIC2;=Q*MA?09S^%/H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR1NK.TF[/^L.X<J,\'CJ!T ]\TT0H&+ ;9';S'8 \OQ@\$'C QD_PCVPN/\
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M45]>?(A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%6.YBJ.0O &<8RRUY;\6/ ;:Q\<? BCQ-K]BNMF^&RSO=HL_*MD/^CY7]WO
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M;XF?#NPUK7OB!XB@A\R7^SX])OOL\NSS")!/(5+2Y=3M#%MHZ4 ?2BRAMW#
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MQP\SJ@5I"/5NI^M &O1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_O.._P"%4>&_^@<?_ J7_P"*H_X51X;_ .@<?_ J7_XJNQHH^JT/Y$'UJO\
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M''_P*E_^*KL:*/JM#^1!]:K_ ,[^\X[_ (51X;_Z!Q_\"I?_ (JC_A5'AO\
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MH_X51X;_ .@<?_ J7_XJNQHH^JT/Y$'UJO\ SO[SCO\ A5'AO_H''_P*E_\
MBJ/^%4>&_P#H''_P*E_^*KL:*/JM#^1!]:K_ ,[^\X[_ (51X;_Z!Q_\"I?_
M (JC_A5/AO\ Z!Q_\"I?_BJ[&BCZK0_D0?6J_P#._O.._P"%4^',_P#(.X_Z
M^I?_ (JNN"D<8&*?16U.E"G?D5KF-2I.K;GDW8****U,PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH YKQ]X(MOB'X3O_  ]J%Q<6]G>[!)+:2!)1M=6X)!QRM=!Y3*H5
M7..^XY./8U+10!PW@R_\8W?B+Q)'XFTRUL-*@N1'HUQ9N/\ 2H<R<R#S6(."
MG9>0?:J?QX\,:IXV^%.LZ)HUFUWJ5SY/EPETC'RRHY^9B!T4]^M=]]G.[<&*
ML1\VW'S'U/%.$9\M48(R_P 7''Y4 2UY'\6-+\4GQYX#\0>'?#Q\0QZ0+\7%
MJMZEH?WT2HOSN?53GBO7*@:)F49"Y;&[G\\<4 >)>(+CXK_$:QDT(^%K'P18
M7<+)>:K>7Z7KQQ,55EB$9^]LW9SC=G&4^]6A\3/AC>W7PMTGP/X8M$73IKFV
MM+R?:HDB@5_,:Y(#)D^8JLXZOO?N<UZ^L.WG.6QM&0.GIQBFF ]!MVG=N##.
M[/\ GI0!RG_"H?!BM\OA+0>G\6F0$9'3C9^N<US'P9\)Z_X!NO%.AWMDMOX6
MBOQ<Z%-'=-*3%(6S%M9BR+&JQY! R6<\]3ZS4*P;23M0%NOR\GUR>^: .6^(
M7P_3X@>&YM*DNGTV=7CFL]0M^9;2:,AHY4!Z,#G)4J<<9YKC+/Q5\5O#EC#9
M:AX$M/$MQ!'MFU>SUN&VAN#_ 'C')&&4_A7L51JKKMR5]^I/YYH \U^&OPKO
M_#^O:[XK\2W-GJ7BO7"L=PUI'MAM8%&U(H7*B3& ,Y]%'5=S6/A#X=U/PS_P
MFAU.T:U&H>)K[4+;+JV^!]FU^">N#QUKT:H! >AV[1MVA1C;C_/2@#Y_\;2>
M)O\ AI:VE\*"QN+^T\,1O=Z?=R[#>6HN9-T:MM(5MS)ANF0<G^$[MGH?C/XD
M>--(N_%7A^#PIX<T*X34DT_[4EW->7HW;)#+$5VK'N& .OS;P^X;?13X(MCX
M[/BPSSG4!IO]EK$& B\OS/-W$8^]N[],=JWEB95. N5SMY_+/% ' ?\ "-ZG
M_P +Z_X2+[(W]C_\(S_9_P!IWICS_M6_9C.?N]\8I/&7AW4]8^+'P\UNTLVF
MTS2?[2%[.'0>5YD*)'\I.YMQ!^Z#7H/E-YF["?ESC'3/UH:#<0=J$KT^7D>F
M#VQ0!X/;Z+X_^%_B3QI_PC'A"Q\46FO7DFK0:F;J*V,;R9S%*C,#(%)R/F&?
MF^[O^7I_@7X3\0>%](\4KXBMH[&_U#7[S4"UJX:.19%0>8@ZA,KP" >F0*]2
M:'=SG#8VG '3TYS31 >AV[1MVA1C;C_/2@#@?@/X8U3P3\*=&T36;-K34K;S
MO,A#I(/FE=Q\RDCHP[]:3X0^'=3\,_\ ":'4[1K4:AXFOM0MLNK;X'V;7X)Z
MX/'6O03&?+9%"*O\/''Y4T0'H=NT;=H48VX_STH X'X\>&-4\;?"G6=$T:S:
M[U*Y\GRX2Z1CY94<_,Q Z*>_6L*Z\=?%JZVP67PUM-,N)FVI>ZCKD4]O%[O'
M&%?'TR:]=$9\M48(R_Q<<?E38[<QMNR=S+SEV(S[ F@#A?A'\,)/A]HMY)J-
MS!J/B35KB2]U2_@A6(/-(2S(FU5)123C(&268!=VT1_ ?PQJG@GX4Z-HFLV;
M6FI6WG>9"'20?-*[CYE)'1AWZUZ+41C/ELBA%7^'CC\J /&]6T3QIX%^)WB+
MQ#X;\/P>*M-\30VYGMUNDLY[2:",1@AW.UE*CTSG;TV_-7\$>&/'C?&JZ\6>
M*;&S@T^ZT-[2U6TG5ELD,T4BV[?=+/\ *Y+8*Y/#=A[4T3,HR%RV-W/YXXH^
MRA6)!R3P<X^[Z=.E 'S3I_AWQ/XE\4_$5-$TSPAXCT5M?9I[[Q7:R2N]PD87
MR,#>0D"L%4E0,$E3ABH[SX6>)-7TGQ->> O$?A[2=+O;6S_M2PET"(I836YD
M ;$9Y5EE+= 2<9]&?0UWX :1JGB:_P!;TW6M=\*W6I &_7P_?&UCNG!)$CJ%
M.7R3D]#EN,NQ.SX)^$FC^!;J6^MWO-4UB=!'<:OJETTUW,H/ 9L  !0BX4 $
M(H/3D I?'CPQJGC;X4ZSHFC6;7>I7/D^7"72,?+*CGYF('13WZUA77CKXM76
MV"R^&MIIEQ,VU+W4=<BGMXO=XXPKX^F37KHC/EJC!&7^+CC\J;';F-MV3N9>
M<NQ&?8$T >:^"?@JFB^"M>TO6[Q=2UCQ,LYUK4X55'=ID*LD?R_=7<V,]RS8
M&XJ.>\/W7Q0^'6FIH)\(P>+;#35^SV.JP:I#8 VZD")9(W))94XSW]SR?<JC
M577;DK[]2?SS0!Y]JMU\0['P=IMQ#I.BZOXE2?.H6%K*\5N\1+Y$#R8P^-GS
M/D EN#P*Y;P[X>\8>*OBU8^+-6\,6?@:VT^UDCNH8;F.ZGU61P%022Q@91%5
M&&02K(.#P5]I$9\M48(R_P 7''Y4U8F53@+E<[>?RSQ0!Y#-X9O=&\1?&;6K
MJ630=-U;3;8VVL6[B5T\JT=9)%C4E@8RPZJ,]JX'P3X*\<^(/ ?AR5_"OPXF
M@_LV.*V.L6,LUQ)"<LI?;N53(/WAP3R3QN8J/I:XTU+VTGMKE(;F"6/RS%/'
MYB,I&"K _>'UZUY9#^SC::?";72O&GC'1]-4R>3I]CJ_EPPJQW;5!C) R3W^
MN: .>\0:KKGQT^!?B/2X]"CMO%5K>KIMWIRRHR)=0SQ-(T;E@I&PYZ\-E<OP
MQ]9^(UG<:UX"\2:;90M/?7.F7$,4"X!9I(G11SQU-3>$? ND> ]%32= L8;"
MP1BXC&26) W%F.2Q.!R3V Z "MWRF92K.<=MIP<>YH \)U_X:^(5\-_"W5M)
MTRTU75_"EI$MSH]VZ;+G?%&K;)"=@=&CW*W8[6YV[&6RT_XB^+OBQX3U[Q!X
M4MM%T;2VO$2&"]2:YA,MKAFD<-M(9AA=@7&XYQW]T,!V;=[=,=NGTQC]*:MN
M54'*B3;\VT !F['IVH \J^,'AWQ9+XH\&^*/"NEVVNW6AO=";39;A82WG)'&
M2K.0.%#]2.H_!/&FE^*/'FC^ Y9/#O\ 9NH:;XEM-1O[%[Z.;R((M^Y_,RN[
MJ,;<DUZQ)$[+@2%1MQQC.?7)%-^S[AM9%"J?D"GI[XQQ]* /+?B)X.\36?C;
M2_'/@Z".^U:UMO[-O='N)5C2[M#)YN$=N$??[_W3G"LLF;K&C^-_C!#;Z)XC
M\,VOA'PNES#+JEM-?B]DOXHR'2&,Q;=@+JNXYS@#'0@^SB,^6J,$9?XN./RI
MJQ,JG 7*YV\_EGB@#@/^$;U/_A?7_"1?9&_L?_A&?[/^T[TQY_VK?LQG/W>^
M,4GC+P[J>L?%CX>:W:6;3:9I/]I"]G#H/*\R%$C^4G<VX@_=!KT'RF\S=A/R
MYQCIGZT-!N(.U"5Z?+R/3![8H XJU\57U]\5M1T."&RDT;3M(BNKNX49N8;F
M61Q'&V&R T4;-]W/3/49[NL?2_#%GHDM]+91LLM]=&[N9)YGF9W*HN<N20-L
M: *, ;1CI6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!YU\;O#NM^*OA?KFD>'[=WU:\B6)%258CL,B-(NXE1AD
M5EZ]Q[US\/C#XC6MO!;V_P (H[6V@B\J."#Q':I'&!C;M7&T8VC''':O8!&?
M+5&",O\ %QQ^52T >-_"G0_%WA'P+XO:;1ET_4Y-1OK[1]&EFBDBB5T5HH$,
M9"K&'##"D<,3P:[GP!-XAN/#=I<>)]-M]-UQ_,^T6EH 8UR^5PP=@?EQU/7-
M=']G.T  *HV[54X"X/&!CTIYC/ELBA%7^'CC\J /._&/AO5-7^*?P[U>UL?M
M&E:3_:0OYMR#RO,A1(\(3N;<0?N@UZ*RNV[!7VZ@_GFFM!N(.U"5Z?+R/3![
M8J:@#PZXM_&_@KXJ>.-<TGP1_P )#IFN?8RMP=7AM-ODP[#D-D]>F!^5$W@O
MQI\6_$&D7'C33=.\-^&=/NEO/[%#1WEU=S(!Y:R/AD$?S39QSM?;C.'7VU5=
M=N2OOU)_/--CB=5P9"PVXYQG/KD"@#ROQ=\/;WQI\7O#5UJ.FVL_A71=/N)
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M:AXFOM0MLNK;X'V;7X)ZX/'6O03&?+9%"*O\/''Y4T0'H=NT;=H48VX_STH
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M5WBS_H&Z)_X#R_\ QVCZK4[!]8IGUGOHWU\F?\-7>+/^@;HG_@/+_P#':/\
MAJ[Q9_T#=$_\!Y?_ ([1]5J=@^L4SZSWT;Z^3/\ AJ[Q9_T#=$_\!Y?_ ([1
M_P -7>+/^@;HG_@/+_\ ':/JM3L'UBF?6>^C?7R9_P -7>+/^@;HG_@/+_\
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M/+_\=H_X:N\6?] W1/\ P'E_^.T?5:G8/K%,^L]]&^ODS_AJ[Q9_T#=$_P#
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M>M&:^3/^&KO%G_0,T3_P'E_^.U]8]:QJ4I4_B-8S4MA]%%%9%A1110 4444
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M\8$^%FJ>&[:[T:\U6/5OM"@V+[IHS'LV@1<"0GS!G++C!Y/2K_\ PLJ[\/\
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MBQN9<,<J=PP3@^PKS>U^.>N^(#=ZGX>\ WVM^$HY=D>K"[6-[E%^^T-NR[I
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M_&+Q!I_B/1M/\8^!I_"=KJSBRM=0344OE^T,/D1O+7 W'@'GG)X )&A\5/C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;IKZS/*LG&UX1$7(YYROKNKZ)\/Z!'X;T#3-(MI))+;3K:.V@:8@N51 BDD
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M5D_%KQII/Q>C@^'7A&YM]9N-7DC.IZA;QBY@L;5)$D,OF!U0G<5QAB"0R_>
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M<;H23%^S;>:=<>-?B1/HVL:CXATYAI_D:MJ\CR2R!8Y0V[<%+%64CA1QM R
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MLSIS7^H)HMNPO\P$KE2?DV+\N!UX/45].5DP^%],MM6N-5AL;6#5;E L][%
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M4\OR/MGDIYWE;MVS?C=M]LXSS4MYIL-]:RVTT44UO,ICFAD7*2(1@J1]/\*
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M 0#C*?,=IW=%X*T/2/@_\-K+QMK-HNKZQJ'E/I]I,,B-7<2*4QNRP4>9O."
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M!R,A3P3R!T^I'YB@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH :W6O$OVL/^2?Z;_V%8O_ $3-7MK=:\2_:P_Y)_IO_85B_P#1,U=&'_BQ
M,JOP'RAM%&T4;11M%?1GCAM%&T4;11M% !M%?1?[7GW_  G_ +MY_P"T*^=-
MHKU?X[?%?2?B>VB'2[>]M_L(N!)]L1%SO\O&-K-_<.<X[5QU$_:P:V-86Y'Y
MG<^%;,_&[X$MH*M:S:_I<L<2/<L8DCVO^[;* DJ("$RP.64Y'>N=_:4U*+1Y
MO#7A*S:26VT6V6XS(X;+!?+3<H  =0H(;TD(&WK7/? OXKVGPMU+5?[0M9I[
M&^AC):U56D$J$[1AF VX=^<YZ<5R'CSQ.WC'QIK&M_.([V<E$DP&6)0%C& 2
M,[43//7-8PI/VOD:NHG3\SVW_FSD_P"?^8A53]D?6(H]6\3V$K[)[F""Y@MP
MC<QHSJ[9QC'[R$]<X<<=0.5_X6MI/_"A#X(^SWO]J_\ /;8GD?\ 'UYW7=N^
M[Q]WK^=<'X/\6WG@GQ%;:U8Q0S7D1D)6ZW/&=Z%6^52O&&/&<=/2FJ<G2G%]
M[A[17@REK6C7?AZ^N]-U*%X+ZU9H2DC#/)QG.><]B,BOH/P%:OX5_9O\1W6L
MLMO_ &Q%<S0K(&8L)HU@AWC&?G?;@C(PR\UC:Q\7/AQXXEM]0\3>&=4;5$B$
M)%K-\B('+!0PEC+?4@5R?Q>^-%U\2%@T^UMOL.B6\QE$,QWRW#9(W.1C:#&6
M78,\N3N.!A2=2JE%H(\D=CT#]D+[WBS_ ';/_P!KU\Z[(VDA+EO+A^[$O"GZ
MUZM\"?BOI/PP;6SJEO>W'VX6XC^QHC8V>9G.YE_OC&,]Z\HVBMJ2:K3D]C.;
M3@O(^J/A?XBU&W_9_6Z\-0KJFJZ:952"9&93^]#X !3?B)@1M)R>/O9%>?-^
MU9XN5<FQT4$Y(4V\H)QUX,_&/0\UR?PN^*US\,[N[:*RAOK.Z*&:W9F1SLW;
M=L@/&"5ZJV0,'UKLM0\;?!W5-0NKZZ\+ZY)=W<SW,\@F90\C_>; N<#Z#BN=
MP5.;YXWN:>TN</\ $;XI:W\2FM$U:UM()-.\PHMK&\;98'KO=NNP5Q6T5VWQ
M<\?V_P 2O$4>H16<MO%#"+=$FD!,JK(S*[A1PVUNF3]>]<3M%=U&*BK)'--Z
MW/HS]D'[WBS_ ';/_P!KUX%K&@W.@ZQ_9VI1-;7=D0LMED#RV*[@K8..1R",
M@]B:]\_9#D13XN)8#:+0-DXQCSNOYBL>#XT>"/$6J:=KWBGPO>-XDL-BPW5C
M*7C 1_,5@K2+C]YE@I#8Z9(XKA51QKS:1TN/-"%V;WBBQD\)_LP6NB:TWE7U
MP4C6%P2S.\YG"-G&TA%<-G&&0XSQF#X+VZ#]GGQZ%SLD%\2C'('^AQ]*\Y^,
M7Q;;XH7UHD-A]BTZS$J())2TEP&*X9QT484?)\W4_-S6K\/_ (LZ1X3^%GB/
MPU=V][)?:E]H\J2%$,2^9;K&NXEP1RIS@'BI=.?L]M;W*YE[3R/)MHKZPD\=
M:UH/P+\/:[X8LH-7DMK:".\%R&*QI&A60X5E^[(!R,KM^;.WYA\G[17I_P )
M/C9-\-89K"?3H[[3+BZ^TNT1V3Q,5C0LI.58!%;"$#)(RX'3HQ$')*R,:+4=
MS6_X:J\6OD_V=HL@P"P$4NX'JO F.<GL.:X7QI\3-6\=>)+/6[F*.UOK:)(T
MDL3)$$(<21N<N<%2Y/TKT.P\;?!S2[^TOK3POKD5Y:S)<P2&9F"2)]UL&YP?
MH>*\S^('C!O'GC&[UW[,=.%P$S LOF,,(L9^?:O\*G^&HIJ/-=1*E==3V[XB
M>&6^,GA_P-K^FQM]JNIX]/O'M;5O]&4L?,D;(X2&2*5=IP#N/S<C/)_M+>)(
M[SQ=9:!:V:PVVBVQ"JF$^:55W#()7:$V*.,ALXXP:F^#_P >+'P+X4;1=9M+
MRY2W9C9M:+$<(PR8VSMP ^6!^8G=S]WGRCQ'K U_7-7OS"8UU"]>\,;.6(#.
MS%,^F=OY&E2IR]HE+9#J33BVNI[?\+=%T#P#\+9?'U]ICZKK&^18D*?>_?".
M)<,=H8M&&,A <;V]@=+X4_';Q+X_\=:;IDVGZ>VG2"1IYK2)]R*L;%6R9&P"
MVT?B!U.*X3X9_&R+POX<G\+Z_8MJ?AZ59(5^S*L<T<4@8NF 5#99NN01EN3D
M ;-I\>- \'QV.E>#= N--T5KR&YO9+N4S2E00)%C1G8;BJ( Q<=_E[UC.G4D
MW=&JG%(Y/]H;_DKOB+_MV_\ 2>.O1OVO?O>$O]V\_P#:%>/_ !4\66GCCQUJ
MNM6,<T5K=^3L2X4*XVQ*AR 2.JGO75_';XKZ3\3SH9TNWO;?["+@2?;$1<[_
M "\;=K-_<.<X[5T<C3I-=-S#F5IH]:F\=ZSH7P+\.ZYX8LX=7DM[:".]%T&*
MQI&A60X5E^[(,9&5V_-G;\P\S_X:J\6OD_V;HL@P"0(9=P/5>!,<Y/8<UD?"
M7XUS?#:&:PGTZ.^TRXNOM+M$=D\3%8T+*3E6 16PA R2/G Z;^G^-O@[I>H6
ME]:^%]<BN[29+F"0S,P21/NM@W.#]#Q7/R*FWS1N:\U^IYK\0/B!J7Q)UB+4
M=0M;6"=;:.TW6<;($CW%^2S'G$@/YU[+^U['SX1&2#B[)D_BX\G'\S7C/Q \
M8-X\\97>N_9CIPN F8%E\QAA%C/S[5_A4_PUVOQV^*^D_$XZ&=+M[VW^PBX$
MGVQ$7._R\;=K-_<.<X[5O[-\]-6,N;29I?LF_P#)1-5_[!LG_HR"O.?B7_R4
M+Q;_ -A.Y_\ 1DE;WP1^(6G?#7Q5>ZGJ<-U/!/:/;JMHBLP8M$<G<RC'R'OZ
M5RGB_5H?$'BK7-3MU=(+Z\FN(UE #!7=B V"1GYAT)K1)JNY6T8<R='EZGNO
M[7@9AX3<1OLQ=Y;;P,^1U].A/X&OG7RQN*@C( .&RN<M@]<=#UKWAOCOX6\8
M>%[+3/&^B:A?RVQ0L]JZD3LL8'F,0T>TLQ?*@8Z<]AXKK^I+K?B'4M4$"PF\
MO);OR6^=8P[9V#IQ1A>:"Y6A5I*3NBAM%?1O[3UO+XB\/>&O$&E0O=:5"LK2
MSA#M19EC:,LA ;##OC@X!Y(%?.6T5[?X%_:%M;/PO_PCOBK3)[RRCM&LTGLG
M&7B*A!&T>4 &P'Y@V1T]6)B%+G4X] IR5N5GC%GI=[J!N5M;*>Y>VC:69(5W
MF-00"S8^Z.2<G  !R17T'X>LY_%W[*MUIFE1?VC>6[./+CCQ@K=+/\N<;SY9
M#?+G)XZ\5R>J?%/PAH/AG6-*\%>'+JT?6+=K>\FU&9F7!!4':9'+':[]6&#C
M(;MS?PM^*US\,[N[:*QAOK.Z*&:W9F1SLW;=L@/&"5ZJV0,'UJ:BG4A>VP0:
MAN<3:V<][/#!!;S33S2K%''"AD+,W097('XGBOH;]H!8]%^$O@_PW<RJVKQR
M6T:Q0DAG,,)60JV!@*74Y..#GUJC:_%[X::1XAG\26'AK53K[&:;SI&"J\L@
M^8G,S!0?93CL*\J^(GC^^^(_B*;4[]%A4J(8+>,\11 DA2?XCDMD\9+>@"TX
MJ5>HFE9(:DHPT/8O@O;QK^SQX\ !VR?;LHQR!_H<?2OG7:*]8^'_ ,6-)\*_
M"SQ'X:N[>]DOM2^T>5)"B&)?,MUC7<2P(Y4YP#Q7D^T4Z*E%S;%4::270^C/
MVOO]9X3_ -V\_P#:%0_$AWUS]FKPGJ&EIYT&G&S\YP1$(MD;P/M#8)Q(=OOG
MCY>:Y#X[?%C2?B@VB'2[>]M_L(N!)]L1%SYGEXQM9O[AST[59^$GQZ_X0?1X
M=#UBSDO=,A+&*>T"+)%DL_"8"M\Q&,D8Y/\ LURQIS5--+5&SE%U'?9G&_"7
MP_>ZU\1O#\-G:S7\UG=VUU.PQMCBCE!9RV<8"G'N1@9R,]W^UB,?$32O^P;'
M_P"C)ZFTGXS>#_ MW;_\(;X;N-/@NIXSJ<ET6=S"FX!8U\XC< [88D =,'.5
MY+XW?$+3OB5XJLM3TR&Z@@@M$MV6[158L&E)("LPQ\X[^M;*,IUE)K0R]SV5
MNIZ9\9_^3>? WTLO_2.2H_V0Y%5_%)#*P9;/[KJ<8\_(.#U%<;\0/BSI'BOX
M6>'/#5I;7L=]IOV?S9)D01-Y=NT;;2')/+#&0.*R?@_\5F^&.K733VS:AI]X
M(Q<+'MC<LLA*R 8ZA21MS@GJ1UK-4Y>Q<;:FO-'VMSSS:V<%&SR>,'*\X88Z
M@X.,<\'BOHO=_P 8<X_S_P A"N ^)WCGPCXCT^ZC\.Z+?6MYJ.HKJ&H75Y*0
M92N_: -[\?O&^4;1TJU_PM72?^%#?\(3]GO?[5_Y[;$\C_CZ\[KNW?=X^[U_
M.M9J4U"RZF49*%[=3J_V1]8BCU;Q/82/LGN((;JWMPK<QHSJ[9QC_EI">N<.
M..H'AFMZ+=^'KZ[TW4H7@OK5FA,<C#/)QDG/.>Q&15WP?XMO/!/B*VUJQBAF
MO(C(2MUN>,[T*M\H*\88\=.GI7KNL?%SX<^.);?4/$WAC5#JB1"$K:S91$#E
ME4,)8RWU(IM2IUG-($U.G9[FSX#M7\*_LW^(KK666W_MB*YFA60,Q99HU@AW
MC&?G<+C&1AEYJ/\ 9!_UGBS_ ';/_P!KUY]\7OC1=?$E8-/M+;[#HEM,91#,
MV^6X;)&YV&-H,99=@SRY.XX&+GP)^+&D_"]M;.J6][<?;A;B/[&B-CR_,SG<
MR_WQCKWK!TYNF[K5FJE%5%V1Y3LC:2$N6\N'[L2\*?K7T;\9O^3>? __ &Y?
M^D<E?..T5ZQ\0/BQI/BKX6>'/#5I;WL=]IOV?S9)D01-Y=NT;;2&)/+#&0.*
MZ:R;=-I&--I)I]3G?!?C[Q5\+X8I["&6'2[HMMAOH',%PPPG&<9Y.<HV,@C.
M>*]@\.R>'?VDO#NKP7^CQZ+XBA6-I-0M@ [?*R(X;Y79/W9RC$C 'S9VD>?^
M"_BEX=C\%VGA7Q?H4VIZ;8RM<6T]HVURY8D;U#(#]]^00.@V]ZWIOCYH/A#P
MS-I7@/0KJRDF9YA-J,A=8)2%4.JEY"WRCH6 RHX.XXPJJ<G>,+,VA*-K2/"]
MHHVBC:*-HKTSC#:*-HHVBC:*8!M%?HW_ (5^<FT5^C?;\*\G';Q.S"?:'T44
M5Y1Z(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?'/[:FFZL?$V@ZC+--%HPLEMHY=P,8
MNO,<L"A8KN*E,'&/E//R@KUO[%^D:Q8^'=:N+Y+BVT:X:$6"S#8H*"3S=JC@
M9RF>!RI_NC'TGY3KG!7 'R@<#Z'_ !_R8TLQ'Y85(U1.%51M"_3 [_Y]P#D/
M!?POTOP/KGB+5;"2\DNM>G^U7BW#+L1M\C[5  XS*_7-<_\ M2?\D)\1_P#;
MM_Z41UT?@G0_&&GZUXA?Q%J]K>:3-/NTF"U #V\?F2'#D1)D[3&.K=#]2WXS
M>![_ .(GPUU;P]ILMO!>W?E;)+IF6,;94<Y*J3T4]J .?V_'#U\ _G>_X51^
M-USX1U"XTO2M>GUC69I;>>YA\)Z!([-JL68QOE1 "0A&5)9>C;=Q! ]FKR_Q
M]\._$DWCFP\9>#;_ $V'6([)M*N[+6D=K6:U+-(NUHQO1Q)M8X^]@#*X.X \
M^^!]W;:+\7-3\/>']%USPSX9GTD:D='\01/&Z7?G*GF(&=V*;..N,H?1<9GB
MW1M#M_'GB6Y^+7A[5=3TUIWGT[Q%#)=26,-B1^[A=82/+*.2JX!+-*3TVNWH
MG@7X9^-K/XER^+/%FM:9J#R:9+91Q6,906S-<K(J(I0;D"*?G8[LL1[U-K6A
M_&*&^UV'1];\-7>GW<DKV-UJ4<L=Q9JP^1 B(8SY9Z,VXL<E@>%4 Y7]H[P?
MHVH? Z/4_-?6[G1X+>.RU:6]:222*26&-Y)""JRF15YXYS\M=WIO@_PW\#]$
MU74_#/AK49$D$1N+33/,O+B?:Q50B/)G(\UB<=@>O K,U7X$C_A1+_#S3K]2
MZ6GE0WUTIQYGFK*1M&=B,P*\9VC'#5TGP]T_QU!:/'XUN-%N)H4A2WFTAYMT
MI"LLK3>8H7)^4C:H[YQ0!G:'XVL_BI]O\/WWA'Q-I5M<6+^>VM67V5)(W(5H
MPP?(;YNPZ \UYM\$O@WX-FU7Q+JEQH[27.B^++FVTR;SYP+>.W\OR@0&Y"D$
M;G!SWR.:^B_)82(5VK\V7]3P>.GKC\J\A\+_  Y\?^!O&^O3Z9J>@WWAC6]8
M;4[B&^25;B$2.ID$852-VP;1N8C]VAP-QP <?\.?@_I/Q&UGXA3>(GGU'2(?
M%-\D&C_:)8[=;E9 PN<*P/F;7"YSTS[8Z_XW7/A'4+C2]*UZ?6-9FEMY[F'P
MGH$CLVJQ9C&^5$ )"$94EEZ-MW$$#L/AEX)OO!?_  E7VV6WE_M7Q!=ZK!]G
M9CMBEV[5;*C##:<@9'N:Q?'WP[\23>.;#QEX-O\ 38=8CLFTJ[LM:1VM9K4L
MTB[6C&]'$FUCC[V ,K@[@#S[X'W=MHOQ<U/P]X?T77/#/AF?21J1T?Q!$\;I
M=^<J>8@9W8ILXZXRA]%QIZ3X'L/CEXP\6ZKXN\V\TS1]1FT33=%6X81Q+%M\
MVX)C96+N6'RD<8YW_)LWO OPS\;6?Q+E\6>+-:TS4'DTR6RCBL8R@MF:Y614
M12@W($4_.QW98CWI=1^&/B[P?XJU'5OAY?Z2MKK#O/?Z7X@:=X$N&V_OH]F6
M);;R"0/K\NP YWXP>#G\#_ 'QA8V^IW5]I[2PS6B7SF5K6$2VZBW5VQE%*/M
M)Y4$?>ZU8TO2[?X^>+IKS7[J%=$\-W\MN?!C@,1<([(DUV<[6R5;"+N3IACA
MPVOXF^%'BSQ5\)]?T+5-8T[4=?UBXAN0?+>"SL50PG[/$ &9D0QN58@$E@2
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M!XV\&?$FUTR_\$6$T_Q(N;BVNM/>WLWBGAE!20M<;ML;[8T((8R!2Q(!!)H
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M?*,[\<XP, '.>-_ <?CG]I6SL+J^GL].3PINN[>R9HC=VYNI%-NS!N(VW)N
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M/*D;3@\XQSTK0\MMI!VODY^8^IY'Y5+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!%Y;;0!M3!S\I]#P/RIGV0?WL8.1M&,>N,>O^?2K%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!#) )-X*KRNP$\\'KD5Y?=?LQ_#J\N);EO#,$4TN\R"WN9X5?)W8PC@!0>@
M P!P !Q7JU% &=H^C6NA6,5E86=K86</^KAMHPB>YV@ +^%:-%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"8-9FL>&].\06Z6^IV-MJ=NC[UAO(5E0'!&<,#V)K4HHZW%;2QR__"K_  ?_
M -"IH?\ X+8?_B:/^%7^#_\ H5-#_P#!;#_\374457,^X61R_P#PJ_P?_P!"
MIH?_ (+8?_B:/^%7^#_^A4T/_P %L/\ \37444<S[A9'+_\ "K_!_P#T*FA_
M^"V'_P")H_X5?X/_ .A4T/\ \%L/_P 37444<S[A9'+_ /"K_!__ $*FA_\
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M_P#P6P__ !-=111S/N%D<O\ \*O\'_\ 0J:'_P""V'_XFC_A5_@__H5-#_\
M!;#_ /$UU%%',^X61R__  J_P?\ ]"IH?_@MA_\ B:/^%7^#_P#H5-#_ /!;
M#_\ $UU%%',^X61R_P#PJ_P?_P!"IH?_ (+8?_B:/^%7^#_^A4T/_P %L/\
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M_P#PJ_P?_P!"IH?_ (+8?_B:/^%7^#_^A4T/_P %L/\ \37444<S[A9'+_\
M"K_!_P#T*FA_^"V'_P")H_X5?X/_ .A4T/\ \%L/_P 37444<S[A9'+_ /"K
M_!__ $*FA_\ @MA_^)H_X5?X/_Z%30__  6P_P#Q-=111S/N%D<O_P *O\'_
M /0J:'_X+8?_ (FC_A5_@_\ Z%30_P#P6P__ !-=111S/N%D<O\ \*O\'_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>krys-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krys="http://www.krystalbio.com/20210930"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krys-20210930.xsd" xlink:type="simple"/>
    <context id="ic410ffc714874120b71c8155d66af84b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1dc32338fed74c97ac6221ff6cb01741_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i62b974e3062741518c63511eaaa01aa5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iebef65754afc438aa569cd6c2fec349d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9aa15eaaa2f140849a241da763e04fb2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3709c8cd63614284a9610906266d0ebd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2061c660b06d4c9bbc11d16373c8f063_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i191055abec7b4144af0047f02b74e20e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ae7f575f30640149beff34d2c2f617e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i321a84171d8a42ae87ecd9326ac313d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40e7561237f64188bc3c6ef3786ea8c5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d79a58b3e124f8a93f15786db349364_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7988751036404fc89eab96bb474330c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9b21bf40faac4746a6d98991f9063b5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a9c5a9d8dcc4e6ea4fd5c9f8e96d621_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4aad2be9b4df4f7090d2f00cce76d403_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic3ec7da3b1424b85a57097d6c554f644_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4555af1344b5488aaea0d72479cf0596_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0b7bf6f5591b46edaa5e23d7d6b6d15b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8bc922e8a45e4864948e7e52a210bbfe_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c8a7560e4e7401cb82d7df6b06ca5d8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i27020da178fa4cab8a2ad787440d1369_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i44581efe982d4dff9526f3d982194139_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7f8d1355d9204ec8b58c5c853065bc30_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id45a96a79a604c8db109413461f12acf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i39b992f7893b4bac997ab34d477d4884_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibe11ab4cb70e4898bed01c9fa46af4c0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i68a155eabc104ac39191d0d03971f31d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic296d4384977465fb82b5010ed0ea42f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e0ff4743b9f46b8b6897b102789984d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8dfb9569024b4ddcba80967d823d97b7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fa9f713e891499cbfa3fc8da6fec325_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic524439cfc7a482999097af4b55a5fd7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i48b5190d89144635b7cdcb97ae657284_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9e0ff72fb3da4a59a200925afcdc7e65_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if9a04a026e0f40dfa4a678165d4d3da9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iabae1d6edcd44228a05c3a846d30a2a3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c3172719de6407c94ec038f29804c92_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06802d6ce84540babb361a9ca632edf7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2dc0520a90d14ee7bc0c963570c38886_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia85bc9503824447aacbf3a433d92baa0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i049d3f1f3d9c468bbc710632bed69c2e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia9af2e9614184f199df0100b95b2f2ef_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i74071e3de9484ae09acb8eb907fb8765_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ide40bf231fce4273bf66acd14c1d53cc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i269d31cc46944354be67150726d053a7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ida0dbff202384819bd79871ce53f52a1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i29e82c0f6cdf46378b20a960d57eccfc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i21fb4954033b4b0b93ef3aa15fc789ce_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i218df3debedb4042ab2ec6698e70d179_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i633113795b2445609b4d35249439ee5d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7a07000796ab4a10b2efb0c04206a552_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i12b693b748af4c179dafe11803d10f9d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id56e37cfb5b8493ea7ea61e4a78142b6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if7b3e8282d5e4574a43ae348d5c92c8d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icdcb5badd1de447fb11c3b9a221fd47f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7fd8f55248c2407aafd07129677d082f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib7b5967563e74e4aac849273cf4c06b3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifeea9ac7058f4e22bd252caeea9844f2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49b09cfbea34490790bb69bd5752f88a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee47238ea63d403bbafeb419adbbebcb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee384afa0dff40c49580804ce4258745_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc9e27c9f1f0448e9f321a4ae000e86b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i32320f6c16064db8acd6e60f9ef524a7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iafe2b33ae24b422a847884207b6bff68_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5feb07b8aad34436985280cebd165fd9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibfc9353033fe471090a517b829a2055f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6d755a61291247e5ba23687314064f9e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7757281c81f42c3a6bb1ee3db3f83e8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i167897773af54ee49c97a24df909a026_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8aa3213055e3456e9e82b846221a93e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2a6515d6f7304602a6523f858a283c84_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c81b84b50ef47a0b86f109e196ba146_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b12af6efb72401a82a1e6a4b4c57dd0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i480d95bb53374899b607426942f95dca_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1ab6aacae2304361b0a72c97b35ee627_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc527d5b83e74effaf86ce8c575e458a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5a05d3b447e84b38864ccb769d5da5fc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7336d71fe9424bb2a9bf72b1fab73a2a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9480bff926bb4e4d8942dbf68b065b31_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i070c705902be4570bce920e02b91537c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2b7a535fd48142c7a5dcda9d399c631a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifaa636ac23904975afc64924b8d01488_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i690f4828e5af45768504fbfe9abf5724_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i273373a6ceae4707bb9cc2cdb83bbbff_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0ab38c37055a4a71b0214378f4574d16_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i60050340c9ed4f90870cf907d27f9bfe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i388aa2cdde1b460b8597bdff3339972b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibb0b6fc4e57d4890b25ef6de39c2fdd4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia792c56b64d848e8878f44d2d236a376_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0b82a410df0441049ce87afb941806cc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id7cf6e72bd844925bb9e2348bf8f610b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5c3d137419ce48cea5dcac2591a043e3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie01d97ca6150480d87ec6af171de89fb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8a2eb16e1cce408fa52eed5e879feb37_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ide270ebcff6b4424baa910b00caf1be1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id92b64b50e3f47dd88ac7a91d623e520_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i459ec248d46840ba8f88fd2b1cb42941_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i751bd4c59343464787b18cf531e5ba6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85f22c8a22b747dc8c7ef55057b16a94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2214f04c270c4e8e98c8dcb8e54f8278_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i443bbe79aab14ee3afae2ad98fc04529_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2fe2739a8ded43368c826619c379d66f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12454311b50448ccaea121ba9277c57f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad8ad72123e9462a98dbf3e4ec7a9939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a40d442dc8b42cf817bdc09ed7f53ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i36fabffff72949f4b082a440b13e4c81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic68505d0a06e4e8f8922085fadd5bf59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2eca019dc0c428095839c77f4815829_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d6178f3db244647aae1348be50ad904_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8a2da3d7596b4625832ab659cb505863_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i58cb6e2879a24124bd2b0493f3c58a56_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i491c64c69c5740d9a40094969e3b6070_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1df18665bd86458f8795c8e7043272a1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idf127646e3d4429283df0e2fb130d95b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie77390b63e8b461882829e033c650015_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id6a9e853ed55449bae567c7f13b9c39f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7bb1d188c9c42d1af6298345aa0983e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i73cfb9402d17457b94e8a0005fcfa94e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i278e5912864d433589d7d35fd5a102f1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id78abfaea77845eaa82d10a53ce7a880_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc4f34c83c884eb3be6bb60125c76063_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i552d49a6c87f436ebf2aeb62b171e6bc_I20200121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-01-21</instant>
        </period>
    </context>
    <context id="i91240de4fd2c49149368668c1fc1aa2c_D20201015-20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="i51817723d8bc4777b149972dc507b6d6_I20201005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-05</instant>
        </period>
    </context>
    <context id="i1a7ea7f3f0af418a9798c126d95ba2fb_I20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-15</instant>
        </period>
    </context>
    <context id="ibdb3c79bb37d40598236a397bfdf2732_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3b4d91bb10244ecf85e9ff55bf22c6a3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i780d412ff27c4f4fb4ad7befad90ed62_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7481ea7a3508451e84e2ce446d95a16d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iae859592e93741fba5e8767be4c58a3f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i48eae196563f44c886012909931c2a7d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7867867a17654c0bba0b47e105576b16_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i808f837ef3eb42e09cf35d83a641a5ce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica6cf359423442cda103cac2e7b58836_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34e1df8bf9c941ec85693b9f008abbf2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icefbb0dcf23b4a9db9500e432e160acd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icae80f11bf7c417fa7f665a031b58b73_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="ib295489090d1497185afd643ec967a56_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i1760613e671947e5ba8f0fd15472bece_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i0310113aa0194f0ba193480ce6faf7ef_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i2d81be4c0fa64dd0b8e80538f57a09e8_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i35e810f93dfa47a7ba2d68780daf21d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krys:StockSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6cea238b09064f7bb11eb8a0267838ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krys:StockSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib33152efbe744812957d7c93ebcf8473_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7666a417eef840ce9941f0b9297bde02_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic84fce3d22ab4e95a1361b9dc14e7326_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i2dacc94700004db9ad609717389032af_D20200521-20200521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="i64975891a997407ba786da1993f9bad1_I20200521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-21</instant>
        </period>
    </context>
    <context id="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d1fbc3d234f4c31903d00f50bd07271_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5feb93df6b024f7cbfaad880dd55f616_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01f2bb01dacd44a89c7370650b2b2cca_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d40c5e7efd84df4a8f860d865bd0141_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e84783b0eec4936825763ed74abe018_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7444f7d4fc9f40e4b7424b6ec2b0fd54_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff24ad40df3743eca1aab0a8298c6f52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i915b796477f1445ab800e1f8c3513038_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0b83729187442bdba220a841af20bcc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5eb5f40093234fb2a5fbe54c4b287a17_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i60121faa697c4cf4bdba3ea3cb5a3562_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c1f98d79c5f4e3aa04f39f090ddce51_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7affc8789534432280b25eb22852bb8c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie26740af942247b2a3bb8eb3a07f6bef_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i97da03d07b90493f982743fb141e7298_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i65d5be9cd51d4b70b5ec51f29beb8aee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibd8493f9588d450d89ac8a3c4f8dd0bb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2a828aba9334f18af2e6159a18dfa2c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5e0e48d0c15d47f7a3586bad35785d87_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i95c821ed52594cc09bc5d3e97fd84ca7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1224c3cee3aa43cfa95fe86ed4bcfc62_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4451954ae1a4edab2286b6d5d667fdd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id703799af79f4f7a929cf79a1de29747_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8eaea3be6bb40f18cd2f3f4801f7642_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i132e1504fcb94c2395a26312d77352a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib02e0c13ab2041b283dbcc71cc381e44_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i24202ad4adbf4f7eab4c44f57bec5ea6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia0e866668c45429e8d1f0d8e8b8d3a48_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i61932feef1d64f7bbbc45f3ed5b46e1d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib4c4bdc17ee04d84a5123fc95c1f8964_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id851b0ef34164eb1badf918d62103e06_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i84499c680dce48a880d22dfb5d4f52a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i769dbf11dfe64b2d8b252dbee0ed9486_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>krys:segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl8zLTEtMS0xLTA_1a1ccbb1-2c86-42a3-b93c-4a88252ce1bd">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl81LTEtMS0xLTA_3734a0d7-2fa9-47ff-bc3d-18410516b028">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl82LTEtMS0xLTA_044f1f4d-dbde-45c0-ab46-49757c662f35">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl85LTEtMS0xLTA_b7d4a4ee-8bef-47fe-ae49-0d2f45dd305c">0001711279</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80L2ZyYWc6NTVjMjIxMjQzZDI0NDQxZTkzNzFjODEyZmY4ZDVlYmMvdGFibGU6MjE0MjYxZTZlZTczNGY5MTg1ZGYxZjEyMjJlMWQwZWYvdGFibGVyYW5nZToyMTQyNjFlNmVlNzM0ZjkxODVkZjFmMTIyMmUxZDBlZl8xMC0xLTEtMS0w_5bbdd412-8a12-4a65-bef3-17847eaa05df">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDYx_3e38c258-80e1-4950-9262-af4ee2bb639b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6ODlkOWE0MTY5YThmNDdhNGFiYjk4NjBkY2IxMjFmNDAvdGFibGVyYW5nZTo4OWQ5YTQxNjlhOGY0N2E0YWJiOTg2MGRjYjEyMWY0MF8wLTAtMS0xLTA_0171c398-baf3-476f-ae7a-f5f281f987c6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDI_3b6d5395-d5e2-4d94-bafd-68557a9f9bd6">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6NDFhZDRiNDUxYmZjNDkwOGE2ZWFmMTY1NTBjYTI1MTAvdGFibGVyYW5nZTo0MWFkNGI0NTFiZmM0OTA4YTZlYWYxNjU1MGNhMjUxMF8wLTAtMS0xLTA_34429d68-b729-49de-a57d-8e47b8704c1d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDYy_fd955793-b4d9-4ca4-aebe-89de443ecf2a">001-38210</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY3_a8964d6f-a024-4550-9b27-3ce066e7a880">Krystal Biotech, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6NWI4N2U4MDhjYmI3NDk0NWFlOTViMDc3MmU3MWIyNzQvdGFibGVyYW5nZTo1Yjg3ZTgwOGNiYjc0OTQ1YWU5NWIwNzcyZTcxYjI3NF8wLTAtMS0xLTA_7531d682-b6e5-4384-863b-40fe3c9a8f2a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6NWI4N2U4MDhjYmI3NDk0NWFlOTViMDc3MmU3MWIyNzQvdGFibGVyYW5nZTo1Yjg3ZTgwOGNiYjc0OTQ1YWU5NWIwNzcyZTcxYjI3NF8wLTItMS0xLTA_f92ea663-793a-46d5-8c45-03a59fadc8b3">82-1080209</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY5_6d80a8eb-746e-4349-a865-c11fb1ce0342">2100 Wharton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDcw_86f5d6ba-b329-4f92-860b-3c86634c87f7">Suite 701</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY0_84b1a627-7ef4-4d49-9b2d-7775bb159bb6">Pittsburgh</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDcy_8536fded-7954-4a0f-8505-30fc1c8bea44">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV81OTk_df835c9f-656c-400c-a823-9121af06e5a6">15203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDU3_c4331ac7-4e4c-47f8-8baf-bb407f74c470">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDcz_a8dbb74b-d2f6-425c-b249-0ad4baeaa232">586-5830</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6MzFmODE4MTIzMmUyNGI2MTgxMDA3NWQ1OTk4NGQ3NzQvdGFibGVyYW5nZTozMWY4MTgxMjMyZTI0YjYxODEwMDc1ZDU5OTg0ZDc3NF8xLTAtMS0xLTA_eb6c0af1-5133-4f8b-8075-ea89e05eb0fe">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6MzFmODE4MTIzMmUyNGI2MTgxMDA3NWQ1OTk4NGQ3NzQvdGFibGVyYW5nZTozMWY4MTgxMjMyZTI0YjYxODEwMDc1ZDU5OTg0ZDc3NF8xLTEtMS0xLTA_e1fcbfba-d392-4301-8004-3ad5e6fce95e">KRYS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6MzFmODE4MTIzMmUyNGI2MTgxMDA3NWQ1OTk4NGQ3NzQvdGFibGVyYW5nZTozMWY4MTgxMjMyZTI0YjYxODEwMDc1ZDU5OTg0ZDc3NF8xLTItMS0xLTA_ac95fff2-6527-41a3-a241-1600e1b4d777">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY1_8dfc7c06-a0ff-4f8c-a800-d9d2d4024b65">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDY2_762fff34-e639-40f8-8ea2-ce4bf1779bb6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6ZTAzOTM1YWViN2E2NDMwMmIwZWUzY2Q1MGIzZTUzNTgvdGFibGVyYW5nZTplMDM5MzVhZWI3YTY0MzAyYjBlZTNjZDUwYjNlNTM1OF8wLTQtMS0xLTA_ac37778b-8172-43fd-9818-e5edfb73daa9">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGFibGU6ZTAzOTM1YWViN2E2NDMwMmIwZWUzY2Q1MGIzZTUzNTgvdGFibGVyYW5nZTplMDM5MzVhZWI3YTY0MzAyYjBlZTNjZDUwYjNlNTM1OF8xLTYtMS0xLTA_c4ef5d64-dcc1-47cc-a2c5-410a5913bafe">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDU4_8b44f28d-08c1-4d81-86c3-0f21f3407ae6">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDU5_40bc4fa9-5d13-4ce6-aa67-b5950c6dd6fe">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yNDYw_ea70ceed-4bbc-4d8f-8a28-89de3f4d3aa1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1dc32338fed74c97ac6221ff6cb01741_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xL2ZyYWc6ZDBmYjM4OTE0ZTBjNDQwNzkxZTlmNjUyODVlODNmYjUvdGV4dHJlZ2lvbjpkMGZiMzg5MTRlMGM0NDA3OTFlOWY2NTI4NWU4M2ZiNV8yMzkw_fa8ce1da-35c0-4978-8bcf-19415e7afa7a"
      unitRef="shares">22237984</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNC0xLTEtMS0w_2c2a0c06-3f0b-494c-9fee-74cad59e2442"
      unitRef="usd">286614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNC0zLTEtMS0w_ae576392-b969-4dbc-ac47-6057d8595db4"
      unitRef="usd">268269000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNS0xLTEtMS0w_aaf446a6-dabd-4e7e-8f3f-fd6ba48c5c5c"
      unitRef="usd">56479000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNS0zLTEtMS0w_e8e8b613-73d8-435b-bf1c-c15a992e3af4"
      unitRef="usd">2993000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNi0xLTEtMS0w_2a56711b-69db-49cc-bf30-adca5a19ccce"
      unitRef="usd">2719000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNi0zLTEtMS0w_b39ffe54-1f7d-4d28-b0f4-00c5eea3a99d"
      unitRef="usd">3796000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNy0xLTEtMS0w_48d1c9bf-8d7b-4a98-86be-0774d66754c0"
      unitRef="usd">345812000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfNy0zLTEtMS0w_dbe51281-11e1-487e-ae8b-e11bf6427bf6"
      unitRef="usd">275058000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfOC0xLTEtMS0w_8e42aafc-2395-4ee2-9127-a48e2e7a3e33"
      unitRef="usd">78642000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfOC0zLTEtMS0w_c8f5bc81-8e70-4f2a-9ed0-182c08165e20"
      unitRef="usd">30876000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfOS0xLTEtMS0w_27d7369b-70f0-4809-845e-82772b2ad47b"
      unitRef="usd">19237000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfOS0zLTEtMS0w_6c71b3a9-1276-4688-899e-62351153671a"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTAtMS0xLTEtMA_21c670d3-0df4-4487-b92b-4de82d8093ee"
      unitRef="usd">7342000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTAtMy0xLTEtMA_1748dde9-24c2-4e53-9306-5c0e1b650c80"
      unitRef="usd">3298000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTEtMS0xLTEtMA_06af6c0f-cbce-451a-8ca3-0da692b572ce"
      unitRef="usd">62000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTEtMy0xLTEtMA_254a068d-f54e-4e49-845a-c181f79e22c9"
      unitRef="usd">1612000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTItMS0xLTEtMA_6fd5350e-d54b-475d-8ea7-08b035846324"
      unitRef="usd">451095000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTItMy0xLTEtMA_2992e6ec-7e7d-4e82-be48-6248ac66c3a8"
      unitRef="usd">310844000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTUtMS0xLTEtMA_d8ba43d9-13dd-48e2-8c8c-8a8bd704bbd9"
      unitRef="usd">4757000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTUtMy0xLTEtMA_61a24648-d364-4bcf-8557-0157ab5a18f3"
      unitRef="usd">2105000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTYtMS0xLTEtMA_79594e78-6a12-447c-b760-15cb4e015aad"
      unitRef="usd">1023000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTYtMy0xLTEtMA_9defe35c-4ec2-4308-a8b8-5486638c1871"
      unitRef="usd">638000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTctMS0xLTEtMA_900cd813-6ec8-44cd-87d2-f90f7ba4c0f3"
      unitRef="usd">29999000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTctMy0xLTEtMA_6d4f6ebd-7cea-4778-b8ba-0c235cb57c39"
      unitRef="usd">5109000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <krys:BuildToSuitLeaseLiabilityCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTgtMS0xLTEtMA_f1814ee7-5a20-4543-9ec2-83cadf1570ad"
      unitRef="usd">0</krys:BuildToSuitLeaseLiabilityCurrent>
    <krys:BuildToSuitLeaseLiabilityCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTgtMy0xLTEtMA_398b7156-d334-40ad-bc0e-92d85776c97d"
      unitRef="usd">7600000</krys:BuildToSuitLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTktMS0xLTEtMA_5686bce7-38bc-4660-a645-c79a42e13e12"
      unitRef="usd">35779000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMTktMy0xLTEtMA_7edca33e-8e7f-4d10-ae5c-5262d557da90"
      unitRef="usd">15452000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjAtMS0xLTEtMA_6a0036b8-48a6-42f0-9262-cc6e1660abbb"
      unitRef="usd">7079000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjAtMy0xLTEtMA_52dd66a4-e5cd-4dec-b780-205e4721940d"
      unitRef="usd">3308000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjEtMS0xLTEtMA_dcfdf11c-20ec-48f9-99ba-c37975d76adb"
      unitRef="usd">42858000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjEtMy0xLTEtMA_6eaf0e30-c266-4a49-b9b0-f9485033a2f3"
      unitRef="usd">18760000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjItMS0xLTEtMA_044db5df-d31a-4ee6-8de5-373eb23a6e30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjItMy0xLTEtMA_8efc53c3-4b6c-41ff-adfb-ddbf46a25de1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzIx_43c00e04-e262-4c28-84fc-19f5af5cf99e"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzIx_9a10bf21-dbd1-4905-831e-910e234ff74d"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzM1_9f6c36ca-02b8-4b00-883a-69140f0e8168"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzM1_afd08959-5701-468a-89b4-bd3114c6c5e8"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0Xzg1_9b687658-16d3-4aee-b6b4-d1b6bd84f0f8"
      unitRef="shares">2061773</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0Xzg1_cd756276-b383-484f-b8b0-162f57079b82"
      unitRef="shares">2061773</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzExMA_c9d7aad6-39b5-4bfa-92a9-cd1c7a3827cf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmMzMzQ0NzMwN2E5NzRlY2U4NDNlM2MxOTcxNjAyYTU0XzExMA_e7105f57-9a56-4380-b27b-613f7cf775f8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMS0xLTEtMA_2dabe325-6654-40ab-9cb7-3cacdbe0a259"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjQtMy0xLTEtMA_14179fd5-5d33-41d2-a17f-4d8ea2862d67"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzE4_372f866d-3679-411f-8be2-402f2a53d16d"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzE4_6873c728-e3a2-430e-b5ff-c7bf4ee51667"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzMy_28780e3e-81fb-4b68-9b04-2bc4d5b93025"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzMy_eecad1b6-241c-4d55-aa49-4975229ed93e"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzgy_2a594522-cc57-4134-b35e-69c9a03425d9"
      unitRef="shares">22237984</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzgy_f0f6e903-ead4-4930-b960-4516c72719e1"
      unitRef="shares">22237984</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzky_4d50beec-c074-4128-a10c-2bca41ca9b6e"
      unitRef="shares">19714220</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY5MzMwZDIxZTlhYTRmYWQ4YTVlMGZlMjYxODU3NThiXzky_a2e8276e-b49b-4e24-a4c5-cdb2664618e1"
      unitRef="shares">19714220</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMS0xLTEtMA_bbdd81d8-3d62-4849-84e5-36c47546fb4a"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjUtMy0xLTEtMA_f7be4b6d-8094-4983-ba67-98e529357f92"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjYtMS0xLTEtMA_fa17bd98-f6f3-4d44-8214-92ae7f16b795"
      unitRef="usd">527229000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjYtMy0xLTEtMA_a15db3a1-ec79-4a4c-9be8-a4eb6180cc43"
      unitRef="usd">363292000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjctMS0xLTEtMA_1375ed48-bf45-4cf8-95f4-194b7908d7c6"
      unitRef="usd">-14000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjctMy0xLTEtMA_0763d219-233b-4d44-b18e-e9f087e35ff7"
      unitRef="usd">6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjgtMS0xLTEtMA_edc16784-25cd-4397-a2b0-49707ea441ae"
      unitRef="usd">-118978000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjgtMy0xLTEtMA_46cde1c1-dc2f-4cf0-96e0-824420663f8e"
      unitRef="usd">-71214000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjktMS0xLTEtMA_266f07ae-1ead-4b55-a0b1-8f89e740f247"
      unitRef="usd">408237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMjktMy0xLTEtMA_cf8741b0-d1d9-4ba1-8208-3418878aba5c"
      unitRef="usd">292084000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMzAtMS0xLTEtMA_fa9ea149-731a-4db6-aa09-b937e402fd6f"
      unitRef="usd">451095000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xNi9mcmFnOjk1ZDY0NDU5ZWQ5NzRiYjlhMWNlMmI5MWQzNTUwN2VmL3RhYmxlOmIyMjg2MmFiZmJjMjRmYTg4NDNmZDFlNWQ0NmZiOGU0L3RhYmxlcmFuZ2U6YjIyODYyYWJmYmMyNGZhODg0M2ZkMWU1ZDQ2ZmI4ZTRfMzAtMy0xLTEtMA_ff9a4a09-301d-486d-98d0-6f474d1bd850"
      unitRef="usd">310844000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy0xLTEtMS0w_fe2a29ad-7464-457e-9e43-fca0af9b720c"
      unitRef="usd">6080000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy0zLTEtMS0w_d8ba9ffe-a303-42ac-b915-ad8c22e75923"
      unitRef="usd">5100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy01LTEtMS0w_9f8f5113-880f-45a0-8f79-5ce3049a0df6"
      unitRef="usd">18875000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy01LTEtMS0w_d4d4d113-fa8b-4e3a-bc21-aa803829aa3d"
      unitRef="usd">18875000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMy03LTEtMS0w_892c1a8e-cd57-47ad-97b7-7ac389f98aed"
      unitRef="usd">12264000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC0xLTEtMS0w_dd55ed5d-d137-48f4-811f-d4c3894650c6"
      unitRef="usd">9572000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC0zLTEtMS0w_b0071b0a-5e83-430d-8d7f-aca75f165a32"
      unitRef="usd">4580000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC01LTEtMS0w_af9d19af-e2a0-499d-a610-7d057552e5af"
      unitRef="usd">27524000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC01LTEtMS0w_e13bf50c-bcfc-441f-b2eb-fae190676ef9"
      unitRef="usd">27524000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNC03LTEtMS0w_e6e5f78d-28fe-4753-adbd-14fc94699a5e"
      unitRef="usd">10315000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNS0xLTEtMS0w_02c85a43-3fbf-49ef-9d0b-82166d4795e3"
      unitRef="usd">15652000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNS0zLTEtMS0w_2cd4cc33-d6d8-4ae2-b8b6-12aa7376bacb"
      unitRef="usd">9680000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNS01LTEtMS0w_f0571c4c-0f53-4b73-862c-caebdc300cbc"
      unitRef="usd">46399000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNS03LTEtMS0w_e3a8d914-beaf-423c-ad39-45dfa72cb57d"
      unitRef="usd">22579000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNi0xLTEtMS0w_7f661bd5-729e-4e92-b7f9-afe26f2a3aa6"
      unitRef="usd">-15652000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNi0zLTEtMS0w_ad9216b9-f538-4a48-81d0-386a6a7af866"
      unitRef="usd">-9680000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNi01LTEtMS0w_4424ed0a-ce99-48f7-8d7f-dfc683b7665a"
      unitRef="usd">-46399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfNi03LTEtMS0w_535902e2-5a24-472c-a098-96f507c6dde8"
      unitRef="usd">-22579000</us-gaap:OperatingIncomeLoss>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOC0xLTEtMS0w_d71d13db-ed0c-4479-85ab-b05100e4e7ba"
      unitRef="usd">63000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOC0zLTEtMS0w_76a46775-42c7-4c9b-af10-b62cf6ecbb12"
      unitRef="usd">70000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOC01LTEtMS0w_a240387c-0333-4411-a245-2ed9f6a71c19"
      unitRef="usd">127000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOC03LTEtMS0w_680c23ba-433d-44ce-89af-0ccc7f1affb9"
      unitRef="usd">795000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <us-gaap:InterestExpense
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOS0xLTEtMS0w_de5ee3de-6a3e-4698-a492-060db19d06dc"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOS0zLTEtMS0w_2fb91f99-aff7-41a9-b22e-ea2446c0c8dd"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOS01LTEtMS0w_a1dcb3bb-da22-483d-a7cc-fe33fdab9c85"
      unitRef="usd">1492000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfOS03LTEtMS0w_cc18be20-c75a-4ab6-b159-49a806a35fa3"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i9aa15eaaa2f140849a241da763e04fb2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTAtMS0xLTEtMA_9e66a2fc-c802-4b87-9d91-006cab7477fb"
      unitRef="usd">-15589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTAtMy0xLTEtMA_91e9d415-194e-4eae-a090-ce5955599e24"
      unitRef="usd">-9610000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTAtNS0xLTEtMA_cde5e2a9-ede8-4b6f-8975-e5c9af065d2a"
      unitRef="usd">-47764000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTAtNy0xLTEtMA_1dc1c119-58f3-40c5-9ab2-bbde52839a38"
      unitRef="usd">-21784000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3709c8cd63614284a9610906266d0ebd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtMS0xLTEtMA_c8ac9d4f-8450-4a72-bd4c-4f0b835408a5"
      unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtMy0xLTEtMA_1f584842-4939-48e2-ad1f-a1d553318c26"
      unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtNS0xLTEtMA_746d8e84-ee2f-4d8e-945a-6eb9de278cbc"
      unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtNy0xLTEtMA_2e4c8c5f-f8ff-4fd8-a63e-c26cda204ef5"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTEtNy0xLTEtMA_b7e18a63-2d97-4226-a467-443d21db5127"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTItMS0xLTEtMA_73388789-d1be-45fd-a389-bbce19180b14"
      unitRef="usd">-15582000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTItMy0xLTEtMA_39e46218-69b7-4162-8365-654501a33ce4"
      unitRef="usd">-9630000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTItNS0xLTEtMA_91d4131a-89c8-4d26-930a-cd78954215d9"
      unitRef="usd">-47784000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTItNy0xLTEtMA_6296ca81-58d8-4e78-9911-462aea1f5e0c"
      unitRef="usd">-21774000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtMS0xLTEtMA_17b2fbbe-1f7a-44d8-ac3e-909aed7dd4f0"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtMS0xLTEtMA_423563c4-81da-4a12-89ff-2ed76a196941"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtMy0xLTEtMA_79db09d9-1e2e-40e6-b10c-c9fc9963857b"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtMy0xLTEtMA_d33fbc29-30c4-4ffe-993e-8194a8c382b1"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtNS0xLTEtMA_38ff4121-f25c-416a-b68f-e2514a9f3863"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtNS0xLTEtMA_c1998dc7-3a7c-4607-bbab-86957a5b8707"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtNy0xLTEtMA_65a95427-59b8-4aac-ad89-4df077ff140d"
      unitRef="usdPerShare">-1.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTQtNy0xLTEtMA_adc0e817-035d-46f9-8a21-973a8d758a44"
      unitRef="usdPerShare">-1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtMS0xLTEtMA_879543fa-1c2e-4470-880f-eba17b0757d8"
      unitRef="shares">22212266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtMS0xLTEtMA_88afa434-aadf-41c3-91a5-df18717863e3"
      unitRef="shares">22212266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtMy0xLTEtMA_5ddecceb-ad9b-43e5-acef-14776f2d213e"
      unitRef="shares">19676016</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtMy0xLTEtMA_6f19be9c-5461-4ae9-8f31-d8b0eeaae9be"
      unitRef="shares">19676016</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtNS0xLTEtMA_921b9ab1-503c-4c26-a490-7eacc952cf2b"
      unitRef="shares">21893656</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtNS0xLTEtMA_f87a75ea-9796-44f8-bc1e-8d0d467bfb31"
      unitRef="shares">21893656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtNy0xLTEtMA_50811767-fee5-4889-b9fc-f75624086dd0"
      unitRef="shares">18477495</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8xOS9mcmFnOjQ2NTVhYzVmYjUzMDRkZWNiZGJiMTA1ODYxZDk5MWFmL3RhYmxlOmUzNWIxOThhZDliYzRhMDE4ZGZmYTZjMjhkY2ZkNzMxL3RhYmxlcmFuZ2U6ZTM1YjE5OGFkOWJjNGEwMThkZmZhNmMyOGRjZmQ3MzFfMTYtNy0xLTEtMA_c9a0d0a1-d67b-463e-bc58-0c5a8e36f35a"
      unitRef="shares">18477495</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i2061c660b06d4c9bbc11d16373c8f063_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy0xLTEtMS0w_b207b2bd-0f45-43f5-b13d-d1b6f8324449"
      unitRef="shares">19714220</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2061c660b06d4c9bbc11d16373c8f063_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy0zLTEtMS0w_9ecebf68-50d9-4697-8699-cd7f393a4f09"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i191055abec7b4144af0047f02b74e20e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy01LTEtMS0w_2e0ba060-f45c-425e-ad83-4fc626e91486"
      unitRef="usd">363292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ae7f575f30640149beff34d2c2f617e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy03LTEtMS0w_4745af09-9f68-4126-9ab1-19e358e37471"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i321a84171d8a42ae87ecd9326ac313d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy05LTEtMS0w_e25b37ff-a7bf-4274-8d63-3efb61f10e46"
      unitRef="usd">-71214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMy0xMS0xLTEtMA_dd4fde96-a9d0-4052-8267-fe9496814b5a"
      unitRef="usd">292084000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i40e7561237f64188bc3c6ef3786ea8c5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNC0xLTEtMS0w_2f639208-265b-4a5b-a5f9-8d301e772f20"
      unitRef="shares">2489837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6d79a58b3e124f8a93f15786db349364_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNC01LTEtMS0w_c3a39ca3-7f87-4ac2-83c5-864f1b281bcd"
      unitRef="usd">152033000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7988751036404fc89eab96bb474330c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNC0xMS0xLTEtMA_7359dbd2-0768-4b0e-bca5-39e43c1a8bbc"
      unitRef="usd">152033000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6d79a58b3e124f8a93f15786db349364_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNS01LTEtMS0w_22cffb2a-ef8a-4fdc-86f0-75cc5fbc5aa6"
      unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7988751036404fc89eab96bb474330c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNS0xMS0xLTEtMA_b8ece724-122c-4b2e-8f49-b54fd3e000cb"
      unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9b21bf40faac4746a6d98991f9063b5f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNi03LTEtMS0w_0a70c12d-43fb-477c-824a-c4594080b085"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7988751036404fc89eab96bb474330c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNi0xMS0xLTEtMA_2718da50-d5dc-41d0-808e-11dbb6deca06"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i4a9c5a9d8dcc4e6ea4fd5c9f8e96d621_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNy05LTEtMS0w_61df2195-d19e-4905-b2ec-ba7d52d3d86e"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7988751036404fc89eab96bb474330c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfNy0xMS0xLTEtMA_f40a58c2-232f-4672-89f3-ee47c5fc0a31"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4aad2be9b4df4f7090d2f00cce76d403_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC0xLTEtMS0w_565ea254-dcad-459e-9f6c-accc4f5a3a74"
      unitRef="shares">22204057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4aad2be9b4df4f7090d2f00cce76d403_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC0zLTEtMS0w_c3b799ea-d149-4f71-a278-39fe4cab74bd"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3ec7da3b1424b85a57097d6c554f644_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC01LTEtMS0w_9f2f28ee-84b6-4079-ab90-51d55f2ce340"
      unitRef="usd">517675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4555af1344b5488aaea0d72479cf0596_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC03LTEtMS0w_18647436-9ac3-4a50-ab5e-0d152ddf6102"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b7bf6f5591b46edaa5e23d7d6b6d15b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC05LTEtMS0w_b2c5f318-63fe-40f1-aaf0-c2bad724e0d3"
      unitRef="usd">-87026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8bc922e8a45e4864948e7e52a210bbfe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOC0xMS0xLTEtMA_7450bc7e-04f3-46e7-8800-03d6f2a997ce"
      unitRef="usd">430652000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8c8a7560e4e7401cb82d7df6b06ca5d8_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOS0xLTEtMS0w_9b01587e-0834-4b0f-9445-8ac4437f0cce"
      unitRef="shares">975</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i27020da178fa4cab8a2ad787440d1369_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOS01LTEtMS0w_96ebb8f4-9253-415a-9b14-8dde13bd0d36"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfOS0xMS0xLTEtMA_86c61755-0481-442f-8e46-308770197a37"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i27020da178fa4cab8a2ad787440d1369_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTAtNS0xLTEtMA_b9732ecf-b08d-450b-b568-5c9f156740a8"
      unitRef="usd">4261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTAtMTEtMS0xLTA_7878a4eb-e97f-4cc2-ba96-451b94a6c921"
      unitRef="usd">4261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i44581efe982d4dff9526f3d982194139_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTEtNy0xLTEtMA_ce8be204-4ff4-4071-a0fd-a46872674bda"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTEtMTEtMS0xLTA_12cd6d21-9daa-4843-833c-c39ec9c140a1"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i7f8d1355d9204ec8b58c5c853065bc30_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTItOS0xLTEtMA_2b707a4a-0fcb-4e37-b934-d3d23fed861e"
      unitRef="usd">-16363000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3be93284c0964f5fbea16f0cf77838ab_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTItMTEtMS0xLTA_dcc46401-347f-44d7-81d8-bd1ec0aa2773"
      unitRef="usd">-16363000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id45a96a79a604c8db109413461f12acf_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtMS0xLTEtMA_19d391ab-3060-499a-b39d-622d1db29cfd"
      unitRef="shares">22205032</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id45a96a79a604c8db109413461f12acf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtMy0xLTEtMTAwNDk_4aeee7e9-bb87-446b-9cfb-d1be15aeacd2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39b992f7893b4bac997ab34d477d4884_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtNS0xLTEtMA_752da646-7327-4266-b9b1-9ca3130a8c00"
      unitRef="usd">521950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe11ab4cb70e4898bed01c9fa46af4c0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtNy0xLTEtMA_aeab23f1-060a-4427-a472-efbf1a80ccd3"
      unitRef="usd">-21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68a155eabc104ac39191d0d03971f31d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtOS0xLTEtMA_63da5448-333e-4c8d-8f3a-9f1129fad223"
      unitRef="usd">-103389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic296d4384977465fb82b5010ed0ea42f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTMtMTEtMS0xLTA_1df0411a-dfaa-4289-9821-fc7a90d0164e"
      unitRef="usd">418540000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5e0ff4743b9f46b8b6897b102789984d_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTQtMS0xLTEtNzcwNw_9d016f56-919b-460a-8041-42c092442bf1"
      unitRef="shares">32952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8dfb9569024b4ddcba80967d823d97b7_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTQtNS0xLTEtOTQxNw_b9a419af-bc4f-475e-bf7f-d157c0c8beb6"
      unitRef="usd">1534000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTQtMTEtMS0xLTEwMDIw_60c652f1-cfbb-463d-810a-23ffeb4d8c65"
      unitRef="usd">1534000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8dfb9569024b4ddcba80967d823d97b7_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTUtNS0xLTEtNzcwNw_4cc72d6f-f9ea-48ef-8a74-2bc6ce33c955"
      unitRef="usd">3745000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTUtMTEtMS0xLTEwMDIw_3d167049-3aef-43c0-9615-ca2e77503a01"
      unitRef="usd">3745000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3709c8cd63614284a9610906266d0ebd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTYtNy0xLTEtNzcwNw_c7dd6c78-9da5-4091-8997-89843e215d08"
      unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTYtMTEtMS0xLTEwMDIw_6355b8d1-4769-457e-8d84-f75afa2258b6"
      unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i9aa15eaaa2f140849a241da763e04fb2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTctOS0xLTEtNzcwNw_020bf5fa-6cce-4d64-8d3e-d377cd9b3d6e"
      unitRef="usd">-15589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTctMTEtMS0xLTEwMDIw_b13afb01-736b-413e-841f-c910d0f5f168"
      unitRef="usd">-15589000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6fa9f713e891499cbfa3fc8da6fec325_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtMS0xLTEtOTM4NA_33ee4668-d91b-437d-88a5-c40a40eb1ad1"
      unitRef="shares">22237984</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6fa9f713e891499cbfa3fc8da6fec325_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtMy0xLTEtMTAwNTU_d18ca903-6846-4892-8349-3da86fcc5b53"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic524439cfc7a482999097af4b55a5fd7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtNS0xLTEtOTM5Nw_8ccbba26-9122-4a01-86c4-29da29e0324c"
      unitRef="usd">527229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48b5190d89144635b7cdcb97ae657284_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtNy0xLTEtMTAwNTU_f75395ac-9c57-45f1-a8b3-69e4a622126f"
      unitRef="usd">-14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e0ff72fb3da4a59a200925afcdc7e65_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtOS0xLTEtOTM4OA_0ed63630-6687-49ca-a917-a529f5b4da44"
      unitRef="usd">-118978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjU2OThmYTFiNjUzYTQ4NWJiNjA1ZDc5N2UyOTVjYjg4L3RhYmxlcmFuZ2U6NTY5OGZhMWI2NTNhNDg1YmI2MDVkNzk3ZTI5NWNiODhfMTgtMTEtMS0xLTkzODY_2e8d56fd-ceec-4172-9efd-bafde48be1c0"
      unitRef="usd">408237000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if9a04a026e0f40dfa4a678165d4d3da9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy0xLTEtMS0w_a373afc4-6638-42a3-8394-97629e02525d"
      unitRef="shares">17354310</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if9a04a026e0f40dfa4a678165d4d3da9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy0zLTEtMS0w_7b30e982-debe-4127-aa26-64d83e363470"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iabae1d6edcd44228a05c3a846d30a2a3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy01LTEtMS0w_82c723b8-3d75-4e28-8e5e-c8402b577a4d"
      unitRef="usd">241951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c3172719de6407c94ec038f29804c92_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy03LTEtMS0w_efb11455-dfcd-4687-b428-3cdf6898b2d2"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i06802d6ce84540babb361a9ca632edf7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy05LTEtMS0w_ca40ff9f-b677-4119-992c-1f7511dfe00b"
      unitRef="usd">-39047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2dc0520a90d14ee7bc0c963570c38886_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMy0xMS0xLTEtMA_013d2576-8927-4064-8a71-826cb5d64a9a"
      unitRef="usd">202914000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia85bc9503824447aacbf3a433d92baa0_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNC0xLTEtMS0w_c4882511-7f9d-499a-bac9-f2151ba82920"
      unitRef="shares">16254</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i049d3f1f3d9c468bbc710632bed69c2e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNC01LTEtMS0w_80425348-513c-4fbf-bd63-dbcc61e59d69"
      unitRef="usd">243000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNC0xMS0xLTEtMA_e5623ac0-b272-44e5-9e35-bc8bcc12d0f5"
      unitRef="usd">243000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i049d3f1f3d9c468bbc710632bed69c2e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNS01LTEtMS0w_72f31854-2749-4a0f-952f-52132b4ba14f"
      unitRef="usd">539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNS0xMS0xLTEtMA_6517ba79-df4a-4737-8a94-0c584d87e002"
      unitRef="usd">539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia9af2e9614184f199df0100b95b2f2ef_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNi03LTEtMS0w_9ef0885e-88c4-4cc3-82a0-95be5082df26"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNi0xMS0xLTEtMA_fd0f0346-af87-41c3-9228-bb7eb2c80e6f"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i74071e3de9484ae09acb8eb907fb8765_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNy05LTEtMS0w_f91a203b-482c-4854-8a6b-e00137192f58"
      unitRef="usd">-5341000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfNy0xMS0xLTEtMA_b9bd453b-3159-4249-8852-05983963469d"
      unitRef="usd">-5341000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ide40bf231fce4273bf66acd14c1d53cc_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC0xLTEtMS0w_5e212b6e-7e99-4d7b-9dbe-1956ce1037d6"
      unitRef="shares">17370564</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ide40bf231fce4273bf66acd14c1d53cc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC0zLTEtMS0w_b0d73435-dce5-4cbc-b836-8a2f10d4a1f1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i269d31cc46944354be67150726d053a7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC01LTEtMS0w_bcb5bcbc-6385-45ad-9a08-73b3e2f8929f"
      unitRef="usd">242733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida0dbff202384819bd79871ce53f52a1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC03LTEtMS0w_f40747a7-eca3-485d-8345-f091622e109f"
      unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29e82c0f6cdf46378b20a960d57eccfc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC05LTEtMS0w_d2709aca-7a76-476b-bb39-24fa967ae132"
      unitRef="usd">-44388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i21fb4954033b4b0b93ef3aa15fc789ce_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOC0xMS0xLTEtMA_e02ffe16-603e-416d-8a08-eede15439fd7"
      unitRef="usd">198369000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i218df3debedb4042ab2ec6698e70d179_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS0xLTEtMS0w_2c933597-ff75-495c-a819-3cc5a9350dec"
      unitRef="shares">2293495</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i218df3debedb4042ab2ec6698e70d179_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS0xLTEtMS0w_e63e28a0-32d4-454e-8e0e-8b86e18452d4"
      unitRef="shares">2293495</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i633113795b2445609b4d35249439ee5d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS01LTEtMS0w_2acc8f55-c57f-4857-9e41-5dc73273b8f0"
      unitRef="usd">117337000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i633113795b2445609b4d35249439ee5d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS01LTEtMS0w_984d7363-ea0b-46de-bb81-3a8b0e8015fc"
      unitRef="usd">117337000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfOS0xMS0xLTEtMA_bc73a28a-9972-43be-8b5a-36e3dc36b5c3"
      unitRef="usd">117337000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i633113795b2445609b4d35249439ee5d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTAtNS0xLTEtMA_11ff8f55-fc4b-4dd1-8037-1291f367d8c7"
      unitRef="usd">807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i633113795b2445609b4d35249439ee5d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTAtNS0xLTEtMA_61f85f37-f5a8-45c0-b0e4-14e44ae548de"
      unitRef="usd">807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTAtMTEtMS0xLTA_6e10dfc5-b567-4467-bb3f-64090ac8a3b8"
      unitRef="usd">807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7a07000796ab4a10b2efb0c04206a552_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTEtNy0xLTEtMA_11a2e715-2c2f-43f7-9265-b4ef13a50869"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7a07000796ab4a10b2efb0c04206a552_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTEtNy0xLTEtMA_579a3377-89a0-4443-8f09-0301b5721f35"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTEtMTEtMS0xLTA_62a32ed7-268b-44e6-b4ce-583f56d167b7"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i12b693b748af4c179dafe11803d10f9d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTItOS0xLTEtMA_1ed0bcd2-17e5-496c-85a9-55f3098cc4a3"
      unitRef="usd">-6833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i12b693b748af4c179dafe11803d10f9d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTItOS0xLTEtMA_f98dbcd6-f586-44ef-ada3-df063cc3145d"
      unitRef="usd">-6833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id9628508ad0240e38043fa29dd24cd3c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTItMTEtMS0xLTA_d0def37b-3249-40e5-a1b2-b3a28d84156c"
      unitRef="usd">-6833000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id56e37cfb5b8493ea7ea61e4a78142b6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtMS0xLTEtMA_a7ef988d-4f7f-40c4-afa0-0f602afda0f2"
      unitRef="shares">19664059</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id56e37cfb5b8493ea7ea61e4a78142b6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtMy0xLTEtMTAwNTk_7b9fe146-e8a9-4c19-8480-09093cae5b77"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if7b3e8282d5e4574a43ae348d5c92c8d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtNS0xLTEtMA_41b07845-2428-44ef-b2ac-55409eb8b34f"
      unitRef="usd">360877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icdcb5badd1de447fb11c3b9a221fd47f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtNy0xLTEtMA_7f613b69-f6f0-4dee-a2ea-4c5c6a36c7e1"
      unitRef="usd">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fd8f55248c2407aafd07129677d082f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtOS0xLTEtMA_46473a37-06f6-424c-bbec-878f69b9a04e"
      unitRef="usd">-51221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7b5967563e74e4aac849273cf4c06b3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTMtMTEtMS0xLTA_5e283316-89d8-45eb-b4fc-e9e43e8ffddb"
      unitRef="usd">309696000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifeea9ac7058f4e22bd252caeea9844f2_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTQtMS0xLTEtNzI3NA_c2dbd8c7-8d92-4aa7-8a5d-722af0539140"
      unitRef="shares">42811</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i49b09cfbea34490790bb69bd5752f88a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTQtNS0xLTEtNzM5NQ_c8f55f09-7654-4a6b-8e1b-d2d500956553"
      unitRef="usd">298000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTQtMTEtMS0xLTEwMDYx_e7da2240-7f3e-4189-9d3d-d696d9152b24"
      unitRef="usd">298000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i49b09cfbea34490790bb69bd5752f88a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTUtNS0xLTEtNzU0MA_f05e3085-a107-4392-96b8-858bb7852bf1"
      unitRef="usd">1356000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTUtMTEtMS0xLTEwMDYx_6a537e27-9adc-4640-bf1b-f873e3f378a5"
      unitRef="usd">1356000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iee47238ea63d403bbafeb419adbbebcb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTYtNy0xLTEtNzY3Ng_13ba7eb5-47d4-4083-8dfd-26f01d8099dd"
      unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTYtMTEtMS0xLTEwMDYx_fc54f4c5-636b-4f66-a0ba-a0ad65557e2e"
      unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iee384afa0dff40c49580804ce4258745_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTctOS0xLTEtNzY4Mw_11fb5db4-1950-46bc-9004-0cdbf8789971"
      unitRef="usd">-9610000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTctMTEtMS0xLTEwMDYx_cf63b851-f474-4e9d-b076-28aab7a01413"
      unitRef="usd">-9610000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifc9e27c9f1f0448e9f321a4ae000e86b_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtMS0xLTEtOTM2NQ_cdcb1f74-b87b-4d6d-a49d-518b87acb8ee"
      unitRef="shares">19706870</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifc9e27c9f1f0448e9f321a4ae000e86b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtMy0xLTEtMTAwNTc_d7c8e7bf-53bf-465d-a0cb-8f71fecb5dc6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32320f6c16064db8acd6e60f9ef524a7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtNS0xLTEtMTAwNTc_7d146231-a628-429b-8938-7965f152f494"
      unitRef="usd">362531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iafe2b33ae24b422a847884207b6bff68_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtNy0xLTEtMTAwNTc_7383f727-70fc-414c-a65f-1a52408339e2"
      unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5feb07b8aad34436985280cebd165fd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtOS0xLTEtMTAwNTc_449a4406-9bf4-4d4b-9bad-7a5ab7cdf5d5"
      unitRef="usd">-60831000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibfc9353033fe471090a517b829a2055f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yMi9mcmFnOjg2ODU2ZTgyYTFhMzQ1YzlhMzdkYTk4ODI4MWNiY2VjL3RhYmxlOjc0MDQ0MjIxYjI4ZTQ2YWViNGFmMjcyOThlYWEyYWY4L3RhYmxlcmFuZ2U6NzQwNDQyMjFiMjhlNDZhZWI0YWYyNzI5OGVhYTJhZjhfMTgtMTEtMS0xLTEwMDU3_d0c264bf-32a1-49db-8339-759fa7fcc5b9"
      unitRef="usd">301720000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMy0xLTEtMS0w_87214abf-384d-4d0d-8d93-1775ecca0150"
      unitRef="usd">-47764000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMy0zLTEtMS0w_005e4dc2-6e29-4741-a7c6-898ffb500ace"
      unitRef="usd">-21784000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNS0xLTEtMS0w_118856f7-7a46-4e7b-8c92-39e39ed8105f"
      unitRef="usd">1985000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNS0zLTEtMS0w_c8738636-6460-45ee-adf2-b30a9839dac7"
      unitRef="usd">1361000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNi0xLTEtMS0w_75692747-4308-4e5d-9df1-634f1ffbc9a7"
      unitRef="usd">10174000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNi0zLTEtMS0w_f9513a94-45fc-44a7-b951-c6f2d38ea8c7"
      unitRef="usd">2702000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNy0xLTEtMS0w_97d9e6cd-355f-4e66-a8bf-238a81d5fb24"
      unitRef="usd">0</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfNy0zLTEtMS0w_37bc3f4e-3895-460a-8836-f670c33387d6"
      unitRef="usd">-33000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:OtherNoncashExpense
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfOC0xLTEtMS0w_4ab11895-18a5-4942-88ba-31612886a0f3"
      unitRef="usd">1492000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfOC0zLTEtMS0w_d98018c6-e11b-4443-ad07-a25fa2faf969"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTEtMS0xLTEtMA_f1fb9840-4ef1-4b20-bcc7-9d60642279a9"
      unitRef="usd">-814000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTEtMy0xLTEtMA_b5cbed93-063b-4c4d-9716-803994361a90"
      unitRef="usd">-489000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidRent
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTItMS0xLTEtMA_93a7bcc5-bd1c-43ea-8c78-260ad743b624"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidRent>
    <us-gaap:IncreaseDecreaseInPrepaidRent
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTItMy0xLTEtMA_a9483f1d-6a5e-4320-b6c8-0cbccec4b43f"
      unitRef="usd">2400000</us-gaap:IncreaseDecreaseInPrepaidRent>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTMtMS0xLTEtMA_61f8c1f7-4ae6-4bb7-8a7a-670d77bb2c09"
      unitRef="usd">-240000</krys:IncreaseDecreaseInLeaseLiability>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTMtMy0xLTEtMA_23f0f13b-8fd4-46f4-823d-28003609d45e"
      unitRef="usd">-165000</krys:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTQtMS0xLTEtMA_3bf7f335-2088-47bc-9189-a5865e087b49"
      unitRef="usd">-225000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTQtMy0xLTEtMA_b9fb08e1-84a0-42fe-ba7a-b2fa905ba266"
      unitRef="usd">725000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTUtMS0xLTEtMA_9caf74a8-5f28-47c8-835e-efbb741f2503"
      unitRef="usd">6726000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTUtMy0xLTEtMA_29cf507b-345f-459c-a68a-f74ddafbe051"
      unitRef="usd">980000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTYtMS0xLTEtMA_b961e20b-bfbb-4eac-9add-5439c0120dbe"
      unitRef="usd">-27038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTYtMy0xLTEtMA_0cd25e66-9ace-4546-a4c3-145490095317"
      unitRef="usd">-18059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTYtMy0xLTEtMA_9f14c9b8-b268-46cf-8de2-fc577fa82026"
      unitRef="usd">-18059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTktMS0xLTEtMA_05a3c897-4d51-489d-95ea-b29a275c57cb"
      unitRef="usd">27453000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMTktMy0xLTEtMA_401d0ea0-c455-429b-b0ca-7f57380b9505"
      unitRef="usd">7636000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjEtMS0xLTEtMA_e1de27af-770a-4ee0-b6f3-c5703c3c615f"
      unitRef="usd">83810000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjEtMy0xLTEtMA_fd55b527-948c-4d5a-97f2-0fdba420662c"
      unitRef="usd">3205000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjItMS0xLTEtMA_49ddcbff-402f-4197-aedd-fa21e7727bf9"
      unitRef="usd">11033000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjItMy0xLTEtMA_d5a73094-6e73-4641-9480-43ec05556b37"
      unitRef="usd">5877000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjQtMS0xLTEtMA_78eaba1d-7505-4620-9dde-cb4717568192"
      unitRef="usd">-100230000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjQtMy0xLTEtMA_bd45b505-685e-46d3-88a1-eb55c76dd299"
      unitRef="usd">-4964000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjctMS0xLTEtMA_65102006-047c-4f58-a9b2-8e81f54290ac"
      unitRef="usd">153573000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjctMy0xLTEtMA_a74a3673-e259-46d3-b462-6a8aa8c2dd6d"
      unitRef="usd">117878000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <krys:PaymentsForSuitLiability
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjgtMS0xLTEtMA_54cb1d97-c0d4-44c6-8f13-9924e910cd0a"
      unitRef="usd">7960000</krys:PaymentsForSuitLiability>
    <krys:PaymentsForSuitLiability
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjgtMy0xLTEtMA_7e67dc44-7f18-4d2c-b6d1-92d1e48437c9"
      unitRef="usd">0</krys:PaymentsForSuitLiability>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjktMS0xLTEtMA_801a409a-98b8-464e-9190-36700ff3f415"
      unitRef="usd">145613000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMjktMy0xLTEtMA_9fe1f158-f9ff-4530-a46e-000e809e62ac"
      unitRef="usd">117878000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzEtMS0xLTEtMA_a4010d8a-c679-4aa2-9798-d4a3401adfcf"
      unitRef="usd">18345000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzEtMy0xLTEtMA_81f3d8db-4603-4455-82a7-238ed3584ada"
      unitRef="usd">94855000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzMtMS0xLTEtMA_9c023986-6b99-485c-bc71-f0957611c131"
      unitRef="usd">268269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2dc0520a90d14ee7bc0c963570c38886_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzMtMy0xLTEtMA_4284d1e2-2061-4722-9b11-0c58f179e64b"
      unitRef="usd">187514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzQtMS0xLTEtMA_b8edf62f-9a16-4ebd-aade-c2b878997a15"
      unitRef="usd">286614000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibfc9353033fe471090a517b829a2055f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzQtMy0xLTEtMA_89ba8fef-5e89-4bb1-b9f8-db4701310727"
      unitRef="usd">282369000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzctMS0xLTEtMA_3ab45185-57aa-405a-99bd-234914c2f7c5"
      unitRef="usd">23213000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzctMy0xLTEtMA_36ea6f2a-408e-4c1d-9345-67f36073add6"
      unitRef="usd">3173000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <krys:OfferingCostsIncurredButNotYetPaid
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzgtMS0xLTEtMA_af26ef16-62bd-4c5c-a018-3945693c1f0f"
      unitRef="usd">11000</krys:OfferingCostsIncurredButNotYetPaid>
    <krys:OfferingCostsIncurredButNotYetPaid
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzgtMy0xLTEtMA_11916686-bb92-442c-b203-5c7017d60879"
      unitRef="usd">0</krys:OfferingCostsIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzktMS0xLTEtMA_6c14f57b-a117-4c82-b977-1054d767ef64"
      unitRef="usd">4396000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8yNS9mcmFnOmMyYTc3ZDc1ZDIxNjQ0NDk4MmY3NDAxZjk1YTUwZDQ1L3RhYmxlOjQ2Y2IwMDY3NjkyMzQzNjJiODJkZTYzNzA5ODAyYTkzL3RhYmxlcmFuZ2U6NDZjYjAwNjc2OTIzNDM2MmI4MmRlNjM3MDk4MDJhOTNfMzktMy0xLTEtMA_4a570d48-1826-4435-b090-84d953b075fd"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zMS9mcmFnOjkxMWUzMjdjM2ZiODQxYjk4NzJlNzUzYzM4ZWJmMmE1L3RleHRyZWdpb246OTExZTMyN2MzZmI4NDFiOTg3MmU3NTNjMzhlYmYyYTVfMzMzNg_2861aba2-afd4-4c9d-be75-1a19f4c512f0">Organization&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Krystal Biotech, Inc. (the&#160;&#x201c;Company,&#x201d;&#160;or&#160;&#x201c;we&#x201d;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a clinical stage biotechnology company leading the field of redosable gene delivery for the treatment of serious rare diseases. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#x2019;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#x2019;s office or potentially in the patient&#x2019;s home by a healthcare professional. Our goal is to develop easy to use, medicines to dramatically improve the lives of patients living with rare diseases.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company had an accumulated deficit of $119.0 million. With the net proceeds raised from its public and private securities offerings, including the public offering of its common stock completed on February 1, 2021, the Company believes that its cash, cash equivalents and short-term investments of approximately $343.1 million as of September&#160;30, 2021 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#x2019;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercialize product candidates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zMS9mcmFnOjkxMWUzMjdjM2ZiODQxYjk4NzJlNzUzYzM4ZWJmMmE1L3RleHRyZWdpb246OTExZTMyN2MzZmI4NDFiOTg3MmU3NTNjMzhlYmYyYTVfMTcxNw_fe70a343-237b-4423-bfcf-dc4d613590f2"
      unitRef="usd">-119000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zMS9mcmFnOjkxMWUzMjdjM2ZiODQxYjk4NzJlNzUzYzM4ZWJmMmE1L3RleHRyZWdpb246OTExZTMyN2MzZmI4NDFiOTg3MmU3NTNjMzhlYmYyYTVfMTk3OA_aaa0e071-f907-4343-bee4-849722896d2a"
      unitRef="usd">343100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjE_ca0fa73b-ea5e-4173-821e-fb0fadc98746">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;), as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), the Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), and the rules and regulations of the US Securities and Exchange Commission (&#x201c;SEC&#x201d;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended September&#160;30, 2021 and 2020, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, as filed with the SEC on March 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 -7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress ("CIP") is not depreciated until the asset is placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and nine months ended September&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation-Stock Compensation (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Due to the lack of sufficient history and trading volume of our Common Stock and a lack of Company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the lack of Company-specific historical option activity, the Company has estimated the expected term of its employee and non-employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU 2020-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjU_cf4dadb1-d734-4d68-adc3-06969c25de21">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;), as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), the Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), and the rules and regulations of the US Securities and Exchange Commission (&#x201c;SEC&#x201d;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended September&#160;30, 2021 and 2020, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, as filed with the SEC on March 1, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <krys:RisksAndUncertaintiesPolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjI_444d0a18-fd68-4a45-93ae-3222ee63e27b">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2021.&lt;/span&gt;&lt;/div&gt;</krys:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTg_c6149fd9-07a3-4a3b-bb7d-c561eeeaaa48">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTU_64ba7b38-e6d3-446b-870e-a3e01a0d2d71">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMzczNA_6dcb7a91-7144-4c88-80e5-b3745f595234"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjM_04522fca-94dc-4245-960e-891b01b70ad5">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjY_96249dfd-4a77-45f6-998b-25a0b3166e3a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the consolidated balance sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTY_b67b042f-eaed-4c40-b796-2bafafdc14b3">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjQ_ede074b1-5a66-4a82-b6e8-737a121bf94e">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 -7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress ("CIP") is not depreciated until the asset is placed in service.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <krys:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTk_940ad529-cd93-4435-99fb-a3a7b58e7548">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 -7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</krys:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6d755a61291247e5ba23687314064f9e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RhYmxlOmVhNjYyYjE1YjQ5ZTQ5MmQ5ZWM3NjRmMjI1MWFjNWNhL3RhYmxlcmFuZ2U6ZWE2NjJiMTViNDllNDkyZDllYzc2NGYyMjUxYWM1Y2FfMC0xLTEtMS0w_01bffc98-a17a-48ac-a793-1020a97d2ff9">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id7757281c81f42c3a6bb1ee3db3f83e8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RhYmxlOmVhNjYyYjE1YjQ5ZTQ5MmQ5ZWM3NjRmMjI1MWFjNWNhL3RhYmxlcmFuZ2U6ZWE2NjJiMTViNDllNDkyZDllYzc2NGYyMjUxYWM1Y2FfMS0xLTEtMS0wL3RleHRyZWdpb246ODg0OGRjZTJiODYwNGZlNzlmZDZkMDc4OTA3M2RhZjlfNA_438c5a44-bb8b-4d0e-a546-7b41bf41d3f9">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i167897773af54ee49c97a24df909a026_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RhYmxlOmVhNjYyYjE1YjQ5ZTQ5MmQ5ZWM3NjRmMjI1MWFjNWNhL3RhYmxlcmFuZ2U6ZWE2NjJiMTViNDllNDkyZDllYzc2NGYyMjUxYWM1Y2FfMS0xLTEtMS0wL3RleHRyZWdpb246ODg0OGRjZTJiODYwNGZlNzlmZDZkMDc4OTA3M2RhZjlfOA_8a7f9b0e-e3b0-4274-bbc5-ecbe19840992">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8aa3213055e3456e9e82b846221a93e6_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RhYmxlOmVhNjYyYjE1YjQ5ZTQ5MmQ5ZWM3NjRmMjI1MWFjNWNhL3RhYmxlcmFuZ2U6ZWE2NjJiMTViNDllNDkyZDllYzc2NGYyMjUxYWM1Y2FfMi0xLTEtMS0w_0ed4d033-121d-4108-8417-d6345d8cb209">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5Mjc_796c33da-e769-4c1d-8253-ee643e9ec809">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and nine months ended September&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i2a6515d6f7304602a6523f858a283c84_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfOTg5MQ_66e7564e-7e18-44e3-9d20-0c5cd4316de6"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i7c81b84b50ef47a0b86f109e196ba146_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfOTg5MQ_743c5570-cd1c-45fe-98ff-3e86b342b98a"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i8b12af6efb72401a82a1e6a4b4c57dd0_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfOTg5MQ_a6e9b0fb-3615-4c99-8f0c-b7e51b7d031c"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i480d95bb53374899b607426942f95dca_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfOTg5MQ_abe3023e-fecf-4fb2-8d31-61f3540a6043"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MTc_7fce9385-64d0-427b-b21f-099ef09b192c">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MjA_4dfa7576-0587-49eb-b5cd-d05b95af8d88">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5Mjg_be95c7cf-c321-428d-8158-42dab3bfc660">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation-Stock Compensation (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Due to the lack of sufficient history and trading volume of our Common Stock and a lack of Company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;Due to the lack of Company-specific historical option activity, the Company has estimated the expected term of its employee and non-employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5Mjk_b2718b36-4a23-462e-a33e-aee81e6a3cf1">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNC9mcmFnOjRhOGI5ZGE1YWUyNDQwZTA5Nzg4NmNjYWEzOWRmYWJiL3RleHRyZWdpb246NGE4YjlkYTVhZTI0NDBlMDk3ODg2Y2NhYTM5ZGZhYmJfMTc5MzA_bf829481-2325-49ae-b086-bc58115928fc">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU 2020-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RleHRyZWdpb246ODMxMTYyMjVlZDMwNDI1ZmE5ZjkxY2QxMzk2Y2UzNDRfOTU5_5a8d632e-ae5c-453a-a4a0-9b12b2c31082">Net Loss Per Share Attributable to Common Stockholders&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 1,900,638 and 853,336 common share equivalents outstanding as of September&#160;30, 2021 and 2020, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except shares and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,212,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,676,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,893,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,477,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RleHRyZWdpb246ODMxMTYyMjVlZDMwNDI1ZmE5ZjkxY2QxMzk2Y2UzNDRfNjYz_865a2741-a363-405b-9690-9cdba735a683"
      unitRef="shares">1900638</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RleHRyZWdpb246ODMxMTYyMjVlZDMwNDI1ZmE5ZjkxY2QxMzk2Y2UzNDRfNjcw_d24cf128-e401-45ae-b3cf-813b61ad8662"
      unitRef="shares">853336</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RleHRyZWdpb246ODMxMTYyMjVlZDMwNDI1ZmE5ZjkxY2QxMzk2Y2UzNDRfOTU4_7453effc-e7b4-488e-a5ab-669b395b1c76">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except shares and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,212,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,676,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,893,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,477,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i9aa15eaaa2f140849a241da763e04fb2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNC0xLTEtMS0w_9e66a2fc-c802-4b87-9d91-006cab7477fb"
      unitRef="usd">-15589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNC0zLTEtMS0w_8418bee9-b2b2-471c-99a4-8e315b0aad10"
      unitRef="usd">-9610000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNC01LTEtMS0w_cde5e2a9-ede8-4b6f-8975-e5c9af065d2a"
      unitRef="usd">-47764000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNC03LTEtMS0w_1dc1c119-58f3-40c5-9ab2-bbde52839a38"
      unitRef="usd">-21784000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi0xLTEtMS0w_bd0353df-4d85-4173-849c-e9d33b4a6cd5"
      unitRef="shares">22212266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi0xLTEtMS0w_d07db897-c32a-4c7c-a8e9-5416234e95e1"
      unitRef="shares">22212266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi0zLTEtMS0w_152534a7-bc96-44ba-98b1-d863d546af19"
      unitRef="shares">19676016</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi0zLTEtMS0w_29cbdb18-fd5a-4ed0-91db-7c8b443c6d87"
      unitRef="shares">19676016</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi01LTEtMS0w_921b9ab1-503c-4c26-a490-7eacc952cf2b"
      unitRef="shares">21893656</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi01LTEtMS0w_f87a75ea-9796-44f8-bc1e-8d0d467bfb31"
      unitRef="shares">21893656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi03LTEtMS0w_50811767-fee5-4889-b9fc-f75624086dd0"
      unitRef="shares">18477495</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNi03LTEtMS0w_c9a0d0a1-d67b-463e-bc58-0c5a8e36f35a"
      unitRef="shares">18477495</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy0xLTEtMS0w_302908e3-9bfd-417e-95c6-89625efed515"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy0xLTEtMS0w_3ce6b38f-aadc-4243-982d-dcff35690bc8"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy0zLTEtMS0w_53e62097-7cc4-4fba-9f8e-b180d9c048b6"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy0zLTEtMS0w_af45da3f-21b3-4571-b8ea-2c9033881de5"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy01LTEtMS0w_38ff4121-f25c-416a-b68f-e2514a9f3863"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy01LTEtMS0w_c1998dc7-3a7c-4607-bbab-86957a5b8707"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy03LTEtMS0w_65a95427-59b8-4aac-ad89-4df077ff140d"
      unitRef="usdPerShare">-1.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV8zNy9mcmFnOjgzMTE2MjI1ZWQzMDQyNWZhOWY5MWNkMTM5NmNlMzQ0L3RhYmxlOjQyYTkzNGI1NGY0MzQ1MzQ4Y2I1MWNkMTg0OTZlOWE4L3RhYmxlcmFuZ2U6NDJhOTM0YjU0ZjQzNDUzNDhjYjUxY2QxODQ5NmU5YThfNy03LTEtMS0w_adc0e817-035d-46f9-8a21-973a8d758a44"
      unitRef="usdPerShare">-1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfNTEw_f61d28bb-3008-43ff-8da3-3e1dbc125120">Fair Value Instruments&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2021 and December&#160;31, 2020, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfNTA5_c1ef7690-3e8d-4daf-8f20-b517c22a9b90">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2021 and December&#160;31, 2020, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ab6aacae2304361b0a72c97b35ee627_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNC0xLTEtMS0w_fe8021cc-b4d1-43b1-8d28-cdac38a6dbe7"
      unitRef="usd">286614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1ab6aacae2304361b0a72c97b35ee627_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNC03LTEtMS0w_8c889cdb-506d-4b54-bd62-0196ba7a7038"
      unitRef="usd">286614000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibc527d5b83e74effaf86ce8c575e458a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNC05LTEtMS0w_0b5b40e8-926e-427b-baea-68daee1f9f7f"
      unitRef="usd">286614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a05d3b447e84b38864ccb769d5da5fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNS0xLTEtMS0w_7044a784-2269-4fe5-91f5-82f5ad3d2b16"
      unitRef="usd">286614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a05d3b447e84b38864ccb769d5da5fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNS03LTEtMS0w_e2c8bc77-cd0e-4a89-afcc-06bde235b03b"
      unitRef="usd">286614000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7336d71fe9424bb2a9bf72b1fab73a2a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfNS05LTEtMS0w_7cdba01e-0202-4f09-a8d2-1c62f16b5797"
      unitRef="usd">286614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9480bff926bb4e4d8942dbf68b065b31_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC0xLTEtMS0w_de85521e-14b0-4cf3-bee5-68ac0b04ad7a"
      unitRef="usd">22490000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9480bff926bb4e4d8942dbf68b065b31_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC0zLTEtMS0w_4ac67a0b-78be-401c-a21d-7989e543ce39"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9480bff926bb4e4d8942dbf68b065b31_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC03LTEtMS0w_4a156203-eac5-4814-b6cd-26eb4ceee211"
      unitRef="usd">22492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i070c705902be4570bce920e02b91537c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC0xMS0xLTEtMA_0309d9c2-cb2e-44df-981c-c3d574d80e16"
      unitRef="usd">22492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b7a535fd48142c7a5dcda9d399c631a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOC0xMy0xLTEtMA_5df74e2a-77d1-44a1-976c-ff4feb9070c6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifaa636ac23904975afc64924b8d01488_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS0xLTEtMS0w_ef69d577-e35c-453d-be79-f44f779ba5c5"
      unitRef="usd">37683000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifaa636ac23904975afc64924b8d01488_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS0zLTEtMS0w_188092db-a5cb-4fef-9ea1-6ac2639c6096"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifaa636ac23904975afc64924b8d01488_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS01LTEtMS0w_ae0a5d70-e0aa-4cd8-ae99-dda4e0382d21"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifaa636ac23904975afc64924b8d01488_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS03LTEtMS0w_37f531fe-48bf-4cbd-9306-be1328978eea"
      unitRef="usd">37658000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i690f4828e5af45768504fbfe9abf5724_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS0xMS0xLTEtMA_e659977e-fc0c-469d-80a7-ce25f7d85f47"
      unitRef="usd">29465000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i273373a6ceae4707bb9cc2cdb83bbbff_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfOS0xMy0xLTEtMA_f75f3fda-525d-4792-b4b0-ef3a1fc0c194"
      unitRef="usd">8193000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0ab38c37055a4a71b0214378f4574d16_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMS0xLTEtMA_bfd4fdd5-28b2-4e8a-ba4f-83038e2760f2"
      unitRef="usd">15567000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i60050340c9ed4f90870cf907d27f9bfe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMS0xLTEtMA_d867ea85-f9eb-4967-a468-b08d75c20a24"
      unitRef="usd">15567000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i60050340c9ed4f90870cf907d27f9bfe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMy0xLTEtOTE2MA_13f67633-827c-46dd-9212-0ed77276eb1e"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i60050340c9ed4f90870cf907d27f9bfe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtNS0xLTEtMA_9bf759cf-703e-46dd-aad0-0f2f5ef9e82a"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60050340c9ed4f90870cf907d27f9bfe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtNy0xLTEtMA_a142b544-e256-4552-9821-dcf2b00ce421"
      unitRef="usd">15566000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i388aa2cdde1b460b8597bdff3339972b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMTEtMS0xLTA_289d9af5-4bc4-479d-aefe-8069ac170b0c"
      unitRef="usd">4522000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb0b6fc4e57d4890b25ef6de39c2fdd4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMTEtMS0xLTA_5c2495f0-1894-4380-8438-6461b0d395e6"
      unitRef="usd">4522000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia792c56b64d848e8878f44d2d236a376_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTAtMTMtMS0xLTA_e52005de-9fd9-49c0-9084-445c9899c311"
      unitRef="usd">11044000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0b82a410df0441049ce87afb941806cc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtMS0xLTEtMA_d8d6e673-9b97-4ac2-b6ac-cddddf1f982d"
      unitRef="usd">75740000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0b82a410df0441049ce87afb941806cc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtMy0xLTEtMA_f1f4fd8f-6c49-4d52-9cba-436fadbbb45f"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0b82a410df0441049ce87afb941806cc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtNS0xLTEtMA_b4212426-5b3a-4e2a-bcf4-a68795f08e3f"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b82a410df0441049ce87afb941806cc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtNy0xLTEtMA_7d91fa44-0c2d-4d7b-ab59-39c0d282253f"
      unitRef="usd">75716000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7cf6e72bd844925bb9e2348bf8f610b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtMTEtMS0xLTA_63d4f0e4-ecec-4087-bd91-ab80f2ed8034"
      unitRef="usd">56479000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c3d137419ce48cea5dcac2591a043e3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTEtMTMtMS0xLTA_107f7ce5-ba37-4fd2-ab61-c7b646168dd9"
      unitRef="usd">19237000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItMS0xLTEtMA_0b822786-fe8b-4316-8855-28978496dd12"
      unitRef="usd">362354000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItMy0xLTEtMA_e9170931-f060-440d-b63d-fec25298a276"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItNS0xLTEtMA_fbd2593e-05b0-4ad5-a114-f6b104312ffa"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItNy0xLTEtMA_b53f66df-e890-4094-863d-5f099e15cb9b"
      unitRef="usd">362330000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ie01d97ca6150480d87ec6af171de89fb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItOS0xLTEtMA_96b12b1e-32ca-459a-ae1a-83e3e537505b"
      unitRef="usd">286614000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i8a2eb16e1cce408fa52eed5e879feb37_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItMTEtMS0xLTA_f035b468-7c40-408d-bee5-afb42117caef"
      unitRef="usd">56479000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ide270ebcff6b4424baa910b00caf1be1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjNmNzg0MWZmODE0YjQxZWU4ZjUzMmFjNzVjOWY2N2IwL3RhYmxlcmFuZ2U6M2Y3ODQxZmY4MTRiNDFlZThmNTMyYWM3NWM5ZjY3YjBfMTItMTMtMS0xLTA_f83f18fe-aecf-4f33-9050-1ae5e3faf6d8"
      unitRef="usd">19237000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id92b64b50e3f47dd88ac7a91d623e520_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMy0xLTEtMS0w_fe80a5ff-6135-4d24-9c64-a6a3c3c9b79f"
      unitRef="usd">268269000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id92b64b50e3f47dd88ac7a91d623e520_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMy03LTEtMS0w_0d2d204c-38d9-4bbc-aa9b-3c6a4997868f"
      unitRef="usd">268269000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i459ec248d46840ba8f88fd2b1cb42941_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMy05LTEtMS0w_6a7b939d-1d5c-49e1-8c25-05430a8b2b10"
      unitRef="usd">268269000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i751bd4c59343464787b18cf531e5ba6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNS0xLTEtMS0w_753c30ce-31dc-40d3-8473-24a1db32d4ba"
      unitRef="usd">268269000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i751bd4c59343464787b18cf531e5ba6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNS03LTEtMS0w_8e286d9d-a348-4ea7-a023-b397e9ae0baf"
      unitRef="usd">268269000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i85f22c8a22b747dc8c7ef55057b16a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNS05LTEtMS0w_e0707dbe-cbcd-478f-b0da-55c890a84c1d"
      unitRef="usd">268269000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2214f04c270c4e8e98c8dcb8e54f8278_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy0xLTEtMS0w_6f4b3f4c-1e20-4e16-b13f-f8a53698b1ff"
      unitRef="usd">2986000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2214f04c270c4e8e98c8dcb8e54f8278_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy0zLTEtMS0w_039dc931-0253-481d-8307-cd747d8678d6"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2214f04c270c4e8e98c8dcb8e54f8278_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy03LTEtMS0w_e67d1677-e9c8-42df-87f8-ac29a4bf2200"
      unitRef="usd">2993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i443bbe79aab14ee3afae2ad98fc04529_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy0xMS0xLTEtMA_6f806c7a-81d6-4493-9db6-cb3f4f9c1953"
      unitRef="usd">2993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2fe2739a8ded43368c826619c379d66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfNy0xMy0xLTEtMA_a9ebee2d-de07-40e9-a5d8-39f54156db37"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i12454311b50448ccaea121ba9277c57f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtMS0xLTEtMA_9e1eb2b0-1e55-4e29-97e3-35ffef278a7e"
      unitRef="usd">2986000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i12454311b50448ccaea121ba9277c57f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtMy0xLTEtMA_b2806112-cccf-4a0b-b018-298bb8736272"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12454311b50448ccaea121ba9277c57f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtNy0xLTEtMA_b3161fa1-a65c-43d9-a018-978015a38204"
      unitRef="usd">2993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad8ad72123e9462a98dbf3e4ec7a9939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtMTEtMS0xLTA_0416c5f5-7650-4972-aa7d-0847d109af5f"
      unitRef="usd">2993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a40d442dc8b42cf817bdc09ed7f53ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTEtMTMtMS0xLTA_20915829-a654-4fc5-a385-0d80af94004f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItMS0xLTEtMA_805c5aad-2b42-4eef-94bf-a67083bd1d1f"
      unitRef="usd">271255000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItMy0xLTEtMA_79e60c3a-4d26-4b62-9ff1-66512b09c28d"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItNy0xLTEtMA_e8ba7788-ee68-43e7-92d1-a930c5a558e5"
      unitRef="usd">271262000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i36fabffff72949f4b082a440b13e4c81_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItOS0xLTEtMA_ab3c9b16-a0e7-4159-b4b5-45622577281a"
      unitRef="usd">268269000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ic68505d0a06e4e8f8922085fadd5bf59_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItMTEtMS0xLTA_4cf389b2-b929-40bc-b296-7f368e88d47c"
      unitRef="usd">2993000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ie2eca019dc0c428095839c77f4815829_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RhYmxlOjU4OTU1YjM0ZmNjYzQxM2Q5NGNiNzQwOGM3MWVjZjdhL3RhYmxlcmFuZ2U6NTg5NTViMzRmY2NjNDEzZDk0Y2I3NDA4YzcxZWNmN2FfMTItMTMtMS0xLTA_67ce7189-b9b7-4a92-acce-d37854a913bf"
      unitRef="usd">0</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="id7cf6e72bd844925bb9e2348bf8f610b_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfMjcy_c7c66446-21d8-41d9-aedf-108efba87494">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i4d6178f3db244647aae1348be50ad904_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfMTA5OTUxMTYyODI4OA_9d09c9bd-ca9f-497a-8768-e199234dd235">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i8a2da3d7596b4625832ab659cb505863_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80MC9mcmFnOmFhMjdiMDNhNzMzNTQ4Y2Y5MTU3ZDNmMmNjODgwZmVjL3RleHRyZWdpb246YWEyN2IwM2E3MzM1NDhjZjkxNTdkM2YyY2M4ODBmZWNfMzU4_b02cd64b-3674-4540-969c-1ca48fa67cd7">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMzgw_ef21118e-5335-47a4-be92-e39d34fe7efb">Balance Sheet Components&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $474 thousand and $1.4 million for the three and nine months ended September&#160;30, 2021 and $399 thousand and $1.1 million three and nine months ended September&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMzgx_5cb2bd64-8733-4c76-aee2-4249d4bfc307">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i58cb6e2879a24124bd2b0493f3c58a56_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfMi0xLTEtMS0w_6b35ecb7-3828-46e6-89d2-3ffc31cd3199"
      unitRef="usd">70211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i491c64c69c5740d9a40094969e3b6070_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfMi0zLTEtMS0w_d8127067-5a46-48ea-8429-592d36709e0e"
      unitRef="usd">23031000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1df18665bd86458f8795c8e7043272a1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfMy0xLTEtMS0w_382112d8-a645-461b-8b74-cefb91f3058f"
      unitRef="usd">5723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idf127646e3d4429283df0e2fb130d95b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfMy0zLTEtMS0w_f87acc61-9662-4636-aeda-b33c9359fbf4"
      unitRef="usd">4631000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie77390b63e8b461882829e033c650015_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNC0xLTEtMS0w_55ed84c7-5c5a-4ec1-b746-5f87ee3ce4e8"
      unitRef="usd">891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id6a9e853ed55449bae567c7f13b9c39f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNC0zLTEtMS0w_3a34c3c5-7e87-47c3-832a-857c182074fe"
      unitRef="usd">870000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id7bb1d188c9c42d1af6298345aa0983e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNS0xLTEtMS0w_471a9c5a-3e56-4715-87f6-64578a5f28e3"
      unitRef="usd">85000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i73cfb9402d17457b94e8a0005fcfa94e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNS0zLTEtMS0w_ddc2a24a-69ad-4bcf-af4c-2df13d567e75"
      unitRef="usd">82000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i278e5912864d433589d7d35fd5a102f1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNi0xLTEtMS0w_e53e540e-6450-4bd6-b8e3-27a168dda3df"
      unitRef="usd">5485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id78abfaea77845eaa82d10a53ce7a880_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNi0zLTEtMS0w_f9a10130-bc8c-4c07-9b13-8a797d472072"
      unitRef="usd">4630000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNy0xLTEtMS0w_1a2fa103-4bcf-4ce6-941e-c52647eac30f"
      unitRef="usd">82395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfNy0zLTEtMS0w_808b94e3-9437-4454-ab52-d97a228fcd57"
      unitRef="usd">33244000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfOC0xLTEtMS0w_f5031622-1324-43fe-94ba-f304de9571b0"
      unitRef="usd">3753000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfOC0zLTEtMS0w_4a7c882b-867e-4220-8fda-5ed59a1dde8d"
      unitRef="usd">2368000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfOS0xLTEtMS0w_e4195725-2b4f-4048-801d-3852f8054a7b"
      unitRef="usd">78642000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjg5NzI4MzIyNjAyZTQ1NmM5YzhmY2YzMjBjNjI4NWY2L3RhYmxlcmFuZ2U6ODk3MjgzMjI2MDJlNDU2YzljOGZjZjMyMGM2Mjg1ZjZfOS0zLTEtMS0w_8ce935b8-c365-44ac-a7ec-14c16445a136"
      unitRef="usd">30876000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMTU3_d2457f49-e4d8-43fe-948b-82cd3a888dcb"
      unitRef="usd">474000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMTY0_a1339a53-ade3-47fb-9d20-a544749a4570"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMTk4_49943db2-4a95-473f-b8be-87cb2d8a118e"
      unitRef="usd">399000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMjA1_10b600bc-a0f9-4ca8-bd56-f311fbee1b92"
      unitRef="usd">1100000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RleHRyZWdpb246NzVhY2Y3NzA5ZDcxNGU1NzhjZTllMjk4NWFmZjM0YmVfMzgy_116c22cd-6634-4604-a761-83fb13d42b1f">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfMi0xLTEtMS0w_2f071066-2530-48d4-87ea-2648f54172cc"
      unitRef="usd">3743000</krys:AccruedPreclinicalAndClinicalExpenses>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfMi0zLTEtMS0w_c5265bba-f0c8-4ea6-bd91-0a14c286553c"
      unitRef="usd">1735000</krys:AccruedPreclinicalAndClinicalExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfMy0xLTEtMS0w_403097fd-63d7-4bc8-bdbf-ed473829d531"
      unitRef="usd">1903000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfMy0zLTEtMS0w_aa6ecc1a-ae55-4137-b98f-d04395815721"
      unitRef="usd">642000</us-gaap:AccruedProfessionalFeesCurrent>
    <krys:AccruedPayrollAndBenefits
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNC0xLTEtMS0w_e2bde78c-dec6-4ebc-8eac-6c37f1a37fe7"
      unitRef="usd">1799000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPayrollAndBenefits
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNC0zLTEtMS0w_c11ec3f2-e69f-4710-a964-27402fb16d7e"
      unitRef="usd">1486000</krys:AccruedPayrollAndBenefits>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNS0xLTEtMS0w_e627f735-c7b9-45f0-9f8f-2c75356abd3b"
      unitRef="usd">32000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNS0zLTEtMS0w_6311022d-4886-43ea-a902-b1c729a58445"
      unitRef="usd">40000</us-gaap:AccruedIncomeTaxes>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNi0xLTEtMS0w_74f15b95-3492-496e-bf43-ac7bc973e29b"
      unitRef="usd">22064000</krys:AccruedConstructionInProgressCurrent>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNi0zLTEtMS0w_1eb61152-c2bf-45b4-bb9f-e266a357080d"
      unitRef="usd">1049000</krys:AccruedConstructionInProgressCurrent>
    <krys:AccruedFinancingFeesCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNy0xLTEtMS0w_85440ac7-2d65-440c-ba84-ab629b30f3cc"
      unitRef="usd">447000</krys:AccruedFinancingFeesCurrent>
    <krys:AccruedFinancingFeesCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfNy0zLTEtMS0w_4461e175-0d08-4665-9e63-3bfd1a740fb3"
      unitRef="usd">131000</krys:AccruedFinancingFeesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfOC0xLTEtMS0w_75aa164c-9961-4668-b9bc-da8945087fd3"
      unitRef="usd">11000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfOC0zLTEtMS0w_5f7e832f-2efa-4719-9c3e-41b3b4314c64"
      unitRef="usd">26000</us-gaap:OtherLiabilitiesCurrent>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfOS0xLTEtMS0w_c4b7c945-516b-42b5-85cf-d03a7fa4d7c8"
      unitRef="usd">29999000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80My9mcmFnOjc1YWNmNzcwOWQ3MTRlNTc4Y2U5ZTI5ODVhZmYzNGJlL3RhYmxlOjZjMDVkMWFjMjNmYTQwMTBiY2JjZGUwZDFiMDZkZmI1L3RhYmxlcmFuZ2U6NmMwNWQxYWMyM2ZhNDAxMGJjYmNkZTBkMWIwNmRmYjVfOS0zLTEtMS0w_8418e689-9e8e-4cc8-bac8-6b7b90c2824d"
      unitRef="usd">5109000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTAwNDI_7eac6911-9aab-4953-aea8-d5d9c7787b37">Commitments and Contingencies&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Contracts and Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and expired on October 31, 2017 (the &#x201c;2016 Lease&#x201d;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 44,000 square feet.  As a result of the lease amendments, the lease expiration date was extended to October 31, 2031.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 26, 2019, we entered into a lease agreement for our second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord" or "Northfield") with an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"Ground Lease"). A cash contribution in the amount of $2.4&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $10.0&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of September&#160;30, 2021. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, future minimum commitments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded operating lease costs of $339 thousand and $836 thousand for the three and nine months ended September&#160;30, 2021 and $148 thousand and $458 thousand for the three and nine months ended September&#160;30, 2020, respectively, and variable lease costs of $65 thousand and $183 thousand for the three and nine months ended September&#160;30, 2021 and $60 thousand and $88 thousand for the three and nine months ended September&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreements with Contract Manufacturing Organizations and Contract Research Organizations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various agreements with Contract Manufacturing Organizations (&#x201c;CMOs&#x201d;) for the manufacture of sterile excipients that are formulated with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. The Company has also entered into agreements with third-party Contract Research Organizations ("CROs") to provide research and development services to further the Company&#x2019;s analysis of its product candidates. The agreements entered into with the CMOs and CROs provide the terms and conditions for their respective services, which may include research and development activities, storage, packaging, labelling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of September&#160;30, 2021 under these agreements is approximately $2.6 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $744 thousand and $3.3 million for the three and nine months ended September&#160;30, 2021 and $1.3 million and $2.3 million for the three and nine months ended September&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Preparedness Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate, B-VEC. These contracts typically call for the payment of fees for services upon the achievement of certain milestones.  The estimated remaining commitment as of September&#160;30, 2021 is $3.9 million. The Company has incurred expenses under these activities of $1.8 million and $4.1 million for the three and nine months ended September&#160;30, 2021 and $582 thousand and $1.1 million for the three and nine months ended September&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASTRA Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2021 is $39.4 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#x201c;Agreement&#x201d;) with The Whiting-Turner Contracting Company (&#x201c;Whiting-Turner&#x201d;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work, subject to a guaranteed maximum price to be agreed upon in an amendment to the Agreement at a later date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $78.9 million, subject to certain additions and deductions by change orders as provided by the Agreement, and the date of Substantial Completion of Whiting-Turner's work under the Agreement is March 30, 2022. Whiting-Turner&#x2019;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#x2019;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2020, a complaint was filed against us in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and Chief Operating Officer, Krish Krishnan and Suma Krishnan, respectively. The complaint alleges breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserts were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#x2019;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, we filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. On July 29, 2020, PeriphaGen filed its response to our answer and counterclaim, denying the allegations in the counterclaim. On the same day, Messrs Wechuck and Krisky filed a motion to dismiss the third-party complaint on various grounds, and we opposed the motion. On December 1, 2020, the court ruled on Messrs. Wechuck and Krisky's motion to dismiss our third-party complaint. The court determined that our claims for contribution and indemnification based on PeriphaGen's state law claims for unfair competition and misappropriation of trade secrets can proceed. Our breach of contract claim will also go forward in full. Fact discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PeriphaGen is seeking monetary damages, injunctive relief, attorneys' fees and costs. While we are unable to provide any assurances as to the ultimate outcome of the case, we believe the allegations in the complaint are without merit, and we intend to vigorously defend against them. We are currently unable to estimate the costs and timing of any litigation, including any potential damages if PeriphaGen were to prevail on its claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received insurance proceeds during fiscal year 2021 relating to legal defense costs and expenses associated with the PeriphaGen litigation. During the three and nine months ended September&#160;30, 2021, the Company has received $954 thousand of insurance proceeds and an additional $619 thousand has been approved for reimbursement, which is expected to be received in November 2021 and has been recorded as a receivable within Prepaid Expenses and Other Current Assets on the Condensed Consolidated Balance Sheet as management determined that the amount was probable of collection. The reimbursements have been recorded as an offset to our legal fees included in General and Administrative expenses on the Condensed Consolidated Statements of Operations and within Operating Activities on the Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <krys:AdditionalAreaOfRealEstatePropertyLeased
      contextRef="ifc4f34c83c884eb3be6bb60125c76063_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMzYy_7cc21594-3d9a-4e1e-bbfa-c417a04d7a97"
      unitRef="sqft">44000</krys:AdditionalAreaOfRealEstatePropertyLeased>
    <krys:PaymentToEscrowForReducingLeaseRentals
      contextRef="i552d49a6c87f436ebf2aeb62b171e6bc_I20200121"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTgxNg_255bc3c9-89b0-4cae-9eb1-f5caf4a55fa2"
      unitRef="usd">2400000</krys:PaymentToEscrowForReducingLeaseRentals>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i91240de4fd2c49149368668c1fc1aa2c_D20201015-20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTgzMA_91ca6a9b-31cc-450d-9f63-27ab04e2a7ea"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:ConstructionInProgressGross
      contextRef="i51817723d8bc4777b149972dc507b6d6_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg0NA_837142fb-3067-4260-833f-af05a74d36da"
      unitRef="usd">10000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:FinanceLeaseLiability
      contextRef="i51817723d8bc4777b149972dc507b6d6_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg0NA_c912095a-0dc1-45f9-b492-b5550ff41dc6"
      unitRef="usd">10000000</us-gaap:FinanceLeaseLiability>
    <krys:PaymentToEscrowForReducingLeaseRentals
      contextRef="i51817723d8bc4777b149972dc507b6d6_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMjEwNA_1fea3d8c-b4c4-4e6d-ab67-2e8fefe41ed5"
      unitRef="usd">2400000</krys:PaymentToEscrowForReducingLeaseRentals>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i91240de4fd2c49149368668c1fc1aa2c_D20201015-20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTc4OA_2c02b7c3-5e06-4eec-8e16-269e6b576568"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:EscrowDeposit
      contextRef="i1a7ea7f3f0af418a9798c126d95ba2fb_I20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTgwMg_28321cbc-0a1e-46c6-bbfa-0cfbf0d56bcd"
      unitRef="usd">1500000</us-gaap:EscrowDeposit>
    <krys:LessorOperatingLeaseLiabilityAnnualLeasePayments
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg1OQ_2df5c464-e57c-4551-9229-6cecfc64cc35"
      unitRef="usd">82000</krys:LessorOperatingLeaseLiabilityAnnualLeasePayments>
    <krys:CumulativeEscalationClausePercent
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg3Mw_a25c9c09-2ce5-4c8b-b511-216f814b736d"
      unitRef="number">0.10</krys:CumulativeEscalationClausePercent>
    <krys:CumulativeEscalationClauseTerm
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTYzOTg3Nw_43d54d8d-330e-466c-a23b-99af25802541">P5Y</krys:CumulativeEscalationClauseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTAwNDM_3df4527e-ac9f-43ca-8177-2d0c1dc1231d">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, future minimum commitments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfMS0xLTEtMS0w_1003fb4e-3337-4054-8ea1-d601e91c8b4e"
      unitRef="usd">255000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfMi0xLTEtMS0w_b248d1f0-5812-43bc-a4a4-cc2059760263"
      unitRef="usd">1094000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfMy0xLTEtMS0w_836bb2f4-150a-4503-80ee-d6ce60b6df61"
      unitRef="usd">1114000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfNC0xLTEtMS0w_808651e9-b302-411b-8fda-c3f7bad0750c"
      unitRef="usd">1135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfNS0xLTEtMS0w_3183300d-e6f9-43b4-99ed-052a689b9931"
      unitRef="usd">1162000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfNi0xLTEtMS0w_90394464-7fee-4bae-ac38-2d3c8d9f2ec1"
      unitRef="usd">12786000</krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfNy0xLTEtMS0w_384cb42c-7bcb-4d0d-9fe7-fc1240c9eb50"
      unitRef="usd">17546000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfOC0xLTEtMS0w_4261c4c5-c197-407f-ba12-ea2bdfeb352e"
      unitRef="usd">9444000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOjZjYzZmZDY3NjQxMDQzMDJiMDMyNjJjZDJhNDc5MDU2L3RhYmxlcmFuZ2U6NmNjNmZkNjc2NDEwNDMwMmIwMzI2MmNkMmE0NzkwNTZfOS0xLTEtMS0w_0a587cbe-d31d-4062-b9a0-15bbedd590b0"
      unitRef="usd">8102000</us-gaap:OperatingLeaseLiability>
    <krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTAwNDQ_f8e7f86e-a298-424e-97b5-43d8361d2541">Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfMy0xLTEtMS0w_596b8690-865f-42a5-96a0-f9ca25229d42"
      unitRef="usd">7342000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfMy0zLTEtMS0w_fcc41958-ea9f-45a5-b132-2eaf23fdaa0e"
      unitRef="usd">3298000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNC0xLTEtMS0w_0a5863b9-538d-4a85-b7da-9ca10311a70e"
      unitRef="usd">1023000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNC0zLTEtMS0w_3c288e23-705f-4f25-984a-68428c12a583"
      unitRef="usd">638000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNS0xLTEtMS0w_5f1ed284-a42d-4731-87cf-ad2c3184b540"
      unitRef="usd">7079000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNS0zLTEtMS0w_0b3b824c-3224-45a1-bc0e-7e2e93b81409"
      unitRef="usd">3308000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNi0xLTEtMS0w_17dffe06-421c-4f99-b8af-6c2a020c0749"
      unitRef="usd">8102000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNi0zLTEtMS0w_803b9016-a9af-4c03-bccb-2ee7e7e737e6"
      unitRef="usd">3946000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNy0xLTEtMS0w_c55111a7-e7dc-45f4-8b10-03dbe4153bf9">P14Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfNy0zLTEtMS0w_14370a36-505d-493b-ad76-24166971b201">P16Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfOC0xLTEtMS0w_4716ef83-e973-4fea-9a77-d130bbb730b4"
      unitRef="number">0.092</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RhYmxlOmY1ZmFhYTYxZmU2ODQ2YzliYjQwYmQzMjNkM2Y1YWQ0L3RhYmxlcmFuZ2U6ZjVmYWFhNjFmZTY4NDZjOWJiNDBiZDMyM2QzZjVhZDRfOC0zLTEtMS0w_48152e9d-24df-4065-98a4-3d3e31bf98b2"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDU5Mg_c81ff07c-797c-4295-9dda-c419921d8da9"
      unitRef="usd">339000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDU5OQ_58313833-9309-44a0-ba95-d55d22a1df36"
      unitRef="usd">836000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDYzMw_6ce904c8-c6d0-4332-9256-2be4809491a5"
      unitRef="usd">148000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDY0MA_e731d197-9719-4fc1-81f2-d502656c5502"
      unitRef="usd">458000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDcxMw_fe0fe6f4-0273-4fff-be75-1fd28802e542"
      unitRef="usd">65000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDcyMA_ceadc5d4-42be-4509-baaa-b1f251a71c6f"
      unitRef="usd">183000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDc1NA_03ee01d1-b6ac-4b9e-9a0b-3b38a3a5cc14"
      unitRef="usd">60000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNDc2MQ_7b352619-41bf-4a0c-89ef-6f070f23454a"
      unitRef="usd">88000</us-gaap:VariableLeaseCost>
    <krys:RemainingCommitmentAmount
      contextRef="ibdb3c79bb37d40598236a397bfdf2732_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNTgwOA_f799c0c9-eb13-4716-95da-34fc9ffa68e8"
      unitRef="usd">2600000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="i3b4d91bb10244ecf85e9ff55bf22c6a3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjAxNw_806b4c23-de2b-4884-8bf1-599a58f278d1"
      unitRef="usd">744000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i780d412ff27c4f4fb4ad7befad90ed62_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjAyNA_35c9e12a-be79-4526-9aba-5c2c3f36adfc"
      unitRef="usd">3300000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i7481ea7a3508451e84e2ce446d95a16d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjA1OA_ae499920-30c6-4c7f-8380-c467ceebb7f0"
      unitRef="usd">1300000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="iae859592e93741fba5e8767be4c58a3f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjA2NQ_23486b3d-c2f7-4bf3-a7c3-df12619fad23"
      unitRef="usd">2300000</us-gaap:ProfessionalFees>
    <krys:RemainingCommitmentAmount
      contextRef="i48eae196563f44c886012909931c2a7d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjU5OQ_100848db-93f6-4066-ba5e-06e3473315e9"
      unitRef="usd">3900000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="i7867867a17654c0bba0b47e105576b16_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjY2Mw_3c352e54-53d9-42a8-b825-370115f4e0fc"
      unitRef="usd">1800000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i808f837ef3eb42e09cf35d83a641a5ce_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjY3MA_91691859-50db-46a8-81ff-3a6d0c5c258b"
      unitRef="usd">4100000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="ica6cf359423442cda103cac2e7b58836_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNjcwNA_fc727774-407d-4f8f-a4e7-116b1add0054"
      unitRef="usd">582000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i34e1df8bf9c941ec85693b9f008abbf2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTY0OTI2NzQ1MzY2OQ_8c29f995-17ae-4ba6-aa38-2bcc82ab69f8"
      unitRef="usd">1100000</us-gaap:ProfessionalFees>
    <us-gaap:ContractualObligation
      contextRef="icefbb0dcf23b4a9db9500e432e160acd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTY0OTI2NzQ1Mzc4Mg_a7138087-314c-4b1c-9002-8eb1e68da6b1"
      unitRef="usd">39400000</us-gaap:ContractualObligation>
    <krys:CostOfWorkPercentage
      contextRef="icefbb0dcf23b4a9db9500e432e160acd_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfNzgzOA_f9e94f7a-c7a6-4c22-b996-e2131692d965"
      unitRef="number">0.0175</krys:CostOfWorkPercentage>
    <krys:LossContingencyGuaranteedMaximumPriceToBePaid
      contextRef="icae80f11bf7c417fa7f665a031b58b73_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTA5OTUxMTY0NDU5Nw_9d6e2133-6fb6-4725-bb44-0908fcafdffb"
      unitRef="usd">78900000</krys:LossContingencyGuaranteedMaximumPriceToBePaid>
    <krys:LossContingencyReceivableReceivedAmount
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTY0OTI2NzQ1NDk0MA_1e88f5aa-e6ee-41e7-b173-f29db64c5823"
      unitRef="usd">954000</krys:LossContingencyReceivableReceivedAmount>
    <us-gaap:LossContingencyRelatedReceivableCarryingValueAdditions
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80Ni9mcmFnOjhiMmE2MzEzMTU0MzQ3MjZhZjE2NjM3NTJmNzg1YjE2L3RleHRyZWdpb246OGIyYTYzMTMxNTQzNDcyNmFmMTY2Mzc1MmY3ODViMTZfMTY0OTI2NzQ1NDk3Mg_4626f2d6-a856-4b80-9296-e9367825ee78"
      unitRef="usd">619000</us-gaap:LossContingencyRelatedReceivableCarryingValueAdditions>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTc1OA_616c6645-a03a-4a4f-b622-1d09fafefc12">Capitalization&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2021, the Company completed a public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program"), under which Cowen will act as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of our common stock, par value $0.0001 per share, having an aggregate offering price up to $150.0&#160;million ("Placement Shares").  Related offering expenses payable by the Company were $172 thousand.  The issuance and sale of the Placement Shares by the Company under the Sales Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form S-3. During the nine months ended September&#160;30, 2021, 262,500 shares of common stock were issued pursuant to the ATM Program at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting underwriting discounts and commissions of approximately $524&#160;thousand, resulting in a remaining $132.5&#160;million available for issuance under the ATM Program.&lt;/span&gt;&lt;/div&gt;On May 21, 2020, the Company completed a public offering of 2,275,000 shares of its common stock to the public at $55.00 per share. Net proceeds to the Company from the offering were $117.2&#160;million after deducting underwriting discounts and commissions of approximately $7.5&#160;million, and other offering expenses payable by the Company of approximately $463&#160;thousand.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib295489090d1497185afd643ec967a56_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTU2MA_a3e94126-518f-4f7b-88cb-7f04c4a37420"
      unitRef="shares">2211538</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1760613e671947e5ba8f0fd15472bece_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTU3MQ_8a106d86-ee24-499f-9238-a51e642a8687"
      unitRef="shares">288461</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i0310113aa0194f0ba193480ce6faf7ef_I20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTU4MA_083aca1e-4be3-409e-8638-cb248d8c5076"
      unitRef="usdPerShare">65.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ib295489090d1497185afd643ec967a56_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMjc1_f80cc1eb-36c9-45bb-9e23-45fb5a795684"
      unitRef="usd">134900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="ib295489090d1497185afd643ec967a56_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTU4OA_d4c96043-b2dd-43d8-8b53-02a3510baa3b"
      unitRef="usd">8600000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i2d81be4c0fa64dd0b8e80538f57a09e8_D20210201-20210201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTY2Ng_6a9a2014-5f58-4443-b66a-cc6c51c88698"
      unitRef="usd">198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i35e810f93dfa47a7ba2d68780daf21d6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfODIx_2375f7d0-136d-465b-9f3e-d4714fe8cfee"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <krys:SaleOfStockAggregateOfferingPrice
      contextRef="i35e810f93dfa47a7ba2d68780daf21d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfODc2_5901cff6-3e8b-499f-9704-bfcc530df5d4"
      unitRef="usd">150000000</krys:SaleOfStockAggregateOfferingPrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i6cea238b09064f7bb11eb8a0267838ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfOTU2_306d364d-fb50-4c12-96cd-f3eaae9167fb"
      unitRef="usd">172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib33152efbe744812957d7c93ebcf8473_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTE4NA_e64e46b3-fe25-4d89-ac8c-9aeeaf9951bf"
      unitRef="shares">262500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7666a417eef840ce9941f0b9297bde02_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTI4MQ_2e2c3e2b-183e-4d63-883f-0c9768a06b72"
      unitRef="usdPerShare">66.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ic84fce3d22ab4e95a1361b9dc14e7326_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTY0OTI2NzQ0MzU3MQ_8daa17d2-cb69-4575-980d-c961755825a5"
      unitRef="usd">16900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="ic84fce3d22ab4e95a1361b9dc14e7326_D20210201-20210201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTY0OTI2NzQ0MzY0OA_0eebc9ff-5e04-4048-a2d3-820f6f6cec27"
      unitRef="usd">524000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <krys:SaleOfStockRemainingAvailableIssuanceAmount
      contextRef="ib33152efbe744812957d7c93ebcf8473_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTM0Mw_2f87982e-386e-4972-bcaa-f519aebbbdd5"
      unitRef="usd">132500000</krys:SaleOfStockRemainingAvailableIssuanceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2dacc94700004db9ad609717389032af_D20200521-20200521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTYwMg_ab98f263-928d-4031-a3e0-8e06867cd014"
      unitRef="shares">2275000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i64975891a997407ba786da1993f9bad1_I20200521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTYxMw_9c04491f-9907-46e0-a90d-e002e3f78da2"
      unitRef="usdPerShare">55.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i2dacc94700004db9ad609717389032af_D20200521-20200521"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTYyMQ_598384da-790d-4957-84a3-5e381de7fe6f"
      unitRef="usd">117200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i2dacc94700004db9ad609717389032af_D20200521-20200521"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTYzNw_6a492fa4-b3e1-419e-8c36-348645fe0daa"
      unitRef="usd">7500000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i2dacc94700004db9ad609717389032af_D20200521-20200521"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV80OS9mcmFnOjkwM2Y3MTk0YzQzNTRmZDliOTM4OWVlMDA4Y2RjNzJkL3RleHRyZWdpb246OTAzZjcxOTRjNDM1NGZkOWI5Mzg5ZWUwMDhjZGM3MmRfMTA5OTUxMTYyOTY1MQ_5a1428a5-387b-4397-b10b-e7e05adc7867"
      unitRef="usd">463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzI5OQ_1dc3d91e-0e1d-4649-9153-0604de5030cd">Stock-Based Compensation&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted to employees a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd non-employees ve&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;st ratably over four-year periods and stock options granted to directors of the company vest ratably over one year to four-year periods. Stock options have a life of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 322,500 and 1,122,450 stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2021, respectively, and 195,850 and 740,250 stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 50,000 and zero stock options to non-employees during the three and nine months ended September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2021 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and nine months ended September&#160;30, 2021 was $348&#160;thousand and $1.2&#160;million, respectively, and during the three and nine months ended September&#160;30, 2020 was $1.7&#160;million and $2.9&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value per share of options granted to employees and directors during the three and nine months ended September&#160;30, 2021 was $35.00 and $43.73, respectively, and during the three and nine months ended September&#160;30, 2020 was $27.44 and $30.58, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value per share of options granted to non-employees during the three and nine months ended September&#160;30, 2021 was $33.93 and $33.93, respectively, and during the three and nine months ended September&#160;30, 2020 was zero, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $51.9 million of unrecognized stock-based compensation expense related to employees and directors&#x2019; option awards that is expected to be recognized over a weighted-average period of 3.3 years as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $1.7 million of unrecognized stock-based compensation expense related to non-employees&#x2019; option awards that is expected to be recognized over a weighted-average period of 3.9 years as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $79&#160;thousand and $182&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2021, respectively, and zero of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense of $3.2 million and $9.0 million for the three and nine months ended September&#160;30, 2021, respectively, and $1.4 million and $2.7 million for the three and nine months ended September&#160;30, 2020, respectively. The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. Restricted stock awards have a life of ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted zero and 98,800 RSAs to employees of the Company during the three and nine months ended September&#160;30, 2021, respectively, and zero RSAs to employees of the Company during the three and nine months ended September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSA activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, 98,800 RSAs were outstanding.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock award was $78.89 reflecting the closing price of our common stock on the grant date.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs of $491 thousand&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $1.2 million for the three and nine months ended September&#160;30, 2021, respectively, and zero for the three and nine months ended September&#160;30, 2020, within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares remaining available for grant under the Company&#x2019;s stock incentive plan were 1,381,481, with a sublimit for incentive stock options of 379,921, at September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwMA_c8eed7cf-781b-40bb-a6e2-36c590b3c2ee">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9d1fbc3d234f4c31903d00f50bd07271_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQ0NQ_1382492f-38ff-4e59-ad4d-0297c4fa5a67">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5feb93df6b024f7cbfaad880dd55f616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwMw_b128b803-a0cc-42ff-b507-0b7becafc7b4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjM0_46750a4d-79cd-45f2-af48-8c6278a2a91f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i01f2bb01dacd44a89c7370650b2b2cca_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjU5_b6234009-3cc4-44fc-b271-a8eb1a89adfd"
      unitRef="shares">322500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9d40c5e7efd84df4a8f860d865bd0141_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjY2_11669642-ed56-42a2-8978-a81eb4d7a601"
      unitRef="shares">1122450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzc0_a983292b-53aa-459f-b4dd-7f36a9ee0b27"
      unitRef="shares">195850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzgx_1a276c17-c230-4c5a-a8d6-b90edfdc2ee2"
      unitRef="shares">740250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7e84783b0eec4936825763ed74abe018_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNDc0Nw_b59b36dc-13a2-476f-8c0a-6976ab747683"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7444f7d4fc9f40e4b7424b6ec2b0fd54_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjc0ODc3OTA3NDA3MQ_70fe0b57-734a-4af3-bb04-146df43e74f4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwMQ_7419c657-2755-47eb-9950-e95e2446d3be">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2021 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMS0xLTEtMS0w_83b843bf-269b-4157-903c-3798c6fe265e"
      unitRef="shares">853614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMS0zLTEtMS0w_36864415-0903-4aac-bf03-bbe6363cdf51"
      unitRef="usdPerShare">40.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iff24ad40df3743eca1aab0a8298c6f52_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMS01LTEtMS0w_2df20362-8ef2-4df2-b7ef-c93418a9e622">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iebef65754afc438aa569cd6c2fec349d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMS03LTEtMS0w_2826dac3-f3df-42d7-ac9d-c6694f98c686"
      unitRef="usd">16804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMi0xLTEtMS0w_e4f7787f-12f5-43b4-ab76-21edd85d7764"
      unitRef="shares">1172450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMi0zLTEtMS0w_dc6ad491-62bc-43e0-b315-76d7bedec0fa"
      unitRef="usdPerShare">67.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMy0xLTEtMS0w_c4531693-2150-4bf2-8777-35e856aa71c0"
      unitRef="shares">49726</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfMy0zLTEtMS0w_c4f23728-cea3-4f78-8d2e-e60ccbc482c9"
      unitRef="usdPerShare">38.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNC0xLTEtMS0w_79f42be0-cfee-4dd9-b6d9-241faf78b8e7"
      unitRef="shares">172000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNC0zLTEtMS0w_7c8e4e4c-e1a9-4d6c-921f-6ecd155a8f5d"
      unitRef="usdPerShare">61.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS0xLTEtMS0xMDI1Ng_ee6270ce-3c4e-4003-80c3-5fecbc24b790"
      unitRef="shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS0zLTEtMS0xMDI1OA_28836dd3-6889-410c-81b0-4b46d9310a85"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS0xLTEtMS0w_4f442bc3-d170-48f6-aeb9-5e5cd1cd1ea4"
      unitRef="shares">1801838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS0zLTEtMS0w_2831a30c-4c6a-4ab8-b7fe-8bb9a6b2aa28"
      unitRef="usdPerShare">55.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS01LTEtMS0w_c7df0bd1-d980-4de5-8652-ab8dbf2fb38e">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNS03LTEtMS0w_7d659cfb-d0f3-42f8-a980-168344680b95"
      unitRef="usd">9456000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNi0xLTEtMS0w_7579ffa4-f648-49ca-9c8c-8adea6ae8c31"
      unitRef="shares">265843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNi0zLTEtMS0w_8fddfa5d-4aaf-4bc0-bb47-364d43e9d467"
      unitRef="usdPerShare">30.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNi01LTEtMS0w_5b7a9ffc-dc8c-46b6-8412-52a8b77f7da5">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i62b974e3062741518c63511eaaa01aa5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjcyMjMyOGZhNDg0YTQzYmU5NWUxZWZlZWU5MGFlOTU5L3RhYmxlcmFuZ2U6NzIyMzI4ZmE0ODRhNDNiZTk1ZTFlZmVlZTkwYWU5NTlfNi03LTEtMS0w_898fefdd-f465-4e53-8358-55ee4dc684d2"
      unitRef="usd">6087000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfOTA1_3d2219aa-ab06-4608-bd7d-fb542ae2222b"
      unitRef="usd">348000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfOTEy_db12f33c-f1ca-444c-8c27-1b479a3266fd"
      unitRef="usd">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfOTY4_50b97ef5-dade-496c-807f-ec61f4f8d820"
      unitRef="usd">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfOTc1_b10ad57a-ac47-42a5-a1c8-437d6a3bcde3"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTExMg_ce4242c4-c1a4-464b-b7ec-0336eecfb212"
      unitRef="usdPerShare">35.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTExOQ_1f8cb51e-cd99-4161-9e8f-ce4841468bb8"
      unitRef="usdPerShare">43.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTE3NQ_c3e34e53-d007-479e-bc7f-601d2c48319f"
      unitRef="usdPerShare">27.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTE4Mg_c2854862-deba-4fc6-9e42-3836d4337f3b"
      unitRef="usdPerShare">30.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7e84783b0eec4936825763ed74abe018_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQxNw_46e2d238-5924-47c0-8a80-e26dceb87a69"
      unitRef="usdPerShare">33.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7444f7d4fc9f40e4b7424b6ec2b0fd54_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQyMw_52207225-e9b1-49d7-b9ac-71463b54ba85"
      unitRef="usdPerShare">33.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if0b83729187442bdba220a841af20bcc_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQyNg_a7d93b3d-988c-4aa9-bbff-01232653d672"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5eb5f40093234fb2a5fbe54c4b287a17_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNTQyNg_eb6dcc70-8b9c-48b2-9f3c-9683652e7059"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i60121faa697c4cf4bdba3ea3cb5a3562_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTIxMA_3779fe43-1661-4701-b3cd-d8ec505780a9"
      unitRef="usd">51900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1c1f98d79c5f4e3aa04f39f090ddce51_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTM2Ng_80158543-fbc5-4092-bafa-c6b9b64e6095">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i7affc8789534432280b25eb22852bb8c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNjQ4Nw_f2416aa8-bc2e-4e3b-b653-ff1b912e0f6c"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfNDM5ODA0NjUxNjQ5OA_a24c8823-d170-4149-82b0-6bd34f2e9497">P3Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwNA_99371ba2-086f-41a5-a8c6-7627294fb623">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020 as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, 98,800 RSAs were outstanding.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock award was $78.89 reflecting the closing price of our common stock on the grant date.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs of $491 thousand&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $1.2 million for the three and nine months ended September&#160;30, 2021, respectively, and zero for the three and nine months ended September&#160;30, 2020, within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie26740af942247b2a3bb8eb3a07f6bef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfMy0xLTEtMS0w_7bc2f43d-c560-451c-beea-6fdf51810959"
      unitRef="usd">673000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i97da03d07b90493f982743fb141e7298_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfMy0zLTEtMS0w_4763c5a9-fa72-474e-9111-ccd5a0e1fb11"
      unitRef="usd">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65d5be9cd51d4b70b5ec51f29beb8aee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfMy01LTEtMS0w_cca657c2-2058-4a57-bdc8-91f320010980"
      unitRef="usd">2273000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd8493f9588d450d89ac8a3c4f8dd0bb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfMy03LTEtMS0w_912ad4e5-cb7f-4fb3-9487-0fa4ce0b9a7b"
      unitRef="usd">714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2a828aba9334f18af2e6159a18dfa2c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNC0xLTEtMS0w_ad2ef856-8347-4ed4-b052-0ecc8ca96429"
      unitRef="usd">2502000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e0e48d0c15d47f7a3586bad35785d87_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNC0zLTEtMS0w_6d762da1-e280-40f0-8f7c-68f33a8ba4da"
      unitRef="usd">1012000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95c821ed52594cc09bc5d3e97fd84ca7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNC01LTEtMS0w_1cdd1ba5-24cd-4102-ac06-3f65ea1a5df0"
      unitRef="usd">6742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1224c3cee3aa43cfa95fe86ed4bcfc62_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNC03LTEtMS0w_41e071c3-dcdc-4d80-9499-ebfe759d140e"
      unitRef="usd">1988000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNS0xLTEtMS0w_626dc61a-a413-4f47-9738-71891ab0cf8e"
      unitRef="usd">3175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNS0zLTEtMS0w_c20acc6d-a015-4c70-ab68-5098a138d66b"
      unitRef="usd">1356000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNS01LTEtMS0w_d9451063-1339-45de-b512-2bb83a0472e2"
      unitRef="usd">9015000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmRlNzE5Y2EyZjMwYzRhMmU4MjdhNzUyNzY0ZDU5ZWE3L3RhYmxlcmFuZ2U6ZGU3MTljYTJmMzBjNGEyZTgyN2E3NTI3NjRkNTllYTdfNS03LTEtMS0w_90c88b14-ba42-4389-a0cd-3ec8ee32234e"
      unitRef="usd">2702000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTc0NQ_8d07c18e-d8cb-4d92-947c-8a543d33f675"
      unitRef="usd">79000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTc1Mg_5b37fbef-45f0-4024-b295-dcb3e4460f84"
      unitRef="usd">182000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ib2a74633f0454964adb14e384ed39ca6_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTg0OQ_85ef792d-8cdb-4941-8d54-da9400d3295f"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7eaab373ede2465a9095c4fa09ff3d94_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTg0OQ_ace512c4-1d58-4bff-80f9-bc2d9a43f323"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTk5OQ_e9c671dc-9ab0-4001-a429-3c0f71814fc3"
      unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjAwNg_b3092904-3909-4e18-a87e-5b2f26e43e69"
      unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjA1NQ_f648c18b-96c1-47ee-af5f-75238b5cf230"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjA2Mg_0ed7e2f8-f300-4f10-ac34-d1b00c221929"
      unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwNQ_5c6fef0a-5378-4d76-a50d-71ea16c0f98f">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2021 and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMi0xLTEtMS0w_bbb4d48f-339e-4800-96d3-8b43351ca28e"
      unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMi0zLTEtMS0w_f2e25f68-cadd-4154-bd23-8db644592abe"
      unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMi01LTEtMS0w_f94172c6-ddf4-43bb-b965-0a8f1940424f"
      unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMi03LTEtMS0w_069a7568-5c08-45ca-b1bc-d3da85dac8d1"
      unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMy0xLTEtMS0w_0dabf538-ddf0-42f2-bfc5-a6a3c2ee79c0">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMy0zLTEtMS0w_eac853d2-9b45-4b16-bced-d30963b6abdf">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMy01LTEtMS0w_bb8c98aa-c1e8-4aa5-b3e7-7d1f3e00b328">P6Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfMy03LTEtMS0w_053dbd73-5c07-4108-9ad1-3de8aa653476">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNC0xLTEtMS0w_dbb33404-306f-4320-a51b-4f5cda0fe44c"
      unitRef="number">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNC0zLTEtMS0w_421ed92a-cff1-4d62-8b1c-5b7dd300c6eb"
      unitRef="number">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNC01LTEtMS0w_c045ada8-4359-43b2-a961-a23013d1d5bd"
      unitRef="number">0.0105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNC03LTEtMS0w_79dba72b-a051-4604-8047-a91089cb67b9"
      unitRef="number">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNS0xLTEtMS0w_b96033f2-320e-40a0-8c99-36ddaa878b2f"
      unitRef="usdPerShare">53.69</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNS0zLTEtMS0w_543078f4-3d4b-4e9d-aee6-d242c2c96e48"
      unitRef="usdPerShare">41.89</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNS01LTEtMS0w_d32b919a-daf5-41ae-ae5c-8f93cdcfbc18"
      unitRef="usdPerShare">67.15</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNS03LTEtMS0w_54042fb3-bf56-4fb2-ad55-96e214280410"
      unitRef="usdPerShare">46.46</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNi0xLTEtMS0w_7f102c9a-180c-4e8f-988c-6b3dc2a12157"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i915b796477f1445ab800e1f8c3513038_D20200701-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNi0zLTEtMS0w_1fb1cad2-2af4-44f2-ad44-d47338a1f303"
      unitRef="number">0.1085</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i130fae2d0d194d4797da0fc8d648a7af_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNi01LTEtMS0w_4a4e76db-126b-4d09-81af-ffc3e7e01b91"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="ibf048825292740a3ad1c5feb40c0dfdd_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmNiZTE3ZjYyYjQ2ZjRkNDM5NWEyZTZjYmE3ZjdkNTU5L3RhYmxlcmFuZ2U6Y2JlMTdmNjJiNDZmNGQ0Mzk1YTJlNmNiYTdmN2Q1NTlfNi03LTEtMS0w_e18c4aa1-887f-4cb2-bba1-d44ca33b6913"
      unitRef="number">0.1085</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id4451954ae1a4edab2286b6d5d667fdd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwNg_579e070b-5d62-42f3-8c53-80fe12a5e06b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjQ3MQ_d956c829-454c-4ac2-84e3-2d214503ddc8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjQ3OA_76a31096-5883-4cfe-bcbe-6b81feb145ec"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id703799af79f4f7a929cf79a1de29747_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjU2Mw_1aa8779c-446e-45df-8f54-272db5883ffa"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia8eaea3be6bb40f18cd2f3f4801f7642_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjU2Mw_bff6776c-e10c-430b-96ff-b8135aaef7b3"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzMwNw_39bf9ba5-a17f-4f65-a823-7512cf154027">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSA activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i132e1504fcb94c2395a26312d77352a0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMS0xLTEtMS0w_a3794d76-3b52-4c64-861d-06fcd1e64310"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i132e1504fcb94c2395a26312d77352a0_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMS0zLTEtMS0w_2bcd228c-33c0-4ca1-b281-80404e099bb6"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMi0xLTEtMS0w_206be581-e369-4ba3-b8bc-b77faf9f2a73"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMi0zLTEtMS0w_7e56f25f-0e21-4e8c-bd57-9682720b352f"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMy0xLTEtMS0w_27e349da-bdf5-430d-8edc-5aa2027532bb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfMy0zLTEtMS0w_bacf110a-b087-4388-8e11-fae087341868"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfNC0xLTEtMS0w_3696343a-2b40-4407-bff3-e8a877b45fdb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfNC0zLTEtMS0w_a9b8a249-318f-4c24-907f-dc5676a92622"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib02e0c13ab2041b283dbcc71cc381e44_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfNS0xLTEtMS0w_d52bb82e-5975-4532-b37c-a95e9a75e859"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib02e0c13ab2041b283dbcc71cc381e44_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOmQyZTBmNmUzN2I2MDQ1YTk5Y2U4ZDczMjZlM2QwOWQxL3RhYmxlcmFuZ2U6ZDJlMGY2ZTM3YjYwNDVhOTljZThkNzMyNmUzZDA5ZDFfNS0zLTEtMS0w_24994108-7d51-45c8-9dff-9bf7d6456a24"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib02e0c13ab2041b283dbcc71cc381e44_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjcxNg_eebb76bb-e029-4e02-a42c-cb749eb722f9"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjc4Ng_12422e56-c69e-4e24-b8eb-5aa2aae2837b"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjkzMA_3ef6bc74-e7c6-4506-8f69-24ef4694a509"
      unitRef="usd">491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMjkzNw_9e6fa221-4d48-4385-a6cb-28783a5b6be9"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia8eaea3be6bb40f18cd2f3f4801f7642_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTA5OTUxMTYzMjUwMg_2cb96ea5-7846-4ffe-8e9c-83d226877a8b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id703799af79f4f7a929cf79a1de29747_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMTA5OTUxMTYzMjUwMg_d9681128-3a3f-4f8e-9745-f43833627d1f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24202ad4adbf4f7eab4c44f57bec5ea6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfMy0xLTEtMS0w_9b5a96a8-0011-492e-9523-63ee04906855"
      unitRef="usd">491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia0e866668c45429e8d1f0d8e8b8d3a48_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfMy0zLTEtMS0w_2ac61694-4695-434b-aa1b-3df0c0631d92"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61932feef1d64f7bbbc45f3ed5b46e1d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfMy01LTEtMS0w_a0e4e2f9-1ed9-4f18-9fca-fe46b18b4496"
      unitRef="usd">1159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib4c4bdc17ee04d84a5123fc95c1f8964_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfMy03LTEtMS0w_d22316e7-9408-4e5e-a7b0-63eb588d74d1"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i348212cd87ea4d1086eb7c0f96b4829a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfNC0xLTEtMS0w_ef2a1ade-5813-443c-ad4b-89990b2c573c"
      unitRef="usd">491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id703799af79f4f7a929cf79a1de29747_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfNC0zLTEtMS0w_cf12c678-5b90-429b-ab41-133b4c72d442"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfNC01LTEtMS0w_69d1ad25-9fd2-4491-b56c-44f9419e3b5b"
      unitRef="usd">1159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia8eaea3be6bb40f18cd2f3f4801f7642_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RhYmxlOjhkZTFkZDkwYTVmMjQ5OTliNGE1ZjRkZjRlMDFlNWNlL3RhYmxlcmFuZ2U6OGRlMWRkOTBhNWYyNDk5OWI0YTVmNGRmNGUwMWU1Y2VfNC03LTEtMS0w_1e2fa292-b889-48cb-a584-0fc31490cf63"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id851b0ef34164eb1badf918d62103e06_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzIzOQ_8b83090a-41a5-4376-82db-da373f5d710b"
      unitRef="shares">1381481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i84499c680dce48a880d22dfb5d4f52a8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81Mi9mcmFnOjQwNTNhZTM4M2RlODQ1OTdhMjY3Mjg1ZDkyYzAzMTAxL3RleHRyZWdpb246NDA1M2FlMzgzZGU4NDU5N2EyNjcyODVkOTJjMDMxMDFfMzI5MA_247cf3f1-990d-4f79-8726-980fb09bb909"
      unitRef="shares">379921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81NS9mcmFnOmEzZTEyNWM2Y2FmYTRhNzI4ZDQ4NGJjNzRmM2VjZjViL3RleHRyZWdpb246YTNlMTI1YzZjYWZhNGE3MjhkNDg0YmM3NGYzZWNmNWJfMjU5_348b8ae5-1705-43e7-be58-a5c3ad43cc2d">Related Party TransactionsIn December 2019, the Company advanced $420 thousand to a member of our management team to cover the personal payroll and income taxes on their taxable income from NSO exercises. This employee repaid the Company in full in January 2020.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <krys:AdvanceToRelatedParty
      contextRef="i769dbf11dfe64b2d8b252dbee0ed9486_D20191201-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81NS9mcmFnOmEzZTEyNWM2Y2FmYTRhNzI4ZDQ4NGJjNzRmM2VjZjViL3RleHRyZWdpb246YTNlMTI1YzZjYWZhNGE3MjhkNDg0YmM3NGYzZWNmNWJfNzQ_ff4b9941-49e8-4c2c-8fd6-4c866c92b511"
      unitRef="usd">420000</krys:AdvanceToRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ic410ffc714874120b71c8155d66af84b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyN2I3ZTc4MmE3YjRmMmM5ZDU1YzA5ZjA4YjdhNGFlL3NlYzo1MjdiN2U3ODJhN2I0ZjJjOWQ1NWMwOWYwOGI3YTRhZV81OC9mcmFnOmYxZjQyMTY0ZTBiMTQ3Zjk4MTEzNzgxZmRmNDA5NzBjL3RleHRyZWdpb246ZjFmNDIxNjRlMGIxNDdmOTgxMTM3ODFmZGY0MDk3MGNfMzcw_c17dafd0-5b80-498a-8c8c-e0a4d33a30b3">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152404548472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Krystal Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1080209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 Wharton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pittsburgh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">15203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">586-5830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRYS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,237,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152394417768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 286,614<span></span>
</td>
<td class="nump">$ 268,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">56,479<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">3,796<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">345,812<span></span>
</td>
<td class="nump">275,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">78,642<span></span>
</td>
<td class="nump">30,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">19,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">7,342<span></span>
</td>
<td class="nump">3,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">451,095<span></span>
</td>
<td class="nump">310,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,757<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">29,999<span></span>
</td>
<td class="nump">5,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_BuildToSuitLeaseLiabilityCurrent', window );">Build to suit lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">35,779<span></span>
</td>
<td class="nump">15,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,079<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">42,858<span></span>
</td>
<td class="nump">18,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.00001 par value; 20,000,000 shares authorized at &#160;&#160; September&#160;30, 2021 (unaudited) and December&#160;31, 2020; 2,061,773 &#160;&#160; shares issued, and no shares outstanding at September&#160;30, 2021 &#160;&#160; (unaudited) and December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.00001 par value; 80,000,000 shares authorized at &#160;&#160; September&#160;30, 2021 (unaudited) and December&#160;31, 2020; 22,237,984 &#160;&#160; and 19,714,220 shares issued and outstanding at September&#160;30, 2021 &#160;&#160; (unaudited) and December&#160;31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">527,229<span></span>
</td>
<td class="nump">363,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (expense)</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(118,978)<span></span>
</td>
<td class="num">(71,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">408,237<span></span>
</td>
<td class="nump">292,084<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 451,095<span></span>
</td>
<td class="nump">$ 310,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_BuildToSuitLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build To Suit Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_BuildToSuitLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152402264104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">2,061,773<span></span>
</td>
<td class="nump">2,061,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">22,237,984<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">22,237,984<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152404672904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,080<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 18,875<span></span>
</td>
<td class="nump">$ 12,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,572<span></span>
</td>
<td class="nump">4,580<span></span>
</td>
<td class="nump">27,524<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">15,652<span></span>
</td>
<td class="nump">9,680<span></span>
</td>
<td class="nump">46,399<span></span>
</td>
<td class="nump">22,579<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,652)<span></span>
</td>
<td class="num">(9,680)<span></span>
</td>
<td class="num">(46,399)<span></span>
</td>
<td class="num">(22,579)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,492)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,589)<span></span>
</td>
<td class="num">(9,610)<span></span>
</td>
<td class="num">(47,764)<span></span>
</td>
<td class="num">(21,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (15,582)<span></span>
</td>
<td class="num">$ (9,630)<span></span>
</td>
<td class="num">$ (47,784)<span></span>
</td>
<td class="num">$ (21,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">22,212,266<span></span>
</td>
<td class="nump">19,676,016<span></span>
</td>
<td class="nump">21,893,656<span></span>
</td>
<td class="nump">18,477,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">22,212,266<span></span>
</td>
<td class="nump">19,676,016<span></span>
</td>
<td class="nump">21,893,656<span></span>
</td>
<td class="nump">18,477,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income (expense) and other nonoperating, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_InterestIncomeExpenseAndOtherNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152391453480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 202,914<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 241,951<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (39,047)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,354,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,341)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">198,369<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">242,733<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(44,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,370,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">202,914<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">241,951<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(39,047)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,354,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">301,720<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">362,531<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(60,831)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,706,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">198,369<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">242,733<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(44,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,370,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">117,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,293,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,833)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">309,696<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">360,877<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(51,221)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,664,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,610)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">301,720<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">362,531<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(60,831)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,706,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">292,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">363,292<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(71,214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">152,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,812)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">430,652<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">517,675<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(87,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">292,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">363,292<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(71,214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">408,237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">527,229<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(118,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,237,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">430,652<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">517,675<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(87,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,363)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">418,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">521,950<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(103,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,205,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,589)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 408,237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 527,229<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (118,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,237,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152404486120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,764)<span></span>
</td>
<td class="num">$ (21,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,985<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,174<span></span>
</td>
<td class="nump">2,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Loss on disposals of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidRent', window );">Prepaid rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(225)<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,726<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(27,038)<span></span>
</td>
<td class="num">(18,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(27,453)<span></span>
</td>
<td class="num">(7,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(83,810)<span></span>
</td>
<td class="num">(3,205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">11,033<span></span>
</td>
<td class="nump">5,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(100,230)<span></span>
</td>
<td class="num">(4,964)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">153,573<span></span>
</td>
<td class="nump">117,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PaymentsForSuitLiability', window );">Repayment of ASTRA build to suit liability</a></td>
<td class="num">(7,960)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">145,613<span></span>
</td>
<td class="nump">117,878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">18,345<span></span>
</td>
<td class="nump">94,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">268,269<span></span>
</td>
<td class="nump">187,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">286,614<span></span>
</td>
<td class="nump">282,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment</a></td>
<td class="nump">23,213<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_OfferingCostsIncurredButNotYetPaid', window );">Unpaid offering costs</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial recognition of right-of-use assets and modification</a></td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_OfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_OfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentsForSuitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Suit Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentsForSuitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152473304328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery for the treatment of serious rare diseases. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy to use, medicines to dramatically improve the lives of patients living with rare diseases.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had an accumulated deficit of $119.0 million. With the net proceeds raised from its public and private securities offerings, including the public offering of its common stock completed on February 1, 2021, the Company believes that its cash, cash equivalents and short-term investments of approximately $343.1 million as of September&#160;30, 2021 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388436216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended September&#160;30, 2021 and 2020, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, as filed with the SEC on March 1, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 -7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and nine months ended September&#160;30, 2021 and 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation-Stock Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Due to the lack of sufficient history and trading volume of our Common Stock and a lack of Company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the lack of Company-specific historical option activity, the Company has estimated the expected term of its employee and non-employee stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388322520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 1,900,638 and 853,336 common share equivalents outstanding as of September&#160;30, 2021 and 2020, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:47.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except shares and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,589)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,610)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,764)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,212,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,676,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,893,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,477,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.18)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.18)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388436216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Instruments</a></td>
<td class="text">Fair Value Instruments<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2021 and December&#160;31, 2020, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,044&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,740&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,716&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,479&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,237&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,330&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:22.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between one year and two years.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388308232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,211&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,031&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,485&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,630&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,395&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,244&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,753)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,368)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,642&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,876&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $474 thousand and $1.4 million for the three and nine months ended September&#160;30, 2021 and $399 thousand and $1.1 million three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,064&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,999&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388436216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and expired on October 31, 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 44,000 square feet.  As a result of the lease amendments, the lease expiration date was extended to October 31, 2031.  </span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, we entered into a lease agreement for our second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord" or "Northfield") with an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Ground Lease"). A cash contribution in the amount of $2.4&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $10.0&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4&#160;million.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of September&#160;30, 2021. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:83.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,546&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,102&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,342&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,079&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,102&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded operating lease costs of $339 thousand and $836 thousand for the three and nine months ended September&#160;30, 2021 and $148 thousand and $458 thousand for the three and nine months ended September&#160;30, 2020, respectively, and variable lease costs of $65 thousand and $183 thousand for the three and nine months ended September&#160;30, 2021 and $60 thousand and $88 thousand for the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various agreements with Contract Manufacturing Organizations (&#8220;CMOs&#8221;) for the manufacture of sterile excipients that are formulated with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. The Company has also entered into agreements with third-party Contract Research Organizations ("CROs") to provide research and development services to further the Company&#8217;s analysis of its product candidates. The agreements entered into with the CMOs and CROs provide the terms and conditions for their respective services, which may include research and development activities, storage, packaging, labelling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of September&#160;30, 2021 under these agreements is approximately $2.6 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $744 thousand and $3.3 million for the three and nine months ended September&#160;30, 2021 and $1.3 million and $2.3 million for the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate, B-VEC. These contracts typically call for the payment of fees for services upon the achievement of certain milestones.  The estimated remaining commitment as of September&#160;30, 2021 is $3.9 million. The Company has incurred expenses under these activities of $1.8 million and $4.1 million for the three and nine months ended September&#160;30, 2021 and $582 thousand and $1.1 million for the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2021 is $39.4 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work, subject to a guaranteed maximum price to be agreed upon in an amendment to the Agreement at a later date. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $78.9 million, subject to certain additions and deductions by change orders as provided by the Agreement, and the date of Substantial Completion of Whiting-Turner's work under the Agreement is March 30, 2022. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against us in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and Chief Operating Officer, Krish Krishnan and Suma Krishnan, respectively. The complaint alleges breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserts were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, we filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. On July 29, 2020, PeriphaGen filed its response to our answer and counterclaim, denying the allegations in the counterclaim. On the same day, Messrs Wechuck and Krisky filed a motion to dismiss the third-party complaint on various grounds, and we opposed the motion. On December 1, 2020, the court ruled on Messrs. Wechuck and Krisky's motion to dismiss our third-party complaint. The court determined that our claims for contribution and indemnification based on PeriphaGen's state law claims for unfair competition and misappropriation of trade secrets can proceed. Our breach of contract claim will also go forward in full. Fact discovery is ongoing.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PeriphaGen is seeking monetary damages, injunctive relief, attorneys' fees and costs. While we are unable to provide any assurances as to the ultimate outcome of the case, we believe the allegations in the complaint are without merit, and we intend to vigorously defend against them. We are currently unable to estimate the costs and timing of any litigation, including any potential damages if PeriphaGen were to prevail on its claims.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received insurance proceeds during fiscal year 2021 relating to legal defense costs and expenses associated with the PeriphaGen litigation. During the three and nine months ended September&#160;30, 2021, the Company has received $954 thousand of insurance proceeds and an additional $619 thousand has been approved for reimbursement, which is expected to be received in November 2021 and has been recorded as a receivable within Prepaid Expenses and Other Current Assets on the Condensed Consolidated Balance Sheet as management determined that the amount was probable of collection. The reimbursements have been recorded as an offset to our legal fees included in General and Administrative expenses on the Condensed Consolidated Statements of Operations and within Operating Activities on the Condensed Consolidated Statements of Cash Flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388318808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization</a></td>
<td class="text">Capitalization<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed a public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program"), under which Cowen will act as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of our common stock, par value $0.0001 per share, having an aggregate offering price up to $150.0&#160;million ("Placement Shares").  Related offering expenses payable by the Company were $172 thousand.  The issuance and sale of the Placement Shares by the Company under the Sales Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form S-3. During the nine months ended September&#160;30, 2021, 262,500 shares of common stock were issued pursuant to the ATM Program at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting underwriting discounts and commissions of approximately $524&#160;thousand, resulting in a remaining $132.5&#160;million available for issuance under the ATM Program.</span></div>On May 21, 2020, the Company completed a public offering of 2,275,000 shares of its common stock to the public at $55.00 per share. Net proceeds to the Company from the offering were $117.2&#160;million after deducting underwriting discounts and commissions of approximately $7.5&#160;million, and other offering expenses payable by the Company of approximately $463&#160;thousand.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388470392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd non-employees ve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st ratably over four-year periods and stock options granted to directors of the company vest ratably over one year to four-year periods. Stock options have a life of ten years. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 322,500 and 1,122,450 stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2021, respectively, and 195,850 and 740,250 stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 50,000 and zero stock options to non-employees during the three and nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:38.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,614&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.31&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,804&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,843&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2021 and the exercise price of outstanding in-the-money options.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and nine months ended September&#160;30, 2021 was $348&#160;thousand and $1.2&#160;million, respectively, and during the three and nine months ended September&#160;30, 2020 was $1.7&#160;million and $2.9&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees and directors during the three and nine months ended September&#160;30, 2021 was $35.00 and $43.73, respectively, and during the three and nine months ended September&#160;30, 2020 was $27.44 and $30.58, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to non-employees during the three and nine months ended September&#160;30, 2021 was $33.93 and $33.93, respectively, and during the three and nine months ended September&#160;30, 2020 was zero, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $51.9 million of unrecognized stock-based compensation expense related to employees and directors&#8217; option awards that is expected to be recognized over a weighted-average period of 3.3 years as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $1.7 million of unrecognized stock-based compensation expense related to non-employees&#8217; option awards that is expected to be recognized over a weighted-average period of 3.9 years as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:36.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $79&#160;thousand and $182&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2021, respectively, and zero of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense of $3.2 million and $9.0 million for the three and nine months ended September&#160;30, 2021, respectively, and $1.4 million and $2.7 million for the three and nine months ended September&#160;30, 2020, respectively. The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2021 and 2020:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.69</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.89</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.15</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.46</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. Restricted stock awards have a life of ten years.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted zero and 98,800 RSAs to employees of the Company during the three and nine months ended September&#160;30, 2021, respectively, and zero RSAs to employees of the Company during the three and nine months ended September&#160;30, 2020. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSA activity:</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:50.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, 98,800 RSAs were outstanding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock award was $78.89 reflecting the closing price of our common stock on the grant date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs of $491 thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $1.2 million for the three and nine months ended September&#160;30, 2021, respectively, and zero for the three and nine months ended September&#160;30, 2020, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:35.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares remaining available for grant under the Company&#8217;s stock incentive plan were 1,381,481, with a sublimit for incentive stock options of 379,921, at September&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152389776056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsIn December 2019, the Company advanced $420 thousand to a member of our management team to cover the personal payroll and income taxes on their taxable income from NSO exercises. This employee repaid the Company in full in January 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152389694856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152393253960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended September&#160;30, 2021 and 2020, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, as filed with the SEC on March 1, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div>As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of certificates of deposit, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 -7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and nine months ended September&#160;30, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation-Stock Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Due to the lack of sufficient history and trading volume of our Common Stock and a lack of Company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div>Due to the lack of Company-specific historical option activity, the Company has estimated the expected term of its employee and non-employee stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152389605656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Summary of Estimated Useful Lives of Assets</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 -7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful lives of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388460552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:47.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except shares and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,589)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,610)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,764)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,212,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,676,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,893,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,477,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.18)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.18)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152389822328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2021 and December&#160;31, 2020, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,044&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,740&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,716&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,479&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,237&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,330&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:22.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between one year and two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388436216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,211&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,031&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,485&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,630&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,395&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,244&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,753)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,368)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,642&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,876&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses And Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,064&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,999&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152389823992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:83.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,546&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,102&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</a></td>
<td class="text">Supplemental condensed consolidated balance sheet information related to leases is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,342&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,079&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,102&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental condensed consolidated balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152393837144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:38.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,614&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.31&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,804&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,843&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2021 and the exercise price of outstanding in-the-money options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</a></td>
<td class="text">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020 as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:36.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, 98,800 RSAs were outstanding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock award was $78.89 reflecting the closing price of our common stock on the grant date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs of $491 thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $1.2 million for the three and nine months ended September&#160;30, 2021, respectively, and zero for the three and nine months ended September&#160;30, 2020, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:35.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options, Valuation Assumptions</a></td>
<td class="text">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.69</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.89</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.15</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.46</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSA activity:</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:50.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152477020760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 118,978<span></span>
</td>
<td class="nump">$ 71,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 343,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152404360056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Recognized impairment losses for long lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152423292296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152389575768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</a></td>
<td class="nump">1,900,638<span></span>
</td>
<td class="nump">853,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152402395448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss per common share</a></td>
<td class="num">$ (15,589)<span></span>
</td>
<td class="num">$ (16,363)<span></span>
</td>
<td class="num">$ (15,812)<span></span>
</td>
<td class="num">$ (9,610)<span></span>
</td>
<td class="num">$ (6,833)<span></span>
</td>
<td class="num">$ (5,341)<span></span>
</td>
<td class="num">$ (47,764)<span></span>
</td>
<td class="num">$ (21,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">22,212,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,676,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,893,656<span></span>
</td>
<td class="nump">18,477,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">22,212,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,676,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,893,656<span></span>
</td>
<td class="nump">18,477,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152385918552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 286,614<span></span>
</td>
<td class="nump">$ 268,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">362,354<span></span>
</td>
<td class="nump">271,255<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">362,330<span></span>
</td>
<td class="nump">271,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">286,614<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">56,479<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">19,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">286,614<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">286,614<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">286,614<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">75,740<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">75,716<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 56,479<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 19,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market instruments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 286,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">286,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market instruments | Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">286,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">22,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">22,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">22,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">37,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">37,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">29,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">8,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">15,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">15,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">11,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 15,567<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152404790712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 82,395<span></span>
</td>
<td class="nump">$ 33,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(3,753)<span></span>
</td>
<td class="num">(2,368)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">78,642<span></span>
</td>
<td class="nump">30,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">70,211<span></span>
</td>
<td class="nump">23,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">5,723<span></span>
</td>
<td class="nump">4,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 5,485<span></span>
</td>
<td class="nump">$ 4,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152393867144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152404685048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedPreclinicalAndClinicalExpenses', window );">Accrued preclinical and clinical expenses</a></td>
<td class="nump">$ 3,743<span></span>
</td>
<td class="nump">$ 1,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedPayrollAndBenefits', window );">Accrued payroll and benefits</a></td>
<td class="nump">1,799<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Accrued taxes</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedConstructionInProgressCurrent', window );">Accrued construction in progress</a></td>
<td class="nump">22,064<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedFinancingFeesCurrent', window );">Accrued financing costs</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 29,999<span></span>
</td>
<td class="nump">$ 5,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedConstructionInProgressCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued construction in progress current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedConstructionInProgressCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedFinancingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Financing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedFinancingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPayrollAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll and benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPayrollAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPreclinicalAndClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPreclinicalAndClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due.  This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152390303992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 05, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 21, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PaymentToEscrowForReducingLeaseRentals', window );">Cash contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PurchasePriceOfPotentialBuildingPurchase', window );">Purchase price of potential purchase</a></td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments', window );">Lessor, operating lease, liability, annual lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CumulativeEscalationClausePercent', window );">Cumulative escalation clause</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CumulativeEscalationClauseTerm', window );">Cumulative escalation clause, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid', window );">Loss contingency, guaranteed maximum price to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LossContingencyReceivableReceivedAmount', window );">Loss contingency, receivable, received amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions', window );">Loss contingency, receivable, additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember', window );">Other Contractual Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember', window );">ASTRA Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CostOfWorkPercentage', window );">Cost of work, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember', window );">2016 Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AdditionalAreaOfRealEstatePropertyLeased', window );">Additional area of real estate property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AdditionalAreaOfRealEstatePropertyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional area of real estate property leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AdditionalAreaOfRealEstatePropertyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CostOfWorkPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Of Work, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CostOfWorkPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClausePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClausePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClauseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClauseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Liability, Annual Lease Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LessorOperatingLeaseLiabilityAnnualLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Guaranteed Maximum Price to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LossContingencyGuaranteedMaximumPriceToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LossContingencyReceivableReceivedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Receivable, Received Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LossContingencyReceivableReceivedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentToEscrowForReducingLeaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment to escrow for reducing lease rentals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentToEscrowForReducingLeaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PurchasePriceOfPotentialBuildingPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Potential Building Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PurchasePriceOfPotentialBuildingPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RemainingCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RemainingCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additions to receivables pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152404947768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remaining nine months)</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum operating lease payments</a></td>
<td class="nump">17,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">9,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 8,102<span></span>
</td>
<td class="nump">$ 3,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152394100984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 7,342<span></span>
</td>
<td class="nump">$ 3,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,079<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 8,102<span></span>
</td>
<td class="nump">$ 3,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, in years</a></td>
<td class="text">14 years 7 months 6 days<span></span>
</td>
<td class="text">16 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152387042056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>May 21, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="nump">2,211,538<span></span>
</td>
<td class="nump">2,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="nump">$ 65.00<span></span>
</td>
<td class="nump">$ 55.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="nump">$ 134,900<span></span>
</td>
<td class="nump">$ 117,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="nump">16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SaleOfStockRemainingAvailableIssuanceAmount', window );">Sale of stock, remaining available issuance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="nump">288,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=krys_StockSaleAgreementMember', window );">Stock Sale Agreement | Placement Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SaleOfStockAggregateOfferingPrice', window );">Sale of stock, aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockRemainingAvailableIssuanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Available Issuance Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockRemainingAvailableIssuanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=krys_StockSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=krys_StockSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152392362744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,850<span></span>
</td>
<td class="nump">1,172,450<span></span>
</td>
<td class="nump">740,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 348,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-based payment arrangement, amount capitalized</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">322,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,122,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">1,381,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="nump">$ 27.44<span></span>
</td>
<td class="nump">$ 43.73<span></span>
</td>
<td class="nump">$ 30.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,175,000<span></span>
</td>
<td class="nump">$ 1,356,000<span></span>
</td>
<td class="nump">$ 9,015,000<span></span>
</td>
<td class="nump">$ 2,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 51,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 33.93<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33.93<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock award granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock award outstanding (in shares)</a></td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 491,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,159,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">379,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krys_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152393922104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">195,850<span></span>
</td>
<td class="nump">1,172,450<span></span>
</td>
<td class="nump">740,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,801,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- average Remaining Contractual Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (Years), exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at September 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152393112312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 3,175,000<span></span>
</td>
<td class="nump">$ 1,356,000<span></span>
</td>
<td class="nump">$ 9,015,000<span></span>
</td>
<td class="nump">$ 2,702,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">491,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,159,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">673,000<span></span>
</td>
<td class="nump">344,000<span></span>
</td>
<td class="nump">2,273,000<span></span>
</td>
<td class="nump">714,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,502,000<span></span>
</td>
<td class="nump">1,012,000<span></span>
</td>
<td class="nump">6,742,000<span></span>
</td>
<td class="nump">1,988,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 491,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,159,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152388120088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) - Share-based Payment Arrangement, Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of the award (years)</a></td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 8 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">0.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 53.69<span></span>
</td>
<td class="nump">$ 41.89<span></span>
</td>
<td class="nump">$ 67.15<span></span>
</td>
<td class="nump">$ 46.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.85%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.85%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152404261960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152390336440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AdvanceToRelatedParty', window );">Advance to management team</a></td>
<td class="nump">$ 420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AdvanceToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AdvanceToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #PY:%,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  \.6A3GN$0M^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)^FJ:.CVHGA2$%Q0O(5D=C?8-"$9:??M3>-N%]$'\)B9/]]\
M ]/J(+6/^!Q]P$@6T\7D^B%)'=9L3Q0D0-)[="K5.3'DYM9'IR@_XPZ"TA]J
MA]!P?@T.21E%"F9@%18BZUJCI8ZHR,<CWN@%'SYC7V!& _;H<* $HA; NGEB
M.$Q]"V? #".,+GT7T"S$4OT36SK CLDIV24UCF,]KDHN[R#@[>GQI:Q;V2&1
M&C3F7\E*.@1<L]/DU]7=_>:!=0UO1"5$Q6\VHI'\5EY>O<^N/_S.PLX;N[7_
MV/@DV+7PZRZZ+U!+ P04    "  \.6A3F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #PY:%,LA$T^204  '86   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9A=4^LV$(:O3W^%)E?M#,&6G)!P)F0F!&@9SH% :,_03B\46XD]V%8JRX3\
M^Z[LQ Z,LO:T-^"O??-X);^KU6@CU6L6"J')>Q*GV44GU'K]U7$R/Q0)ST[E
M6J1P9RE5PC6<JI63K97@01&4Q YSW3,GX5':&8^*:S,U'LE<QU$J9HID>9)P
MM;T4L=Q<=&AG?^$I6H7:7'#&HS5?B;G0OZ]G"LZ<2B6($I%FD4R)$LN+SH1^
MG7H]$U \\4<D-MG!,3&OLI#RU9S<!A<=UQ")6/C:2'#X]R:F(HZ-$G#\LQ/M
M5+]I @^/]^HWQ<O#RRQX)J8R_A$%.KSH##LD$$N>Q_I);GX3NQ?J&SU?QEGQ
MEVS*9WN]#O'S3,MD%PP$2926__G[+A$' 8P="6"[ /8I@![[!6\7X!4O6I(5
MKW7%-1^/E-P099X&-7-0Y*:(AK>)4C.,<ZW@;@1Q>CR5;T*1+LE"KD0V<C1H
MFCN.OXN_+./9D?AS\EVF.LS(=1J(X&.\ RP5$-L#73)4<"[6I\1S3PAS&;7P
M3/'P!U^?$G9N"_^ XU7Y\0H]#\W/7Y-%IA5,N;\1R5XEV2LD>T<DKZ2?PX>@
MR?-V+6P9Q\.IVWU$*/H51;\=Q6/.E18JWI(GL99*VXAP*:UR@1"=541G[8AF
M0D4R,#.*P)RVI@A7VL^AG[Y\:9@&@XIMT'+,% <+*QSH>+IPK26/,RQ?PXII
MB.I<ISK26W(3Q8+<Y\E"*!L+KN&ZM.L-&741GO.*Y[P-SY-81>9C@63=\\0Z
M>KC.G=IFFL?D,I):^.$)N4W]4X2/NK77N6T(04\J&#MNAO&$S#5,,B(5F<H\
MU6H+_P,K=H/ZU34&>6#(M WD,W\GMP%,N6@9^04I,L@-DD/6I>[09>XY1LAJ
M0M:&<!($4#*RD_T!^0;/D8?4GCM<$F:@2WY #=+PGG #RAF&6KLW]?X[ZO-&
M6E%QR7D>P709N)BMT+H64-S-/P-.S1G,Q6>Y2:UPN-PLTCI;Y&H58G1UC:"X
MLW^FJSZ5F9)O4>K;AQK7G$TPM+I84-SC/Z/-9&$:?T;KX]\OKDC[S/4PMKI8
M4-SABT&<P*KZ. HNT*,, ZDK!,7M_9OT(2>S4*98B6@0Z0_/NOVAAY4(6M<(
MBIO[<Z2A7,DEH>SGQ2]D+OQ<0;:L6+C25"9)81;2?\76G75U8+A_0VD/HG1%
MYMMD(6,;48/ W=/+'".I2P##_7J?%7+][H<\78FCE;1!Z'XROYI@JT56FSYK
M9?K37"FS#BH7/T6ZP!-R:^?0H/CRN=_X2%9[/&OE\;<IK&++KM L&_D>U4J&
M*S:0U>;.6IF[6:'!Z@*L<R65=:HWZ$Q\'_I>6*^(H!3#Z&IS9ZW,?9[P&!9;
M>0:W,_LX_J_E/ZLMG;6R].M$J)696;^"@@[!0Y,U3^UYPP6;R&I#9[@?[\G>
M#]?_99MBQ<+5FK!J>V>M.H!Y*& $L33A,DT-":O=G;5J 0ZM&18-Q=8"><@U
M5.C46*RUK2^5^X6RV7QZ&S/&O,'YL#=RWBQ47FWL'N[+$^C<@J)[NXFY[<<O
M&P2:$N35SN[AAESUD3=19DKSB^"*W,!%ZX?7(-:TQ5%[NX<[\6>J70-^G N7
M>\164=[!SDLK7Y\"F *HVS00[^1.6&=X@Y0+?>Z 4C; &B"O]G4/]^-]$3P<
M1&RWHD&NVZ6LZUF'TCG8V3.V6&QX9L0WG6JYR5==K395)\56HE,_7N[(?N?&
M53,2BR6$NJ<#^-14N<E9GFBY+O8)%U)KF12'H>"!4.8!N+^4T(_O3LP/5%O-
MXW\!4$L#!!0    ( #PY:%.3E2NXQ 4  -T6   8    >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULO5AM;]LV$/XKA%=L*6#'(O7>)@::%,,&["6HV^TS(]$Q
M44G41,II]NMWE!3)%BG9'[892"S*=\?G[D@^=[QY%M57N6=,H6]Y5LC;Q5ZI
M\MUZ+9,]RZF\%B4KX)>=J'*J8%@]K659,9HV2GFV)HX3K'/*B\7FIGGW4&UN
M1*TR7K"'"LDZSVGU<L<R\7R[P(O7%Y_XTU[I%^O-34F?V):I+^5#!:-U;R7E
M.2LD%P6JV.YV\0&_NR>15F@D_N#L61X](^W*HQ!?]>#G]';A:$0L8XG2)BA\
M'=@]RS)M"7#\U1E=]'-JQ>/G5^L_-LZ#,X]4LGN1_<E3M;]=1 N4LAVM,_5)
M//_$.H=\;2\1F6S^H^=.UEF@I)9*Y)TR(,AYT7[3;UT@CA2P-Z% .@5RJ8+;
M*;B-HRVRQJV/5-'-326>4:6EP9I^:&+3:(,WO-!IW*H*?N6@IS;WHD@A*2Q%
M\"1%QE.J8'!',UHD#&VU88E6Z,OV([IZ\Q:]0;Q G_>BEK1(Y<U: 09M:9UT
M\]VU\Y&)^;:LO$:NLT3$(=BB?C^O_I$EH(X;=>=4?0V>]^Z3WGW2V'.GW*^K
MBA4*42G!SQF#;F_0;0QZ4P:IW",(#4KT _NKY@>:P0S64+6F@L:4WF^'#8F"
M 'LWZ\-Q2"QB042"N!<[0>KU2+U9I-N]J-1*L2J'E!Z85/D4S-:.?S2_'WAA
M/$)I2I$X=NT8_1ZC/XOQH6(EY2EBWTJ]2&436:'VK(*],9VY%K9O @KQ&+4I
MY(9Q8$<=]*B#6=2?A:+9!0 #<V[/CS 9033%2.@[?F0'&?8@PS.A!2JHU$L3
M4KU.2YW_)2J8LF$-#1!A%'ACJ*:4ZT3A1#BC'FDTB_0743Q=M$XC8W8<$S<<
M832E'#N^N,<7S^)KJ&\E=JM:LIELQV8$72. II!+XHE,8V<XXYU9A+\W.Z80
MQ>K\HNQ,'4,(QB@M,C@X6K>G,(^H"%^P;V:@86-:S\=.[(_AF7(N=B+/FP X
MD 6^C"TR3A]YQA5G<Y2!!\[ \Z3Q(4E$#8L:E?2%/F;,ZKQK.A_ZX\5MD2+8
M\2<<'Z@"SW/%J^,E4(8NOL0.90R*ISX2+U;()B5@A[ACR*94X$XM^8$X\#QS
M0$BKFLTRQV06._06_HCA,X9OBNDU.8%_H! \SR%W-<]2I 34UUQ=%&R3)IPQ
M5%,D#)R)TP\/1(+GF>24[LY%U4(1?F@4$Q8Q['O^U!$S4 D^PR47!-(DB- Q
M 9I2+G#=!+Z!2O \E[2Q/!=#DR4\$AT5!!U$4PP#&4_DFPQL0N;9Y%[D.6]9
MN*UT1:%X\<2*!/"BJ]^$8BAX:P,^;UAWK.]D21-VNX"65++JP!8;9&L2_@5#
MI\X/'$7P+ 5LE4B^[D66LDK^T-1-XU5T:OBH$2'G2MT=@RV4(JFG>(_>.-<.
M?#"00H6@B:C9>^AZEO!*_R&YIY4^UFH%=3S_&_2H0M]_AP/G??L?0:NE6/[(
MJG;\VG2AJ[J@=<JAS7O;Y ]ZJF.QKKF"R99.@)=AZ)Z:[2;F4L+YNFPL%.+U
MK:B55/ *UH/&,P7AQ.!E>*SKB9P]\V9%3E,UT#4YT^/!!@ 2G,E3]+_FB2RA
MREW&D7=J5^O@>!EB;TF(<YJWE@[_LV0M$4Q5LN:*)K.>LL0L5(S4S8F<IFXH
M9,A\(?,A!>Q0P< AJQO+%2^@42\Y'+I6D);.EX2$C,G (N<&4+A/T!49JAAR
MMHJI\SIKKF2ZXD7D<*3M]3W:@4%#!&.&KKHJQW[HF@7*RKABL A-=&UD*&'(
M? ES##YE.YYP:V=)S*IDA7$4AV,^LPF&F.")LIX,!0RYI("19T_V#J]9FGA.
M9/:9%CE8$="&3, =:A@R7\,8-4*S$2^&'QFW2=8FRB)G;:+61W>/^N+W5UH]
M\4)"R;H#1><ZA !4[5UJ.U"B;*XC'X52(F\>]XP";"T O^\$%!#=0-]P]C?:
MFW\ 4$L#!!0    ( #PY:%-'V&& W@(  (D)   8    >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&ULI99+;]LP#,>_BF#LT )=_4KBI$@"M"F*[3 @:+#M,.R@
MV$PL5)8\24FZ??I1LNOE_>ARB"69?_)'FK;47TGUHG, 0UX++O3 RXTI[WQ?
MISD45-_*$@3>F4E54(-3-?=UJ8!F3E1P/PJ"CE]0)KQAWZV-U; O%X8S 6-%
M]*(HJ/K] %RN!E[HO2T\LWEN[((_[)=T#A,P7\NQPIG?>,E8 4(S*8B"V<"[
M#^]&86 %SN(;@Y5>&Q.;RE3*%SOYG V\P!(!A]18%Q0O2Q@!Y]83<ORJG7I-
M3"M<'[]Y?W+)8S)3JF$D^7>6F7S@=3V2P8PNN'F6JT]0)]2V_E+)M?LGJ\JV
MDW@D76@CBUJ,! 43U96^UH58$X2M X*H%D3G"N):$+M$*S*7UB,U=-A7<D64
MM49O=N!JX]28#1/V,4Z,PKL,=68XDB+#AP(9P9&6G&74X.2!<BI2(!/K6).K
M,54@3 Z&I91?DX_D _&)SG%5]WV#'-:;G]8Q'ZJ8T8&8$RAO21S<D"B(PCWR
MT7'Y(Z0H#YT\V)3[F'U3@J@I0>3\Q8=P#*:,G6F(G)$G)C!Q1CD92\U<I_VX
MGVJCL-]^'@D6-\%B%ZQU(-@8NQ24PA+CHTU?;DA)%5E2O@!RQ03)).=4:5*"
MJLI[O:^\58C$A;#OZ7(8PL>@W?>7ZU4\9;7!WVKX6Y?Q5TU Z,+D4K$_D.T#
MKGRVUU#P,^-^6\QG&&Y@MQOL]KNPF=:+_<CM/22=,$GB+>+3=AO G0:X\RY@
M_!)K0T7&Q'P?=6>'9KO"QRPV2).&-#E*.I)%@6_)?[1S<E8[G[+:@.\V\-T+
MX,_JY>Y. ;O[>_D,PPWF7L/<NYSY<"/W=ALTBN*DUVUM\>X:AKTD;$71 =XP
M^+?'!)<3G^CDVN49W'LL#X#[:_ND/:1\H6K.A"8<9B@-;A/TH:I]OYH86;JM
M<RH-;L1NF.-9"90UP/LS*<W;Q.[&S>EK^!=02P,$%     @ /#EH4TDY;7?9
M!   !A,  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6RE6-MNXS80_17"
MV(<$6,>B[@H< YO8;0-TNT&RZ3XS%FT+*XFN2#O9?GV'E"S;XDC-MB^V+F=F
M>(Z&PR&GKZ+Z+C><*_)6Y*6\&6V4VEY/)G*YX0635V++2WBS$E7!%-Q6ZXG<
M5IREQJC()Z[CA)."9>5H-C7/'JK95.Q4GI7\H2)R5Q2L^G'+<_%Z,Z*CPX/'
M;+U1^L%D-MVR-7_BZGG[4,'=I/629@4O929*4O'5S>@3O5[02!L8Q)\9?Y4G
MUT13>1'BN[ZY3V]&CAX1S_E2:1<,_O;\CN>Y]@3C^*MQ.FIC:L/3ZX/W7PQY
M(//")+\3^;<L59N;43PB*5^Q7:X>Q>MOO"$4:']+D4OS2UX;K#,BRYU4HFB,
M801%5M;_[*T1XL0 _. &;F/@=@W\'@.O,?#>&\%O#/SW1@@: T-]4G,WPLV9
M8K-I)5Y)I='@35\8]8TUZ)65.E&>5 5O,[!3LSM1IO#9>4K@2HH\2YF"FR<%
M?Y /2A*Q(E^VO&+ZNTK"2HTL("DW.EOVG/PNI"1C\OPT)Q<?+LD'DI7DZT;L
M)$#E=*)@D#K49-D,Z+8>D-LS((]\%J7:2+* @:6(_7S8/AFPGX XK4+N0:%;
M=]#A$]]>$<_Y2%S'I<AX[MYO[F!T_E_TQ7^.?B:&UZ:+9_QY/?X6;UN=+7+
ME=^Z\HTKO\?5(Y><5<N-2:F4[Z%F;77&82E3>PJ-)UWZ]K/0B8'/_O0[V*"
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M>:4!\'XEA#K<Z #MT=?L'U!+ P04    "  \.6A3;-KX.Z,(  #&-@  &
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M@(&3E:"Y3OBAX,; 7Y\4/S$9E_SY\NH)'X#"/\E[P/ ?@Z<#8_D&S>!(+T0
M4JB&7;0,(T6\XJS'Q&5YL.'5_WG#@)A>D^N2[5BU\T1INL:4Q./'I]32EM"_
MR::<78AUZ*FDZHE?!=O=LC? /0CXI'DEI7,K=EH5G5!VDRH.%,,<RN71O7(Y
MW'@%>B8X0V%3IANY)I*,AG8D!%HY@5FR;I9:NFSOQE>V9D$=4L'1<UR5!95O
M$ZU?V%YH:BJ:/%8+1Y+'6J#'ZK&"Q($!Y@C=K_=Q$<*\]'0J,]E/%$"#B#Q/
M,TY;#YB4H(A0PVJ2^1N*T1M8Y)]:),(J>DX@9Q:F)9 M]ITJ)I-#&:T^ES#=
M!.,D.N1A3J;W(F\1-V[_XN../F?L0P%93D"I%,GB*N.Q-[;?4J-IH$K9G\>R
MU+(P^USM26EM2\O:A[M&!QN2[U2WLXCN0)!-M 'VO?L3BW/(X\IL3 M.U5@B
M#J%[-9^<Q;R+/"HOI*3DQIJ.5!<E+FJ$%Z^Q&-."G=F+[A\6A&8>GCJ:^_M7
M<[6LV,^<+_CE* #.KY'^8"5=!0D3C((R7$B%7#)-7NP07WP!*G23OBXG,9R1
M9I&(P)PH+ $$NMSP]YQ<T5=:;<%Y<[<+^QR"U&FFE.@*#*LHV>O#Y]'5LG@+
MG'?\_2*'A@*39CB=:8O_*\&\', (.J60' -HLE?-(:=%QWA7UCZ02,>X21PA
MXP)N7YT.:!/?G84W4,2X2J<VQJ(MW?)%H6^AF77@&,U..8O+HQ06#.*X?P;O
M7@Y<4L\:[8NQ8Q6#%*-?*9=CE=M8-UU!OENBX"!ARAH1QV++_0G)AB4<!<=M
M(B3@6K*@)NWY1]=6IYZGTIZ0R+*FO(':Y62A\T)2;.MXXLR!VG<=91=J593A
M[Z0&V.*!R34[N;;@T-%+&9V:4 %?23*=@?^*>A34$^'J\,^&K99!NHQEP"UV
M2GKEN0+BD"?X6\8]#"*D*EI#-5+W <Z;&B$$I2)6T^Y(J]62O/C)+I$<9<7&
M5ENF-<B\RN\T6*)GI;4(VY,NI],IS<[UDO,LBP_(3:C6#(LT]6+2;Z9%8ZMO
MEGV2%^*H)QW79H2=5H'("XT=8$JP&$7ZP#9VZ-AG^ZW+XN71EEKA$OVB)VD(
MC28*SVGN2V-S05YCTMQCB+\>ZL_(/GHPSH^S=(#<ZD!U@:0VXI[]NK^C>Q^Q
M"P[%3V:5W?*H./]6+[P>NM9Q=\FP^G^BO\/X''4RV/6KQO#SI(#8DYM(-#?*
MLV>1C35KU7A!FB'LDE]X-BI)QQSWR@#A @]4O'EW]H D2=J9#I3$ ^Q?QR:?
M92BUJTTI)T2FYZC&_Z8A'6\TH_V)@L!/[.>N177S$!1;]!H6:[Y/59Q<6:I\
M<_]>5[W;TD"0=._)52H&H^J!ZZ"*5%Z5I(<'>J3_GQ!/<N^)#VFN23&2M0>*
M(=C^NLWW9;W,TV(/(,BPE@E*6J0MPFP((.]C:A,O&<00IM1(K =1S"%U^<3\
M=+8K)@L<U_MC*#=9:[Y<FU'.V'C*H1VGICC+9GI:MAL90/WLL-A25'5ZTLGN
M.3_H@^IB5G*7*@I,E[TEQQ\:[RNN;UX@R=JYLOCN\=4BKOW-&7V/;\X>T,@0
M&;=?GY,P=6$YV=0RYN)41_?1(=!]D-_0<FF"I<>RSV!Y9BNQ4R5?^57M-NIK
MI\L37G']9/!"'@&TC?[5L5-*I\_7[V. L6^VH^#6=("3S"?2DE3\T/(3'<GW
MC5QR!6\./Q\=E,8M\D% 521'J! -4_32=I41B6FZ$\O]G-.PY2/4=6W>LY5*
M']_ Q1J3V]0]7=Z)"/)NZ%A@-+URP8@2ZA7G*?)\=E:"4[DMLTZN7-$8'...
MG@IM?A!T5C(V/"?W7Z$53.9]2\9>O>+[5H,0SRLE]4B6JP1K%&4L<(#2\M/A
M*B]YA\;(>1Z.R>"XXN0_S55]XK@LY"I2)"5 \")/S29#7NC.UK?):\3& VL^
M-V4G'1@V,1\WSCKW['U\>Y[.+VN3TS)^>B"2LQ1D9'5V^Y*&%N.*'<]=:'E?
M:HH]L\^Y=H;LX[#8Q(/JJ) <92J%QM(">Q1..%)PU>G#?CM,RM\9&.+D^JZ5
M,#X&@LP93184'9@>H8 >8KT\%=C'Z$+)!5"-YR9DAK,S1?+W3GU-S@Y&T9;V
MF$PG4PTUY+F(@@HAJJ6.!4A,3#)/\T"CC33<$M%YR^*,,DU1AI4I/YX5)7(0
MFGB!>HOLIC>DZ]I2&\^6$\$F%M,F0X0"6@]"<H2]L^)*_OQ+!*9SSE:5*[K[
MPCIFG?+UI-306MDPWI>\'06<3*2J.9O!53)J\6:]*(8=-W[X$+1(F!_10GV>
MYXF"Y*-)XGSEI+ 7&>$LL945AJ3$8:*0B(%12 <#'_+DB"\S>;-M,08ZAN9K
MZ1>-QR!M&/950T?M8^JQE?ERR;836N56AN+5]W#Y/(%,]+V4<0\6Z:M8?YK<
M465W2%[%2=/6=!M1J^B_LSR,[5 4GL/6J?6X7*XY]2_<X)8=-!,J+$[2[ZV=
M3E+Q/0L:_8LE,08-D.$6B3$7XTK$(.DLD/FG#VF[Q9C5Q8N-:0>:)A0GI'NP
M\Z,YVFSD307):_#;%K[;9R6[/%T\:-6/1;>T[D0TB9:>1MI"&FX+!\2E0N$$
M"D2Z,E<#!0F#5GWCEAK TL:^VQB$W.DD4;;9]#K[_?$&F]&8S\<=S2JU&R\O
M[)PXFM /%:O!?R'V=98F!P3)5+>&YRP2E"-CV'BJ\5+I)_(<!R:U=1?KYY*9
M9/W6+U#%.(P@73 I_F85 BDGIR]217E2H5 X&'5!Z)5U*>>CA16Y) [H:CHY
M 2]4%Y:I+;ZG6-LX+7BL49R_N"8A)G8I<89.MXBN:U20$>EK\\"NUU3H'=_Y
M:+4@80U6DK6CK=K)>&321<*<0ZOO2X5Q4+;?NJ[BUN<^<:28N@N'SC)ISJ10
M?50IC[7($R"8B9[&(FFM:NS4L=+>-5KO5\@9!_BX11VEY[M94=$,E@UC1(P$
MS\19>?4I(J%NT %M;5 MBQN>'7W.@GR1>SSUS/<GF"<G3\T=OTGV^7SSV\OO
M%I.-SYFB*2W9"W#TP/BVF'XQ]N*HR)X3%4TXG\O>=$;!+=\))##Z(9KDZ/C%
M![FX&*W\($O(9O&G+R?D#M)ULMLY#P&-I6\>8CP>U/W2%&?B@V<W&+.@;'X\
M68":JRHD'54V-S&^_LCM-BN-*4FCYB/+07-/LX:I<,="X7, A(_G-^76TQN$
M<CW5UKGL'(E)IYIF#/C09#I3BX5Q#CX[X!^*;]P#;1AK34AHD<F+<;;^"6X\
MO#-E5E$R?)/>13-LYVLJV*2I'TJ/G[#J?.-N'XSK5(Z<#$_.O4Q-K8)8%Q[6
M:WHS D% IO+W\<4\UE"0.#0L2$*@],HD1"1VP8E_6D?/XIS*I]3>R6?\.2>B
MHH&=O$\@/8W#C$LT*H>#[&XB-]GSJG791OE%^$N9968NM4DB;ZGP$&ALW>P&
M8-92)E8JBCV_47UO?+6D9V\O=V7/^YB3QVQR)/O^HYYR+/NHSY*5V3=)GX0]
M.8%-N&I8"N11RGQN/WF[8QP>US8F3S@BNM ;>-2?C?7$K+E^\.87[9D),FQ9
M-$QZ'E\R;:&:5TP=9G4V=W[BA \:DE)!#R<.D)LYHZU6AGH^9>V#OOI<9J7+
M8RG&<2IF).3)]=C&/O ^<=!?(^Q7\W/T1IJ\W)._Q*,U=9/+<2SD9G+(90Z<
M;3A(BA><J#C71.[:B:JMK+ZK$K' K-W?9Z_J"144[H]M=$S49D^?K2 F+[&D
MD[XXY8TUL@;V%-0_U^"J'9R%5&]TLF*Z)\[4U-I#1]*ZQ1/@J+$FO>*2!X^$
MMM+T;,P.AKR@13?LLE>.YSWN ?RCIS[<%+]T/%8RZ4U+Y2Q.$>QE&E=*E&'@
MVF8"B_,Q8 R?K'XSY7YZ95.&]"93U[(<:0! R!@/QM=Y*"^P,IS).</R--;"
M?VOKI%<E.!^*6(+)".!.O_PS UWF7WG,8(6B-]IY N?'UUQGWQVCC0/ID*";
M<3+S)^KJ3+^*#<B#X4C]E0 "_S*2J3[$1+<AF#=_@9V_(5V7\IZ^)+,L/AR.
ME6K;4\+(O1.M,@ YF1J=&S@]7%:KD&D.B+O=I$?F$Q'TFU;>8W^(&ZA:6-0Q
MD9C R(C"%VP)P=,F+,THJC22E$\DO>?AA,FO;72^]8,6Z@.@] <DPDON+IU?
M,"C/?H+BS=@.Y4UOAE7/^/W1Y<4YO7G^GM-@$F@HSBFCSA+JUU:%\Y8Y>L'U
M%B2;;\O>4W=+WEVGX^?DP '542L3!/U_$4.=KK3;V0,V6FV]K(=.S@%(9B2!
M9Q3EAS:TIW%+;\703QP(];%(2*HL:U]^RYQ\/6T'[/U OXK2N*$IKALJROV9
MJLGO] T#9'+ [[SB2[OJL]_B>) X96K..(5*'V6XR+:Q<IXO'\V/FL%:)R[C
M)A5MDEG/+M'!@YH[)7>U5T0OL4=+L^EJVE#\"7MDTP&^PN?35II&9P>5)PBT
MDR;?6;$R5O&/YT<S!N.<A;P42!UM'#P%I5D&]_SBCJU"7()P!,V<\&1=G$%D
M+>CBG'6+G4<>%DH,8Y/(/B"3%$J.A#!]6()$:^_D#2?ZH98[P@;\'K+C849$
M5VZV_<.T _W.R676.QY__\+L)#7@)!/*GB8P),4T:3AC7' L5BB ,Y6"%GX/
M\E.<8>R(/IC"J >G5$6X2<O0;^=DQUNY*FMHIK+?_,\8S/]."X]FS/V$ )?M
MX\;+N9].>IC]2%5CNPW_%%>0U]KD]ZK2M^G7OJ[E1Z[&V^6GPGXVW8;\=FW7
M>/1B^>U?SJ1/'C_ OODGKU:^[WW#?U)=V79T ZZOO>_C!]H@_0;:L_\%4$L#
M!!0    ( #PY:%/(S_5<]@,  -H)   8    >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&ULM5;;;MLX$/T5PMB'%%"MBVW9#FP#N72Q!;9!4&^W#\4^4-+((D*1
M*B]V\O<[I"Q%3N.@0-$'6\/+G#ES2 ZY.DCUH"L 0QYK+O1Z5!G37(:ASBNH
MJ1[+!@2.E%+5U&!3[4+=**"%=ZIYF$11&M:4B=%FY?ONU68EK>%,P+TBVM8U
M54_7P.5A/8I'7<=GMJN,ZP@WJX;N8 OF2W.OL!7V* 6K06@F!5%0KD=7\>7U
MU,WW$_YE<- #F[A,,BD?7.-CL1Y%CA!PR(U#H/C9PPUP[H"0QO<CYJ@/Z1R'
M=H?^I\\=<\FHAAO)O[+"5.O18D0***GEYK,\_ 7'?&8.+Y=<^W]R:.?.9B.2
M6VUD?71&!C43[9<^'G48."RB,P[)T2'QO-M GN4M-72S4O) E)N-:,[PJ7IO
M),>$6Y2M43C*T,]L[G#=_Y9:DWM09%M1!>3*&,4R:VC&@1A);F1=HWY;(_.'
M2O("E%Z%!F,[A# _QKENXR1GXBS))RE,I<D'44!QZA\BYYYXTA&_3MX$W$(S
M)I,H($F4Q&_@37HA)AYO<@;O U6"B=U0B&]7F38*]\U_;^!/>_RIQY_^=J%_
M1QQR337+B4!G[IP;=-;>F;YPSEMG/71FFN24YY93 P7)GDC!]JQ -9\!?P8&
M'4T%Y.!/$@+1/2@L#"T13;"D:$.%QRVL<A\W':DR601X;DR%4Q 9*P;B47_J
ML6R=Q"+PW;(]Y2"PEI%;QJV+] MYR[JQ+[-VM'K(%UF][[(2MLXPFBS[_,I3
MIIAJW^$I#:B?B.%R?%9BW*WOCTY>&FU^B,2TMCY/VV ?/(+*F09/S8_+QFFI
M/:,]:.."XB"21HURE_V1\8&J F7]IP+E,L:_.%A&49!.%MYY,9L$DTGZ<VE1
M+PF><P->J>ZP>R0TL(D,&O!UG3\%A DO@[NI7N=NA6./=,\P#]"?&E+A$I$,
MP$F1<XOUBI1*UAZ\V^=N;V&,XK4-=)(=9H%^3!$H2Z2*EY3EN%MP0!CVWOLC
M?;^&E//C&B(.4D1%H'!J*H"3\DGN\-"?]GAAG"@#Z^*C$T1:C;EC;I@,:MGM
M-J?'\VXO\.YX1RZ^"&H+AE%/[3M;N_,DU26Y.YOH'^0BG@6SQ?*=,Y=!&D?>
MFLZ#>3KU9A('\P6:MR DWF4MXM>7!R/SI<CQZ]0=QM$D28(DQE^:DAC#S-,@
MBE."V(OE)$AGV+L(IO-Y,%W.CF5MB'6R4L@I&L];GM%XVE)/QO'"&[$S7BO]
MX>"^165V_E7ACI<5IKUZ^][^X7+5WM?/T]M7SR>J=@RW)X<279$,OA-4^Y)H
M&T8V_O;.I,&W@#<K?'R!<A-PO)32= T7H'_.;?X'4$L#!!0    ( #PY:%-:
MU/Y_5 0  !0+   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;-566V_;
M-A3^*P=>L"6 8EO4Q7::!$C2=2NP#D'==@_#'FCI6"8JD2I)V?5^_0XI67+0
MQ,.VISU8YKE]/#>2YWJG]&>S0;3PM2JEN1EMK*VO)A.3;;#B9JQJE"19*UUQ
M2Z0N)J;6R'-O5)43-IVFDXH+.;J]]KQ'?7NM&EL*B8\:3%-57._OL52[FU$X
M.C#>BV)C'6-R>UWS I=H/]:/FJA)CY*+"J412H+&]<WH+KRZCYV^5_@D<&>.
MUN B62GUV1%O\YO1U#F$)6;6(7#ZV^(#EJ4#(C>^=)BC?DMG>+P^H+_QL5,L
M*V[P096_B=QN;D;S$>2XYDUIWZO=S]C%DSB\3)7&?V'7ZD;Q"++&6%5UQN1!
M)63[S[]V>3@RF$]?,&"= ?-^MQMY+U]SRV^OM=J!=MJ$YA8^5&]-S@GIBK*T
MFJ2"[.SM&RXT?.)E@_!6&JL;2K@UUQ-+V$YCDG4X]RT.>P%G >^4M!L#/\H<
M\Z?V$_*I=XP='+MG)P&76(\AF@; IBP\@1?U@48>+_K[0%\+DY7*-!H-_'ZW
MHJBI-_XXL4?<[Q'[/>+_G,Q_@P,?-@AK5=(Y$K( RU<E!6 VY*,ER8.J:B[W
MWW\W9^'LE8&,FTW@OX!?&K'EI0?A,@>^Y:)TYI=TJB\-2<!@UFAA!2&N]F!$
M(<5:9%Q:$'*+QCH/",QBH?0>N &U!BJ1Q6J%NJ^31W^-6<<-/9=DE.D:_?DK
M]W N)#FL&D/*YN+J.9CS1O(F%Q;S"[BKE+;B3\PI0F/A)ZV,Z;YW1:&Q(*?
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MI2G*+S<TMJ)V"B1?*TI;1[@-^D'X]B]02P,$%     @ /#EH4W#PI$'W P
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M'5K];=_AWN']=\)'IM=<&A!8DVE\75!GU7WO[2=6M;[?K92E[NF'&_I<0>T
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MMP>K(XVLR@S0L^* RP_'CWW^ O()"^A4<6!4[E$#.H'HG#MBS\4S,3\Y8?^
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MQZ+-H:J5.<42V 1"L1C%8!(E8%::.A/>9!S,=C^9JPP+;:#EK):K5. MCZT
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MWK#?8=J]>;F.50MZ9QHK:U5.S;G@8""< -^G2MFZ@PR:A\>K_P%02P,$%
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MJ%DEYXFHH)9>TQWVGV&LYRSPE:A=_(I^B,T_)*+TCK =P:R@5698Y>/X'XX
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M&AP]-;1N>'XEW*CLJKHRZ]ZL3*WZH;JH:SOV@^G7U3O;FMIH7WT3_WKP[.%
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MXG5K25\J3>LLMA\38'?\O%/T?W.MG<<!:K4B*:WL2)'3Z D[[T5= I,!2X
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MADW9(0 V*B/)DB ".\+2,85.4Z#FG:X$>I84<()VV'3%$!\R-S\D<_/#82/
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M @66HE'^P;;?<)O/6>#+K:+XA;;S/<L2R!OR5F_!K$!+T_W%9GL/>X"+P0>
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M41-QY/&B?X_X09@T5Z;2:."/VP6%3TWRYYDSALT90W_&\!3G78N#6L$]-^O
M/^']]TJ\\-PGF,LEW+YPD;L\7]'+=36G'9AC6FEA!9JW,G_^T*<UPDKE])H)
MF8'U!02S)N:6=NY547*Y_?FG,0M'[PRDGI=[ OZ#%S_B91POT_""Q1:,R*18
MB91+"T*^H+&N:PC,8J8H;&Y<Y%0XB\4"=5,]C_Z ::T-O9;V*/\E^M<SW\*E
MD$1858:,3??Z+9C+2O)J*2PNNW!;*&W%7[BD"(V%CUH94S]OLTQC1J3 U]S7
MP#'PB_F:_*XLZ@(^<_V,/E\'^8?+L N_*9F=M6%D@T0;PNL6_U52+X"-DR )
MA[3R!6#OCE;M[CF[>;6PRO*\,=IO[/_W^E/[.Z;LVO5"@3H5A%7RDC++6#"<
M#("U4$YQ4KQ7NE3:)7:AJ$@0C8)D' $5AB5=+\7CUG<2#),8QD$XB>!K;]Z#
M3+V@EKYEZ-Z7Z?:PO<(XB),14;F,NCLA::"&0<P8A&$P& [;=(SB8#0<0$RG
M3[I>"EN7. F&HPF$DX!%(WCR#A<0)2R(8I?FF'[>KU9&@Z,JU.X7>X!7S?M_
MZ;]D'+!D<JK_FMUS=FW_U4:O^J_6G]IO^P\I9>[^L.AOBB66R@@++)B,$QBU
M@,&$>N9MJ67S'YSV]6>C,&"QJ_WH.!%.G[#CE'B$ULK5Y>F-"]6T!2W:8AUT
M-HT0]*6A"Q.41-@BUZ TT"5M>KZ0!Z"_&,B;TI]%6Z#=(!Y N@:P&^4%TWOK
M6]8_F!;H&LC\3$0?!%5)NQL<&FTS=MWNIHW6?#>S45=F0A)97)'KH#>*.Z!W
M<]!.L*KTL\="69ID_')-HR-J9T#[*Z7L7G '-,/H[&]02P,$%     @ /#EH
M4TZ^M8#4 P  M @  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK5;;
M;MLX$/V5@= '&Q"BJR\*; /.I=@%TFV0M-N'Q3[0TL@F2I$J2<7.?OT.*5M)
M@<3H0U\LDIHY<V9X1N/%7NGO9H=HX= (:9;!SMKV,HI,N<.&F0O5HJ0WM=(-
ML[35V\BT&EGEG1H1I7$\C1K&9;!:^+-[O5JHS@HN\5Z#Z9J&Z><K%&J_#)+@
M=/# MSOK#J+5HF5;?$3[M;W7M(L&E(HW* U7$C36RV"=7%Y-G+TW^)OCWKQ:
M@\MDH]1WM_FS6@:Q(X0"2^L0&#V>\!J%<$!$X\<1,QA".L?7ZQ/Z1Y\[Y;)A
M!J^5^,8KNUL&\P JK%DG[(/:_X''?#S!4@GC?V'?VTZ* ,K.6-4<G8E!PV7_
M9(=C'5XYS.-W'-*C0^IY]X$\RQMFV6JAU1ZTLR8TM_"I>F\BQZ6[E$>KZ2TG
M/[NZ8H+)$N'1*^!:-:V2**V!T1>V$6C&B\A2&&<<E4?(JQXR?0>R@$]*VIV!
M6UEA];-_1/0&CNF)XU5Z%O 1VPO(XA#2.$W.X&5#SIG'RWXIYP<4S&(%-]R4
M0IE.HX%_UAMC-2GFWS/A\B%<[L/E[]&G1JHZ@:!JN-?43MH^ Y,5W/[H>$L"
MMR'\A?:M0I\%=OUZ:5I6XC*@AC2HGS!8_10!7R)(2K54U$S&.B)VAU K03W)
MY19&7-*)Z@PYF?$E4,4M-AO4ONPW6!XW20BCKY)U%:>*C4DNDLK4]?U%$*U6
M6R)BX /,XC!-$EJD61AG"=PAM<Y.B0IX0V9/V'B53<)9FD$>3LGD8Z<EMU1_
M3[WF!^OO8EXD,)_%7IN=)19#4M[.J-KN&3G-)S!/X8YME&96Z;X #9-=3??8
M:9?FB^<DS,G>Q8WAB[),..YOU(T@PZR80):%:9[#NBR[INOU4B$5O>2L_[B0
M$VN4MOR__F"4A;-)-H81^4_G8SAW+52M>3C-4UI0N>>S*9Q1W610W>2754>T
M=4>4;P_T+3=4TS61^$P2T'#=:>WRO.-LPP6W',U;0CP;ZVTAGH+B*:C+7/F@
MY3&H> EZTB8Y_"YUG@BX:R+&O*1;=AR&S<",ZA[.\HR>23C+)J\\54URIOLD
MZQK),@F+. -W5X,->];$U"-O4&+-K3.;%07]YO/I8&C9@0"R%/)X."O?:Z T
M#>-I3@AQ7@S6-9?TW7(5*96A*'D^@X0:Y_.[1:4.3*='@5,K%F%!M#Z0^I.X
M>%-DT:M)TJ#>^GGI+J>3MA\JP^DPDM?])'HQ[^?Y)Z:W7!H06)-K?#$C#>E^
M1O8;JUH_ES;*TI3SRQW]K4#M#.A]K90];5R X8_*ZG]02P,$%     @ /#EH
M4Q)I@HRT P  9@@  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULG5;;
M;N,V$/V5@=HM$D!K77VM;2!V=M$ &VR0I-V'H@^T-+:)I4B5I.+UWW=(R8K;
M)NFB+Q))S9PY,SSD:'Y0^JO9(UKX5@EI%L'>VGH61:;88\7,0-4HZ<M6Z8I9
MFNI=9&J-K/1.E8C2.!Y%%>,R6,[]VIU>SE5C!9=XI\$T5<7T<85"'19!$IP6
M[OEN;]U"M)S7;(</:'^M[S3-HAZEY!5*PY4$C=M%<)7,5D-G[PU^XW@P9V-P
MF6R4^NHF-^4BB!TA%%A8A\#H]81K%,(!$8T_.\R@#^D<S\<G](\^=\IEPPRN
ME?C"2[M?!), 2MRR1MA[=?@%NWP\P4()XY]PZ&SC (K&6%5USL2@XK)]LV]=
M';['(>T<4L^[#>197C/+EG.M#J"=-:&Y@4_5>Q,Y+MVF/%A-7SGYV>5:516W
M5&5K@,D2UDI:+G<H"XX&+A[91J"YG$>68CF/J.AP5RUN^@KN%&X):6_@@RRQ
M_+M_1!Q[HNF)Z"I]$_ !ZP%D<0AIG"9OX&5]XIG'R_Y7XM?<%$*91B/\?K4Q
M5I-Z_G@C:MY'S7W4_+4LZ%"5C4!06_C86(=_RR6OF@H^UZB9HP"?D&0&=^SH
MV;U4^S>#N',\,S4K<!'0036HGS!87AD7DZIHL=J@[DL9PK;E474\BK/"-+1Y
M&NP>J3Q5S>3QIQ\F:3+^F;!ZML*Q-7! PF &MDK002?I<$F.JC%47',Y.TO/
M184+C>[*<'.[UTCAO5PNX4=(AT-GDT(2QM/<#3,:)HD?YFZ8>8.A&XY2>-Q3
M:+:UQ#1)P_%D=*KL*:-_<(6ZJRS%2L;A,!]1Q8V9P8TD##06IF&>YW#G:B<M
M/#'1^ UKO05G&RZX/9+[)$SB%-[0Q;#7Q?"[=?'0U+5 QY ))\N2KD#T C5*
M\))9FJR88+) >/ 7]XUL;V=WS=VC\!96M3IZ43__0>:<0-$3*,X);#H";>?@
M9P3T,X%.&MR<"6,&%XUD3<G)YO(%/<(U%MU*XE?B,^FT@#/PO>.]VKYOC!.=
M0;^9XS#+4WIG83J=P+K1VFU?K;3G]<(&DL!(6Z-LTAVYYR_C,!Y/"2B+)_"H
M7!U>VWP7;DH2^N+O?\J;/1';'<*SP%M7TE854J7@B$P;2/+!")+1(/^W9TF7
MCVJ(.F6-,!VD\(Z>.;Q[26C1V=U?H=[Y#F?  [1MH%_MF^A5VSN>S=L.?,OT
MCDM#?+?D&@_&)!/==K5V8E7M.\E&6>I+?KBG'P'4SH"^;Y6RIXD+T/]:+/\"
M4$L#!!0    ( #PY:%, 3(5<<@8  /P1   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;,586U/;.!3^*YHLW0TSP;&=Q'$H,!-HZ?+0E@%*'W;V0=@G
MB0;;RDH**?WU>\[Q)2D$=]N=G7U((LO2N7^?CG*TUN;>+@"<^))GA3WN+)Q;
M'O;[-EE +JVGEU#@FYDVN73X:.9]NS0@4]Z49_W0]Z-^+E71.3GBN4MS<J17
M+E,%7!IA5WDNS>,I9'I]W DZ]<25FB\<3?1/CI9R#M?@/BTO#3[U&RFIRJ&P
M2A?"P.RX,PT.3\>TGA?<*EC;K;$@3^ZTOJ>'B_2XXY-!D$'B2(+$GP<X@RPC
M06C&7Y7,3J.2-FZ/:^GG[#OZ<B<MG.GLLTK=XK@3=T0*,[G*W)5>_PZ5/R.2
ME^C,\K=85VO]CDA6UNF\VHP6Y*HH?^67*@[_9$-8;0C9[E(16_E&.GER9/1:
M&%J-TFC KO)N-$X5E)1K9_"MPGWNY-KIY/[@%/U*Q9G.,==6<KBZ-_(N [M_
MU'>HAA;WDTKD:2DR?$'D1+S7A5M8\;9((?UV?Q_-:VP,:QM/PU:!U[#TQ,#O
MB= /@Q9Y@\;G <L;O"1O(0T<W+'/E_(12\R)J3&RF ./_YC>66>P7OYL439L
ME U9V? E90BC=)6!T#,.L"P>?[."PRX^+CG44ZI,Y1YWA;I=^,T"Q$QGB"Q5
MS(6CC%7P4E_!"H>O*YV__A*'P?BU%98UZ^4&$ZCYL#+H,Q<QI =;H^E\;F N
M'8B+PAF%<$S$K<Q6(+H7!:K0*RN+U.Z+;K O/JZ<=?A(YD@GWD "^1T8,0@X
M>[Z(1X->% S%GACZWB 0$\_'<1#U8G\HWF$.4*<(>L$X[ U']"H:>\%(O/T"
M)E&4L.YPTAN'T3Z^&L1>$(@S620(:GRE#0;#S$"1C"Z)\'V?%D:!%\8H8ZD,
MO0E[HW)^''OQY*G-6&VN,KHJ.;0G]O$SB''/:.2-8S0[P/$$;8QJVSCXN_>'
MT:@7#P=DLN_YH1A[%("HY\=CCMHFQ*H)\0.'V !2K<6B+).9JMD,#*##X@[<
M&J#@Z233EJPO<[LT*N%RTRLC$IWGF.@JZ\4NZ]!UE@)5C+<%;"*CB@-<=(#"
MX+$J'^NUX&/4X&/4CH_R-"!U90WNX"+,'(Y!7$$F*;=.BPMK5Y3XS;X:3&MI
M4LM.70'"6"6THUQ2OML%LU8;Z6 \M$N9P'&'TV$>H,/8J\ E%M)BJA)MD/"$
M;++)4:^()MEV""J'S,8ARH#:<NI;G)9.J2K=&HFU*(465F<J92&8*L<$9CEW
M2S"LS!(H>)];& ".3($.BKQD:2"6?JDN&+/25B1C15=M0_Y0W+#(;;Y_(ND#
M:6IY7^*#M&Q&W54A5RFA>/^;,>83I$D6;%D*#]A1+)FPB24874/"5=@+^6F,
M-/,."@Q#QCMDBN>G(F:G1D 0"X0(;3\($8KC(8TG<2QNM,,-+Z8.M2 [C8BT
M>@-$/[& 'XQ8[Q@%3CGZSYWLB4F,-.*+JVM<LD84;\/+$TSE4ID*^"@#)+IJ
M-C5<5@27@EAC3O9*^L(NAEL<.@"VN*"5!6CAG,A64.F4RNM:;NKX1ZJ7G4)E
M>\-)T!0(1WT/N1<;ERRCG3]7B3V*PA*X?\L>>[SO*QC]<^+P>ZW< @MY_G)Q
M5"XVD)-)4H:'0ONC^/M?0=." #R#)W2,<6\0ON:2#D:3K9GO8N%[ EH.B*@Y
M(*+6 ^*<0'%;@V*;ZVV/YTM;ILB=>3F]B^#;=3P'7W7",= 0@BKG%./QSL<P
MD3LN*B&TLC7V3C.)@<*.3V/GS+)*VW*=0L95Q\LV'=NZ[K+D R9ICG6V\>+?
MTO9_5&=T%F_144DS#QJ90&7820JDWE<"^?'5UJC9X\#D%#B&%!-9]Q$I'9O'
MR L'].7C5S I1U?*WA_,R =LBX"84!B*?. %)!K[QR'^!)X_XJ<HPI^Z;Q5U
M1)]T-=C #;R(2G08$'O6#28^1]XP$N=E [E">F9==2&C'M^+2=&SF98:'S<U
M/FYO@MIO)+WGK<S._N93H7!MVW6BU8R7^YP?O&/@:;!UM?BPXH(B\)*;=I.C
M:96C#[HX>$!G<(H/$LD,^OSRL.&9>E3?&*JSM6[I;TMAS]>?-_>#Y^]V6[$#
M$4^4[<I_?^M&GH.9\_\.%MES5;CR<M[,-G]M3,L;_69Y^;_(>VGF>"40&<QP
MJ^^-L5<UY7\-Y8/32[[?WVGG=,[#!<@4#"W ]S.M7?U "IH_?$[^!E!+ P04
M    "  \.6A3GC>1]DL"   3!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6R-5$UOVS ,_2N"T4,+M/5GFZYP#*0)AO4P+&C6[3#LH-A,+%0?KD0G
M[7[])-DUTC4)=K%%D>_QD:*4;Y5^,C4 DA?!I1D'-6)S&X:FK$%0<ZD:D-:S
M4EI0M*9>AZ;10"L/$CQ,HN@Z%)3)H,C]WEP7N6J1,PES34PK!-6O=\#5=AS$
MP=O& UO7Z#;"(F_H&A: C\U<6RL<6"HF0!JF)-&P&@>3^'::N7@?\(/!UNRL
MB:MDJ=23,^ZK<1 Y0<"A1,= [6\#4^#<$5D9SSUG,*1TP-WU&_MG7[NM94D-
M3!7_R2JLQ\%-0"I8T9;C@]I^@;Z>*\=7*F[\EVR[V%$2D+(UJ$0/M@H$D]V?
MOO1]V '$V0% T@.2_P6D/2#UA7;*?%DSBK3(M=H2[:(MFUOXWGBTK89)=XH+
MU-;++ Z+;WI-)?M#?4\OR*2JF%M23NYE-R/.<3H#I(R?V8C'Q8R<GIR1$\(D
M^5ZKUE!9F3Q$*\91AF6?^*Y+G!Q(O(#FDJ31.4FB)-X#GQZ'SZ"T\-C#H_?P
MT+9@Z$,R]"'Q?.D!ODE9JE8BDVLR5YR5# SY-5D:U';0?A])D X)4I\@.YR@
M%2VG")4;,YL!]S6M([GV).X&;HHXOODTNLG#S6YS/H:-XB3.AJAW$K-!8G94
MXI2:^IR4]DO@N64;RD&B(?9\B:F5Q@L$+>RQ;\"@<*Y]!60?E*59&D?1/]+"
MG9%US\57JM=,&L)A98'1Y>@J(+J[@IV!JO%3O%1H[X1?UO;5 NT"K'^E%+X9
M[F(,[V#Q%U!+ P04    "  \.6A3*Z>4BK\"   M"   &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6R]5EUOVC 4_2M6U(=.VIH0OKH*D( PK5([H:)N
M#],>3'()5AT[M9W23?OQN[9#1CN@G2;MA=C./>=<GUQ?,]A(=:?7 (8\%ESH
M8; VIKP(0YVNH:#Z3)8@\,U*JH(:G*H\U*4"FCE0P<,XBGIA09D(1@.W-E>C
M@:P,9P+FBNBJ**CZ/@$N-\.@%6P7;EB^-G8A' U*FL,"S&TY5S@+&Y:,%2 T
MDX(H6 V#<>MBUK?Q+N S@XW>&1.[DZ64=W9RF0V#R"8$'%)C&2@^'F *G%LB
M3..^Y@P:20O<'6_9/[B]XUZ65,-4\B\L,^MA<!Z0#%:TXN9&;CY"O9^NY4LE
MU^Z7;'QLOQ^0M-)&%C48,RB8\$_Z6/NP XA;!P!Q#8A?"VC7@/9SP/D!0*<&
M=%ZKT*T!;NNAW[LS+J&&C@9*;HBRT<AF!\Y]AT:_F+!ULC *WS+$F='"UP>1
M*[)@N6 KEE)AR#A-924,$SF92\Y2!IJ\(^,L8_;S4DXNA:]1^[%/$S"4\3>#
MT&!&EC=,:_6)5X\/J+?)M11FK<E,9)#MP2?'\>^/X$-THK$CWMHQB8\2+J \
M(^WH+8FCN'6[2,CIR;YM35_/$AUF2?X^%PTY'E*SAVSVKRD]\:O=E$_;T;8/
MT;Y0,U^O$$ N#13ZVQ&Y3B/7<7*= W*?JF()RA8K-DI%G59M"?E)#IN3>-JN
MH[6M\V'4&H0/>S+I-IETCV8RNZ]8^:?:$ZY>P]7['R;V&[G^T=1O()4H^ ,R
MPHJ2,N7LXU)KU,)3C4-4Y]B_,T)QT6CT]F3?X?8ZO1U7H\95?TY>C$A>C)@=
MB_ &A#O]KP"5NXM'$^>DK^5FM;G;QJZE/UN?M"ZFK3WK"=Z%_NKZ3>\OTFNJ
M<B8TX;!"J>BLCV6C_.7D)T:6KOLNI<%>[H9KO,]!V0!\OY+2;"=6H/F',/H%
M4$L#!!0    ( #PY:%/F9'>)R (  'P)   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;+U6R6[;,!#]E8%.+9!&BYTX"6P#=A:T0 (8,=(>BAYH:601
MX:*05.4 _?B2E"R[0")?G%YL+C-OWKRA.!S74CWK M' AC.A)T%A3'D5ACHM
MD!-]*DL4=B>7BA-CIVH=ZE(AR;P39V$21><A)U0$T[%?6ZCI6%:&48$+!;KB
MG*C7.3)93X(XV"X\TG5AW$(X'9=DC4LT3^5"V5G8H624H]!4"E"83X)9?#6/
MA\[!6WRG6.N],;A45E(^N\FW;!)$CA$R3(V#(/;O-UXC8P[)\GAI08,NIG/<
M'V_1[WSR-ID5T7@MV0^:F6(27 2084XJ9AYE_17;A,X<7BJ9]K]0M[91 &FE
MC>2MLV7 J6C^R:858L_!XKSMD+0.B>?=!/(L;X@AT[&2-2AG;='<P*?JO2TY
M*EQ5ED;976K]S'395 -D#DNZ%C2G*1$&9FDJ*V&H6,-",II2U/ %]HQOM:%6
M$\S@26->,;BWXFJW,],:C89/-V@(99_'H;$T7; P;2G-&TK).Y0NX4$*4VBX
M%1EF__J'-KTNQV2;XSSI!5QB>0J#Z 22*(E[\ :=9@./-WP'[UKRLC*H %\J
M6MHC:H"(#+3,34T4]D08=A&&/L+@G0@+93\[95Y/8,%("W_;!?MY;\WAFT&N
M?_4$.^N"G?6FLRMEU922;4M)?"G?JF _X@!>D2C=P^V\XW;>BW1/5E(1(^VA
M<QIP(JK<?LB5<B=S)_\?>*""\HKWA!QU(4<?K_U%%^SBZ-KW(Q[6_K+C=GDD
M[<GF@/9QM+N.HH]7/]Z[_>*CZW\ <G2P '&RHY?T8MU52E"K.'H=<KIQXU[H
MW1T6#_Z#T+L++1X>7^A^R)Z3'NXU1(YJ[=N^!M_3FM[8K79/BUG34'?FS;OD
M@:@U%1H8YM8U.AW9JT\UK;Z9&%GZ]KJ2QC9K/RSL\PB5,[#[N91F.W$!N@?7
M]"]02P,$%     @ /#EH4\HF+E-] @  C 4  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&ULC51=;YLP%/TK%D^;U!4":==6!"E).ZW2.D6-MCU,>W#@
M$JP:F]J7I/WWNS:$L:ZI]@+^N.?XW,]TK\V#K0"0/=52V5E0(39786CS"FIN
M3W4#BFY*;6J.M#7;T#8&>.%!M0SC*#H/:RY4D*7^;&6R5+<HA8*58;:M:VZ>
M%R#U?A9,@L/!O=A6Z ["+&WX%M: WYJ5H5TXL!2B!F6%5LQ .0OFDZOEU-E[
M@^\"]G:T9LZ3C=8/;G-;S(+("0().3H&3K\=+$%*1T0R'GO.8'C2 <?K _LG
M[SOYLN$6EEK^$ 56L^ B8 64O)5XK_>?H??GS/'E6EK_9?O>-@I8WEK4=0\F
M!;50W9\_]7$8 8CG=4#< ^*7@.D10-(#$N]HI\R[=<V19ZG1>V:<-;&YA8^-
M1Y,W0KDLKM'0K2 <9E^I4+YH:]D*#%M7W ";(QJQ:9%O)##4;*GKF@*^1IT_
M5%H68"S[P.9%(5PBN&2WJJLFEY9WUX!<R/=D81V;34,DF>ZQ,.\E+3I)\1%)
ME^Q.*ZPLNU$%%'_C0W)O\#$^^+B(WR1<0W/*DNB$Q5$\>47/\O_AT1MRDB'D
MB>=+CO#=<*.$VHY#_G.^L6BHI'^]P3\=^*>>?WJ$O\^7#S^#QU;LN 2%EE$3
M6^2JH,=/&#SELJ7XLM+HFF$%+.<R;V671EVR0L@6Z5Y1A4A7(0W)S4?<KV6V
M4W;FE;D!LLLFES1/DHLTW(TC_J_=Q5F2).>#6>=Y."KL&LS6][LE%:W"+O_#
MZ3!2YKZ37IPO:-1TD^$/33>G[KC9"F69A)(HH]./),ITO=]M4#>^?38:J1G]
MLJ)Q"<89T'VI-1XV[H%A &>_ 5!+ P04    "  \.6A3#?1+Z<D#  #Y#0
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M2Y(A@ZQZK5K/%97H8D8DIL4E"#TO9^CBTR7ZA&PD%%(@6FF4^ R=\/P]9[4
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MSG5\XHP1%)Q\4^8&E'?M)B>>&%#N(>K(D+0S)/VH(>W*^!>6I$,L,8+>66)
M&2PQH R6V ?G0-A=MOH2(2#:NI+-SM3U=O>46WT\/^F?NC>/KJ%_#O>:YAKR
M2[ZY%,'FO*650 79P%!@!BQIWEPTFH9D.WT*73$)9UK]F,/=C' %@/<;QN1;
M0PW0W?8F?P-02P,$%     @ /#EH4W:%W:L'"   9#P  !D   !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&ULS9M1<YLX$(#_BL;3AW:FB4$@@3I)9E+GVNM,
M<M.I+[V'FWM0;,5F"L@%[#0W]^-/8.(E1@AL\\!+8FQIM=**3[LKZ>)))C_2
MI1 9^A6%<7HY6F;9ZL-XG,Z6(N+IN5R)6/WR*).(9^HQ68S352+XO*@4A6-L
M670<\2 >75T4WWU-KB[D.@N#6'Q-4+J.(IX\?Q2A?+H<V:.7+[X%BV66?S&^
MNECQA9B*['[U-5%/XYV4>1"). UDC!+Q>#FZMC],;(OD-8HBWP/QE%8^H[PO
M#U+^R!^^S"]'5JZ2",4LRV5P]6\C)B(,<U%*D9^EU-&NT;QB]?.+]$]%[U5O
M'G@J)C+\*YAGR\N1/T)S\<C78?9-/OTNRAX5"LYDF!9_T5-9UAJAV3K-9%16
M5AI$0;S]SW^5(U&I8+L-%7!9 7>MX)05G**C6\V*;MWPC%]=)/())7EI)2W_
M4(Q-45OU)HAS.TZS1/T:J'K9U2<>).@[#]<"?8G3+%DK&V4I.D/3K6&1?$03
MGB[?%W_1;S_7P8:'11D>S]'UA@<A?PC%F9I29U/U"YJ*V3H)LD"DZ.V-R-3O
M[Y2X^^D->OOF'7J#@AC]N93K5%5/+\:9ZD.NR7A6ZOMQJR]NT'<J5N?(L=XC
M;&%;4WUBKGXC9JJZ752W7E<?JY';#1_>#1\NY#FMP_<>7:>I*(?E-N /0;@=
MA#O!TW4BYDA-VF_YV"1!O"A*_2'C9/?%1YX&*?K[5C6 OF0B2O\QJ.?LU',*
M]=P&]0J;Y4W-\@\"C*<;^*TH6HC*7__-%?8IM=V+\:8ZP)IBU,>4[8J]TM3=
M:>H:-?V<R#1%]VI >!C\JT;KLV*05LVM'%)IG^QI6"_AZ94C.^7(8<K=JF>A
MU8[4VC[##4-#=ZU38^O7D4RRHMF)3#-=H[36J$.Q0_8M5R^&/1L3HE?/VZGG
MF=5;+!*QX)E C_G+L-F^#)G,>*C3U=/JZEA[NM:+Y;I2K-?5W^GJ=WL?]F%F
M>-?83C8;(@IL"TAO]6FH4AIIXX&NG $(=F5ELHWZ3I=JWI]E(HG0'4]^J*7D
MX=7R8AH4X+<]2(#;0'#;C/!#K>;4\4A=C^T;K5X,,^8TF P@;ILI?BOCQ9$6
M Q;;9) 6 US;+;P^T&)U+-L,.]Z^Q>K%K 9S ;EM,[IOQ4:$R#;U&LAJ^X,T
M"^#99OWY0J6L=OAIRAG@AP'6N"NL86!UBN*.E-:5,RD*E,9F2I=S"/V'CEE<
M<<71'B2H,8 :]^AK8PU_M6;3E#.9#4B-6TA=F V;>@Y$QH,D,@8BXU,]:%RG
MJT<\=]\KU13#S*<-Q@ .8S.'NP<_N.X7[T<_FB(-X0\&N&.SWWQ  %1*ZA0!
M88 W-L.[,P[K/%9VM.G^&&FPW>C^. !MQPSM\J52+#S!=W4 O8X]Q/?. 68[
MN!>KE6*J.06=TUH6ZVBU2H[$#.X;\9"A=&>:]XB_2FJEBN+*?5.FU*INEFVC
M9\$3TV "L9U.Q%:3ZW@OVP&F.X-DN@-,=[IZV2USB];FELZ]=CJ[UPY@W>GB
M7G>PF"IQ%\1!M(Y,0P.T=@;IBCM <\=,\]/>.+/LUC?.!9R[77'>P7[\5XO]
M7."Z.TBNN\!UU\SUD^S7(AL7]C-!S 6RNV;ZWLE8/*.H,!D**ML;RJ*MH:];
M25V[@[07P-PUYZ\/"DU*689]@-=: +'=?HCM:IQLDP+ 8]?,X_;I<&04ZP*:
MW4&BV04TNSUF2=S6+,GK[18@+S&3=R*C2"2S@(=HQ5?"A',"6"6#Q"H!K)(6
M=[DU3"4:#QB[K,%3(0!*8@9E]P"4:!(2#:T#/XG9L^T*!E+?V,M[W]1^97>O
M!8][L^VT^(T $ D=Y(0$8)*N6WLMAM'LUAD, [0D+=MU=<,<'_L08" 9Y$X>
M!3S2?I+#M)[T;4 %!8I2<[YW(I.53/*V'V3M!,=KF0 ^.LC<+@4^TI9-N/8M
M^#H7'8_Z#<D)"FRD?9V+H'4ZV@VM QEI;P<?J.[D0T-FE%:./O3C,U+-$0B/
M$K^A?2 @-1-P;[:?MC)0 !\=I)M( 9&TGWPLU25:7=ITY 0(Z+4YB/MV.7YA
M\(!]WB ]2 ] ZO63</7J?J1O-V52/<"D9\;D_?GT'"WD1B1Q'E@AOA#Q[+F2
M*3!U$I#H#3+<]H":GIF:[:N%5X>E30AMV*?Q )>>&9?=5PM/$V0WM%XY"';@
M-E;S:N'5/<:SIND'U/3,[F+GV5_?HLI'OV&Q\@"*GAF*K=/_M.7#!SKZUA#?
M$!] ZIN=R*Z6*L54+>42W'0($##IFS'9Q5#'KR<^\-)W!FDG0*W?3V3N:WQ/
MVW(;\D ^D-0_,G'9*8/K S?]04;B/J#5;_%##TC+37Q-.&XX-.)73L_V MB)
M7P>L40$@K']D=O+D%"X#N+)!PI4!7%E+A'[(7&%UPII,Q8"QS,S8B5 ^T&,P
M4[,ES2^1S,5*ID%VVA+( *ULD&AE@%;6#UI9':W-2R #LK(6LC::I_UD& .N
MLD%RE0%764N&L]55+P701E>]?(\TS&T\&<: N.S @U=-#OV$U9G;$$ZPRHV&
M7J+\"3OD.)5M56\LM(3Y;;/T-)S85N4R@C7(V-^V*E<9K%ZB_\F+G*[VJMQ5
ML%K.P':PUPEW!*S*101KD$F"_$(KJ-B2)NALKOJ._'X:?URY 9K?OU5#NU"@
M0*%X5'6L\SSAD&QOM&X?,KDJ+H4^R"R34?%Q*?A<)'D!]?NCE-G+0W[/='>Q
M^.I_4$L#!!0    ( #PY:%/9A,.ZD0,  &P-   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;+U778^;.!3]*Q;J0RM-!VP()%42J9/9:BO-KJ*F'P^K
M?? 0DU@%F]IF,MU?O]>& ),0M"O-]"6QS3WW'A_;!S,_2/5=[QDSZ+'(A5YX
M>V/*=[ZOTSTKJ+Z6)1/P)).JH :Z:N?K4C&Z=: B]TD0Q'Y!N?"6<S>V5LNY
MK$S.!5LKI*NBH.KG#<OE8>%A[SCPB>_VQ@[XRWE)=VS#S)=RK:#GMUFVO&!"
M<RF08MG">X_?K4A@ 2[B*V<'W6LC.Y5[*;_;SL?MP@LL(Y:SU-@4%/X>V(KE
MN<T$/'XT2;VVI@7VV\?L']SD83+W5+.5S+_QK=DOO*F'MBRC56X^R</OK)G0
MQ.9+9:[=+SHTL8&'TDH;631@8%!P4?_3QT:('@!'%P"D 9#_"@@;0.@F6C-S
MT[JEAB[G2AZ0LM&0S3:<-@X-L^'"+N/&*'C* 6>6-S2G(F5HX_;,2A:E%$P8
MC=ZB#6R9;94S)#.T5K!QE/F)J-BBWWY4O(2E-%?H3P"]OF6&\OP-0+YL;M'K
M5V_0*\0%^KR7E89X/?<-,+7U_+1A=5.S(A=8;5AYC<+@"I& X 'X:AQ^RU*
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M85&ZOJ7KAE7;ZJ);*8O79O6XP2\;T"X ^W.E['/#W9WMM]+L/U!+ P04
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MRL$[-8)?.?BG1IA6#M-3'6:5P^Q4AZ!R"$YU""N'L"B',G]%\B^QQ(LY9X^
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M0K:F6:2_B_UOK)S0T-@+1*3R7[0OQ[H]%&1*B[@$ X.8)\4_?2D#T0#@00>
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M2H<\S1>Q1.3_P;$<:X] =!"2I258*4AI5OSBMS(0#8#BZ0:@$H#. *@/X)0
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MF)0LS2]W!,>$ZP'J_88Q>;K1!JHSJ=D_4$L#!!0    ( #PY:%,$CDMWOP,
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MK &^7TIIGA?60?V_P/0/4$L#!!0    ( #PY:%.'F 3D, (  -($   9
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MB1V8EJF2LQXD9I0DM%+HAL.B8W<")YA"DL .*9PNGT<7M,M]$D:R.WR8/9+
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M2VC7N%9E<_1GW0^;^2=02P$"% ,4    "  \.6A3!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #PY
M:%.>X1"W[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( #PY:%.97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ /#EH4RR$33Y)
M!0  =A8  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( #PY:%.3E2NXQ 4  -T6   8              "
M@8P-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  \.6A3
M1]AA@-X"  ")"0  &               @(&&$P  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ /#EH4TDY;7?9!   !A,  !@
M     ("!FA8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M #PY:%-LVO@[HP@  ,8V   8              " @:D;  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    "  \.6A3?G7G/ @&  !9%P  &
M            @(&")   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ /#EH4R#1K@[R!P  NQ$  !@              ("!P"H  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #PY:%-RB2O>@QD   ]-
M   8              " @>@R  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    "  \.6A3R,_U7/8#  #:"0  &               @(&A3
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ /#EH4UK4_G]4
M!   % L  !D              ("!S5   'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    "  \.6A3</"D0?<#   ,"0  &0
M@(%850  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #PY
M:%/1G$JP.Q,  %$W   9              " @899  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ /#EH4[97=09[!   -@H  !D
M         ("!^&P  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    "  \.6A3@C6)Y$,(  "$'   &0              @(&J<0  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #PY:%.9>FP7:@(  & %
M   9              " @21Z  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ /#EH4TEE@BQZ @  J 4  !D              ("!Q7P
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  \.6A38*?X
M[C,9  #53P  &0              @(%V?P  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( #PY:%/7S>RVH@(  +(%   9
M  " @>"8  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M/#EH4^VE)/+* @  '08  !D              ("!N9L  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    "  \.6A3J,?O3"($  "8"@  &0
M            @(&ZG@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( #PY:%-.OK6 U ,  +0(   9              " @1.C  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ /#EH4Q)I@HRT P
M9@@  !D              ("!'J<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    "  \.6A3 $R%7'(&  #\$0  &0              @($)
MJP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #PY:%.>
M-Y'V2P(  !,%   9              " @;*Q  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ /#EH4RNGE(J_ @  +0@  !D
M     ("!-+0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #PY:%/9A,.ZD0,  &P-   9              "
M@1O)  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ /#EH
M4Q*:F*Y] @  M 8  !D              ("!X\P  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    "  \.6A3/FQ:=QH#   W"0  &0
M        @(&7SP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( #PY:%-1\)=XIP4  ' 7   9              " @>C2  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ /#EH4U/EYD7L @  >0@
M !D              ("!QM@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    "  \.6A36'J412H#  "J"   &0              @('IVP
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #PY:%,\#MC7
MFP0  -X1   9              " @4K?  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ /#EH4]YQ96!<!@  FB(  !D
M ("!'.0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  \
M.6A3_TJ<Z<D$  "?$@  &0              @(&OZ@  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #PY:%,$CDMWOP,  !L0   9
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M;',O+G)E;'-02P$"% ,4    "  \.6A3:NL%\8\#  "!'   #P
M    @ &/ 0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ /#EH4[[+,T&9
M 0  =1D  !H              ( !2P4! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ /#EH4R/5;@VH 0  N!D  !,
M ( !' <! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #( ,@"5#0  ]0@!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>193</ContextCount>
  <ElementCount>302</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstruments</Role>
      <ShortName>Fair Value Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Capitalization</Role>
      <ShortName>Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsTables</Role>
      <ShortName>Fair Value Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/FairValueInstruments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/BalanceSheetComponents</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/StockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Capitalization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail</Role>
      <ShortName>Capitalization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="krys-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="krys-20210930.htm">krys-20210930.htm</File>
    <File>krys-20210930.xsd</File>
    <File>krys-20210930_cal.xml</File>
    <File>krys-20210930_def.xml</File>
    <File>krys-20210930_lab.xml</File>
    <File>krys-20210930_pre.xml</File>
    <File>krys-20210930ex3111.htm</File>
    <File>krys-20210930ex3121.htm</File>
    <File>krys-20210930ex3211.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>krys-20210930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "krys-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 193,
   "dts": {
    "calculationLink": {
     "local": [
      "krys-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krys-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "krys-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "krys-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krys-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "krys-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 359,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 31,
   "keyStandard": 271,
   "memberCustom": 13,
   "memberStandard": 28,
   "nsprefix": "krys",
   "nsuri": "http://www.krystalbio.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.krystalbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Instruments",
     "role": "http://www.krystalbio.com/role/FairValueInstruments",
     "shortName": "Fair Value Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Balance Sheet Components",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Capitalization",
     "role": "http://www.krystalbio.com/role/Capitalization",
     "shortName": "Capitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Stock-Based Compensation",
     "role": "http://www.krystalbio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Related Party Transactions",
     "role": "http://www.krystalbio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Subsequent Events",
     "role": "http://www.krystalbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Instruments (Tables)",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsTables",
     "shortName": "Fair Value Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i6d755a61291247e5ba23687314064f9e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i6d755a61291247e5ba23687314064f9e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedPreclinicalAndClinicalExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedPreclinicalAndClinicalExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i51817723d8bc4777b149972dc507b6d6_I20201005",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PaymentToEscrowForReducingLeaseRentals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i51817723d8bc4777b149972dc507b6d6_I20201005",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PaymentToEscrowForReducingLeaseRentals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i62b974e3062741518c63511eaaa01aa5_I20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i2d81be4c0fa64dd0b8e80538f57a09e8_D20210201-20210201",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Capitalization - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
     "shortName": "Capitalization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i2d81be4c0fa64dd0b8e80538f57a09e8_D20210201-20210201",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "iebef65754afc438aa569cd6c2fec349d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ie26740af942247b2a3bb8eb3a07f6bef_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i82b7376560d547bea66bfc64940f6cfe_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "icf15b9c98fcd4c008dbacb1a083ca5fd_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i132e1504fcb94c2395a26312d77352a0_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i67d54cb2001848aeb43475ee9cbc4b7e_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i769dbf11dfe64b2d8b252dbee0ed9486_D20191201-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AdvanceToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i769dbf11dfe64b2d8b252dbee0ed9486_D20191201-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AdvanceToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i2dc0520a90d14ee7bc0c963570c38886_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "i9e0b1819c03f4aa4ac375a025da3e55c_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.krystalbio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20210930.htm",
      "contextRef": "ic410ffc714874120b71c8155d66af84b_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "krys_ASTRAFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASTRA facility.",
        "label": "A S T R A Facility [Member]",
        "terseLabel": "ASTRA Facility"
       }
      }
     },
     "localname": "ASTRAFacilityMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Program",
        "label": "ATM Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "ATMProgramMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_AccruedConstructionInProgressCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued construction in progress current.",
        "label": "Accrued Construction In Progress Current",
        "terseLabel": "Accrued construction in progress"
       }
      }
     },
     "localname": "AccruedConstructionInProgressCurrent",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current Liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedFinancingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Financing Fees, Current",
        "label": "Accrued Financing Fees, Current",
        "terseLabel": "Accrued financing costs"
       }
      }
     },
     "localname": "AccruedFinancingFeesCurrent",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPayrollAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll and benefits.",
        "label": "Accrued Payroll And Benefits",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "AccruedPayrollAndBenefits",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPreclinicalAndClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical and clinical expenses.",
        "label": "Accrued Preclinical And Clinical Expenses",
        "terseLabel": "Accrued preclinical and clinical expenses"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalExpenses",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AdditionalAreaOfRealEstatePropertyLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of real estate property leased.",
        "label": "Additional Area Of Real Estate Property Leased",
        "terseLabel": "Additional area of real estate property leased"
       }
      }
     },
     "localname": "AdditionalAreaOfRealEstatePropertyLeased",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "krys_AdvanceToRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance to related party.",
        "label": "Advance To Related Party",
        "terseLabel": "Advance to management team"
       }
      }
     },
     "localname": "AdvanceToRelatedParty",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_BuildToSuitLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Build To Suit Lease Liability, Current",
        "label": "Build To Suit Lease Liability, Current",
        "terseLabel": "Build to suit lease liability"
       }
      }
     },
     "localname": "BuildToSuitLeaseLiabilityCurrent",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale",
        "totalLabel": "Aggregate fair value, total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale amortized cost.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical supply agreement.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreements"
       }
      }
     },
     "localname": "ClinicalSupplyAgreementMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CostOfWorkPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Work, Percentage",
        "label": "Cost Of Work, Percentage",
        "terseLabel": "Cost of work, percentage"
       }
      }
     },
     "localname": "CostOfWorkPercentage",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClausePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Percent",
        "label": "Cumulative Escalation Clause, Percent",
        "terseLabel": "Cumulative escalation clause"
       }
      }
     },
     "localname": "CumulativeEscalationClausePercent",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClauseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Term",
        "label": "Cumulative Escalation Clause, Term",
        "terseLabel": "Cumulative escalation clause, term"
       }
      }
     },
     "localname": "CumulativeEscalationClauseTerm",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "krys_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated useful lives of assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liability.",
        "label": "Increase Decrease In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_InterestIncomeExpenseAndOtherNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income (expense) and other nonoperating, net.",
        "label": "Interest Income Expense And Other Nonoperating Net",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseAndOtherNonoperatingNet",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LessorOperatingLeaseLiabilityAnnualLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "label": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "terseLabel": "Lessor, operating lease, liability, annual lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeaseLiabilityAnnualLeasePayments",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LossContingencyGuaranteedMaximumPriceToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "label": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "terseLabel": "Loss contingency, guaranteed maximum price to be paid"
       }
      }
     },
     "localname": "LossContingencyGuaranteedMaximumPriceToBePaid",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LossContingencyReceivableReceivedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Receivable, Received Amount",
        "label": "Loss Contingency, Receivable, Received Amount",
        "terseLabel": "Loss contingency, receivable, received amount"
       }
      }
     },
     "localname": "LossContingencyReceivableReceivedAmount",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee stock option.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-Employee Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_OfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Costs Incurred But Not Yet Paid",
        "label": "Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Unpaid offering costs"
       }
      }
     },
     "localname": "OfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_OtherContractualObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other contractual obligations.",
        "label": "Other Contractual Obligations [Member]",
        "terseLabel": "Other Contractual Obligations"
       }
      }
     },
     "localname": "OtherContractualObligationsMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PaymentToEscrowForReducingLeaseRentals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to escrow for reducing lease rentals.",
        "label": "Payment To Escrow For Reducing Lease Rentals",
        "terseLabel": "Cash contribution"
       }
      }
     },
     "localname": "PaymentToEscrowForReducingLeaseRentals",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PaymentsForSuitLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Suit Liability",
        "label": "Payments For Suit Liability",
        "negatedTerseLabel": "Repayment of ASTRA build to suit liability"
       }
      }
     },
     "localname": "PaymentsForSuitLiability",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PlacementSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Shares",
        "label": "Placement Shares [Member]",
        "terseLabel": "Placement Shares"
       }
      }
     },
     "localname": "PlacementSharesMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PurchasePriceOfPotentialBuildingPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price Of Potential Building Purchase",
        "label": "Purchase Price Of Potential Building Purchase",
        "terseLabel": "Purchase price of potential purchase"
       }
      }
     },
     "localname": "PurchasePriceOfPotentialBuildingPurchase",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RemainingCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining commitment amount.",
        "label": "Remaining Commitment Amount",
        "terseLabel": "Estimated remaining commitment"
       }
      }
     },
     "localname": "RemainingCommitmentAmount",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties.",
        "label": "Risks And Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_SaleOfStockAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Price",
        "label": "Sale Of Stock, Aggregate Offering Price",
        "terseLabel": "Sale of stock, aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingPrice",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_SaleOfStockRemainingAvailableIssuanceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Available Issuance Amount",
        "label": "Sale Of Stock, Remaining Available Issuance Amount",
        "terseLabel": "Sale of stock, remaining available issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingAvailableIssuanceAmount",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental condensed consolidated balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_StockSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement",
        "label": "Stock Sale Agreement [Member]",
        "terseLabel": "Stock Sale Agreement"
       }
      }
     },
     "localname": "StockSaleAgreementMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_TwoThousandSixteenLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen lease agreement.",
        "label": "Two Thousand Sixteen Lease Agreement [Member]",
        "terseLabel": "2016 Lease Agreement"
       }
      }
     },
     "localname": "TwoThousandSixteenLeaseAgreementMember",
     "nsuri": "http://www.krystalbio.com/20210930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r133",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r175",
      "r181",
      "r205",
      "r206",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r348",
      "r349",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r175",
      "r181",
      "r205",
      "r206",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r348",
      "r349",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r175",
      "r181",
      "r196",
      "r205",
      "r206",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r348",
      "r349",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r175",
      "r181",
      "r196",
      "r205",
      "r206",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r348",
      "r349",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r133",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r305"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxes": {
     "auth_ref": [
      "r12",
      "r13",
      "r252",
      "r322",
      "r338"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due.  This amount is the total of current and noncurrent accrued income taxes.",
        "label": "Accrued Income Taxes",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r151"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r42",
      "r43",
      "r44",
      "r340",
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (expense)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r44",
      "r50",
      "r51",
      "r52",
      "r80",
      "r81",
      "r82",
      "r258",
      "r350",
      "r351",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r245",
      "r305"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r242",
      "r243",
      "r244",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r207",
      "r209",
      "r248",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r209",
      "r238",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r118",
      "r126",
      "r130",
      "r142",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r256",
      "r259",
      "r275",
      "r303",
      "r305",
      "r321",
      "r337"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r38",
      "r77",
      "r142",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r256",
      "r259",
      "r275",
      "r303",
      "r305"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 3.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r138",
      "r144"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r135",
      "r139",
      "r144",
      "r325"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r137",
      "r144"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r210",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r79",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r25",
      "r69"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r70",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r69",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r276"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r160",
      "r327",
      "r344"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r305"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.00001 par value; 80,000,000 shares authorized at \u00a0\u00a0 September\u00a030, 2021 (unaudited) and December\u00a031, 2020; 22,237,984 \u00a0\u00a0 and 19,714,220 shares issued and outstanding at September\u00a030, 2021 \u00a0\u00a0 (unaudited) and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r55",
      "r329",
      "r346"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r109",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress, gross"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Debt securities, available-for-sale, term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r67",
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r67",
      "r149"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r56",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r93",
      "r95",
      "r97",
      "r98",
      "r99",
      "r103",
      "r104",
      "r264",
      "r265",
      "r330",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share: basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r56",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r95",
      "r97",
      "r98",
      "r99",
      "r103",
      "r104",
      "r264",
      "r265",
      "r330",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share: diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Share-based payment arrangement, amount capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r106",
      "r143",
      "r193",
      "r194",
      "r242",
      "r243",
      "r244",
      "r253",
      "r254",
      "r263",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r350",
      "r351",
      "r352",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r326",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Available-for-Sale Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r267",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r176",
      "r197",
      "r198",
      "r203",
      "r204",
      "r267",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r197",
      "r198",
      "r203",
      "r204",
      "r267",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r286",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease, liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnSalesOfAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.",
        "label": "Gain (Loss) on Disposition of Assets for Financial Service Operations",
        "negatedTerseLabel": "Loss on disposals of fixed assets"
       }
      }
     },
     "localname": "GainsLossesOnSalesOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r67",
      "r148",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Recognized impairment losses for long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r154",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidRent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Rent",
        "negatedLabel": "Prepaid rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r117",
      "r283",
      "r284",
      "r332"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company, Capital Share Transactions [Abstract]",
        "terseLabel": "Investment Company, Capital Share Transactions [Abstract]"
       }
      }
     },
     "localname": "InvestmentCompanyCapitalShareTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Future minimum operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r77",
      "r127",
      "r142",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r257",
      "r259",
      "r260",
      "r275",
      "r303",
      "r304"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r77",
      "r142",
      "r275",
      "r305",
      "r324",
      "r342"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r77",
      "r142",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r257",
      "r259",
      "r260",
      "r275",
      "r303",
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyRelatedReceivableCarryingValueAdditions": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additions to receivables pertaining to a loss contingency.",
        "label": "Loss Contingency, Receivable, Additions",
        "terseLabel": "Loss contingency, receivable, additions"
       }
      }
     },
     "localname": "LossContingencyRelatedReceivableCarryingValueAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r45",
      "r47",
      "r52",
      "r54",
      "r68",
      "r77",
      "r83",
      "r85",
      "r86",
      "r87",
      "r88",
      "r91",
      "r92",
      "r96",
      "r118",
      "r125",
      "r128",
      "r129",
      "r131",
      "r142",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r265",
      "r275",
      "r328",
      "r345"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r118",
      "r125",
      "r128",
      "r129",
      "r131"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r288",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability",
        "totalLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r292",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term, in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "verboseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34",
      "r305"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r59",
      "r61",
      "r136"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r210",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r305"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $0.00001 par value; 20,000,000 shares authorized at \u00a0\u00a0 September\u00a030, 2021 (unaudited) and December\u00a031, 2020; 2,061,773 \u00a0\u00a0 shares issued, and no shares outstanding at September\u00a030, 2021 \u00a0\u00a0 (unaudited) and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial offering of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r356",
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Project management service fee"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r150"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r152",
      "r305",
      "r334",
      "r343"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r152",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r251",
      "r318",
      "r368"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r145",
      "r146",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r194",
      "r245",
      "r305",
      "r341",
      "r353",
      "r355"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r143",
      "r242",
      "r243",
      "r244",
      "r253",
      "r254",
      "r263",
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r290",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Initial recognition of right-of-use assets and modification"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Capitalization, Equity [Line Items]",
        "terseLabel": "Schedule of Capitalization, Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule of Capitalization, Equity [Table]",
        "terseLabel": "Schedule of Capitalization, Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r209",
      "r237",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r209",
      "r237",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r298",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r210",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r215",
      "r227",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock award granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Restricted stock award outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r217",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r208",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r210",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r233",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of the award (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at September 30, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r75",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r50",
      "r51",
      "r52",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r106",
      "r143",
      "r193",
      "r194",
      "r242",
      "r243",
      "r244",
      "r253",
      "r254",
      "r263",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r350",
      "r351",
      "r352",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r106",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net, (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r193",
      "r194",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r193",
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r77",
      "r134",
      "r142",
      "r275",
      "r305"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capitalization"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/Capitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r14",
      "r323",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r14",
      "r323",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r78",
      "r197",
      "r204",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r289",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r94",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding: diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r93",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding: basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r371": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r372": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r373": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r374": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r375": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001711279-21-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001711279-21-000031-xbrl.zip
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MW8+*GS]P:[V']<^4@;^8$3P#6M,,2\5D, 9Q']>V,@".@%>_HN^+NY J#S$
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MA,;$"DVM9"HE2H/]\B8&C!6B'J.H5U#[S3]VL "UQT6@TD7+K6* T8P,1N#
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MZUSDO4^A5!EM$99.,!%HBIEHHJB/*) (SF]1KW#%Q&K^I)JAGR4EU<@*&A0
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M2JKV+M5H0LPK9CB O^@T=S@J+=BOANI7B:$6$Y15'%L4(F58L&"Q-3YJK+P
M;40#$LL/:5-OS(;IW$[8+S@'*)YN_BFD"TJ":!5C6CNAD'>!J=2,UA/BH^4>
M8"TQ:OFI\=#YB6M*W-IL*4T;%J'!N\#8QR"8)5Y9PHFWH'Z#UTP5/@;6>%2
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M2QL3LD :^_D_<"4@BG*Z9S^E):X^*$Y%] '(ISE0TZ"8*8YX1E%TL/(V&,:
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MHC!$D0R3MHL)3/*1\15?XS\FEWWW@L?'-[DPP<[QQ8^,=7)EJSM2^)C8C$R
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M3IH'L?$27;YI[@[JA^CS!^*(00Z)C$9D,Z:9RW0,(9/,&<]U((R1M2VBQ+K
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M''G:RJR>:IH+2AC3:7=$)G!+BG,]HWAXI8Y^0!VU;H=)P)I(C&TFM$]A$N=
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M,!5UIK4UF:-22^ZE,![0 B/K:NEZA%1]?)8<'50B^A,B>BM5(9B(0)MFC@@
M](;IS&J+LJB9XHA20U+B$%;K4CQUJV'YVOB4+*[PLM?IM$9UJHM\QB1D,/#0
M=>E(]V^-WB#4Q.^S/ 3\/&;XLM_:[+;:?ZT-\F&X+\>W)KG=]2]O3[&2YBFD
M^4Z5&<28M]S'S%-L4B,<D2D?>$8E#990(X!@27SNR?'2'/Y^'AM3\=_S\M^-
M-5$A.DX=S9@5 /APC)GQT6;>V\B$(=P'_"C_E:_NQL-J^VZ=C3!MG8WGJ:2Q
MR%H9U^;:MSY-[EW\I-7U(&^;F&[P8E"+H-(_>8@AST/"*T"O/VK_^UO:YY^0
M'YZ9/,S$&=UKO'J@;_5H- 7S_&/R_?QP8 ;!OS/M8;AY^ACHHDHU3:&:W@[J
MDRYQ+S4Z^9\SY#KONN:]'NYWZE_J7^ Y7^HPMMTT[O8Q.4IC:-=)_7*_Z2X;
MY]M7Q\TC]#]?]BX_,.H0"HAE(46[F2,J4RRZ#.O(3>0N:AV^;;\>X: ?\Y4J
M#BH=!VF#D8T$9]YZG#&->*8H#IG&*!#*8I3,KVVAC:3V\ ,6\MX'M0N3USXE
MTOY1>Y3M^HGD_=EQW).ZY-UFQX+W^MO#P5DO!QWM*S9<"!O6\0<=A:/"F0R1
MM(MG$<J4HB83&C,445!8J&\HL@<YZB>L8,51I><H$SU2FNN,2X13(RB3*6U9
M9L$'Q<P)QP-P%$'KH-C2?U/HMA&7U<PU=6OFIG$Q@,GE1)2C:-CH[]IAN!B$
MC@WYZ#U%Z[4D!+7?AETS]"VPR[\7,9V=X&Y?AHO+4'ET^EZ_/ZRD;T'2=PKZ
MW HE!5<9%A[<;A-"9@5(G\?PCP>,BF*)]'G%38OE)N<E%ZF?GZ4*N G8)QU<
M1,!<)()ZE]HJDHH?(8'7I?RZ]L@#'Y1*:X\-3ZM@P_5"02]$$3_>P_(AJ=D?
M#OH#&&NK>UJ)SD)$9_>ROOW!:2^-\2*CVG* UM%DFAB=.8^=-%01Z>*"5''%
M3R7DIR QXJ!V,PU:) -M@C)+I,T$IA%824J>3'NW-SV@[MT0%A#U8QBU9#I[
M.D1]=U)51N>\3GP_K&>*F&25MO%4W7*K):HW-E#",R%X<4#49MI9F5%GG+<!
M&<)U=<[[%Y#;Y^Z97LGM#.3V5A=4AJ6.GF?<4W"PL">9P<5I+A4,48)X(9=1
M;F>[-[_4&\,I(:37_9E=X9GMZ8V&4FWHS4X8C[X!T(\Y0/3/)SM[ER?-]AG,
MJW/\_BT[;KYKUU^?M.OGQY?[.T>TT3QK 4!G'Z@D40GA,RJD!E'&,5,V$##&
M)!+#J<?"_]"6\,R2"BKV66+V$4I2)XG* C5%Y="061YCYJ2-+ 2.1;($<]@/
MGD^T]Q8O5EMW2\&#]:L/1$F%0CI1CJ--.7LJTQ:QC%C'/+= <L*?&K&:SU94
MQ4Y+R$XA.)/VG3+"L -(RWEFTH$"IB4G1 >O:5C;4M5.\#/N!"](FU<;=PL4
MO5/0Y(9K!D*6.<<E@%'*,DMYR$#W:H,H(SRU-RH%*U6[#TO 3Q%%$32B63">
M@0*G*+-:I(J26 !JE5BG1'Y"U@F5ZUI]W=NS[#O!"]OZK31OB23EX]4'@#G(
M O+)')(@*1@\.H.12QC:  PRVHIO988O$RM5FG<)^,F0H(@4(;-,@T\6",L,
M<SQSWA(AF, J:5ZLUR5FZX0\ 42/LEI&G3%^W8W@]1JLQ46 I?D4VE=3;PNO
M]B[2<^_^WE(UU1;2#ZF7FZU?:[U7V*N,^G0428&#K5@ZXRL< Y,AHF7F![>0
MEJ)PQFI+VG/OUU:2]K.2=K-9&Z4-S J?*:23$Z1H9HV0F5:!$TVYC)HL4-)^
MJ48>VS#FM*RF7;LP+0_HH^;,16M@VE6YS<5V^;HFS#] E[WNRQ%5*KWS)+US
MI_MG-%A:KU461:09\XQEH&)8RB8.,F)AI>9K6YQ(P/]5F<T5%N#Y- :K!'@V
M GP#' SFWE*#L^!2:@CX[YFV08$C'RPX\,@!-=>VJ*#K1#^U5/?R9'F5!#@X
M-^P,VRGS9=(0M->YR,-9Z/9;GT*MU87WH?;;N'/HX^6T2NVA_#87V-"'><*K
M!UH/3DA0]!Q\>9L >\7ZO^GU^XTPV(]-<UEIGB=IGCM]0#&5/'BF,AL9SYB+
M*M,\L@QK!J@!*2^=6-O"7^_7?,7W54A@^:U\)69S%;,; X^DH)Y@G1%*[0BA
M6ZQ"%G1$2@;*8Y1K6Z**"<S-M/L06ZXU^,6" 7,VZT_P*@["P,!P_:[)N["H
M_5NTVAF1JM(_3](_=]I\!N^PD(IEI*C>3[7,#+$H9=HA&0QCV 0P\UBM:_EU
M9>W';'T5'"B50/\X;J@$>CD$^@90,.%\P YG'LB7<#O*M @H4X0Q@H2@48%
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MI'V@P2HA-0W"&*.J[=D*7/M\5DII=^<M92)RJ14QEB.RT5*;T6E&#%?!RZC
M68?6)^5=>TU":TL9W-I5?;M>\DKK\7*RV1GDTK7Y>% > #=_M]-/-Y]Q;V3;
MA&L/*9V1/EB)]A\' .U<\%DX$"):[IVC35%)2MFDJ"2E8L'3RNL;Q4\.,:]V
MBJ]'F'\/1GO/9HXP QC#D4X1G2W:D=8Z@A!B2>9,,N\,MYRB':FZ7#Y B_@[
MAI&LLS36_C!M(%44;!29942U ,IX'S2C:#'Z%)4-//T-RMW@^[J*8TW7S:LP
M5CG5K6!LQI]/@4L!AD@F H'LT6J,2I#H0U L28O+5OSYHF)8Q; ZM75J%U,/
M-E'/#+.!B@S.@0M"2T>YC$XD*4-5#VU0#[,F=Y**"Q<H\5QS I DL4E(XH-!
M%<%XJ:3^0 IB<T*%KY>K9F^3IB-YL:C/6Y)WTN?R^\VA\QO9P*%VRZFK5%=I
M_0VZG?C^=-I8_F!PD6=<THQ?]J=948V7J@&^9S.X]T?ZO]/>J#=.K]+P8R^D
MB:K_(X7!NWYSE4;K5V4_C[)_-6,+:IX%,Q((UV!+Q=M,K.292,YPO<$[!GEK
M6XIYJ]U6<:^@7%>IKM)&K-)#&KM5=;9+=<[:R4HR[9VV).):$]!"$^,L$!JD
M@6ATHI2W37ENR,GS1:OXSCO7ZW=0*GO]CVDJ*1MY]%R]F75JZ]36J;U3SI5U
MF2>K&# #F5D;,W(0ZJWT'-_(<].2IB;6I9)8D](>%[C\[\%1F<]?$)U+;]/]
M_JL43H=(/-)H9XB\I/]NUGF_E\;[^<!]KG1D'CK2FTERL"E38V0BQ@0@$((@
MACN*YKQ/DAH>,U?7]GRHHEE1;XVF]B&-L8IZ[4"]62,L1YJI $5<+ATA&.*>
MY=P0[W7R/!B:;NAU4\\J%Y1$W+V=(]SD]4RRNNSJ*M55JJM45ZFNTCKD^6J@
MFB41DP4#+E'K@C?)6ZJS-UK)6Q#CNR3\(F&8\.5"C2OGG8?SSN;Z9LL<I\(3
M,#S@#UDRXI0G"5=,:&9YEF9K6W8%7*W&,G>J;Y7?%LKO$@S;*K\KEM]9F]5;
M'T&B! LF+0$.EA@C.:'2&F$56K,VMDJ"U^[4\.\+\>ZZ83CLB#GJ\#[F<KLQ
M ?69"Y9# JZ%STJY$!D$%J4(H>DLN'@":RVWNP#([,_FJLJ$G-VK1'2R"#%1
M>V*C3X19J4)B5.BH)N5V->U*-6_F?)M;HFYZ.8]'5[7C;N!32^&N#G<N2N%Z
M&K4 (4D,21((/A!OA$(+A6=&(SB6V5U+X5;0J:"SNE)!R,$%"P&Y..!^!I^4
M9I)JKB*5PNG;@4XM%73/R'.1RN"#E[[@C1(&D4>Z2*RCAJ"^$(EG8[G-)6N1
M=[68,W.Q(D]%GA72'4>CSQGA11@PS/JHK=$,]:G(DCMV,_)4<%DNN%Q$5V6@
M&K33) 4GBL\U$B- DDPM4YRC034!EXHK%5=:ZS;F-AD>:%8A9E!"&U]*(2H:
MI4XAY._84;6\ZT/ S\613^2Z'-(Y@A"D"&CEB??"$@X9%U"[Q 3?V@;H"F-N
M[S&NZ%/19W7V%,L>K 2$%P^>>BM2%LXQF8,V-J1J3[4"<R[5@:$\Y\044524
MMD8*24^QJ%**B4D0-D>]M<VLZ0HU;X[; U=875;PY4,*WZ+55S?H\'R^PRS.
M3,RB].J*'BAPYWD*2EF3-(U,V^GQ.9P=GRM!:UG6=@'5JYFC+AZL$-)JDG/I
M3V1E( [-9B)"D,X*27%=ZA9YU%LD*9%*IS$B> 0"$A(QB>(/;U1B!B2^C.9[
MEUO1Q0UT19>U*(&[!E/5D-5OKA%2RGD-5VD.ZT&A7<"$+OFJ %)1ZR$*R<$B
M"TU)QK_!X[N8$;7"Y'+1^.*DAKL03):2!*ES<:9J8A,P(F/0HISOFTSK[GBL
MN\,:B%HH09*CGH"*B7AO&!'.>)H,+1X#M#I+Z)*XVLMH84U]%4S70@=435U7
MJ:[2XUZE><Z8K>)&4N,BY4"3,!1$=MS&R"%$$:K&;+W&O)10@,3)H8%+K"T5
MNX4OIJUT1*@D8A#*RR!NUIF;4HWL(65O"86[UP]P:IF3.K7K-[6K-2QK.<_6
M*M'=@YWQWH4292SGQBV1 Z#A&2,CA@I-&+<L"Z6C";KNGKI[KM\]BF4C,VZ7
M+)TA($O[%)J ,$@ +DDP,6UM&[JHRZ*"?M6G=6H?R=2NUJ*ORJ;5RF9WXB%'
MA8/:)C$:<Y#$2Z4) /[P7F2B@%KJ@G'"F^NUS::4O7M(L5RX^O@&.1VK:[BN
M4MM6:5T#(NZX2O7(LJVD3#NJ\5FT5<Z#8]3SE#T-%#A53DH^-RFK%8A;0<9>
MC$M%IW._D>-),TEXX)D@Z];$<H74#%)FPB$G+_VTZZZINV9VUTAMG1!:$V,=
M108/@IA,+:&",B\U9UG(K6VF:BSJFJN+QT6]UG65'M+34N&Y)?!\R</"G> I
M:L*5\:4)ND*%'A*11F2I(E/:ZVOQN493K+2UP/I!3?67UZFM4UNGMDYMN\JC
ME'JI5G@-QF4(3-OH<F+,4!$9S?8VX1JUJO9J*=O+\?Y,_$Z*U(?("=.E]*15
M@1CI+)$R"VI-".#$7$2_;HCUWA#9FH@;0I$LC2H4/A,7G2 QXU*%(!C(N+6M
MNN::>H"WKJ)3@?G>@7D)!G>5PU7+X:PM'6E,66A/1&EU@$LHB6.>$U^2%J(!
M)E6X21#O4^[F#U6X]JAM+?H=_'K:3QU!;]_NX*;!/^X^"%(EH4/VTANP(CF=
MG&()G#8,D"Y,JU@M6@ZD]D%8"'UVQS.Y4;A$2 1,))!+MCD-0%QVE-"L*'<Y
M.IIYJ6+550JZ5,Y;R&IA,;EWM_YES+JI[-[]B'O;'(LWUN-;?/CKB7+7L*T[
M05SMMK!*=#L[1C[8^;1W\.&M]A8-4U D&;1WT52UQ(!!B+/4BN"2]%K?M>E"
MQ;>*;QN%;UE[D0PW/,H$4H,#X9( $V6P/)AX.WRKA4CO&^1F<JN >:H-2,*!
MFXDCQW,7B)1 ;?+&"\A;VT+1KM&+I[=7?*OXML;X%F)IA((C8S$!Z.P9"\);
MQSG+$?^^&=\JA"T;PB["_7163'AE25:9$H@I$<>30[(F@W)"!9W8UC;0BEX5
MO38.O>;J39YC2<+G8 ('JIW+D6K&K=(Z4L._ U^U2<6#@-S,@1LHT,()3:C*
MJO0U#L3[%(C1)BN+.HA"VMJ6K(NZ:)'&QH\$XQXSP*T1NLT!;EY[B4@FE4@:
M$C@7#%BN1<@0J/*BVI[MP+39PTN9N!&"*6)L+(4]DB<><B#))A#)Y!RC1^.3
MVJZRBT<#SR,6-4YXT188FWY<F5-RU@5-I<F0./>12QY<>=4 Y+-,,GT6.6%K
M&X/6H='OYX>9^)[8VWD;>/2E%A4QT7*"2@1_<S(2S;G+5 K+@*(IR;N&7659
M-<BTQN^NT=3.P:W >FI#]LD) $NUI=ZCT1&EECP;X_X&ZVYP@-6JM4L&L[US
M,-N5>[^_;1H!E+Q7K20@F"E/3&*>1!XEKI%44HJM;6ZOMC6LXE:1K$YMG=KY
M#'#N-"@A,@4)5H&+GD$2!E(4-CA5E40KE,2%_?WBT^[SUY_?)AT=YT")SDTK
M2F.)C2*2B#9WM$QRS^&!U,2*@HC7O+CY!I4*J 4=ZBK555I'^VX.5U:M?MHJ
M2O#GC-WX)RVY?50F04U))**:@+"<6.4-,=)XKPT2@LRVMEE7R#95Z*B84)&[
MKE)=I3;JUR68QE6_KJ]^O6)R*R>%3EP3ZV(@H-#X1IWJ239:))&%-DZV3\-N
MSMGV3)'Q4@IK_B+CZX=6U4=:I[9.;9W:.P4.IP2:"Y.<$A&H\-[EY(&A]O(^
M^>!OP5_.(XAK?<X6<I37Y_D4>U]?B[UW;YGP3B<O">@(!*@1Q,0<"5>9LFBH
MM3%N;?.K.16UED\%P/68VGD < D&7 7 =@/@%2,M!PD9@B1**$\@*T4<]0Y_
MN*BDE&C I95#X",X$9VC0/$&>9.JSZ^N4EVENDIUE>HJM6F5YG,3(",N!>!B
MSJ48G)6&&@HA 9=&@YR')==BHBOAO>$\QQ@-?]C]5#JU>QD]$&8E):!\()92
M(#1$GXTVUFJVM6V[BMV>^%8I7B<I7J:M6Z5X15)\Q7H-60EO)",9-!!(-A)/
MM2+<..>UHPR8:)4<+_=TL15U@5^EDW$Z]FDX5W'@27[R9'*>"IS-.#CU1VF2
MH_RH*P3G8!/7P6:&V 0FV2PX<^ 2/F,RRD]3_!?-M*T5@A<"HW?G2;7[![N\
MY*'%X%E&%/)&>P)11>( \4@R@Z^XX$U*395@3577Z'GK-"U'7E;C.%^!C+?-
MG7=CW9(ES<%ZXMLUM3/O!&ZU-O J<>U2;>#P-NI@DO:92($_0$D$-AH\,5FS
MG +:44'=M39P1;6*:AN :H(+3K,*N-451&]<B"HIFFW*DH/3MT.U6I7IOJ'M
MO"+P%-IT9*"X8,2I4A:86T0U*PS15LG,),]@H90%YETIYJR$4J&M0MLF0)O+
MB7LA7.+@@7-G0!L#G&JO?,[*W QM%;V6C5[?$#,MC,B::Z)I#@08!,0QF0ES
MJ'2H$0*I]K6A&Q6X*G"M)W#-X^&7.7F$*>-<% !"62.YH2'YR%!*HKT9N6H=
MX ?!M_UOV!F =0!4$>LS$(C@\3<7B7;2>1UBEE%N;9>>#=>0LQN]^Q7>*KRU
M%=[F.;_,P0HIJ! Y@6;44B<9HAVWCE,I<S4YVP%JEX\L_Q1O(PU<@<]$<,<(
MV(@V)U(UHJ7-3N<0I+>E&C#KZC6C;LW9YC_'#N^(_\;>Q^U_X8^SASMVPW>]
M_N3V_#(&A80;>SAYI=>/^-=3P9[(!@J7*H6,GHEA<\6G)4>X%[XOF+P(YL%A
MZKA0*A>Y_A><ITY_,"ZGGT-\N615CM.[H3OJG+CAN%02'A^F44+I=:>Q-VY*
M'I5138H?]9N)=^7EW.N[?NCA%T=C?*%)RWQROK;?3N#T@8 _T3@U/YX,1DVR
M\M-A.G+CWL?TXZ=>'!^>(<G,%Z?[@5Y\Q7E\B-/QS5]IUV)]=VGDY0F;_5D&
MU("4Y-KKI UWVD/FP48I [69&J_+X<-;+K?.OG0XO-#*[Q+QP^0^$)=QS$_=
MT2?W9;3US\M3A?/TS=+,-:O7S>'VO_P0[W+-P&:N=F5-[GT!KL0"- OPO\,O
MN'V/.C_U4";"8;?SLA]NWL5M>>IGYR+Y;%8D7YT+8I'C9VYTV/GY:/!IU/KQ
M_'".-O^X\5D7VG]7KS/%E>92,Y>6U^$%7KA1#-^H*IR=(W<R2D_/?ODQ]D8G
M1^[+TUZ_&6/SI1\OW[#<X-M F'*_R=L7TO>$3B1P&FXSO?/T[2?-6]\HT,E[
M&K]IS8UOTR?LQO>^=UG&GR!CN]-EO_\>LL#[>5A]J\NV/J3I[Q7)-%+[.FIU
M/B)[FQ%-E>-*3(J_!X9)HA&^TMG%CQV..B]0UF,CVY>"MBZ->1WJ7]QRZ#^\
M[",5&YSB->+HBD/@NGC:.2ARRY<=K3^VK!'?&$6\J3-'YY&(964CK@+YKA_Q
M_DD:H@F!9LT.6ID?FZ3;V^R=A?IJW693S=LHZWX?<NY]D)O_M'$?S)>3.L\
M']C)>,N1WK[-V'5#?" ?XBW'-L\920!&<PZ:@=& AH37+!@F953*90.3DB>,
MLDD6!-OL+(B]5U.7XO'NE]<'0;QY'MB;YR\_[[W_G>X]_X#W?"WVGN]\?O/^
M WM]\.>G-\]_9Q<NQ=_Y:_ZR9"6(O?<?ONQ^_?WKWOM?>WC?#V\.7G_=P^?;
M?[Z#U_WP]8I+\?F;]Z_?[WS:>Q_X_L'+KWO/=_GN\4N\WQ]'>^]WQ6ZY-S[_
M_L%>/@_.>T4_O36:,W#%E6@@$H@TEHX^@C"M90K!429+'Q_=U0H62'^X'L;N
M-8WIFUO>NB%B!:0U!R2=G/-"BQ03!R6=I58&R([:G$6T,$W+8H\B+6M- .GK
M.2!1*A/$P(E*W!) E4*<#J7QH<G92TI=*,5$6%>;E@#2!G'[ZX5OIDQJ9SSH
M#!.*6^@=I=+?<%(6$E\MOX?BZSPM#M%>OS,XMPC<4BR"MI#^^^3U$SW#GW#9
MYOWP/)W@'NA-NF^X?NRXXP$^VM?FA3L5H[FMSFV?8EHM49Y#'<TNTDX_[LPL
M455.<RBG\WCOHIP8,T:JK(EVH @D[8D)EA-A$_XO&D9E+N6(K9&+EB-N'V.N
MDKQ$AEDE^2$D^8)F!J.%44(1!8J6AMJ)N)@Y\8(Z:X2-+NBFL+B:-VEC#:CF
M>M",^VGX=75"-@^?5LLTFC( /WW;(:%"TSS0U)LA&5HJRS64AD+4(,F0D=B8
M&5$",D,;.%A7H(EVF;YJ <];).QF?+BW\D*W-,4>O12OEF54*5Z&%%\0C&PE
M$\X"<HN2605.$X\OD: RCZ5"O"D$@W<UY2T2XD?EQ_C/M*-)B1<;C%!H2KQ>
M4Q>BXT:C=*O^)H_4 EHRP[BY&$<IYCTJ"Y5*/6^$HM%^WFD6IT+3/- T>^9G
M=;1)A4B$E!D)1JG7;7PF7!AG6)2YZ6-\MVH<U8^Q1E*\S).R*K;W([87C$)H
M'T2&1(2QDH"BCA@C%,E*TR"$,#JJK6TA6B2QC\I?L3?HD^8$K.3R#--H7!T5
M[7)4-!U$<)7*(KV8+$U%HSG0:/_9#(D YQDK0,2,0S2RP!&-O"."*<:-48YF
M41RH8-MDWU0G1?LHQ.T,@2J\"POO!96(UE!F@B*),4\ 0! 7J2:.R^QX=MDJ
MNS0+8'7NB;/$+WS8]'V)7]4G'Y4_Y=FAZ[_#RUT._FE8?Q,F<M1SOG=T]T"@
MV]IU#WF-93)>+B>YP*U=\-^&Z<3UXAG/G:SRH !U)YP.AZD_7L21]BCTYS*C
MYR\KS)?],$QNE)ZGR;\O^]/E>IYRPL6)4RVZTX^-;JWF^?R!JQ>%.<:[.V\S
MR]X:H 129@0\I\2'H(F-I:8GY]HZU*J&U5.[#1;H^_.I58%>C4!_.1=H+X-/
M)1N&*H$T.4 D5C-%#!76@E ,5W=K&XQMD4 ODW&N#0$I5*,>UCWX8=V-"/4'
MKD\%HKF Z.4LL[#"::02DOC( @&1'#%!&\(5=5&#\*J>V*VO**\XN6T.CWD5
MZ*4*] 6S<!:,R"P2Y61"@2ZF@@J&T(!BG@)X$+E$!^&&V:@DM_6@%?\I>_W<
M7?7ED7DO'BKY?P(]'X9?1M?@3K,D_SE;D0H]<T'/[BR74"R;P+(FX)(BX+TF
MQFE'E*91:^]YH!:A!Q;J=E@=%.V5V>5[**K,WHO,7M %+C+-3)2&61$(J S$
M<!$)-Y0*16T$61H#JJM9AP\BLX_*![$3 @YE/.J<N"^ETN0C\T,\+%NXV5 Y
M6Y;?)JM2T6<N]/E]EC$(GW460N*B&$- ET[GS%CBI%$R4:,]%,; %T&?ZG1H
MK_]P"82A2NL]2^O,H87-GIK$B %'"?"<B"_\WO.,*R>]XTIM;>MKI'4SXH37
M@3 ,3]-WHR9N$RFSF89,:X.'K\6LLH[_N5BKLY/7\V*H,^]52)L+TOZ\=/P1
M7-;@#)&Y]-C4P1 C9"(I>X]+G[FD8FM;=357+3J)K9Z+M>0A5:;O4:9G7!HV
M9$FU)P)*$J*TI?.D<00%/4:7?:*2;6U;,V__HG7Q:PC=9HZRMU UOUM83(MU
MG&L?C*U'Q>32C.:WX>!C+Z;XTY<_<6U?]L^![:)P>\6UN7#M]2Q7\5:QA&M*
M/)(3 LD%8G$[$PG"!HJK'7VI7ZJ[5)C%_24/U&SR7ITICQD:'JYV<86&>X*&
M"\I#0^2R5%NP+B2D/*"(@R (PU\MKJ443#]8K''=+2W;+38S"-8;XKE"HU>%
M3 RN,\E!:IV=P1556]O,=*F\&G^\!IIE2J;/'N0,,J'1&VO1S&4M'G*#.LY<
MWWGH9?]C&BVC\] C2B]LPVK>$-%_.@R'KGC%![ES,BQFY_A+XR%/_W?:.SF^
M:Z#_^CK(5FQ9SL$#?G-?FJ8 !X.=@(LS3+]-U^NW(]<?[_3CB[,EJSQ@+A[P
M8=:@I-*)8*PF$"4C8&PD5J9RGF<=UQ+90/"-00GR:NF?&K*W$7*]VJC_*M?W
M)]<7_!XHBS0Y2@)(28!;3SP-CN@LM3#46TGEUK;N*G'U4*N-47T;6WQC3<A2
MK^'!C>#6$,2V,J2=CZYW5"*<?AX,2UG$5RF<#AN3Y7GR%4[G@M/WEXHO)(:Z
M4;M,M*:.0$HEHRH+@OR(BB""8J4UBQ%=PUJ24E7C%#>,)E7A7JYP7W"E'*7T
MDFMBP81B"#EB=>:$YN@=<*H4#UO;HLMI2V*0-]]/,QS@$\=1)P\'QQT4F>E.
M7P8365^;KKU$9+I</^-J%6C:G2S8%S3FG@V.CE+SN/OYU>%@.!ZGX?'+BR6L
MN#47;EVJVP VQN!S)D Y_F!6$Y=BQ,W'6=*::Y_MUC9C7;IXV>;JP&FOL*^8
MF%1A7YVP7Y 49"5:4 M$)2T(*&"%KM!2KB50*:7"';"U+;M&ZQ;)^F/UZJQC
M$&;O_*CSGH,PUQ&.US<"\_P$NP;.W!&'+Z6K:I.<=RP2+6GID\$I01J62/"@
MF9;*,,M+_SS:Y6()KJ#;"=$:.8D>+2JT*YRNHL(24&$F+3:"] 40E"D5MU04
MQ!C'2/)2!JUBY!9-,>A:=;4\;\LP86TBY]H?-O=(8^9^[O5=/]28N<WPQ;X<
MC4YQ.5/QO8;!\?&@/,$@?.AV^NFQ1<NMA0?V;,'V\[-FN9I.YU6YSZ7<PZ6:
M=I(50J8(!1T(9&F(LYX3DPS+$KBE+B#EEZ(K=76T;K!,/YRCM<KT4F1ZID2N
M!B>4%B1Q:2>$W:,Q3Y0SSIG 8U2QG)WHKM%7,RE;ZU!=)_)XO3C^D4XFD0^%
M;^R\.OACI^-/>T>Q,QYT1J>]\8*%<Q]'J,IJR$=3F/,L3J5$I>#RU(*<=P.G
M=[.$0T+P+%I- BT%.2$H8C(3Q%H.R3(:(G4E>->J&FRV1A+<IL:757:7*KL7
MQ$(GI6, (#HS0R#R0+R*C%@>60(#0H?E-;]L7TS9.AU\GDQ]XAW_I9//?58+
M'G[.DTJ[F=BU6L_'#><;YS[(>KYQ1U2[E"9H*'- K2/6^%(N !*QS%*")A3%
MQ189F$1S"617L66Y0%I3?6:)_I%'# NK=9Y46+@_6)BM(I)89M*0;$L8JA24
M.%")X*9+AMJD>.,97:H7Y:%*A\BY#D"7>.QT?Z5#'O0A'Q?A[$V+@99 NX9\
MEJ(3S2^E\L1'!*":S] :3EDT1_G_BXNE^2.-QL->&*=8WMCIQ\LOS'SR-YR,
M0;Q:_#4<G98%>O$Y-(WL_W#C]"+G%&KJUEP*Z.NEO$PDI8Q&XTA0VA)PCA.K
MK2$1G,"W7,PA-V6L!"Q<D;Z>S+47'U9++BL^M!L?+@BJ8;C\)GHT6:D@4&IA
M&.XTX<*D**0!%]W6MH6ND6W"AZ7$X*U#]%2-P+H%#CZ[B2]VW+CCT[M>OU\<
MEZ6D68,ME4;>I":23UE)+<'E ,(X)Y4-406.."O QK<OBW9@7+"'T@X5[.<"
M^]W+C3PH%]8HHKQ%,FAD(!Y-!I*1#&C%6&"XKMM<F2Y75XN:5C:X,6+.8Z"2
M4V2!D4%*V@<:K!)2TR",,:J(.;-5S-=)S&=*FW$#D26.3%XQ IJCS><9(S1(
MDYFV28$O-I_N2G8UV^+!2=WFAFY]EZ>DTH;L)H9ROT7[KYNE!X6R_[F_\6\,
MABONK88DJ.(:F&0F(( SAG:^HPR)6T/5'M315S%\+@R_E$7KT?S.BF=B'5,$
MDH_$N9)%R[W1QEKMRGDR-ZJK%L?P>87H@:/@*AA6,/P&#'T.5DA!A<@)-*(>
M=9)I;TJ19BIEGMBM%0S7"0QGG)36.Y-3)C(9M%N]9\3;;$CTH"G:K%1S7<"0
M=\7B=NNJP/ &%R9O01JQP"'%P:D_2FWNP'';I]P@L^+Z=.)7IR<G1ZD$*KNC
MSO/>*!P-1J?#23' O4&?-&;'19^.8H#4#.1-\G__V3]QB$XG\S?O6-@-ML9L
MZ;HA;@PA6G4\R$D/P>=%::D>>^,"/B_[33?U^-/I>&\P?IW&O^$6K21H+A)T
M*<E:. ]HY4LBM7,$:"G":]$LY (L@\"S#L4B%%V^M #C%OGN*U!M*%"M.C"E
M M7] -6%M294<BKS@E$F$0@L$BM $J6S4%0+W,:J5 MGK:H%L4%6PG=)XB!G
M_#X2_S 870VH73BI=(UA]KHA;@S,+H$/SN3%[D\WT;.RARJ +@Z@E[+;7>8J
M9::(XLCO(,A '&6&" M261%8IB5FE[4H.79%GOT*/VT:6^O2]2LL+1^6+G@=
M8Y8I913QWG("4!+W.15$!DV9CHH:O<F)^^UE=B]1[GKNJ#-,8?"N_(ZR.,B=
M9FK(()/34>JXT2B5.)-^[!P/8B_C@Y?/57_@(S&S5^L/_*,\Y'[^<Y1VRK[;
M]V.'#Q]?]L^2-WX>#/=/TM"5 XG_E/2.6EKE;@A]J0B!"@RRU)XXQC021\.)
MMUH31B5$K73*"DJ196&O]C2M'L(*7>V$KGOGCA6U'@"U9L*5G=0T@B',<(6\
M4DCBJ:7$0+12>*IECDOCE<OV&/YS7#I.XK^Q]W'[7_CC[-8SUPH)=_-P<O5>
M/^)?3P5[,BF7<$^RUUSQ:7%U]\+WI9$7:3PX1(88PN 8G^9+<0[V!V.\GQOB
MRZ7OS3B]&R+!/''#INKD^# AI3SMN]/8&Z<"WV54H\EO3:2,*R]/2T;A%T=C
M?*&II/;D?*6^G;#I P%_HG%J?CP9C!HF^W28CE#@/J8?/_7B^/ ,/F:^.%F5
MI_3B*\[C0YR.;_[*L1N^Z_4GP3W\LA9X@,7Z[M*HRQ,V^[,,J $;R;7729?$
M30^9!QNE# B/U'CMP*6WW&R=?>GP/.+HQ+U+Q ^3^T!<QC$_=4>?W)?1UC\O
M3Q7.TS=+,]>L7C>'V__R0[S+-0/[G@"M/KJF68#_'7X9E<":GWHH$^&PVWG9
M#T\FJ/,-]K1U!'N-,(\'G6?G<OIL5DY_/I?35^=RVOI!_7 ./_^X^JRWDXJ2
M['9U@+.[V*Q [*\?'KNTQ2YMMXD"W#L]QBN')5AYETG03Z<C?)C1Z'D:A6'O
MI.#I3C_^Y$:]T7[^;8C WQ\WKH,#O.M/1TV5[8=D/%]WSQC/^P^?=__Z\RM^
M]_TN?X.LY??/K]]_@+VOOQ[M??WSZ^NON_#FKU_QWB\*XSE*__[CRYN_XHE'
M4KE_\.+SFX-=?,[=KV^0M>P]_[FW?_!.[![_*?8.D+]\/3QZ??P:F<]_2[+5
MU[UW"*F*.>\X8F<I08N[B_BD)6&.V0Q!,I[IA,CV^J<I[A3V*4K#Y,B%H*Y$
M*4O+(23#HL]@C)!(?''2W4F1LN%IVMK>'[YS_=[7J:?FTKI_@Y[XWO16S8<G
M*_*WM[MIWZOO@?>J%>"U^-OY 3G(F508SNF/SR;DI=O\R::R,AA>^LRG],V[
MG0%>!A5B#Y_;#4O,7!_)XN@?31^/U \(CH,)X4>\[."\[IP,>T<=)KL=3IEZ
MTMGO=W;=,!QV!&M>TMU"CCK3ARG+7RADX4*E3[/K/$/D1&.DWW.=([QI>>>\
M7'=GRK\*4KO.<Z0]GPH!>X;4=7@RF#Q$=Y(^UE@CL=,;CQKIG5S]FXGJ_.<_
MS\JEKI\_?/!?3_NIPVSSW.;R<_?Z9_?$NYQ=8.=T-$86B(_^&S[L?\;Q27F:
MBY?[3<SAL)?&;OCE?'C30>%'.Y\.!T='7\C@$QI5G=&I'_5B#S_:+>99<_N3
M4[SIJ&FD@I0=)\Y]*&3T9)@"[HM"Q"?#/_MC-$8-@#NM-_,4S= FR\2A&9O]
MSMA^3642=M((/X%,?S29G>:)4,R.OG0^]/%Q.VXT^>39YMMJ_MKZ1[?<^FRE
M[G6(Y?ON[#$[HP^E2M:@A+"4G7DSJ6ZK4/^5)L;%[$"1CG;\9)/V\3'>70C$
M47+%6FLF,/?249,H.4QQ,"K&5^==PC6,Z0B-!-QX9S,]1F8[/JN37QYS<#KJ
M#,M=8V]4C/?1D\Z?HZ8NQ"F*/FZ'?MD1)VAME-7':[AQIS?J>%<($\I^ZN-4
MIH3W[2!HG.!D(&Z<'*7/G8^](5Y[_.4$Y0DWQ[]?_9>PLCD^I4XI7C-.G8\I
MC ?#T>2B:(#V0@]OA_MK^MCEB8>(_*=E=7$C]T=E4 UI"^GH:-K7'=D6;H&R
MYXY/C\8]O'=G4%1$9X02FHYQ0,60*U]HK&7](WX/=^^Q"X?XY#@W>)?^Y/*H
MVWV:G <T?^.HR^WPZPA[@U+S-S6U=<ID#B9SB?<J^_1CF=+I%#[IX$*6V3HM
MWV\F\FRD91E07>%N^XC<X6-YT@[:$L4I<U2$</HJ&N?C2<"RB^7M(L6-!L/[
MN4X<E(M=#*9,7'.EDT%9KM[T6A/)PN_A:^<?/AP@,/HO>)7#Y([&AZ$L/2)4
M1G*#-W!'B!3XO.\&N/EZS4Q''-O1X*2#(VM ^'2$,GV<(B[6="WBT!V[QB-0
M[GM<ZB.GYN9E$2=AUY.G&)57RM[ZU!L??KOKFOOV^OW!Q\:P[<SL^//=AT\T
M.CU!F!I/RB\7*VS0/%"CFH83L[KXG#K-,2>NR;O!(.):]T^S"Z7C= ,KQ4L2
M\-%^V J_[/ZV]8]O/H!L8Z)]>LV#W09'[I<4W^BXN)XF_Z?W?Z<(L3.]+M8%
M 7>:[?(JG:#@^C3E*8(6C<7998UUZ&)1M"Z$TXF@1=RJ!4(::/N?^\\9EG?K
MK/E'FCA07[AAJ;\SVKD8P//)\Y^[3=5C,R(.PN>]3V]STM0)$(0+[<N1NB ^
MATQB@*B8D);FTBN7V2=7^U@@FAX=X2^(P05CRH;IIW%!N*8I$H).;W1&/ M1
M/#GU*%,-XB,[^ECP>I1"Z4S?:Z!K$CHQ*I1F6FEM2EB:KYV'#19%A%>;;737
MZ.FC-)ZHR9^3'YX6!LBNV\L>]5WZF*::L+F2&R$IO5H1 9]S=(CX1U#K'4][
M;S>NB499G. X/^.F&R=$XM6(P&*9HFA$ORK#.<#1O+P8S".6@ ]B?^=MF?9$
M2PTB2S6!(@L^)2 &K.;<6!6YV]K&EY]<#7<[DX!"SV_&4E3!1T>X[U"?GO&N
MQL(Z.AI\NK0U\<6,G'PB+$>NW[]L_34,?%RX*%*PB;1]'G<8[Z <C ]'$T$K
MK\>&"A4O.2KQWU$4QHTE\4<JVKR1D*+@&26_/^GLC+ZU%QMW04,V>B6 J7,T
M&"%I*+9%P],FT1WX;F$RJ":GIB/>*:82TUY&=WHRF%"BT6E W3_*IT=GW*;L
MN>Y$>CZ>F1KG?&+J:3@3<?Q,/ VE%03:&;'AAPU=;,X*#HL4G[%K-&;+Y2>L
M'/EA&8"+*,UE)IJV5 V3F1WJ.4TK8<@((\/30DG2A,&>3<>Q^X*S7.CQ](;?
MC+H\SFG_"(<X_76,5E^O9(66&9N=V&8/G,UN>20D\O^?O3=M:NM8%X7_BHI[
MZMZDBF;W/#BG7$6,G>/]!MB)<5SX"]4C" N)H\$V_/JWN]>@)2$P8I3PVKN"
M05I#]]///.:)69E+=E(T:)R5PJ01)>TC*9F#' !L3+[(1URZ#**N:Y/.M*O[
MT7#)D$@*>M^-:D0*D[2E)@Z-3Z*^>UPPZU'2W2+$$M,K]^*\&4]?5V;K1!A$
M%A2!Z/V710NMGJF'P^05*%AD5CNS+NV/(_=.@9MH (PZ4Y='M?X([[C&>,:)
M1/J#E"@T&>9QIIE#-UZ8]E2HM 4]Z:^ZV\L&6$*WR-9&246)1)@_2U;#] "B
M5 E9I>_UUL]8;:)DULO-:31R,O9T1U]J69ALM7Q5Z9)(VY^U9^-FDIOBHBEC
MS62<HFVUOZ2$6XBPS<@3%M%ALOZ;[H*F^Z#T&!3XWR#[<CSMN1\7EL&5A]:X
M4:\X/Z\R5!+^FHOJ$<G&VZQYCLTX\,5?I/9%HT%DG;W-](KXI(JC-'U#4Y!L
M%KI#-R-<1MKC:%(-^WG!0W^<M,7\YIKSE*2?@%TAT@*<P @SK!X1)QI,TR\
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M$P$%)Q0'J(UA=;K1HP7-BO#8'"I>%#]_;G3\>&0#==H9!)P@%$3#5H*(A01
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M$.FJJ*);X5VZLU"3LJ,QK3['G.?=,<Y'P!8^['3>G;'^'K6<GBV]L3]09]9
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MERP#WAJ/E*10*9Q[G=XH.@HOVDL2(.\FPWXWMP72V0WY/?T^^EGT/ZDUP8A
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M?HCRTO^>CO!-0Y3MYT&L46-\GP<%14I+F;0_<9_;T^,CXQ6SP@9@"4: 8NE
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MY8/%P=9G,W]_1I9^3Q]U2ZHK1*I3WS5BF!&J!3!6<4"IT4!)@X"3G$26S'5
M:ATQI17^#XLG6%D3CU&"X%ADZ=Y!H) S0%AI*"66.RDV7B.UR07?A*AEZ>O
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M7'HLN5,.:$(EH%X+H"$FP! EO-(>&GU7QWG+ UXX#Y L8&REQM@(*IR55OC
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MSA!12^(71LMMT45[Y>H67:S>@MLK7]*5+?JU5ZXN^JU1\'J9RK(7E*ZTA*&
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M;4HV+[MX1CKY^(ZG)U7.?\_/*)I4X\=F$[O=$]] U_S0-1F")Q*)@6J.+*=
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M>U+]IY#T_UY&.LI/I.N+6?Z-KC^VKH\I ==$T&@"<("0<BV5'(-B.6*!14:
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M3I*S(FHE 1^X%]JR=)O'H=GP13><[KX[H(QKZ5A GB:%N$L,6>7A>$@D^R$
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M^:S!2;+M7AD&,(?1$V\%O*P]69/RV0B+!0.<(;$57!2/7X'XPV[^SBQT60)
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M^^5CKG*!=^% 9YIF*PM(;TJ(1V&0#3P@3$UN?&V%S:2W>Q);,^5J7.9^IBB
MD>9RW*9TF/*DO$O6!JUQ (::Y*B%7R,*3X,KYP>.4.TT9LAB[Q&G( -.8(6
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M1?IS%HI&:<+M5A;RVA.NG<B34EHE1&@2B#/'D75*(DIB"%H$I20ON0!J=B[
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MS^7?J<VNP(<&KZ3BF9$X#F>'DXE9$@.8##(Y?443N=8L"F:$2IR;3*F"5H;
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MOIKPIME 8])"(LURL;H8.')84(2C]]I;(SDUF7")>5NE/&&ODY]%$T7$D>N
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M,;*".,23\)EQ1<Y]SG\CR_+4K[R#ZPF<\2\><>X9Q] @SK-'G(G>ZKECDZ'
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MG]0&A9DRQB9E$D_*&FH\_&Q)B-0HKFYQ"C>H]YP$]B/=.3\@.5Q6&0 \+B-
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M4H)T'YTWIQ]?__;QX^G%N7-\_@;^=_S+'Q]//SH7;YVWI^?'YZ]/CW]Q7E^
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MC"491-AMAYUSX&8F+F/=8.$NZ*C?4FIKP9RNN^0>*E!X2V1ZEO7 %CR6"P2
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M<AGCF[Q"$J->$E"$&5SNTI[!HK[5?HW;P]$0]NL\1@C$JQRH,Y8LTXV:@/Q
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M.YT>:&UP.*?!)$%AMB:^PHPAW&_W+4MWX@?CN!_XD\='9!XW;AI$.?0Z87_
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MB ,7T414?UVV::)K @U&B4.2Y-2=00-Y3/B;C)5/LP!OW+S,DDA19Q[S@.T
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MQ-%YC!Y6["A5E=JA0*GO-I:>=.U(S0]S6)9*OVT>3.;>D$2W-7@S6(J*KHH
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M0CF-/>X0RB^A+"*;V[:@L#S-G)Q-*RW0!,;7X7VS2+!O(]/XT<AU&TDNXM7
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M6SU4J82DM&DREL&1P-VZ %839YO']>SZN(YY'-SE/UFD+'_='%:^!'T7$Q4
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M<P%=MHJ>LE5=7C=TI J-5"742XX?M0&LJV?##1:LD=3Z\J9K<8"Q@^!,EKB
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MNI'#BI-L7-&)TQVS"JGW3@(9 #4/FT.$G(CIPU?S0_#-\<Q&N/*;/!R#01^
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M/GI/N)PS*2/( :PYBP-AJO O9#H5PPBWGF2XR8I2I4[P86X5E^'/1,;0$8?
MTNYC9BF?M&$ %CF#,;/<$^"^^1Y2!5F?]\IOOE?T7@T1/J=WUN&_8ALPJT&[
M.-?!C8 G63CE*FH:XW8U2)1]24[8>44_U(KRPG!QEK"@RKDOAS08=(7;"[VR
M%!FEU,K,RK#YS\CFT\</X8X_ WX>"_BY/ -^WBN[-:++9CX0<#G#!Z958NA
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M>=6UY>IBX<X' R?K6VYVG<":@,,EAKN6QN8G [Q"VT@=RS,BDF O'2IQ7:T
M2H!A(U2./*_<)$3'OI[G?F<L>:\?6=&,^T(>1@J>;W :^U=_H^RXBN;I*O=Q
M!4WPTO W7K6- @Q1KJ(DDB.XY]D('OF&"OF$&L$VRA.N78$0!YVY0Q?.U(ZH
M*I;81"NW;0C9>EMSAEXJEV$J;^J=,33J_BH30;:JBQE_H:J08X8^[VMO"O'G
MT0&,BO:*OJ=1"0LBPWS=T5* )B?0W,/-P@XBJX-7DK9: N.P=9.;"+ 9"W?D
M!U\Q"<!<GQ+F7HGSA4!A4UW7O=CLR!;AMRFT%_FWCU@A\)D+RBAB(U58?-QS
M; 2.1U7C1T9?J1U, N6V5J['67U(XHY>UCOFK.<WMHX&=.-U+?H5R.3_'NX$
MX1()-G:EURJH'F#08A$XZ<2@K@W,B%5_^RCC[>511SN"Q;Z33A]K?@B;[2_M
M706*$]-2^S5^PK1WCK9T%^F9W&F87G6\\3U]_7MP._H'^!=^7_T>?(U?@0PF
M]O8._N^18T_7T1ZOVU1WFT-,TT=D9:*.\V?A4(QB.CB]PDALD<H]AB9=K,1(
M>+VR47^S./9)/YF(L6C'V.@;!FO\_1%2/=!Y#/;@.N_*B/MBE$A][U24H5QA
M8%OVK/10E=06-8?('.DW",',@P#GB81KP4[LBH#W@P!PHW]F2.&Q;53_Y][?
M).&8LH:]E+L0F[1J&/H:5BC,YTK\*[%)!^M]@*/&4HCR=;E)Z5L33BNA'9*?
MM?59C1?'U]1TE?2BUA7&H:T\!CAS 9-W=FQ'E)F, O?Z1N3_/%!6.D)&#[!"
MWJHB3B<E<<3^E.12U*>L^S/:]@ES?+Q=:(/)?I4(*AP+V4]$*'=.LS[=$C =
M1-HAD.DD."_!$YX"1SNO&A0J J-7VWG^GV[^TQZ9<['@:6>[$=I,)@.$\"#E
ML#O(,O6J05QN3MVS_<&4:>\)$:(S(2UND\0<Z,:SW)[4>VK,UJZ/6#GB]LJH
M"BT4C5'A)@D&@ZG::_1PU\LB%AGT!^+.1YA.!#1&[#EB8M/? 4E-*J0V;A(;
M2TC/SQ'ZOXY,(;FK: 939#]\U#/*\I$HR\_^M5"6'_#@(VT3Y5T:<.58LSSZ
M$_ND)7&.5O<A#,O2.5N[(U+W>A!9%"!F.D8'A[--?A2:U$#-0TB44W):)J!@
M&B(VR+^'"NU;56WP39^6ZQEG\:+]/5[+FLDCF:[4I#MYFEZ.H:C/W;/55]E+
M>M3W\+A%;H#_HUXYNNH=TSM#*Z8;0(#9;H16B(-8#7?'>0;J$^#4)!BV3?="
M@WP-P)(96''-[?BHTJ(>B(HI54"=R.VJ$D:^F_9NG,=!LGLR&X[:N.Z.+8P*
M%%N-@5(P39OG':3*' I#H];;8SD'FL57,-_\"C8+_[O<[KZ,\_"FZFYK8F;]
M")[6\R]???\&_^ORRX_E8%ZC.$37(.DWHM9!#H% 5JM.%\U^0N8V;#%4[4>*
M%)QIOR,W(/R6IJ2(H.81]ZV(VS:KDGTOBO+ -&AY2*_'6L@.Y>,5IOFJ7:'.
MXXF!=R2'5B^MIA:"QI4CS8((V6%7>:FO1%1V9+=HUNJH<?'-GH1CP^;_1^,H
M#T76EI#AM]()2(PH85Y&!'":'EJ27R(%,5<Q3#9&.I <"0&W\].W38KX^!.4
MYF/T%M]7**GR0^]?[HS3>&SU.;GXT,3U:=&/W</L/*#9)F-^T]*FHQ.*)9F1
M>F-4J$\*JTGM*"8O)6<_KF)&(TCZO\'>U$"JP;.61@+9"J0931MU9F,7I.Y1
MKDKWDQ"E[92?:K<?K/SDD0U[OI&$BEV^H<I\M4@B:D$T%AO2N;@MNP,_V+U^
M^!:5S.I^BS9WVGZX%W62)44GW#?8Q6!4IQKQ4+Z#<^$N9'%(",-$A#X,3_+4
M?#%2 BOC4FMY&@]-=W'"HE?[20 7_MQNP809RT9FIJ!$P[E(_(32^\BLQ>R_
MI^C*V8N+Q0^CI0S?"G>BX\QO%^OZ%[GW"+PE0_%E;%LUXM[>M@TQ.1JFA!:*
M'R<H,S*N+R-SBTK0G01Z:E1U,9;^(XM5"(KB6.E-;P5&\@A5/;DU1CDSM>(&
M31I%LEII2PK\=,;;QBLN6_7^U&UFO&>]K1+&P&G5+9>?F+L(N<:%A2]W7*('
MDLI5FKC&%84!<9R2FA,T.%$E12$MN;= 5Z:,+],MX 0-^X1[$VY+E(<?B%!2
M R'\@+27(9UA85%XW?ONQ\5KG9*1[PN%[A6[=#2L;44'IE<'_PH7P]1#Z(1\
M5%RN4MY=Q"KHQ!;VCRE.2/X&4CYPQY5+)E6JY?H1W)P2%"-I,QV \2OV47>-
MQ!]D^'5D7M@<-,@E_C\1<U;WIN=-(7[5];[A:+>[)2;/T<#B4&!Y]QWT+TFW
MMQHP5'.QLW-%KTSN+_OV]%/"HV?%S[_K!?529@Z0OI=N&*]H&/2@R4=_).V0
MS>(UC"4&REB05-.U0<@?-L! X@+A"-Z$OV.-$\7H>C#YW)&VW,\*H%(M-IWX
M2@E])\@NK(=4D\==_+PIU>]WXIZI/M+86OL$!))^6JMOG5;+Q.GH602X:2IN
M-$HD4$::E)FJMA.KH&XR,A]W9;>R2G8T'FSYG=4RGG,'+'35\)%=8<2YW8,1
M7N1Q1?RAV$-(K89\(0H/5+B2,3SO<DWLFR?MBK1<R-V"48'9VF,<'AYTK3=[
MN*\PJ:Y.GD A^\C1"91HN$*];4LLT4VP^V$?=ATD0,&?6L'<=PRZDGD/CV82
MPL2 ^KCO!"ZU1P*%C/&.:>XPR\Q]!_+$WN> E$Y>*:(=_:NC:7X %/##%5?^
M\'].8(GN@_Y$;!K;'].N9D)3%$^F-)@,*_'LME?5P@N*PS&_GBSCQ>+;T;K2
MX>G*NH='*+2'$5IJN5.IO;+(F"B7B?-!W*',@%LJPC48H3;<,_B8)F+A1QT;
M#=_]9=\3$)G"&5&B,C *R$SKF[9= 47+V3#^Y/*F"RZ_B1_P):O\T (2+P<8
MMZ@CJL)V881#!.O6MW0_.D$%]S*CO(E-6,R5A#N!C" ]F$44#)9G%H<ZL\/W
MVP/]%RW='@KT2 %A&@@I79-)!/#&\3MG1J0$P6SZHUU3\?,)(U^<[2NT^/7[
M<+\!9.3?!3$J7DCV!C-ARB/#*Z539.OY%O)WC.JKV.V-OC.9',<[Z2DRQ]:&
M,I E[F])!V9(-C,#&-TL:Y9O93F,2+SD<W7<#+0$-_;+YA"=C'X9+LQP%O5U
M#'7X..MW A;HL9>$%%-(]YU!GQP)*NI3DQ%'B.L]3VDL\T#92Q_IGQ(^N;78
M5MJW1N&MA_A&N&B64+^<$\\QB;X/OR1'+X67V71/]%>SH:8C"ENU58\HK@*\
M,$D?Y245Z-NSY+"31%M8L9_W7=VO:E7/PY3KKY#:3%-92B7SW,/\$!\P$'UP
M,J#X^A>+-PI3-1)W^:(BWZ=]S$?VGE6!7"8P\VX)\0J;/%S=(S&2,M$^U->^
M.-?J'UNK__Q<JW_/K;MJ/JZ#OP*?<KQ+1T@=.S^%I!(1,L^<7NJ+FYQ;.!G;
M/24(=J)!<>-3.+'Y2X<RZNT=V41*D=C3PW6NXW8!).7PI6LML6&<*4:"FE6O
MDO.<"8"E>8T2 .V*RU(5NKGH[F.+B/);,(4=J1A1]KN0,>:9NQWQD@O(,WW0
M[43C*%/<.)8KSETJ6(:KZEBE[@H9&TK8T$2-/XO$AJHE\S .L:D.8E"NC&"Y
M%@3LJU_355S+!G)V.=K3G_R3PR?(8RC]GN:]J9',;K<1(@1UG(DK:SV21>+[
M)#*K4Z6A-8@;IP;LK*@+9!4L4JZO6<-AW5*!0^,K51^3S0WV=LI>;$ CQ)T2
M4>-:D&X1]))U$7HW46,"T>F M(*-99)HLL#_9U^+4TPY#E-_&K7JC$FF'U8$
M7BPB&G^81& Y1K/XK6.RWO&(C*]8/$)A?>@Z%BT56*&X17Z<]3.FARCK&&C\
M2QS[M!$1.$T$L?P&RO:OF!#>G9Q"R-,>8B(@[MJ<E8L8RYS'9=(!7 D+#ZXC
M]O ^-V8L=> +E:PC5L2DK3$TM!K)[_4?HOJZ" 2AC(0]E7(QS?/X:PHDOOB)
M._&FYS+>GJ+;R<QYY"B+K4Q :(C:.67R8+\\7'AA%Q:YY3=%M>,*S5>\+U9=
M>=< <GI70<58Q;##IG3R%-D]PW)DPLPJX5GLE>+"HRH N-8]1=K1DPGXIU^-
M^>C[.\"HLN&>_AYT&O7)XVCR\5%]SAW$__G@(?_E"]*GB^4#E]V 5\>< (-P
M"@&27D*,ODQ$0?:-.0.6H)23KPW#8\J/W7Z(>41:O'N"] \SDW.'_/(S2=]V
ME<]$SB5$"+N_V="+93)1J)$H4,]0L@,)?+B"VN!DF]J=$D]HB8TLB1H$QCD8
MKF^(7,F4-JW[;K^##RNY?T)0E&&T)$)ZW21%@!*'N^H%I<]+CNRR+3<7;.C/
M48Z+C$0*,]V2.1"D!J5=U;RX$EII39C9<;FD-$TRH;IZ\=>T2$W5;K3;RW_F
MUX(A*RP7EVSE9=L%MP$50<)/'HKQ1A4;.=G0&:NCGV6C1,[&DDN4]$HQ$0U>
MD[!]ZQ55I\>Z6>,!REKTG+.' >-K)'>7>JJ(DJ_;3:M-#09/8N! 5XGX%RUY
MOQ"LYH^TT^F?WG8' 6T&1^W.E>+IH?Y3BY=16YX)9,@%EWH2G%=3_,EM);,<
M%SB@G"BOR)Y>SS!?C&=H;FMNZG7U;+B!DC!\I7@8)T9*J\U^-66..8/T- 6M
M%P^R.+\+L_@R\I8 ??I/JT<#O4) V-NZWZK@EJTK9KE&3;:D$,9J-.)-XK0
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M3%>5PL*8ON@J[@2AQG0_V>/K5_)<]D)YV!:N/E7YW,3 A-KGEHR*P)\W+GF
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MX6;)N&[HV0I5X7E%GG!%(N'-JK9#A3)J6CL&27TB_](SY.J\.$^W.%KO#U%
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M)8.J3@M051%H_TMW&C"!BU68-;QB)%@F#":C845F<2 LT%L7#!/]!CP#9 P
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M:7ZTZW(_IP4JR48"3>/3V,#.D89\SQ5G/G(L:VA_],R/%QUYJTFSF'!^)KQ
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M07$LBUMV\!AAW9;/*SR"8D[;.*?\> 2'A4>0:8_@"NGF[Z%0K!$RPM=@A&_
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M'1>3VN))K>/DVD1D$.=W;8[M<Z/I/6.6CF9[2IFZA*!>]JU+_DZVR^EYSDZ
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M5.^/J@@4Q#Z8LJ>.0Z@VY0WFO]I<_: -/BL3^SZ3FEX]B9[-Y]2?L/ !/%*
MG<>H/9!)[-AR+GK-U-#_G&-N<^9NF$>=.6=SPB4E(NW>-8,9)Y.+EO)C[=A[
M_>GB\0%H$C?)"<B:GGK= 1+BWB4]B6D5^A<M 0"X)!R;)G=\SDG5C@.)@."A
M@?Z_[[^-W:K]!Q([</\=W7?(I&KW@83Z=(O>*^H1O$?4N6A=,<A-6T@]^_IP
M:\HPM-"P><POYIBH\K$+B1_\0>TDD6TC3?6AL]IVA4L@B'/O?]0_K]IV1!PU
M,1"N&$5INNQHKB6+'L;#9QQ4WR$^$,,/@KG448G\)795E'Z<$2)%E1'?R,L
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MR-VEMU%H^LTO"DUG_5GFR01BX>>;_/YHUBT6*P>#P#/FK96$)@&E3W+Q0]!
M<25\-)Z;V*P\:FNBAU0VM2\<[DG$]3*=R)25*M1W2%$WCAA%7E2IWGSCVI/G
M,?ZK:>Q**?<+./^)KR>GJ=^>C$=^^A'>82SZ2\XX^1'-EEH,_$L& -UIB^LN
MR&"(Y5*S*)T3HE''V+W.LY$K>+E/=@VMP#D(+P*1,BHBG4Z(FH">*T4-1U4
M@#:'%]:G<4B!Y8#Q?DMRN 4('B)>8<JC<HL4[2L4<VM1I1H=,8K&>"IY\*91
M;[IMXY4'SNX^>I#N"H+6(+TMC1 "E51G2P25 H/^8O>E\Z30K0R$G$6;\X#;
MIB<?UJ-Z_"#=%02M07J;IF><:BYY)#J7'KX@)/%@.&$0/0OH.'+9IH!P6W._
MZV:TIUIQ7DHW<Y&[RRCW4C=G&,^""9I-:I;J&N9F=".TW+\WO8D8JJV+%W#2
M01R?,WJ:GAYCU#3^=_]R5*HD*0N9@%08I:G2^4MJB_H@4(WJ(%K;YMC9/40-
MR8?8$TIJB:A>2[8CW\$SW^^''I<2HG-:O!34RE".O!4W63->VHL9HB %YF7,
MDK<IXKR=GB$9\CTAI8)@ZA:]E!/GQ2NY*#1+SBN*P1*!OH8Z&RCWJFA")<])
M.2DE:[,[?0LQ0^INLR=X["J2BO6>JT[IQ4')%Q?7,-UZ8'+$&'4)J""@3-DH
M5D"LUSAW;=%%!9LD;0.?[>C=L'/.@VP2U(;8'B3;'H7ORGZ9L=QD;3,1,DDB
M8Z $E64FKKP-)D;9J.GRO62M@RG]GX*IC>54ZQ##*CTWVZR,$G,9#"I1+FSI
M+!@L"9$:@H@&L%(J(=<]N'#_2.N@P?PU;%A]SC?4(RN7#8QHH"9S7.K2\+ZY
M7*EU<9$X[2Q5067.VJ2]ODG:.@BR?PT$M1%76Q2MW$VQM)I7_9VN-8Q2UH'G
MGA*=2DVRT)XXYM'5IT"I#(S+W";\VI7R=3#H_@,PV$K8]0[E^_%T7E)54&K2
M_01_Y*4#%]!'LY%BW"!2.1VKB0W4DU)ZGGGP#%RC\_AWTK16/I'^Q7RE2B)J
M?#S@I1]W??NM5]/YHNLO.Y^_+XSLSLYKZ5>V,OPT718;Y:^+C1;XT3;G"%J0
M4>? 07,&[7@RH??&;J&C[R!RO2?6:HW8*"8AHO2"4!4UD4JC<V8=(Q%LU-HJ
ME(]9RS?>9O0VS?XNA?5B/(^3V?RT@Y$JMZ<$[@E$J="/L!H#$IH(!^5UR@*T
M;M/"9FT2A[#=LA\8K=<8<%<I[KTYX,CS)"7Z 408ACZ 8ZC0BS=@H\K)ND2M
M:'0'QIH4#F&OYF$@UD2&=;(7V_#B8LNI;"O,%R.C>%3,%H<$R97>8)#-2Z"4
MG4^6.I>Y:*;";Y"RG^:M07-GF#5$*R/1U\X<_3%TG#1HA7$A15>[S3;HHVG>
M^@# VJ[;ZR:B;*;05UARG07/_'P\'W'!(=.^\,9:U#Q*EHYK:("4,32RX#1K
M$\EO2NFC5O#UL-=4P \'0VD\DT"!*%XV9:+#.#1Y1QS-@8*@SK-&UU+M!,/J
MG+FZAOW7#B/KJW/Z)=A^5N(M*,?O50 G)76E7L<1*<OM>"(*DBS/S&GC='H0
M=JU'_J!.SS6%ZH:KMX'T][6D[R2])(BN2-=.!0%>E686@DBF++& EM'&1 WG
M0L?8)G=7A?PAV*!'A=OMA;__$#<ZH6+RB42:2G=^AY&1])[XS I[9/"-[H^I
M&>+NK6WY0Z*OB@@?7]IYM.*G/5CB&0D9;.IYE4D/E7R^Z?$KB,IF 82'C!;;
M1@2^E9IPJY*CE@G)[;<$.8PT1AU+H'1VQEA!J#<8]PBKB/=>$ &&.\NBR:%-
MT\6]N0&/) VR"3#;. 6;0.'ALI(CSYGRV;.+C=)D'?$N19*58U8+GE3DS5;P
M$/S.!P3<?J3VX)'2S2!/)LFB]YH8ZRDZ3*DTQV7X,O/2,]>IU.CXXMY"_.;=
M;!^QCMP>"XW]VF=^4KJJO3\"6)2#'[-I[[3%(TBG$YCE95,@?_,&[.T+)W8;
ML(Z?6G'2E=HTWGO;.#AIDC6*B "I%&QEC+--),J YX9*XU*;3:3UKWNO..-^
MY8Q<V2?E)A"N^V)*Y8A%I4]T N%94 )8HZ9A]](U!%>Q.F9NZ9)32S3UC/"5
M:KU^IA%_G\ MAQOO[F5&(VA#F2#<T4AD9I18Q7 RRH..R2A(;5K<U)K!H/J'
M-</@@\C[@6WM11WO\MJ891'OQ65_UTIXVUG?34G8CSW>B3$U,D9K$S!2EDKN
M$R/9E2;Q1@14CLH2)U6(FBJ35M7+'7'EVD/N%#M?C/(6%QA^/H[])5W/+WZ]
MO+\(J;9,<DH\2_V%$9IXHR1)2GG'@C!R=3?W_DG=/]P0;&Q#J=^(@NOSOZ;%
M/2=MEF$^1U;YR4NX=EF\U E#)R Q8P E.0#!Z-P2$S+&X4#!A48[?_?2-9C4
M2EOP-!!2G63<DB!_AJPJ8'X&4\CC!4Y3&VXB#X19)\\[H3G@AE@K(O=.F"#5
M1DKDJR&&L*&V;\6Q&Y]K*XOSCC0?_!><6J(N6QDY 2'*X5J'WA\M/20X=9YB
ME.!$HTJTKV@90K^&_2N%;85151&46R\6W6G?6+4<OIY][%!1+?53N3U*T@!$
M:X41@D/KYERF1$<#60!( ^MEX=<9;<.>"H\5!6VX7Q44EYW=KMNJC$&BC-F3
M1",KM\>5_KJ,DQ@, \:Y=6R]/=5[!MFP!<)? 0([\[IN5Y]K4UL2@SZ*$,Q[
MXKCV1'K)2>!2$B8=9=PHGAJ=_[R#H"%T1MBCM:@AEN970AT?C\_;</O2J7M:
M3KT"HAJN)0E>GBY.._@-0Z?CT^.K@\_EB/2R_?SV>9/*%-2Z6JH=6RKM:[Q&
M<P-P<]C+EAN7XY_"*!MK#"]E YH)]%H3)S8E!!]HH1./-+HVAQ[7I7!7[7?O
M.'],TWC>-Y(HRSWBHT^/RZL1!1F4<&B3C<!%:'$Y!DL#<8I#Z<D;=&S3/GPK
M<H>0N6F*O%7=V5ZH]:^[7VE[(R!$6_KH<AI+%TB!TV<8*&BFG8V1,A<:7WF_
M>5^B?=5D[P5#-03SJ.SO=G6OU6D8H@VN7.VZ,8ZUM,++XCAZC7$!*Q<5E!(5
M+P-/01M#69O-T4%8X>4X[^#8CY'MW9O\$C6XG_P?^&[$@E ZLTRT[#N<JWZ-
MXTQ\LNAQ.ZI]&T6Y/<V/TAYO@L&-['$]\58SRNLRY7=4!!\^P^03_(8:YF@^
MHL9EE84ER([B0H1B:\"@Z1%)\FB4=6W*8[:E^%&:]>90W%6T>P=B62H?/L]&
MRF=G10JE<Y@F4NM ?&1 K/+HU H*8!]0&5X1.H0MH4'";AM!/@S:$#XP\B:
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M8R3QUE)*$J\"%F6JZ9 N1V,-C[D1R/MB86]]&0Z,Y8.H_%@:.UR0?SEE+/"
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MNXC]5C?I7676L_'U;CBO%]7+<1Y^&N9S&'4@E<E$ =FQG"0Y!8+NO8AD683
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MD@G-/Z1ZBW;_T&AK.*9L9<=2S?>%>\A6P)<L^?637+DW1HE-<\KKI/>=WF
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M__GFR!IVW51+!A]03R\MT&6RMS$Q=-[O701KPP[6NK;3(+SO5+G320HP0+\
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MH[]")R"]L?0G/"!FAMT+XI<E\#DQ@"XGI/)7_W'5,Y$*9&1S7MI/E"*,J"!
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M8X-GV1J/)TN$DSVZL?Y;MZVX !/GPO/]86X0"0=X_\6UAQ2/5_256T&=UJ#
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M*AJ.VHR?F^LZ _W]PO--#$L.+W/_UW,V^W^).?[].>W]/:?'Q>J5'PV:TAC
M>S_]_FGK+:?GK/0Z-3M:*W<=0S=ZS&L0#_I+[33J^Y>]=,[_<%O;P:^G,$+S
MLO"1]Z,JKWAB +O)M$FY[18,D/2':Q%7-Z[OGCKU>'+_F<=[_3_#*O\3K]2_
M"Z<-SM6EH5GB$"8F?^7,;YI,3N^D,4!37L??>1*.,4]KG"O!<<)QPG'"<<)Q
M^AM.>I\'',1E]2H^ET?N#NQ]\?.B8GH8[5P[]X3DO3N@K4S[KV10Z@?KGK5D
M#33,N?WC@VL<E#TI$D/W62L6JZ?0#$7UD#U4/@:8.J4[X=M!"YJ?VNX(Q&H!
MVS! H[&D&Y<Q0(C==A<2 ]C6',(A:,D'Q<J CR12U"0$NH2X@P%J3EE70F:2
MD5@](*-%*!36BA%#'WH4634P ,70#.P8/0#=6H<B':..+&NPINV"O\< 4*P=
MYSS6Q+2(XZ#UXECK0DM-$ BL+9DR<+QPO'"\<+QPO'"\<+QPO/YO\;KIRP@<
M?;31AHV&HNF:MFH^^@:40588$!=&%> 2 1@ SC<)G7GC+QJ.*ON==[P_R38&
M0 I<W:&?L@6/-5BM?[,PL<0 VG#_C9&:36C9X%?EP&6B*N$[/'H+<,-[?">'
MTM9*6HM+ 9I\?V:@\F>C'"3SA:_*O?FS/N _J;(V:)U.Q?D71N/&;ZGYDYU[
M_F3BKY9AP*[3G^WL_B<3%]U[%X3C]9_P H_\>0I>!OQ?;+M]EX%&(5UVV*]7
MEY<_Z:H_Q #F9;$M<+D7BYV9FM%>*==3)?;%UR';'9/TC8%CI]V73[O;';'/
ML,9@)UI#(.]@R;&3HV"ULA>\[?7F?,1<R-5%R4WGH-SVHB$O[:T'P6-9[K./
M&!.D\Y;#N1N=(Q9]-/_">^U^X]*__=O[?S>OWI^($D?F:*C'KXB%3DU0?'<P
MF3=7@^% UF:._.*;G/$'RLS%3<7MD9P>7(<!(J5;'B]G(\C M$=>^CT"A\J/
M\@S;K*X\=QZSH(B(RG54*-7;:*]X'F=C[5^/D#QB;9H3?'*@86[T:K7U1!;^
M>7?=Q(S@[-@WB#=32D710TBQ4X@*\MMJS>$)EK@A!B )I%XQ(:J65GCYML/'
MRUR^S[@DL8A)=5%(&4V@'<Z&?-\M>_##*2R%RU WH^R:#)G6DR7?M#M_P;H&
MPA7__E?T?SFO>-!\#MQINQ8#)$X8H#& RJEG[5*0\K_2JT#O+SQ8K9HU;CQN
M>Q[RB%K98X&6J=!<-_KYUY2A/N-* [X=FMHOT'/5['XS7W7L<NT%/4DMBCU4
M%0PHA2ON4NKIE]PWU1>!U5D9O$DHW_2&GGZ<GZS2@%5(1O"%N/K+J@ EQ(;2
MW0+_]%"']C A%J;/9/O"V/G[$ .T;9Y2S#BE.(B4W>:'U9N0C'@[J2>OVI'S
MS_((LCS03&I+V;A#_$I\P'-%V8IA(#YC^YF H]Y"Q8+)?VG!3^KW&/]77S0<
MK_^85S0:.S8 *_MMI%)51?#YP':96U#&KN>)#VCN2KSF#U=J6&]Z X\8F61"
M!.\7>8.+H2%D2QN5OXX[  N> E5#M@T0>LL&98?!NF=)-?8:EPZ-X'-F@H<=
MOD'X69YSMCT%S^.Q:SEIAQ+-4WY)'U;=O^(1J7O_S<R-XX7CA>.%XX7C]=_B
M19]&MUU0$US"YW"I4?7RE[(],E7GVF:O*EF+(&+]_8+*T_]=ALM_)5/!HIHT
MH&C&U_Z2" $8ZD5X0$X;M 0#-"7"4K;&#H\07_DF!UXLRQBTUFR'KC7!%S'
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MOO2R;P#O/_/*/%37U&].N:.XJ>N0\D<5,X)A8$?6"P/04LHTW0U^N,^ED9I
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M2_7Y2ZMG1>P*OSI9R3'/T?FF5(_R>V( T>14NLO&$JB.T@,,P!Z)>AG(L?9
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M0R5'63O,:V;47=B3S09=R[+6@M:T]%@S>E:$_L;/3J]6=I8N6K1!F2:4'KE
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MK?1.UL2$HZFM_'5CA>FJ27D@^@80#A2:_)!CBZH>JZ@H7]LFCB02YPE2]3M
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M#;24@K5S4$L]R6/(MJ]PD=*5Y1D]STO3B5 5I?S1"GI[_2IZBXC;.2@5\.Q
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M_Q;?] 9 )E-^58+GK"6WPSM];X4IRA].P+QA@N>&?"X^=B7&WZV-P(I];(2
MA'(MT<P:-E/I0_4>L5G.;LX'0(&=7-ZQ$W9:<O)]H8&X/?\T_7K2/,5/G1T_
M.3[CHLY7TW*IF$V)9 VB)TMAH(^EZ*W51WF&>4T#?O.M)E#E@_+3<,0[WZH6
MHC].O69$0B1JAG$_^_,=E;T<Y:57EFLK=Y=Q)"NHF"_K4]5Y.M\7+9C$L"ZN
M%>S1 "TEI]Z2A'GH@=(3^%)E<7&1.K-YK&#*HZO9?=AXE1Z5;H'&9&!>*Q((
M[<=S,E8DFXV[VHY<JA4;^+<S1)VHI,;:$^U5,8'$;ZL<&!]D0;JG\2#"EH.=
MBS,8QRM<CEVE5J>O;X)$UGDIFHA_NP'\NA.4KNJF+M6I7[1;!Q[D<]/.T"/1
M]?"<E)V=.?H/BMU=(PBM[/RF0,1CTW+/*J$C(M=#C (LN^1-C5?+E9X@Q>NE
M:[;Z>*.#)11^S+4"'?1T=YVJKH?5/V3ZWNW+(>,&.3Z/+R390:7'E3E0*6A_
M.HKQTAG8Y+[Z=_>[3+3#G<AQ2!O=VSUY&T$WWCZH$;4%<RM]O45TK+#O%'AH
M\5BJZ[5'QP4_%\R.\XXE 836GY FM0L[,FD"S^0[93SVN_<Y'/JLE>^/@[7:
M[*U>GJAS;OFRWXP=4]<<8\)>@PH\#54U#7%+I)069"Q?5/OD6^^A4M__G,Z*
MZE12]3=.V]WN&#-RZL[\^^QM8H,KE(R8LED/PG(6OMJP^\)FE7SK!'1G<=[)
M-TE1X]R[U\[ISRO8=N^=[_J(N%9FO7[QGQ(@PU'CL"[C=AW=Y-I[$US62K7J
M7=.H&K$NU --,'A5C&U^.^"#[ZWA.02XM#SJ.<6C#AX+\V=D1,*WB.-3&!;W
M;P!W@$1;\#M>FEBOB\A*MXH8%T]_1:HE>F) \5UZ?[LXBXTVNV#P1'%%MII#
M1&?'K$X!1Y\9TUC;6 '0._"L%A-/X']0*AO2_1& Y%G)MMN]3NV#2%]E0517
MXS^?^_Q&4]'= &P*:Y(ZBK=\&27GYX=*>$;#EJEYPSH:[(A.O^[U#(!>7H_
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MMDVV \N=T1%*JJ:(G@&327--&5<.JM/8T \='Z,]BN/T,NIF3D]%5YF'+;Y
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M3:"\B;@%;%;OY:#QDF\!ZJS5'>2!=U E^!^HXD'IZ;7-!0/+G6BBE$"&"-R
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MD[.%DN^2M,'YRFJYJXV#W.9)A>'WW"2U31D=JD>I["@(X]%N]S84&/K8^19
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MJC!UBO%%]^ \_?F+C/]X9G(S:1O$BZA**#PTKU)'N6V9M](^VLK:[EU;>Q>
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M1JE-#5Q;4IG)XB2G \,'>AG11970ZG'/AB,YE>FB #$Q/F\FFM=WP,'S*.(
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M&'RZ^*K *P[W#U*)<VZS8ZPE_3YBI!&G6^_0K!@L,*X;<,VW<';(L1:3^AS
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M7*;-\'= P;\$>>?H"EW ]T C_@XD6:V\R7= ,[X#"=C_B>E/3/\EID32A=U
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MP<%H@K0E>1<1^'>+V7]B^X_!QHOA;"[VL&BNJ/'-C/IPENWA!TYCR+R;<Q3
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M+J:XOH;*Y%G&><, 4\7Q2Y\I /I[94Z5)6>B%,OMSB:;<3.(+SJ)2V^$SLN
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M.]F,B)*,8F21=CW^7>6H6I%\9V?;Z]U;0V#)PP(_/#HSIN845/G&*^A'GM;
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MWJ@'[0T;2MWZ,7<:6>L$%3PXJKVX7-@N7D%!6QR=%^@6J@_ "G'8ZO"<_3Z
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M^C^164?LR_]3DK:<J=^U!+81_!W%],CM ^@!Q\WHT@.K1!C^\?UDKQ28HZ@
M$3'@7SCD&7&H>L#PLJYCA3+K^T*0$ G 1K?O.&2<:?4XDYZ.ZWJE(NO%G$+U
MJ)RB5NLB("-.=J33F*X>O7_<WMZ0N"P]:1_1R7FI1."]7WYQ_RD/1'E%SS!8
MS"H'YSGRY'+Q7(:='4OJW>%L1O:GND3P_<6"] D:VDT2(-LF^HYUXVV,[!LK
MCD9SW37?PE8*%7OS[UO=]A12Y5UDG]0;,TY#:PK%4 )GCC>G0OBS(>'530?S
M]UV/)?C:RZJ%WNO5\EV0:.$ZZ ?C\9($B1^8\-;IZ"<H_:^1W_37?SP6X;VY
ML+FKYHANT;]W%]0%9[\RF<W0R7$L5*%%P]EZ9!6.,J;AZIA6>;.XJT_%[1XJ
M% @,N=2D3D$?&,"XFD6SY_E]F#? AL/F7D/UU&X_-JCP\B?S96ES1RJ7>-W]
MM#\B?-?,JSBW/!Q0#\.7:^?B(]/YEJ]QTF.E[WR,VD# L_L+*\+>JHB!K/EC
MJ[;:Q.+V12SKK5J\Q436PSL28A*'#[-CTR=T?G^=>X#@#Y>$!.]G75W7AM(G
MS'@';:"2C<%-;Q=G5A9;8F3=Y$F UFBQ%[A0TP5&1WY@Q::#\0##T^Q-HMZN
MP(?I=.(1"+E74OH;@O^DD^WB'I!5V<G-YR2&4)FF<LK7'3"M#7W"OM"W".S+
MV\[OP+*3EVL1)-!?6N7&B_<-BG5T)[8=O/SCC<SVOXK6C?0FO (\F('-4;*4
M&37^C6HV]U]6@,RZY&4[[)(["<!@)WMSM*2$_U8U^GABFA?\+O"J<@WM8*(T
M.*BVX93UYR'!:AX/8O'6WFV=P-+?.-#YN&OQ@YLY7;*Z0V[KZW=I9;15ZQP7
M.B#EDTG.#[X,:M'QVB"4037[HXC'C3/@GF!VQYF#DNW?KP,YQF"6$!KOH%EZ
MK3$/E#8&Z%D;C<*FN2W:3R]N6;#W=O-"'5U!_;V.&P0/]%QK9VSNH(O?-QN=
M*:N4 X-^KOE6X0 K>"]SV& M9JKV="0'BIM0$EB'P&R%C24)<-NI:>9H \WT
M?G>*4://U1=%\QG)/(=UI)3IG/ZU[C8*..U(9L5PV>NZUI)CC84>!1LWCU$E
MVS]4BXPK.B9\?5SM >12R?BFA2INZ-^HG2(PR2W1_!WZN4E%$ZEAD25Z!4^<
M"M9T*"20(904 NGY2 6F0.U5H1BNF#=H*;FA>L5+-5Y>!79'T371GZO'2VE:
ML_F(.$8\/FP3\>'A=-+@9]0?Z.)N'!Z1^0[#KFA 8SRQ'",?SS3MGR\-=!?,
MYU*0?=$A.L_/>"9<[_?(3%R'EV>%5QX_<! Q>FDXYO@4TU>;B-K.\&"VCBD\
M6_Z 5?NU9<<<R'#>_!ON'7KP"2X[)U+&=0+[OGMY:O:QSD#@-F6XA<P'G3^D
MQ=O"RX%A]7*.D07KM0>%WEEU1@H'^/Z:'5&''2_!N*7%I&FH!.?R$M37LN:S
M+BY6K6'$0^HUK*R^,_4'."_H?(=,4^$I>0C V?@"#IB'8[$*FM8=Y]_KA,;_
MLJE-;%&SJ3PT73PTE<2[%_D##YS0 VG"/W.)-:+A[$[^-)776'+";P6N1U"1
MWW9VJ]YDY.3-TOK=T8DX#_0*"&>1K?QUS4LL^<:V.S8<-?R.]N,+10MF\->J
M_7Y6MBO6M6$I7EGE\*EN*UGXX7)W<*PO[/=3T9  %R$G%AKJ=A(RFV3X'">3
M #+0SH/8?:(7?#*V@=COH<\:2QON;@1\5C$XN<EK7A[L1=C5;!IL,/E7;E];
M_+_,HT=&WZ'(>FT<SGC!XMZC=8C75 V-[?I<[S.,,#2^N.B!C=6#>&.*GQ+2
MKK(A9$8'Q:\]:.ZM_W28%:EK\W+O?A:@M6O5[D1-T,14+J;:65-9?'U]AJ9H
MM<70W>8UQPW97^T^OS8-5T>.1YE3MA=QY\VYV[6_?6:%6L7CTHS'B#S@Q_3:
M9?50R4@&A^*7R[JC_NV,FXT--*\)9K431&9<P?2C*H-HWKUP@U]Y+V*K>GJ
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M_NFK/5-C]QZ"MV+F*[($IM\.FODPZ_09/SQY_._6OCQ3U/J<0<MCQ@;G^45
M>POGRZJ=<UH9+SZ9%U6>=_8IJ2->+&.GG<Q3LQ[+>8)4M9Z=^ 2TJE[$:Y$
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M)7H<.MB!8GT40EGIV,T'?R K_!VUVBA #Z[$',/:]'ZX53/'*Z]!F?>OUY,
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M#(3K8#PN-WIL2.OCN9DH5\"J8L.9?YHO'K$*+#B]U5^))(CX(&;)FE@Y(D@
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M'"TOU[_Z#LAJI&0PU<ODQ!E\P76V5?D.?"\WJ<R1>E66TET98X3O:Y$-?;=
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M>!CA0OB$K:>)J[B,*B*WHQR8]FU=%+KT2&NWB.S_8N^]XYILLK[Q*"HJ8E1
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MP?R:+'I7Q1[)VK?EW'!H_'4>6YOC]U[Q\1.I<I@&D[MZ4K[F1D);C:-Z3^R
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MRM?TX+N /S=E2E&>(!M$NUDU\.C@'?&6E_J8D">P[(7U=%=*SM/2S'<6A)G
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MJ3 F(OX$_(R:5!\9W8&8+WG%IY3G!'M)G3AEVA]0_=F?:5K&TD;YH5SNKB0
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M!.485G1YL6$JX.U\@=-\'_AXM'K6,8S*E]Q-+H7_L%=]D\8R&=QZG"I]6Y_
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M#_M$.9/0=GGBIR6&U1=+0;%L:H\$0/<72L0LI7W4OI(/6KLP*"P''.Z&-05
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MA)C7,;!CRI.QM5@#[LP@ =X[=7I#E_A"+&^>(PX\93SAA>:/O.Q1$D?ML,5
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MU0%UQ=U5.HJ6=95-MYL'BT[)GB-3;-\+?%VOT-0PU#'NIP*3N7U8O*Z,\9Q
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M)[28NP;!9_$):+DO+YX_;]'Q/O.92[-"I8TOMKQ+U81^R!MI$*35C-?@U*.
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MQ9TFBL!?YE5/*Q(_.*.;><[Y*GE!@%L3*'.U(+G55PD.P/M@S7[(G_5CBY/
MCY 0^?8Z=?OOWYNN_OK.Y,="MPXN]A1\$3"P_Q-Q+)2),FQ<D>2F4-%/?7GI
MS*RESIRVO"^B3X3_;QR:%UW.WI=M\(R+_O>255GO8F$FYPV5/O,+6A8(P=K
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MF!N_B*5<@1&8<^RQQQO%P24[?RR6N'S>"P>/AO=\>&*<?DN'^\2;4J#]3LJ
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M [A=)3A@#NL9N'PM&XC=[00]HMA\NX=DS %JCU[.7GUAZ-NO[4>:/,X*4F2
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MOQPD5X%7A]#PE*7;X6KW5F7YZ6=UBD>>U@>(#H4=ZGUX:'5IADY6Y\7J>8U
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MN-_OOJF P^2/,(A85C5>!1UZI[QFSQ)55Q)0I,/7Q\9F,F<OOWSLOD?Q 7]
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MFWRNGG!*!AR7#I-ZNH+=?7 XL:KS%&HR(,8+!3R[R'].!O"3 :PZ!#'':V3
MZ%TR8!G_MW<GY;%C4""IEIOQ,PE*? :L]%U<7N*?GZD8VE=E_R?;_OJW:6@(
MU.=ILV0#QA%OT29(!GQT(@/:L60 ]C&TLQ;+3Z1D))(!*61 /#QL)H+]]Q_X
M)M_/)#?)@.F"<W;Z1>(JL35^MPW= 5VUP:>0HF))9$ ?&=!C0@;0(KNA1U>
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M[/O2W:6J#U(U^:]^[]DZ*$Q?QTK^6(2:UR>UC7P->8$Z%&KX$60M_B'RR65
MS'-?PU"=7G@BB16?AUDVP[3'2,!5-2N>^5#=G9VQUAV_I:/WOJHJ$?RM*S)4
ML%YP], IRY#X85\<?CUM/!QZZ;UKLM_W+R\1U+IJO_NF(U7%C.J;,; .Q]=
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M+N[O/V8\BI2@HXIH#TZ?OMRO)[65MKI) LS8F'$3<I<=/+3O<^\YQ-A3#)(
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M71]R?D5F?0G>5N[[>UW=_Z%\(J9C%8I5W24!#D]9D0 '@MCOG0L[=?MW/$F
MH]</CE\8//1XW\9WS;\;M=LO4E(U5%B<@(7GP,)>0&T,CTT+]+YN A,;]3$B
M^^5?>5S9S%[<]H,3 VH&,[_0OQ:5^E?)WUWR:<4(3P+OO9@6@,N0CM!1OOO1
M(J$'B!B%3AMW]Y$KR#I#?Z;[?_D(X!+]KV+_PV)"AR^WNK'8JH,^\J=_/N[^
M5>P?6FRM+CZ50HE(DQD(;U7!:\^8#)V!A1YE=D1L5&$E^T=]MF!$^#1NJ8;C
M_>94,I\QS5$N\3X,OBT).6 D =IY!X%AWN9'N<>W2?*,#Z!/9AAW<GVCORM\
M;S=#XU.2+4MZ1H']H=[6\%_ZO,!BTO*?H-K_E&(QO=#?&+@<XLN/M)(G\"49
M$!F,?/".H2#B@*'NTF2(6 <OBVRX-L]J-*+Y6S?O$.\I1S@3<9-K,6*\0CUA
M9CZS]=TYS4OYS_E$*(F1'NUMNRW>%WX2<7S!I.O9N76G)GMWC(Z(I9;KS1Z6
MC"]5=2B;NBW>)4OB"(R();ZL5$Y+_YLW?445N3[]0D?\\A'9G[I8>H'SL>(<
M=NTG@,H*CG2.G44?:B_/_IJ-&EBGR;.VS),M:E2E+ KW>.Y$^@0]S?.J&U<?
M8J)$A^U1^G5:A!XGX^N[^N^(U/@1 <X-A 06Q21]*.;@3$3G6S4H.H;<2EM\
MD]\W@)?!F"KB.^;BR_+I+ST<&;D06VJY2_7H_;='D+#0)EK'F2R!Z3WVD=IG
M1^_*./*)U]?ZLPUG)M0!57 ";&)[U?@A"6 ]=5"X9)/+]% 8\FBU:2Z\39(Y
M-^E.U:9+=-G?.#R!>M>D/X]O_8>59'-.^:N^8(_B*J^R#ZH5'232X$6WF_42
MA>X_&_/PFB^2M6* A- VEMQ90]8]&4[YN;$\>%$:689U]774YUC&>\J'G*A2
M=BHI?42!>JN-_5I<C=<\%15)@/OG!Z*M.M4F=X&!1L<WO@,6A3?KF0G=&YO9
M_W2K5E:7QBR,KC/WWEI@W1,=C=+R-31T7 ^'DCR#UV+1XOZ4U/_Z/@D =$[)
ME#8J^KD[I5'+:A0*R\R%ILQ2F7-HA&94#:B/_E57'^6K^C.*_ \KJ2XD8[#\
MRW^!6C"68ZN6,/QNPPE*+BEJ"61@&58.-,_28[K?Q0^UE*4G ?)F*NS:7ATU
M)2(K]'9FO49;4KZ%S422 .<*QOE@&Q+OV@@0U_K"/&B9W7&?%EA]"0:_X(MJ
M&AR&UE>UO,[!4+%PV+F4_K6]'?WH_J<4SK]*_D,P?N4(3RSO/>I_8?Q_=C&/
M9:HR'97H'CNF[PEE_[RARMA#HO@F:#UN1Z '13U@#&U+:CMR(@94U7PI>7#I
M2]A/R?=/0WRI( $BZ.,LL_)) &2K+QOBSL\)</S"(2)67C"?I\/@V]$JM;!W
MZDIR,_,;=1;6R)+<DY\OQF](K<.S]E+);:E^3H"?+V'8RW2*Y?R:NV3)/HG
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M\%EQ@@0@!QT51+P \59+EJB4'(;7_?2K/S%0('/HW K:X="'SBZ3 &7]QS4
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M(5KO49)2A=Q-A#"ACZ(ZR0 >%:ZMF2?'"I^*_.KJ]3]6?G]R\?R;!@=\/\]
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M*P5<C@))N[=.EVU\N%)E0Z$8@M;8W[*VD]N>1.\M3Y@*#)]ENA4T/+*GM_J
M8BULP"1 %:7*"XTF<'\,XOON-\\XNFV\YE4;3">2+I^U>OREBPP(\AZ-LIA5
M"_JM8IG= K/RQ-!MM25U-0L\;7L5NV)&P<ER#QH"/+Y"YZ%-NO,PFW_2W0C_
MX86?4KLMH$^N6<:3[)FRD[XS6FLS@]Z>:4K4_*1=@955C8?CB*N/**^G<D1=
MJ;^7#(TM_N7R>[H$P,&YC7V8H+A.!MAOR"J8Y":1 4_J-:L3D3O%AS(JL(\N
M)X?O]#9#/&(*J@:Q+^+WYK2Y9$<:*:H')KR;*WF2,W[W*+VG1PEUGCC%;I/Z
M"ET"0NP5"?.93\NUX)YR'H]YL ,AOI/Q*9;HRM1EY_P$XY%R&<$[M6KSY3[1
MELD !U 'JS^)Q_]JF<D?0F5P6N>3F!P/V\#"*<NIF6=U6!^SGJ'[MU2OES-V
MO']GI^Q*['\7F%D].\=4<T?:4>BY;L,=#E"ASN^8^IR.G';UL#L*);UU7434
M5F2#]\O-\WVW1=A7-V)DWH8NBC.ZFES;/+HSXN4)YG//NL3<K%6_LYJRU>WU
MI^B<;;R<?<+'?,Y"0[D\M47'?=U/S>(V_7G%(_MU^>*#5LG)^Z.DWJ*9V:G9
M:V'-H<[1^O1INM_>[/3\R6U00$MQD$>3VR_RRNR<BMM9:"Y;-)NN/GY%3S6C
MP;'.H43%[T?U:>0@1Y2Q7U1Z2SN4SI[;F$[S(@?F^T WA6]#M=^FZ\1OI<BA
MX/4L3*H H1;LL#0O-K!!XY!'9Z1U =I">9V: 9'GYADTL7S;P'3$[PW'6K)^
M1IKDK3L$!3(@M.W&G]TT'CGHLV+1Q?-!W;SLW-_NH5 ?F>]+:H&NV#5S/>_M
M/'',\O?U=K+S<%&>R_,8PV(WN =\='=OJ428'G8[_]'DB157E@K\]4QO?J",
MZM$BB22_3W3\G/55A9,TE'S<HEA8NYOGR;<](Y1M+^2=)3_XQJ+,27Y3YP^"
M@*14YCA]>A=2A<8/ZCX4:3R8O0-.OYE=U 7E"D(:?6X<R5M=':V96G^N*:>:
M"&_;6U'#]_&8KE.O([,/41_?KGQ(RFA_94?S3EB=6HV>6M?Z^IF\BB6B5->E
MJO;2J5G7SX)Q-]M#SSQX"X@ZBMS6,6NL3MZ;" V-Q+Z\EMB%UCHZ+T!]4/*[
M1!504;B1V70-BE56F5CHF99:G9V]?^6E?5K$_=X F5S_11@3PDW##*I6Y6'K
MP'3I_425UM,7WE71Y2\B.:R/N4W./JG[0^6#W?N-F; CWQE3\ZDYZQ_7FK(7
MYB]IO7.BW_X0F*=KJ5^ @SQ$$\O:"TUG7?24\MSN.'B^^O24&ATY10O_(X]6
M]Q[6C&^OUHZ)H [I7,Z+GYM[8HI@2-V#-B=>DQAU+FT"Q?@-,AWG:X^6^\&E
M/5Y-FPNJW]F<5?U^>AKODHZX?H]; >B-GY[KH.<3\C(6W![&9U.OFHK;:!GR
M7XA *\>5R<EZ+Y@/>CU5&3X[_":/1F7IK TI0_:W(+'5_.<2^V$D[)1DQ/CB
M2+E'33&?KLS[+_6:AO*4.-7M<^ _MZZ(&Z,',I89X#/9_A5D0!;TQLY[K; 6
MI#R]_,#8P$CCE)1Q#5%L4+,ZOD^W.J;GA_BAMT5I3^H)2DV/:H<P7O'?OZ%&
M"15!XUR"22"Q=#>,/2HC Y3H7Q%S2,J$E,9ZD&]*ZT0K=1\6>!I*#L+1U2U:
M9 ##J0T^'XA]1@9$VY$B3^UQ@A<A*!@!<7I+JB:V91R(#5LGB\DX-WDVMXYY
M_/*Q7=?9WQ-=D?I#1'\5SS1*^'-R@M>M<V."(SH/R !:);CM">3%[V$V[Z6W
M_]TW*8IL\\"?B:".%/&I".B2[F^\&!3I]XBQ&R36?Z7P>SZ2JLN44]8V2!>=
M_X>"X>]V%\I'G?]"G.\/!>AO*>$*X/Q#_/J_4"#^1F'T\^ ?XAI_"!3]5C!4
M_YO9N\N@R.,4J<*U0:*:))B4N?@B=$,KK8BG3E3<'4VP;]\+BCL\/Y"[<G>L
M8O\P >/#W4 F>?7P*> ^?'+-CDZ?VE" 9=A>2+Z\ LMYFAO@V\%8NYVCYH^\
M,9#A9A2R@2M[H_^:1RPSZJ\+-KG<]O\,T@8,BGQJR$^BRSD]M*RDW63$9B\9
MP"K,XEP!Y_W2NYSP99L-$KC/!]U$EIJK1 7#=!+DS37AZXU+(!5X88137*'"
MFY+1YQ-8D&''6)*(B)"Q9>FD5*> S_E9XL[S&NEPVGWK]$M/I5,A@[X=$>&0
M!SL'X%CC % ;_ H)20JN9R8#H!U-WY"F^5-5'X4(^[H9;C,=]E^RU[M"BS$2
MP2AYE8<*:TY"'\/^)-M)XCN@]71OX#%!N#Q9)EDY@>L*9%#ZV/@/@F-ZG0:=
MP@;&*G?;KE1>72BO_-N,"/_#YK'U:3/GOWV^3#5LMB X_ 0C%^NO?!/'[>;6
MYR+RR?F8@2<R"@E79\NO,5'$4!HW#84Q+.L8?'LI7B&]58):PT\)4P@(;'ZJ
MS#W^O]C[#JBFEVWO("HJ"J*@4J,"4B*]UX@(" A(1ZJ(2A.0W@)!$5$Z2%$0
M(@("TJ2W $J+TGM):*%W$FH@[4,]GGO/O?=[W_&]=\\]]WV/M69EUF)/V[-G
MSV_/?\_L-VF5KVMIO=IQNIC.&[A;Z&'1O(OJ7QP25]7?^3:'14I<  >=G#I6
MDU."!#63 ??66.PM3L)ILQ?]S]>]T*V-U(_AC+\^&3FS_@9R1]1\>K#(@:$W
M],F"04*9YWVW>XRZD1=_C:TT)?V'!.3+MYZD"ER6O^#%K-OEN.9HU;M6YEW.
M!'GI7-H0B7[@RDA H'L=&.:@);3/MP2.$MBQ9PHS3(F1-[6*=UT/TH9U!&"&
MES7<T M]<3;-M.8.Q^W%EC/:"[N\:.O/@&D@0$MTM7I.9:[;"LFL?3K%BK6C
MPX>[DV^/:4$\9&,MP)^_'WX/ U,:V+)/]<[6=*3NO'BH@RN6YK3-0OFZV+R,
M$L-"7[BMLI.YP]50\Y8SO[HHS(K_\>'"PH[9.\M%RN)4,%HJ.!EB*?&Y:Y86
M,75FM^Y!S*7.A.27R&SB;($B$C17,*PRZ?1<G@-:KTT&'#WS1DSK@U_"YXWS
M(>":N3EY8X$W!:D>(6MM%W3B+^H5TB;Z=3S@NVZ0";R;&VB3BR/(O5-X7Y;#
M&OZAGS.R)7'CLY94,'"]EQE/L_7UHXMABON^#&_+ WM%JW.20F68[557IS<<
M,\O+KX^YQD"]'VVL(_)!7QTXWAQCT@K>[*1%PIGTP\OB*+_,EIPQ6#AF#8 >
M80W(*G4ZOF!^'D7,SC0>W_5>3UD\F-#:(1+0$+9R8P64'"B6_7W#!JL7]UR>
M+.I=1A<6A1)-#18+T_VKM?4HJNO$[+]+T'$\D'8AT:R_O2DYO#1]Q\6[7!>%
M2G>2^@*&?]S=M1JD5T&O")_0+S5:=GB:?=E?;S#EJG>;)!D0_W)\R#/O*VL#
M>.V,E2**;?@*EE?6^(8 F)%K'.9"Y8RK@O"M7;]V)=K@DE8_7CE>:F9[/X%6
MFY0.R=-?+A17[W@-CVQ_KT *AC-@HY'DJD_DN8^J06D^BC0M$PZN<3M35H@T
M2:=3.GZ3][*_<;-X+*L"B^N>[T,A\>^G=[>P.-\;@?H.!C+,EN_5@7%B<U$I
MKC3@F7<2VZQ+WWAX_#^8CTT++^B-?OZ\?('+#OES)2_:2U,F1SF\:!2(8RI?
M6B)>?>_;B;>%6S J&W_VRM.+>^*OWFL>>-OI:44?D27%*UPC;XU(O>.]8/+M
M2Y<K$),#V3<\KT8$DP&/<6!<R'C%/J+K\#5YEI9(_0Q>^3;*4>5<\PC;T-1"
M=%=XV;<;/(@>"&NJC6>!][MYX_NO/#DNL,W6]U](B @Y1W,Z(A"%AP_WES"?
M\!E<1B8GIV32*"[7EI[.?"DMG!9#3^@<(4X9?MT< +-0M!%.R>HEUU-1+6&+
M&I!MM!!0$Z0!$4A#I+V+2C1+LE53)SZ?L."(P7_FB4BJ==JIS)/[QODXG!7Z
M2!<]YMWCHO+QJ 7Q:1*0TWYA7SSA8*KHC%NHA2CO6L\7U@>:V,B -0?S+>@_
M28W]1'#O[&R;;::F7(_R 4$S%!G =*/Z$0&\M^6T7]%['6><V6.#6&]C(='.
M0_.)ER?562\U#V7NY9ID"Q%//,BU*PACB"3&2V5^Q?=J.K#&5;4G^CT&%:_G
M//JMYGT,$W'CZ*H;!5D+.66WH ,F95<(0N8))3J'W4T#WFGYQTW/2IFQ-#].
MNV6.2'O<K%^OT4&KBR" II+JCK=O:VBY&/E&IM1H:0U<WKJ^@VR+P5,!2._2
MZC"S25D(/%YR!FK \%*>=5[>FN"UHG6M(@ZZ[8-]*'FYE<^\63@,/;OL8]1F
M0'VF<H9-U=O.#6@32O+A(FZ#FQ/OACZ\Y.[28%6F[[5%'2-B5(<IV 3O;K\@
M PYPD@&3\V1 $#25#.@L@>'H!,B L^:=I<W0R_[;WI *BSFH<^7VFTJPC>&#
MU;&V-Y5R"G.9&8<G+[89WWW8XX2*TZ<<NCL )("(M"2_=#+@XW,HK@J,MIB'
M;JQPD0ZJDP%-W2O.L%9@33#_V=WQ$4?B!^]HF)QX[H.7=_(>^SS4:H_TL=>@
M?VF8K!89*WCOD&&7JQ'L_]$]E>^]8_G6N?7(E7M8J^U03&9$J<-I-"+H71^<
MT_E^E,FB>+SR+0.5R <1;5) "5GK$ L<E^%R=2[A-&:U<C+RW,<+V$LU94C0
MK>E#*WQQY<F(ZN(47\NSB7O%I).LC(8\![.YVC?$VG+!PQ."&6#:3;$HAO*7
MJ_CE'=W3.,BFKZGU.F+-LC6(Y+G#_!A]($Y"2A__\AX55BI]X\)H16=E'9Q5
MOTZZ\>_Z_EM.R>6+[%KM?)BI)P-D\.&%SL!7%X1Y2%.,"A<C2]AY+OG%2& Y
M<IZ1 :,,S_?!'1F@N ^:;,&8BQ8D_DB<X1Z0@-^'_(].D0%8M]_TR!^B(,@D
M7[?1Y;BW2GK9!&IG^2)<TTHG,:9P,0AX!41+8B#M*QGY'NC$M3J"&?!O&+Y=
MT3D3.=:00$U86Q4/;Y&!U ,DK$'G$<2-!5@28[-M\R37*<<XZCGN8=-(A)S(
MAM4[^Y^H44*^^RQA4PN_# WGCF,L X' .XIA9(!T_=_R2C/X$Y-&Z2"2O=Q)
M9&S2%#KO[M][EE"('ZI\6-=!FH+^LOH+KD_]NE5+LW*19 ?R^_F^_711*-'?
M_+V)$O2BAPR83ETB [:/])(!FPXS[G_W9:;$@EHDH>ETQF^NQKLEC&/GG,D
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MD2JABJ9CW;<2_YCPGO\M&#12(E3T)42;*EBC0;Q0K!"N[O[TZO$+K]374,6
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MLT'W,SSB/5\QPL"D+Y"+5$\R 3(Y@?"=']:0P)E]H!B9YV=98LB.P:._!A>
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M.M?0%VX,Z38X^]?]8GC4]6?GCLY-2G%^^7G"^Z=I#*7]N=N#SHI\\&@Z65?
MY\\*!\6AP2%=^5Q3U$4$+FSN\XH7;\WC3)?93UY7H,IWU4R<C;UC#7Z"ZH*
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MHB!<Q=*&U;)#]'K%PA4*'HB:&2['GRQQ+H@#)C^L:+GXHIZV)B79?G2IOO8
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MIE1:1E^9:8N^OW;JG7*5]UV/.5XF[), [>"C??-6 3BZI-;F;AN93>R.G7.
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M"1""I.EM92?3Z3?O2^#C";A345IJ;<]Y]YX8J&4SA:9S@&)^:W3 [_IQK(\
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M:^DCNS7/$>D^56NY6VT+%A;/:"IO%AC,$P6-C/1]^#"9K07-X\;WTDW4&%J
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M$;QMAI$G4I.OWO3/J4>.=_[RL$CP+#R/WF[>,9Z3D5M%&^G=VR.^QX 5KO-
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M!V<1VBXJ@N=1AKW&CHVH)*SL6MGK:TZ'?)MD4[5DM)@:Y?-YG>H]QUR0?-"
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M-V9A]-(?G+/F;FPRS6AD]P90VC?)^-2'^K."[-,"YNO-U-%PQT&I;T(=?]#
M[I<PIR=IFDA[DMO@S_QFZ)M@"D2T^!I1F(-[IN!;=:/YQ#=PA=[V./U #OQ
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M7AEWN*^&3X]5T,BF_U3S0@(_])$GH-M==Z6>\7]Y?G-\I ETA;T*8U:PG<6
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M2R4B(_4MWIMI<&]E0Z2SS;PT33REN++#GRFD_+D>BS=2AH>-"IX6EH%A(%Q
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MX5W%4;S6+WN?"/!G0A@=D0H0R&X3 <W]1,!9X9:Z/3(C'(4?$1 "S<<5XXF
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MZ2D6E>CN5%@LC,"R3V)S=C-_;M(I'5[W5UAG$EI+":NXE3\TI"E3);:Z*T1
MT69=)5@2]',#6!;C8XFK!/V,+^+GQN??6(^Q/M8MMP8+?,#S?OIY_&INQB2W
MO A)KZVN&)\C> P].PU*!?[< !R2X\(Z#8!HF;(#M67%GQLYUJ7%S->CBO@(
M&_S@8?_/31^Y1(7%%*R?"#"9!#L2',$_-R0]_\;Z6[!^*HLH<4O-^_%I(&.E
ML]/IE.!_5EKZ-]9_"-;5[^/+C\?O;&-T#)F) ']?(N"T-CKF6+M0)@)D9>^"
M7;JQ6$]HQ?9 );[32"C$E @(.,!*R._@;QX;[)&&DLML$JM&!F SO<V>'NN!
M%C@B .U9B.L/D;@Y;&!KG:>K"/J)F+\3\2N"8]W/9.N6H_-/P"/_(*R!2J7?
M#JF6Y=CMX&!V5Y<6YH-W>]T\&,,U2<ZZ%]6![5XC.5)"+A]9EMY"XJ695\OX
M7-4VZJQB<$\QLQ7T]T+T#I5MFL!9AJ\D.M)2K5?MLXYM/8?]PBZ#:_"\U\W3
M'G5'RIV!G]?O)J:@_W0NHTQ#_V2K\??!"CE&,/4=055<[CIS<T[@'F^8.OI>
M\6 ^PB/QQ5JYG%$:9BP'55B&Y9K$0@KLC1A%.BUJ+V(6Y$^4A'V8M65[Y=V#
M$9?6'%11#]6A\?S2UXTDCZB605'=JQC"2;D+E/3?B.N5;$!QO0)B^A\Z5YOD
M//*&#=KJ(F?'7HSP0OW=VQ.I$]8=;)ZTS>E-HMZXCP[<52Z;3$T9?2B4U/C<
M@+$JRS@PEV<(P>6 _>4-J7Z\H;[YX_\-:_RWPVK-T<)^=;":!9Y<8*1='M?3
M,$HP+%7V2^%9X,;>YRTC=)1-AT$*7)<WS7(:R>N-:)2*3D-N/?-&INM/-U&Z
MU<^-/J1)L7Y^67GSNI6);@Z?A(A3&AV**Q4A0#5AG22],V-9)FM^I-5.=JMH
MVM_;>R=M&%IAW0LRG98]4WL"8Z7U3I7?]AN7^F*1RS5X\0KO&!'PM># Q'Q=
M@3_%8IY;V8;)@M;*0<//'/3?O+Y3U\M_@@7\9\*J-"%?.KB3EE8R,N_!KC<'
M"C)DP23B,X_WE:6LH\!Q9[N=.8OB.OR^T5;=LD' (C01_$S*J1S,;*=I%OK4
M:[J1',\MHX:%[4]:WIKSZAVI86VD_))0T>]7$ZY_55LWU'0XW..7'0S^8U]<
M[Y;L^=^Z"?\;ZU_&*N\(M\'5YNP5_F'\Q]J0E_@G?>0R_U2D_R^)E2M\O$CK
M&YU[(JTJA3&MO=I?]ED< ]FSH\=^:AD^3(N$$U&9TT/VZH_E\M,0OZ:<5XG1
MN2M&M ]K@Z_E=_^:1_V?@NBX:!]Q:J1? P19!(*+$3K &&44$0"<M8HGN![J
M[)2Y@1TBJ@BB4WFVCSRT._R:)X@ G)@8F@J-SL$'00[)\(5JQ> V,9>CZDWL
M+.@A;/^I03ZYU6;+XUS%F FI&4'K_I0A*P7/$0-E2\OKUN]6?TUP_2^@HGNW
MKX^<#0X.] 8BG:&%:[KRT1.SZ]K ET/<R@;5JT++SFS)YC=F'=BL"S>-9+Q[
MO"\/5]]&J2+.UV9^-C32>[IN:) E=K$ZQ#;-:6 S5%"*C,Y5WQ'ZP2%XED[%
MT5HWLVIP1V)E*!3N6 )4E:?S[:-]+ _X5?"^Y#U@9CBVT/+6S*4!N[W)H=U\
MN_3H 5>'L+:.CGK@*WM=6"M.M[S\"T8#H1JB%UA2&:A0'<?[3E8[K(GRKD Y
MA\AJ3C=MF3"D 50/H?0$(2>58E21T\&K(U0251;2XUQ<=P!\B4P1\L!8I^K1
M7J,BER"G"#I/@6%;IP*M7>V*!R\LM#Q69[3/+#3<,0N:HP>E>I$E+HOVA^3P
MB"XJ9%89W%\9TLBACWM;\EC>@>W7)+7X);F%372U4Z%+"SOU ,X%OEY I1>X
M>636IB9+RM&B9TW.=.U)N!PN+W,?#;V*_P3+(P*H<%0H]LR/,U.KHWUX2&=%
M<>)\K(,]#:M0I"*%(D(7OMH!LWKU<6,J*O9%K(3#2V<"%3(\?DZ-2G?%G1/T
M;)#/[_#"&?8[50D5WUXW[:@M&] L",A8M]>935L1 4U 4IS$IS7M,LFPO5F+
M77X[+C>SE_HJ?C>:8AI\,=H%[A[][X[?V.I.9I7Z63Y)^\4Q+]K'.LS^M(_E
M3OT6N+QB:<FR!<D&O )1>5]PU8#KSAQ;K'Q9I2EVI?A,,8T'=;;V$8+)V-:!
MJKKD$[6/\0$X R@&5FWE5."B/B+]P6R!"+"84;9?6.Z=87 3[QG&Y:T1[ W&
MCD1O8H(>?]Z^.K3<..1O)1@K:BH;K*(+E_R',_[? <A^U;FU12V]N4 PMY$\
MK=8+W]] E_\G0%E5'N#*@+MF= '<J$$5!'HY"/Y"!"S/=L=L@E"+"UZS G8S
MR]N.!_,U*WL'4%$BP/\@_9@0EXX[UF@95:P=P5OZ$Z&;"& G@&=FJ[90!^Y8
M!\/8*@[1R: \PQSNTE7:>(Q6JRCC8(08MY>7HGJ_O#W;Y=\R0R6WD^H#C\@C
M/1DQ=_,])5!U33;FZA5%2:--[O&3?/0CBN;W=LT]E9@ Y#30.^[L7E[V3WQ[
M19M<R>?14:B+388\_27KUF.VU1(N:-ZRRGM/7&:OO! J5&8*JO0=LE^=2ANN
MO:+)\V0IKQ;RYBN.XMHG!?J QD\9P?53US*" ;\.HGU8*K_(7G+U1C1[DZ+8
M0RQ0BDZYEF7T]M)-;[6CN>1OR'%2?.DA.=(BB.?W7G1],]M0RS+LE)<5K6IP
M:T"O7?W"N:\*_F/7.$^\RF'B6'_(H/[ ]GY!9^X2I%BM@<]D;M1WN\3&:JEE
M;0VA[M'L<8:M[W(P)R!.7J*#?29E%&I+U^AY!5.1B3-%;K849^H9Z4[J3<.2
MK^Y<D7CU;L&GL)$QTF5_OBK%J0!%DROY-=8N)#>6[O1@J.7&=\Y?%OOU&V!6
M.IDMWKJ7(.4)&O+F]N0;J1;+?F!]:G\Y9K'=M:OH?$SKY79-DWXJDQ[>/N>]
M0I-YQ:;S('B$GQ,5S5KD5*^)^>)AU/CGDAS/$,;Z%X^'6]7%NZT5-/R?=D":
M4D=SPRQ:GBPR;3S'G<& /^$$,7H9&#O-I!&/=9!45W1W8H;4<O3M-QTYF>&-
M*:/IMGC>1(P=BE0-DSHW#6JJU!>[^73&+4W?)3COVCB'PFNZ!*>[?6F"!K(S
M)5KO<[34<U%B+FN2@J&6+3>/)?)[6-2GOQSV\\>@+L8CSW<YG>H$/MZ;!!,X
M!\%Q@B?CDVSZAVI[CX6M>2?'Y@YN>K(L [$=:B*S/G,X:6B#M$.,^*+*L'I8
MFEYU&*%[IWIV\W3F@YD7^"IG*?,MUF6VO $/[1="V5:QV3<4FQS@B(>T[RTW
M OOEZ5H<?]-^\;\$*/XTW=/(GPKI?L\;/?_2"K"LV$P=$FDP&2 )7N0%=29A
MSS_Y[-_M0 0@WZT D=%4%X@ XU7P9"H8)ML-G)!=ZCI,F#YP73\ \ZS01M-"
M[AI@II[8&W;&W5H,CH F-@=DK&!5JV:TKV9G91>2EOQZP18,N,ZRE:1[C73)
M:-RIU%,?,\&RR&V(X& B I2JH-F[3]VU TH,:':.=A\,WMC#ABD\.'"X;?NE
MI@LB,<U%ZQ:V*S;3JZ$7EG)VM5E3T\KC7@$10.%@O(J]IA.1$<R;\)MT;Y:T
MV$:<1=3%.2(@W"#9BM_?4R?9!]0_103H;JY+J0=,['2L#:#%EV&Q;.;!GHP3
M0J<O%^,X[34?JEP,>:%)-^^YBR7_ CP#\YO$.MN^4E3BPUNO>L-"TC$N"LB:
MO/&5";.T*-O-B@]%94]-A"Z0V+TG22'I_5*0GV:=R:#SO.AB'IUU(GP5R_S8
MS\5DY7@=-;)^TP9A*(PU((M!>Z'D ,MX!B) Y8/H1EIL?+ZEI-T[Q\,;,%4I
M&ZT6@ZK-+;C.!^E0LZ<7W$[ /CQ^7' VS+"K(Y_MJ4I2?YH1]DI !-H+67YI
M&<][C.*CZ,9P3.:JI%U@"6:CI$K*AJ>%;Y)O\_)38]84^!. !!=,Q@+Z6"M/
M,DAWX_KM@;>69<ZJ\E?Y3*U^M57Q \(.U ;B(OLX$!$8[H7@,,07I5.G K9N
MMWCW-WN%#%00 ><Q8HT$*KV(#;YS]_N[X)[;&]BGFP<(*9<-4O'V_4*_E(L&
MF WUEN?F!KQ&.6V+#0..E@K)/R\D:?YO(<B_-=P?E(;C1]8C1FFW]B/F%6KM
MJ-9LLC:\[NLIE28GGS6]_K[]:-[?>8#,.C^Y[FVX?;?LUSV%:DF#9,-/#!#S
M=_?3]V)L];62'3_N.9-89 3+_>:5_3,@5"$C0%!AKR,"GH6!B "%&6V=/TV@
M)X\LEO!\+'ET+:-8Y$_9YJ-;G3 %*^4A*]8IG;S_<5!LF4TGG;@X&X\*X-I'
MIB?T;"H[]NU ?_;GH>YI(5,(V/_C[CW#FHZ:?=$@(%)#+U*B=*D*TDM0!$0$
M!.E5I7?IH88B(%U BDB3(KWWCO2.= D]07I)0$* $ [N>Y]]]O.^SR[O.??3
M_; ^S?K_5YNUYC>S9F8!Y*,>A.L21FBW9;BIK"L <[]L\@X4;[>/R[S>!N1&
M\?[_IN07Y-Z<LHL,6%G\T7-OC_'I['/":X ?]L3\[36 LI+Q&A#NIXFQU<08
M=BZ&,BU?I:*I,J[B]W^=>&\5CL6V.RS\&-YLEPVP][R*K]7[':(YRR)IY!8/
M%KU\5J>M/9_F_5\+0NU7A')J>HV3?T:^7G:_J6^(_)Z\".(KXL2%E&"@?;[Z
M48__=$P=6;35OV,8C;F:N\=:)EWJW\/71;5$,HR)OUO9TTE;R:61ZIGLK')1
MN&,.A$![TPO#3IG]KH2.U62:YJTW+&I=1OK'8SH?##<H^ND[L8 ;8M*WW6?*
MBH='K^Z<S+LRNGRVS'"-@W;GC_DOK+G 0G0-!+#&^!S YN+%(B67UM[BUO#+
M59$,CW/^E3\@.KM WNFI2[7VJ./9C^8BXI=E"C(&GLKGX;I!'$T5OI_MM3&Q
M'-HBXA+:,V9N(<K,OYEX6"RRD3A=P7>5,S\? !75GOO>?>,_="GL$P$?&*"3
M^>K5V"3*<MM%'O6\7Y)1:UZN="?+U>PULG'M&"N!<HGUS)]5.H8DGAV,.+$V
MQ1@W?N$_77J9O=>2X5&I5U&F@]!N_)O,-\AM/2E&X RD1*O_8.9?VEE-\3':
MTOX\J+R!IJ1<LV23?0Y*U1"@R6:K_UF%2W\6FSD]1M]DDGYC(5-YV)C)^5%[
MKB&'Y2"K"*GNE+UH+%JT&+D-<=GG9X9V%\Z*&#C-;78_?#"1@#? (3D$S@P0
M$C731]+<#.4N,O,P^JJD9;*IPV'=<\-'L#DW5@HOS3/F[,BL,'VG7R?,\=D6
M.<VC'IZ[CZ*7_N+2?L]_"4[U008.K+L1-V*%0VB.:+\UQE$29!_MQ<SV!13K
M!RYXW\F(8\N.ZJ0X%2:IQTSK70.&R3U^1CXG96\^%Q$]"_";5Z9_0;<S[,?]
M]6%%1K&JBGOB51*C,6ZB@]D:EA-0:I<0P7&@?3!B,8V/K+3I>]])),^6'69.
M\6>5I!PSD](S1NI1]3&2G$/R7,3UK-U/WW-/F>^%Y^X+9@D/6II8WG[COV(^
MXU_0I/X==&07"-[?MJ5"#6!I3M_%MCG3$$!SDF5>!!R!)2=^ZO\JG&O31_M=
M90UTI:!(A>K$@DO.E:HM[QVW=8H&X3>X;P8F'^!/M0L,UTO_:AZ/Z+D& ! _
MIC-X>8=VU6Z8)=WK7[;'_%\5G4"WXI[;9JZ)A:!,@*H2'2C]82$1408:?_XQ
M'A?M%_1CFU\_;]V<SJF=^)+D"2$!12=!5MK,K@<QB#T%4H,LP=I4;61#*6']
M&=HRR6#LKFGQP*?1-&J;JZSZ*DO<;FW&6G!P?* #J,\WH*-ZW=1L_-BEVLC$
M<(2LEM]B.#9ITV(G.-WC3^)M@Y^"&_63?P;--E9D'^;6#TF=5*6M9KL;?2E;
MII@B%;P[#%O1%%EAM(AZ()HYF$,(3C;UN860PN*!AR--]ZH$=8<4_=ZE>CZK
M7*AA9NHCOZ<KH B0VLG^_;K@X/VB,AA:+W1D'VE]M>#/VNZ^*V<WJK$BF;^"
M)J^W.'-5/A2-BA_E].!S35=*$W_/B"CF (W'63E$?.'Y$M>?V?+-[M8IYQ7>
M8Y_!=E--A!*ZIKW[[.=73^82L!BXHS,M7^3><FA3<&9.3+KX<K 8K9;._ZF]
M _]_:'\73>VCJ;SA75&%W*@7@/.S=9>#QC67Z"S9J3:>O!VS>PTSGB")X92+
M%<(P_Z8LY24]:XZ/XP^!G/JM9O;H=,_8L8,E% QFK#PU)GM(Q:%$D&+-0P(@
MDNI_-!:HA^NM<;HJE*78+9@I1PW><T=+87YP9/]>I=N%-GH?T,KJEIAB!7YB
MFQ^7$B.D"W9?@L8SG]9T?V,,2:@F6Z_I?T8:QLMTL:NE56Q5/7*WO/O(?<6?
MYM(' H(3Q=2YD-G)LZ <['T+AA>?<E8'\6TE<;QS\^*[[76/A2\Q@+\$LWAI
M!.%8$VK_OMV"]<T\+ X@@J6LJH=+/.IKRVU-]0 \4G4-@42>Q(EVXX:@-8[@
M.TYO4.!(=N-*EC'G9\][/(PL-0"VR;7A:4&*JI.*M$\:?9*V5C&\*]LX43NJ
MQ&^@GI3M-5X.D%UK%_Y/:%8=0B-CUZT\8D*,N7:% 4<"1BZG'2"O =%,>/<Z
M%YP4"#Q9EK;^5%RNZQ_$(B?@<[DM5G&E0M%E;2&2=<NN]###&BV=_L4H*>OW
MWW2CJ<N/D0[AF->7][$<*,WN:P"1_47C!X[4US-UQC(+&Z;*)YOI!K2#KIL(
M)F?^#2!L?FTE%:D);VNQ#G8'H_6^V;;448F+6EI:1[^1XE8@DPD5)\;329&R
MT"I\D;<1%Z.=L7-X&%AN[B#N:YK1Z)U*M0!39%87."/C>)ZGE>+-@Z=#D0_O
MT,'$7@,([R!=PH0K/2;(=QC,>+*F/",/+9J,C1_DRC*$N[;GWZ_!TX']XC*H
M8+P4BG H]C>XRBH3]'3HK+7OX$#6N9J9JSF+TC;2IR6W%<!$&(^#BFZ$SGK\
M?@1R<7T^(J>J#8G^"B_7>!:S8N^[G&LR)%,LP*2M,$(=,OI-/_.;MRC=D@]B
M"!1K,KV:VKWO8QX*7LO#T<_6W[>#QY.98;RD."/O9<UY=CPM&^;T$:FN>D5Q
ME&Q04]S%6>126>89+:<]15HJ\_'PP)G#\&W6<F\DG\BAOG9^2+X;4-$\);L!
MVK-*BI7!3+O;K(L([A^6(6:<RP0/&89K6VP^?=8\WSKF:_F^7YG^]$!9M[()
M;,6J<:1VE=;&Y0V7@BTX'51P)2*T/Y?T6?-\^18P#OGPE .F"N/ )R@:<S+Z
M;'%G)FXTRI/K@:I\J+PD;F[E#D:0L\4Q#C8?^8R?W18-#F!VH+4K&)]5>!H.
MJ 6*B-:%CT$*LK&T)7.[%U2>R./G@OY]QL7EIU!Y@USP'A.[[2M1,K9U#>#8
MCTHR#/^Z7R?L*SK9SE_'V>7@\)![UO.MPZ/XP3"Z$ 721Q9WO,)9;B]1QCA-
MC* K!X +%EVXAQB;"CN81-"?:#DO?E6>::[)@_NUGS5"'ZEL\@57?P04(SH4
M"=\O/?AQ//)^*R//PS>U!QIMQHPI7Y=QH<3X'E0XYI]SQ291PX8!@F0EHO7S
M'!Q9=]Z\^#0P*B^#F\\BQW 4#^6J$L"V/NI-''!W_TC06QZ7#6M*SB"D\ /T
M"C$%:>=C*Z\!!$>H7(PW?+,@1ZVH_'LVG%5:D?!K;^&!:->*/>4/-]!(XL[@
MN@9S' -($U**%D8.]()B?.?CVO2+3.V1JS[\]/$43HA8[>6W\I91B\LU)>N?
M^Y\0L':A1 I)/ 7EP@L?*&\?RX Q#ZPRY[Z1F&+E'1R@8MJ;MI[!H@.D;N,?
M?^;64IT0+@_N^@"N7B.S$1$?Y,5L:W;9Z&<ZYM!P4(/!8*N0(TQI*?>97/PH
M?K'EN]CZKW:5T6 GZ$+J#RB)O^AW3%+W>ZB5(M?4SKRTVLN3?D-$HI8($^L7
M@X^&3 HR/UXZP2Y/K@%K&8VI6EBCV?)WB0<"UC^M$N CC"O/6H-U?P&HONBI
M/OPU2'$E,9=8H*%SOK,]]&'K0,HR\-.DJIH)T:O_RBZG8_TFC\O09P!L$EC/
M9;.+7+T&6)IQI_UL^+:ABM9KY53F7KQL[[WE==C_GAC]&,_/^Y([I-?IG'%K
MI\__!*4(]^[K_-!"WE%9VK.V^-7N,&52;\CY2\]G;X)POD<?)P+AK=< ,N$^
ML3FGB$CF;N)\:\7W'I5UY0-+W<D4KF?-LG_.X$%RW%'1!_A,L.7W#T6S1Q;3
MG[7$*5N1#R-5 K_LS,LO0W*(BXKD?WVMTOU!<)O9O5%.-/YDM?#QYE?[ZE^C
MM#3':]F%9G5X@G0T)GR?'@[$9$F3>9X=3,LIW6LV;;X?,=:(O09DF[\ I.?1
MW.ZGW9(<8,NWV>E3-=.]E,.^F WDQPB=Z<YRU(5 7&"C@OG.T75*-%M;WE+G
M$[Z 4R,^T8=:B65MB.P*L)%FW;?83%4K,XI9GN-3K/SGFR898$1CQYTC0\-K
M@3;QR*,G38 @W5 6UD+\O=,!_U>WRH;724*&5WN)\/?4-O$R0AZ*FGFB$'W2
MC:&!-'OI<ZGOG3Q)GY .B"B7ST$^!Y4W4>LT;O(3]6>)S?TQ7TA?[*-O^9#@
M$%NP<\+<GE#KG/R-PNOS M8)^QAOWX'[H.")U=O,F8O?;81EFF408(]O.:(L
M5=_(JNWLM0U ]&G9 $BO(K8BF<&5+."S,SB(U?:6/1]]RW/T[?&M\5F61"+7
M>&>[P*FOBNYUL8N=%\M^/PGJ=-3?ESSO>2^BL82'R3[!O$Y16/[Z_5#G&I!Q
M^0I_NXC^F/MHG!0@-<@XH5E4<*G=,!8USN1]BXC 8G47#*X <.>FU3@/#"]5
M'.'JY?]S8]3-6H,](R0Y$:RBV:Y_K@%WHTY>UT^O)3H4(QK#']M9)NJ3%$6?
M?4G+ ,AL_9P/]Z?#G)9@%5#!5?,>EZQ\*Q?]ZHJJEAF'D$3K2(1,Y]S#A?NK
MQQD<#]4+'^,=U6EIB747XY-!AA Y ^:!RZ(SKVZ&Y2"^">"W:1K0O-E&N_DG
MX?M.DN/XKJ%'\\@<8KM8[N6^8%VMS-E!?PU,<8$_[\\#3]-W,+2?0W1RG6[M
M,VL*K25+46%&Y6UU0TQPJ8EM("%*OM#>_^L(J\@FA)-/@^FM-1$K4K_!%K_
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M6"?#(EPENLTA-U9TGZA'.N*7T>_"$_6IHV0)0I)6J>B94[I=L]D3E?V&G6L
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MYL'RD^LJYJ7,9CVI[GGO=(#Z^9.H$*N+^H+Q1IX9SS_3=!?, #6_O"WO7C-
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MT>@H1*&I7HH;6@6Z//9;-):CEN%OSO4,V:D0XJ(<?!669/%"T>D=(_[ ,"'
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MG.&54GF=-#C;CHH96:NZ_WU@_I:_2AB7I;.OKY<^O>1M/QJ&/Y30.KH7&V=
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M.B,2[I;O%?F.9<*^^YO%YHIE5ZJ&(S=WT52L2)SF"&^(VMQ6XP3(KX;9_^X
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M3N;);;UZ,>*SG$9$5?3#G[G/TRGYKTY;_-G3'ZUH*W=' L/P@.:'QC0F<>@
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MY3P?*CF:P*2P[U8GUB,-<TD(C@59/ME 33>;M(P)ZR!,(F6>R/1P 3XBB:F
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MZ)H\7[U?(SJKQ1H&HO/"IE:%Z.,,;:1+\I3H(6JB;NIN'\@XDSP/8 ?>N23
M!U-"[#B$V&0 6ZQ86>C!Z;K<02L16:OB,HO!034E=BL<:[?ZHNZ.J<1M"ZPF
MD !\NZ8DP/N7\'UQA?Q.B7CSZ,'FKLG)OCU:6L@*:[U]66FD.[;FD&TWODT>
M%?P@^Z9$$,Q>@@&GT8Q5,'YJXF52]IZX\, MF;@UJ")2=8  S>*;ZW>:%D@
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MG3WT3P6,3(&868,U)J9V@G?OL>I_F-]U%_=XX491OX?0]CNUMC=B<ZDH!A)
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M1);CO)-18M RB!W*-0;+DPLJZ ?QK_^R5<-&_Y]MH?P%0*B@!:MB<!#, N=
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M4DC38*^SD,8GQ=;EVRD^E2G!,R=F5 .:2O34'O'F+W=822C7 HZX $*LP3<
M?Z?\^-6D2B2J99HB-O%NV=&>!,7UV/&)V 68C:A'2W#6J8%5IN&A4FU^L80:
MI(P[06O5#<)P [B[A2DNG+<QV.SH1WA'2O,([,DPC=VCCF 61!6L9GEFUDHR
MJS U_/K@.XFNB1(=!F"4M-',!0-)]*Z-R>3<E(N73\]I7 #&451/67G[I%.N
M.J]#ZZYS&RG=S&OFH!%Y\KR;K:L'I'!'GEFH?708/3Q"UCL+ D0-]GZK1-T
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MIB#L#)E'-D3BSOP/()9,=QQ)/4C?-]5N^OB#^_US\4WH,_6%,_A+]%U?\1M
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MI8WO,)8*(U",<3OK(':RRK%&S7<FD2L_:=<7?2SJ'"?B,+OR/-%"T@Z12W@
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M$<O!/=V3@+75/,FCI>A@</E21WF+Y.T[<6#-O?)4WC'9=$!9MI=Z\*^V$^8
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M'9U =@OLWW\%2]X7>$%G(E(7Y(N&*WZ:28WY2MH0&Y>;#DW>,?EHY'#(A.J
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MLI*N<5)&(#U.P;L[X.(LZ,Q\"%V0,EDS"U [6FBYK\3OQ#YZE](++)H;KS-
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M($1[E@3H:\DD 6:]K A&01GHYR!<W;3\XQU..6!+F/<EO[(8M\!9[Q;/,1+
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M.^LT/IMVJ\<6.+'..G#WJ/W2KQ[\HSD,H'_F,/AY@>QODQC<NW6!.?5+\&+
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M72BCF2#)YLO/*I=EVA"E/8U/E-,+U^@S3Z&+$EO'CI[30&N2;\S"SA7X#!P
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M)=WPP:MB-1/BL&HU?&[\F^92N9AG]VI7S'V;S?1O5# EF3R9?9;4 LA?5R.
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MYW-O4$$9NQZVO_TV161P$>/4].;ZO"J30CN3HLX9X%KU A?M#CJDCKEQ]GB
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M5U3\,J>RJQ(8YQ?<)$J[E'QB;K73VV^G1WH6$G=2NL*%)#PIL0=OS#FNHU/
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MV@/\!,F*+?>0S*9)+WBO'XDUH0-<UWKRW],^_CK\=0K ?'/''C^#MOX0\_;
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M"DWT9V>-[34\8W*Z=VY%?0LC4^5.6:)V_%1B <PMX<=38]]J1*51UTTDJI@
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MLX79&\[0T6Z2#5M<_I+"XF_YAC-R_!3 N$ZZ,(^^PADMXLG/WRB(I.2H$)O
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M@4!6NO/.L@S9=E";!R7*G!G?:%S7S[SWG(%=LRMUYLWLFWV_0+\P*>9Q+XO
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MT9-^ZM$TJSY:KQ!S"M$%>GYZPY-&=+8LCUC4^P.0(/S^:41</!Z1JPFQ#YG
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MEQ_$Z%RS>\%)QL!#LE?!QY)N15A!U$[T?9X*S=-X3R"(>C/LL!2&50F+E"
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M%LC-\NY"7IW:H2(VW; [57\2_#2H[2AU*7F:=P7(U:)XOY)8G99!HV.0>2Q
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MZ,6W-WM!?#8@3LLRL"J,^5]+</\30/WO,&!)<6KZ'-LTJ&][5U8?3]L )P"
M=X G& ( &P9<5-V&'& L"0 (&P$0 K//A.XX<MF<!!_/B=2<0^G^.WE^99TS
MD4U>+%[ (W8;EML@?X7+^J?6CG]S_TUZT/\O_/^X\,\'!B\BO^S@T?CI=F]S
MMR4@.O>H")#0+]7$:HEIA]3V+R;%X6G[*OZA4@Z:=(DT!/P.P[14E%Q@S^]K
MD;F%L"H.78X$_\)M![9KT:;=\MLYW#;;3-$;W6<69\WE2'2N'^W97,?6Q*RI
M^R$C"(#FQ#$"8'WIWQX4)=PC/Q>\/Q]D[S(<QM"A=/2 $Q,:_7NB_R84 IUS
MA#C%7CXX".AE</[GN(.Y,0&0'LYVCB4 < J^NK002PL98!VP$I,Z/@."_06/
M%O+7ULQ&%=C^!D^%JK/Q/&'E_6<XMK\VIU^AI70L?KOLO.7<A6'6#QGVWXJO
M]1>5_G]<>A,"($R6R6>1K>RB5)GC .ZT;PA5LY$B'M$?U%TA )AJ-LV/AT]S
M7"U+>^39J'BB-;9[#H5QP[=#6MOC%0MP4*$I[JE'V?_I"WFPW\6VT?JTT6"M
MUY5GR*K(K('!JC?19*\D:.3DGFPI5744);;@ :.X)^#.>\:^_OU"/%2;24=L
M5#CQH7(^M<&+WWM2!U8[?CH>K_?&Y^HC!/3-$&T_EMX>.,K3&7OY! ?[LSFP
M/I"WBN:O;Y#TB1J J(W_ GDO_HS_4?P]ZUQWX.^5(60GVWNFRB&/2%1>0UOV
M\XPE804MJ^6N@[7Z-NU+92^Q2.N=$#UAQ<7]M&\L0)XNC/CGNV&R4OFV\(^9
MI2..*Q4)ROV]I0KOW(Z:+AP<!7CCL?'Y9EC(8G_8D3&7 6S'(S\_WT?ZXX,G
M/61L6F:M@KU,SJ#8(>GO;&3RU)L0$IR,?&AFMX^WI=RP:3D<QM2Y]EBAOR.\
M_9:_[@97&!HVR;O$%>+_$"PS4@&DWB)]W0#5]=7]BF0&WOMTAUDQ3"3!I:]^
MO-[C[0]IS^S?M672PA%Y;4VV\F'<1989_PH/*T,MW'VH&AB21EJ*_;XP/4]E
M_WJF)7?NRX%5^7V.4Q/)]E7']UD5GM\V_'B["0#;^3OV<\18J2*'&OZ.BM$"
M?/]*#[LBFUBK\N3- FDAE-'BLI1NV.>Q,P8]N]?QQ]*:P?Z7N#8+TX)4=F4S
MO;F3I/O9M?=73E.J^T9-]I$5GLFUWBP.E\ V@I? LEBI']LUHQTUHS#YP74U
M2P4V_M9?5==_2W.CS'Y$Y8Z%85+L.]6W_9Z%:Z0XE3RD_5H1\^M?9LMA_5H>
M>:(Y%"!;NW#2:$J\\'U4(]3SERG$[OJ+W%>@&?RV_XRC OX4I@E+0E@BPOWY
ML5D$ )DYCF,*?IP[X=_##YW,#";"[:QW:UV,XO(WU5(KIJ&Y>FD/=$IN'D@5
MC][73C%]:*5BYHMQ6;+ ^F8:7 1=A^$4"DQR@N)R.WF0:VJM @8T-P=>!K%+
M"C14S/MT#X"1#(WLZ?8832(4M@1#L[QT\SBN^<Q$L>5)E&W.E[M-!T7-9997
M1>[)^+^Y>U\-C&'A'-\YP?#J8F$+M;/Z.E%#9(L(A\>5,34"@[2:Z:DSZ^MR
MFVE ;(EOQG8,2*FY1A/WT.QQ[&BN[ZMS]HHGWVGZ[\OH<RRPT_4I]4AP[NH?
M\T4+MK!8/.&/M-90TL2>?(:Z(,<RL9S00IPC-J=@BZ\WK\DC00_V^3:39^P+
MXF+V6TKC7*NLN:[7CDY"\4*@#S/FL[:L+!C6M/QZE"B#\X.:R8A=2H'GD!HB
M]S22#Q(?<7Y9N!=H5&59IHE?YI1CON($3?/RGM*#]56+=J4JV4^4CH*S/%>*
MYE+B2=-FW)"Y!(!9'<6Q"Z4=AGBI/?'J@WGEBM%/TX;-$'>&VS,"JQ$L^:D9
MS"1+8LR!5P,\X&F<V++"Z=X\$*1%6B#F[:6!^S'A$-MQ$O?.N^!;Z"=.'=1^
M:N*-QR8W'2P7X&UMV)RLN8>S*37Z(8??Y7OS[?9?=+''"<B;["MJ(4<U67AS
M,<!0T;WK6/L3LQ%SZV0;VQ,:4MT;6]>\BI;D;23IG;,_-L&X+Y)EY7YUNBRE
MTV]5NF_F+^4W>=I9NIZG27IWWO,[G?UDO4O43!S!"!C"1F*&EIM/DOI"%V>O
MK;=^:(#:'$<JK@ZTV5DUJ*K6^)!M%SM?=Z5WA=6N%N4OP,)A8#_TWDL,RZ%X
ML<F<#]Y*K^3KT]#OBL*MAV;X"M^ETJ]8\V6V>+<+J"]\ +_8S[X]/E8-F73!
M*VL& U'K!,!+C@PJP[_R5/P_OHB2-1>?FL[:'6J7$I&0BI:_)I;1&BP\"I?:
MV4,MU5:DOE2]T?*^A@#P@&Z;/P:='U,,B1EW"L@^RI</I$UUM&'U4,5ORD*1
MGGX6"IZOVG1;9(:\'N<KTC5P@-?1\&,[C$1@>;<?NQFFQ4&>)82;\=GTK8]*
MZ%"&< !DDL(L?G'^H_\M]&B/]YT:47ZWNS,)[ZV 40X#SP(W'MGG1L#$Y\5@
M@[81_KG/MC0D'*J[L<.-Q_*/AT@*-DJZR>9=>-"6+EHHE!GIVA8!0 E^4J 9
M(WVQ^M:K_T@2]LO-0/X^VCE]R4$WZ/@^+]?,UXL%AT61@ICE[!*0?K>AIWP9
M7Z_\[U3R[:3D#3TT!.H(UK5DB'K*LB;OZ_.8WI]NQ(7M)88)]J5F+]B3JM)6
M'\8+\>6AVG+X-5R!8#8V^E(UD%67>-XK:P]4S&]<^_8+9@/-'*G->2\$DI4!
M8Z7SD&6#:>%KOOK!./^+Z#JB<Y7M-.91L(6=ZXD1PS2%D8;E 3N'^*7_9B.%
MVRXG +XDMT,.>7+Q))=_M5VZ"V02EQ[3AJXFCN)R00^#F9^_3-R_-*5$-J2C
M-KC!\\$9X_8$M!*- ,UC.J4,%MZV2_.]-RG1B"@_:@AG"T=Q'7@D1%_.6Z$H
MTRB ;2B21UGOF$=H9-SBGY&S\#0N# 3 P.]T[-U+;Y%.Z3A><#41?Z5EJPQO
M>[&Q[L^.[S&[@4U%FZMC+?*F9UH6ZP5D# K R9_7FOF''96\?VGK;SA48MW1
ME_,3:[Q@>K?9Z(;BO.*04UOYK;@4 14N^96D[O^N?UG_WCV+(T,"0-3_\#WB
M#M#!)1!"LE>A+MC&REM:-N;HY#\HGU@Q9_EUYC.1\FFPAA_OP3F>S!2] =I>
M1D;X/^RUJI16C&'>=""GFGWN_7YED>D'[VWE7!;);7,#L-5%#%@$,]TV!,IJ
M,[^9YN>E'/M(H-!3\UX/K86W4QQ6Z>5A?Y \92U68E%25FR1#3"]::10NQ=U
MM2;\(73.6J9:%&*GC3?TZX'H)!XH[<DIM>+IAG#O,K88!<HL;O[(F1?H1/T$
MY.=M3V/.QCMK8#@:^,+<C]^J;J3':^EVH@T.D\9;:J_8U(HYH&KIB7,-T?_;
M*GE[5D  ) $_/, ^1XLTS5_!/9ZB^NP!.O0EA0B_9N@I:YBMS8[+3_'HUQA=
MF6?YLW<!08&PI6+47.K],/^J=%S@@<$NU[#S%T7M+$!*'@-Q+MWV/#H.U(\/
MU"$ &JLNO?O?P$5.3/H%>1X!\-'MTOW4^5M7(0M\\OG ->@<5!IZS(I]?>ES
MF@&#M&TU\&Q1"W-9%SGX 8$0\N%0D=2>C$<LXA@39',ZENMNTUZ@/ =\G'V(
M"\."2ANV%9O$#S+S(3P_ 6ZS5^HL5_C:X#CF1"[MN"X0+0#$\T"Q*G4V!,"S
MWY %$PA.EVU*!Y%@CJ6@^MU_FG62%8.U.7^()5ZD:A.D 1$ +8R."8R[59',
M@P6MQLT%'?M\6LOD+,O:?E)MK$07<6!2]/RR1&@#IVWEZ^=++'X_?2,/$H+$
M$]0/:#72ZV33U=Q,O?^5UNOF\9W9(I9 =N8/U/W;)DR@OXU8!@$ _YO:JK.V
MYSAJ1O1X422.A6X]GSQ<NJ_]3K/0R"[(Q*]Q!29%[C8<>GW5)C<Z['O\?V*:
MX_^9OK+F/["]& D&?N]>"AT?5*#[_C?^F-GJ-LXA]R0_6B*V!-O]_KP\[IRN
M *@#)$ZQ94MI65M+[:D"[2NA9&,XK>-Q[N 3RBD[5SO;'UM7J%4J4Q4 CQ_M
MC26ZF+_TI"T@4J!]_5]*6 "\ W*YM!Z4V](O-<:"M<L31HON)IAN=*?X.O\A
M0UB#_ M$U)/8R<RM=,8&TO!\TYMG[6<48[7ARE4!.3TQ2AS1=%8R+TM")QL9
M=HA6Q'S+IA+=4NA6CMB=?0-D]GWZ67X9V]U-?WP;[O*\'R;5/YPFMT&,/$1,
M?6Z^F^#Z]-=%F2:&EQ?)%=R;76K*WYQ:Z)S!?6/E8D"9JXJ%-P&M__$HE6J1
MM$WPMD-"[[6RI62FZ>/AD3M1'(]5'OS2J WOYF*"TJ\PAYWQ-;]_AKZ^'>M[
MB/S);<NH\&8%C-P]8O8@ )C]:8E6(?]YRGJA<ZF.$IP&MKFG*U/=^$-J"_VY
MPCRD5;_AKX?/[/+^NH>/M%=:/[00>#DS(^:$6'E4OQV:TYGX5;)8(1L>.M9>
MGZ2EN>O1R_IA]=:RPQVZ+(P%IA]EMY"J2/&(OR#JNU290^#^2A6<>L;I>]P>
MCT@<W)7TJA5QFY\L_\MBJ45]^U]=@6=$>%#.N2!E8N?*C8\1[@%*KL*VQ.NI
M#@9PK,JYVA:>!\,X8XSU-AF*I1?C=LJ.I<_6C?!Y_]B$E !0A'RUPG5ON?6!
M7V&#2:'R?&#NFD$4HQ.)IQO)SXK'U!2Y!Q8BHMRM(CS1M"E^"Q,=#+#?V@QW
MN5S7#]=A:MYR"$;[J=+B-ZYN =.E.K>$KRD52^TJ $""[;4LJDV(.W6\&!X6
MZ1.C08]IP\(*7E^#^!5XY M$ [T,].RXGTGI:[5%+7OEY6J#Y*=J3UJ+LUCT
MJ!U[FZ0B/^M#]V63));OX;B[]*/NAH$J4MEU9OVL_\B8K1=0&NWJS>J&9 $R
MDP-.U_]WLR7V7F36/7VW;$X!$FD5#W<KPEZ14]FMX"P-S;*)M-IW2YCF=!WG
M>:S[7E_N-5 EF6TN/V]"BN2IY(ZP4)2K$&J:>;77!MD-ATC:7%V637%/RV"M
M1]RC"K]<N 5I01*MK#0ET,8&ED#'.QOUR!#'PQ\.I-^H RKUWIE4S]'GW5LD
M-8O?9JLL"+TTPRTOM3<"/:VB]USK*'PCCL3VS%2_-I$;G[=$G2+]9?P>H6ZN
M/:_P-].%6GZ2]B/+N&F\],NG@1Y;KRUNC>^H(P=T.DXW/"8=J[-I3*-*1J:7
M4A9%6O62C(ZFH)S#MF0[:3"K4)(08KY4%6;&,VGEJ\E-NJM>5WP6CCI^%L(3
MD-8 ]JM6^]?<(ERETSX%R#(M(I&HVRWRUX? <K )^P_ ,-%MY8+$%^KB=@)%
M+UME8\A)I.8"++WF/BP7FF"W%PM?+^4V&3\JY+.&Z@06>NH/Q5!TJ=ZG,5XM
MGKRBM,Q4XRJM7UE8-7'ZB@41PN9(O./VDCT&VC/?TOGZ8]PX5!.\%B#_?@C/
M#F9,FZ+? ]_/V<1SQ+!*U<G.L>C5WN5V'1!@;WH_[ZER->H2J ;[<E[S<TN-
MPV;2VPTO$>.<5B_Y%Z[7ZYJJ\A^XTCM+ 9;E>AWI-93-B%C>:_I_.VR3Z7;*
M9H'%I7\[2U-:?4(S^#_,]OK/L>Q7H@-A'!?&'"=^#X,\_D-3;XZ'U&$1&VRK
MD/QYQ!X.X7VXUA _6ZTHG71 A34SHL()N*&G=SX$'Z_C<#Y:%XGR2NGC_GNU
M^/ZYX[5Z(#,TQ]N21S]O)Q4T-1AFE@I<[%.3M6"%V.!:+QNK:/;\#Y0W_]5U
M?\/.CINXN>$*&#A>=Q=#L125ES_AE]1B-B9[(?TNGN.VTMJ,_ XO31:-X!QQ
MTLE#;5+9<>(%MK S_58@#2A?:?A-?=A>2R+$HC861:VM/[?Y=:HUYEOZ+[.L
M*-#>]+8I?5Z?I]3OC4,<7>*"A8+"L\$)/]JO%7W._S4?]+Y+9"RO?"S9=+H,
MPUYD_#9+OO2!0L6(0*&S0.&0'>HCM?)L642*/QTR/ ,C:BI9WU?'>=_"H3W?
MF)5]<3YX"AD"_<Y!X?*_V/L.J*BV+.U"4!1$5')&07*0*!(%)(F @(!DD0R2
M)$M!(4B0*" B69+D)#E+1G(.1:XB2"BH(A0%553]\/J]_KM[IN=_KZ?[S9M_
M9MUU5FT6]^Q[[SE[G_WM?<)VBF(TKV0:$]ED9$#9YMB\9'/[V]C2V_/8TMCL
M>6RIY+&TH1()796'QXL*@Y]"2YB (AH_[;&H]'CEI] P7XJM8E%)OQJZ0-5!
M3EO.9^:>CFMU&N_ OH,M\/5. ^.WO"X@GVQC60*65;Y=,JZ(E&O9?NX309WF
M7ND&X6U8NHG#PB%1537I2=4-EK>7XE[:& >L^*L0N<1R+;MS5-6E'$;EQOI]
M;R$%RL*[E^>QB1"U^Y7HXT-OOILW>%YA@CG>W]0,W8Q<_,(]=[R1M-1,BC$8
M;1;P<H0^&UENKJFJ:;!G4Y.]P<J3%_7LI15U1V"+>:=G5367:[SWH^K8VP$1
MM@K:T[%A'"6NSK\>O#P"1#L[=37V(2/AP:70H4 P-B3#@ ZFM?Y][_-"S,Z,
MY"NFQ!Z&ZT=;80>PVNZJ5^DW&MUS,7?AQKOO1#@<[Y2-89H0^K<K0X#AU&T5
M')O06JA(":-VD(UZ>D=:L$X6C?8'R_)!OT&3ZQ,80KC/@^'#67GS D/OA9=T
MHVH-Z[&R^[=8LJ).74V2:_F7C4K;TQG. !09ALH2HB9*%UHD0BIDH9=7R#S#
MHOBJH%\\8\>KT]W'-?VUP,V4S4%W:;9#(H$(VZZ[9U_]R. ?R=@>?_MC3#TM
MX#@+*8%2@PP%.4#*(;[,&RT.Z+LU.(!RV!.TY/RBRRP3T/VH-,>^#TN"<1OV
M$^4K$%;EE1O>2#/! 6"7LTP/DY&P:5AZK6N*QY9)EG'MQF1^:$KYC<I!(\&W
MYWW2BR ,,4=0!A78ZI'UO#<U^&YG(LTHXL;1G[V^UEHJ. :R:E!CTJCY.H:Q
MA?)*C\[>IN9UCZ&]'5?K3V"Z@ ,P-NI]U312TMR;VO99EH'Q7ELWH5W+I:YI
M\4I0"3A6>]OC &W_?MFHPN^P)1Q%-EKCKNR$O0!\@J *<W S/-5N-=CS+=2F
MO%$X8.^.[A(4_\BCS<W>[\&^6X\)E)$MDM ?G#BNLV(8!&P<7$@JZRVX=#A?
M<W796>60,?74!K];1.,,H.E1-FL$-\] 8"_,5ENS;9%:5*2K"7T[3^2@#$+/
M6KZ^!!.AE#2?B:!$0&1VKE+(;#PSM\2VR-FVRF3/F\\N-,S[LP?X'K3-/@7F
MQ#@7S8B]-)=N*7:69D:1+4>".FGU0IM[W$ZM->I5JVK+G3@MW5^M#T0 H^O*
M/W[SDSX%>/FN=T9?!CY"O6'+@!K[;*>1CSB2(G4#>'985?="PK\CF/IKE_72
M:IGQF1/F)<D0R:T+]\>358=%JIJ:E*7'S>UM,T^'CKH.B%'6B^"&#+P?<C Z
MCR#JV>C]T921EKZRO$/>N+,O[9$6 5K#/1*6SYQKE.Z6KLWAAG!^EJI"9>)1
MHL-L7SL7Q?%7B2D9-!]&"]Z+(FQ?(,6.6"&(3K/I'M;$MZQFC_K"&_R6YJ<R
M&%"EOO:^F_CN-$Q>>Z2F^^#H.]5E%Y4&ZM2OM$JF8;.Q]$\(#OZ#H?&?4>[9
M9MGF:C[Z]L AOCX3BT_NFPJJ;7F?_R.WU/GV'@XP;2!9BJ3,R8P$A/?B &8V
M>RW3!A_#>/S_)7^=^<9FM@0:*8X2?HTX %=2F*Y>K91.0!C'E]\XR_M3P?^W
M9T"Y_QO_J]*46"BADZPT,XQ;Z,$_+0B7M:\^^O@E:2X-%A1Y#\:]'WSQ48"Z
MR["?C#QJF&!<6W*DP7%R*P(:9E:O<.7]C+E_[3H.,)%VRG'!CHM?8@W??'\8
MRK3>LGJ0';5LP>3^9KOHKO)A-VK_ 9FVI\]-@90PFC^M/H*F5Y%&5K6$-%\:
M<Y<B?!*GWABG:>AZ6XD\A9I=\MV-$!T# /*GQ,:K"4-]!_<Q]<,U1!T1=Z$L
M45D,O@V'W?)G>,C(J6,W+$FO+?+:E,XD;ZEU=6V=H8*AL.+S588N>4'$6\>W
M4P8UEV?+:X-8R2JC$H>F<NT '\.B!^GD+UH14H.%4L;\1EN8GSPK(S!G((4>
MR@0!U!04V4@J\Q;H"*XKR2\$?1)T(IH^,F+J.<#8X$D/-[_X0N?*MY.>.U6Z
M8@L\X"JZ)D_2#D@)0^  8+K.!'&9$+?H:S;UX1MIK C1#(J<#YM[#U]H<E'Y
M]M01UT'ENY0_+-$>?',XD.(%;C0/V%I?L?9)K('I$/*,*KOZ$VH_H'5PSG/^
M%JTNMKL(WU5*:WK3K3ULGFMTL&7"E(,Q0"1T%!;6-3/8TDJ^OEA9BF]/>[#O
M[<G3K']!S/PX:ZZT\28I@_,K[@JXQCN,T4F%S0(G_+ JLJU]7:%P0XA&&#WG
MT%O0S$AY"H'/#':WBM$ #D@6MY/4UAT][CV&1O<5 P_A+1#/SI9P Y*NTFSY
MI5E[&[ZDD8^'CO%];Y58+_((O"/TZVHB_8[*QP$NMRS 01A6T$LL;&JZN6_U
ML'MQ7W)PIDMB/0QP('7&UBDEQ=)_2%U)9'\A!R$#64A \*O )<M0(E4.CV9*
M,A(I?WPK('@;S+I#>*0VHJ&)>CWT9AE19]\.Y=^^!)'YB@.\H(&3#JU1[?OE
M1_B@GQ :-IS&/=YO-MIV\DNK/2Q-:Z;&:*,J$(;M1[3-<52!#L6?&^Q%#5<;
M(OLN*K("#"/$=M,:]:SA8Y"JH_## >TV:>91O?8%OE'8J&&X30Y9ETZ\C%=$
M=A :D9HH*=8N2@T@U41K(779:[O54WW%F/<'N>P0QO@=9%[FR. IH$">Z=R
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MZG0R$II7.)FJD[/2]H&!0S'9TZ)22VN2+>.W6C0UIWJ_#YOR#]*ZNT%PC2H
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MW8=RY/0$WYF3#DPO89Z&0"BK.(8K9S?<J&$&LJ5&LJORSAW^ 10O)0X29#@
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MJ-V9HTYFTN13.KM8/*>#/ V*D:!<HOAEHG3BV+H@[T?".1P['DR7L<S183@
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M$AEHE_^=GY6< _!')? S1D'0 3N8UI]^?M5DHB(FG[%JWSVZ32;<P*38/=_
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M-G['P>\3(PU:&@72'FUF!>JGH=4:OP;OZ^WSLM95Q]YR;O;]/I?LW]->>GK
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M?+UD8CY?_&>+-OZJVBBHW0-4<+KFMWX?!WBO='JX.WD^^S4DLZSR P> 5^,
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M@KBY[7PY1++&$6UD+CI2L=DTU!AY;H.SP:#:<0>9.3N1/8S<;EG#7]33+$V
M4/D&G74_IVCZC@C=>5U@R_6&[7.!4ZG$ 5SRSBO;KZ*"%LW.&U+MG/-Y95/^
M#C[T^9"O=<[YO#+ML=^MH],_OT/J:IEQUST=+()\&TWP$HV]\,N'^?_9*/]P
M^VGR]M?/X6H](4S#J \#70OXDG& RU85YEG'+S2JZ8*T3"5$M_NUW-K7<S51
M7J5MZ:289\TH4/:\EU-'O6YJED/\<DVB3C3_+8?N[TY0R>L=YBUV)\EY3)'
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M*7!IQ^;,SZ?Y#KP'Q=SM"W<JHZWJ; O:G2YEW':,%39C_>3P+0ORK/6XYGG
M)3PSM=.L;=Y#)UK@W;*ZD/Z*AG'68*_V>,&'>X8[1M'UOIT SS-_@J'QHGL1
M#F"5&PI[VR(ZLZ*GZC';();X06G"6=I1!6 Q95U@I_N:(:*F/GZ^.=7V^B65
M7;9GFGC/LUP% ,!^0I&U]$KU= >F5F-C\ZI@:AYL'_+9Q/50T<&PM&=@ A^=
M4#J7J)0HKI4%GI$#TC=)HEF0;^X^W)&B'7/@_G?WZV-B!(EDKOGIQL5*;S'Z
MO\>33D8_ $I.\,5>EE1S#,)N)UP?( "Y)W^,(2>-5UEG4'A]!2Q9FIRH3'2?
MX;7K:/,KU'?(T$VOA&63#,9\.);AVG=L__/&M!/N=[R!@L]#/8*-9QL;.;2$
M>JA?OG8,+-RBY6\#7>[[_&.]HZ8T1[_[3GF3H2YS:^SQ*[^7PX2?E=YE[T$9
M+=+GM9/V^,,7R!"*5?:0Y(U&^=/4Y61>::40M;&OL0L.P0\>CIJO&ATJS!6)
M^WN7M+2E,2-TF_)]TSND2>+:/YKN'Y]6,8R<J0B@D(F,51N^V/GUTD69KR5,
M'HH"*SVNZ68/Z!>W-SCCEDI#C.,^HI4^?9&;Z=C#VV=\K9<#HU@SK?@D \^6
M%)\^!HUZ]W1C@"J+!R=36?/&L],S YZNPKK(X8R8U22%AT275.;4Q>@//U\C
MU4&=PM$*C;'@]8[W"=$T]EYLJ6?^H^WU*(G][M<[PO/:&I-% PNIODX@.V+.
MI$E9KA5W=%TI$WRQ@U>I@Y$A5N821L@6<\>%-8;99]:>_.75GH?W+;A3(MMO
MA3I^$BM%L^;%+2_D-IF#DU+"RHN\C)L?TSLK(<@>,!2ETV-(K\6*<(JT\$V4
MT$X0@_M+=@I*IN62JX/<)<JC$[V/$Z2H@H"VGU'@SI(#-75B5'P\-9L\-Z4E
MWAM\)I?Z$[U(OQX#AK?2Y!,B%I6R^;QS'PN=57CI96]+Z$TGS"FAN>X#7N
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MR#1A/IX3[6*C>R_J29:CH7E!"K"]IC2C.Q9S8X171"-\D=Q=]5/6Q[TI38L
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MP+,;CO<\&JB5N%>@]'7"@5\<XL9T%?9@+@5/UWZP9=RBKC98O.SOS;Y$^(V
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M*7I/V& ^2ZZ@>Z^)+-(?8#_[?J?@(NK<MN_>_HTZQS/[/&D_SF3E)HV."?\
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MXF-##;+A5D*R-7HCEJ6]8-PG=;$IE2.^D+\X;##^XVRTKRLWX!I5]^)C7AT
MI]#2J'LQ9FZD4^D4/@*M2T,!.)B-!TB/7.I;%],>*G@>9G/6)LQ*X*+H9]$9
M=D/]2G>WH:6'Z/O]'OEC&\Z#N))NCF@'.0$*(($"2,O)-\'OS;QS@7"D7DYL
M33U;617MH#>I]L7D[6WF]TZ"KZCM3PL0.B4^/8&E#6MW5#VA:N-GWUR,)4)1
M&\#F1UF6 3(C!=LF3BR!MX?NS!:^NW1?=.%".=5^\CG!-RX&Q*%EOE/X:A28
MU2=I1!N!]\VU&RY=!XX97[R5\W+R!1?[ZL"JV>/+0SG'Y<S(VN<>N;+9&[B\
M\ H<4'Q1K2A.UN1KH  >QH H +4I8]/_,Y%P#YA.,>=OO]CL48S67;+5,)D!
M5L;4S$;Z3=9.]K;_*55J9<1I['^7Z_)+:&.YFOJR#GH/?ID"L$YK6V X\N=J
M:4O^E%^MFA:A *"'>R7F:N'@][O#NKL<?[HXQU3(@VOGE_#^L@!ZO6),<^ZQ
M%"-L?MT9/45X3KRN.W;ER#CBL/I45&H@LZ&HZLXEV=U\ARRR'^WA,HB0RV $
MY 0VG>FP_0Y-T+NCLVNAZVMB)BL%GQS9!COMRZT-0=-3&A0 </@W)6;J8$*D
MK"+!FU5,X,W(.3+3-=JV98WY-%,.R'$R0ZP![#=5YSYF3LKN2^VO$RSW_F$3
MS[]S@2UV>E1P&!1^,\WWT69#1493F2\=&4:U[[J>1P$$&D*CK03,X5%63/V/
MBH?+(9;,.J7NCI^1MN]_*&\VQB1RWO_$D\J?2!<]#/]FUS#+C--M =)R8IZ=
M[<:#34?KE@8XGYRF9N_A/'7"G30[<K&FZ!@1-"@)Y/:I;!FKGRS D//<<B "
MUT+?RM_]9F#TD(/>\.+$";7'/!^3 )O.44H*"6@C[$9D/E$0U77#L&^#GW7"
MP>C2I. +M;'>NFQSN8>W+!Q):W6,UU=!''4NJ4"\:=Y*0F7)/>?SUTT4C"%\
M"^^9IEHKY<8ROBN^2_TXHHXZ9(.-J(U3*TGT'5R-ODY]3F\4>@N-3Q,T5@JV
M&/U&$L:(O#BES%DXM=W-^:DX,7B:E<)>K>FZ]J#U)39="?$XJBE^<C<WO/K6
M.3Y>''MY>!-$EWHEB I7OY-=8;?PVAZ >;,G7V830?@J_4 10+MQ66J0W)5Z
M,=D(*[R<6""S^^6-O$D/_>;9JKDP(Y]7]*'*3Z@Y2>V+\[([L"FH_X[4HI]X
M<XQN<\/9<MTSICT."O(YXY@$)(<=UY6O,0N^_J8"\F\0.!X="F!R_YN<[E^E
MT-OC_5RW^+<<7:7K>+5-,"TL-'U4_O*L?P2OT;7TG F=:TIE5"@HE06T"8FO
MNOCVE !YS+)K?OTI!7"WFJ%6:;SA@M5\F7$,N<O+?<H'8HZSW/GHE8@X/[A8
MY2PZ5'EI[<K,H02B,;)B7'%W5_N__*[+?S-[8E,0OPIM!,@.1FWGU\EL98<;
M;0\0R:3Y7+7E(@.@<Z<'7^$DC<J[5B51 .7#L*RVV4!A(\CE 0-+->$G'^?/
M?;:;BWND5WU>5H0]N'N8VLE<L:W5.>QF>%1&GR>,<<4^ Y^HYGEV0+,JUL1%
M1?T"X*/;Q,-"WA&@-.0-/@(;=Q1G+LF)&I*R/#&U0E=N]TS$R&1M]TR7P+IF
MHKUI9&[1I*I1H^!W  ?4 7,_$#3[S.MU5RGF(+0^CV<_1E*]\UW.,G*.:7MW
MH72G"]3JE]A,@)T>#Q#D"HIUW%7F6NW%1!A^%9AC:#7?B\Z8'T^PMH+CJ+])
M@\X$"+NG6RSTWGW^.0GT(>W=]?.%_HZ"T$EYR-L!HB+N*1*XMHNC#5]_.'&1
M/%859HO8_#8F.$HNZJ3K<W\1A/,#S->!9R>MFZ>_QJPG%XD4KQ@=I\X8%[B6
M@[",Y&%];5"D H]++5^9IO=F"B.ST[-WV"= KR"G+D0'3-B4]-IFSVVU/B7>
MP?)EH9E"O96X87IA@??OGE=Q=PF[_"3>TDKCE64K';L"_7-+8,BV;QUHUI+I
M7I7=E#^WK..<7<154V9EX=>,$EG9;%1;P."-=<GI46_DC5NH*PUE] P7LX\K
M--IS"ZDTJCV3L3@PKB4*8=<_9!!%>]<^5U2>'4M(H=][\_U:HK:( Z<F74!K
M)<"->^#YYC"PF2GDA@]T%E$^Z\S2#O&H21G,QSQ>^W'1KL\080-.,:7B+9E*
MPVX\)POY2#1*BHJWC(FNQ[!B*A"#!?.06I/(JZ]?G3(2#JGLM$7'TG;<XFPH
M(\<QAF"S- 8\EB)-QU>8;[W^P%G4X7@Q_PDKO';:R]T,="@Y*,&Q%?)WGX[N
MDFY/#<4&()/X%S0-MM%NM ?^[F;@LTHL*XB;>/<TO-> W@O_>NF[O(5%DW'=
M5UCY:]F-Y",>Q0H7X)_/< -?*;%7]Q6ZVPG<ZM,&=O;^X'QMK%CQMF$]I8QJ
M@6L!CJK7FB6UA3HB6&) ZM*$\S&>2UXMN:,L;B=0!03D?3=,Q_5"8Q3B>3[>
M>]<1VYU<I"J(R+3-YUPXOL=\3D8DXG4+3^&4\J7Z&[K8O=9D3FCI> L?L#K$
M)8K@@#J72NB@MDNT/6BX)J[:?8K0NJ(;=2AO2L%>@9D\+!G'[U<DWB^ICO4M
M=!ILYND^'\^GE\L-N?&=<2K8-G60J@1=1&_/!6IB8EG:];.I\[-!Q+M85[C6
M&[XX2_/D"6]'@ZN(%K%-M,LW%%$>""&<+Y^I^Y#YMJ_ 2%T^Z637XKO'W)4N
MUON&-<^MT&@&/N<S/L86 Z)CDJD'W1"?L?NWPSP>TCUDC2Y>8G!#T.&MG@4Q
MF?N(MS Q-',ZB1;R]45=,$[28!XL?E#M+:1WDPN0. L*]^@2FG4*MV$OKZH8
M+%NRK8M5?EEC;ZW7I&>^(%I%_7KJ(U-"]48LXIA, [W(])WG%ZJQG:Z3IB*.
M").'8=)6 B(\QX^#!=^GA$03!U-YL:"6C1,FET(S\<FJ]7V? RM&QN+K"KPA
MS*KWF:FNMKIX[4<370]%\/YM$D,:=B@U/H<U5S,!8N\R\N:$[W?MZ$5?A:\[
MO#=N\4GA;K1VX+2:@TYAN^-]G=E'(C-B4:A)@=A'-*<S?U8_/7=Y68P-(SHO
MVW0-0(BICZG/S/?JNQ7ES$ASK>A'2?8]&DX,6)[<%<1AKV"=/YW\?4<>R*!\
M*3P3+/A5XBZ7+^]"1)@RO\BXV[3(G-/8+9#ZOWLQUW]U@6IA2AB+S,KV>>$[
M6W[IE/2C/?$GA@JV(%_-[55,UU-H$U,^M.>0M4_/40"HW#OX-5R SZ'&X2/Y
M#'9PDKNTDJQPI';(@V9 _M,%?DC:/?5E,OL<RNTDTL%3)K'.WR> G/$PC2%]
M/56= CBI5G*HE1R2+S2. HA,)Y^)L28'<I I "$*@-VJ^CFI[P :R@F<!&;A
MC85V+W'OQ\(P1/7-O_-5?5)$&/DA>;H%>F4.BGT) 6XM->SM@_"YH-F3PZ#%
M/NC&)A1GN/K^3XW_]";PYWOG!:;_0?8_R/Y#9#LAS,2L-] FUOQ9V,^2LB<+
M!L#@]H5$\IG /T-F1@$P!%TN:F$ZZ[-XE]Q)8-IE3)_C3@<E[?$'1/1F,V^Q
M>O30!/%%_0DPY$'X<G^B2"CCA3PIS\JTO[E#-D>#>$0!.*- [S9!^-M2L/UM
M,($()QH"_QS"3B?3.FR >/D;>8D$:DK<%>/>#R% #T<1:G';\>E;H?GTIRHP
MO9^@@AMV>4GD$_5!ZA.Q]A(@3*;^]\V]&?1 ?8#VG70YP5Y"KIM;UKGZGYC/
MR6_F-QK;LOSD;2'L.\#9X4H/,.V*7]:&:DG8 -E?NXG\ 90)N1UZ3QT;WVI6
M+W)S,7<M6@27DF\\" UULD,P#>[H3D6Y,V01=Q-#21)0S8UMT/&?=@V(T=WD
MGOU5<=T?E?J6P$[3TPV?" WQ@6) 05>R4E8[JG3[4.3>OE;VUXWU;FHLG/I3
MXZ.HGZ*<3+44=@?7DLVAO,$6^<'XYM_UKX*_5VW+9^*QV_1);JPAPR B^A-3
MIA,F+0,L.8B[']@C ,3J1W'1!"-RGPE9#$>-MVTR&R[L5?<3$<FLB1TB&Y#&
M.)S4Y9H^&KW[^ Z%KF:I%*IS@996-FNKS!J'%)7%F&TVK2R@[[^=-6LR>G-L
M7__2J:MR/_BFXE>257T7&X&1T]A*HI#[T14>A\KS/L=7\_*BL:#>T K^.=Y(
MUW!@+*1W-W*:X^K;PDGGJ)R4XR?[([.*?^?H[-^=_M'[5_ZN@DL#5QU[((YV
M-JC@DWW_[\D5Z$XB1PV[-?/X(OV-/<N,>7'FR#?$FWCO? CRV[0 -ZCOK#L+
M<?V,&VW>Z6G&12Y<O'A4L@I77W3.CQL_B[#6WP["FQO"_+S#RSG"4)MMW5L"
MI2*XBGU3Y$2V=3/C)V/W,F-^;&5;#$[XFY_WJR[8S_2:Z2@-(7O8]WE&\&F_
M'(RE5Y_:A6[#^:L-'-)I:M=C9)'<OXS[)MS_][P$?WM!V_E3:EMX4%?#"4_X
M2]J6+)/Z 2<*H$RIY_!S:MNY"<W;\K:]W##-><!UI#HFSNBV">%[2/44  M\
MS7FM1]CV0!T.OQ$T/0M>YR&I^@WW6>*7AW.L=)EQ/%4V)_NB[==^+8GOHLF_
MAD3Q3Q?8V=N(/H.UJJJN% "?))78?S[+FM]^S8)$X:\2[W'7T]1\U-]C=HS(
MCU_G:>S-/2)CCCA$_KR.Q-!G4L;!]513,I8(P_?-PS>8OE, ,:##?S/7<BB
MJTSV2FNV"= Z$#]9TM>6T+P)0NL>&:@(5Z$_0L9T:\_]>H7O3R &=B.E(Q7C
M0?/*&*')Z,V>O? Y*!(F0@'X!*D3[8\.1/#]@&]^VHU;1_X.3OUWZ$?&,YB-
M[KZ>O\:>M4(I:78?B$OO $T!WU  7$%'+O6O6<1LQ0Q"R;_5V_31!V0#OO[
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M#N9GUN$W3_;_[D[]R?QG9%K&L\U*CO"4'Y>V#ICL1_='__P48 WY\X\BHW$
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M)^D#IH4*]S60P'OQNP=3%%MH3QVQ52"5%18/OMOPO=J96S#9R%\Y,#)5QXD
MR.GO65:2K^2\(^>,9=YO?FK3PY_'/F(6=Y[B#2Q"D2XCWV;LU 3U:M:2>91Y
MA+(N'/4QGKZ/&>WUK8>J7N=*A;M%"$* [JX\3K(-E&<JDPCZ3KDO)=5AP'@_
M*<TI^=H2BG7Q^!SQ=#(WW[\DI9->V-ERX=]M9^76%7*R!?&.Y'?=X,G=Z<2T
MW69=9X_&I>>0ZF!L#'D&TJ.Q9;7VI-?$\TPK&?QZB@1^ CMXA^4X;_86*"C-
M=3YO\?))T^UBJ;4#BO.=T!Z6KCCM&+G/5G/I?-CA>MI)2O0X*5(J^,*1.](&
M_F9O]Z]#UW]3 L:H-_>P";EJ2QA[\=#OB9C_1U!L0JR?M.@A9!54_EW:S7[N
MR 7;W^.48LFPP+6K!OM>IX;2E";' 0*#),'GL3@ _(,9%M3RC0^#.*Q<MS_$
M;@#=,+;U&@H:/B2>5/.:#XP'8H77P\*/?(8EI:B?;S2V-JG(LO!X;+Q0ER4'
M_%;2$%D0K'I&. BJF"&$U?8LDRO2Z7__P5+A1AL^&*6J@_*$M227*G?@ #>:
MI);W# PGJL)9JELG2Z5G\E5C&SU&$B7*]N?$+- ?=XQL+2\U.&AIZ:>-<D$Z
MZ8X9MSH&?<C5#7L?_I[^C'BN^#Y@- ED$)E^NX;M;-'6.GV$ \C'49=N5[@,
ML2YUT:A@DSW37 */;^NKW7"HI];3Q=\GT1)C5^7Y-*$3>G2RRU7>0KZ]MNHQ
M91%GLT;2L;@4<=MVZZUAXEM?.I372FD<:^+*P*T\ZT-5^UE28<70]W[$YC/1
MLL!XET^24W*\50X4&QK7^CY]#<A1NI]0[$/^H;K_]T6GMMTX@*WYR.X)3/-]
M^1)2RV[X9NE.?K!ZQ(LD)%BI#0%YYPRE1_GNR$PNHWT3G2I':ODES6O*'&(#
M%=9(^VLZ)S1M'V<9")IKWRAF49$0& :]BN_=/5G)CBB;0>88E=+5S!7(/T]9
M"T.&;33=7:'G:DL#5G\]5I!NSYD#'_)T1=\U&C1<KG_IP794@@/HZX:%55M/
M*$V9*MWXP*326*'/P6'+]"PSC!WP>R@;W.#[H2KH+9 .T@XRG6.+"OLR9H_&
M>^EX%;1%/:P(+3?(>;-T WO376U%?S']VA9/[GDM>%; 17 .N4%UI-?:Y,-5
MOT$PY0LBH[-@=8FMQ@&^K'6,Q=,H);N9%5RX);_=WVVN_P7HM^T?RD3II;2P
MIUY\*GI)/RD0@(I&Y%JIA2[VQ%CTH*];<ODH>C+09ZV8JZ14L7$\201O*BQ$
M0?.2VRU, <VC5GLX+3JO1(U_YH%1B3[KDMR*>NGBY^_OGV;GK^O57W-(HHL=
M;98?V]'P9,_E]I>=QYOU!.IGA+?$#5+0G!^L8+:T @I3ZT9.]Q2K)R@_L;^P
MFN>\\LD,O>!^ZG7HH,HH(KJZHV+B^G/;=3[L\Q).ZE>O4'+JN)G-[:BNEF$*
M/>(QP6L@M^K+99S\2_>IF$ Y0GF<;\AK"U:7,!S;"\7*L5$E<?;(G 7UJX^,
MVOS3%PGO9?.\E9NM@/H07GSN;?_=V."_@C@XK-GQUPY0RA=JC;('[_+M[2FC
M*<6P0VC#= L<X+W]P0^/N9,6WU3;[:'V,B^= !R@(^C")ZX47- K'Z@*]L*\
MID.$U:IP@-[$F!-7._3\^7X:1J>IT-3!.-=4.][$;#?AJ^)9UDA'AP,R!0<8
MRLNX@/@\'I:?_U<1/>LR9TE: 1A"E#0KFW:'6L^,L8#A\PF&TSJ*Z:44U_=F
M-OW6K_O7:T1BY^[L!#2"T@FQ!#1-Q1;BHF+M:A:>=70M[ILC,3MD6^;O^=<<
M.60VJCURWR+"%BW0TF7A9B*88YF/.(!T:XXG25K&E0S[2H/^RH>=7-RO*$ R
M2_#2)*H&T>B5QI2/$3RO):IE7XZ^?D8K^,V4\515EL<UI=%>.HP]^]\F>126
MG,?&&(+\I-W.4YIDBW9P '+?^P8VXB7K/ZJCJM?U99PDOM1L;1CQ3G>2E9GJ
M!/8JG=$F'0(#@$0_HH-]Q5"1Q=LB=Y[KH\*?H\TS]1LK,STJ6YBO^^&'ZF1(
MD4JWM!JYUS]V\<BH28_I"]2(D#KO59>E^.+R>Z(ODE(1V'IW=W 'E'I>?[[/
MVN5.I >WSDUO*&T(51##<L24>5K\B/=#^'EO6--5F-2=T=6H'8UQ^]<K'J%$
M4.:G8;I^"M2F*?C'1=D3EG>0_ 5N]*0TY^'>BL7N12M114XE-K5)S?VV_%V5
M2ZJ'=6JLM\FXU:C-3J>^+@TW!2 M4/+%WG1P*6QDB>'T_(*A#=@=:L;40/#@
MB=_M+WEB$<A],:AQ:;%SQG,RL3&4P==>8FJY"#.IWE%9BJ[?-<KKW1YL>[(E
M-@P,*"",1T:EN6X<:HH&)3I9"G1S?H>QB)HS1E%%]S2#QYIP@-56/R'2T"5B
M%RC)EI/!(Q^/M5-'HTINF5>(+XY:NL<R7QD<#%9RJ'3>Y55_&^3*X]10G^\Z
M3W0ID>D"X6,D\FUT:FDB=Y>LCGC!K![FKPV5LKB[XCK>HG1*8!>5+\M?5!X$
M(G8V(=F.,U#SL=SPB-47$)3W/E2XKZ=Y[#!QP\GX[8X<JWJJ9VS0U%=GLDCV
M'H/HS# N_!=_GT\+SOC\]%0"28NP;X7U(/*0DXT%-K"[YFLX@-5"<V]<.LAW
M86U50N<06H2-7VZM&&FS@RRG8YC3YQ(][::0T3.8]-W35SXM)LF-KL>&/H@(
MRPRHYYYQFKE&O*'AALP*#N#GL'*7_9EZPN:%@3<VG?W'PGGU+\6=ZZ*?KYT%
M02US#*JF$N_/=F6QY+YGQ/05G[/US%YI9NK-W1&F/,Q;BIK<%M/SS5"$,J'*
MT2"4;8];DMYD:;4MNN0QYB%;["F"='\!!W"C/*N""?3GKX6=RL/2=P=*O*7'
MF1#RP?L6DU7.UG@^@;Q[CQ]<[[JD#- \'O+\^%J:IK5N6]\XF,3FF[5$OA$P
M^\JZUJ,7FNDK4DY;/Y"YYS72_*Y!HH9IU?"#]O39Y]V+-"@?B!M,1,5B5+,]
MLWKZWLJ&^A'F7%^(7G&CC!FANTC;B, !>D;HB%]-"A%E6]RNVA/3M1O/=>4E
MU,@J55V)B+)=/Y)TYL>H?=-I%AH%VGUX15'YE&F04T4CNZ$E;Y%R\5[9N +:
M:%#X5)3A55C]N8VMT<NQ,Q#_K-4^TS8-*TEZ?Y-_;X>K9U!Z[F;MGM0QU,DE
MEU[IN]$)L#&TQ7NU5+LN4EEU0I+:P<[#U(M33_J'O_OP5SU%C6SG8<VIR$\6
MJ*::;S;/FGE+!+AY#0)[1)12O=1RDP2V21]X(90;FE971KK6$<*O#S!U0BR;
M]1VU8\TDNO;MRT@H^')4SD=U+?C^3@$,=O_'_6JI>-D"WFW+%.$"SH'&\FWV
MI<. ZB@OMU(^F$@WO<!*3>*&<:.*$]M9D7.[ZTF//,7V\W<[BG)$*P4:Y#I"
M\AFS'@,I;L<Y1X2K)IPHM]XT:=0,;.;U:W#RH_'/X8-QNV96#[WNK&W,-A?R
MO:MI][6#F+#-:25B;&MJ*$R7>/1FTGSH7I?3C 6NSA_3KRX=9KF?8(K>7H 1
M>4L<X-'!S8M/<\P$4;R%(?ZLO_W,>AQ5J^M_MN+V",Q;,\#<R6Q.7F.09ZKK
MJ'[AR=(#Q'U*P&L8]2UT;^NZ'.+@5 </![B6,$!-<Q*B@/S&@@/0C 2WS5[N
M*1+^1!GN$NHBJN-=8UU2_HD\C:IT]^UBE!)H!'4?6=T:AY#/.V#X:0'FHB)#
M4@RG!.B,U#T8![AR 8\B@?#\W0M0*04#8FB4L8*.HS^U[7>> SX]066U+$KA
M )PBT9#^.B!*TQ5RS( @Q9+\U#1H17T&!_CJU05""29BK-:S<  0"(",;]U8
M@D6A+X:=__-/ER'_\;G_+(JLA&@,!H,_J_V3[PZ3V/M59B,73EU3C\YNJNG)
MC.BJ5EST9(POQ;3PKBWV;D?L5>RW.'QZK]$^^=.+0?#9&IR"R#UO7$A(_3OI
M7_<4@N$L I^1H@+^,F"Z*LC&QG+GKTTV=V+"1$@/N8(NNF9B&Y'JU04P QV2
M7[Q3D"K</KQ84="5@7.2+VT!T_C6KD0PZ$K[J8DM'0,I^7DJW\8%+M<S'H,>
M^K(?IUYT/?>TZ54!/G4I$$MA5WM.V'2!N0(403W030;"\,Z3(!B/CDY3_^M#
M:/55-A/HL(I,A+B"0X'6 6DWO1UY0 [/2^>_9TKC[Y@R2&:RDY/V3U6).S?P
M(>%XW5,K[8(R0Z"[I(41/9\RC6>MMZS=OA_$+M#34424]1B>7&E.[V$0&I>D
MS1@HM%$=L"\Z),!W+I;3(K_-WUO[_0V>T*%.F]C8$JPV./O#Z8NK2]<=>M^?
M@OS:S[2#NW  >AL0)<;.-G?S4,4M-WN.VRXCQ$*'\Y'KAI_\W62\AYUVG99'
M$7<<M*.,Q+XE"LESR<-Q ('C)E\9I5+S:\XZ+"PWK#UML?(.\*/5Q AO.U@R
M/:<$#WNGI-_@]T63A 5W5\)!T;4(LG;F&]G7%E!#B$I]E MT>DO<KB0B2$';
M,F%;!/(A 9_6R..4=,MHJA,2. ON-"*QXZ$<J7]#TCT1L)'::E34UW&#<"+6
MFQ*9?R'+R#S(M#3H_(;G;H]F[_JI3E6!%EHYS?6*F*]Y<N&;S'@)J<LX0% .
MPD,#!Y@Y$XNFC9^<U:#S>JFTY0U$/Y>,+:D-=<[?FQ@L]ZGHBG]"D,\[6O]%
MBUN@3Y*!Q+.V,]'/G:RSW[67<[KM%:E_>\3#U)F3(>]O"-B(0C+LR=?-^Z%)
M*]H2[_R%7_"ZQ<X])'2BR]RC;Z=_1-$;4O!Q_3@K+(AK5@2I+^]Z1\S8W#CW
MAKN:1?SYV@SRB=N#)M-.\P?OV]: .4[2($1WK5_3 Z=B(_PW9N:ZGU>4*^D
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M%P) /V%SWYNJPH, :#NW1FNIVANI%+,WX_)Y-BDZ@?7!C?54!\41A_,_!I!
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M+00 &9P8/P#GQQ@W%&W .3 "\%33DGBMNJE(9P*@3B.(@=IIP#@MUB-WFX@
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MH7DSDX@5H\<VG!]SC7J);M4[X>FJVAI_TI#@KY[[K]A:P'$(7_.Y@VOCI4P
M9#R +:3N$@"AF7^A_D+]A?H+]1?J+]1?J+]0_[>@=F&+=E@%/!T5CAT\E4\
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M=HIR(XY0RP:H//?.N(SW69CYL4J<"GNL>)0U&Z$P$3&Y/O%SW]@&4_<</DP
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MW*Y2%J#:GK>*D'_%<3+$>Z>)YKU?KB0')AN;M)"TRP1KX3OBL47BNS&7<@K
M4XP!:U]F:W1)'1'V31)L2%^91E1\<)$0B-T23I,ZT>9:>U'?TUI\W)@IU+FJ
M@$/F%H\N;]<UTL4@T[I>LG(642<XFPV$'#O2&N5&T@070Y_V?56@+&3+ACJ/
M:^I7<^_>O0]G%/=+:#*\M_K.N IS8S&UHF!SG(T?791Y.0&YR2!7(A[)7M90
MQ1GGIV48:QC5%)9\-%LQC/ _@ 3KZA\6K@8?%I(.J%3,4,9G3,L$OV54E4$D
MK3P*+P]/\TQ&90,\!+SVT;N+E9&8'KEJS''XRS3])'UW4-=K@9$L?>]OCO>S
MGI\\2]_++ML!A[K#,@K:RPF  #@8:^7B_FI!X/'#>G3]EGG5=PS'#-UW1[V8
MH [*I2Z2*"GGV9J9"_$AY6<012@Q3JH*HU/>50@QGE%#TE;?.3!H85M\*71<
M]8E3N5K\*7QGG$>[W@7-T0HB0Q=E(*&79/"L$R(&[BX,4-N=K*2^O=B$H=@E
MWL<OWR,TW]<H<SC[W,(*%5K/T0VSRNC*I$H-KE;7CQP>J?'H*YH)8A099F1R
MC/(>= +LZWP>0YZCP>U40/V^++=<??1.Z)=G%V8: Y I13LF,^+-M78<\D9-
M'Z^N=URE(4)@]^9.D7:-Z'O3FM'R\#%^NR).^' H?URO[:TH",^QG5&KHZ,J
M45=7)M*U^8QK,0EKM]]4#/9WL375-+I@$%1T.YEA)R;@[=QI*,\#>0:G ?5L
M;P-CK*>3.XH N& CY59>,8R39CV 6C-^"DJDC;CKR\-B*]G%P-!AC6B;OSCO
M-H*_#BE1AM(?Z08)B+[ #_:*R]%M=U=KQDD'$#4=TQ MX^]C;5ZAD]KF2";J
MQ1T\7W^%8/T&E$?M..NB3/,4Q%#"JD5*9?<,T9>O"AS[Q0QAQ[X8;L[3X)FM
MQCT*.T)OMVR4]'C;^79_.DN]M?'-39ZGFJ25AO/NQ9!=_!WLG=..-'3(68B!
M6V-I_4.KKP-' :]JN:OLM%N22V;N4I)4%Y&@X@,KA*YYJ6,MH)D;$TP"&/$5
MV8>TK_5DJH=534W$[::_GS(!VK$):,13+%=ZUWFOB<D*B76'?S!NRTSF5(S>
M<M7:RY9W!/00=U!5GH6E7,[-I J=I_523+>AKPIL-6:NJ/!386+V^S3?YP!,
M6GVF=9G(OOK1TYF0IN+>G+Z)UC0@]E1KY"4&GIMAX&8WY5)?,U).&PN?OT7+
M0S/G^-&T4W(;W[]=%(\S0C>VZ< %03QHL5PKB_PYN2-OC58]]]1NC+98Q[+6
M#F5F#E@MR8V$K]CMUL "-*2>HP K:%4^+0!Y7CDHRLK[:W'*])Y^?2F4-NHN
MI23C@&$\U3!.M@D[C7G!Q!6NM?Y$6OK:9)5I$P?Q1P]/C]%:2"N,%IO4GJC3
M@.I35HH2X"R/2V0+9PD8VI&8=.!3[I%BG98':3S4H-P>W)RG]++*..\(!OSN
M4("UHX)<,<]J"N?H_DC/5V\E_ LC%W,I)2AW^0?@DOQ9KJKX-AL5F,?\.L8]
M[&68\^[ZMN$',#F_#X>7%S:>KMC!X<XG&@_+VN&%A,60K21[TWVE[P+?._0L
M:@Q-25PU%\ ?\'Q#/CR&6$2;QWC:-T7/'#+=JJIPI/*=?0X7/UI)"FI:1\8@
MDZ>WG:*-(/Y>U[TS<$H81)!%W.Q6Q<#WLT2)R;#@I;;.TV;UR\KD+]-:?"6@
M1%CSZ<4T!-GN%:Q;%W0QJ8'LU.849)6J';*Y?4%@PS"NHTFB_SY)^G3T'U<K
M:@3 AUNG>'HAW&VX;>,1%,=! $P:ZZSLU\^7NR>55#&_/>YWFFYPJ(6U0H X
MD=KZ[VBZC/0Y-^.WP@8_W#[MD.E)\BL],25Q-'O?Q2IE-[-#Y(]N;/4H>H]2
M"_MY)ZW(T)IIJM4L+K$HYW1E[FA8A']KNBKH^&;_7?<3&ZK%G-"%6>DV*7YC
M]L'#R,NX)_17RS3J$Q<4\@TYD!!!'<?P%3_B"X#V3CE^>YM!/!ON)D;A@PN4
M#0+!?I555I_(^*!O/6]Q06]9;XE\EWZ6]-MF!?'U#XRW2@^+ QII0.SK='@6
MS-NRQ;5R$C>?>8?LJRK++1WBSL[7\RW(NOVG=%UO?NXDJ9GHAUW/0E,%U[OX
M"!W,W\ ]'17(CI \V&;NK2D?8KBI<;DC7+UKWZ[+Y-D;RAD3>%@Q;2WV];F$
M7=V$WX)=LIYBJ96O<;J3CMG\5#7%OY/5?QP<=9_1+9*HN2F,LH83<)9P:!.Z
M2VP][JIIU/4ZV_I8W_:#QT<RV89OUMFWHB\N#[*PI$H) B[4@"?K%HXBB[$D
MK7#.\51O?67WJ56EBD3DZT!ERU6NXZ= *_[UF@C &^[IYH$\'#/6I<!+=D1T
M333ET;Q6[:A+:+AB488&^9Q)^MQF^473\F7=FV]%71<&WNWB67&BPUZR^<I0
MV>W<)+BRCGG83NS,R]+W0X'6 '2AIV$%]ATJDH8 :-%=+&; 9CX9$3)0&SEH
MH"1)4JWR=-1>,0\?3/@<MW#6U.X*[HDH6_APK ^+$!7@DD=/A'A)+XSD< Z]
MP(;P-%76*JHN5;JSY"E0D]R,>O&NGX1VR!I(CH,L NFM/1"MFV>"? )6<RCU
MX8HN+AOG6O.NZB!YX9HZ/P75W.7)"3<..8P7M;$QMN[%]_J::FZ3D8,ZC;@C
M.=?+DQPK"G-UBK-A+*AQ7ZK0*[J+@6&2-UF9T!8.J&LUJ,'3B5C<LTC\W:/A
M!T^A6]X\=<"DWO>I#P]%M]DD!E<QXN]=9F^-H2)6?K8@Q\4^?WR7%?Q)^=K5
M<V$%3-#_0<L'%MYHD4:U!J,ZE+7S;) G #J87L=48;")RET^8ZLM.=K>V2&'
M1IEA_C)BNXF9V!07;ZH6:&#:]>3R*;C?&U&RJGW]V:);"::*F>P/(2F),DN
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M1F)W3Y\ *#M1NX$3Q= %YU=L]T?:Y,]9Z0Q:%Y<BI>7D+O"0)@>JM[&YX5D
MEPS^A'[FRL:*HS=UL)XY-H,V4O[P?)>\37JF:*-'68SU[0\;)BRO(*RZBQYL
M61+WPJ]Z,:/?3!4'NRB'LV;5#'F]<++-45GMOU3_%@^)N4+1J7%E9N%_L?<>
M8$T^V[[PBZ"@-*5()R!(KTHOB8HTD8[2006E":$) 0)!$) N(* @H!0!:=)[
M#45Z%21T0D<@H08(R<=_W_/MO4^Y]^YSS[W?.?=[_L_[K+R3/&MFUII9[UKK
M-\ED5IO4I:?PRC1S'&!1062@5*+>TCL&5//>C6\XZX7!6#PUVM_7_[;A$+1!
MLFB3.G]:!1Y?U'Y#W9 K2BBN_@E*5A)4K_*Z!EV,*0D2KX"$6\EAJ7:G&I-J
M#T'EZFR2<4H?/H)@0D#WTRAZG![Y1SP$YY$-]\*@8!.=F:=FA*'T16=%[92#
M$5$QH%.2X06?Y>KE!.XEC"LSG6<3)TH7,X6^E(LYF3!P(@(T%@XVEF7E=<]V
M330F+BIE*U8S[R4M^1W,#MKHXIS.QR\TV3B)\\*8%-L@Y4"GDQ\MG7*K$_G-
M<(VH)]L/W_GPY&I/I9UDD. 5QBK\;1YAF<*EY5YET#GJ9X-M)8Y=?]T!0\M5
M\*JD>S7OS(%W%+R!L*,6W==F3#$!#.MUL>'9-5@R)DY895E=NE%0BT]4\8W[
MKA!8;RVV6@D@E]\ ,VU\MV^FAGL_+8*%;O2J#KVR5%$-UD_R+Y\T^_PHUNE;
MT !E8##;:V[CSV;[H& P>3/.&S.AB3G,$6TXJDIW.18U3;E=9^P6U$.KQE&0
M'#MOV5DR/P?"(4S&>$*4U(MF'/4L3)_W">S0=]7<BDH;INY1=&7FM"=M;W#S
M6)BCL4^ A;4VL6-S0NNA4K)QL+83P9#&N?Y@J5@>_+J $OXMR)5ZMZKS"!J;
ML:=#!'Y[C"(.<]RM)'#&6+^N6::$>S^E!RG-3=\:PBHC'LN6%70^RA'EY&E]
M[+8,R+([M_:<>/]#J./7V5<E._Z=EVN^8Y4KB&L-;M\F8=5MG.R8A=N.U1/K
M'@$1$6W4TA3TBDM+ET0N2(!N7_B\"IP\!^!8YWEAR-L,#C"_ RIM:<1>D@B\
MT/;.1O((6?:-=_7<TBAD%KHX>TWC8H2D$N#B &;7#4:P-,AGPAQW[1L@B[^*
MD_RO^[ :E2>A@-F7]TN?UG-QNDWQ_J;\D@?GQW9F8 T[K&YCQFMSS(J_<-3=
MS9D3&:0>_Q%4C;KRSM )^GRROEBNU\ZN=8ZF05\V*@=K'7T@JD $#$)!I>LG
M 4E1(H6+W _C\]Y=WS,I'O%(JSW^_DB/M%W*WT8-E\9.X,:6!,-]T!=KTATJ
M#LJJX@JE<.YZ*E1Q&J'W9)ZF!=XL[;QKL]$,;$M?;,"JI=?9O97:H3;KITJ1
M"N".,:J-N'XOUB4GAI77]AC@#40F_=ZD#;4"XZ#>>28X6OVA[09)19'Q*C!O
M_,)L:Z]DG(U]IRG8&2DZ4;4U OF"$U?!7DK-'E!2+^8KR+?0F6 KVAH7V&)\
M_VSVUB7+J]M(N>F[2WKD YMTXK^%*]1JIHXTR%P(HUUW@$[_.F-+-'1R%7D"
M0I[IFJ?OZ#=C0S\^%\4'\,7O6E?Z8/(3K1V>-1K;H[EUJ>M7BJ X ]]5_&W$
M'P>!5CH0@2G(WEQ?PF\B@#U=/=M*;=H!>9=42Z_/_D_2ER'R%-A<!R<78K(0
M%M2KORO=71&IF-R@ID$QM_0Q(I3+-A0.> PPQ5^$02,;)#%($PS^W'RH8XI>
M84E8*1YWX/=K0MJ^)V]Q8^F<@:3=%A),P+;3SX!;]@A,))P;0Y/AX>MYAM >
MDTHU%U[[)5TWH_::*N&V^$FBH6"W#LUE"Y=+.]%21" <0HL7]%_4!/--6JGF
M\*.:!O/L,2ID&]DNX9,FW^V. X74>06FQ@.58]5'7N*5<R8=JJX=RR1]SZD0
M8*[Z,?3T+K_\2<IQQK\S,5G[P\?3PX+;3L2^'<[9RA[J3ROG+:E9D@*: /:3
MYPYN(N,?SCY_D0S@KZ9OZF([<[+79EFQNF%P5L_V%&'(-56YZQ.:@M-)@SR)
M%(MWENBT).1;%F-#P%RC :R;&=<:&/,?C(_[\I8Y7:]--XWS/+J?\"PH._<]
M\_.[(EI50^VV)V'_6"X2B-O"*+:#KK[RAQAAJ@IH$N O5T8K^=.W[9M^.@YP
MW%!D+/L2E5T";)]?3TA3,+F'EKE($#UNJM.LZ<N".$ZK$E2IX@?UN37;\9)-
M!L.G5RJG*5E)\U0)__EU?X=,] *$$\:WU]I$B46\AKI(.SG?VM V&[]?T5 1
M]QU;KLD3B'<A+6:"P 2M/<]3C32\ZGR:N,:0]/5A<2F6K1U/NY>:#![F!11)
MVJT?OE*0Y\^S<QKMLN8B$1%6MR;V*>>N.7&RA>F.')@+#W]==Q"X5ZH4S7,<
M$W+T[L>7V]\#/6+FV3*N09;J\3=/'.=.=#GNFTF>ZC/WLL>2V_72+;L=SM3\
M@J0+?\4:!XE7#H9;D6.IZ*9RDL(.=RJZ>"3B\&N)]$^NW&TU_!2'&^>/!7/@
M,A%LIK"N-M:8U$NE'!]'BE^^"GE145LA8MLM4(_<.>I4!C^99PRXH<D*=\?I
MDU(Q$<:?] O>[:A+3V/>2_>GS7$C O\.T%?' 5F Q$C31J0S8C/"7_4+K7OB
MMNG\Q3I>:#A[MS\*&#")/TVUD3EKE!Q@HGR%Z>TBT$_ [Q.N_*R0]XQV7]&^
MBY[@@5:8SFBF[=#SVM["<I(&OV;F<->XJ#N)SPTGL.(B[X^A#E?5*\=VI KL
MI8TGW3@R,U\SA.BHY#VC54+0 !>^_\/9QWKS)0*'XQRM9[\OM9U>]4^Q2HYG
M: .G/*-@V0]YLG5;),Q;\H]^<$1[$)AP'G\L%,'FK#(>CNVS[5 Y^2(=O:_.
M\1:X4<2-_>"YDNWR2R:Z3WU[:-Y%#MCS_W<"Q>AF !>$(+6&Y>PC*'$)FACM
MI&"^?,;DMYE)O$';?':"I*6>C^),:D_;Y42CW"S3OV &.PC7L%ZYA7!P\\AB
MV7C:MC2UL$6\5[76UY>I;]_8**;6\'IN!%BF@<*4^!<M#;5_WL#.$-+R^;)<
M1%.U1A;MBXK>%V2_OBD7A^]X/N!63<Y LAI BF/Z<FXH*8APO*9WGA.GT+CH
ML^9D<_-N[A24NJKG;I1S*;PABIU3G5GOFQ3BA;:,-D@%6Y0XLY22?8((+^%*
M.D&3Y,892&S?V?8;JQ-'SD58T58F(.O$PSV=FJFS* H/J$WM_-5&+C X7ZF)
M[GO"42O'S]*&3VS&Z"[$Y&,&5<9%*J/51!U7-HU2CL5E98Y5,L762?3#%'7<
MXK;M+X1U94\1@2N8:S4@9H<?$LL/@E?LXH["2@MUHV<YZK&R';HA*%NSRH%H
M)2* LEY'N>VN1E$L."A5#_;6JHAS'9 %6Q*!?R292!?"J![68H5;"-Q!YIYE
M0X29PP]++^@@:729+TDTY(0\XB&LP)XN,UQZ.( 6EMJ"6@W.3+U77S_A[&F>
MAZZ)-]DN>C&PY,8C(V^QY-&B?"_QY$I-1GC3Y29L+OY&\[.D6?'?)5?-',O/
MOGQPB1"=2G3-%?&F(GV]+5SUF99D!$[[%-O;R2GZ$VZY,NN0 LZ2"?^Z5N#:
M)I<DVN3<*EE6ZBT"-I#K4B1H1^%:YU<QD!80L\G4AK<QRD^+:CP<OO*X\HV6
M2^:,9>E[@]B*=*-K1W43JGEX2:QW,/Y1WL8<K?A^8N4XQVKS"/[.:,-EURF$
M/V=?J6CU.PV0=;*-DC8FJR-="*=;LF;VM33748%0ZD;] VS>:O<L[RG$[BW0
M]R-45JC]@M:%._*.0"EV7>;<Q!O(7,@[6=VIY T^'W]<\E_X[42/]@YSP6MC
M#1>\/EXO\LC2A1PFGWA]@M>B+\B9Z8KN[6[K]?Y0OLLU@<#*MLK.GL?%-\:_
M#:8ZSA(7*;4?(RIN4P^KUKL7,RS'+ 2Z*G?P1S1<\R^&/\! WCY)FA&I@%3[
M?Y5G>1.[>C\O%3"@N?)I*;;S'-AW@J@]K8-G^3 RM?-K7X>*MP^F+*]OR&WS
M)BD6F);7LFOTQQC+LV-H]7)\70N;*VE[=V-Q*I&W+BF:G%4\B1N5GQE0G-#Z
MQP3"<S/-86H1"Z)[SN=H"[$ (O3L5LNFK9QE]<U$UTQ5-WFDSZR1#DAED/Z"
MNV/#(E]9,_E4I[R(S>O/=*@3FI:(N1D)375]^++0LI?V?8SD !%(>+%=^WD-
M047@W*A2&(QZ%<UVMZ[!NM2R:#IHNP/A=;%0?(_N<^<J3^;M0X/]+?6%V,@&
MT&*1^F.<#R*[J/C[CC(A>?%2VKQ6Z-3IVN'S<.>&H#LG^'IJ[P7:<+SV?(:X
M'O9>=>2SGPE6%341(F93%NK,U\Q#GFC=*Y1[5JLD2;8D01[_[PI]3W'A1.#F
MW(+XZ&,B, +;I#7"0;%:G6:$UWZ+HC9(U_43JX+GOE(SHC<I'O/'92,DAYIV
M61CXO*[2N,TU_@/!:X@<:@V&_^.H+2"XY/KH>7P@ @LY/Y?# BNI+^VU[96F
MS"+;8UW-6KN?&? P*R;P<FJLCWJMNEXA K3._#AG;+ ASM\I7YH(A(E)E19/
MFLY(^HCP.@6E&W!,1?GTNBN?[-BM-+_8"4:!F^=!-+@$,Y\#!]%5IS2A<:?P
M) [1K$\9,US^V>5?5^1(OF=!R<%%\Y PLZ380L>F&UB^7)KR1>T'4F%]H2 Q
M-@KR_D-[Q-O/ =YTE$_H2,A209?@M C,SD)QPL+6 W.?'6>EF5VS<BD[SV+T
MQ?><48IZY&[6LG EG'4N7NLGWA>NHG3R-<QYL?$N]_"((8,P>)YS89+"[ED4
M#V7:-]+YYS'@N))4,,>:E6*D%990LJ!L_M!DJCVY:F2M;K%GO#7X.-J]A.WZ
M7)+J5*!,3(, P"&.3 .O+LQU%!FV)/E&)1.8,[2=77K&=SR4WV38_WH679X4
MJ[0W=_;Y]W3S[QF,G_H$GG1ACLY)%UQTLV'+(\>LW^T6,J?"(^$TF[8BR7.Z
M"Y!A<)Y?'25PXA7&*](,C;#B$:_D7NDR.MZYWSG'-SLPPR8,)7E.]4V')48!
M77!A"_'_PQ57B8KFF,A\1R\OW7D0NPG;QZRP@8;A-G7.O>CM^V%7%!)^&8.R
M<9Q(='*4DODW7'U_PZB4OYHSO?;PXX4W;B+F\*D@F^?/MDW@V6XQWOA4Y:7.
MY1B=NVAYKM<QL\<E-\<"F''UK02AL5?0L.23!ZA-FKVY]0 NAUFR&N?FIM@7
M)DE3/WAI2WJ_7]#V;MV:A[Y!7'WY>6R[I!"DTY0R+)YMYZ01\(/!O" ]+P?D
MXGOA=GV1>],-O69* BE'_>N?%5(@14&]\55EA5@;RR4P@!5=1<XQKJ?,EMKE
M;Z;LT[^1;!]"F>Q47<N^%J.E%EL3RD7_*2[=L:H(4_VH"6.-5+ZA&"GIL9"F
M\K"^X87WY USU;*[+%/QFNOOE+%WV%<[=VAF<*F+N6U;MT3-5M72$5OB^UMR
MQQZ=9*X5Z>:KR]-?DM_Y!MW]9B6!<\K$<V)E7U<.DJO*A'A[%Z/6JO6[W'A+
M9\SZTWXLJKUTK_VQ&N@;(KP>\ ^$:NM_(/0*D*9<Z3W5PS<+G#M^N7(NF\K8
M*;7+'+?3IM&-'BFZKW^#Y6'(CKJ2R(:I_MOJ8R^&I68879C5Z3JJ^VOX9!Z+
M+8?UJ#.O(KK+A\_=#T43$0CI/4=<T%3H62H1H" "A\:)M0T[LEN<+WX[=\XT
M[GTZW+%HRL)T=<S28A]G%<"5FD<>3YAXIQ,!+2RI#N8FTOELW^]6>]7L72[_
M ,M Z@DI#MJ%#.3,XRY3;$QIEKVL<>2A<&7].\M?)=LME2&$9T;,TTN>:@$]
M5@WI@A70R[B]5MET:HQU))[2SZW W"'9P'&\[&;.<G9T6'2*)CLYVI7#M?:T
M]<')>#TFK)W A]%-SH-],>\H=>PN,;-0O2[J7,P315'4]OWFE\?LDA;IS$'N
M;,+_N(.?)O58Y,<G(]XT:YL3 4UTB4DQ3X<51=,$^"8,U"ZAY9)D!IIJ&F6/
M:E/?RS32#A0DOZCCKHZV; 3@J;GVG*#2L6+(@N.ZV=?HQ?TF>_+HI!5$N47?
MKU.EN <U&C/&5)^__KP:/:4Y95FRQ3W/06[VLX$Z;W92:L(XY2 I[K9//.VM
M?GP;=HO,ID1_S^_GEGE+,[-T$<TI,CF &].[/A$Q'K]Y;U:UV>E%P@JGR=VK
M8/-;6QRE>Z''FW:+LJUG*J8XQ$(_;=O)F\=,L^SI(_Y@M-[Q3Q0%BG=/XHTK
ML^P,U_<UA2%R26Q!2XHX,F-RJN.0D_.[D[ I)UMUM,O-=YJ"-8'TM9,?;+F8
MR1G70=?%LJQ#"%(>M[9B-1NHO!DI%F?>]GJ=G(Z#\S%'[=;7 MB<K#BQ.9V)
MSQ'P#9[4.W120F_U1X4EE(XC-#D_%-M9XA#8X,YT^OJA2@0=#*H34N3%LO\K
MUZ=XB933HGCJ'L^K%]$>4Q=A7"RLX358V:  &MQUT7O^8E/M)T;/#C>F\[TK
M@_HYS=WB,F9M+TRB/Q7DWR@%@^&T?WQ;$L#BI- <TC\>)=J'<"C5ZGY>W71)
M8UBIPUM.LIZ)>7./"/CQC%0.!C.AD@.5;CH_S^O*@2&1UR4[GN;?Z;,Q?2/,
MEB\WF/0+@DS_Q"@6VX\[6K#N0(2G<]2,OE+V1II)"1AU.645M6A-8^#'["[:
M@<)B0Y-/!R0H@/4 9;XYG'%@= L.J7,W3,@(=%LIMD$YVA5$#]=KNHDK*H A
MS$;@IHNTU/95W^^@9,.>WE;WEAHN/,^!#:* GI![)BY1,D8NAK\1]'!Z?[0N
M3C6@0[3!>M**J^*GW:F*Q R#>;70@H[)-C,YZ?1C\L@ 5EA\5\<(K*#%^_"Z
M;\Z^$S3_UR:ML*EE)K=)AB.\9T-"#I+<WT ZV,3ZH\ZN0YMSJJWI&C8C%'[;
MC6-,(;&JWMDU25CL)ZR89WKK=&3X0[C(I1$&P=.?ZAUU,F%0]"#=--X,<UB0
MOUZD.)@+BV 1RRX-;8^=:=N\S&FJ?M,82'+07*^<0L&9LF!'IV9.1(#)R5?K
M[I)T@YE.Y$O"'>>>Q_.]W'NR:/?$TYK6 2=2LR&"I(I_,3)K,X"U?G1[*?&W
M2Z7 <LQBOPG\[;6KG?#RX50WF_@6S#>2.9B+(LR30T%8ZUA:"[;UQ:2$=5[W
M9KLCV-3L[E$OC>::NY-[0PQZ 1$)YS@'69A5Y)GO2)?A]\1TI[,'TL(*-7%+
M>DWFOZF%"[RYJ&R/#GK^W8<3_4G_^=1V'KAN:YV_E!/H=,L1[>C?H,EFQVEO
M'[:CWUT3S68SYSS"Y,A9ZE&X0%W&H67SNU>B][1UT&(ZZTM3*[+HF#1AW_]Q
M#\*4AAB7Y$*G%'"YM_/*AIGFA\G^AECA?C;K&+SO^-;_VODN SADBX)XK*?Q
M2.7FS3$15M7W]_N,G4)%:TW@/>X:\_L_UC24YL(0=G\LOA@:QNJ-*D%>)I=B
M$J:5DB\IR<S_*%,4JE':)I7'%PSG_9L[%JEJI2A-I5^,I:"FY]@096?EO1<0
M K4>G'B[%VZ[ATL'10_^!;^_7]LA)]_0]GZT#DIX2V%+Z>/6,KN2?ZAOD%PK
M>Y3MDST+<.JI+%YY>">SOA)3F9\NG@*IF.Y7<NPJV9Z)>*<0%=.4YC0F\)G"
M)E#]^T4KIJ<\,>0/KZ3\;S@3KQ!$"Y/5QF1N(":]"'?'*B]+*T;5*N8F0#_,
MQ2AX%FW\GS^5[T_ZD_ZD/^E/^C].)+(&+IN:I@I'X15$@!K5!?X"F<R*O\LL
MDHUOIR,'#B^5OQ^C?U\E).D>'Z7MWS42W352"\*9I;,0@<^QA'L)1" \BW ]
M-Q2RQD,$WF43@46GC,T/B%4U(O"X'3%8?72[>-I?8-I?..X<K.8OQ)Z<H]0E
M00@NY1QXP6P(09#C*[H$OHP)"2(P$+SQ*_;XD+#R:BHVARTVQQV"J522) )W
M0?@0?B) KXX7U:5"#*D3 6Y-(M ^?- 'V?M\4L5#\&^N3?-"KZNAURUB_P4/
M$: T1(+VKQ&!'P8(K)2_!RU^#5STE@AD0+?M+&M.]&M.C'G^!1.B;0S3=4:&
MV&7(P&N#+)!$0(&VX!ED=>KTXX0+^+T+./&/,SK_GN=?R/FG,G\J\Z<R?RKS
MIS+_U94YOA#]\\<?C8[O'%^F0DRPG >FS9HBP?%HIUWEJ%P=3X*T4VQFA+"'
MQ'^!4/TG_=<GDL:+/JN=+YYCEM-9$IO&/V4Y$\A+5!SW!J.(P*ZX*1&80"'6
M:*V\GA*V;C>+3S#1&G8U^Q !901VD- (:B "Z<VX52)@%9T9G=DL S&BG44,
M6N,]B$")^@YDM80@?]Y"EGV6_6?2HXR]"2+ 3@0VAT\'CS>)0 SB8 TE@!(
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M,TFZO$^>LH$71XNS;[)V5!8787[;^QH&U^M;NE.6B%,FMCM^KNZ?X'WB,?@
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MGC+F$8]H<LF\C1-;**6WQ.0G/>K!Q/R5F*'^AA.*-<G1J(*=&P#T=]W,7U?
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M^]_])0CY*._Q)[OB/C5"?#:\ >K5'P7S7*J,PPZB"W]K29B@_[=/'D1W_]4
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MD"3:CQ.2W"%HYT=;A?'(0%\I";,GV-4B?F4Y<9'YZ1&HK_!\'6-7__Z!' 1
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M9^?V\ZN/XL#"JJH!2-\RZO(IC/(81%:??/IF%-&7UL,[OM(T3<JG6IKNK[8
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MFWS\ZC3YQS9MB5G<G&'398*DBK]RS\,HOOY]0/>@].(>:;,UF=)_#^T1!V4
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M6*U;$5]!L-4MI6N(N0&@DA>>?34>_MQL9\S>*<$6/SN/LF(=H*9Y]C%3M(W
MG/#)$\^ Z"FV6P0+2[E%9+-J))ZFV>PM2AOL#!\$1^,'G%M)H?J^*T#LIT4Y
M.\I3D];/^6T.K,^_+\_6Q2B=(VR79(@O?<;]'MEI;"UPU%179:G7X!T3)B*Z
MO^8J<;MN0*,\+2 FC0K=]-F4OD67JRO<Q-ZNXF6+5)#4R0X$R[APVI<D%6.)
M"<-?252DB=$J0'7%\S"F6PH:Z;I)E[=QY<N@<#K$HWKLT\3H F2:TT>W!QX<
M*_QS76PEJX*M6K,!DT5/_*6_#C(P$-URIC1#NAWG#;X3:+,J9$W%,M,A%Q_
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M&10BPXN!1=0Q&Z+7KA/JFSK@9Q>F80\] W@9G0[RII.>UA_>)=PYW 5L^+V
MB%]28DB0M"(7&>.GF2,=PKFFXHGE'VEFBQIT[2T>Y.VQ)Q+Y[M>9J8SL7<M
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MS/W48?8/!)F&C2?7I9MZ0GHNB'>':MVBR?5TP1P&8C8!=5Y6ZAA88,6BM:+
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MJ V\#'#H40*@IN$PNEX6)7;5)V(809F4-9O3:8J_NG(_3E[X-E%I0HT]79@
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MPH0)$R9,F#!A\O\.MOW)?P!02P,$%     @ /#EH4X%N9+40I   /Q ' !4
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M\CL'&U=GOM5"EOFZX-M1[G%Q:NC2HY89Y[)?EO11ED^TN4%#-0Y!C?X_*IS
M  4;I/_VR]:DOF0NQJ%H,3X[X&L-\__U09-H?+#*@1B>KKWF)O)2Y7P/Q\)X
M4WEQR$+.[5BH)<I<"HV7&A 45 +4??,O1_UW6[2P:,$O4-M<\0O/M6?XM()[
M+Z7QI!WPKW*'+J\9T\W_#N2%D(7V^D^8LGD5UR5\H/1I]MK@7*Z*ZBWX/"__
MH2< 8KXR/\VD]N 9HP(*[:YK$<0*9D$60(0$11D/,4LS&Q&T:&MJ4K@'M02Y
M C568, "NA3@3BGXBB[,! !\^29E_2L['; AOULT/5,ZL'3NH:QXNMGE\P9\
MRA=S_@-\;?Y[K\=O\$I_)_\X+ZS64N% U=:G*;65%4^*EJPRM'G,+T9)?I&+
M5=G^2Z4M, B;"=H_V[0WBL8X&-XJC<LM_?2F^62J+Z:=+-]^GY<SG*5I$E ]
MS^4B@3A.$DB))!#AA',692J-$A>Q.=?0U)1F7T-:I&XZ<I94.Q'Q0=7 "G*:
M)?#5P/2H$9>8\"H09QL;51TNF7PH#1>O[Z<+=T_2J,WRX8.D^IN;4S9?S%<_
M/FHCUD6AM6@6B9 FH: PH8I#' 899$@&,$X4PSR+!2;,12 NMC@UI:AP@D4+
MU$TB+O-KIQ5>61M8-#98007V!FS@WH M8'_J8<V-5QFYW.JH>F)-PJ&PV-_H
MIC#5[$E[Z[+0SWZ=EZOR??U$\6J]^IBO_BY7G^A<S' 0T" A"92Q,GL1"$'"
MN((RQ#%/8YQ$(;)>\KG<WM34Y=?EDT:E9SHU<, -<H=E#0N&+=:!_/(VM+ZT
M7%5H00L7:+Q:7U9 (P8&LE\6'9:)_+(YTH+1U:RZ+2+9<]2YG&3QF/$6ENQM
MVEMB<KBMAP3?WO_E4Y$_%/2Q76./%&58S_,B+,P><8@@2U0&D0R#*(EC'&-[
MP3U\^M3D5>,##4 '.3CBS$)"KV%B8,'<(:'/ROD1&PY2> TK(PF?S2OBIFWG
MC.Y4LJ.;QM.M<WCW5.KL1?TFGN^7^O.7Y>KM]R>Y+.6,"(49EQBF*-+33)%Q
MR'"<P#0+)69(L(B'LZ.=[8OSIH-FK%X_N]UZGZ]@BQ+(&J;;'/.02KL991]F
MQI&K#1MO+[#A/%,\8[/7>>%A&Z/. L\8>#CG.W=9OT_YRS=:R%=Z\BA>YX_F
M@?7B5%'H3JUVS%[]V%[RB?XP_W3[&RW$V_]:ZYGF^V6Y*BJA+^]6WV1Q_XTN
M[YZJ#:"_:HQ2O%_6,2&S($RX%$C!5+]#$$L20Z:=&!B($$5AR% DG3;&Q@(^
M-:>H1@=^/U^"TMA7_L%-<$;K<#LEFV(W#BR1E3W0Q"D*L&LTV+$:L!]@][K&
M<E"9?@-JX\&.]: R'ZRT_: AX 8T[XI^56H2_(GQV-WF5>5' S_J\#%VEQR.
M2Z.WWV_ JU9*O^4+\?[QJ<B?*V1E,S>BB5!)&'(8HPA#S!,&*54$RI@$(A$Q
MB;C5[-JBK:D-*QNH8+Z#U6UHZ:+6;C3P1-C  K[E:A?FY=FYL\I:T.%5&+O:
M&U7++ P_E!^;6_HIQCLZ+_Y*%VOY%]W$NJB?O/G'_YS+0C_RVX\W^2.=+V<L
M2!3!,H4BY7HNC!(!LS!04")!XH@QE 6QBX8XM3XU53$X0044;)!6D6 ?;__J
MIBUNG6"G-H-1.[#^=+$*OM9P/:I0+YJ\ZI(;@E&5JA<YA]K5[R']U.RC7+U?
M\OQ1?LC+<J:T--$T%) Q@B"FD80T%!P*%#),LP0+'LY6FU,'%S^IO:<[J=&9
M Q0^OQL-#BPT+C?EV2<LCC.:9#@T^]S2$!9 $D2Q_H.FB+$0AZETD??^A(T@
MWSX(HU&<)@D.8":4@%B&$:11$L"4IQ(K0G&$Q.Q9%BP?G++=5H8G#3SI^;B&
M^9@W*S77L&@WH/5F9N !RU!2 P._-]#^ &Y7JV+.UBO*%A*L<O")^@TK.LF$
MUS%IOX51QYR3QAV.*:<O<ALSA)S/WBY7>G;^]E$6#_/EPY^+_+?5-S/!I\L?
MLU!_O@&A*50LUJ.'2F-(1:+9X@'G$JDL"(2-&%YH9VJR6$,%+590@P4-6KO/
M_!*UW1^\1\(&_O1[<F7]P5LR<>+3+R7_XT/^_(M^0OW5ZQ^JC[WZS"\]=Y0/
MWM*X]M.WO=Q'M/%GD\C@3OU:RMNRE*L9CW$F1)C". YB:/(00)K$$B9$("I)
M)!&+^D<:'[0V-4&HX,%<P74I 34('5VF;F[M!G]OC VL"$<1QAOV-%A0H1TJ
MO/@,*0.&%A^V^()AQ6>,[PXI/G=3/PFY?:;SA7'YWN6%.9;Y1?)U,5_-9?E&
MLM7V;Z^;\/H@#145C,($T03B@#%(8NUN2!&E- E)&!.K$^4]VY^:S'SYEA<K
MJ%MZ!//ELRQ7/=;H7;O 3GL&)'9@-3+XP!;@#=B8 E5>P%(;<P->^S[UT),O
MKT+EBF%4Z>I)T*&8]7U,/WG[I+M'FOC?^MQY%9UQMUZ9C$<FB=2,!I12PB.H
ML,S,:2P&J>3&9<I(G'&"8KL$&9;M34V^-G!!:?#>-/$K(-]"=M.R2WS;:9='
M%@?6JBV!7VH":[#@SH) 9XFRI,6K)%UJ<U0)LB3@4')L;W-?B7FM)W:WA:2O
M<R%G3 DA4H:@8 IK+2$(DE3/O&@B):)QRN(HM5UZV7WPU$3#8 ,&'##H[-=6
M]LBZO)C2EX*!OWA+ZYU62TZ9VFMY9.]!HZV'G(*_NP!R\O=]P]S-^NF7%5U5
M.W)[60(05E)Q,S516(_E<80@(R*"J2!!%(51AJ736-[1UM0^R68E?X.U9P*&
M+G;M1FY/G W\#9^ERWLF!@L^/$?+GV]OY,CYBX8?1]%?OL5--<IB-?ML8AW;
MHWK:JP]0AJ$(0PDQ%AP2+A$,2)HHE'(4QE:;(P?/G9H:& KGY6K.Z0+LA"_8
M:<$A9]W?_15,#/R-GR'!8S#.&=N[OF=]R\ZWK/]V^!T?/G.4;_:,(>WW>>[7
M_4;PSW*EZ9?B+2V6VODN;SE?/ZX7YFC8&ZGF?+Z:*292%6 &@RP4$*<X-O%Z
M"":IC#'1$_.(.^50NMSDU+[@'81 U!#=1G(+EH.0ADRE7,]/LAAB%$M(D/:>
M9":3+$G2*)7!;#<EZU@\7\PW^[,Q;><Z^7U+!U;7%BQHT8+?[S+9 #Y_#LK9
MD;)GQZL_9='LJ&Z5/0V'WI7#G7TC4FZ%T.]8V?SG@VXMG*F4IIRR$&92QL;E
MPI#&>GI&4*1$FA),["9EG:U,3;Z;"(L&XDW[ S!@P=W28<WD/+&7%U"\T#6P
MCO1FJD<T2@<35\2BG'KJR)$H'88=QZ%T7=S7HRNE"89^(Y_E(G^J#I$MJQ-G
M:_VQ?<G5ZC=:R#HGJDF)6F5$G46(B"R(&$RE293),@&S2/_!:(P2D=+0,6JW
M%XJI"4=K1'5T8,>2]NB^X\YROYZQ=5<&YGMP#Z;&?[/+\TU%?&L$:*T8)[/O
M58QZ]GKZ(!G9$;J"K&/?Z)J'^7.7HAG"F!$:9E R$D$<AP@2Q1E4<:;T%(V@
M5 37NDO1U%2OTPFX_RV_WEV*KG"7G.AZ27>IBRDO[E(TB+L4O;R[%+FX2]&5
M[E*U_\PN'\IG1X?ROS_-ZU3F33J/C,0!#E4,$W.$!Z>*0I9&M*IS$*@$1R)Q
MS]_B ]G4!*8NWI%7J0M,3J@&K#D.U)6"8^#NL_.S7J13AEZ;]Y!N9=N+@R12
M\<FX_TPI7M"-GPK%)ZDG<YUX;:"GO+?[EW>JDAV3_T!+7)U1Y9:5JX+RU8PF
M$@4D9% F"='2'2>013*  5<H3!A)(DJ=I-NFU>G)<KO_GBNP"_M?VFQ*7UOH
MEODUW3K!4H!]4SO"QN?5K+J+I@M+?@71JN5QQ<Z%C",A<[JY9_Z4^=)4O]A/
M43\+.$M3P1&DR(A2I @D$2(0Q8G,!*,XX=@I3\JI5J8F0@U(L*A//O6L2W&:
M4#N!N9JF@06E9>BP^H3'="9=#/A-6W*RI7'3DW09>Y2&I//BGAZ*?##R\ED^
MY84Y55:O:QVN J<F2["0$0R54J9J7@8I(1PREG EHS@P22)</!2;5J<F#@WH
M:E7XS])D:W[Z5D44O5^JO'CL$6)I1[ZE9^*;TJ$]DX;-#>!QUM6=:/+KFEBU
M/*YKXD+&D6OB=//(V8\WR9ENRW+]6*>I-)7^WA52M@F:/VO7:L9%@A&*8YB$
MC)L2?1(R[=I )57( OWJRL3I7/S@B*>FB@8C5!HDF+>IQ?4$VC&9SO#][+"^
M-I7>F_ZZVTZBNQV[;^J"LL9TL$DW_[GKG1@OO;%K/TTCK[$UZI\CH;%K)WC+
M9.S<<(^20!]D6>;%F<)OM\OEFBZJ?VMPE;,@9BC($(*<T11B%NDIMQ(2)HP'
M&0F#D&-N73+(M?6IC28U_AN0;Y*0'$[%352&,:/^!7AJ#'$HN>/<0]UCQ^"\
M#SP.M)1W59:L+:A_T0X"@U+N4 5I2.I'JI+DOPO<:BKUI;"SYI+S0\>KR=37
MWKV:3;T?,K5",._R0LGY:JW?Z+])DT](BMMG;=6#_+-^^.J-'A W ^>,T9@0
M4^!.IHA G,D89FF"( YQ*#@F28 G4B;&Q:RI#8,-]J:.C,@7"UK4"4NKG!R3
M*2GC].H,/ 5[L1=B^O,TRW(T.P3=@)8BT' $*I* 86EGWC>!*=T@_3Z->9]?
MTWZ.R>$@W3E>+9Q>Z'I,,U_K7YC-AR_KIZ?%C]L'/8,U>)ISVF$42I00 2,5
M)!!'@D :QPJ&D20QCW"*,_LRM)U-36WD;,&"&BW8P'69KG23:S$=]$;9P&/+
M6;;ZE++M9LUA1N>-O9&F;QL6RYI%VB+^HZ?YF14AG9.Q[B>,-_.RLF1OFF5W
M1[\YU:]?[HLJ&\2/;:K!-CL(1C2A:6H2!H4FM:F$E' *41)K\20\H]PJ?]?E
MIJ:FH+_^\<L?P4.N!ZUEO=W]()?\!R@WL-TF'QT<VTT(_# WL)#^^@6T*'>R
ME0Y0<NPR&UY=UX[F1G4G+YM]Z.)9W.$EZ]@F@#26BB24*2A(%FG%X 1FBB&8
M1$&LA$JP2J_).#;5N-VC]%E]PW3/\6JG$A[8&E@B^A!U;8JQ06-MS[7UDJG%
M+L737KK<_?CFK7Z.,,]ZMZ /,Z0X"6FB((H5TA,O'D*"!(8H"$2<D8PQ8A5.
M<O3DJ7WV&W# H+,_E+E/5_>W?14) W_-EO8[';4\:6NOXY7[3QKM2.5) W:/
M49Z^H,?RA]<0@(.%FK??9<'GI?Q4S+F<95&((\H"&*4Q@1CC$&99FL%0X)!+
MA@E25H=SQH4]-;G8K";39C59-FC!DX%[U3;'R"^$Q?+/)+MYC&T*\*I[F^)5
MLTW17+>W37$FFNQX(Z)E %043/(=<5CLFN2[,M+"6?TNU%M6?/>=H?M;6^7.
M=4W #Z#5.Z/,._-<O3-TYYWYK5MN?*W+C=YWG6M\XZ$9;[UP=(;WUA[';[UO
M^IAW\X4L7NM9S4->_)B)+$QB',<P(]I3P91%D"6*PH"F(HMYDD3**IW6F>=/
MS;FH(8(*(VA!NN:)V6?P\L3D2EX&'HW=*.F1$.:DX5>D@ME_WLA)8$X:<YS^
MY?1E?68O\X?E7,TYU7+!>;Y>;L[/S&655N;]2CZ6,YRJ!(68PBC2WS)6808S
M)A,H,JQBD0:)#.QW<>W:G-JGO8,:;&&#%C?X:I"#"KK+5J5E!]BX^MYI'=I/
M?U%&71QC[\R.Y=7N,$RW##\UT+TYGT[\='N.=H\:T>USLFW?9W.[U4>MW0//
M[K,T-07:7][+XC&<!4F<A"Q!$$55-@62019C 54H,1>8ISBZHOSN90!3T_6C
M]:"BQ=R<ZS!5-&_ ? E^2%I<5:W7HG?LMIB&Y'Q@T3\Z6'"TJ++!WYPP,!8,
M5>;7GKH!*_]:@'C!8L#V%'77!W9X3C\E_)"7Y>N\$ED3)O)95DGD/TLNY\^F
ML.=K6A0_]"_KV; 0\VHN;(Y=LX@+"4.24(@#BF$6D4AW'=435VI";(B+'O:#
M,355-%8 OC7C1LMB:\$-H"UL-S7LV4-VFC@\[P,K8T7YZUW*/^]0?GN1<F<I
MO(XQKX+8$\JHLG@=78?B>.73>CJ+)D2\*L]>?M1&-X6[(Q91X_=!(G@ <4)3
M2+D@D-$$485)()35Y+ZSE:D)7'WJ9)DO80/0K-I+UQKIIPFU=.*NI6EH3ZUB
MJ 9X [80/?IB70SX=;A.MC2N5]5E[)'KU'EQCW6^5^OY0MSG7];SU?[QT*:>
M^2R)@E [/QQF2&@1T%X/9"P04&(4)I2P3"EEO<)WJ;6IB4&%%ZQR4&K$S;3/
M,>.>'<L6RW@^N1M8(6K:[G-@P#:SM9USXJ\OZ$4/_AP6[7SR.-)RW95\NBW:
MV?+3N5QW\2'C+=39VK.W1&=]4\^3\OR;%.N%O%,7]V_+<QNX]\8;G)$D8P))
M!8-491 3%$)&TA0&.&4BYI0FD5MB9E_(IB;EK6%5EF&+\\IEYX%E\+4RTC7-
ML[=NM_,D7Z0SA]X<&K<?W0^)^^;<[SEO;^C&/:KMF]2CT];>&^BSY[X%84X2
M5JW1Q>M\*4PM-8UG6>:+N3#K :_HPN39_?)-RM5.;M=FM> ^KP:MLD*TS=)*
MPTRR(!8P1)A#C*(8LB3"$$4!C90B*DQB^\WZ8<%.>OC8,1AL+ :[)H/&9E 9
MO9M^%S1FFUE%;;C+%O; ;XA--,%T^GVLD>;.5Y??MUW>##M6^8/'?PM<(B"F
M\S:,%3JQ(P3E[EO!-V\%WWTK6/-6E-5;,=]Y*XJM$%0K"_["+L;IE.YXC8$Q
MC!CH,0Z;^Q$B([4Y<IZWCVMSN+GQL<K;9SI?&%SO\J+*/#.37&4!YS',PC2&
M6&8)S%*BH,@H92)-N6!6#LK00"?GG%0P=P)4:(L8Z!<"/!C,(^5CN]3%EA/7
M"73<T-[%]3G3:F,W$^$2W.YU^Y\[NWV\[&>6?3*-?&:7P/X<&<HL*?>6<\RV
MO7[CS6M:?C/_;S*;/=.%F8-_EN6JF',]PIE?W"[%_C_L7%D7R7N_Y";5AGPC
MZ__JOR_60DOEV^_\F['.Y-1^JY3DJUF8*F[274,1F /R22I-6:D8(BP#%7/)
M$AG,5KD>D.U&H7'A.XU-&R.&T[F/E==;PS;!DES;5]6GJ7Z06TO=!JB1WPF[
M86NZ/3WP8&9,N0'F3[!CD0E4:HVM?VGZ_?#?]FZH20 M"^#W+0]_N $;*D#+
M156R =1L^!OH7J87O0Y_(YLPZJ#X,MUS.%2^$(H)U"AZ^_U)&IO^FNL99K4G
M6E6OH3A*F)0"2AH'$ <H@$RE*>2(9E&@YW(D=*N_-CSFJ4WC6I2@K.I_UVDG
MGC>07[!>T9D^'W@R-TQ/3G]>=ZYFT>;]V!H_Y:)%W5TUC>F> ^Z?8^;GWA&#
MEBZZT'2_X>Q6_)]UN:KV8N_S-@2:+C[1N1Y37].GN9[55!"/RJM_-O.-<KZ2
M7V3QK-6U'H@_2YX_+*NGU&4 ) IB&J8!)&ED I^Q_BF(*,0D12P->*2RQ&4L
M&QKPU :RJ@XT/)$T17XW/SM6WAN\N^V&L2EUXL!CV.VG]Z]O3H]06QFXV<[2
MS&KCZ]R4T-O:Y&]0&HMXKR/2X*!''8[&ZH+#L6BT=D>>5]VUHV.=8*=\OZSQ
MW9L%N?=+/6M<EG->JU.($CU]H@%,HRR!F"L"F9Y+02QQ3$4<2\3'V11S #VU
M 6F#KDG$E2N0-WFXVK1;8J3IE4O7#SR_&JA#IS_!NMO.J!K3S<IT;;P9UMJ7
M92KU@WITU#2F5R[ ?X[Y58^N\#;!ZM-VSX&MS3Y=%Q,R./.E&85OO\_+62)Y
MIC*EH))4ZND1"6'&LPQ*$8<AIB3&PJT@>5=K4QM*FD)E6Y".XT8GLY:"[XNO
M@97ZB"KPU2#T&6QOPX1?*>QL<5P-LS'^2'RL;GH9=WBG,-GM4KS]_C0OJB=L
MA&X69CB6:81@3%@(L8BI'N"U!K$TDR@-L<)!,EO*!Q/Z-HXW?!&SU?=(ZN]Q
M%_F0F[7Z]5HLM%NDI^UJKXQGE<6V'*MVIW6WC^,'^^G*G\\)WK&[VJ#?L7SK
M%D_'"[;NIDFYP)=1_U3^KW4G^'9^[1ON&6LFBU65FV\ERSOU1C[EY;RM#QC1
M-*!1A*&D*8+8%%M@2H3:#8X98D&F2.Q4<*VCK:EYO;M0S>J)J,$ZQFQU<&L9
M8.6'L:&CH0[(:G .4&K-@@^_<44=[8T;!'39\*.('8M;>AS:O.6\6%=2I?$O
MM":]DDNIYJMRAKD@@4099&'*($8\@5F")8QY%B@1Q"()N?5QR[/-3$TI&J"F
M"()!6GD4K,'J<,;M/*W=2N&/K*'WV!J>&I! HP2O?/+D<(K/"U\CG;_K>K]\
M':"[R$?GT;?S=X]W:.VB!7O'S2Y?W<^9VD2$O)F7?)&7E=?6%DU,(Y8E 4,P
MC!B&6"D.6: RR(590Y0TCKE3,<JNQJ8FDCL17CMH>]>E[.39SK/RQ=[ JMF?
M.&??RH81K\Y59X.C>E<VIA^Z5U;W](SWJO+=M:F^4H92PDD&"<9*S\(R C,J
MM'@(36M*%5:)<#F>L_=T)Z$8X?1,M;4#KLE$N4^>G1CTIF1HGZG).>DMX5FG
MP7[C@?9:&#=XYY1Q1Y$V)R]RK_7TIO$"WVD5H(N_2UJ\T_]2SH(X#&@L LA1
MFD*<,0:94B',@DS%*,&4*:NUDXXVIC;(MS!!C1,8H*!":E_XZ1R=W=^Q)Y(&
M_II[\.-4!>H" [TJ09U[YFC5H"X8M5L1ZM*E/3?Y:)66PD3X?M2=>Z?N"[HL
M]2"O9WUO<I. 8,94F$K%8JB8-.NDB,-,<0%E+)%$**!![):3\&*34_OT#>+J
M7+[![+B;=IE?R^TPKZP-O9^U2QCX6N/S&2A@38;?7:/+S8Z[[6--P]&^C?V=
M/:MT2.V!R/W2()NLJ\U&4/EF+6<1I3$.M<./PB0UT4<9I(A2B!$)<13@@-#8
MQ?^W;7AJ4X-W:[,+!A[GR_GC^A'DF_HY=9KJI@BM:R4.VUZPTZ AN!U8B6K(
M9GO\H![13L+E50Z8!"8*W6/1#4>J_);9L&U\W,(:CI0<E=)PO7_DL*<Z!.O]
MLEP5E:-65MG][[_1Y?YFMQ2;2)@LXT&",@PY#Q3$01Q AB(,29 $61+3D(5N
MKM5XV*?FH[U[P<BG'CUOZ?1-LS^']AZOCX9J8E5W" !UG9.5IN H5DK?/Z7(
MJ/Z=-XT8J1[X?XYHJ?X=XRUNZ@H(UU1ZKS."S1A&BJ4IAC$-),2A]M-9@"BD
MH0CBE&4TEE8EI$X]?&H#RMMM0?,F-5^? N\-<9<7^*ZA8V ]=F"B9UWW?9.O
M+.K>/.P%*KKOFW&ZG/O!-3Y]U%H!;I<F%9&6AOFS_*3[L:Q*$?^8Q:E*1:9B
MF$8TACA+!"2)2"%3(8Z#F(<JP]?[FIT8IO:)UXD-7AT[&F_[)#;HTRG7N('>
MJ![1G3N1> !\K1%;94_WY(1943>",]6-8P).D151=LZ-W:-ZA&P>)U[;7QJ8
MQ0DG4:+[1&0!@IAC"C,9I3",1823@"),F'7DYJ76IJ9Q'WI7N;O(:[=X>6=K
M8)G:I#]IL>K9XV%Q-I_L.01T^F1QI+C.;<I/T:;\-'/L@YJ+OB(\;0GJ#/2\
M^)#QXCUM[=D+^[2^Z<KHSSJV1 MY^^2Y+/^B6UH74MPM/TL3WC1?/N@+/N;+
MHOVK'@_FY8?Y4KY?R<=R%DD>A#%24*F00!SIZ21AJ81(I$P03%4@9:]P41_H
MIJ;AVS#)FZ90;Q4GO6,A:$T$57V:QJKJJETS064G^&HL!96I?4-3O;P$=M[O
MBW7MP /.B_1J_[A9G^P/$VCK!>'+1.;Z)/=L**_71J[,1'*GWLV7=,GG=/')
MG-PR4X,VQ#W!B12<*LAC&6E_/660) I#$LI$)3S3KX'522N71J<F^1O,)HQF
M@QJTL'N?+;#J ,M5"<^T#KT,<3VC_1.:6% T3%Z3KH9?)KV)!15GLYS8W#O0
MKO_9.J&;-$Y'9]?_)N</WU92W#[+@C[(-M'3)Y,(?"9$1@7.$B@BBB%."8&$
M9P0F7'&>1"35_^)UZ]^S 5,3S!9<O?\O\L6"%B5XDD4="^ [%,#WZ^ I'N %
M.WD"00'=Q:'W$@6>R(ER UHJ0,/%)J$@J-@8,31@H'X<-S[ MQ$36 \?OHN<
M(P6&PM%O'/TK+>:F5EBU]&222,^"3$0D3A/($J$@ID@[\JD,(9:!" 6B&0\R
MEX'NJ(6IC40MP&:QDVN(CF&[QR3:#0]743.P?F]8:>)O#3Q_@GK6<J^*=]S*
MJ))TULA#S3A_8;^/>C_F]D ]S 'A?+U<F4H06E[,WMXL$H&*L AAJD@"<1!0
M2-,DA;$,3)YKK'CJE S %<#4)&'C6-#&L1 -9E!T%7SQTQEVVC$DQ0-+RU%L
M_Y$?U^*OZNM49>FXUP/'?<GSJD[.($85K[X4'6I;[^?T3%:P7,W%?+$V\0I?
MS))HM6KZ]KNI[2;%.VVF<<O6]7;JG7I+"U.QV92$JYRRVT<#9Q8%5"84)Q"E
M)M$I2D)(I. P5IRH,,@PC@*G"C0^4$U-)#7DQ[P)W=^M) KR]:I<T:6II7<#
M9&,D,*\86'W3#A9=\/6BG@R:7':&%_W[I5R!15[6:P!\Y]F."1>\O !V&CQZ
MMPXLS+OV@*U!X.U>'^[89/JOM<JH=#V9OP&U91X31/@DVF]B"2_(QDU(X9/,
MHT067A_>;PSX+$NI;S(U0-_(9[G(GZJ,VW6,:)/PD@0AHZ&24 F408P%@BP5
M 50DHK%*$F9263LHO$6;4]/O%G*U/RVVH-WTUH9L.S7U3.' 6KG'W@[>-A9Y
M@'2C#@1YU3B;=D=5, <B#O7)Y=9^ZO/V\6F1_Y!MY:O3ZX$?\^6S+(TC;%;^
MRBK/U.[OS2+ QWSU=[EJ:F;]MQ15]'NS2#C#*F1QD$90H@A!DY8?9H*:";Q
M(>,"R<2I+-4HJ*>F@+^:J(D&9UWUUUO5Q''> CMAG5S?CKCU=+)RXL;6_8VF
M>I%3_W8%?LA--45MIW^'=M0N\3H8C(-\U.%DU,XX')#&;;SGD%8KX&>Y,/51
M[O,W\W)5S-FZ\N&+&GD=B/;K4C_U-^/T+Q_>25G.0BF45 F!@J8AQ!&*($TQ
MAR(*4QD(Q9%;L:K^4*8W^&SQ;=:7ZY!2L_HQ+TO3<XZC3O^.LAQ*1J%_X/&A
M]= ;*TP^F5T[3%V>C255?^QUE3'&XT!P-:%^U;T_G'$E^VK:CG3X^B?V$]=/
MA<D=M?IA3M>M3%&5_UK/JTG)O7Y>DW(N)%0R%&O9S+" F"<",D01I*%2&4O2
M+)-.WKY%FU.3RQ;R#:A UZ626M@WP !WTTH;WNU$T3.; ZO?AWSY #_,G[7P
MW>M_GYL]_BK2?("\?P[,>)4QFW9'U2L'(@Z%R>76GK&T:U;.Q9P6/W;2#%8%
M,3,22+.: *,DD1 +A6&6" K#*$12! %AS"T'P;F6IJ8VUV00/<NFG9IXX6CH
M&?9^OE#?944O,> W+/)L:^/&+UXR^BC0\.(-?1,(O5_RO'C*ZR#$*I;_M9F;
M%#]>YT)J34!9C"(&>282B#%)3>[_%*I4\C!01#%D==K'LKVI*4.37&</\PVH
M4)N)0X,<&.BN^8>Z>>]6CP'8''H6YH'('NF+K.BY(J-1]_-'3G)D9>QQWB.[
MV_K*RY='NEB\6I?SI2S+&4H("CF6$*69J4R0,"TG*8<(I4DL.<*AM#I7<^;Y
M$Y6/"B-H0;H*Q3Z#ML+0FY=QA,"2DAZ?_$G#K_C$]Y\W\B=]TICC3_CT9?WG
M!_*_UF:?]-D$>+F>.SUS^X1>P2U$4&,<YG3I!2*\N[4G&QO=J^TR^913VWE]
MWS4VJ611-)LBGVAQ5U3#FJC.V;?!1S..2:*GM0J&.(P@5B*&&<D8Q'$BF,FD
M&6*G"L-VS4YMB-J@KK?$;\ 3+<!S5?3-QU%-R[ZP77KSS?# 2K,E]TM-KL9<
M;3A4J)O:>IM(2I\K<2Y$>5Z,LVIZY/4X%SJ.E^2<[NY9"IV6)DK)_.?M-KCZ
MLS3;$ERW=?KW39[*)$AQD&411(E4$".:09(0!A.1Q)@P+(523K72KP S-7TS
M(&^ ^1/L8*TV%-Y7V^P]"G=<U5EV4C=6%PPL@!7OANO##K@!6UM QU5-]M%!
MLY#ZX-IOY?=K (U;&MX#=4>UXWT\<VK51?ZL'[$Z=\2[^N4;/:1LDD'-8B4S
MQF.36PEG$&=(09JQ"/(X#&)*1*JP4P:^R5@VM?&A0CA67I+17A_+N?I4\$YH
MQ!JOO$G-46>&D^H28*@"VWR$/T,-E)[]_Y-42'&U;EJI4<;NU/&JJ_0%.+*S
MT%/321"S-&6Q2;=H@FNE6:^2!+*(14D6QT(PI[0-(^.?VL#? H9MUH<' QD*
M([;*B&V]"+;Q!4P$1%Y;7E_ZTD[#-%V#_]\!N/D?,<3_3QC(_T</UQ,9E%]D
MZ*T] 8,T7VH@3?RN1"S&IH92$&I9QTQ/EPE)]!N5()G%&25QXG3*^V0K4QO&
MFLG&!J7C$9*31-H-$5?3,W2DP0$S T0\=U+@]ZC&R9;&/8719>S1 8O.B]V^
M^K)8S>[G*Q/V^'XIYL]SL::+O\U7WZKC&T9]OLV?[O,Z%*)YA15B5!(4UWQB
MR0-( JJE(4T0BI* (665TZ='VU-3B J^\5ZW!MB)1!_>NZ5C8#8'%I031'K4
ME"NXZ5(:_=@=E=%_.U28/NV.HCM7$-*JT36/Z)F,T2Q)&-DKY#?M1<V?I0FO
M?)0F^0!=F).Z_YDO3*ZL/^NV/N1E>;?<)LZY+>:E_M6;M:GL4'M2'^7J3MW3
M[[-8"I2*4$]7$Y%!3)C^*:4)S&(>(V+F_M@I2=E00*>F?EM[P(.V!/S>9!W[
M@RG90I_I?&$2<4*5%[ TAQS*C86.61^'ZO6(IUE*>0K3@&&(<48A8XI J8>O
M((I8F"HUTTXVRW^F?M\%_!(]/^^[\3]8/]MYW%/HNX''V+O7[V_ &\E6.QGI
M;L#MWJ=J3L#<@)WN;:P&?ZZZV1C^AQO I+Y6@EOQ?]9U7]\ JK3B &VPQ]RB
M W>)WQRD0X$=-U?IP)0?Y30=NKV>VP_\FQ1KX]KL)UT5=2&I>_.YS$2B)),X
MABJ@ N*(1]IA$!1RQ$.$<8RSQ"V,P*+1J7D +6;CN1\D(Q9M:;>O%7+7:DTV
M/6"YW.Z9UZ'7R#U0ZKZ4[<"1W_5GFX;'731VH.)HI=?EWG[2]$'J1\G]QV\*
MG3:+Q^6;M?PHOZ_N?Y.+9_F7?+GZ5LX4RPAE*(%1IK1<X9A#&B0!S#@6*B <
M16Z!K'V!3$W"](L9N6E3[RZPTZLQB!U8PVH3;@[UZV9;3_K&Y IB$GRB<W$#
M_BYI >Z6'O?FKB71J\CU!C.J\%U+V:$87OV\L>O957^87""W2V%RA'S4;WBS
M](H5$IPD!"JF.,0)43 +50!5(H2B(DIDYK1"- 3(J0EKA;1'.J%!.M!39,;
MW3*P+&][9(#]NB&YFTCUM@Z@TXIKN()J?U78+-KJF_C@[?=[W7Y=!K6>^,]8
MA'F6"@)CAE*(D4BA]G<IC&24<(J9]G =DZD<-S(UA:UQ@K??P19I$PWEF@CA
M!*/=DNF+IZ$#%7I0U",QPGD.KLB.<.*A(Z=(.&_6<9Z$CFM[%B"JB[:W*1)P
M2JA(I8)Q8O+?QMH/HSC6 B\)QUD0QFGL5!M]__%3^[1K=(X%>_8)LW-Y^M,P
MM+/2+'4-D#[BM,U^J]GL-S%N69J3YAW5ESE]5=]",56RUT^T6/VH9$ _TH0
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MGCG1QM1<X(/BB_\*_N_@CX'^7[BMPOBO( IN]#^9_V\6BP!=K[[E197ZBJ[
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M4I+Q% ]1 :X%,#7'3+^^\3"5WS:4VZG?D$0.K'N]*KT9&\8O]7;(WHN4>-N
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M[H1B"O>(<(LGW+^UGR#YD<>=0;PI(1#@C!!)8YAAICUH%,60D4S!E!!.PC!
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M# EDD8Q@0H@D.$ RLDL9WJ?QJ4E,@Q=4@*OU[GS9N0=U/?UVBC,4J4.O2N_
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MC11E83B4+8?E3JY'7Y%M-GQTQE9T/F"\R H;._;B*JQN&.80WJ8D D$J1JG
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MD&Z<$ 2>R)RPMW%7T;6)<BSG*A1A:[PZ1QNWTNN:TV?U7E>_,(P1#EJFM@7
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M"_5:\>UG)9[6M<#A00[CE_5JL_GS<JW8PM+7+V;HGY1>K=47]ON,Y%RB')6
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M0_5\5L_F^95&>1P['=@]@=T?")QO>Z^V,R9@@6@) ;1MR3 29F5(80%HP:B
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MIHQ=7[O:SN2WVM(XNKT.B$3H5G=YO!?H3-?K^.4N=/U?&2A]=U8&LD]P&AK
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M@DMF#@LTWJG-1JF.[B6-]9MZT]Y<](/^>;X1;&%3GS..TTQ)68""L1)@@DM
M.>5FU45-/(!T(3GVB0F&FS*UUW<MH'W('9L_5/*P6FZ_^?8IOF%ZW-ZOXX >
M>\.L<L)F7;L:(=TEVU7"E7D!SLU;;.^/73G7'B76I7 OJ]MA#?I>N<&<45\!
MM\-VRM8!KNBOV_VZ6;?7%]MI%8JGS:S$J- %)0 R30"690ZX4#F FJ5:RZ)
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MZ4+C<;./7T><[/7%H6G+5\JV9EF\74KU^_]2SS,$4TID 0'4RG O22%@E.5
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MH\>84PM &Y,3M0LZ#^>9Q W5#B[HN_%A8$PC$^ .SMV9/+8/X4]J),)1F0=
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M@X][]-,3DK.#G[[?OS%T^J!_GB_-.FIN6Z:8J*RJ<6@Z \Q@QA3."0:D*'*
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M[_YJC)YOJM8/7]3OVY\,T'^=84&1$*PP<4:* 4Y3!DAJY6EXQHB46G*=^6R
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M1FRCQ\U\C#0%9YF2L<;M>LVU[^)WYJ=__;O=;\P?]D3ZO_[=_P502P,$%
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M?WOS(7W&LP#3V7(59JDNL)S^RW+]S3?S%%9KF?^0KI\>_8WZ-[C\-:C? BY
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MY\B,!V_7EWPL$.*E ^^B5$%*LIYM(+)9?YQ&>,W2CCN)LP.?]\TTQ.GI.G-
M;M>Z=NSS_)2$OJPNV.K[#=$DDDSV($6J^01/40$KM:R(N\)T"*B>JOP_P(/9
MDL)Q?>'F%R!-%-6!%;K!U[U 5$LIF"%0,(.@%&8(7GO(3&)4+C'5*+O].$WC
MIK3;8.!QH!VBD Z@=9)2[3*Y?!>^U\3I958B%6$#YXZXT+;VJXW@A--@?10F
M2UMB:)-&?)B>;B!UD+;O'H:'B[X# -T.$"Y%=?D*>)*SX4%;#DXQ0Q&"311K
MTA_<INRL%9&E<H3P["Y=XQZ$C0 UH"HZ -:=[7&57D]I<4[$W!/AA*?D?%*^
MME3WH QMG*#)D3":"V55Y.K)$NC!;-8/*1TWN70<:S:LND:$8RTKF_QR3B+]
M./] #L3#>ROJ3':96Y#*.5 ^"8@N8K7A7'NA.*8[;MC]LKBM5AHWL30P=H:7
M;0=VZP&HLZ!4\K$^5*WWS)@<1)DB,$.^)Y=>E_!4?>V03OJXZ:5&MN= D7>0
M8GCDZ+Z9.!/!6N4%2!<K0V0XG0T)M-5!,!>,$VWN8G](6C>^5+MX;UCU]&6D
M)IE+Z5)T8(*T=>=Y"%A[]%C&.4=OO6MS@W*#B&Y<HJ/D#'82>0?6J3Z:G6XN
M#VMMWWQ6MP+.4F7%2K199@FBU(<..B%XJQ6XXH/T-AG?J(S]":*Z<9+:H6DH
ME71@BYZ0D$LE&LRZMAXW]15- E\;1*&27--6$86U2:@?F$(_A@/5#EL#*:0#
M:+V[7'?-TJ;VF"6%(7 /QB.O@]@21,\#F&+(]%9'TS:KD+Q+S-@/4H;1\_VR
MR(.$W@%N;G2)V-"OA$F9U59#0=29CI'3@1TSV*2U]NAY;A3!W:5D[!N\)H@Y
M2-P=P.4DY_4E9CA]%Z;Y]>Q%^#(EWVM2,@LQ!B)>5M07 KQ/H=2Y&A2"QJ!\
MJXSDPP2-ZV4W L\0PN\!0RF=GYV?U@>JZ\1I;62TP,\X6TZ_8IT-=X9OYLOE
M[[AZ6SZ&;Q,N4,AZ,4ZQ)5+@0$>]=]I!X);SQ(++V.A)Y6Z$CNN+M\)<0V5U
M@,7WN K3&>9?PV)&8<7R!KLOL4S3=#7!X(-E*("QVO&?:>)(4HQ!LLL*4<7$
MVSQQ^C%MXWKHC1 WL$HZ -E]04U*25*&^CJ&6]HFS$2(3$4PAF=EI>&.AR.%
M>^.6W#4"T8$B[R 3]:/X=Z*9T\20A>29)L\Q6_ !&6COO.&Q1.G:O!?_$67C
M NK8&<[#E3,8V$9HBO)NK9//N)HF<KIO,314AY3;2QRM7<H3G!VS=PI*"@.E
MB\!"(B-8$I+5HG 1";O&6"U4:.-]'*-WRNW\"4G\[6*];%['QN]PL6Y<.:']
MB)D7BF\24Z!<4D#Q#@=,:&462F37)C>Z'7UCI[8&1M'32:Y!E-2!3W:;JTV#
MU)/SU>?Y8OJ?F"<FEBRY(Q[H)"!NR(@'5SQH.C&*STDE;'.X/DW7V#FQHT+M
M(*5T"K'7R^4Y<6)-JK/#' 7((M89]^0>%%^@:&9Y"('%1NFRQVD:.V,V K3V
M4$:GL+K9VMD:KGSP'DIQC'A* 6*R"K!V8 BLUL4>X[3<KZUVP_38" #;5RT=
MH.S&1<7C1WXN6F0ZXZVLPQ"SJW<7@@3'K1 B9*744V/J![DJ.L@I:Y@::XRV
MH=73%^+NG?Q%2I)*;3U"\32Q4DL\&.>@8Q+%*32YM+%I3Q U=M[L> @[2!T]
M(NOBX%=2!JS3NRVOLQRMUK45K@;+7,R!CG[>J W'(P1MA:C!1PV,AZ@]U- C
MFFZ>\BSK%(Q=#VI:MXG0$#UYE=HRIJ,DHRO;W%4>/-!D\,$%X^%J7X4\L^[4
M5X)=SLM%V3;]--0:R1MWM/5V=K#$[ Y+MDS4[LOY0(G;S;7W%1%7(%82T2@A
M@>.F0;Z"6&N=0Y):,B&<B&W*RQ\A:+"G&A=]_ZX[8QAG?>'10;"L=C65%#+;
MH" ;Z[,POL34IDCL49+&3<(.@8A'7V(<)/T.#LSWI LBH#;+?8E?\72^;N5V
MP=5$"H^N> 5<&C+0#!TX7BR8S&P()07NV[SV>9*L<>$TD.KO%58,I8<.0/57
MG)&,3HF7DWPVG4VK?.J4Y4MV.*?-):T%Q-ILTM5@!;DD_T)B9,+9H-N\QO\!
M8>-F\-L :TA== "M>T*:),/1.R7 IEJDFV,!9UD&0<ZEHK]ZJ]O<!MTC9=PL
M?1OX'";O#DIUKABXKH><J$B 3T@@YT%34.L1?"*.I*F#>RTJF6-;R%P3,Z[-
M:>H;[2GQ#D#S^WPVO\W%97?M2P'5BW345H#6D<PF-PE<%!:LDM&X@,[[-I>$
M/R1M7"O4 E##:F/L)AZO9_1!N%S=YN2B3\E-5FL_Y<(R-SEFD$*1Z>;<DN.G
MZX4!1V&X3)'?>=;Z2$./758=U[\>6-OS8XB^ \?HDK=+ORYGZQ,3$6)-JRFO
MR>(2_1"B%++$*$QJ<_]WAY!QS[<V8!I"YKM#QF\@,\-/-<WV<3#D$-AOG-0F
M<!V=Y.3/R01*H"=NK -=3,Z<$:6NC6]TBXQQZQ&:'&)[2[D#?^BQUT5_S!88
M3NNUX[_-3VM*_Z]A.JL,OIU=C[DY64R7]*.7]-?9I\T$VZL720RS"<(SX++.
M)2%I@C<A@8BI>$[AB;2-VLDTXFC<TH8F[GP/NN_@@'U !%>LU(><R3@)UE-D
MH[CBM)TE<1:#XIYG.DC:)+2>(&K<$H@62!Q* QT8U,OW<Y?U0+^$Y31-)&:;
MA+)0N/&@@JJ)FH20&#=,V!)L:=/$YD%RQJUX: &@PZ7>@1VZR\3+Z>GYJM;]
M<)>"BH'46RO**/J#*)V X$@FCB?#=9M7BX\0-&YAPS'@LX_D.P#0W[".3\%\
M\I4"HT_X^_E9Q,7;<J\\8[,[A!<JR?HZCM4Y"T45\ ))=,5A]AA,:M26;2<R
MMP*;?TY@:Z>E?B%XL:'N%PHII96F(!I2=!943@9BBAZ*I^"=$?-"MRDQW9'0
M[3)G[!\ AX.HZAG7=#WPLKI%'==C#[B/4+OU(PZ'?VC[Q'MP*W7&8"W8>GNI
M@HT01/*0C3))!I44:]6280OR#N]!<;'(Q]JSG!Q2S"I3..P8)W_"^$ [U00@
M1Q63]B:[1@_0;M/1S=/9@7!QOPW%WE+OX B]HGXCD1H;SV?K/IS?ILM)-G3J
M>R.@*$O^0!*Y]OR)9)2ET-&*('B;O-J39'6"J#WT_1AT#A9^!TBZP\/+^5F8
MSB9*<XF&G$ECN0:EA";Q$#N>I1Q9#HS^;!-./D1.)\@Y7-UW0\J#9=\!@&[4
M^/^&U3V<%,.5%87B8$>1B*HSQSW3&KAD,B 7/OOF?2HWI(P+G '4^_A[BCUD
MW0%8'NF3>,$,%IELC4^,]?5.@+X*G!5P2F8?+$^,M\DV/$G6N'?8PX-H.!WT
M *@?-T&\8"RZDEA09*-=K:(N(A%C09 #H"4G+\ *;#:9:3L2QZW=:@"T)KKI
M '1W^R!><.&Y=M$Q8D!K"4H4"S$G"3P:@22_8DP;I^EA>L:MHA@>3@-(O0/L
M7'F3;XB7U_3E<H*<N!?6  6M=(8+H\ C1;6L8-3).>T;.=OW:>FDB]& ,=I^
M8NX *"=O7[P^6:T6TWB^JN+X.-_TO;N\]'X_/SU]-5_\&19YPE0Q)4H/(EA!
MV\HX\)HB$1,9YTE&*TN;"H0=B.PDB-L3#W>/MD;*Z0!W#[3,5#X%)HH$ERL'
M+"?P/",P'PL=TS8ZWZ8J<,\.ILU0U$SM/^Z1NXL.]D;1EW6-%NV5Q6H8+-U_
M],^BMD8',%X1&X+1V:]# )Y4%+XP+QM-I]_OMJ[947<T)!VD@7Z 5#?$IBG)
MS6K"=5>EW_'/]4^6DV!89#)&2.M:'N,\1(61HEB+H<1HTMT!J$/:J1^1-VYX
M=U33-:BF>CD3[S.UV5S77!7CM+:<02$I5:X<.)LYN15&.R.L-XT>S&]'W[@!
MX<@ /$17'2#P)/^O\^5FU-['^2,9O#6+,:QO]<_JFY2U;M\C.1#+Z0H_X.+K
M-.%&'.\QS3_-UI^RF7;D*5S6GAQAH:("%6I+?Z$0LM;>!9-M9FU\O-:<C5N3
M?RS4=X6/#O9+LW<+,6;I8Q+ K ^@BE^/OF" D45GO8@DB7^\-RO-7@H<:W]T
M@8>]]\577,1YDP=_R1;I# :0K#[#L3Q#"&A >6N39%)8T\9EWOW!7[/'!L?"
MX/Z2[\"@/I"22%I'GX.%S.HD%6L-.%7?3[B@F"N^<-ZFH^*>::%FSPU&3 OM
MHH,#H_E?9[E14LCZZ!7+#%PV"52N3R@$&5(GZ7\YQ<ACF_3U?DFA9B\)QDL*
M[:*!06%T_-KM%V'Y^=7I_,\VK3>O/_U8E=J/\#-80\VON(DKJO,49M]OQA(?
M%X&"B+1N\7E5E"NC-C9[2]A)JE[Q<HB& H5@$LO6V9!-J]83.Y(Z@"=5A?]N
M,?\Z)4G_\OT/4M/KV54'I!-:[NO&@;P4#NTCKC!%8$J+VE;$@6.TV4K17".C
MC2?:7/7N3NO8;3M;XNX!SZRE)CMPWV[[GD$[):7SP$4E7CM6!RXJR)S1\2%4
M4:;-^/G=O?YVG88:Z_Q)YW\7!72 GAO9I=_GLT1B6U^A?YS7--$L34_Q%GL?
MY[M*5ACR/NI+CBA%O0\(!8*T&706S"I##DVCR3BM.1NY =)Q,=X53#K8-B^1
M5D[3C;IG^>1LOEA-_W/]UPDK&"R%;H!96%")/'D7N(2DR*%/P>=6C4N?(&KD
MXHJNT#-OH\H.4'G9_.+V-<"$)YN2SP)20D<;G_Z(VCJH<QA"SCHZUK RXQX]
M(Y=G](S% 138 0QKHGU9A8<UUQY.Z3_EA/ZV6DX<SY$Y)B $^D,5@^"#2A M
MCU)ZISEK$T(^3M/(Q1L]PW$@1?;3$O&R(6B5\W5S1^&2MD@>>IV$5$>'QU2K
M5AA+I3CN?6J3HGR F)'K.'K&XJ&JZ\ NDN@62,;])6[^>T-8%SF0*TEE%KG'
M4H"5O!XC*,'5>R3.57(BFRQ,FWJC[6D<UVX>.?YII+HN0?EN@5_"-+^\H.=.
M.^4+^Q\-67@?4NU)A*"D\63_4P TQ<M0)T_H5KG@?>@=.^79!CT_!.G@JCST
M*&\+V?>DBXE./!8I'1BGB1TG,WCO2NW=C%8+CT&T:;;X)%FCCX,8%8 [*V94
MG%WTE+_+RYOZGS?3$*>G]7[>*QV8\AYL1$W;)EKPRBE(N8CHLRK\[B#F1UOX
M/[W2Z(,?6D)G>%EW>::>I#0_)[_Z7?A^\0"R&!UK1]M<AT,'11%]4A&*3[7Q
M$2H1VO2]^B%IHW=H'\=0':*@7A&W."<Z+O90=80OCOTKB=[XV41;Z;U !&T%
MHQWF.<1<$I!CG!(C$^U$FRCX4,I';\P^&EY;J;<#.&\?W4TRQ?@B\03!U-RH
M2G4V!P8@;T-XVK=T5C2[\-Z2QG%-ZO%OPUNHKH/>[H]PMJEG>5B03#/F9- @
M-&UW$B0'9VP&E^IN9P73<<'Y!*UC!R@=% 4-I<D.#"BY,9<OAM+_/I\ND'BE
M';CZ_NXTS%9T5-0BX_4HVDFVS*I,6YQE7AO[%K&9(EF0V>*TI3W:IGO2]C1V
M64XT&%KF1U%=%YF;>[R=? W3T^IPOYHOZ@73]<N<EQA7DX!:4VQ7 &VJ0[RL
MAJAS@*)TU)Z[K$R;IXL[$MIE+=#1 #J@$OM Z6*>$//R%4FZ\O-;6%5^OM/>
M>S$_/<7U251;]L\7*S+99]>'UW(BM8\Q5'<F.E?;]&>((E+PJ+)";6)@N4V'
MS .([O(FIQEZCZ3<#IR [24[X2HJJ;BNW=OH)''$F9->@)6*&19CSL6/[*AV
M&46U0FDCU?4;1;V:SL(L/2Q(KYSP&B-Q6!M),@I,/?DY$#DY_)ZIXDN;YK&[
MTSIVKKZ#*&HH379@0&^>%;6Y"/&%;\N-5LT3G:*V0EO@ZT:&R42()#)(T9JL
ME+12MKEL_"%I7<9,@V'CB4/]<$6-/4G\TL&N[O3Y='5]#>:$X!&+!,M+(A$%
M ;&H6I.<,^U49KW>;FKX8RMT&<<,#9KA9-Q/8>/VHB-_@>(N1R:?*U-OMFA/
M.)<D""6LS59Q*<8^3;L,2%K9KD:JZ\#5JVS5_]>$U5<*M6B[O2?_9#%-A/WZ
M XJY;G_CQF]NFK'<O_A*I^?U7?NOW]+G,/N$[VD?_5K(EUY-1&2E<%X@!TN^
MC#4%G#46)--61>8SLZX)L(_+Y]@7],=T,3M&T'/?7Q,I%).RSG^H=VZJ! L>
MI00MG-"QL.ADF]SJ062/?=W_;-"_DWZ[Z09[&,LE>AU]LL1C)M_-E0BNT%\E
M&I1:<R]<FRQ6>T@W'.C^?""]BWX[:8ET^9#F*G$WRU>>W?IUS?4P5ZNSIF 4
M0GUAJKQF$%74!#D?C$&>4J.G<5N3./;@^*,FMYKHK8.<UH74UD\!\G1U3EHD
ME^B\4O++^>KW^>H_<%5[BTZ2L(G7%\]2UF<!2CEP-<3QT6DM@@G9M?(/MJ-P
MY Q7&X#<LY<-M#5V?NLM>=NUW^:+^7+U"#LFH DA:= %9=VZ#D(AGK(M+N@L
M'/UPJTS7C]<:.>?5%$8MQ-V!#7M?1Y>_+7\L<?V$Z6W<C(]Z/;N,Z5[-;Y3!
MWGY*$$A:T;HZ>JB^0M&VU->H!NK\*A>3MZY1N=,!1(^<#SN*I3N63ON=3?]V
M\2G,+ONUW*)VNPZ&M_[]0#T*'Z=IH"Z$%^\N:O?E^>DTW4RJ)NE2;3, ,7A6
MYU62^Y82!^XBXY(E'76;XMG':3K4</UROB10+Y<O<9D6TR\7+6=^"<OI\FUY
M=T-/'TF\OYS6BZO(!9/:)D"320I.<P@J)"B\4 P?&/.B32O>W6D=N<G0,$BZ
M:Y<:J^QYF*/KL0.O9V6^.%M_\V6=VGAZJ*5ZZJ,;&+&M.6EOWSQ7WBI%6%2U
M+E+E!,ZX1*C,/&I?BFK4&[F=?;L[R//&G-B76&BIU40D[:-WM5V'KT.JL@ G
MB@%3%.>:,\54&ZO^8]JZM5^[(.5'LU4/5$D7!;H/9!'))J]+-C_>*=D4SJKB
M8B9 *$6\Z0+!UQL>8VWR(;/<:'#8]C2.W ^M#>P:J:C?X_+#^=E96'R?EP_3
M3[,I;:SZ6..>;/<Y+;?\Y($.RWWX.,)9R0IWUB$D[>I+%Q<IUA..3%0A!TX;
MA8V&F;0[*Y^4[[4S6;MD*6<%&%:GT(@0(#KE00IEF&#%EU8CI+>BK]\S<P?$
MW&O#.+QJGKOA:F_ QC%D8QFT)$OM'JLA\,+7B2H(%NM8#JEL$HF)^.R2&YN8
M^,X"WS=_7N\:(5*,2E%T[,C'5*9D"(852!$]>HJ8>:,RK>WHZ]:@[8*8>TF,
MX54S]B72^^GR[]6E_&.6<%%#G-7E;K[!$&H=:&4!@44'RI8$T2.#(*QS/D<,
M4?[(>FV]6K=^_#[(:2/C#NZ._ECBV_+K<C4]HW!T.>%%9U9;214OZ S7Z GR
MTH!#8ZQ+12-OTXCI-ATC-R%N8W4.$'4'0/F GVI\^AZ_U(;PCYE,I=>I7@J*
MR=T#E5(=UA4U2&(I,R=L5&W>^VY%WLC]A-O :GC%=("V%W.RL;/58C.XE^SN
M"Z)ANJI?3;!(3T$,!^.-JR-EZL;1"8IP-H7 "L8V&'N"J)%G+[=!UE!*Z %/
MFUK*']5:WBV97V^B"6/>R&0*:%6?LRA)L;,GPYV+S21%Z:1N<S-Q"-4C3SMN
MA,ACJ;$#R+X*T\5Z(OG;<E%?4B_IB-/SLQM,&52RY-J_+M97]9["$V_I*U94
M%-YS*VP;;&Y%WLCCCMN <'C%=("V1[LJW8MOL@PRU7<4I3 *BI6'6/LK.*NT
M9(IK;QOU(-J2PI$G)+?!7!/U= "[UV=?:#=51MXN7DZ77^;+</JVO)G7=IU?
M,6]:LM_C47EA8HA06*A;RQJ@P-J!M$F&Z"UB;M32? ]J1QZTW :.S=76 33?
M('&!Z]+*>ZPXSH,NR8..F6)WPQ5XB112)56+.GU]5]$$@4\0M5VFECTSI VE
MA0X 16XJ$@&?7^)7/)VOK?>ZR];9EW-:Y,.\K/XD2=\+W(5"(22'P R"*JEV
M3.(!4#)FI1(">9NKWKW(W0Z$S^V^H+WF.H#GP\/VWEZ6>+Y>YP+(NE<7Y-+)
M=1B3%9*VG-6T S/9]1A4 1M8")D8+*7-Y=4>Q&X'S>=R(7$LK74 S,K8 C\3
M;\3'9M[:PSE.U#EE22*TAM4"+6DA"F' 1JMI+Q;R,!H]T=N2PNT@^-SN-9KH
MIP/<_8Y_WI#88CZC+Q/>B/'O\D=[B Q[<1")D9H3->",XN"+<=QY'UBK)\L[
M4KH=#I_;14A3?3WW@J6/M2%QPW*EB\\_:K'20SRU+U7*A7LM")VX3B.74"!:
MX\ 5'Z1GAO'<YL7D\*5*ZZJ&RQOI_,<2R_EI#>"OYMJN)7SS$E$R64* Y&--
M+HEJP(,&*7@6V25E[KI[C]2/;+]FM_5'N\#@5A5)(WD_=P,U\)NJPQ<]JBGK
MZ!V6#8YGGSADF>LHZ\3 99[!"QOK@)H0&\UB:V3??GR$3+P+(B!#,.O>4$D&
M")+5J?)%<(J&E(]A*[OVX[6ZM6>[J/V6/1M8OATX_H]>MOSR_2-]Q,FWZ7*2
MDXI( 3/PQ"3YCI*#XYI<5LEU*DXE+MN\0]Z"N'$PU@0,VUZ#[:F9GL%6&7HY
M/PO3V407*X3C#$0=O*B2=N!=$<1AB/4I!Y>Q39IM"^+&-6B# V);P.VIG0X
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M.2<)$V.7/Y^$8(7/.I.CS\D1L&@A&E[ HDO""^_BE@G#;5<<]QQK!J$6\N[
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M"4RW(&[<^O9CH'%H#8V=&KYYI?;ITP(_$3N7?LO:EYYP:Y)3+(&,2H'2)*U
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M01XH.:>P" <B6DT'(IV*/A0#NHBL&4//79MJG_T3P2>XJC\I%%Y,_NXCEPY
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M.H^ELY$HK]+4^57F";1G?*CTHC1#V9'?YE?_?K_*M:DQ$Z#6&RL2O=#DC6I
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M@)'*LZOMXQY 98H-O.'\#U+"5%+E>)<)V.>4[ /.8&!M&1Y_;3&R6H/\]T+
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M.3,P7V-A;"YX;6Q02P$"% ,4    "  \.6A3_JZJ=@8P  "+& ( %0
M        @ &G80( :W)Y<RTR,#(Q,#DS,%]D968N>&UL4$L! A0#%     @
M/#EH4\ZHN&3Y2P<  N\* !0              ( !X)$" &MR>7,M,C R,3 Y
M,S!?9S$N:G!G4$L! A0#%     @ /#EH4X%N9+40I   /Q ' !4
M     ( !"]X) &MR>7,M,C R,3 Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( #PY
M:%.\03H9S6   (1Z!  5              "  4Z""@!K<GES+3(P,C$P.3,P
M7W!R92YX;6Q02P$"% ,4    "  \.6A3IDNM;-@'  "M*0  %P
M    @ %.XPH :W)Y<RTR,#(Q,#DS,&5X,S$Q,2YH=&U02P$"% ,4    "  \
M.6A3'=_M]<<'  "(*0  %P              @ %;ZPH :W)Y<RTR,#(Q,#DS
M,&5X,S$R,2YH=&U02P$"% ,4    "  \.6A3D7<[ST$%  "1*P  %P
M        @ %7\PH :W)Y<RTR,#(Q,#DS,&5X,S(Q,2YH=&U02P4&      H
,"@"; @  S?@*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
